<SEC-DOCUMENT>0001193125-17-019730.txt : 20170126
<SEC-HEADER>0001193125-17-019730.hdr.sgml : 20170126
<ACCEPTANCE-DATETIME>20170126160900
ACCESSION NUMBER:		0001193125-17-019730
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		16
FILED AS OF DATE:		20170126
DATE AS OF CHANGE:		20170126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAPTYSBIO INC
		CENTRAL INDEX KEY:			0001370053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203828755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-206849
		FILM NUMBER:		17549788

	BUSINESS ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-362-6295

	MAIL ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d320192d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4)<BR>Registration No. 333-206849 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">5,000,000 Shares </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g56x38.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This is the initial public
offering of shares of AnaptysBio, Inc. common stock. We are offering 5,000,000 shares of our common stock. The initial public offering price of our common stock is $15.00&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. Our common stock has been approved for listing on the Nasdaq Global Select
Market under the symbol &#147;ANAB.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters have the option for a 30-day period to purchase up to an additional 750,000 shares from
us to cover over-allotments of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups
Act of 2012 and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#tx320192_3">Risk Factors</A>&#148; beginning on page&nbsp;15 of
this prospectus. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Price&nbsp;to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Public</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Underwriting</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Discounts&nbsp;and</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Commissions(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proceeds&nbsp;to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AnaptysBio,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Inc.</B></P></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$15.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.05</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$13.95</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$75,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5,250,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$69,750,000</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain of our existing stockholders and their affiliated entities, including stockholders affiliated with certain of our directors, have agreed to
purchase an aggregate of 1,946,666 shares of our common stock in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on the shares purchased by these entities as they will on the other
shares sold to the public in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares of common stock to the purchasers on or about January&nbsp;31, 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL; font-size:16pt"><B>Credit&nbsp;Suisse</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL; font-size:16pt"><B>Stifel</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:ARIAL; font-size:14pt"><B>JMP&nbsp;Securities</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><FONT STYLE="font-family:ARIAL; font-size:14pt"><B>Wedbush&nbsp;PacGrow</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The date of this prospectus is January 25, 2017. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><A HREF="#tx320192_1">P<SMALL>ROSPECTUS</SMALL> S<SMALL>UMMARY</SMALL></A><SMALL></SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_2">T<SMALL>HE</SMALL> O<SMALL>FFERING</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_3">R<SMALL>ISK</SMALL> F<SMALL>ACTORS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_4">S<SMALL>PECIAL</SMALL> N<SMALL>OTE</SMALL> R<SMALL>EGARDING</SMALL> F<SMALL>ORWARD
</SMALL>-L<SMALL>OOKING</SMALL> S<SMALL>TATEMENTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_5">M<SMALL>ARKET</SMALL> <SMALL>AND</SMALL> I<SMALL>NDUSTRY</SMALL> D<SMALL>ATA
</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_6">U<SMALL>SE</SMALL> <SMALL>OF</SMALL>
P<SMALL>ROCEEDS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_7">D<SMALL>IVIDEND</SMALL> P<SMALL>OLICY</SMALL></A><SMALL></SMALL></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_8">C<SMALL>APITALIZATION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_9">D<SMALL>ILUTION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_10">S<SMALL>ELECTED</SMALL> C<SMALL>ONSOLIDATED</SMALL> F<SMALL>INANCIAL</SMALL> D<SMALL>ATA
</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_11">M<SMALL>ANAGEMENT</SMALL>&#146;<SMALL>S</SMALL> D<SMALL>ISCUSSION</SMALL> <SMALL>AND
</SMALL> A<SMALL>NALYSIS</SMALL> <SMALL>OF</SMALL> F<SMALL>INANCIAL</SMALL> C<SMALL>ONDITION</SMALL> <SMALL>AND</SMALL> R<SMALL>ESULTS</SMALL> <SMALL>OF</SMALL> O<SMALL>PERATIONS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_12">B<SMALL>USINESS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_13">M<SMALL>ANAGEMENT</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_14">E<SMALL>XECUTIVE</SMALL>
C<SMALL>OMPENSATION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_15">C<SMALL>ERTAIN</SMALL> R<SMALL>ELATIONSHIPS</SMALL> <SMALL>AND</SMALL> R<SMALL>ELATED
</SMALL> P<SMALL>ARTY</SMALL> T<SMALL>RANSACTIONS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_16">P<SMALL>RINCIPAL</SMALL>
S<SMALL>TOCKHOLDERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_17">D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL> C<SMALL>APITAL</SMALL> S<SMALL>TOCK
</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_18">S<SMALL>HARES</SMALL> E<SMALL>LIGIBLE</SMALL> <SMALL>FOR</SMALL> F<SMALL>UTURE
</SMALL> S<SMALL>ALE</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_19">M<SMALL>ATERIAL</SMALL> U.S. F<SMALL>EDERAL</SMALL> I<SMALL>NCOME</SMALL> T<SMALL>AX
</SMALL> C<SMALL>ONSIDERATIONS</SMALL> <SMALL>FOR</SMALL> N<SMALL>ON</SMALL>-U.S. H<SMALL>OLDERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_20">U<SMALL>NDERWRITING</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_21">L<SMALL>EGAL</SMALL> M<SMALL>ATTERS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_22">E<SMALL>XPERTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx320192_23">A<SMALL>DDITIONAL</SMALL>
I<SMALL>NFORMATION</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_24">I<SMALL>NDEX</SMALL> <SMALL>TO</SMALL> C<SMALL>ONSOLIDATED</SMALL> F<SMALL>INANCIAL
</SMALL> S<SMALL>TATEMENTS</SMALL></A><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those
contained in this prospectus or in any free writing prospectuses we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to
sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through and including February 19, 2017 (the 25th day after the date of this prospectus), all dealers effecting transactions in these
securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or
subscription. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who come into possession of this prospectus and any applicable free writing prospectus in jurisdictions outside the
United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you
should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth
under the sections &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case included in this prospectus. Unless the context otherwise requires, we use the terms
&#147;AnaptysBio,&#148; &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to AnaptysBio, Inc. and our subsidiary. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology
platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation <I>in vitro</I>. Our strategy is to advance
the development of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced wholly-owned antibody programs, ANB020 and ANB019, neutralize therapeutic targets that are genetically associated with
severe inflammatory disorders in humans. ANB020 inhibits the activity of the interleukin-33, or IL-33, cytokine for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma. We
have completed a Phase 1 trial of ANB020 in healthy volunteers in Australia under an approved Clinical Trial Notification, or CTN. We believe the results of this Phase 1 trial demonstrate a favorable safety profile of ANB020, which was
well-tolerated and for which no dose-limiting toxicities were observed, and favorable pharmacodynamic properties of ANB020, where a single dose was sufficient to suppress IL-33 function for approximately three months post-dosing as measured by an
<I>ex vivo </I>pharmacodynamic assay. We plan to disclose detailed data from this Phase 1 trial at two medical conferences during the first quarter of 2017. We have cleared an Investigational New Drug application, or IND, with the U.S. Food and Drug
Administration, or FDA, and a Clinical Trial Authorisation, or CTA, with the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, to initiate Phase 2a trials of ANB020 in patients with severe adult peanut allergy and moderate-to-severe
adult atopic dermatitis, respectively, each of which are anticipated to be initiated during the first quarter of 2017. We anticipate top-line data from these trials to be announced during the second half of 2017. In addition, we plan to seek
regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma. We anticipate top-line data from this trial to be announced during the first half of 2018. ANB019 inhibits the
interleukin-36, or IL-36R, receptor for the treatment of rare inflammatory diseases including generalized pustular psoriasis, or GPP, and palmo-plantar pustular psoriasis, or PPP. In November 2016, we submitted a CTN for ANB019 and, if cleared, we
plan to commence a Phase&nbsp;1 clinical trial in the first half of 2017, and anticipate announcing top-line data from this trial during the second half of 2017. We subsequently plan to seek regulatory clearance to initiate Phase 2 studies of ANB019
in GPP and PPP patients during 2018. In addition to ANB020 and ANB019, our wholly-owned pipeline includes novel checkpoint receptor agonist antibodies that we believe are applicable for treatment of certain autoimmune diseases where immune
checkpoint receptors are insufficiently activated, and have demonstrated efficacy in an animal model of graft-versus-host disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to our wholly-owned antibody programs, multiple AnaptysBio-developed antibody programs have been advanced under our collaborations to preclinical and clinical milestones. Our collaborations include an immuno-oncology-focused collaboration
with TESARO, Inc. and TESARO Development, Ltd., or collectively, TESARO, and an inflammation-focused collaboration with Celgene Corporation, or Celgene. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our TESARO collaboration, a Phase 1 clinical trial was initiated during the first
quarter of 2016 to study an AnaptysBio-generated anti-PD-1 antagonist antibody (TSR-042) in patients under an IND cleared by the U.S. FDA. We anticipate initiation of a registration program for TSR-042 by TESARO during the first half of 2017. A
second Phase 1 trial was initiated during the third quarter of 2016 to study an AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022) in patients under a separate IND cleared by the FDA. We anticipate initiation of a combination trial of
TSR-022 with an anti-PD-1 antibody by TESARO during the first half of 2017. Under our Celgene collaboration, an <I>in vivo</I> toxicology study using good laboratory practices, or GLPs, for an AnaptysBio-generated antibody was completed during the
second quarter of 2016, and a U.S. IND was cleared by the FDA and a Phase 1 trial was initiated in December 2016. Including the aforementioned programs, we expect that our collaborators will advance four AnaptysBio-generated antibodies to the clinic
by the end of the first half of 2017. Through December 31, 2016, we have received $65.4&nbsp;million in non-dilutive funding from our collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company is led by a strong management team with deep experience in antibody discovery and development, collaborations, operations and
corporate finance. Through December 31, 2016, we have raised approximately $104.1&nbsp;million from investors, including Biotechnology Value Fund, Cormorant Asset Management, Frazier Healthcare, HBM Partners, Longwood Capital Partners and Novo A/S.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
developed, and will continue to develop, antibody product candidates that leverage emerging insights into biological mechanisms to treat severe diseases with unmet medical need. The following table summarizes certain key information about our
wholly-owned and partnered product candidates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g28j55.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced, wholly-owned product
candidates are summarized below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ANB020</B> is a potentially first-in-class antibody that inhibits the activity of IL-33, a pro-inflammatory
cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
dermatitis, food allergies and asthma. IL-33 directly mediates release of disease-associated cytokines, which recruit pro-inflammatory cells that mediate atopic disease. Because ANB020 inhibits
IL-33 function, and acts upstream broadly across the key cell types and cytokines involved in atopy, we believe that its mechanism has advantages in the treatment of atopic diseases over competing agents that block only a subset of the cytokines
responsible for atopic diseases. The role of IL-33 signaling in asthma has been recently genetically validated through human studies published in the medical literature. We have completed a Phase&nbsp;1 trial of ANB020 in healthy volunteers in
Australia. We believe the results of this Phase 1 trial demonstrate a favorable safety profile of ANB020, which was well-tolerated and for which no dose-limiting toxicities were observed, and favorable pharmacodynamic properties of ANB020, where a
single dose was sufficient to suppress IL-33 function for approximately three months post-dosing as measured by an <I>ex vivo </I>pharmacodynamic assay. We plan to disclose detailed data from this Phase 1 trial at two medical conferences during the
first quarter of 2017. We have a cleared U.S. IND and a U.K. CTA to initiate Phase 2a trials of ANB020 for the treatment of severe adult peanut allergy and moderate-to-severe adult atopic dermatitis, respectively, each of which are anticipated to be
initiated during the first quarter of 2017. We anticipate top-line data from these trials to be announced during the second half of 2017. In addition, we plan to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in
patients with severe adult eosinophilic asthma. We anticipate top-line data from this trial to be announced during the first half of 2018. Based on our analysis of publicly available data sources and interviews with physicians and key opinion
leaders in the field of atopic dermatitis, we estimate approximately 1.4 million adults in the United States are affected by atopic dermatitis, of which approximately 280,000 are diagnosed with a moderate-to-severe form of this disease, of which
98,000 are believed to be suitable for treatment with systemic biological therapies. Peanut allergy is the most common cause of food-induced allergy in the United States. Based on our analysis of publicly available data sources and interviews with
physicians and key opinion leaders in the food allergy field, we estimate approximately 1.7 million adults are affected by peanut allergy, of which approximately 600,000 are treated by allergists and approximately 400,000 are at risk for severe
reactions and therefore we believe are suitable for treatment with systemic biological therapies in the United States. We estimate, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders
focused on asthma, that asthma affects approximately 19.0&nbsp;million individuals, of which approximately 3.6&nbsp;million have severe, persistent occurrence of this respiratory disease in the United&nbsp;States. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>ANB019</B> is an antibody that inhibits the function of IL-36R, which we are initially developing as a potential first-in-class therapy for GPP and PPP patients. GPP is a life-threatening, rare, systemic inflammatory
disorder that, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field, we estimate affects approximately 3,000 patients in the United States with no approved therapies. Studies
have shown that GPP can be associated in some patients with mutations that lead to abnormally high signaling through the IL-36R, which we believe can be addressed by treatment with ANB019 irrespective of whether a GPP patient has a mutated IL-36
signaling pathway. PPP is a non-fatal form of pustular psoriasis that we estimate affects approximately 150,000 patients in the United States alone. PPP is believed to be caused by increased systemic levels of IL-36 cytokines, resulting in
inflammatory pustules on the hands and feet of patients that cause significant inability to stand, walk or do manual work, which we believe can be addressed by treatment with ANB019. We believe ANB019 is the most advanced therapeutic antibody
targeting IL-36R in development. We have submitted an Australian CTN for ANB019 and, if cleared, we plan to initiate a Phase&nbsp;1 clinical trial in Australia in the first half of 2017, and anticipate announcing top-line data from this trial during
the second half of 2017. We subsequently plan to seek regulatory clearance to initiate Phase 2 studies of ANB019 in GPP and PPP patients during 2018 and plan to seek FDA Orphan Drug Designation for the treatment of GPP and PPP. The FDA may grant
Orphan Drug Designation to a drug intended to treat a disease or condition, that generally affects fewer than 200,000 individuals in the United States. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Checkpoint receptor agonist</B> antibodies are being developed by AnaptysBio to multiple different immune checkpoint receptors for the treatment of certain autoimmune diseases where we believe checkpoint receptor
function is insufficiently activated. Known human immune checkpoint receptors include CTLA-4, PD-1, LAG-3, BTLA and TIGIT. We have discovered certain checkpoint receptor agonist antibodies that have demonstrated efficacy in a rodent model of
graft-versus-host disease. We anticipate that, subsequent to regulatory clearance, one of our wholly-owned checkpoint receptor antibodies will initiate human testing during 2019. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Advantages of Our SHM Platform </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
approach to developing novel therapeutic antibody product candidates is based upon SHM, a critical, endogenous process that generates the essential antibody diversity required to develop a natural immune response to pathogens. Our proprietary
antibody generation platform is designed to replicate the natural process of SHM <I>in vitro.</I> Competing antibody discovery technologies include mouse immunization methodologies, microbial antibody display and human B-cell screening. We believe
our SHM platform overcomes several key limitations associated with these competing technologies and has the following competitive advantages: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Diversity against difficult targets.</B> By applying SHM without the constraints of an <I>in vivo</I> environment we are able to generate an unprecedented diversity of antibodies. This enables us to develop
antibodies against human targets that we believe have not otherwise been accessible to other technologies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>High potency.</B> Because our platform generates highly-potent antibodies, we are potentially able to modulate every extracellular target associated with human disease, and believe only small therapeutic doses may be
required to mediate therapeutic effect <I>in vivo</I>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Functional activity selection.</B> Our mammalian cell system simultaneously displays and secretes antibodies during the antibody discovery process, allowing us to incorporate functional assays throughout the process
and focus on product candidates that are optimized for the desired therapeutic activity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Speed.</B> Our platform technology has enabled us to generate therapeutic-grade antibodies and subsequently advance preclinical manufacturing and toxicology studies to the filing of an IND or foreign equivalent,
typically in approximately 2.5 years. We believe this timeline is significantly shorter than conventional antibody discovery approaches based upon mouse immunization and microbial display systems. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Manufacturability.</B> By using mammalian cell display to generate our therapeutic antibodies, we believe our platform mitigates risks associated with antibody expression, formulation and stability during the
antibody generation process. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Bispecific antibodies.</B> Our novel approach for the generation of bispecific antibodies leverages SHM to combine two therapeutic mechanisms into a single natural antibody molecule. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Collaborations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established collaborations with pharmaceutical and biotechnology companies that have provided us with $65.4&nbsp;million in payments
through December 31, 2016. Multiple antibodies, generated by us prior to or during a strategic collaboration, are currently being advanced through development by our collaborators. Our collaborations with TESARO and Celgene are described below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TESARO Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our
immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize antibodies generated using our SHM platform consisting of the following antibody product candidates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1 Monospecific Antagonist Antibody (TSR-042)</I>: Phase 1 clinical trial dosing initiated in the first quarter of 2016 subsequent to the acceptance of a U.S. FDA IND, finalize registration strategy and
initiate a registration program in the first half of 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-TIM-3 Monospecific Antagonist Antibody (TSR-022)</I>: Phase 1 clinical trial dosing initiated in the third quarter of 2016 subsequent to the acceptance of a U.S. FDA IND, expect initiation of an anti-PD-1
combination trial in the first half of 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-LAG-3 Monospecific Antagonist Antibody (TSR-033)</I>: currently in preclinical development, expect the initiation of a Phase 1 trial in the first half of 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1/TIM-3 Bispecific Antagonist Antibody</I>: currently in lead selection process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1/LAG-3 Bispecific Antagonist Antibody</I>: currently in lead selection process; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Undisclosed Bispecific Antagonist Antibody</I>: currently in lead selection process. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Celgene Programs
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our collaboration with Celgene, we developed therapeutic antibodies against multiple targets. We granted Celgene the option to
obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to
each target under collaboration. We successfully delivered antibodies against three targets. Celgene is currently advancing two anti-inflammatory antibody programs, and has completed an <I>in</I> <I>vivo</I> toxicology study under GLP, cleared a
U.S. IND with the FDA and initiated a Phase 1 trial for one of these two antibodies. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Milestones </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart describes key milestones we have achieved since July 2015. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g320192g34o44.jpg" ALT="LOGO">
</TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:1pt" ALIGN="center">

<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Milestones Achieved Since July 2015</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Program</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Milestone</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Timing</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">AnaptysBio</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">ANB020 (anti-IL-33)</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">ANB019 (anti-lL-36R)</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Checkpoint
Receptor Agonist</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Australian CTN Cleared</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Top Line
Data</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">US IND CIeared</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">UK CTA Cleared</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">Australian CTN Submitted</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Animal Efficacy Data</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2015</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2015</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2016</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4
2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TESARO</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Partnership</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Partnership</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-042 (anti-PD-1)</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-022 (anti-TIM-3)</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-033
(anti-LAG-3)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox Phase 1 Trial Initiation</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial
Initiation</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q2 2015</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q1 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2015</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2016</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Celgene</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Partnership</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Undisclosed</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">US IND Cleared</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial
Initiation</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q2 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart describes milestones anticipated during 2017 and 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g50j92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading antibody development company with a pipeline of novel therapeutic antibodies, which is being further expanded by applying our
technology platform to emerging biological targets. The key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advancing our wholly-owned lead product candidates to clinical milestones.</B> We are working to demonstrate
the safety and efficacy of our wholly-owned pipeline programs, and have completed a Phase&nbsp;1 trial of ANB020 in healthy volunteers in Australia, which we believe has demonstrated favorable safety and <I>ex vivo</I> pharmacodynamic properties. We
have a cleared U.S. IND and U.K. CTA to initiate Phase 2a trials in patients with severe adult peanut allergy and moderate-to-severe adult atopic dermatitis, </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:1pt" ALIGN="center">

<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Anticipated 2017-2018 Milestones</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Program</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Milestone</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Anticipated Timing</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">AnaptysBio</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">ANB020 (anti-IL-33)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Detailed Data at</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Medical Conferences</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Atopic
Dermatitis Phase 2a Trial</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Top-Line Data</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Peanut Allergy Phase 2a Trial</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Top-Line
Data</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Eosinophilic Asthma Phase 2a</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Trial Top-Line Data</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q1 2017</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H2 2017</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H2 2017</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">H1 2018</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">ANB019 (anti-lL-36R)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Top-Line Data</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GPP Phase 2 Trial
Initiation</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">PPP Phase 2 Trial Initiation</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H2 2017</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">2018</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">2018</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Checkpoint Receptor</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Agonist</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Initiation</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">2019</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TESARO</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Partnership</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-042 (anti-PD-1)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Initiate Registration Trial</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H1 2017</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-022 (anti-TIM-3)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Initiate PD-1 Combo Trial</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H1 2017</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-033 (anti-LAG-3)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Initiation</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H1 2017</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
respectively, each of which are anticipated to be initiated during the first quarter of 2017. We anticipate top-line data from these trials to be announced during the second half of 2017. In
addition, we plan to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma. We anticipate top-line data from this trial to be announced during the first half of 2018.
We have also submitted an Australian CTN and, if cleared, we plan to initiate a Phase 1 healthy volunteer trial for ANB019 in the first half of 2017, and anticipate announcing top-line data from this trial during the second half of 2017. We
subsequently plan to seek regulatory clearance to initiate Phase 2 studies of ANB019 in GPP and PPP patients during 2018. For both ANB020 and ANB019, we are conducting, or plan to conduct, our initial clinical trials in Australia, and we plan to
then conduct further clinical development in the United States and other countries. We have elected to pursue this strategy in order to benefit from certain financial incentives that Australia makes available for biotechnology research and
development, and because we believe that Australia provides a streamlined approval processes for the initiation of first-in-human studies and that the clinical data we generate in Australia will subsequently be accepted by the FDA and foreign
regulatory agencies outside of Australia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Continuing to expand our proprietary pipeline by generating new product candidates using our technology platform.</B> Using our proprietary SHM antibody generation platform, we are able to rapidly develop novel
antibodies against biological emerging targets. Our goal is to continue expanding our wholly-owned new therapeutic antibody program pipeline by innovating one or more novel pipeline antibodies each year. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Identifying emerging opportunities in key therapeutic areas.</B> We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating
biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes translational biology assessments, such as human genetics, <I>ex vivo</I> tissue pathology and target expression patterns, to understand the relevance of
emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid initial efficacy assessment. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Retaining rights to strategic products in key commercial markets.</B> We intend to retain ownership and control of our pipeline programs to key preclinical and clinical inflection points. We may build sales and
marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing
resources to advance through development and commercialization. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Update </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have not finalized our full financial results for the year ended December&nbsp;31, 2016, we expect to report that we had
$51.2&nbsp;million of cash and cash equivalents as of December&nbsp;31, 2016. This amount is preliminary, has not been audited and is subject to change upon completion of our ongoing audit. Additional information and disclosures would be required
for a more complete understanding of our financial position and results of operations as of December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Affecting Us </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks and uncertainties, including those highlighted in the section titled &#147;Risk Factors&#148;
immediately following this prospectus summary. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates are in early stages of development and may fail in development or suffer delays that
adversely affect their commercial viability. If we or our collaborators are unable to complete </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
development of or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have recently initiated dosing of ANB020 in humans and have never dosed any of our other wholly-owned product candidates in humans. Our planned clinical trials or those of our collaborators may reveal significant
adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to
commercialize and generate revenue from our product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may not be successful in our efforts to use and expand our technology platform to build a pipeline of product candidates and develop marketable products. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have recently commenced clinical development of ANB020 and have no prior history of conducting clinical trials or commercializing biotechnology products, which may make it difficult to evaluate the prospects for our
future viability. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our existing collaborations, including those with TESARO and Celgene, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if
these collaborations are not successful, our business could be adversely affected. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The manufacture of biologics is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of
our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for commercial sale, and to date we have not generated any revenue or
profit from product sales. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product
candidates or develop new product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our executive officers, directors, current 5% or greater stockholders and entities affiliated with any of them, together will beneficially own approximately 63.5% of our common stock after this offering based on the
number of shares outstanding as of September&nbsp;30, 2016; the concentration of our capital stock ownership will likely limit your ability to influence corporate matters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the State of Delaware in November 2005. Our principal executive offices are located at 10421 Pacific Center Court, Suite 200, San Diego, California 92121, and our telephone number is (858)&nbsp;362-6295. Our website
address is www.anaptysbio.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into, this prospectus. Investors should not rely on any such information in deciding
whether to purchase our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mark &#147;AnaptysBio&#148; is our common law trademark. All other service marks, trademarks
and trade names appearing in this prospectus are the property of their respective owners. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.0 billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, enacted in April 2012. An &#147;emerging growth company&#148; may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These
provisions include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to present only two years of audited financial statements and only two years of related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use these provisions until the last day of our fiscal year following the fifth anniversary of the closing of this offering. However, if
certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.0 billion or we issue more than $1.0 billion of non-convertible debt in any three-year
period, we will cease to be an emerging growth company prior to the end of such five-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of
certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to
our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we
will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock offered by us </P></TD>
<TD>5,000,000 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares to be offered by us </P></TD>
<TD><BR>750,000 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock to be outstanding immediately after this offering </P></TD>
<TD><BR>19,159,333 shares (19,909,333 shares if the underwriters exercise their option to purchase additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Voting rights </P></TD>
<TD>Upon the closing of this offering, each outstanding share of our convertible preferred stock will automatically convert into one share of common stock. Each share of our common stock is entitled to one vote on all matters submitted to a vote of
stockholders, including the election of directors. See &#147;Description of Capital Stock.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $65.8&nbsp;million (or approximately $76.2&nbsp;million if the underwriters exercise their option to purchase additional shares in full), based upon the initial offering
price of $15.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>We intend to use the net proceeds that we receive in this offering for product discovery and development and general corporate purposes. We may use a portion of the proceeds to acquire other complementary businesses or technologies. See
&#147;Use of Proceeds&#148; for a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;ANAB.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 14,159,333
shares of our common stock outstanding as of September 30, 2016, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,856,750 shares of common stock issuable upon the exercise of options outstanding as of September 30, 2016, with a weighted-average exercise price of $4.13 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">221,953 shares of common stock issuable upon the exercise of options granted after September&nbsp;30, 2016, with a weighted-average exercise price of $11.31 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,378,570 shares of common stock reserved for future issuance under our stock-based compensation plans,
consisting of (a)&nbsp;513,407 shares of common stock reserved for future issuance under our 2006 Equity Incentive Plan as of September&nbsp;30, 2016, (b) 1,647,163&nbsp;shares of common stock reserved for
</P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
future issuance under our 2017 Equity Incentive Plan, which became effective on the date immediately prior to the date of this prospectus and (c) 218,000&nbsp;shares of common stock reserved for
future issuance under our 2017 Employee Stock Purchase Plan, which became effective on the date of this prospectus. Upon closing of this offering, any remaining shares available for issuance under our 2006 Equity Incentive Plan will be added to the
shares reserved under our 2017 Equity Incentive Plan and we will cease granting awards under our 2006 Equity Incentive Plan. Our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan also provide for automatic annual increases in the
number of shares reserved under the plans each year, as more fully described in &#147;Executive Compensation&#151;Employee Benefit and Stock Plans;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">117,483&nbsp;shares of our common stock issuable upon exercise of warrants for shares of common stock that were outstanding as of September 30, 2016, with an exercise price of $4.55 per share, that do not expire upon
the closing of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">294,779&nbsp;shares of common stock issuable upon the exercise of warrants to purchase shares of our Series C convertible preferred stock that were outstanding as of September&nbsp;30, 2016, with an exercise price of
$4.55 per share, that do not expire upon the closing of this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">82,416 shares of common stock issuable upon the exercise of warrants to purchase shares of our Series C convertible preferred stock issued after September 30, 2016, with an exercise price of $4.55 per share, that do not
expire upon the closing of this offering. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus assumes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all outstanding shares of our convertible preferred stock as of September&nbsp;30, 2016 into an aggregate of 11,520,698 shares of common stock immediately prior to the closing of this
offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a 7-for-1 reverse stock split of our common stock and convertible preferred stock, which was effected on January 13, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our restated certificate of incorporation in connection with the closing of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of outstanding stock options or warrants subsequent to September&nbsp;30, 2016; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the underwriters&#146; option to purchase additional shares. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our
existing stockholders and their affiliated entities, including stockholders affiliated with certain of our directors, have agreed to purchase an aggregate of 1,946,666 shares of our common stock in this offering at the initial public offering price.
</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary statements of operations data presented below for the years ended December&nbsp;31, 2014 and 2015 are derived from our audited
financial statements included elsewhere in this prospectus. The selected consolidated statements of operations data for the nine months ended September&nbsp;30, 2015 and 2016 and the summary consolidated balance sheet data as of September&nbsp;30,
2016 have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus. Our unaudited consolidated financial statements have been prepared on the same basis as our audited financial statements and, in the
opinion of management, reflect all adjustments, which consist only of normal recurring adjustments, necessary for the fair statement of those unaudited consolidated financial statements. The summary statements of operations data presented below for
the year ended December&nbsp;31, 2013 are derived from our audited financial statements not included in this prospectus. The following summary consolidated financial data should be read with &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in any future period.
The summary financial data in this section are not intended to replace the financial statements and are qualified in their entirety by the financial statements and related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands, except per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">8,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">8,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">17,304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">10,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">10,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">2,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">3,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">2,515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">3,378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">10,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">10,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">20,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">13,247</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">13,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,287</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,322</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(886</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,281</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(460</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,277</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(207</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(258</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(5,545</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">3,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(5,266</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">319</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(5,545</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(5,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net income (loss) per common share:(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Weighted-average number of shares outstanding:(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Pro forma net income (loss) per common share (unaudited):(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding (unaudited):(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note 2 to our audited consolidated financial statements for an explanation of the method used to calculate basic and diluted net income (loss) per common share, unaudited pro forma basic and diluted net loss per
common share and the weighted-average number of shares used in the computation of the per share amounts. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of</B><br><B>September&nbsp;30, 2016</B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma&nbsp;as</B><br><B>Adjusted(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, noncurrent portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,973</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma consolidated balance sheet data give effect to: (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock as of September&nbsp;30, 2016 into 11,520,698 shares of common
stock immediately prior to the closing of this offering and (ii)&nbsp;the conversion of the preferred stock warrants into common stock warrants and the related reclassification of the preferred stock warrant liability to additional paid-in capital.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted balance sheet data give effect to the pro forma adjustments and the sale of 5,000,000 shares of common stock by us in this offering, based on the initial public offering price of $15.00 per
share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted cash and cash equivalent amount also reflects the prepayment of approximately $2.5&nbsp;million of the estimated
offering expenses prior to September 30, 2016. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you
should carefully consider the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. We cannot assure you that any of
the events discussed below will not occur. These events could have a material and adverse impact on our business, results of operations, financial condition and cash flows. If that were to happen, the trading price of our common stock could decline,
and you could lose all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Discovery and Development of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial
viability.&nbsp;If we or our collaborators are unable to complete development of or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are using our proprietary technology platform to develop therapeutic antibodies, including our two lead wholly-owned product candidates,
ANB019 and ANB020, as well as other programs that are being developed by our collaborators. However, all of our wholly-owned and partnered product candidates are in the early stages of development, and, for a wide variety of reasons discussed below,
may fail in development or suffer delays that adversely affect their commercial viability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product candidate can unexpectedly fail at
any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical
testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our current product candidates, and any other product candidates we may develop in the future, will depend on many factors,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory permission to initiate clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful enrollment of patients in, and the completion of, our planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receiving marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enforcing and defending intellectual property rights and claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieving desirable therapeutic properties for our product candidates&#146; intended indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively competing with other therapies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could
experience significant delays or an inability to successfully commercialize our product candidates, which would harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs,
longer development times or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is
intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the
patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments for the relevant disease. We may not be able to initiate our planned clinical trials if
we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the U.S. Food and Drug Administration, or FDA, or foreign regulatory authorities. More specifically, some of our product
candidates, including ANB019, initially target indications that are very rare, which can prolong the clinical trial&nbsp;timeline for the regulatory process if sufficient patients cannot be enrolled in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have recently initiated dosing of ANB020 in humans and have never dosed any of our other wholly-owned product candidates in humans. Our ongoing and
planned clinical trials or those of our collaborators may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product
candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain marketing approval for any of our product candidates, we must demonstrate the safety and efficacy of
the product candidate for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. If our product candidates are associated with undesirable side effects in preclinical
studies or clinical trials or have characteristics that are unexpected, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have recently initiated our Phase
1 clinical trial for ANB020 and have not yet initiated any clinical trials or dosed any of our other wholly-owned product candidates in humans. We have conducted various preclinical studies of our product candidates, but we do not know the
predictive value of these studies for humans, and we cannot guarantee that any positive results in preclinical studies will successfully translate to human patients. It is not uncommon to observe results in human clinical trials that are unexpected
based on preclinical testing, and many product candidates fail in clinical trials despite promising preclinical results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that
believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. In our Phase 1 clinical trial of ANB020, the most common adverse events
were upper respiratory tract infection and headache, and the most severe was a reduction of white blood cell counts. No adverse events were determined to be drug related. Subjects in our ongoing and planned clinical trials may in the future suffer
significant adverse events or other side effects not observed in our preclinical studies or in our ongoing Phase 1 clinical trial. The observed potency and kinetics of our product candidates in preclinical studies may not be observed in human
clinical trials. We have tested the dosing frequency and route of administration of our product candidates in preclinical studies, which will inform our dosing strategy for future clinical trials, however such dose and route of administration may
not result in sufficient exposure or pharmacological effect in humans, and may lead to unforeseen toxicity not previously observed in preclinical testing. Further, if clinical trials of our product candidates fail to demonstrate efficacy to the
satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product
candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If further significant adverse events or other side effects are observed in any of our current or
future clinical trials, we may have difficulty recruiting patients to the clinical trial, patients may drop out of our trial, or we may be required to abandon the trial or our development efforts of that product candidate altogether. We, the FDA, or
other applicable regulatory authorities, or an Institutional Review Board, or IRB, may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable
health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their further
development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of
these developments could materially harm our business, financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if any of our product candidates
obtains marketing approval, toxicities associated with our product candidates may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional warnings being added to the labeling, significant
restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on
preclinical studies or early stage clinical testing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required
regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to commercialize and generate revenue from our product candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to continue to develop our product candidates, and to have the potential to achieve and sustain profitability, depends on the FDA
and foreign regulatory authorities permitting us to conduct human clinical trials and, if our products are safe and effective, obtaining approval from the FDA and foreign regulatory authorities to market them and subsequently successfully
commercializing them, either alone or with our collaborators. The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and foreign
regulatory authorities. Though we have cleared an IND and CTA to conduct clinical trials for ANB020 in the United States and United Kingdom, respectively, before commencing clinical trials in the United States for any other product candidate, we
must submit an IND to the FDA; foreign regulatory authorities enforce similar requirements for initiation of clinical trials in other countries. An IND or foreign equivalent requires extensive preclinical studies, and there is no guarantee that the
FDA or foreign regulatory authorities will allow clinical trials to proceed based on the IND or equivalent submission. For example, although we have initiated toxicology studies for our product candidates, the FDA in the United States, the TGA in
Australia or other foreign regulatory authorities, as applicable, may not allow our clinical trials to proceed in the regulatory authority&#146;s jurisdiction if we are unable to show safety margins acceptable to the particular regulatory authority
in appropriate animal species in our preclinical toxicology studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we or our collaborators initiate and complete clinical
trials for our product candidates, we will not be permitted to market our product candidates in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA, and will not be permitted to market in other
countries without marketing approval from foreign regulatory authorities. Obtaining approval of a BLA or other marketing approvals is often a lengthy, expensive and uncertain process over which the FDA and foreign regulatory authorities have
substantial discretion. Other than submitting and receiving acceptance for our CTN for ANB020 in Australia, obtaining clearance for our IND for a Phase 2a clinical trial of ANB020 in severe adult peanut allergy in the United States, obtaining
clearance for our CTA for a Phase 2a clinical trial of ANB020 in moderate-to-severe adult atopic dermatitis in the United Kingdom and submitting a CTN for ANB019 in Australia, we have not yet discussed with the FDA or foreign regulatory authorities
the development plans for any of our product candidates or the designs of any of our later-stage clinical studies. We thus may not have the full benefit of the FDA&#146;s or foreign regulatory authorities&#146; current thinking on trial designs or
product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development for our target indications. For example, although we believe a small pivotal trial, potentially with fewer than 100 patients, may be sufficient to demonstrate substantial evidence of
efficacy of ANB019 in generalized pustular psoriasis, or GPP, patients who have IL-36RA genetic mutations, we have not yet discussed clinical trial design for this indication with the FDA, and the FDA may disagree with our proposed trial design,
including the number of patients necessary to demonstrate efficacy and/or may require us to conduct more than one pivotal study in order to obtain approval of a BLA. In addition, with regard to ANB020, although we intend for our investigators for
our Phase 2a study to enroll only patients with severe adult peanut allergy, the protocol does not preclude enrollment of patients with non-severe adult peanut allergy. It is possible that our investigator could enroll patients with non-severe
peanut allergy, which could provide us with less information than anticipated with regard to ANB020&#146;s effect on severe peanut allergy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as
to outcome. Products, on average, take ten to 15 years to be developed from the time they are discovered to the time they are approved and available for treating patients. The start or end of a clinical trial is often delayed or halted for many
reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of a clinical hold for safety reasons or following an inspection of our clinical trial operations or site by the FDA or other regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing challenges; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient supply or quality of product candidates or other materials necessary to conduct clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and contract research organizations, or CROs, or failure by such CROs or
trials sites to carry out the clinical trial in accordance with our agreed-upon terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical sites electing to terminate their participation in one of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability or unwillingness of patients or medical investigators to follow our clinical trial protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">required clinical trial administrative actions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">slower than anticipated patient enrollment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changing standards of care; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safety concerns; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability or prevalence of use of a comparative drug or required prior therapy; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical outcomes or financial constraints. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates may not be effective, may
be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities may refuse to
accept any application or may decide that our data are insufficient for approval and require additional preclinical or other studies or clinical trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing
could delay, limit or prevent marketing approval of a product candidate. Moreover, regulatory authorities may determine that the clinical and other benefits of a product candidate do not outweigh the safety or other risks. Changes in marketing
approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may also cause delays in or prevent the approval of an
application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience any of the issues described above, or other similar or related issues, we may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain marketing approval at all; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain marketing approval in some countries and not in others; obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have the product removed from the market after obtaining marketing approval. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may not be successful in
our efforts to use and expand our technology platform to build a pipeline of product candidates and develop marketable products. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific
indications. Our business depends on our successful development and commercialization of the limited number of internal product candidates we have in preclinical and early-stage clinical development. Even if we are successful in continuing to build
our pipeline, development of the potential product candidates that we identify will require substantial investment in additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in multiple
jurisdictions, obtaining manufacturing supply capability, building a commercial organization, and significant marketing efforts before we generate any revenue from product sales. Furthermore, such product candidates may not be suitable for clinical
development, including as a result of their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we cannot validate
our technology platform by successfully developing and commercializing product candidates based upon our technological approach, we may not be able to obtain product or partnership revenue in future periods, which would adversely affect our
business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of our current focus on our lead product candidates, we
may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial
products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. Our understanding and evaluation of
biological targets for the discovery and development of new product candidates may fail to identify challenges encountered in subsequent preclinical and clinical development. If we do not accurately evaluate the commercial potential or target market
for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development
and commercialization rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have recently commenced clinical development of ANB020 and have no prior history of conducting clinical trials or
commercializing biotechnology products, which may make it difficult to evaluate the prospects for our future viability. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations
to date have been limited to financing and staffing our company, developing our technology and developing our two lead product candidates, ANB019 and ANB020, and other product candidates with and without our collaborators. Although we have recruited
a team that has experience with clinical trials in the United States, none of our employees have experience with clinical trials in Australia or the United Kingdom and, as a company, we have no experience conducting clinical trials in any
jurisdiction and have not had previous experience commercializing product candidates, including submitting an IND or a BLA to the FDA. We have only recently initiated our Phase 1 trial in Australia, and have not obtained marketing authorization from
foreign regulatory authorities. In part because of this lack of experience, we cannot be certain that planned clinical trials will begin or be completed on time, if at all, that our planned development programs would be acceptable to the FDA or
other regulatory authorities, or that, if approval is obtained, such product candidates can be successfully </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialized. Clinical trials and commercializing our wholly-owned product candidates will require significant additional financial and management resources, and reliance on third-party
clinical investigators, CROs, consultants or collaborators. Relying on third-party clinical investigators, CROs or collaborators may result in delays that are outside of our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we may not have the financial resources to continue development of, or to enter into collaborations for, a product candidate if
we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or
clinical trials or abandon a program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial
once commenced; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions imposed by the FDA or foreign regulatory authorities regarding the number, scope or design of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in enrolling research subjects in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">high drop-out rates of research subjects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inadequate supply or quality of clinical trial materials or other supplies necessary for the conduct of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater than anticipated clinical trial costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">poor effectiveness or unacceptable side effects of our product candidates during clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">serious and unexpected drug-related side effects experienced by participants in our planned clinical trials or by individuals using drugs similar to our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">varying interpretations of data by the FDA and foreign regulatory authorities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently,
any predictions you make about our future success or viability based on our short operating history may not be as accurate as they could be if we had a longer operating history or an established track record in conducting clinical trials or
commercializing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other
known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product
candidates, our commercial opportunities will be negatively impacted. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology industry is highly competitive and subject to
rapid and significant technological change. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical and biotechnology companies, established
biotechnology companies, specialty biotechnology companies, emerging and start-up companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development,
technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing
biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our
target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could
make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or approval from the FDA or foreign regulatory authorities or discovering, developing and
commercializing products in our field before we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For asthma, our competitors include omalizumab (Xolair; Roche) which has received FDA
approval and functions by inhibiting the binding between free IgE and FceRI; antibodies that bind IL-5 and inhibit its interaction with the IL-5 receptor such as mepolizumab (Nucala; Glaxosmithkline), which the FDA recently approved for the add-on
maintenance treatment in patients aged 12 years or older with severe eosinophilic asthma, and reslizumab (Teva), which the FDA&#146;s Pulmonary-Allergy Drugs Advisory Committee recommended for approval in adult patients aged 18 years and older for
the treatment of inadequately controlled asthma in patients with elevated eosinophils, despite an inhaled corticosteroids treatment regimen; antibodies such as benralizumab (AstraZeneca) that bind the IL-5 receptor; antibodies that bind to IL-13
such as lebrikizumab (Roche), tralokinumab (AstraZeneca) and anrukinzumab (Pfizer), which are in clinical testing; antibodies that bind the IL-4 receptor alpha chain, such as dupilumab (Regeneron) and AMG 317 (Amgen) each in clinical testing, an
ST2-binding antibody which Roche has in-licensed from Amgen (previously known as AMG 282) and plans to advance into Phase 2 clinical trials, and CNTO 7160, which is another ST2-binding antibody that GSK in-licensed from Janssen. For peanut allergy,
our competitors include DBV Technologies, which is developing transdermal products for tolerization of food allergies, while Aimmune Therapeutics is developing oral products for peanut allergy desensitization. For atopic dermatitis, our competitors
include dupilumab (Regeneron, Sanofi), which has recently been filed for approval by the FDA, crisaborole (Anacor, Pfizer), which has recently been filed for approval by the FDA, and VTP-38543 (Vitae), which is currently in a Phase 2 trial. For GPP
and PPP, our competitors include marketed therapies such as secukinumab (Cosentyx; Novartis) which binds IL-17A; ustekinumab (Stelara; Janssen) which blocks IL-12 and 23 cytokine function; and acitretin (Soriatane; Glaxosmithkline), as well as
therapies in development such as guselkumab (Janssen) which blocks IL-23 cytokine function, gevokizumab (Xoma 052) which binds IL-1 beta and BI-655130 (Boehringer Ingelheim). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, an abbreviated pathway for the approval of
biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as
interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product is approved under a biologics license
application, or BLA. To date, only a handful of biosimilar products have been approved under the BPCIA. However, the law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and
meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that if any of our product candidates are approved as a biological product under a BLA it should qualify for the
12-year period of exclusivity. However, there is a risk that the FDA will not consider any of our product candidates to be reference products for competing products, potentially creating the opportunity for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biosimilar competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional BLA, rather
than via the abbreviated pathway. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not
yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could
be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, are less expensive or capture significant market share prior to or during our
commercialization. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able
to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Even if our product candidates achieve marketing approval, they may
be priced at a significant premium over competitive biosimilar products if any have been approved by then. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller and other early stage
companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for planned clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biotechnology industry is characterized by rapid
technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete,
less competitive or not economical. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors
and others in the medical community necessary for commercial success. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our product candidates receive regulatory approval, they
may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety profile as demonstrated in planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of the product candidate as well as competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product candidate is approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the use of our products, if approved, such as boxed warnings or contraindications in labeling, or a risk evaluation and mitigation strategy, or REMS, if any, which may not be required of alternative
treatments and competitor products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the product candidate as a safe and effective treatment by physicians, clinics and patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of product candidates over alternative treatments, including any similar generic treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment in relation to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the frequency and severity of adverse events; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of sales and marketing efforts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable publicity relating to the product candidate. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any product candidate is approved but does not achieve an adequate level of acceptance by
physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If companion diagnostics for our product candidates for which such diagnostics are required, are not successfully, and in a timely manner, validated,
developed or approved, we may not achieve marketing approval or realize the full commercial potential of our product candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
companion diagnostics are developed in conjunction with clinical programs, the FDA may require regulatory approval of a companion diagnostic as a condition to approval of the product candidate. For example, if we use a genetic test to determine
which patients are most likely to benefit from ANB019 for the treatment of GPP or PPP by designing our pivotal trial or trials of ANB019 in that indication to require that subjects test positive for specific genetic mutations as a criterion for
enrollment, then we will likely be required to obtain FDA approval or clearance of a companion diagnostic, concurrent with approval of ANB019, to test for those genetic mutations; we may also be required to demonstrate to the FDA the predictive
utility of the companion diagnostic&#151;namely, that the diagnostic selects for patients in whom the biologic therapy will be effective or more effective compared to patients not selected for by the diagnostic. We do not have experience or
capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. We do not currently have any agreement in place with any third party to develop or commercialize companion
diagnostics for any of our product candidates. Companion diagnostics are subject to regulation by the FDA and foreign regulatory authorities as medical devices and require separate regulatory approval prior to commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our partners, or any third party, are unable to successfully develop companion diagnostics for our product candidates, or experience
delays in doing so: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of our product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our planned clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific genetic alterations
targeted by our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, although we believe genetic testing is becoming more prevalent in the
diagnosis and treatment of various diseases and conditions, our product candidates may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either due to the additional cost of the
companion diagnostic or the need to complete additional procedures to identify genetic markers prior to administering our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events were to occur, our business would be harmed, possibly materially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The manufacture of biologics is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers
encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or
stopped. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of manufacturing biologics is complex, highly-regulated and subject to multiple risks. Manufacturing biologics is
highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the
production process. Even minor deviations from normal manufacturing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at the facilities of our
manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our manufacturer
is not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny BLA approval until the deficiencies are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost
overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we or our collaborators obtain regulatory
approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to
meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be
impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scaling up
a biologic manufacturing process is a difficult and uncertain task, and we may not be successful in transferring our production system or the manufacturer may not have the necessary capabilities to complete the implementation and development
process. If we are unable to adequately validate or scale-up the manufacturing process with our current manufacturer, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are
able to adequately validate and scale-up the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we
will be able to come to agreement on terms acceptable to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Capital Needs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for
commercial sale, and to date we have not generated any revenue or profit from product sales. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an early-stage biotechnology
company with a limited operating history. We have no approved products and none of our product candidates have progressed to clinical development. To date, our revenue has been primarily derived from our research collaboration and license agreements
with third parties, including TESARO, Inc. and TESARO Development, Ltd., or collectively, TESARO, and Celgene Corporation, or Celgene, and we are significantly dependent on such collaborators for the successful development of product candidates in
these collaborations. Our ability to generate revenue and become profitable depends upon our ability, alone or with our collaborators, to successfully complete the development of our product candidates for our target indications and to obtain
necessary regulatory approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant operating losses in every year except fiscal year 2014
and during the nine months ended September 30, 2016. Our collaboration revenue was $15.8 million and our net income was $3.5 million for the year ended December&nbsp;31, 2014 and our collaboration revenue was $17.6 million and our net loss was $5.4
million for the year ended December&nbsp;31, 2015. For the nine months ended September&nbsp;30, 2016, our collaboration revenue was $13.9 million and our net income was $0.3 million. As of September&nbsp;30, 2016, we had an accumulated deficit of
$50.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our operations primarily through private placements of our preferred stock and the issuance of debt.
We have devoted substantially all of our efforts to research and development. We have not initiated clinical development of any product candidates and expect that it will be many years, if ever, before we have a product candidate ready for
commercialization. We expect to continue to incur significant expenses and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increasing operating losses for the foreseeable future, and the net losses we incur may fluctuate significantly from quarter to quarter. Our revenue has been historically derived from
amortization of upfront payments, research and development funding and milestone payments under collaboration and license agreements with our collaborators. Our ability to generate future product revenue from our current or future product candidates
depends on a number of additional factors, including our or our collaborators&#146; ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our research and preclinical development of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain existing and enter into new collaboration agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct additional preclinical studies and initiate clinical trials for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approvals for the product candidates we develop or developed under our collaboration arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional executive, clinical, quality control and scientific personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of our products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain coverage and adequate product reimbursement from third-party payors, including government payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or in-license other product candidates and technologies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieve market acceptance for our or our collaborators&#146; products, if any. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable
to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability because of the numerous risks and uncertainties associated with product development. In addition, our expenses could increase
significantly beyond expectations if we are required by the FDA or other regulatory authorities to perform studies or trials in addition to those that we currently anticipate. Even if ANB019 and ANB020, or any of our other product candidates, are
approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of any product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently only in the preclinical development stages for our most advanced product candidates. If we do achieve profitability, we may
not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain or expand our research and
development efforts, expand our business or continue our operations. A decline in the value of our company would also cause you to lose part or even all of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not
complete the development and commercialization of our product candidates or develop new product candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a research and
development company, our operations have consumed substantial amounts of cash since our inception. We expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we continue our
discovery and preclinical development to identify new clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, and we and our collaborators initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product
candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating
as a public company. We believe that the net proceeds from this offering, together with our existing cash and cash equivalents and funding we expect to receive under existing collaboration agreements, will fund our projected operating requirements
through at least the next 24 months. However, circumstances may cause us to consume capital more rapidly than we currently anticipate. For example, as we continue to move our product candidates through preclinical studies, submit INDs or foreign
equivalents and commence clinical development we may have adverse results requiring us to find new product candidates, or our collaborators may not elect to pursue the development and commercialization of any of our product candidates that are
subject to their respective agreements with us. Any of these events may increase our development costs more than we expect. We may need to raise additional funds or otherwise obtain funding through product collaborations to continue development of
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we need to secure additional financing, such additional fundraising efforts may divert our management from our
day-to-day activities, which may adversely affect our ability to develop and commercialize future product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at
all. If we do not raise additional capital when required or on acceptable terms, we may need to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significantly delay, scale back or discontinue the development or commercialization of any product candidates or cease operations altogether; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek strategic alliances for research and development programs at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relinquish, or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate staff to conserve resources. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we need to conduct additional fundraising
activities and we do not raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating
results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our forecast of the period of time through which our financial resources will adequately support our operations is
a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#147;Risk Factors&#148; section. We have based this estimate on
assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both short and long-term, will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates and future product candidates we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and size of clinical trials needed to show safety, efficacy and an acceptable risk/benefit profile for any of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and foreign regulatory authorities, including the potential for such authorities to require that we perform more studies or trials
than those that we currently expect; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain existing and enter into new collaboration agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to establish, maintain, expand and defend the scope of our intellectual property portfolio, including
the amount and timing of any payments we may be required to make, or that we may receive, in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
connection with licensing, preparing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing technological and market developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market acceptance of any approved product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of recruiting and retaining key employees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of selecting, auditing and potentially validating a manufacturing site for commercial-scale manufacturing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of establishing sales, marketing and distribution capabilities for our product candidates for which we may receive regulatory approval and that we determine to commercialize ourselves or in collaboration with
our collaborators. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a lack of available capital means that we cannot expand our operations or otherwise capitalize on our
business opportunities, our business, financial condition and results of operations could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Raising additional capital may cause
dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources,
including up-front payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the
terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations, or other restrictions
that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant
licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Managing Growth, Operations and Macroeconomic Conditions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We must attract and retain highly skilled employees in order to succeed. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face
significant competition for experienced personnel. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan, harm our operating
results and increase our capabilities to successfully commercialize our product candidates. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner.
The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement
personnel. In addition, certain members of our senior management team, including our Chief Financial Officer, who joined us in January 2017, have worked together for only a relatively short period of time and it may be difficult to evaluate their
effectiveness, on an individual or collective basis, and ability to address future challenges to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the other
biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we
are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates and our business will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We currently have no marketing and sales force. If we are unable to establish effective sales or marketing capabilities or enter into agreements with third
parties to sell or market our product candidates, we may not be able to effectively sell or market our product candidates, if approved, or generate product revenue. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able to
obtain regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to
perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with technical expertise and supporting distribution capabilities
to commercialize our product candidates, which will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution
capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market. With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either
globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution
systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may
experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant
additional losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our
growth, which could disrupt our operations. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the scope of
our operations, particularly in the areas of product candidate development and growing our capability to conduct clinical trials. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and
financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth,
we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development
resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We conduct significant operations
through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of
operations will suffer. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, we formed a wholly-owned Australian subsidiary, AnaptysBio Pty Ltd, or AnaptysBio Pty, to
develop and commercialize our ANB019 and ANB020 antibody program in Australia. Due to the geographical distance and lack of employees currently in Australia, as well as our lack of experience operating in Australia, we may not be able to efficiently
or successfully monitor, develop and commercialize our lead products or antibody program in Australia, including conducting clinical trials. Furthermore, we have no assurance that the results of any clinical trials that we conduct for our product
candidates in Australia will be accepted by the FDA or foreign regulatory authorities for development and commercialization approvals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, current Australian tax regulations provide for a refundable research and development
tax credit equal to 45.0% of qualified expenditures. If we lose our ability to operate AnaptysBio Pty in Australia, or if we are ineligible or unable to receive the research and development tax credit, or the Australian government significantly
reduces or eliminates the tax credit, our business and results of operation would be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The manufacture of biotechnology products is
complex and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter any loss of our master cell banks or if any of our third-party manufacturers encounter other difficulties, or otherwise
fail to comply with their contractual obligations, our ability to provide product candidates for clinical trials or our products to patients, once approved, the development or commercialization of our product candidates could be delayed or stopped.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacture of biotechnology products is complex and requires significant expertise and capital investment, including the
development of advanced manufacturing techniques and process controls. We and our contract manufacturers must comply with current good manufacturing practices, or cGMP, regulations and guidelines for the manufacturing of biologics used in clinical
trials and, if approved, marketed products. To date, neither we nor our contract manufacturers has manufactured or attempted to manufacture cGMP batches of our products. Manufacturers of biotechnology products often encounter difficulties in
production, particularly in scaling up and validating initial production. Furthermore, if microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing
facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Delays in raw materials availability and supply may also extend the period of time required to develop our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our therapeutic antibodies are manufactured by starting with cells which are stored in a cell bank. We have one master cell bank for
each antibody manufactured in accordance with cGMP and multiple working cell banks and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we could lose multiple cell banks and
have our manufacturing severely impacted by the need to replace the cell banks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that any stability or other issues
relating to the manufacture of any of our product candidates or products will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable
political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide any product candidates to patients in planned clinical trials and
products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial
programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product
candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and
incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of
our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products and could have an adverse effect on our business, prospects, financial condition and results
of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may be vulnerable to disruption, damage and financial obligation as a result of system failures. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, any of the internal computer systems belonging to us, our collaborators or our third-party
service providers are vulnerable to damage from computer viruses, unauthorized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
access, natural disasters, terrorism, war and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our own, in
collaborators&#146; or in third-party service vendors&#146; operations could result in a material disruption of our drug discovery and development programs. For example, the loss of clinical trial data from completed or future clinical trials could
result in delays in our or our collaborators&#146; regulatory approval efforts and significantly increase our costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss or damage to
our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability as a result, our drug discovery programs and competitive position may be adversely affected and the further development of our
product candidates may be delayed. Furthermore, we may incur additional costs to remedy the damages caused by these disruptions or security breaches. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our operations are vulnerable to interruption by fire, earthquake, power loss, telecommunications failure, terrorist activity and other events beyond our
control, which could harm our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our facility is located in a seismically active region, which has also historically been
subject to electrical blackouts as a result of a shortage of available electrical power. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major earthquake, fire, power loss,
terrorist activity or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or
damages incurred by us could harm our business. We maintain multiple copies of each of our antibody sequences and electronic data records, most of which we maintain at our headquarters. If our facility was impacted by a seismic event, we could lose
all our antibody sequences, which would have an adverse effect on our ability to perform our obligations under our collaborations and discover new targets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
existing collaborations, including those with TESARO and Celgene, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not
successful, our business could be adversely affected. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into collaborations with other biotechnology companies to
develop several of our product candidates, and such collaborations currently represent a significant portion of our product pipeline. In addition, we have entered into other collaborations pursuant to which we have provided access to our technology
platform to our collaborators to enable the optimization of their own product candidates. We have entered into antibody generation and/or development collaborations with various collaborators, including TESARO and Celgene, under which we have
generated therapeutic quality antibodies using our technology platform and conducted certain preclinical studies in collaboration. These collaborations have provided us with $65.4&nbsp;million in non-dilutive funding through December 31, 2016. We
are currently aware that TESARO and Celgene are advancing multiple antibodies generated through our collaboration to clinical trials. If our collaborators terminate any of our collaborations, we may not receive all or any of this funding, which
would adversely affect our business or financial condition. Other than TESARO, our operational obligations under each of our collaborations has ended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable to predict the success of our collaborations. Our collaborators have discretion in determining and directing the efforts and
resources, including the ability to discontinue all efforts and resources, they apply to the development and, if approval is obtained, commercialization and marketing of the product candidates covered by such collaborations. As a result, our
collaborators may elect to de-prioritize our programs, change their strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to us. Our collaborators may have other marketed products and product
candidates under collaboration with other companies, including some of our competitors, and their corporate objectives may not be consistent with our best interests. Our collaborators may also be unsuccessful in developing or commercializing our
products. If our collaborations are unsuccessful, our business, financial condition, results of operations and prospects could be adversely affected. In addition, any dispute or litigation proceedings we may have with our collaborators in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future could delay development programs, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate substantial expense.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may not succeed in establishing and maintaining additional development collaborations, which could adversely affect our ability to develop and
commercialize product candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our current licensing arrangements with TESARO and Celgene, a part of our strategy is
to enter into additional strategic product development collaborations in the future, including collaborations to broaden and accelerate clinical development and potential commercialization of our product candidates. We may face significant
competition in seeking appropriate development partners and the negotiation process is time-consuming and complex. Moreover, we may not succeed in our efforts to establish a development collaboration or other alternative arrangements for any of our
other existing or future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and/or
third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. Even if we are successful in our efforts to establish new development collaborations, the terms that we agree upon
may not be favorable to us and we may not be able to maintain such development collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in
entering into new development collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, if we fail to establish and maintain additional development collaborations related to our product candidates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of certain of our current or future product candidates may be terminated or delayed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our cash expenditures related to development of certain of our current or future product candidates would increase significantly and we may need to seek additional financing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to hire additional employees or otherwise develop expertise, such as sales and marketing expertise, for which we have not budgeted; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will bear all of the risk related to the development of any such product candidates. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If third parties
on which we depend to conduct our planned preclinical studies, or any future clinical trials, do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be
delayed with adverse effects on our business, financial condition, results of operations and prospects. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third party
clinical investigators, contract research organizations, or CROs, clinical data management organizations, or CMOs, and consultants to design, conduct, supervise and monitor preclinical studies of our product candidates and will do the same for any
clinical trials. Because we rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials
than we would if we conducted them on our own. These investigators, CROs, CMOs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have
contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties we contract with might not be diligent, careful or timely in conducting our preclinical
studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot contract
with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for
ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Our reliance on third parties that we do not control does not relieve us of these
responsibilities and requirements. Any such event could have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we may receive for our product candidates will require surveillance to monitor the safety and efficacy of the
product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the
FDA may require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event
reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing
information and reports, registration, as well as continued compliance with cGMPs and good clinical practices, or GCPs, for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are
subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse
events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal
of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and foreign regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially
imposed sanctions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the products, manufacturers or manufacturing process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">civil and criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizures, detentions or import bans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voluntary or mandatory product recalls and publicity requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">total or partial suspension of production; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of restrictions on operations, including costly new manufacturing requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending BLAs or supplements to approved BLAs. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event
or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advertising and promotion of any product candidate that obtains approval in the United States
will be heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human Services&#146; Office of Inspector General, state attorneys general, members of Congress and the public. Violations, including promotion of our
products for unapproved (or off-label) uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the government. Additionally, comparable foreign regulatory authorities will heavily scrutinize
advertising and promotion of any product candidate that obtains approval outside of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, engaging in
the impermissible promotion of our products for off-label uses can also subject us to false claims litigation under federal and state statutes, which can lead to civil and criminal penalties and fines and agreements that materially restrict the
manner in which a company promotes or distributes drug products. These false claims statutes include the federal False Claims Act, which allows any individual to bring a lawsuit against a biotechnology company on behalf of the federal government
alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government prevails in the lawsuit, the individual will share in any
fines or settlement funds. Since 2004, these False Claims Act lawsuits against biotechnology companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements regarding certain sales
practices promoting off-label drug uses involving fines in excess of $1.0 billion. This growth in litigation has increased the risk that a biotechnology company will have to defend a false claim action, pay settlement fines or restitution, agree to
comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid and other federal and state healthcare programs. If we do not lawfully promote our approved products, we may become subject to such litigation and,
if we do not successfully defend against such actions, those actions may have an adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous
and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval
process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will
approve the product for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of
our products in certain countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with the regulatory requirements in international markets and receive applicable
marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a
timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects could
decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have conducted, or plan to conduct, our initial clinical trials for ANB020 and ANB019 outside of the United States. However, the FDA and
other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted our initial clinical trial for ANB020 in Australia and plan to conduct our initial clinical trial for ANB019 in Australia. We
believe that clinical data generated in Australia will be accepted by the FDA and its foreign equivalents outside of Australia, and therefore may enable us to commence Phase 2 and possibly registration clinical trials in the United States or the
United Kingdom following submission of an IND or CTA, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without the need for us to repeat our Phase 1 trials in the United States or the United Kingdom. While we have received clearance from the FDA and MHRA to begin Phase 2 clinical trials for
ANB020, there can be no assurance the FDA, MHRA or other foreign equivalents will accept data from the clinical trials we plan to conduct in Australia for ANB019. If the FDA, MHRA or other foreign equivalents do not accept any such data, we would
likely be required to conduct additional Phase 1 clinical trials, which would be costly and time consuming, and delay aspects of our development plan, which could harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the FDA, MHRA and other foreign equivalents may accept data from clinical trials conducted entirely outside the United States and not
under an IND, acceptance of such study data is generally subject to certain conditions. For example, the FDA requires the clinical trial to have been conducted in accordance with GCPs and the FDA must be able to validate the data from the clinical
trial through an onsite inspection if it deems such inspection necessary. In addition, when studies are conducted only at sites outside of the United States, the FDA generally does not provide advance comment on the clinical protocols for the
studies, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a non-U.S. clinical trial was inadequate, which would likely require us to conduct additional clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional foreign regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign exchange fluctuations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with foreign manufacturing, customs, shipment and storage requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cultural differences in medical practice and clinical research; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diminished protection of intellectual property in some countries. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in June 2016,
the United Kingdom held a referendum and voted in favor of leaving the European Union. This has created political and economic uncertainty, particularly in the United Kingdom and the European Union, and could cause disruptions to, and create
uncertainty surrounding, our planned clinical trial in the United Kingdom, including affecting our relationships with our existing and prospective customers, partners and employees, and could have a material impact on the regulatory regime
applicable to our planned clinical trial in the United Kingdom. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We plan to seek Orphan Drug Designation for ANB019 or certain of our other product
candidates and we&nbsp;may not&nbsp;be able to obtain or maintain&nbsp;Orphan Drug Designation&nbsp;or obtain the benefits associated with Orphan Drug status, including market exclusivity. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to seek Orphan Drug Designation for ANB019 or certain of our other product candidates. Regulatory authorities in some jurisdictions,
including the United States and the European Union, or EU, may designate biologics for relatively small patient populations as Orphan Drugs. Under the Orphan Drug Act, the FDA may designate a biologic as an Orphan Drug if it is intended to treat a
rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. Generally, if a biologic with an Orphan Drug Designation subsequently receives the first marketing approval for the
indication for which it has such designation, the biologic is entitled to a period of marketing exclusivity, which precludes the FDA, in the United States, or the European Medicines Agency, or EMA, in the EU, from approving another marketing
application for a drug containing the same active moiety for the same indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The EU exclusivity period can be reduced to six
years if a biologic no longer meets the criteria for Orphan Drug Designation or if the biologic is sufficiently profitable so that market exclusivity is no longer justified. Orphan Drug exclusivity may be lost if the FDA or EMA determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. In addition, the Orphan Drug Designation does not convey
any advantage in, or shorten the duration of, the regulatory review or approval process. Also, regulatory approval for any product candidate may be withdrawn and other candidates may obtain approval before us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not applied for Orphan Drug Designation&nbsp;for ANB019 for any indication, and&nbsp;may
not&nbsp;be able to obtain designation or any of the potential benefits associated with it. For example, we plan to seek FDA Orphan Drug Designation for ANB019 for the treatment of GPP and PPP, which will likely require that we demonstrate to FDA
that GPP and PPP are distinct diseases from psoriasis generally (a non-rare disease) or that use of ANB019 may be appropriate for the treatment of GPP and PPP but not appropriate for use in the general psoriasis population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain Orphan Drug Designation, we may not receive Orphan Drug exclusivity, and such exclusivity, if obtained, may not effectively
protect the candidate from competition because different drugs or biologics can be approved for the same condition and only the first biologic with an Orphan Drug Designation to receive regulatory approval for a particular indication will receive
marketing exclusivity. Even after a drug or biological with Orphan Drug Designation is approved, the FDA can subsequently approve another biologic containing the same active moiety (which in the case of an antibody is the principal molecular
structure) for the same condition if the FDA concludes that the later biologic is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any drugs we develop may become subject to unfavorable third-party reimbursement practices and pricing regulations. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and extent of coverage and adequate reimbursement by governmental and private payors is essential for most patients to be able
to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be paid
by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is
not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or
maintain pricing sufficient to realize a sufficient return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not
available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the
principal decisions about reimbursement for new products are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services because CMS decides whether and to what
extent a new product will be covered and reimbursed under Medicare. Private payors often follow CMS&#146;s decisions regarding coverage and reimbursement to a substantial degree. However, one payor&#146;s determination to provide coverage for a drug
product does not assure that other payors will also provide coverage for the drug product. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support
for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are
challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost effectiveness of medical drug products. There may be especially significant
delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific drug products on an approved list, known as a formulary, which might not include all FDA approved drugs for a particular
indication. We or our collaborators may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or
cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive
governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics
such as our product candidates. In many countries, particularly the countries of the European Union, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing
negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares
the cost-effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for
products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United
States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare
costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in
connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in
general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to CMS and private payors, professional organizations such as the American Medical Association, or AMA, can influence decisions
about reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement
for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, some of our target indications, including for GPP, are rare diseases with small patient populations. In order for therapeutics
that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such therapeutics must be higher, on a relative basis to account for the low volume of sales. Accordingly, we will need to implement a coverage
and reimbursement strategy for any approved product candidate that accounts for the smaller potential market size. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to
establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to
market or sell those product candidates, if approved. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our
collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently enacted
legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and/or affect our ability to profitably sell any product candidates for which we obtain marketing
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Affordability Reconciliation Act, or collectively the ACA, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the
healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the provisions of the ACA of importance to our potential product candidates are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for a manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to report certain financial arrangements with physicians and teaching hospitals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may face difficulties from changes to current regulations and future legislation. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt
to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain
profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More recently, President Donald Trump has made statements that suggest he plans to seek repeal of all or portions of the
ACA, and has stated that he will ask Congress to replace the current legislation with new legislation. There is uncertainty with respect to the impact President Trump&#146;s Administration may have, if any, and any changes likely will take time to
unfold, and could have an impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by the ACA. However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation
or the impact of potential legislation on us. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal
year, effective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
April&nbsp;1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2025 unless additional Congressional action is taken. In January 2013, President Obama signed into
law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five
years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Likewise, the annual Medicare Physician Fee Schedule update, which, until recently, was based on a target-setting formula system called the
Sustainable Growth Rate, or SGR, was adjusted to reflect the comparison of actual expenditures to target expenditures. Because one of the factors for calculating the SGR was linked to the growth in the U.S. gross domestic product, or GDP, the SGR
formula often resulted in a negative payment update when growth in Medicare beneficiaries&#146; use of services exceeded GDP growth.&nbsp;Congress repeatedly intervened to delay the implementation of negative SGR payment updates.&nbsp;For example,
on April&nbsp;1, 2014, with the enactment of the Protecting Access to Medicare Act of 2014, Congress prevented the 24 percent cut that was to occur by continuing the previously implemented 0.5 percent payment increase through December&nbsp;31, 2014
and maintaining a zero percent payment update from January&nbsp;1, 2015 through March&nbsp;31, 2015.&nbsp;However, on April&nbsp;14, 2015, Congress passed the Medicare Access and CHIP Reauthorization Act of 2015, which was signed into law by
President Obama on April&nbsp;16, 2015.&nbsp;This law repeals the SGR methodology from the physician payment formula, institutes a 0% update to the Medicare Physician Fee Schedule for the January&nbsp;1 to July&nbsp;1, 2015 period, a 0.5% payment
update for July 2015 through the end of 2019, and a 0% payment update for 2020 through 2025, along with a merit-based incentive payment system beginning January&nbsp;1, 2019, that will replace current incentive programs. For 2026 and subsequent
years, the payment update will be either 0.75% or 0.25%, depending on which Alternate Payment Model the physician participates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect
that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in
reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability, or commercialize our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand
post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed,
or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval,
as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our business entails a significant risk of
product liability and our ability to obtain sufficient insurance coverage could have an adverse effect on our business, financial condition, results of operations or prospects. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic
treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our
manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of
approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#146;s time and our
resources, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of
development and may need to obtain higher levels prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product
liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other
healthcare laws and regulations, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we
obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and
relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind,
to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities
for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal
government; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare
benefit program or making false statements relating to healthcare matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding
the privacy, security and transmission of individually identifiable health information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s
Health Insurance Program, with specific exceptions, to report to CMS annually information regarding payments and other transfers of value to physicians and teaching hospitals as well as information regarding ownership and investment interests help
by physicians and their immediate family members. The information was made publicly available on a searchable website in September 2014 and will be disclosed on an annual basis; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by
non-governmental third-party payors, including private insurers. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some state laws require biotechnology companies to comply
with the biotechnology industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of
value to physicians </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each
other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our current
and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply
with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that
may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare
and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant
financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities
with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider
trading. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply
with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In
particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations
may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in
the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We intend to adopt a code of conduct prior to the closing of this offering, but it is not always possible to identify and deter employee
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the
imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our market. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in significant part on our and our licensors&#146;, licensees&#146; or collaborators&#146; ability to establish, maintain
and protect patents and other intellectual property rights and operate without infringing the intellectual property rights of others. We have filed numerous patent applications both in the United States and in foreign jurisdictions to obtain patent
rights to inventions we have discovered. We have also licensed from third parties rights to patent portfolios. Some of these licenses give us the right to prepare, file and prosecute patent applications and maintain and enforce patents we have
licensed, and other licenses may not give us such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive and time-consuming, and we and our
current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in
the course of development and commercialization activities before it is too late to obtain patent protection on them. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent
applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors, licensees or collaborators. Therefore, these patents and applications may not be prosecuted and enforced
in a manner consistent with the best interests of our business. If our current or future licensors, licensees or collaborators fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or
eliminated. If our licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent
years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#146;, licensees&#146; or collaborators&#146; patent rights are highly uncertain.
Our and our licensors&#146;, licensees&#146; or collaborators&#146; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from
commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our licensors&#146;, licensees&#146; or collaborators&#146;
pending and future patent applications, which may limit the scope of patent protection that may be obtained. In the past, we have not always been able to obtain the full scope of patent protection we have initially sought in our patent applications,
and as described above and as is typical for most biotechnology patent prosecution, we have been required to narrow or eliminate patent claims as part of the patent prosecution process.&nbsp;In addition, some patent applications that we or our
licensors have filed have not resulted in issued patents because we or our licensors have abandoned those patent applications as changes in business and/or legal strategies dictated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such
prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may an initiate opposition,
interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in
the patent claims being narrowed or invalidated. Our and our licensors&#146;, licensees&#146; or collaborators&#146; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until
a patent issues from such applications, and then only to the extent the issued claims cover the technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications
in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to a product
candidate. Furthermore, if third parties have filed such patent applications on or before March&nbsp;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the
subject matter covered by the patent claims of our applications. If third parties have filed such applications after March&nbsp;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our
invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date
or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S.
filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to
competition from competitive medications, including biosimilar or generic medications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, given the amount of time required for the development, testing and regulatory review
of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others
from commercializing products similar or identical to ours. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition
and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of the patent. However the applicable authorities, including the FDA and the U.S. Patent and Trademark Office, or USPTO, in the
United States, and any equivalent foreign regulatory authority, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If
this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may not be able to protect our intellectual property rights throughout the world. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively
expensive, and our or our licensors&#146; or collaborators&#146; intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In addition, the laws of
some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors or collaborators may not be able to prevent third parties from practicing our
and our licensors&#146; or collaborators&#146; inventions in all countries outside the United States, or from selling or importing products made using our and our licensors&#146; or collaborators&#146; inventions in and into the United States or
other jurisdictions. Competitors may use our and our licensors&#146; or collaborators&#146; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where we and our licensors or collaborators have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our and our licensors&#146; or
collaborators&#146; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of
patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us and our licensors or collaborators to stop the infringement of our and our licensors&#146; or collaborators&#146;
patents or marketing of competing products in violation of our and our licensors&#146; or collaborators&#146; proprietary rights generally. Proceedings to enforce our and our licensors&#146; or collaborators&#146; patent rights in foreign
jurisdictions could result in substantial costs and divert our and our licensors&#146; or collaborators&#146; efforts and attention from other aspects of our business, could put our and our licensors&#146; or collaborators&#146; patents at risk of
being invalidated or interpreted narrowly and our and our licensors&#146; or collaborators&#146; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors or collaborators. We or our
licensors or collaborators may not prevail in any lawsuits that we or our licensors or collaborators initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biopharmaceutical industry involve technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and inherently uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our licensors&#146; or
collaborators&#146; patent applications and the enforcement or defense of our or our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licensors&#146; or collaborators&#146; issued patents. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a
number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An important change introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned to a &#147;first-to-file&#148;
system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us
could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent
application, but circumstances could prevent us from promptly filing patent applications on our inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other
changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those
issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide
evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use
the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The Leahy-Smith Act and its implementation could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USPTO recently
developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and, in particular, the first to file provisions, only became effective
on March&nbsp;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the
prosecution of our or our licensors&#146; or collaborators&#146; patent applications and the enforcement or defense of our or our licensors&#146; or collaborators&#146; issued patents, all of which could have an adverse effect on our business and
financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, in recent years, the Supreme Court and the U.S. Court of Appeals for the Federal Circuit have rendered
decisions in several patent cases such as Association for Molecular Pathology v. Myriad Genetics, Inc. (Myriad I), BRCA1- &amp; BRCA2-Based Hereditary Cancer Test Patent Litig., (Myriad II), Mayo Collaborative Services v. Prometheus Laboratories,
Inc., and Alice Corporation Pty. Ltd. v. CLS Bank International, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty
with regard to our and our licensors&#146; or collaborators&#146; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress,
the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#146; or collaborators&#146; ability to obtain new patents or to enforce existing patents and
patents that we and our licensors or collaborators may obtain in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Obtaining and maintaining our patent protection depends on compliance
with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over
the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there
are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment
or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaborators fail
to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have an adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our
trade secrets will be misappropriated or disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we collaborate with various collaborators on the development and
commercialization of one or more of our product candidates and because we rely on third parties to manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our wholly-owned technology in part by
entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to disclosing proprietary
information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to
share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an
adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, employees, third-party
contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future may be
granted rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property
rights arising from the collaboration, in addition to the opportunity to remove confidential or trade secret information from any such publication. Our existing collaborative research and development programs may require us to share trade secrets
under the terms of our research and development collaborations or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties,
independent development or publication of information by any of our third-party collaborators. A competitor&#146;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an
adverse effect on the success of our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may infringe our or our licensors&#146; or collaborators&#146; patents or
misappropriate or otherwise violate our or our licensors&#146; or collaborators&#146; intellectual property rights. In the future, we or our licensors or collaborators may initiate legal proceedings to enforce or defend our or our licensors&#146; or
collaborators&#146; intellectual property rights, to protect our or our licensors&#146; or collaborators&#146; trade secrets or to determine the validity or scope of intellectual property rights we own or control. Also, third parties may initiate
legal proceedings against us or our licensors or collaborators to challenge the validity or scope of intellectual property rights we own or control. These proceedings can be expensive and time-consuming, and many of our or our licensors&#146; or
collaborators&#146; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaborators. In addition, in an infringement proceeding, a court
may decide that a patent owned by or licensed to us is invalid or unenforceable, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or may refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#146; or collaborators&#146; patents do not cover the technology in question.
Furthermore, an adverse result in any litigation or administrative proceeding could put one or more of our or our licensors&#146; or collaborators&#146; patents at risk of being invalidated, held unenforceable or interpreted narrowly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, despite our or our licensors&#146; or collaborators&#146; efforts, we or our licensors or collaborators may not prevent third
parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the United States. In addition, litigation and administrative
proceedings could result in substantial costs and diversion of management resources, which could harm our business and financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings regarding patent and
other intellectual property rights in the pharmaceutical industry including opposition, derivation, reexamination, inter partes review or interference proceedings, or other preissuance or post-grant proceedings in the United States or other
jurisdictions. Such proceedings may be provoked by third parties or by us or our licensors or collaborators to protect or enforce our or our licensors&#146; or collaborators&#146; patents or patent applications. Additionally, third-party preissuance
submission of prior art to the USPTO or other foreign jurisdictions may jeopardize the issuance or scope of our or our licensors&#146; or collaborators&#146; patent applications. An unfavorable outcome in any such proceedings could require us or our
licensors or collaborators to cease using the related technology, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors or collaborators a license on
commercially reasonable terms or at all, and we could be forced to stop commercializing our product candidates. Even if we or our licensors or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same
technologies licensed to us or our licensors or collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the breadth or strength of protection provided by our or
our licensors&#146; or collaborators&#146; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Even if we successfully
defend such litigation or proceeding, we may incur substantial costs, and it may distract our management and other employees. We could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have
willfully infringed a patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim
proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of shares of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we breach the license agreements related to our product candidates, we could lose the ability to continue the development and commercialization of our
product candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends upon our ability, and the ability of our licensors and collaborators, to develop,
manufacture, market and sell our product candidates and use our and our licensors&#146; or collaborators&#146; wholly-owned technologies without infringing the proprietary rights of third parties. A third party may hold intellectual property,
including patent rights that are important or necessary to the development of our products. As a result, we are a party to a number of technology licenses that are important to our business and expect to enter into additional licenses in the future.
For example, we have in-licensed the rights to certain intellectual property relating to SHM under our in-license agreement with the Medical Research Council, which is the subject of issued patents and pending patent applications in certain
countries. If we fail to comply with the obligations under these agreements, including payment and diligence terms, our licensors may have the right to terminate these agreements, in which event we may not be able to develop, manufacture, market or
sell any product that is covered by these agreements or may face other penalties under the agreements. Such an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occurrence could adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under
these agreements may result in our having to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all, or cause us to lose our rights under these agreements, including our rights to intellectual
property or technology important to our development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise regarding intellectual property subject to a licensing
agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights granted under the license agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the priority of invention of patented technology. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that
we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights or we may initiate legal proceedings
against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on the success of our business. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may initiate legal proceedings against us or our licensors or collaborators alleging that we or our licensors or collaborators
infringe their intellectual property rights, or we or our licensors or collaborators may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, including in
oppositions, interferences, reexaminations, inter partes reviews or derivation proceedings in the United States or other jurisdictions. These proceedings can be expensive and time-consuming, and many of our or our licensors&#146; or
collaborators&#146; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. An
unfavorable outcome could require us or our licensors or collaborators to cease using the related technology or developing or commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could
be harmed if the prevailing party does not offer us or our licensors or collaborators a license on commercially reasonable terms or at all. Even if we or our licensors or collaborators obtain a license, it may be non-exclusive, thereby giving our
competitors access to the same technologies licensed to us or our licensors or collaborators. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees, if we are found to have willfully infringed
a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may be subject to claims by third parties asserting that our employees or we have misappropriated their
intellectual property, or claiming ownership of what we regard as our own intellectual property. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees, including our
senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition
agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used
or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#146;s former employer. Litigation may be necessary to defend against these claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be
available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our inability to protect our confidential information and trade secrets would harm our business and competitive position. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how,
technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our
employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and
consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a
party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect
trade secrets. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our
competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our
product candidates, our business may be harmed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and conditions of FDA marketing approval of our
product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments
permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if
we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain
patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened, and our competitors may obtain approval to market competing products
sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will be
and as a result it may be difficult for you to sell your shares of our common stock. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, no market for shares of
our common stock existed and an active trading market for our shares may never develop or be sustained following this offering. We have determined the initial public offering price for our common stock through negotiations with the underwriters, and
the negotiated price may not be indicative of the market price of our common stock after this offering. The market value of our common stock may decrease from the initial public offering price. As a result of these and other factors, you may be
unable to resell your shares of our common stock at or above the initial public offering price. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable.
The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic
collaborations or acquire companies or products by using our shares of common stock as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The market price of our stock may be volatile,
and you could lose all or part of your investment. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock following this offering is likely to be
highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this prospectus, these factors include:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory actions with respect to our products or our competitors&#146; products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in our growth rate relative to our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of preclinical studies and clinical trials of our product candidates or those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patent applications, issued patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recruitment or departure of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses related to any of our product candidates or clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments with respect to our existing collaboration agreements and announcements of new collaboration agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our efforts to in-license or acquire additional product candidates or products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in our financial results or those of companies that are perceived to be similar to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in the valuation of companies perceived by investors to be comparable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us, our insiders or our other stockholders; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of healthcare payment systems; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market conditions in the biotechnology sector; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic, industry and market conditions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general,
and the Nasdaq Global Select Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market
and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this
&#147;Risk Factors&#148; section, could have a dramatic and adverse impact on the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We will have broad discretion in
the use of the net proceeds from this offering and may not use them effectively. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the
application of the net proceeds from this offering, and you will be relying on the judgment of our management regarding the application of these proceeds. You will not have the opportunity, as part of your investment decision, to assess whether we
are using the proceeds appropriately. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder
value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may be subject to securities litigation,
which is expensive and could divert management attention. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock may be volatile and, in the past,
companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in
substantial costs and divert our management&#146;s attention from other business concerns, which could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our principal
stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates
beneficially owned approximately 84.0% of our voting stock and, upon the closing of this offering, that same group will beneficially own approximately 63.5% of our outstanding voting stock (based on the number of shares of common stock outstanding
as of September&nbsp;30,&nbsp;2016 assuming no exercise of the underwriters&#146; over-allotment option, no exercise of outstanding options or warrants and no purchases of shares in this offering by any of this group), in each case assuming the
conversion of all outstanding shares of our convertible preferred stock into shares of our common stock immediately prior to the closing of this offering. Certain of our existing stockholders and their affiliated entities, including stockholders
affiliated with certain of our directors, have agreed to purchase an aggregate of 1,946,666&nbsp;shares of our common stock in this offering at the initial public offering price. The previously discussed ownership percentage upon the closing of this
offering does not reflect the potential purchase of any shares in this offering by such shareholders. After this offering, this group of stockholders will have the ability to control us through this ownership position even if they do not purchase
any additional shares in this offering. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational
documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our
stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other
stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the
book value of your shares. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price is substantially higher than the net tangible book value per share of our
common stock. Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the book value of our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock in this
offering will incur immediate dilution of $9.26 per share, based upon the initial public offering price of $15.00 per share. Further, investors purchasing common stock in this offering will contribute approximately 45.3% of the total amount invested
by stockholders since our inception, but will own only approximately 26.1% of the shares of common stock outstanding after giving effect to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This dilution is due to our investors who purchased shares prior to this offering having paid substantially less when they purchased their
shares than the price offered to the public in this offering and the exercise of stock options granted to our employees. In addition, as of September&nbsp;30, 2016, options to purchase 1,856,750 shares of our common stock at a weighted-average
exercise price of $4.13 per share, warrants exercisable for 117,483 shares of our common stock at an exercise price of $4.55 per share and warrants exercisable for Series C convertible preferred stock convertible into 294,779&nbsp;shares of our
common stock at an exercise price of $4.55 per share were outstanding. The exercise of any of these options or warrants would result in additional dilution. As a result of the dilution to investors purchasing shares in this offering, investors may
receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will experience immediately after this offering, see &#147;Dilution.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make
our common stock less attractive to investors. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the Jumpstart Our Business Startups
Act of 2012, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies,
including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this
prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously
approved. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our
common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (i)&nbsp;the last
day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of our initial public offering, (b)&nbsp;in which we have total annual gross revenue of at least $1 billion or (c)&nbsp;in which we are deemed to be a large accelerated
filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700 million as of the prior June&nbsp;30th, and (ii)&nbsp;the date on which we have issued more than $1 billion in non-convertible debt during the
prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until
such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as
other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in
our business could significantly affect our financial position and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We will incur increased costs as a result of operating as a public company, and our management will devote
substantial time to new compliance initiatives. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses
that we did not incur as a private company, and these expenses may increase even more after we are no longer an &#147;emerging growth company.&#148; We will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the
Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and the Nasdaq Global Select Market. Our management and other personnel will need to devote a substantial amount of time to these compliance
initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. The increased costs will increase our net loss. For example,
we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the sufficient coverage. We cannot predict or
estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors,
our board committees or as executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a public company we will be required to incur additional costs and
obligations in order to comply with SEC rules that implement Section&nbsp;404 of the Sarbanes-Oxley Act. Under these rules, beginning with our annual report for the year ending December&nbsp;31, 2017, we will be required to make a formal assessment
of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our independent
registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaging in a process to document and evaluate our internal control over financial reporting, which is both costly and
challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting,
continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the preparation of our 2015 consolidated financial statements, we and our independent registered public accounting
firm identified a material weakness in our internal control over financial reporting with respect to the design of our controls over the calculation of our accrued research and contract manufacturing expenses, including the verification of the level
and timing of completion of our CRO and CMO activities. Under standards established by the Public Company Accounting Oversight Board, a deficiency in internal control over financial reporting exists when the design or operation of a control does not
allow management or personnel, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency or combination of deficiencies in internal control over financial
reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. During the first quarter of 2016, we implemented
additional controls to remediate the material weakness, including additional controls to verify the level and timing of completion of our CRO and CMO activities and controls over the completeness and accuracy of spreadsheets used to calculate the
accrued research and contract manufacturing expenses. We cannot assure you that these measures will significantly improve or remediate the material weakness described above. We, and our independent registered public accounting firm, were not
required to perform an evaluation of our internal control over financial reporting as of December&nbsp;31, 2015 in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified all material
weaknesses or that there will not be additional material weaknesses or deficiencies that our independent registered public accounting firm or we will identify. If we are unable to successfully remediate the existing material weakness in our internal
control over financial reporting, or if we identify any additional issues, we may be unable to produce accurate and timely financial statements, our stock price may be adversely affected and we may be unable to maintain compliance with the Nasdaq
Stock Market listing requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales of a substantial number of shares of our common stock in the public market could cause our stock price
to fall. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the
perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have outstanding 19,159,333 shares of common stock based on the number of
shares outstanding as of September 30, 2016, assuming: (i)&nbsp;no exercise of the underwriters&#146; option to purchase additional shares and (ii)&nbsp;the conversion of all outstanding shares of our convertible preferred stock into 11,520,698
shares of common stock immediately prior to the closing of this offering. This includes the shares that we sell in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Of the
remaining shares, 14,159,333 shares of our common stock are currently restricted as a result of securities laws or lock-up agreements but will be able to be sold after this offering as described in the &#147;Shares Eligible for Future Sale&#148;
section of this prospectus. Moreover, after this offering, holders of an aggregate of 14,571,595 shares of our common stock and shares underlying certain warrants will have rights, subject to certain conditions, to require us to file registration
statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also intend to register all shares of common stock that we may issue under our equity incentive plans.
Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the &#147;Underwriting&#148; section of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in
additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that
significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public
company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other
equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our
common stock, including shares of common stock sold in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our disclosure controls and procedures may not prevent or detect all errors or
acts of fraud. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will become subject to the periodic reporting requirements of the Exchange Act.
We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and
reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These inherent limitations include the realities that judgments in
decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of
the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our
stock. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future
earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions in our restated certificate of incorporation and restated bylaws and Delaware law might discourage, delay or prevent a change in control of
our company or changes in our management and, therefore, depress the market price of our common stock. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of
incorporation and restated bylaws, as we expect they will be in effect upon closing of the offering, will contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our
company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors so that not all members of our board are elected at one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permit only the board of directors to establish the number of directors and fill vacancies on the board; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that directors may only be removed &#147;for cause&#148; and only with the approval of two-thirds of our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize the issuance of &#147;blank check&#148; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#147;poison pill&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate the ability of our stockholders to call special meetings of stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit cumulative voting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control of our company.
Section&nbsp;203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our
stock, our stock price and trading volume could decline. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the research
and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of
us, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our
intellectual property or our stock performance, or if our target animal studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to
publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We plan to use potential future operating losses and our federal and state net operating loss, or NOL,
carryforwards to offset taxable income from revenue generated from operations or corporate collaborations. However, our ability to use NOL carryforwards could be limited as a result of additional issuances of equity securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to use our current year operating losses to offset taxable income from any revenue generated from operations or corporate
collaborations. To the extent we have taxable income, we plan to use our NOL carryforwards to offset income that would otherwise be taxable. However, under the Tax Reform Act of 1986, the benefits from the use of our NOL carryforwards may be
impaired or limited under Section 382 of the Internal Revenue Code of 1984, as amended, or the Code, if we incur a cumulative ownership change of more than 50%, as interpreted by the U.S. Internal Revenue Service, over a three-year period. In
September&nbsp;2015, we completed a Section&nbsp;382 and 383 ownership change analysis through December&nbsp;31, 2014 and determined that there was an ownership change in 2007 that may limit the utilization of approximately $5.3&nbsp;million and
$5.4&nbsp;million in federal and state NOLs, respectively, and $0.2&nbsp;million in both federal and state research tax credits. In October 2016, we extended the analysis period of the study through December 31, 2015, noting no ownership changes
during fiscal 2015. Our use of federal NOL carryforwards could be limited further by the provisions of Section&nbsp;382 of the Code depending upon the timing and amount of additional equity securities that we have issued or will issue, including as
a result of this offering. State NOL carryforwards may be similarly limited. Any such disallowances may result in greater tax liabilities than we would incur in the absence of such a limitation and any increased liabilities could adversely affect
our business, results of operations, financial condition and cash flow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Use of Proceeds,&#148;
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and &#147;Business&#148; contains forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148;
&#147;potentially,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148; &#147;plan&#148; &#147;expect,&#148; and similar expressions that convey
uncertainty of future events or outcomes are intended to identify forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this
prospectus include, among other things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize antibodies, including our lead product candidates ANB020 for patients with severe allergic and atopic diseases and ANB019 for patients with GPP and PPP; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood that the clinical data generated in Australia will be subsequently accepted by the FDA and its foreign equivalents outside of Australia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and ability of our collaborators to develop and commercialize our partnered product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential benefits and advantages of our product candidates and approaches versus those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to execute on our strategy, including advancing our lead product candidates, identifying emerging opportunities in key therapeutic areas, continuing to expand our wholly-owned pipeline and retaining rights
to strategic products in key commercial markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to obtain and maintain regulatory approvals for ANB020 and ANB019 and our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance and clinical utility of any approved product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and growth potential of the markets for any approved product candidates, and our ability to serve those markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments in the United States, Australia and other foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of competing therapies that are or may become available; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract and retain key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our use of the net proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#147;Risk
Factors&#148; and elsewhere in this prospectus. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from
those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially
and adversely from those anticipated or implied in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as
predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in
the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in
our expectations, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and
have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different
from what we expect. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_5"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including
our general expectations and market position, market opportunity, and market size, is based on information from various sources on assumptions that we have made that are based on those data and other similar sources and on our knowledge of the
markets for our products. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information
included in this prospectus is generally reliable, such information is inherently imprecise. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate is necessarily
subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors&#148; and elsewhere in this prospectus. These and other factors could cause results to differ materially from those
expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our sale of 5,000,000 shares of common stock in this offering at the initial public offering price of
$15.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $65.8&nbsp;million, or $76.2&nbsp;million if the underwriters exercise their option to purchase additional
shares in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds we receive from this offering, together with our existing cash and cash
equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $25.0 million to fund development of ANB020 and ANB019 through initial clinical trials intended to demonstrate efficacy in multiple indications; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $15.0 million to fund continued development of other wholly-owned product candidates, including our checkpoint receptor agonist antibodies, and discovery of new product candidates to further expand our
proprietary pipeline;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any remaining amounts to fund working capital, including general corporate purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on
our planned use of the net proceeds, we estimate such funds, together with our existing cash and cash equivalents, will be sufficient for us to fund our operating expenses and capital expenditure requirements through at least the next 24 months.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected use of the net proceeds from the offering represents our intentions based upon our current plans and business conditions. As
of the date of this prospectus, we cannot predict with any certainty all of the particular uses for the net proceeds or the amounts that we will actually spend on the uses set forth above. We may use a portion of the net proceeds for the acquisition
of, or investment in, technologies, solutions or businesses that complement our business, although we have no present commitments or agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our clinical expenditures and the extent of clinical development may vary significantly depending on numerous
factors, including the status, results and timing of our current preclinical studies and clinical trials we may commence in the future, product approval process with the FDA and other regulatory agencies, our current collaborations and any new
collaborations we may enter into with third parties and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected net proceeds of this offering will not be sufficient for us to fund any of our product candidates through regulatory approval,
and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending their use as described above, we intend to invest the net proceeds from this offering in short term, investment-grade interest-bearing
securities such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings
for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend
on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. In addition, under the terms of our current credit facility, we are prohibited from
paying cash dividends without the consent of Silicon Valley Bank. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as of September 30, 2016 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a pro forma basis, giving effect to (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock as of September 30, 2016 into 11,520,698 shares of common stock immediately prior to the
closing of this offering, (ii)&nbsp;the conversion of the preferred stock warrants into common stock warrants and the related reclassification of the preferred stock warrant liability to additional paid-in capital and (iii)&nbsp;the effectiveness of
our restated certificate of incorporation in connection with the closing of this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a pro forma as adjusted basis, giving effect to the pro forma adjustments and the sale of 5,000,000 shares of common stock by us in this offering, based on the initial public offering price of $15.00 per share, after
deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted
information set forth in the table below is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table together with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and our audited and unaudited consolidated financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September 30, 2016</B><br><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and par value data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma</B><br><B>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top"></SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom" ALIGN="right">115,385<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B convertible preferred stock, $0.001 par value; 3,963,263 shares authorized, 3,963,263
shares issued and outstanding, actual; no shares designated, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C convertible preferred stock, $0.001 par value; 1,887,250 shares authorized, 1,592,461
shares issued and outstanding, actual; no shares designated, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C-1 convertible preferred stock, $0.001 par value; 474,001 shares authorized, 474,001 shares
issued and outstanding, actual; no shares designated, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series D convertible preferred stock, $0.001 par value; 5,490,973 shares authorized, 5,490,973
shares issued and outstanding, actual; no shares designated, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Preferred Stock, $0.001 par value; no shares authorized, issued or outstanding, actual; 10,000,000
shares authorized, no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock, $0.001 par value; 17,214,285 shares authorized, 2,638,635 shares issued and
outstanding, actual; 500,000,000 shares authorized, 14,159,333&nbsp;shares issued and outstanding, pro forma; 500,000,000 shares authorized, 19,159,333 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,345</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,973</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted cash and cash equivalents amount also reflects the prepayment of approximately $2.5&nbsp;million of the estimated offering expenses prior to September 30, 2016. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 14,159,333 shares of our common stock outstanding
as of September 30, 2016, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,856,750 shares of common stock issuable upon the exercise of options outstanding as of September&nbsp;30, 2016, with a weighted-average exercise price of $4.13 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">221,953 shares of common stock issuable upon the exercise of options granted after September 30, 2016, with a weighted-average exercise price of $11.31 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,378,570&nbsp;shares of common stock reserved for future issuance under our stock-based compensation plans, consisting of (a)&nbsp;513,407 shares of common stock reserved for future issuance under our 2006 Equity
Incentive Plan as of September&nbsp;30, 2016, (b) 1,647,163&nbsp;shares of common stock reserved for future issuance under our 2017 Equity Incentive Plan, which became effective on the date immediately prior to the date of this prospectus and (c)
218,000 shares of common stock reserved for future issuance under our 2017 Employee Stock Purchase Plan, which became effective on the date of this prospectus. Upon the closing of this offering, any remaining shares available for issuance under our
2006 Equity Incentive Plan will be added to the shares reserved under our 2017 Equity Incentive Plan and we will cease granting awards under our 2006 Equity Incentive Plan. Our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan also
provide for automatic annual increases in the number of shares reserved under the plans each year, as more fully described in &#147;Executive Compensation&#151;Employee Benefit and Stock Plans&#148;; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">117,483 shares of our common stock issuable upon exercise of warrants for shares of common stock that were outstanding as of September&nbsp;30, 2016, with an exercise price of $4.55 per share, that do not expire upon
the closing of this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">294,779 shares of common stock issuable upon the exercise of warrants to purchase shares of Series C convertible preferred stock that were outstanding as of September 30, 2016, with an exercise price of $4.55 per share,
that do not expire upon the closing of this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">82,416 shares of common stock issuable upon the exercise of warrants to purchase shares of our Series C convertible preferred stock issued after September 30, 2016, with an exercise price of $4.55 per share, that do not
expire upon the closing of this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, your interest will be diluted to the extent of the difference between the amount per share paid by
purchasers of shares of common stock in this initial public offering and the pro forma as adjusted net tangible book value per share of common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2016, our pro forma net tangible book value was approximately $41.8&nbsp;million, or $2.95 per share of common stock. Our
pro forma net tangible book value per share represents the amount of our total tangible assets reduced by the amount of our total liabilities and divided by the total number of shares of our common stock outstanding as of September 30, 2016,
assuming (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock as of September 30, 2016 into 11,520,698 shares of common stock as of immediately prior to the closing of this offering and (ii)&nbsp;the
conversion of the preferred stock warrants into common stock warrants and the related reclassification of the preferred stock warrant liability to additional paid-in capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to our sale in this offering of 5,000,000 shares of our common stock at the initial public offering price of $15.00 per
share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma net tangible book value as of September&nbsp;30, 2016 would have been approximately $110.0 million, or $5.74 per share of
our common stock. This represents an immediate increase in pro forma net tangible book value of $2.79&nbsp;per share to our existing stockholders and an immediate dilution of $9.26 per share to investors purchasing shares in this offering, as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of September 30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option in full to purchase additional shares, the pro forma net tangible
book value per share of our common stock after giving effect to this offering would be $6.05 per share, and the dilution in net tangible book value per share to investors in this offering would be $8.95 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, on a pro forma as adjusted basis as of September 30, 2016 after giving effect to (i)&nbsp;the automatic
conversion of all outstanding shares of our convertible preferred stock into 11,520,698 shares of common stock as of immediately prior to the closing of this offering and (ii)&nbsp;the issuance of 5,000,000 shares of common stock in this offering at
the initial public offering price of $15.00 per share, the difference between existing stockholders and new investors with respect to the number of shares of common stock purchased from us, the total consideration paid to us, and the average price
per share paid, before deducting underwriting discounts and commissions and estimated offering expenses payable by us: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Average</B><br><B>Price&nbsp;Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,159,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.9</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,434,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.7</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New public investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,159,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165,434,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders and their affiliated entities, including stockholders affiliated with
certain of our directors, have agreed to purchase an aggregate of 1,946,666&nbsp;shares of our common stock in this offering at the initial public offering price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any outstanding options are exercised, investors will experience further
dilution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, the above discussion and tables assume no exercise of the underwriters&#146; option to purchase
additional shares. If the underwriters exercise their option to purchase additional shares in full, our existing stockholders would own 71.1% and our new investors would own 28.9% of the total number of shares of our common stock outstanding upon
the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 14,159,333
shares of our common stock outstanding as of September 30, 2016, and excludes: </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,856,750 shares of common stock issuable upon the exercise of options outstanding as of September&nbsp;30, 2016, with a weighted-average exercise price of $4.13 per share; </TD></TR></TABLE>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">221,953 shares of common stock issuable upon the exercise of options granted after September 30, 2016, with a weighted-average exercise price of $11.31 per share; </TD></TR></TABLE>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,378,570&nbsp;shares of common stock reserved for future issuance under our stock-based compensation plans, consisting of (a)&nbsp;513,407 shares of common stock reserved for future issuance under our 2006 Equity
Incentive Plan as of September&nbsp;30, 2016, (b) 1,647,163&nbsp;shares of common stock reserved for future issuance under our 2017 Equity Incentive Plan, which became effective on the date immediately prior to the date of this prospectus and (c)
218,000&nbsp;shares of common stock reserved for future issuance under our 2017 Employee Stock Purchase Plan, which became effective on the date of this prospectus. Upon the closing of this offering, any remaining shares available for issuance under
our 2006 Equity Incentive Plan will be added to the shares reserved under our 2017 Equity Incentive Plan and we will cease granting awards under our 2006 Equity Incentive Plan. Our 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan
also provide for automatic annual increases in the number of shares reserved under the plans each year, as more fully described in &#147;Executive Compensation&#151;Employee Benefit and Stock Plans&#148;; </TD></TR></TABLE>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">117,483 shares of our common stock issuable upon exercise of warrants for shares of common stock that were outstanding as of September 30, 2016, with an exercise price of $4.55 per share, that do not expire upon the
closing of this offering; </TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">294,779 shares of common stock issuable upon the exercise of warrants to purchase shares of Series&nbsp;C convertible preferred stock that were outstanding as of September 30, 2016, with an exercise price of $4.55 per
share, that do not expire upon the closing of this offering; and </TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">82,416 shares of common stock issuable upon the exercise of warrants to purchase shares of our Series&nbsp;C convertible preferred stock issued after September 30, 2016, with an exercise price of $4.55 per share, that
do not expire upon the closing of this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_10"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected statements of operations data for the years ended December&nbsp;31, 2014 and 2015 and the balance sheet data as of
December&nbsp;31, 2014 and 2015 are derived from our audited financial statements included elsewhere in this prospectus. The selected consolidated statements of operations data for the nine months ended September 30, 2015 and 2016 and the
consolidated balance sheet data as of September 30, 2016 have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus. Our unaudited consolidated financial statements have been prepared on the same
basis as our audited financial statements and, in the opinion of management, reflect all adjustments, which consist only of normal recurring adjustments, necessary for the fair statement of those unaudited consolidated financial statements. The
summary statements of operations data presented below for the year ended December&nbsp;31, 2013 are derived from our audited financial statements not included in this prospectus. The selected consolidated financial data below should be read in
conjunction with the section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in this prospectus. Our historical results
are not necessarily indicative of the results that may be expected in any future period. The selected financial data in this section are not intended to replace the financial statements and are qualified in their entirety by the financial statements
and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,287</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,322</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(886</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,281</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(460</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,277</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(207</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(258</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,266</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(50</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(1,893</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">&#151;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(1,893</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share:(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding:(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per common share (unaudited):(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding<BR>(unaudited):(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note 2 to our audited consolidated financial statements for an explanation of the method used to calculate basic and diluted net income (loss) per common share, unaudited pro forma basic and diluted net loss per
common share and the weighted-average number of shares used in the computation of the per share amounts. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of</B><br><B>September&nbsp;30,<BR>2016</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, noncurrent portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,835</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,179</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,973</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our
consolidated financial statements and related notes thereto included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set
forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology
platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation <I>in vitro</I>. Our strategy is to advance
the development of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced wholly-owned antibody programs, ANB020 and ANB019, neutralize therapeutic targets that are genetically associated with
severe inflammatory disorders in humans. ANB020 inhibits the activity of the interleukin-33, or IL-33, cytokine for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma. We
have completed a Phase&nbsp;1 trial of ANB020 in healthy volunteers in Australia under an approved Clinical Trial Notification, or CTN. We believe the results of this Phase 1 trial demonstrate a favorable safety profile of ANB020, which was
well-tolerated and for which no dose-limiting toxicities were observed, and favorable pharmacodynamic properties of ANB020, where a single dose was sufficient to suppress IL-33 function for approximately three months post-dosing as measured by an
<I>ex vivo </I>pharmacodynamic assay. We plan to disclose detailed data from this Phase 1 trial at two medical conferences during the first quarter of 2017. We have cleared an Investigational New Drug application, or IND, with the U.S. Food and Drug
Administration, or FDA, and a Clinical Trial Authorisation, or CTA, to the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, to initiate Phase 2a trials of ANB020 in patients with severe adult peanut allergy and moderate-to-severe
adult atopic dermatitis, respectively, each of which are anticipated to be initiated during the first quarter of 2017. We anticipate top-line data from these trials to be announced during the second half of 2017. In addition, we plan to seek
regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma. We anticipate top-line data from this trial to be announced during the first half of 2018. ANB019 inhibits the
interleukin-36, or IL-36R, receptor for the treatment of rare inflammatory diseases including generalized pustular psoriasis, or GPP, and palmo-plantar pustular psoriasis, or PPP. In November 2016, we submitted a CTN for ANB019 and, if cleared, we
plan to commence a Phase&nbsp;1 clinical trial in the first half of 2017, and anticipate announcing top-line data from this trial during the second half of 2017. We subsequently plan to seek regulatory clearance to initiate Phase 2 studies of ANB019
in GPP and PPP patients during 2018. In addition to ANB020 and ANB019, our wholly-owned pipeline includes novel checkpoint receptor agonist antibodies that we believe are applicable for treatment of certain autoimmune diseases where immune
checkpoint receptors are insufficiently activated, and which have demonstrated efficacy in an animal model of graft-versus-host disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our wholly-owned antibody programs, multiple AnaptysBio-developed antibody programs have been advanced under our collaborations
to preclinical and clinical milestones. Our collaborations include an immuno-oncology-focused collaboration with TESARO and an inflammation-focused collaboration with Celgene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our TESARO collaboration, a Phase&nbsp;1 clinical trial was initiated during the first quarter of 2016 to study an AnaptysBio-generated
anti-PD-1 antagonist antibody (TSR-042) in patients under an IND cleared by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. FDA. We anticipate initiation of a registration program for TSR-042 by TESARO during the first half of 2017. A second Phase&nbsp;1 trial was initiated during the third quarter of 2016 to
study an AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022) in patients under a separate IND cleared by the FDA. We anticipate initiation of a combination trial of TSR-022 with an anti-PD-1 antibody by TESARO during the first half of
2017. Under our Celgene collaboration, an <I>in vivo</I> toxicology study using good laboratory practices, or GLPs, for an AnaptysBio-generated antibody was completed during the second quarter of 2016, and a U.S. IND was cleared by the FDA and a
Phase&nbsp;1 trial was initiated in December 2016. Including the aforementioned programs, we expect that our collaborators will advance four AnaptysBio-generated antibodies to the clinic by the end of the first half of 2017. Through December 31,
2016, we have received $65.4 million in non-dilutive funding from our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company is led by a strong management team with
deep experience in antibody discovery and development, collaborations, operations and corporate finance. Through December 31, 2016, we have raised $104.1&nbsp;million from investors, including Biotechnology Value Fund, Cormorant Asset Management,
Frazier Healthcare, HBM Partners, Longwood Capital Partners and Novo A/S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to continue generating additional therapeutic
antibodies against emerging biological targets across various disease applications, including immuno-oncology, inflammation and other unmet medical needs. In general, our strategy is to advance our pipeline programs to key inflection points, and
leverage partnerships with pharmaceutical and biotechnology companies where appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have generated multiple antibodies by using
our SHM platform certain of which are currently being advanced by our partners to key preclinical, clinical and commercial milestones, which we anticipate will generate additional cash receipts for us. To the extent that these product candidates are
commercialized, we will also be entitled to royalty payments upon commercial sales of the associated products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2016,
we had an accumulated deficit of $50.3 million primarily as a result of losses incurred since our inception in 2005. Although we reported net income of $3.5 million during the year ended December 31, 2014 and $0.3 million during the nine months
ended September 30, 2016, we expect to continue to incur net operating losses for at least the next several years as we advance our products through clinical development, seek regulatory approval, prepare for and, if approved, proceed to,
commercialization, expand our operations and facilities and grow in new and existing markets, territories and industries. We will need substantial additional funding to pay expenses relating to our operating activities, including significant
research and development expenses. Adequate funding may not be available to us on acceptable terms, or at all. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of
operations or financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not
generated any revenue from product sales. Our revenue has been derived from amortization of upfront payments, research and development funding and milestone payments under collaboration and license agreements with our collaborators. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration and Exclusive License Agreement with TESARO </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2014, we entered into an exclusive worldwide license and collaboration agreement with TESARO for the development and
commercialization of therapeutic monospecific and bispecific antibodies that antagonize PD-1, TIM-3, LAG-3 and/or a fourth undisclosed checkpoint receptor. We received $17.0 million in upfront fees from TESARO in March 2014, and in November 2014, we
amended the agreement with TESARO to include the development and commercialization of bispecific antibodies to another undisclosed target, for an additional upfront fee of $2.0 million. Both upfront fees are being recognized over the same period
that our research and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development services, for which we are reimbursed, are performed, which was extended through December&nbsp;31, 2016 by amendment of the agreement in February 2016. From inception of the agreement
through September 30, 2016, we have recognized $42.5&nbsp;million in total revenue from TESARO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the four targets under the
TESARO agreement, we are eligible to receive up to $273.0 million in milestone payments, which are comprised of $18.0 million for preclinical and clinical development milestone payments, $90.0 million upon certain regulatory events and $165.0
million upon worldwide commercial sales thresholds. In addition, TESARO is obligated to pay us tiered single-digit royalties on annualized net sales of each antibody commercialized from the collaboration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2015, TESARO initiated <I>in vivo</I> toxicology studies using GLPs for an AnaptysBio-generated anti-PD-1 antagonist antibody
(TSR-042) resulting in us receiving a $1.0 million milestone in July 2015. In October 2015, TESARO initiated<I>&nbsp;in vivo</I>&nbsp;toxicology studies using GLPs for an AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022) resulting in us
receiving a $1.0&nbsp;million milestone in November 2015. In January 2016, TESARO received clearance of their IND from the FDA for an AnaptysBio-generated anti-PD-1 antagonist antibody (TSR-042) resulting in us receiving a $4.0 million milestone
payment in February 2016. In June 2016, TESARO received clearance of their IND from the FDA for an AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022) resulting in us receiving a $4.0 million milestone payment in June 2016. In September
2016, TESARO initiated <I>in vivo</I> toxicology studies using GLPs for an AnaptysBio-generated anti-LAG-3 antagonist antibody (TSR-033) resulting in us receiving a $1.0 million milestone in September 2016. We expect to receive an additional
aggregate of $4.0&nbsp;million in IND-related milestone payments by the end of the first half of 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Antibody Generation
Agreement with Celgene Corporation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2011, we entered into a license and collaboration agreement with Celgene to develop
therapeutic antibodies against multiple targets. We granted Celgene the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by
our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement provided
for an upfront payment of $6.0 million from Celgene, which we received in 2011, milestone payments of up to $53.0 million per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research
and development costs. From inception of the agreement through September&nbsp;30, 2016, we have recognized $9.0 million in total revenue from Celgene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, Celgene successfully completed an <I>in vivo</I> toxicology study using GLPs for an AnaptysBio-generated antibody resulting in
us receiving a $0.5&nbsp;million milestone payment in June&nbsp;2016. In December 2016, Celgene cleared a U.S. IND with the FDA and initiated a Phase&nbsp;1 trial for one of the two programs being advanced by Celgene, resulting in us earning an
additional $1.0&nbsp;million Phase&nbsp;1 trial initiation milestone payment, which was received in January 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other
Collaborative Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to other collaboration agreements for which we recognized $1.7&nbsp;million and $3.7 million
in collaboration revenue during the years ended December&nbsp;31, 2013 and 2014, respectively. We completed our obligations under these agreements in 2014 and did not recognize any additional revenue from them subsequent to the year ended
December&nbsp;31, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of costs associated with our research and development activities, including drug discovery efforts
and preclinical development of our programs. Our research and development expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">External research and development expenses incurred under arrangements with third-parties, such as CROs, consultants, members of our scientific and therapeutic advisory boards, and clinical manufacturers;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employee-related expenses, including salaries, benefits, travel and stock-based compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">License and sublicense fees. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. We
account for advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize the Australian Research and Development Tax Incentive, or the Tax Incentive, as a reduction of research and development expense.
The amounts are determined on a cost reimbursement basis based on our eligible research and development expenditures and are non-refundable, provided that in order to qualify for the Australian benefits we must have revenue of less than AUD $20.0
million during the reimbursable period and cannot be controlled by income tax exempt entities. The Tax Incentive is recognized when there is reasonable assurance that the Tax Incentive will be received, the relevant expenditure has been incurred,
and the amount can be reliably measured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are conducting research and development activities on several inflammation and
immuno-oncology programs. We have a research and development team that conducts antibody discovery, characterization, translational studies, IND-enabling preclinical studies and clinical development. We conduct some of our early research and
preclinical activities internally and plan to rely on third parties, such as CROs and CMOs, for the execution of certain of our research and development activities, such as <I>in vivo</I> toxicology and pharmacology studies, drug product
manufacturing and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are conducting initial clinical trials for ANB020 and plan to conduct initial clinical trials for
ANB019 in Australia to rapidly enter into first-in-human studies and benefit from research and development-related financial incentives related to the development of ANB020 and ANB019. Taking into account any financial incentives, we expect our
research and development expenses to be higher for the foreseeable future as we advance our product candidates into clinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and
Administrative </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and related benefits, including stock-based
compensation, for our executive, finance, legal, business development, human resource and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development
expenses, travel expenses and professional fees for auditing, tax and legal services, including intellectual property-related legal services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest
Expense </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists of stated interest and amortization of discounts on our outstanding notes payable relating to our
Loan and Security Agreement with Oxford Finance LLC and Silicon Valley Bank, as amended, which we refer to as the Loan Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in Fair Value of Liability for Preferred Stock Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income and expense from the change in fair value of our liability for preferred stock warrants is from the valuation of our outstanding
warrants to purchase shares of our preferred stock, which is valued at each period end. Upon the closing of our initial public offering, the warrants to purchase shares of preferred stock will convert into warrants to purchase shares of common
stock, the preferred stock warrant liabilities will be reclassified to additional paid-in capital and periodic fair value adjustments will no longer be recorded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Operating Loss and Research and Development Tax Credit Carryforwards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From our inception through December&nbsp;31, 2013, we accumulated net operating losses, or NOLs. We generated taxable income in the United
States for the years ended December&nbsp;31, 2014 and 2015 as a result of our collaboration agreement with TESARO as well as expenses incurred by our Australian subsidiary which are not deductible for U.S. income tax purposes. While we utilized NOLs
in 2014 and 2015, we continue to have a valuation allowance against our net deferred tax assets due to the uncertainty of the realization of such assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December 31, 2015, we had federal and state NOL carryforwards of $34.5 million and $41.5 million, respectively. The federal and state NOLs
will begin to expire in 2028 and 2017, respectively, unless previously utilized. At December 31, 2015, we had federal and California research tax credit carryforwards of $1.4 million and $1.7 million, respectively. The federal research tax credit
carryforward will begin to expire in 2026 and the California state credits carry forward indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NOL carryforward and the
research tax credit carryforwards may be subject to an annual limitation under Section&nbsp;382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and similar state provisions if we experience one or more ownership changes which
would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section&nbsp;382 and 383 of the Code, results from transactions
increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. In September&nbsp;2015, we completed an IRC Section&nbsp;382/383 ownership change analysis
through December&nbsp;31, 2014 and determined that there was an ownership change in 2007 that may limit the utilization of approximately $5.3&nbsp;million and $5.4&nbsp;million in Federal and state NOLs, respectively, and $0.2&nbsp;million in both
Federal and state research tax credits. In October 2016, we extended the analysis period of the study through December 31, 2015, noting no ownership changes during fiscal 2015. If a change in ownership occurs as a result of this offering, additional
NOL and tax credits carryforwards could be eliminated or restricted. Limitations on our ability to use NOL carryforwards and research and development tax credits to offset future taxable income could require us to pay U.S. federal income tax earlier
than would be required if such limitations were not in effect. Similar rules and limitations may apply for state income tax purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical
Accounting Policies and Use of Estimates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of
operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make judgments and estimates that
affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various
other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in
circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this
prospectus, we believe the following accounting policies used in the preparation of our financial statements require the most significant judgments and estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue
can be recognized: (i)&nbsp;persuasive evidence that an arrangement exists; (ii)&nbsp;delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (iii)&nbsp;the price is
fixed or determinable; and (iv)&nbsp;collectability is reasonably assured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple-Element Revenue Arrangements</I>. We evaluate
deliverables in a multiple-element arrangement to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered
element does not have standalone value without one of the undelivered elements in the arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the
inception of the arrangement based on the relative selling price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize consideration allocated to an individual element when all
other revenue recognition criteria are met for that element. Our multiple-element revenue arrangements may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">License Arrangements. The deliverables under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. As the delivered
licenses have not historically had standalone value apart from the undelivered elements, these have been recognized as revenue as a combined unit of accounting. Accordingly, we recognize revenue from nonrefundable upfront fees in the same manner as
the undelivered item or items, which is generally the period over which we provide research and developments services. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Research and Development Services. The deliverables under our collaboration and license arrangements may include research and development services we perform on behalf of or with our collaborators. As the provision of
research and development services is an integral part of our operations and we may be principally responsible for the performance of these services under the agreements, we recognize revenue on a gross basis for research and development services as
we perform those services. Additionally, we recognize research related funding under collaboration research and development efforts as revenue as we perform or deliver the related services in accordance with contract terms. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Revenue.</I> Our collaboration and license agreements generally include contingent contractual payments related to achievement of
specific research, development and regulatory milestones and sales-based milestones that are dependent upon the performance of the licensor or collaborator. A milestone is defined as an event (i)&nbsp;that can only be achieved based in whole or in
part on either the entity&#146;s performance or on the occurrence of a specific outcome resulting from the entity&#146;s performance, (ii)&nbsp;for which there is substantive uncertainty at the date the arrangement is entered into that the event
will be achieved and (iii)&nbsp;that would result in additional payments being due to us. Contingent consideration for which payment is either contingent solely upon the passage of time or the result of a counterparty&#146;s performance is not
considered substantive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in
the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consideration is commensurate with either the entity&#146;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the
entity&#146;s performance to achieve the milestone; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consideration relates solely to past performance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestones that are not considered substantive are generally recognized in the same manner as the undelivered item(s), which is generally the
period over which we provide research and development services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date.
This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the
service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued
expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our
accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to
quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances
in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the
level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Advance payments for goods and services that will be
used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing
of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our
estimates of such expenses and the amounts actually incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense the fair value of stock awards to employees, net of estimated forfeitures, adjusted to reflect actual forfeitures, over the
requisite service period, which is typically the vesting period. We estimate the fair value of options granted to employees at the date of grant using the Black-Scholes option-pricing model that requires management to apply judgment and make
estimates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>fair value of the underlying common shares</I>, as approved by our board of directors, which was determined using the option-pricing method, or OPM, in periods through December&nbsp;31, 2014, and the
probability-weighted expected return method, or PWERM, beginning March&nbsp;31, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>risk-free interest rate</I>, which is based on observed interest rates appropriate for the expected term of the stock option grants, historically U.S. Treasury constant maturities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>expected volatility</I>, which is calculated based on reported volatility data for a representative peer group of publicly traded biotechnology companies for which historical information is available. Because we are
privately held as of the date of these financial statements, we do not have relevant historical data to support our expected volatility; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>expected dividend yield</I>, which is zero as we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>expected term</I>, which we calculate using the simplified method, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches, as we
have insufficient historical information regarding our stock options to provide a basis for an estimate. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have computed the fair value of stock options at the date of grant using the following
weighted average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended</B><br><B>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average grant date fair value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;3.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were 861,375 and 278,910 stock options granted during the nine months ended September 30, 2015 and 2016,
respectively. Subsequent to September 30, 2016, we granted 221,953 stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to unvested
stock option grants not yet recognized as of September 30, 2016 was $2.8 million and the weighted average period over which these grants are expected to vest is 2.8 years. We expect to continue to grant stock options in the future, and to the extent
we do, our actual stock-based compensation expense recognized in future periods will likely increase. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock Valuations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a private company with no active public market for our common stock. Therefore, we have periodically determined the estimated per share
fair value of our common stock at various dates using contemporaneous valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held Company Equity
Securities Issued as Compensation</I>, or Practice Aid. Once a public trading market for our common stock has been established in connection with the closing of this offering, it will no longer be necessary for us to estimate the fair value of our
common stock in connection with our accounting for stock options and restricted stock, as the fair value of our common stock will be its trading price on the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Valuation Methodologies.</I></B> Our contemporaneous and retrospective valuations were prepared in accordance with the
guidelines in the Practice Aid, which prescribes several valuation approaches for determining the value of an enterprise, such as the cost, market and income approaches, and various methodologies for allocating the value of an enterprise to its
capital structure and specifically the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We used the market approach as this approach is based on the assumption that the
value of an asset, including a company, is equal to the value of a substitute asset with the same characteristics. Therefore, the value of an asset can be inferred by finding similar assets, or an interest in similar assets, that have been sold in
recent arm&#146;s-length transactions. The following market approaches were considered in our valuations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Guideline Public Company Method.</B> The guideline public company method, or GPC method, compares the subject company with guideline publicly traded companies. Valuation multiples are calculated from selected
guideline companies to provide an indication of how much a current investor in the marketplace would be willing to pay for a company with characteristics similar (such as similar business, size, geographic region, and other operating
characteristics) to the subject company. These valuation multiples are evaluated and adjusted based on the strengths and weaknesses of the subject company relative to the selected guideline companies. Finally, the multiples are applied to the
subject company&#146;s operating data to arrive at an indication of fair market value. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Similar Transaction Method.</B> The similar transaction method, or ST method, relies on data of actual transactions, such as mergers and acquisitions or completed initial public offerings, that have occurred in the
subject company&#146;s industry or in related industries. As in the GPC method, valuation multiples are developed and applied to the subject company&#146;s operating data to estimate fair value. Again, the ST method can be used if there are recent
transactions involving companies similar to the subject company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Methods Used to Allocate Our Enterprise Value to Classes of Securities</I></B>. In
accordance with the Practice Aid, we considered the various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock at each valuation date. The methods we utilized
consisted of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Option Pricing Method.</B> Under OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the
preferred and common stock are inferred by analyzing these options. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Probability-Weighted Expected Return Method</B>. PWERM is a scenario based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns,
considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our per share common stock value was estimated by allocating the equity value using the OPM at each valuation date up through
December&nbsp;31, 2014. Starting from our March&nbsp;31, 2015 contemporaneous valuation, we used the PWERM to allocate the equity value to each element of our capital structure, including our common stock. For both approaches, we applied a discount
to the valuations due to the lack of marketability of the ordinary shares. We calculated the discount for lack of marketability using a strike put option model and applied it as appropriate to each allocation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determined the price range set forth in the preliminary prospectus for this offering dated January&nbsp;17, 2017 after consultation with the
underwriters. As of the dates of the stock option grants in 2016 and 2017 through the date of this prospectus, our board of directors had determined the fair value of our common stock to be $5.95 per share (for the April&nbsp;22,
2016,&nbsp;July&nbsp;22, 2016 and September&nbsp;23, 2016 grants), $11.20 per share (for the December&nbsp;20, 2016 grants) and $11.34 per share (for the January&nbsp;9, 2017 grants). The determination was based upon the factors described above. We
believe the difference between the fair value of our common stock for the stock option grants in 2016 and 2017 through the date of this prospectus, in each case as determined by our board of directors, and the then-assumed initial offering price
range set forth in the preliminary prospectus for this offering dated January 17, 2017 is a result of the following factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differences in the valuation methodologies, assumptions and inputs used by the underwriters in their valuation analysis discussed with our management and used to determine the price range set forth in the preliminary
prospectus for this offering dated January 17, 2017, which assume a successful initial public offering with no weighting attributed to any other outcome for our business, such as remaining a privately held company, compared to the valuation
methodologies, assumptions and inputs used in the valuations considered by our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price range set forth in the preliminary prospectus for this offering dated January 17, 2017 necessarily assumes that an initial public offering has occurred and a public market for our common stock has been created
and, therefore, excludes any marketability or liquidity discount for our common stock, which was appropriately taken into account in our board of directors&#146; fair value determinations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differences in comparable companies in the life sciences market discussed between us and the underwriters and used to determine the price range, as compared to the prior analysis applied and comparable companies used by
our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our board of directors&#146; consideration of various objective and subjective factors in the previous fair value determinations, as described above, that were not applicable to the determination of the price range; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advancements in the development of our product candidates, in particular the receipt of FDA clearance of an IND for a Phase 2a clinical trial of ANB020 in the United States and the receipt of MHRA clearance of a CTA for
a Phase 2a clinical trial of ANB020 in the United Kingdom in December 2016. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Warrant Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for warrants for shares of preferred stock with conversion features that provide for adjustments in the warrant price as derivative
liabilities in the accompanying consolidated balance sheets at their fair value on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the date of issuance. The derivative liabilities are revalued at each balance sheet date until such instruments, so long as they remain exercisable for shares of preferred stock, are exercised or
expire, with changes in the fair value between reporting periods recorded as other income or expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use the Black-Scholes option
pricing model to estimate the fair value of the preferred stock warrant liabilities. Inputs we used in the Black-Scholes option pricing model to determine estimated fair value include the estimated fair value of the underlying convertible preferred
stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the price of the underlying convertible preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Pronouncements Recently Adopted </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2016, the FASB issued ASU 2016-15, <I>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash
Payments</I>, which addresses eight specific cash flows issues for which it provides specific guidance on treatment within the cash flow statement, with the intent of reducing diversity in practice. As permitted by this ASU, we elected to early
adopt the standard beginning with our quarterly reporting period ended September 30, 2016, with retrospective application of the amended guidance. Upon adoption, there was no effect to our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May
2014, the FASB issued ASU 2014-09, <I>Revenue from Contracts with Customers</I>, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition
guidance in FASB ASC 605, <I>Revenue Recognition</I> , including industry-specific guidance. This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that
reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs
incurred to fulfill a contract. ASU 2014-09 becomes effective for our annual reporting period beginning January&nbsp;1, 2018, including interim periods within that reporting period, with adoption permitted as early as January&nbsp;1, 2017. Entities
have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. We have not yet selected a transition method, and we are currently assessing the impact that this standard will have on
our consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, the FASB issued ASU 2016-01, <I>Financial Instruments&#151;Overall (Subtopic
825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</I>, which intends to enhance the reporting model for financial instruments by providing users of financial instruments with more decision-useful information. The
standard also addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments and requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs
incurred to fulfill a contract and becomes effective for our annual reporting period beginning January&nbsp;1, 2018, including interim periods within that reporting period; early adoption is permitted. We are currently assessing the impact that this
standard will have on our consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU 2016-02, <I>Leases (Topic 842)</I>,
which requires that lessees recognize a right-of-use asset and a related lease liability arising from leases on the balance sheet. ASU 2016-02 becomes effective for our annual reporting period beginning January&nbsp;1, 2019, including interim
periods thereafter; early adoption is permitted.&nbsp;We are currently assessing the impact that this standard will have on our consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU 2016-09, <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment
Accounting,</I> which is intended to simplify the accounting for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share-based payments including forfeiture rates, expected option terms, intrinsic value, income taxes as they relate to awards, and cash flow presentation. ASU 2016-09 becomes effective for our
annual reporting period beginning January&nbsp;1, 2017, including interim periods thereafter; early adoption is permitted. We are currently assessing the impact that this standard will have on our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The JOBS Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2012, the JOBS Act
was enacted. Section&nbsp;107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the
adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards
on the relevant dates on which adoption of such standards is required for other public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to take advantage of the
reduced reporting requirements and to rely on certain other exemptions provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an &#147;emerging growth company,&#148; the exemptions that we may rely on include, without
limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to present only two years of audited financial statements and only two years of related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use these provisions until the last day of our fiscal year following the fifth anniversary of the closing of this offering. However, if
certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.0 billion or we issue more than $1.0 billion of non-convertible debt in any three-year
period, we will cease to be an emerging growth company prior to the end of such five-year period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Nine Months Ended September 30, 2015 and 2016 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration revenue was $13.5&nbsp;million and $13.9&nbsp;million during the nine months ended September 30, 2015 and 2016, respectively. A
comparison of revenue by collaborator is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months</B><br><B>Ended&nbsp;September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Increase</B><br><B>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-amortization of upfront payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-funding of research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene-milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first and fourth quarter of 2014 we received $17.0 million and $2.0 million, respectively, in
upfront fees under our collaboration and exclusive license agreement with TESARO. For the nine months ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
September 30, 2015 and 2016, we recognized the amortized portion of these upfront fees in the amounts of $7.5&nbsp;million and $2.0&nbsp;million, respectively. Originally, the upfront fees were
to be recognized ratably through March 2016, however, in December 2015, we determined that the research and development services would be extended through December&nbsp;31, 2016, so the upfront fees will continue to be recognized ratably through
December&nbsp;31, 2016. We also recognized revenue of $5.3&nbsp;million and $3.0&nbsp;million during the nine months ended September&nbsp;30, 2015 and 2016, respectively, for research and development services performed under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2015, TESARO initiated <I>in vivo</I> toxicology studies using GLPs for an AnaptysBio-generated anti-PD-1 antagonist antibody
(TSR-042) resulting in us earning a $1.0 million milestone. We recognized revenue of $0.8 million and $0.1 million during the nine months ended September 30, 2015 and 2016, respectively. The remaining milestone is being recognized ratably through
December 2016, and was received in July 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, TESARO received clearance of their IND from the FDA for an
AnaptysBio-generated anti-PD-1 antagonist antibody (TSR-042) resulting in us earning a $4.0 million milestone payment. We recognized $3.6 million of the $4.0 million milestone payment as revenue during the nine months ended September 30, 2016. The
remaining unrecognized milestone payment of $0.4 million at September 30, 2016 will be recognized ratably through December&nbsp;31, 2016. The $4.0 million milestone payment was received in February 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2016, TESARO received clearance of their IND from the FDA for an AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022)
resulting in us earning a $4.0 million milestone payment. We recognized $3.6 million of the $4.0 million milestone payment as revenue during the nine months ended September 30, 2016. The remaining unrecognized milestone payment of $0.4 million at
September 30, 2016 will be recognized ratably through December 31, 2016. The $4.0 million milestone payment was received in June 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
June 2016, Celgene successfully completed an <I>in vivo</I> toxicology study using GLPs for an AnaptysBio-generated antibody resulting in us earning a $0.5&nbsp;million milestone payment in June&nbsp;2016. We recognized the $0.5&nbsp;million
milestone payment as revenue during the nine months ended September&nbsp;30, 2016. The $0.5&nbsp;million milestone payment was received in June&nbsp;2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, Celgene cleared a U.S. IND with the FDA and initiated a Phase 1 trial, resulting in us earning a $1.0&nbsp;million milestone
payment. The $1.0 million milestone payment was received in January 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2016, we achieved a $1.0 million milestone upon
initiation of <I>in vivo</I> toxicology studies using GLPs for an AnaptysBio-generated anti-LAG-3 antagonist antibody (TSR-033) being advanced by TESARO, for which we recognized revenue of approximately $0.9 million. The remaining unrecognized
milestone payments of $0.1 million at September 30, 2016 will be recognized ratably through December 31, 2016. The $1.0 million milestone payment was received in September 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that any collaboration revenue we generate will continue to fluctuate from period to period as a result of the timing and amount of
milestones and other payments from our existing collaborations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $10.7 million and $10.4&nbsp;million during the nine months ended September 30, 2015 and 2016,
respectively, for a decrease of $0.3 million. The decrease was due primarily to the recognition of a tax incentive, which reduced our expenses by $6.2 million during the nine months ended September 30, 2016, upon our determination that the tax
incentive was collectible. No tax incentive was recorded during the nine months ended September 30, 2015. The decrease was offset by a $3.4&nbsp;million increase in outside service for preclinical trial work, a $1.7 million increase in clinical
trial work, as well as a $1.0&nbsp;million increase in salaries and related expenses including recruiting and relocation expense, resulting primarily from an increase in research and development personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase as we advance our development
programs further and, in particular, as we enter into clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Administrative </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $2.5&nbsp;million and $3.4 million during the nine months ended September 30, 2015 and 2016,
respectively, for an increase of $0.9 million. The increase was due primarily to a $0.7&nbsp;million increase in salaries and related expenses for new senior level positions, and a $0.2&nbsp;million increase in intellectual property related legal
expenses, primarily those related to prosecuting and maintaining patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative
expenses will increase for the foreseeable future as we incur additional costs associated with being a publicly traded company, including legal, auditing and filing fees, additional insurance premiums, investor relations expenses and general
compliance and consulting expenses. Also, we expect our intellectual property related legal expenses, including those related to preparing, filing, prosecuting and maintaining patent applications, to increase as our intellectual property portfolio
expands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest Expense </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest
expense was $0.3 million during each of the nine months ended September 30, 2015 and 2016. The interest expense represents effective interest of 9.25% and 9.29% during the nine months ended September 30, 2015 and 2016, respectively, on our
outstanding Term&nbsp;A Loans, which had an outstanding principal balance of $5.0 million as of September 30, 2015 and 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in Fair Value of
Liabilities for Preferred Stock Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the liabilities for stock warrants resulted in an expense of $1.5
million and income of $0.3&nbsp;million during the nine months ended September 30, 2015 and 2016, respectively, due to changes in the valuation of our Series C convertible preferred stock which impacts the estimated fair value of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Income (Expense) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income
(expense) was ($0.2) million during the nine months ended September 30, 2015 and primarily consisted of a foreign exchange loss of ($0.3) million related to our Australian subsidiary, which was established in March 2015. Other income (expense) was
$0.2&nbsp;million during the nine months ended September 30, 2016 and primarily consisted of interest income from our money market fund, as well as foreign exchange gains related to our Australian subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Years Ended December&nbsp;31, 2014 and 2015 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration
revenue was $15.8&nbsp;million and $17.6&nbsp;million during the years ended December&nbsp;31, 2014 and 2015, respectively. A comparison of revenue by collaborator is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year<BR>Ended&nbsp;December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Increase</B><br><B>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-amortization of upfront payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-funding of research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Momenta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,100</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(592</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(598</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first and fourth quarter of 2014 we received $17.0 million and $2.0 million, respectively, in
upfront fees under our collaboration and exclusive license agreement with TESARO. For the years ended December&nbsp;31, 2014 and 2015, we recognized the amortized portion of these upfront fees in the amounts of $7.0&nbsp;million and
$9.4&nbsp;million, respectively. Originally, the upfront fees were to be recognized ratably through March 2016, however, in December 2015, we determined that the research and development services would be extended through December&nbsp;31, 2016, so
the upfront fees will continue to be recognized ratably through December&nbsp;31, 2016. We also recognized revenue of $4.6&nbsp;million and $6.5&nbsp;million during the years ended December&nbsp;31, 2014 and 2015, respectively, for research and
development services performed under the agreement. We recognized revenue of $1.7&nbsp;million during the year ended December&nbsp;31, 2015, for the achievement of two $1.0 million milestones upon initiation of <I>in vivo</I> toxicology studies,
under the principles of good laboratory practice, using the AnaptysBio-generated anti-PD-1 antagonist antibody (TSR-042) and the AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022), each being advanced by TESARO. The remaining unrecognized
milestone payments of $0.3&nbsp;million at December&nbsp;31, 2015 will be recognized ratably through December 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2014, we
successfully completed our collaboration with Momenta for which we earned a success fee. During the year ended December&nbsp;31, 2014, we recognized revenue from Momenta of $3.1&nbsp;million, which relates to a $2.0&nbsp;million success fee and
$1.1&nbsp;million in amortization of the upfront fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The final deliverable under our 2011 antibody generation agreement with Celgene was
completed in 2014. During the year ended December&nbsp;31, 2014, we recognized revenue of $0.6&nbsp;million, which relates to $0.5&nbsp;million for a success fee and $92,000 for research and development services performed under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to other collaboration agreements for which in the year ended December&nbsp;31, 2014 we recognized $0.6&nbsp;million in
collaboration revenue. We completed our obligations under these agreements in 2014 and do not anticipate any additional revenue from them beyond 2014, and we did not recognize any additional revenue from them during the year ended December&nbsp;31,
2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $8.6 million and $17.3&nbsp;million during the years ended December&nbsp;31, 2014 and 2015,
respectively, for an increase of $8.7&nbsp;million. The increase is due primarily to a $6.6&nbsp;million increase in outside services for preclinical trial work performed primarily in Australia, as well as a $1.7 million increase in salaries and
related expenses resulting primarily from an increase in research and development personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Administrative </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $2.4&nbsp;million and $3.6 million during the years ended December&nbsp;31, 2014 and 2015,
respectively, for an increase of $1.2 million. The increase is due primarily to a $0.7&nbsp;million increase in salaries and related expenses for new senior level positions, and a $0.4&nbsp;million increase in audit and tax fees for additional
quarterly and annual services required in preparation for our initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest Expense </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense was $1.3 million and $0.5 million during the years ended December&nbsp;31, 2014 and 2015, respectively, for a decrease of $0.8
million. The interest expense for the year ended December&nbsp;31, 2014 represents stated interest of 10.0% on our convertible promissory notes principal of $2.0&nbsp;million, as well as the write-off of the remaining discount on our convertible
promissory notes upon conversion of the notes into shares of Series C-1 preferred stock. The interest expense for the year ended December&nbsp;31, 2015 represents effective interest of 9.25% on our outstanding Term&nbsp;A Loans, which had an
outstanding principal balance of $5.0 million as of December&nbsp;31, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in Fair Value of Liabilities for Preferred Stock Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the liabilities for stock warrants resulted in an expense of $59,000 and $1.3&nbsp;million during the years ended
December&nbsp;31, 2014 and 2015, respectively, due to an increase in the valuation of our Series C convertible preferred stock which had the effect of increasing the estimated fair value of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Income (Expense) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income
(expense) was ($0.2)&nbsp;million during the year ended December&nbsp;31, 2015 and primarily consisted of a foreign exchange loss of ($0.2)&nbsp;million related to our Australian subsidiary, which was established in March 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provision for Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded a
provision for income taxes of $0.1 million during the year ended December&nbsp;31, 2015 related to alternative minimum taxes, which we were not subject to during the year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Years Ended December&nbsp;31, 2013 and 2014 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration
revenue was $5.5 million and $15.8 million during 2013 and 2014, respectively, an increase of $10.4 million. Our license and collaboration agreement with TESARO accounted for the majority of the increase in collaboration revenue during 2014. A
comparison of revenue by collaborator is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Increase</B><br><B>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-amortization of upfront payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-funding of research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Momenta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,154</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,139</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2014, we received an aggregate of $19.0 million in upfront fees under our collaboration
and exclusive license agreement with TESARO, which were deferred and are recognized ratably through March 2016. We also recognized revenue of $4.6 million during 2014 for research and development services performed under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2014, we successfully completed our collaboration with Momenta for which we earned a success fee. During the year ended
December&nbsp;31, 2014, we recognized revenue from Momenta of $3.1&nbsp;million, which relates to a $2.0&nbsp;million success fee and $1.1&nbsp;million in amortization of the upfront fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our antibody generation agreement with Celgene, we recognized revenue of $2.0 million during 2013 from the amortization of the
upfront payment received in 2011. We also received $1.0 million and $0.5 million in success fees during 2013 and 2014, respectively, and recognized revenue of $0.7 million and $0.1 million for research and development services performed under this
agreement during the years ended December&nbsp;31, 2013 and 2014, respectively. The final deliverable under this agreement was completed in 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2013 and 2014, we recognized revenues aggregating $1.7 million and $0.6 million, respectively from other collaborative agreements for
which our obligations were completed in 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $8.8 million and $8.6 million during 2013 and 2014, respectively, a decrease of $0.2 million. The
decrease is due primarily to $0.4 million in lower salaries and related expenses resulting from reduced research and development positions, due to the completion of multiple collaborations during 2013 and early 2014, $0.3 million in lower
depreciation expense, and $0.1 million in lower in-licensing fees due to the expiration of one of our contracts. These decreases were partially offset by $0.6 million in higher reimbursable external expense costs incurred under our collaboration
with TESARO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Administrative </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $2.0 million and $2.4 million during 2013 and 2014, respectively, an increase of $0.4 million. The
increase is due primarily to $0.2 million in recruiting expenses for key senior hires during 2014, $0.1 million in higher salaries and related expenses for new senior level positions, and $0.1 million in higher legal expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest Expense </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense was
$0.9 million during 2013 compared to $1.3 million during 2014, an increase of $0.4 million and represents stated interest of 10.0% on our convertible promissory notes principal of $2.0 million and amortization of the related beneficial conversion
feature. The increase is due primarily to the $0.4 million write-off of the remaining discount on our convertible promissory notes upon conversion of the notes to into shares of Series C-1 Preferred stock during 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in Fair Value of Liabilities for Stock Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the liabilities for stock warrants resulted in an expense of $59,000 in 2014 and income of $0.6 million in 2013.
The change to an expense in 2014 resulted primarily from an increase in the valuation of our Series C convertible preferred stock which has the effect of increasing the estimated fair value of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From
our inception through September&nbsp;30, 2016, we have received an aggregate of $158.8&nbsp;million to fund our operations which included $84.9&nbsp;million from the sale of equity securities, $64.5 million from our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collaboration agreements and $9.4&nbsp;million from venture debt. As of September&nbsp;30, 2016, we had $47.1&nbsp;million in cash and cash equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our existing cash and cash equivalents, we are eligible to receive research and development funding and to earn milestone and
other contingent payments for the achievement of defined collaboration objectives and certain nonclinical, clinical, regulatory and sales-based events, and royalty payments under our collaboration agreements. Our ability to earn these milestone and
contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of our collaborators&#146; research and development activities and is uncertain at this time. Our Loan Agreement and our rights to payments
under our collaboration agreements are our only committed external source of funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Loan Agreement, we may borrow up to
$15.0&nbsp;million in three separate draws of $5.0&nbsp;million each, of which, at September&nbsp;30, 2016, $5.0&nbsp;million of the Term A Loans were outstanding and $5.0&nbsp;million of the Term B Loans and $5.0 million of the Term C Loans were
undrawn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, we amended the Loan Agreement to combine Term B Loans and Term C Loans for a total of $10.0 million available
for draw and delay the principal repayments for our Term&nbsp;A Loans from February&nbsp;1, 2016 until February&nbsp;1, 2017. In December 2016, the Loan Agreement was further amended to (i)&nbsp;allow for the Term&nbsp;B Loans and Term&nbsp;C Loans
to be drawn on December&nbsp;30, 2016, (ii)&nbsp;delay principal repayments of all Term Loans until February&nbsp;1, 2018 and (iii)&nbsp;amend the interest rate for each Loan. The Term&nbsp;B Loans and the Term&nbsp;C Loans were drawn on
December&nbsp;30, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;30, 2016, the Term&nbsp;B Loans and the Term&nbsp;C Loans were drawn in full and as of
December&nbsp;30, 2016, $5.0&nbsp;million of the Term&nbsp;B Loans and $5.0&nbsp;million of the Term&nbsp;C Loans were outstanding. Each Loan bears interest equal to 3-month U.S. LIBOR plus 6.37%, with principal payments beginning February&nbsp;1,
2018 and final maturity in January 2020. As of December&nbsp;31, 2016, the Loans are due in 13 monthly interest-only payments through January 2018, followed by 24 equal monthly principal and interest payments, with final maturity in January 2020. In
conjunction with the December 30, 2016 draw we issued 82,416 Series&nbsp;C Preferred warrants to the lenders with an exercise price of $4.55 which expire December&nbsp;30, 2026. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Funding Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of
capital are, and we expect will continue to be, third-party clinical and preclinical research and development services, including manufacturing, laboratory and related supplies, compensation and related expenses, legal, patent and other regulatory
expenses and general overhead costs. We believe our use of CROs and CMOs provides us with flexibility in managing our spending and limits our cost commitments at any point in time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that the net
proceeds from this offering, together with our existing cash and cash equivalents, and research funding that we expect to receive under our existing collaborations, will enable us to fund our operating expenses and capital expenditure requirements
through at least the next 24 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing drug candidates in clinical trials is
costly, and the timing of progress and expenses in these trials is uncertain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities during the nine months ended September&nbsp;30, 2015 of $7.0&nbsp;million was primarily due to cash
operating expenses of $13.2 million offset by cash received from our collaboration agreement with TESARO of $5.8 million. Net cash used in operating activities during the nine months ended September&nbsp;30, 2016 of $3.5&nbsp;million was primarily
due to cash operating expenses of $16.4&nbsp;million, offset by cash received from our collaboration agreement with TESARO of $12.4&nbsp;million and cash received from our collaboration agreement with Celgene of $0.5 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities during the year ended December&nbsp;31, 2013 of $5.8
million was primarily due to cash operating expenses for the period. Net cash provided by operating activities during the year ended December&nbsp;31, 2014 of $14.6&nbsp;million was primarily due to cash received pursuant to our collaboration
agreement with TESARO. Net cash used in operating activities during the year ended December&nbsp;31, 2015 of $9.7&nbsp;million was primarily due to cash operating expenses of $18.4&nbsp;million, offset by cash received from our collaboration
agreement with TESARO of $8.7&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities during the nine months ended September&nbsp;30, 2015 and 2016 and the years ended December&nbsp;31, 2013,
2014 and 2015 was primarily due to our purchases of property and equipment. As of this time, we plan to focus on our growth strategies and do not plan on using a significant amount of our cash resources in investing activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financing Activities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by
financing activities during the nine months ended September&nbsp;30, 2015 was $40.3 million. The cash proceeds primarily relate to the issuance of Series D Convertible Preferred Stock for net proceeds of $40.7 million in July 2015 offset by $0.5
million in payments related to deferred offering costs. The cash used in financing activities during the nine months ended September&nbsp;30, 2016 was $1.0&nbsp;million and was primarily related to payments made for our deferred offering costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities was $2.0&nbsp;million during the year ended December&nbsp;31, 2013 and represents the net cash proceeds
from the issuance of our convertible promissory notes in August 2013. Cash provided by financing activities during the year ended December&nbsp;31, 2014 was $4.9 million and represents the net cash proceeds from the issuance of our Term&nbsp;A Loans
in December 2014. The cash provided by financing activities during the year ended December&nbsp;31, 2015 was $39.4&nbsp;million and was primarily related to the issuance of Series&nbsp;D Convertible Preferred Stock for net proceeds of $40.7 million
in July 2015, partially offset by $1.4 million in payments related to deferred offering costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2015: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;Than</B><br><B>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1-3</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>3-5</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>More&nbsp;Than</B><br><B>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, including interest and final payment fee<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligation<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Future minimum annual obligations for license payments under all collaborative in-license agreements at December&nbsp;31, 2015 were $0.2 million. These obligations are excluded from the table above as the annual minimum
payments are payable through ten years from the first commercial sale, if any, or expiration of the last patent to expire, the dates of which are not determinable at this time. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In January 2016, we amended the Loan Agreement, which deferred principal repayments on our Term&nbsp;A Loans from February&nbsp;1,&nbsp;2016 to February&nbsp;1, 2017, and in December 2016, we amended the Loan Agreement
to allow for the Term B Loans and Term C Loans to be drawn on December 30, 2016, delay principal repayments of all term loans until February 1, 2018 and amend the interest rate for each loan as described in &#147;Liquidity and Capital
Resources&#148; above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Operating lease obligation includes future rent payments under an office lease, which was amended in October 2015, and expires on August&nbsp;31, 2021. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturing organizations and with
vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the
table above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest Rate Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary exposure
to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term duration of our investment portfolio and the low-risk profile of our investments, we would not expect our
operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our investment portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not believe that our cash and cash equivalents have significant risk of default or illiquidity. While we believe our cash and cash
equivalents do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at
one or more financial institutions that are in excess of federally insured limits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our debt obligations bear interest at fixed rates and,
therefore, have no exposure to changes in interest rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Exchange Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, we formed a wholly-owned subsidiary in Australia, which exposes us to foreign currency exchange risk. The functional currency of
our subsidiary in Australia is the United States dollar. Assets and liabilities of our foreign subsidiary that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the
balance sheet date except for nonmonetary assets and capital accounts, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Expenses are generally remeasured at monthly foreign currency exchange
rates which approximate average rates in effect during each period. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), net, in the consolidated statements of
operations and totaled $84,000 during the nine months ended September&nbsp;30, 2016. We do not expect the effects of changes in exchange rates to have a material impact on our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not hedged exposures denominated in foreign currencies, but may do so in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology
platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation <I>in vitro</I>. Our strategy is to advance
the development of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced wholly-owned antibody programs, ANB020 and ANB019, neutralize therapeutic targets that are genetically associated with
severe inflammatory disorders in humans. ANB020 inhibits the activity of the interleukin-33, or <FONT STYLE="white-space:nowrap">IL-33,</FONT> cytokine for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and
severe adult eosinophilic asthma. We have completed a Phase 1 trial of ANB020 in healthy volunteers in Australia under an approved Clinical Trial Notification, or CTN. We believe the results of this Phase 1 trial demonstrate a favorable safety
profile of ANB020, which was well-tolerated and for which no dose-limiting toxicities were observed, and favorable pharmacodynamic properties of ANB020, where a single dose was sufficient to suppress IL-33 function for approximately three months
post-dosing as measured by an <I>ex vivo </I>pharmacodynamic assay. We plan to disclose detailed data from this Phase 1 trial at two medical conferences during the first quarter of 2017. We have cleared an Investigational New Drug application, or
IND, with the U.S. Food and Drug Administration, or FDA, and a Clinical Trial Authorisation, or CTA, to the U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, to initiate Phase 2a trials of ANB020 in patients with severe adult peanut
allergy and moderate-to-severe adult atopic dermatitis, respectively, each of which are anticipated to be initiated during the first quarter of 2017. We anticipate top-line data from these trials to be announced during the second half of 2017. In
addition, we plan to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma. We anticipate top-line data from this trial to be announced during the first half of 2018.
ANB019 inhibits the interleukin-36, or IL-36R, receptor for the treatment of rare inflammatory diseases including generalized pustular psoriasis, or GPP, and palmo-plantar pustular psoriasis, or PPP. In November 2016, we submitted a CTN for ANB019
and, if cleared, we plan to commence a Phase 1 clinical trial in the first half of 2017, and anticipate announcing top-line data from this trial during the second half of 2017. We subsequently plan to seek regulatory clearance to initiate Phase 2
studies of ANB019 in GPP and PPP patients during 2018. In addition to ANB020 and ANB019, our wholly-owned pipeline includes novel checkpoint receptor agonist antibodies that we believe are applicable for treatment of certain autoimmune diseases
where immune checkpoint receptors are insufficiently activated, and have demonstrated efficacy in an animal model of graft-versus-host disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our wholly-owned antibody programs, multiple AnaptysBio-developed antibody programs have been advanced under our collaborations
to preclinical and clinical milestones. Our collaborations include an immuno-oncology-focused collaboration with TESARO and an inflammation-focused collaboration with Celgene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our TESARO collaboration a Phase&nbsp;1 clinical trial was initiated during the first quarter of 2016 to study an AnaptysBio-generated
anti-PD-1 antagonist antibody (TSR-042) in patients under an IND cleared by the U.S. FDA. We anticipate initiation of a registration program for TSR-042 by TESARO during the first half of 2017. A second Phase 1 trial was initiated during the third
quarter of 2016 to study an AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022) in patients under a separate IND cleared by the FDA. We anticipate initiation of a combination trial of TSR-022 with an anti-PD-1 antibody by TESARO during the
first half of 2017. Under our Celgene collaboration, an <I>in vivo</I> toxicology study using good laboratory practices, or GLPs, for an AnaptysBio-generated antibody was completed during the second quarter of 2016, and a U.S. IND was cleared by the
FDA and a Phase&nbsp;1 trial was initiated in December 2016. Including the aforementioned programs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we expect that our collaborators will advance four AnaptysBio-generated antibodies to the clinic by the end of the first half of 2017. Through December 31, 2016, we have received $65.4 million in
significant, non-dilutive funding from our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company is led by a strong management team with deep experience in antibody
discovery and development, collaborations, operations and corporate finance. Through December 31, 2016, we have raised approximately $104.1&nbsp;million from investors, including Biotechnology Value Fund, Cormorant Asset Management, Frazier
Healthcare, HBM Partners, Longwood Capital Partners and Novo A/S. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed, and will continue to develop, antibody product candidates that leverage emerging insights into biological mechanisms to
treat severe diseases with unmet medical need. The following table summarizes certain key information about our wholly-owned and partnered product candidates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g28j55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced, wholly-owned product candidates are summarized below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ANB020</B> is a potentially first-in-class antibody that inhibits the activity of IL-33, a pro-inflammatory
cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33 directly mediates release of disease-associated cytokines, which recruit pro-inflammatory cells
that mediate atopic disease. Because ANB020 inhibits IL-33 function, and acts upstream broadly across the key cell types and cytokines involved in atopy, we believe that its mechanism has advantages in the treatment of atopic diseases over competing
agents that block only a subset of the cytokines responsible for atopic diseases. The role of IL-33 signaling in asthma has been recently genetically validated through human studies published in the medical literature. We have completed a Phase 1
trial of ANB020 in healthy volunteers in Australia under an approved CTN. We believe the results of this Phase 1 trial demonstrate a favorable safety profile of ANB020, which was well-tolerated and for which no dose-limiting toxicities were
observed, and favorable pharmacodynamic properties of ANB020, where a single dose was sufficient to suppress IL-33 function for approximately three months post-dosing as measured by an <I>ex vivo </I>pharmacodynamic assay. We plan to disclose
detailed data from this Phase 1 trial at two medical conferences during the first quarter of 2017. We have a cleared U.S. IND and a U.K. CTA to initiate Phase 2a trials of ANB020 for the treatment of severe adult
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
peanut allergy and moderate-to-severe adult atopic dermatitis, respectively, each of which are anticipated to be initiated during the first quarter of 2017. We anticipate top-line data from these
trials to be announced in the second half of 2017. In addition, we plan to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma. We anticipate top-line data from this
trial to be announced during the first half of 2018. Based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field of atopic dermatitis, we estimate approximately 1.4 million adults are
affected by atopic dermatitis, of which approximately 280,000 are diagnosed with a moderate-to-severe form of this disease, of which 98,000 are believed to be suitable for treatment with systemic biological therapies in the United States. Peanut
allergy is the most common cause of food-induced allergy in the United States. Based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the food allergy field, we estimate approximately 1.7
million adults are affected by peanut allergy, of which approximately 600,000 are treated by allergists and approximately 400,000 are at risk for severe reactions and therefore we believe are suitable for treatment with systemic biological therapies
in the United States. We estimate, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders focused on asthma, that asthma affects approximately 19.0&nbsp;million individuals, of which
approximately 3.6&nbsp;million have severe, persistent occurrence of this respiratory disease in the United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>ANB019</B> is an antibody that inhibits the function of IL-36R, which we are initially developing as a potential first-in-class therapy for GPP and PPP patients. GPP is a life-threatening, rare, systemic inflammatory
disorder that, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field, we estimate affects approximately 3,000 patients in the United States with no approved therapies. Studies
have shown that GPP can be associated in some patients with mutations, that lead to abnormally high signaling through the IL-36R, which we believe can be addressed by treatment with ANB019 irrespective of whether a GPP patient has a mutated IL-36
signaling pathway. PPP is a non-fatal form of pustular psoriasis that we estimate affects approximately 150,000 patients in the United States alone. PPP is believed to be caused by increased systemic levels of IL-36 cytokines, resulting in
inflammatory pustules on the hands and feet of patients that cause significant inability to stand, walk or do manual work, which we believe can be addressed by treatment with ANB019. We believe ANB019 is the most advanced therapeutic antibody
targeting IL-36R in development. We have submitted an Australian CTN for ANB019 and, if cleared, we plan to initiate Phase&nbsp;1 trials in Australia in the first half of 2017, and anticipate announcing top-line data from this trial during the
second half of 2017. We subsequently plan to seek regulatory clearance to initiate Phase 2 studies of ANB019 in GPP and PPP patients during 2018 and plan to seek FDA Orphan Drug Designation for the treatment of GPP and PPP. The FDA may grant Orphan
Drug Designation to a drug intended to treat a disease or condition that generally affects fewer than 200,000 individuals in the United States. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Checkpoint receptor agonist</B> antibodies are being developed by AnaptysBio to multiple different immune checkpoint receptors for the treatment of certain autoimmune diseases where we believe checkpoint receptor
function is insufficiently activated. Known human immune checkpoint receptors include CTLA-4, PD-1, LAG-3, BTLA and TIGIT. We have discovered certain checkpoint receptor agonist antibodies that have demonstrated efficacy in a rodent model of
graft-versus-host disease. We anticipate that, subsequent to regulatory clearance, one of our wholly-owned checkpoint receptor antibodies will initiate human testing during 2019. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Advantages of Our SHM Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
approach to developing novel therapeutic antibody product candidates is based upon somatic hypermutation, or SHM, a critical, endogenous process that generates the essential antibody diversity required to develop a natural immune response to
pathogens. Our proprietary antibody generation platform, called SHM is designed to replicate the natural process of SHM <I>in vitro.</I> Competing antibody discovery technologies include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mouse immunization methodologies, microbial antibody display and human B-cell screening. We believe our SHM platform overcomes several key limitations associated with these competing technologies
and has the following competitive advantages: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Diversity against difficult targets.</B> By applying SHM without the constraints of an <I>in vivo</I> environment we are able to generate an unprecedented diversity of antibodies. This enables us to develop
antibodies against human targets that we believe have not otherwise been accessible to other technologies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>High potency.</B> Because our platform generates highly-potent antibodies, we are potentially able to modulate every extracellular target associated with human disease, and believe only small therapeutic doses may be
required to mediate therapeutic effect <I>in vivo</I>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Functional activity selection.</B> Our mammalian cell system simultaneously displays and secretes antibodies during the antibody discovery process, allowing us to incorporate functional assays throughout the process
and focus on producing product candidates that are optimized for the desired therapeutic activity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Speed.</B> Our platform technology has enabled us to generate therapeutic-grade antibodies and subsequently advance preclinical manufacturing and toxicology studies to the filing of an IND or foreign equivalent,
typically in approximately 2.5 years. We believe this timeline is significantly shorter than conventional antibody discovery approaches based upon mouse immunization and microbial display systems. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Manufacturability.</B> By using mammalian cell display to generate our therapeutic antibodies, we believe our platform mitigates risks associated with antibody expression, formulation and stability during the
antibody generation process. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Bispecific antibodies.</B> A bispecific antibody is a single therapeutic molecule designed to bind two different targets. Bispecific antibodies have the advantage of combining two therapeutic mechanisms with the goal
of increasing therapeutic efficacy, in comparison to monospecific antibodies that bind either of the targets individually. We believe our competitors&#146; bispecific strategies generally rely on proteins with non-natural formats, resulting in
unpredictable pharmacokinetics and manufacturing properties. Our strategy is to develop bispecific antibodies that are composed of two different heavy chains with a common shared light chain that resemble the natural antibody structure and exhibit
the desired functional activity to each target. Utilizing our proprietary SHM platform, we are able to generate a large diversity of heavy and light chain varieties against each therapeutic target, and then co-mature a common light chain in the
context of two different heavy chains, which permits us to identify bispecific antibodies with sufficient potency against each of the two targets that we believe will provide greater therapeutic benefit. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading antibody
development company with a pipeline of novel therapeutic antibodies, which is being further expanded by applying our technology platform to emerging biological targets. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advancing our wholly-owned lead product candidates to clinical milestones.</B> We are working to demonstrate
the safety and efficacy of our wholly-owned pipeline programs, and have completed a Phase&nbsp;1 trial of ANB020 in healthy volunteers in Australia. We believe the results of this Phase 1 trial demonstrate a favorable safety profile of ANB020, which
was well-tolerated and for which no dose-limiting toxicities were observed, and favorable pharmacodynamic properties of ANB020, where a single dose was sufficient to suppress IL-33 function for approximately three months post-dosing as measured by
an <I>ex vivo </I>pharmacodynamic assay. We plan to disclose detailed data from this Phase 1 trial at two medical conferences during the first quarter of 2017. We have a cleared U.S. IND and U.K. CTA to initiate Phase 2a trials in patients with
severe adult peanut allergy and moderate-to-severe adult atopic dermatitis, respectively, each of which are anticipated to be initiated during the first quarter of 2017. We anticipate top-line data from these trials to be announced during the second
half of 2017. In addition, we plan to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
severe adult eosinophilic asthma. We anticipate top-line data from this trial to be announced during the first half of 2018. We have also submitted an Australian CTN and, if cleared, we plan to
initiate a Phase 1 healthy volunteer trial for ANB019 in the first half of 2017, and anticipate announcing top-line data from this trial during the second half of 2017. We subsequently plan to seek regulatory clearance to initiate Phase 2 studies of
ANB019 in GPP and PPP patients during 2018. For both ANB020 and ANB019, we are conducting, or plan to conduct, our initial clinical trials in Australia, and we plan to then conduct further clinical development in the United States and other
countries. We have elected to pursue this strategy in order to benefit from certain financial incentives that Australia makes available for biotechnology research and development,&nbsp;and because we believe that&nbsp;Australia provides a
streamlined approval processes for the initiation of first-in-human studies and that the&nbsp;clinical data we generate in Australia will subsequently be accepted by the FDA and foreign regulatory agencies outside of Australia.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Continuing to expand our proprietary pipeline by generating new product candidates using our technology platform.</B> Using our proprietary SHM antibody generation platform, we are able to rapidly develop novel
antibodies against biological emerging targets. Our goal is to continue expanding our wholly-owned new therapeutic antibody program pipeline by innovating one or more novel pipeline antibodies each year. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Identifying emerging opportunities in key therapeutic areas.</B> We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating
biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes translational biology assessments, such as human genetics, <I>ex vivo</I> tissue pathology and target expression patterns, to understand the relevance of
emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid initial efficacy assessment. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Retaining rights to strategic products in key commercial markets.</B> We intend to retain ownership and control of our pipeline programs to key preclinical and clinical inflection points. We may build sales and
marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing
resources to advance through development and commercialization. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Milestones </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart describes key milestones we have achieved since July 2015. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g320192g34o44.jpg" ALT="LOGO">
</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:1pt" ALIGN="center">

<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Milestones Achieved Since July 2015</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Program</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Milestone</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Timing</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">AnaptysBio</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">ANB020 (anti-IL-33)</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">ANB019 (anti-lL-36R)</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Checkpoint Receptor
Agonist</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Australian CTN Cleared</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Top Line Data</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">US IND CIeared</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">UK CTA Cleared</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP
Tox</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Australian CTN Submitted</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Animal Efficacy Data</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2015</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2015</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2016</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4
2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TESARO</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Partnership</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Partnership</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-042 (anti-PD-1)</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-022 (anti-TIM-3)</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-033 (anti-LAG-3)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox Phase 1 Trial Initiation</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial
Initiation</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q2 2015</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q1 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2015</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q3 2016</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Celgene</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Partnership</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Undisclosed</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GLP Tox</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">US IND Cleared</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Initiation</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q2 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q4 2016</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart describes milestones anticipated during 2017 and 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g50j92.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:1pt" ALIGN="center">

<TR>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Anticipated 2017-2018 Milestones</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Program</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Milestone</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Anticipated Timing</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">AnaptysBio</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">ANB020 (anti-IL-33)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Detailed Data at</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Medical Conferences</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Atopic Dermatitis Phase
2a Trial</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Top-Line Data</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Peanut Allergy Phase 2a Trial</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Top-Line Data</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">Eosinophilic Asthma Phase 2a</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Trial Top-Line Data</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Q1 2017</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H2 2017</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H2 2017</FONT><br><FONT
STYLE="font-size:0.5pt" COLOR="#FFFFFF">H1 2018</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">ANB019 (anti-lL-36R).</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Top-Line Data</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">GPP Phase 2 Trial Initiation</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">PPP Phase 2 Trial
Initiation</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H2 2017</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">2018</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">2018</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Checkpoint Receptor</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Agonist</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Initiation</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">2019</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TESARO</FONT><br><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Partnership</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-042 (anti-PD-1)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Initiate Registration Trial</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H1 2017</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-022 (anti-TIM-3)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Initiate PD-1 Combo Trial</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H1 2017</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:1pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">TSR-033 (anti-LAG-3)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">Phase 1 Trial Initiation</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:0.5pt" COLOR="#FFFFFF">H1 2017</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established collaborations with pharmaceutical and biotechnology companies that have provided us with $65.4&nbsp;million in payments
through December 31, 2016. Multiple antibodies, generated by us prior to or during a strategic collaboration, are currently being advanced through development by our collaborators. Our collaborations with TESARO and Celgene are described below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TESARO Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our
immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize antibodies generated using our SHM platform consisting of the following antibody product candidates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1 Monospecific Antagonist Antibody (TSR-042)</I>: Phase 1 clinical trial dosing initiated in the first quarter of 2016 subsequent to the acceptance of a U.S. FDA IND, finalize registration strategy and
initiate a registration program in the first half of 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-TIM-3 Monospecific Antagonist Antibody</I> (<I>TSR-022</I>): Phase 1 clinical trial dosing initiated in the third quarter of 2016 subsequent to the acceptance of a U.S. FDA IND, expect initiation of an anti-PD-1
combination trial in the first half of 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-LAG-3 Monospecific Antagonist Antibody</I> (<I>TSR-033</I>): currently in preclinical development, expect the initiation of a Phase 1 trial in the first half of 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1/TIM-3 Bispecific Antagonist Antibody</I>: currently in lead selection process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1/LAG-3 Bispecific Antagonist Antibody</I>: currently in lead selection process; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Undisclosed Bispecific Antagonist Antibody</I>: currently in lead selection process. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Celgene Programs
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our collaboration with Celgene, we developed therapeutic antibodies against multiple targets. We granted Celgene the option to
obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to
each target under collaboration. We successfully delivered antibodies against three targets. Celgene is currently advancing two anti-inflammatory antibody programs, and has completed an <I>in vivo</I> toxicology study under GLP, cleared a U.S. IND
with the FDA and initiated a Phase 1 trial for one of these two antibodies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Wholly-Owned Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced, wholly-owned pipeline programs, ANB020 and ANB019, are described below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANB020: Anti-IL-33 Antibody </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB020 is a
potentially first-in-class antibody that inhibits the activity of IL-33 and is being developed to treat atopic diseases, including moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma. Despite
the key role of IL-33 in atopic diseases, it has been historically difficult for other antibody technologies to generate a functional anti-IL-33 therapeutic agent. We believe ANB020 is the most advanced antibody therapeutic candidate in development
targeting the IL-33 cytokine. We are currently conducting a Phase 1 trial of ANB020 in healthy volunteers in Australia under an approved CTN. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IL-33
Target Biology </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IL-33 is a pro-inflammatory cytokine that signals through the ST2 receptor, which multiple studies suggest serves as a
central mediator of various immune responses leading to Th2-type inflammatory disorders, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
atopic dermatitis, food allergies, asthma and other atopic diseases. In response to pathogens, viruses, toxins or allergens, IL-33 is rapidly released from mucosal epithelial and endothelial
cells. For example, a recent scientific study has indicated that individuals with asthma symptoms express higher levels of IL-33 than healthy control subjects. IL-33 initiates a diverse array of cellular immune responses, including the activation of
mast cells, basophils and eosinophils, leading to production of downstream cytokines, such as IL-4, IL-5 and IL-13, which are associated with atopic diseases. IL-33 also acts on T helper 2, or Th2, effector cells and Innate Lymphoid Cell Type 2, or
ILC2, two types of white blood cells that initiate and orchestrate atopic responses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because ANB020 inhibits IL-33 function and acts
upstream of key cell types involved in atopy and the subsequent release of Th2 cytokines, we believe that its mechanism has advantages over that of competing therapeutic antibodies which block only a subset of IL-4, IL-5 or IL-13 cytokines. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g46g27.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 1. Types of cells and cytokines modulated by IL-33. When triggered by pathogens, toxins, viruses or allergens, IL-33 is an upstream mediator of Th2
cells, mast cells, basophils, eosinophils and ILC2 cells, which lead to the secretion of IL-4, IL-5, IL-13 and other chemokines. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genetic studies support the importance of the IL-33 pathway in atopic diseases. These studies
have demonstrated that certain ST2 mutations reduce IL-33 mediated signaling and thereby protect individuals with mutated ST2 from asthma. This supports the hypothesis that an anti-IL-33 antibody, such as ANB020, has the potential to benefit asthma
patients. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g58l58.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;2. IL-33 intracellular signaling. IL-33 binds to ST2 that is expressed on the cell surface and triggers the activation of the IL-1 receptor
accessory protein, or IL-1RAP, leading to the activation of MYD88, IRAK4 and downstream kinases and inducing cytokine release. Soluble ST2 acts as a decoy receptor, inhibiting IL-33 before it engages ST2 on the cell surface. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that targeting IL-33 activity is a more promising therapeutic intervention strategy than targeting its receptor, ST2, because
(i)&nbsp;ST2 is present in significantly larger quantities, in comparison to IL-33, which will likely require high anti-ST2 antibody dosing levels and (ii)&nbsp;soluble ST2 inhibits IL-33 function, therefore blocking ST2, and likely leading to the
release of additional IL-33, thereby exacerbating atopic disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANB020 Description </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB020, which is a potential first-in-class therapeutic antibody, is our wholly-owned anti-IL-33 antibody product candidate generated using our
SHM technology platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical studies have provided evidence of ANB020&#146;s favorable potency and functional
activity in human and cynomolgus monkey <I>in vitro</I> assays. The high potency and functional activity of ANB020 for human and cynomolgus monkey IL-33 was measured using standard <I>in vitro</I> assays: equilibrium dissociation constant, or K D ,
and half-maximal inhibitory concentration values, or IC 50. ANB020 demonstrated highly potent K D values of approximately 1 pM and 37 pM for human and cynomolgus monkey IL-33, respectively. ANB020 inhibits secretion of IL-5 from primary basophils
purified from peripheral blood of healthy human subjects with an IC 50 of approximately 1.5 nM, which is approximately 15-fold greater than that of the soluble ST2 antagonist, as shown in Figure 3 below. Lower K D and IC 50 values indicate higher
potency and functional activity, respectively. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g68g50.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 3. </B><B><I>In vitro</I></B><B> assay indicates that ANB020 has approximately 15-fold greater potency than soluble ST2 in inhibiting IL-5 release.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using peripheral blood mononuclear cells, or PBMC, ANB020 inhibited human and cynomolgus monkey interferon-gamma release with an IC
50 of approximately 1.1&nbsp;nM and approximately 20.4&nbsp;nM, respectively as shown in Figure&nbsp;4 below. We have developed a whole blood version of the PBMC assay, which we are utilizing in our Phase 1 trial to understand the pharmacodynamic
activity of ANB020 in clinical trials. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g77x14.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 4. ANB020 inhibits the activity of human and cynomolgus IL-33 as measured by interferongamma release from PBMCs treated overnight with 100 mg/ml
IL-12, challenged with ten (human) or five (cynomolgus) nM IL-33 for 48 hours. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical development has also demonstrated that
ANB020 has favorable manufacturability, pharmacokinetics and toxicology to support development. Studies have demonstrated desirable manufacturing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
properties for ANB020, including robust expression from Chinese hamster ovary cells, or CHO cells, efficient purification using standard downstream techniques and stable formulation up to
concentrations required for subcutaneous dosing in humans. ANB020 demonstrated a half-life of approximately seven days in cynomolgus monkeys, retained full functional activity when incubated in normal human serum at 37 &deg;C for one week and proved
to be fully active in cynomolgus monkey sera two weeks after dosing. We have conducted preclinical toxicology studies under GLPs for ANB020. In addition, we have conducted manufacturing under good manufacturing practice to produce ANB020 in
quantities for initial clinical use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Development Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have completed a Phase 1 trial of ANB020 in healthy volunteers in Australia under an approved CTN. Our Phase&nbsp;1 trial assessed, in
single ascending doses, or SAD, and multiple ascending doses, or MAD, safety, tolerability and pharmacokinetic characteristics of ANB020. The SAD cohorts of this Phase 1 trial have been completed and, subsequent to review of the clinical data
generated under the SAD, the Australian regulatory authority approved the initiation of MAD cohorts, which have also been completed. In the double-blind, placebo-controlled Phase 1 trial, 96 healthy volunteer subjects were dosed with either a single
subcutaneous or intravenous dose of ANB020 ranging between 10 mg and 750 mg, or four multiple doses of ANB020 ranging between 40 mg and 300 mg over a period of four consecutive weeks. In our Phase 1 clinical trial of ANB020, the most common adverse
events were upper respiratory tract infection and headache, and the most severe was a reduction of white blood cell counts. There were no adverse events that were determined to be drug-related, and no dose-limiting toxicities were observed at any
dose level. We have concurrently utilized a whole blood <I>ex vivo</I> assay to evaluate pharmacodynamics, and we believe the results of this assay suggest that the pharmacodynamic activity of ANB020 can, at certain dose levels, extend to three
months subsequent to a single administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a cleared U.S. IND and U.K. CTA to initiate Phase 2a trials for ANB020 in patients
with severe adult peanut allergy and moderate-to-severe adult atopic dermatitis, respectively, each of which are anticipated to be initiated during the first quarter of 2017. We anticipate announcing top-line data from both of these trials during
the second half of 2017. In addition, we plan to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma, and announce top-line data from the trial during the first half
of 2018. Our planned Phase 2a trial in the U.K. in moderate-to-severe atopic dermatitis patients will assess the efficacy and safety of ANB020, as measured by clinical disease remission and mechanistic inflammatory cells and cytokines within
lesions, among 12-20 moderate-to-severe adult atopic dermatitis patients treated with a single dose of ANB020. Our planned Phase 2a trial in severe adult peanut allergy in the United States will assess the efficacy and safety of ANB020, as measured
by oral food challenge, among 20 severe adult peanut allergy patients treated with either a single dose of ANB020 or placebo. Our planned Phase 2a trial in severe adult eosinophilic asthma is intended to assess the efficacy and safety of ANB020
among 20 severe adult eosinophilic asthma patients treated with one or more doses of ANB020. Each of the aforementioned clinical trials are subject to regulatory review by the respective regulatory authority applicable to the jurisdiction of the
trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon demonstrating initial efficacy in Phase 2a trials, we intend to conduct subsequent Phase 2 trials and Phase 3 registration
trials for ANB020 in one or more of the aforementioned clinical indications. These later-stage trials may be conducted through collaboration with a leading pharmaceutical company with strong commercial infrastructure in respiratory and allergic
therapeutic areas. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 5 below describes our current anticipated clinical development strategy for ANB020 and our
current estimate of the approximate timeframe in which our anticipated development activities will occur. However, as described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus, the clinical development of drug product
candidates is subject to a wide range of risks and uncertainties, any of which could cause our actual development strategy or timeframes to vary from the description in the figure below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g84l93.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 5. Anticipated ANB020 clinical development strategy. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANB020 Market Opportunity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant
portion of individuals in the U.S. population experiences at least one atopic disease during their lifetime, and it is well understood that most patients with one type of atopic condition tend to present with other allergic conditions. While we
believe ANB020 may be effective across atopic diseases, we have prioritized our development efforts based on unmet medical need and potential market opportunity. We have chosen to focus our ANB020 program initially on three indications: severe adult
eosinophilic asthma, severe adult peanut allergy and moderate-to-severe adult atopic dermatitis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Asthma.</I> We estimate, based on our
analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field, that asthma affects approximately 7.7% of the adult U.S. population, or 19.0&nbsp;million individuals, of which 19%, or 3.6&nbsp;million
individuals, have severe, persistent occurrence of this respiratory disease. As a chronic inflammatory disorder, severe asthma can lead to permanent structural damage to the airways and long-term reductions in lung function. Although many
mild-to-moderate asthmatics respond well to currently available treatments, which include inhaled corticosteroids, or ICS, and long-acting beta agonists, or LABA, severe asthma in patients is generally not adequately controlled by such available
therapies. We will initially focus on the treatment of severe asthma that, based on our analysis, includes 1.1&nbsp;million adult patients whose disease is not sufficiently controlled through standard-of-care therapy. We have conducted primary
market studies that estimate approximately 45% of these patients are candidates for biologic therapies, such as ANB020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing biologic therapies include Xolair, which is approved for the treatment of moderate to
severe persistent allergic asthma patients whose asthma symptoms are not controlled by ICS. Xolair&#146;s approved labeling carries a black box warning about the risk of anaphylaxis, a severe, potentially fatal, allergic reaction, and Nucala, which
the FDA recently approved for the add-on maintenance treatment in patients aged 12 years or older with severe eosinophilic asthma. Other emerging therapies currently in development, such as lebrikizumab, benralizumab, tralokinumab, anrukinzumab,
dupilumab, AMG 317 and CNTO 7160, have yet to be approved by the FDA for treatment of asthma, while the FDA&#146;s Pulmonary-Allergy Drugs Advisory Committee recommended that the FDA approve reslizumab in adult patients aged 18 years and older for
the treatment of inadequately controlled asthma in patients with elevated eosinophils, despite an inhaled corticosteroids treatment regimen. Xolair is a difficult drug to prescribe due to complex dosing algorithms, frequent administration and risk
of anaphylaxis, and we expect the indications for Nucala, reslizumab and lebrikizumab will be limited to asthma patients defined by biomarkers. We believe that ANB020 may have therapeutic benefit across a broad range of ICS-refractory severe adult
eosinophilic asthma patients, and plan to utilize biomarkers during development to differentiate ANB020 relative to competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Peanut Allergy.</I> Peanuts are the most common cause of food-induced allergy in the United States. We estimate, based on our analysis of
publicly available data sources and interviews with physicians and key opinion leaders in the field, that approximately 1.7&nbsp;million adults in the United States have allergic responses to peanut. We estimate approximately 600,000 are treated by
allergists and approximately 400,000 are at risk for severe reactions and therefore we believe are suitable for treatment with systemic biological therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing therapies have failed to prevent the occurrence of severe reactions due to accidental peanut exposure, which often results in
systemic anaphylaxis and can lead to death. Immunotherapy approaches, such as oral or transdermal desensitization, currently being developed for this indication require patients to be dosed with increasing quantities of peanut antigens over time. If
patients are able to overcome the toxicities of this allergen-based approach, therapeutic benefit, on an allergen-specific basis, may be observed after 12 to 24 months of oral or skin patch based delivery of peanut allergens. The long-term safety
and efficacy of immunotherapy is still uncertain, and these desensitization treatments have not yet been approved by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB020 has
the potential to rapidly suppress severe adult peanut allergy through its cytokine targeting mechanism, which is allergen non-specific, allowing patients with multiple allergic responses to benefit from a single therapy, and avoids tolerability
issues by acting without allergen dosing. If approved, we anticipate that ANB020 could become the standard-of-care for the treatment of severe adult peanut allergy patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Atopic Dermatitis. </I>Atopic dermatitis is a chronic inflammatory skin disease that affects approximately 1.4 million adults in the United
States. Human studies have demonstrated that IL-33 is highly expressed in atopic dermatitis lesions and leads to the recruitment of downstream cytokines (IL-4, IL-5 and IL-13) and eosinophils to the disease site in patients. By inhibiting IL-33
function in patients, we believe ANB020 will suppress the production of the aforementioned downstream cytokines and lead to therapeutic benefit in moderate to severe adult atopic dermatitis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Current therapies for atopic dermatitis are generally focused on the topical use of non-biologic small molecules. Dupilumab is currently in
development for the treatment of atopic dermatitis, and has shown some benefit in disease remission, but requires the administration of a significantly large antibody dose (300 mg) every week or every other week, which we believe may not be
convenient for atopic dermatitis patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon public data analyses and discussions with physicians and key opinion leaders in the
field, we believe approximately 280,000 atopic dermatitis patients in the United States are diagnosed with a moderate-to-severe form of this disease that significantly impairs their daily professional and social lifestyle. Existing therapies include
topical steroids and related therapies, however such approaches have not demonstrated significant benefit for moderate-to-severe patients. We estimate that 98,000 atopic dermatitis patients would be eligible for treatment with a systemic biologic
therapy such as ANB020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANB019: Anti-IL-36R Antibody </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB019 is an antibody that
inhibits the function of IL-36R, which we are initially developing as a potential first-in-class therapy for GPP and PPP patients. GPP is a life-threatening, rare systemic inflammatory disorder reported to affect approximately 3,000 patients in the
United States alone, with no currently approved therapies. Studies have shown that GPP can be associated with mutations in the gene encoding the IL-36R antagonist, or IL-36RA, or can be caused by excessive IL-36 cytokine levels, that lead to
abnormally high signaling through the IL-36R and thereby cause the systemic inflammatory condition, GPP. We believe ANB019 is the most advanced antibody targeting the IL-36R in development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We submitted an Australian CTN for ANB019 in November 2016 and, if cleared, we plan to initiate a Phase 1 trial in Australia in the first half
of 2017. We anticipate announcing top-line data from this trial in the second half of 2017. We also plan to develop ANB019 for other IL-36R driven inflammatory conditions, including PPP, which is reported to affect approximately 150,000 patients in
the United States. We plan to seek FDA Orphan Drug Designation for ANB019 for the treatment of GPP and PPP, which we believe may be differentiated from the non-rare plaque psoriasis, or psoriasis vulgaris, based upon distinctive genetic and
translational features unique to GPP and/or PPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IL-36R Target Biology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The IL-36 subfamily of proteins consists of the IL-36 receptor antagonist, or IL-36RA, as well as three cytokines, IL-36 alpha, IL-36 beta and
IL-36 gamma, each of which have agonistic characteristics and signal through IL-36R. These IL-36 proteins are mainly expressed in keratinocytes, the predominant cell type in the epidermis. The role of the IL-36RA is to dampen the inflammatory
effects of IL-36 alpha, IL-36 beta and IL-36 gamma. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g05u85.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 6. IL-36 Receptor Signaling. Signaling is maintained in balance by the receptor antagonist. Mutations render the receptor antagonist dysfunctional
and/or increased cytokine levels lead to uncontrolled signaling causing GPP. PPP is caused by excess cytokine signaling that overcomes a normal receptor antagonist. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Studies have demonstrated the relevance of IL-36 in regulating inflammation in the skin. Mice
over-expressing the IL-36 alpha cytokine undergo a psoriasis-like condition when challenged with an inflammatory stimulus. Additionally, immuno-deficient mice transplanted with human psoriatic skin have been shown to require the IL-36R signaling to
maintain disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent human studies have demonstrated that mutations in the IL-36RA lead to the occurrence of GPP by rendering it
non-functional and unable to dampen IL-36R signaling<I>.</I> However, translational studies conducted by AnaptysBio have also demonstrated that a significant number of GPP patients do not have mutations in the IL-36RA but are likely to have
excessive levels of IL-36 cytokines leading to the same disease as patients with mutations. These findings support our hypothesis that IL-36 signaling plays a significant role in GPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that ANB019 has the potential to be the first-in-class therapeutic antibody targeting IL-36R, serving as a therapeutic opportunity
for patients with IL-36 signaling mediated inflammatory disease, including GPP and PPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANB019 Description </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB019 was generated using our SHM technology platform and has demonstrated high functional potency in blocking human and cynomolgus monkey
IL-36 signaling in preclinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB019 blocks signal transduction through the human IL-36R and cynomolgus monkey IL-36R by
inhibiting the interaction between the receptor and IL-36 alpha, IL-36 beta, and IL-36 gamma cytokines. The high potency and functional activity of ANB019 for human and cynomolgus monkey IL-36R was measured using standard <I>in vitro</I> assays to
determine K D, and IC 50 values. ANB019 has demonstrated potent K D values of approximately of 71 pM and 209 pM for human IL-36R and cynomolgus monkey IL-36R, respectively. The antibody exhibits high specificity for IL-36R, displaying no detectable
binding to related proteins. As shown in Figure 7 below, functional potency of ANB019 is at least 100-fold greater than IL-36RA in human systems, which is measured as the IC 50 of inhibition of interleukin-8, or IL-8, release from human
keratinocytes. ANB019 functional activity has been demonstrated through inhibition of IL-8 secretion from human primary keratinocytes when stimulated by IL-36 gamma of approximately 0.15 nM and 1.2 nM, respectively. Lower K D and IC 50 values
indicate higher potency and functional activity, respectively. Similar IC 50 values were observed in those same preclinical studies when keratinocytes were stimulated with IL-36 alpha or beta. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g56g27.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 7. ANB019 demonstrated functional inhibition in our preclinical studies and inhibited functional activity of IL-36 cytokines with at least 100-fold
greater potency than IL-36RA. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have demonstrated that the half-life of ANB019 in cynomolgus monkeys is more than
nine days. ANB019 is well-expressed from CHO mammalian cells and is readily purified using standard methodologies. In addition, the antibody retained full functional activity when incubated in normal human serum at 37 &deg;C for one week. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Development Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November
2016, we submitted a CTN for ANB019 and, if cleared, we plan to commence a Phase 1 clinical trial in the first half of 2017. We anticipate announcing top-line data from this trial during the second half of 2017. This Phase 1 clinical trial will test
single and multiple ascending doses of ANB019 in healthy volunteers, while also utilizing <I>ex vivo</I> assays to determine ANB019&#146;s pharmacodynamic activity range. Following completion of this initial Phase 1 trial, we plan to submit a U.S.
IND and/or a U.K. CTA to support further clinical testing of ANB019 in patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial patient testing of ANB019 will focus
primarily on GPP and PPP patients. We currently plan to conduct GPP efficacy testing of ANB019 in the United States and/or the United Kingdom using a Phase 2 clinical trial expected to be initiated in 2018 that enrolls GPP patients irrespective of
mutation status. We believe a small trial, potentially with fewer than 100 patients, may be sufficient to demonstrate substantial evidence of efficacy and safety of ANB019 in GPP.&nbsp;We intend to obtain input from FDA on clinical trial design
before conducting a pivotal clinical trial in patients with GPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also intend to develop ANB019 for PPP. We anticipate initiating a
Phase 2 trial for PPP within the United States and/or United Kingdom during 2018, followed by one or more Phase 3 pivotal registration trials. If we use a diagnostic test to select patients for inclusion in our registration program, such as a
genetic test for IL-36RA mutations, the FDA may require that the companion diagnostic be approved or cleared for use at the time the product receives marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human studies have shown that IL-36 cytokines are highly upregulated in psoriasis vulgaris, in conjunction with some upregulation of other
inflammatory cytokines such as TNF-alpha, IL-17A, IL-6 and IL-12. Therefore, we may, as part of our initial clinical testing of ANB019, conduct a proof-of-mechanism clinical trial with psoriasis vulgaris patients who are not currently on any
biological therapies. In addition, we may also consider clinical development of ANB019 for patients with psoriasis vulgaris that have failed treatment with the current standard of care, including Stelara (ustekinumab) and Cosentyx (secukinumab).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 8 below describes our current anticipated clinical development strategy for ANB019 and our
current estimate of the approximate timeframe in which our anticipated development activities will occur. However, as described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus, the clinical development of drug product
candidates is subject to a wide range of risks and uncertainties, any of which could cause our actual development strategy or timeframes to vary from the description in the figure below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g76f81.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 8. Anticipated ANB019 clinical development strategy. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, we plan to pursue a clinical development strategy that involves conducting our initial&nbsp;clinical trials in Australia.
We are pursuing this strategy in order to benefit from certain financial incentives that Australia makes available for biotechnology research and development and because we believe that Australia provides streamlined&nbsp;approval processes for the
initiation of first-in-human studies, which we believe will allow us to begin our Phase&nbsp;1 clinical trials weeks, and possibly several months, sooner than if we pursued initiation of trials in the United States. In particular, the Australian CTN
review process is conducted on a regional basis by a single committee, without the requirement for review by the TGA. In contrast, in the United States, the sponsor of a first-in-human clinical trial typically must engage in a series of steps that
include submission of an IND to the FDA and waiting 30&nbsp;days for FDA feedback, if any, and then separate submission of materials&nbsp;to a review board at the trial site. Although we expect the length of each Phase&nbsp;1 clinical trial, once
initiated, will be the same as it would be if the trials were conducted in the United States, we believe the&nbsp;streamlined&nbsp;approval processes for the initiation of our trials in Australia offers us a meaningful advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we believe that clinical data generated in Australia will subsequently be accepted by the FDA and its foreign equivalents outside
of Australia, and therefore may enable us to commence Phase 2 and possibly registration clinical trials in the United States following submission of an IND, without any need for us to repeat our Phase 1 trials in the United States. As discussed
below under &#147;Government Regulation and Product Approval&#151;Foreign Clinical Studies to Support an IND,&#148; we believe the FDA will generally accept data from well-designed, well-conducted foreign clinical trials that are conducted in
accordance with GCP where the FDA is able to validate data through onsite inspection, if the FDA deems such inspection necessary. We expect that our Phase 1 clinical trials for ANB019 will be well-designed and conducted in accordance with GCP and
therefore believe that the data from the trials will be accepted by the FDA. However, the FDA and other foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equivalents are not required to accept Phase&nbsp;1 data generated in Australia. If they do not accept any such data, we would likely be required to conduct additional Phase&nbsp;1 clinical
trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANB019 Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IL-36R cytokine dysfunction is implicated in multiple inflammatory disorders including GPP, PPP, and potentially in severe, refractory cases of
psoriasis vulgaris. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Generalized Pustular Psoriasis.</I> GPP is a chronic, life-threatening, rare disease with no currently approved
therapies. GPP is a systemic inflammatory disease characterized by the development of widespread pustules marked by idiopathic exacerbations. In severe cases, GPP patients can die from cardio-pulmonary failure, exhaustion, toxicity and/or infection
subsequent to occurrences of pustular flares. Patients with GPP suffer without robust therapeutic options because currently approved psoriasis management therapies have not demonstrated clear efficacy in the treatment of this condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through assessment of public literature and primary key opinion leader discussions, we estimate GPP affects approximately 3,000 individuals in
the United States. We have conducted, and will continue to conduct, translational studies to identify GPP patients for potential enrollment in our upcoming clinical trials in this indication. Given the limited size of this patient population in the
United States, we plan to seek Orphan Drug Designation from the FDA for ANB019 for the treatment of GPP.&nbsp;The FDA may grant Orphan Drug Designation to a product intended to treat a rare disease or condition&#151;generally one that affects fewer
than 200,000 individuals in the United States.&nbsp;If we obtain Orphan Drug Designation for ANB019 for the treatment of GPP and subsequently are the first BLA applicant to receive FDA approval for a product containing the same active molecular
structure as ANB019, ANB019 would be entitled to a seven-year exclusive marketing period in the United States for the treatment of GPP.&nbsp;Although the GPP patient population is small, we believe there is an unmet medical need that ANB019 may be
able to address. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Palmo-plantar Pustular Psoriasis.</I> PPP is a non-fatal form of pustular psoriasis that we estimate affects
approximately 2% of total psoriasis cases, approximately 150,000 patients in the United States alone. Patients experience a chronic occurrence of sterile pustules on their hands and feet, while systemic levels of IL-36 cytokines and other
inflammatory disease biomarkers are also elevated. Patients with severe symptoms may have significant pain and be unable to stand, walk or do manual work, resulting in greatly diminished quality of life. Existing anti-inflammatory therapeutic
options to our knowledge have not proven to be consistently effective in treating PPP. As we believe the PPP patient population to be less than 200,000 individuals in the United States, we plan to seek Orphan Drug Designation from the FDA for ANB019
in this indication as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Refractory Psoriasis Vulgaris.</I> Refractory psoriasis vulgaris is another potential market opportunity
for the development of ANB019. While the approved biologics that target these three cytokine pathways, including Stelara (ustekinumab) and Cosentyx (secukinumab), are effective for the majority of psoriasis vulgaris patients, a subset of the
population is refractory to approved biologics. For purposes of developing an estimate, we have defined the refractory population as the subset of the patient population that does not have at least a 75% response to the leading approved therapy,
which is Cosentyx. Based on this definition and our analysis publicly-available information and literature, we estimate that approximately 5% of the patient population, representing approximately 375,000 patients, is refractory to the leading
approved therapy for psoriasis vulgaris. We hypothesize that IL-36 cytokine function is the key inflammatory driver in such refractory patients, and therefore these patients may benefit from ANB019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Checkpoint Receptor Agonist Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
strategy includes the discovery and development of therapeutic antibodies targeting emerging opportunities in inflammation. Checkpoint receptor agonist antibodies are being developed by AnaptysBio, to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
multiple different immune checkpoint receptors, for the treatment of certain autoimmune diseases where we believe checkpoint receptor function is insufficiently activated. Known human immune
checkpoint receptors include CTLA-4, PD-1, LAG-3, BTLA and TIGIT. Certain checkpoint receptor agonist antibodies developed by AnaptysBio have demonstrated efficacy in a rodent model of graft-versus-host disease. We anticipate that, subsequent to
regulatory clearance, one of our checkpoint receptor antibodies will initiate human testing during 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our SHM Antibody Discovery Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Antibody Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Antibodies are complex
proteins naturally generated by the immune system to neutralize foreign pathogens such as bacteria or viruses. B cells, a white blood cell type responsible for the generation of antibodies in response to pathogens, secrete billions of antibodies
with different specificities into the bloodstream. Antibodies are structurally distinct Y-shaped proteins formed through the combination of two long proteins, called heavy chains, and two short proteins, called light chains. Each heavy and light
chain pair forms a binding site where the antibody specifically binds its target, otherwise known as an antigen, at the Fab domain of the antibody molecule. The specificity of each antibody to a target, and the potency of its binding strength to
that target are defined by the amino acid sequences of heavy and light chains in the Fab domain of the antibody molecule. The other end of the antibody, called the Fc domain, is responsible for communication between the antibody and the rest of the
immune system. Fc domains bind to various receptors and cause immune system effector responses. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g29m66.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 9. Antibody structure. Antibodies are composed of two heavy and light chains paired into a Y-shaped formation. Antigen binding occurs at the antigen
binding site, formed by the heavy and light chain Fab domains, while the Fc domain of the heavy chains form the effector end of the antibody. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therapeutic antibodies are typically non-naturally occurring, or recombinant, antibodies specifically developed to treat human diseases by
binding to certain proteins, and thereby modulating key biological processes. Therapeutic antibodies are injectable products that are typically dosed subcutaneously or intravenously, unlike synthetic chemistry-based &#147;small molecule&#148;
therapeutics that may also be administered orally. Therapeutic antibodies have the following key features that we believe make them more predictable than small molecules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Target Specificity.</B> Due to the large size and complex nature of the antibody Fab domain, antibodies generally bind with high specificity to the desired therapeutic target and tend to exhibit less off-target
binding to unrelated proteins, which lowers the risk of unintended biological side effects such as toxicity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Pharmacokinetics and Dosing Frequency</B>. As complex proteins, antibodies are metabolized and distributed differently than small molecules. Full length antibodies tend to exhibit serum half-lives of seven to 24 days
in humans, leading to bi-weekly or monthly dosing as typical practice for therapeutic antibodies. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Potency and Dose Quantities.</B> Antibodies are typically highly potent in binding to their desired target, with binding dissociation constants in the low nanomolar to picomolar range. Hence, antibodies tend to be
dosed at low amounts (less than 1 gram quantities per course of therapy). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that therapeutic antibodies can be
significantly de-risked pre-clinically for specificity, toxicology and pharmacokinetics, which is not generally true for small molecule drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the first therapeutic antibody was approved by the FDA in 1986, the pharmaceutical industry has sought opportunities to leverage
antibodies as therapeutic agents to treat human disease. Global sales of therapeutic antibodies have reached over $40 billion annually and are predicted to remain a fast-growing segment of the therapeutic market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Competing Antibody Technologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the promise of antibodies as a therapeutic modality, historically it has been difficult and time-consuming to generate
therapeutic-grade antibodies utilizing competing antibody discovery technologies. Such technologies have relied primarily on mouse immunization methodologies (such as wild-type or engineered mice), microbial antibody display libraries (such as phage
or yeast cell display) or human B cell screening to generate antibodies against therapeutic targets of interest. We believe the key limitations of these competitive approaches include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Insufficient Diversity</B>. Each of the prior technologies has limited, and often static, diversity of antibodies available for selection. The number of therapeutic targets that can be addressed by the available
antibodies is therefore limited. It is particularly difficult for mouse immunization approaches to identify therapeutics against conserved proteins that are homologous between human and mouse species; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Lack of Functional Activity Selection.</B> Competing technologies have not been able to drive antibody selection on the basis of functional activity. Even if antibodies are available against a certain target, they
may not bind the correct region or epitope of the protein to achieve the intended functional therapeutic effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Low Potency.</B> Antibodies from competing technologies tend to demonstrate low binding potencies against their targets. Such incomplete binding may not result in therapeutic effect that is sufficient to change
disease outcomes, or require impractically high doses to convey therapeutic benefit; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Unpredictable Manufacturing Properties.</B> Using microbial display systems such as phage and yeast display libraries has resulted in unpredictable expression, stability and formulation when manufacturing is
initiated using mammalian cells, thus leading to poor production yields and product stability. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mouse immunization
methodologies</I>. Mouse immunization methodologies involve the administration of human target antigen to mice with wild-type or engineered immune systems, with the assumption that their immune systems will generate antibodies with sufficient
potency against the desired human antigen epitope to convey biological effect. A key limitation of this approach is that when the mouse is dosed with an antigen that is similar in the human and mouse, the antigen is seen by the mouse immune system
as one of its own proteins, and very few, if any, antibodies are generated. In addition, the mouse immune system often generates mouse antibodies to epitopes that are not therapeutically relevant to humans, leading the resulting antibodies to bind
the human target but failing to convey therapeutic effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Microbial antibody display systems</I>. Microbial antibody display systems
require screening of antibodies, typically formatted as antibody fragments, from a static library diversity displayed on a bacterial or yeast microbial cell surface. The static nature of these libraries limits the range of antibody specificities to
10 9 or 10 10 range, which is generally insufficient to avail high-affinity antibodies against many antigens. This can lead to suboptimal potency, and subsequently require phage/yeast antibodies to be matured significantly, typically with random
mutagenesis, to obtain therapeutic level potencies, which is a labor-intensive and inefficient process. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, antibodies selected using this approach are expressed through the microbial cell expression machinery, which differs significantly in terms of manufacturability (expression level,
glycosylation, formulation and stability) from mammalian cell expression typically utilized for clinical and commercial manufacturing of therapeutic antibodies. Such differences typically lead to difficulties in mammalian cell manufacturing of
microbial display-derived antibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Human B cell screening methodologies</I>. Human B cell screening methodologies involve the
screening and isolation of antibodies from peripheral human blood against therapeutic antigens of interest. The key limitation of this approach is that circulating human B cells generally do not develop antibodies against endogenous proteins because
their function is to develop humoral immunity against foreign pathogens, such as bacteria and viruses. Therefore, it is challenging to obtain therapeutic antibodies against human antigens through this approach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Technology Solution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our innovative
platform is designed to replicate the natural process of SHM embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies <I>in vitro</I>. SHM is a critical, endogenous process that generates the
essential antibody diversity required to develop a natural immune response to pathogens. Our genomes encode a limited number of antibody genes, which are insufficient to generate antibodies against the wide variety of foreign pathogens encountered
from the external environment. SHM enables our immune system to expand the limited diversity encoded within our genomes to the billions of antibody specificities required to defend ourselves against external pathogens. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g66f36.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 10. Mechanism of SHM. SHM is initiated by the Activation-Induced Cytidine Deaminase, or AID, which converts cytidine to uracil at key positions,
resulting in subsequent replication, DNA repair and base excision processes that generate either wild-type (wt) or mutant DNA molecules. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key enzyme required for SHM is called activation-induced cytidine deaminase, or AID. AID has been genetically conserved throughout
mammalian biology and is required for the non-random mutagenesis pattern associated with SHM. AID is specifically expressed by B cells after contact with a foreign pathogen and modifies antibody sequences in a non-random fashion. Through SHM, B
cells evolve antibodies with the potency and specificity required to clear the foreign pathogen. However, within the <I>in vivo</I> environment, SHM does not generally progress to the creation of high potency antibodies or develop antibodies against
the body&#146;s own proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By coupling <I>in vitro</I> SHM with our mammalian cell system that simultaneously displays and secretes
antibodies, we believe SHM is able to rapidly identify and mature antibodies with desired functional activity to high potency while simultaneously mitigating the risks associated with manufacturing. We introduce AID into
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mammalian cells to replicate the non-random mutagenesis SHM pattern observed within B cells <I>in vivo</I>. Starting with a library of either fully-human or humanized antibodies, our platform
generates AID-based variants of the starting antibody library throughout the process. We have demonstrated that the pattern of mutagenesis we observe <I>in vitro</I> using our platform technology closely mimics the pattern observed among <I>in
vivo</I> generated antibodies, thereby increasing confidence that antibodies generated by our platform will be tolerated when used as therapeutic drugs in humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By selecting antibodies based on their antigen binding from the broad antibody library population SHM develops, we are able to evolve in an
iterative fashion the binding potency and function of antibodies to levels that we believe will be required for therapeutic use. We believe this approach allows us to rapidly generate antibodies with high binding potency against a target. Through
this approach, we have successfully generated therapeutic antibody product candidates to more than 25 targets, including targets that have been challenging for competing antibody technology platforms to generate such as IL-33 and TIM-3. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g64c21.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 11. SHM Antibody Generation Process. Our platform initiates antibody selection from starting libraries of human and non-human diversity, which is
further optimized through iterative rounds of SHM and selection. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each evolving antibody is expressed within the SHM-active mammalian
cell to concurrently (i)&nbsp;display the evolved antibody on the cell surface to permit cell sorting selection for potency properties while (ii)&nbsp;the same antibody is secreted into the extracellular media at sufficient quantities to permit
functional assays to be conducted. In this manner, the evolving antibodies expressed by each transfected cell are assessed in a high-throughput fashion for the desired functional activity relevant to the therapeutic mechanism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our antibody discovery platform, as described above, has the following advantages over competing approaches: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Diversity against difficult targets.</B> We are able to generate an unprecedented diversity of antibodies by applying SHM-based diversification outside of the constraints of an <I>in vivo</I> environment. This
enables us to develop antibodies against human targets that we believe have not otherwise been accessible to prior technologies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>High potency.</B> Because our platform generates highly-potent antibodies, we are potentially able to modulate every extracellular target associated with human disease, and believe only small therapeutic doses may be
required to mediate therapeutic effect <I>in vivo</I>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Functional activity selection.</B> Our mammalian cell system simultaneously displays and secretes antibodies during the antibody discovery process, allowing us to incorporate functional assays throughout the process
and focus on producing product candidates that are optimized for the desired therapeutic activity. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Speed.</B> Our platform technology has enabled us to generate therapeutic-grade antibodies and initiate subsequent preclinical manufacturing and toxicology studies, typically in less than 12 months. We believe this
timeline is significantly shorter than conventional approaches based upon mouse immunization and microbial display systems. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Manufacturability.</B> By utilizing our mammalian cell display system, we believe our approach increases the probability of success in manufacturing and commercialization by mitigating the risks associated with
antibody expression, formulation and stability during the antibody generation process. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Bispecific antibodies.</B> A bispecific antibody is a single therapeutic molecule designed to bind two different targets. Bispecific antibodies have the advantage of combining two therapeutic mechanisms with the goal
of increasing therapeutic efficacy, in comparison to monospecific antibodies that bind either of the targets individually. We believe our competitors&#146; bispecific strategies generally rely on proteins with non-natural formats, resulting in
unpredictable pharmacokinetics and manufacturing properties. Our strategy is to develop bispecific antibodies that are composed of two different heavy chains with a common shared light chain that resemble the natural antibody structure and exhibit
the desired functional activity to each target. Utilizing our proprietary SHM platform, we are able to generate a large diversity of heavy and light chain varieties against each therapeutic target, and then co-mature a common light chain in the
context of two different heavy chains, which permits us to identify bispecific antibodies with sufficient potency against each of the two targets that we believe will provide greater therapeutic benefit. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaborations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TESARO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014, we entered into a collaboration and exclusive license agreement with TESARO. We executed an amendment in November 2014 to add an
additional dual-reactive antibody product candidate. Under the terms of the amended agreement, we granted TESARO an exclusive, royalty-bearing, sublicensable worldwide license to research, develop, manufacture, market and sell products based on our
proprietary technology for the discovery, generation and optimization of certain specified immunotherapy antibodies. Specifically, we granted TESARO exclusive rights to three monospecific antibody product candidates targeting <FONT
STYLE="white-space:nowrap">TIM-3</FONT> (TSR-022), LAG-3 (TSR-033) and PD-1 (TSR-042) and three bispecific antibody product candidates targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/TIM-3,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/LAG-3</FONT></FONT> and an undisclosed target. Under the amended agreement, we are responsible for performing initial discovery and development of therapeutic antibodies with the goal
of generating immunotherapy antibodies for use in the treatment of cancer. TESARO is responsible for all subsequent preclinical, clinical, regulatory, manufacturing and other activities necessary to develop and commercialize antibodies selected
under each of six development programs, and TESARO is obligated to use commercially reasonable efforts to research, develop and commercialize at least one product to each of the four targets. During the term, other than under the collaboration, both
TESARO and we are prohibited from developing and commercializing, independently or with a third party, any agents targeting LAG-3, PD-1 or TIM-3, as single agents or in combination with other therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of this agreement, TESARO made up-front, non-creditable and non-refundable cash payments aggregating $19.0 million to us
during 2014. TESARO is also required to reimburse us on a quarterly basis for specified costs incurred by us in our initial discovery and development activities covered by the agreement. For products to each of the four targets, TESARO is required
to make milestone payments to us of up to $18.0&nbsp;million if certain research and development milestone events are achieved, up to an additional $90.0 million of milestone payments if certain U.S. and non-U.S. regulatory submissions and approvals
occur in initial and subsequent indications, and up to an additional $165.0 million upon the achievement of specified levels of annual worldwide net sales. TESARO will also be required to pay us tiered single-digit royalties, on a product-by-product
basis, on worldwide annual net sales, and additional commercial milestone payments if specified levels of annual net sales of a product are attained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement expires when no further payments are due to us, unless earlier terminated. Either
party may terminate the agreement in the event of an uncured material breach by the other party. TESARO may terminate the agreement at any time upon 90 days&#146; prior written notice to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Celgene </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2011, we entered
into a collaboration agreement with Celgene, or the Collaboration Agreement, to develop human therapeutic antibodies against multiple biological targets. We completed our responsibilities under the terms of the agreement to generate antibodies
against various mutually agreed biological targets. On a target-by-target basis, we provided Celgene an option to obtain rights to develop and commercialize a defined number of antibodies against each target. We were successful in generating
antibodies against multiple targets and Celgene has exercised its option with respect to antibodies against three targets. Celgene is currently advancing two anti-inflammatory antibodies to the clinic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the Collaboration Agreement in 2011, Celgene paid us a one-time, non-refundable, non-creditable initial fee of $6.0 million.
Celgene has reimbursed us for specified research costs in accordance with the research plans. Celgene is also obligated, on a project-by-project basis, to pay us up to a total of an additional $18.0 million if certain research and development
milestone events are achieved under such project and up to a total of an additional $35.0 million if certain regulatory milestone events are achieved under such project. Celgene will also be required to pay us single digit royalties on net sales of
products containing the delivered antibodies on a product-by-product and country-by-country basis until the later of the expiration of the last patent right that covers manufacture, use or sale of such product in such country, and in any case at
least ten years after the first commercial sale of the product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collaboration Agreement continues until our royalty
rights on any Celgene product resulting from the collaboration expire, which period will last at least ten years after any such product first goes to market. Either we or Celgene may terminate the agreement in the event of an uncured material breach
by the other party. Celgene may also terminate the agreement at any time prior to the delivery of any of the contemplated antibodies upon 90 days&#146; prior written notice to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In-Licensing Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreement with MRC
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2006, we entered into an exclusive worldwide license agreement with the Medical Research Council, or MRC, to obtain rights to
multiple patents and patent applications relating to fundamental discoveries with respect to SHM and AID by Dr.&nbsp;Michael Neuberger and his colleagues. We since amended this license agreement to include additional subject matter. Under the terms
of the agreement, or the MRC Agreement, we obtained an exclusive, worldwide, sublicensable license under specified patent rights to manufacture, use, sell and commercialize products and methods covered by such patents for all fields of use. We are
responsible for prosecution of the licensed patents and the development of therapeutic products covered by the intellectual property. We are obligated to research and develop licensed methods and licensed products for the purpose of commercializing
such methods and products at least as diligently as we research and develop our other products of similar market potential and stages of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are responsible for paying MRC an annual fee of $55,000. Additionally, for each product developed and commercialized under the MRC
Agreement, we are obligated to pay MRC up to an additional $175,000 upon the achievement of specified development milestone events and up to an additional $275,000 upon the achievement of specified regulatory milestone events. In addition we owe MRC
royalties at 0.25% of annual net sales for worldwide sales on a product-by-product at or below $750 million and 1% of annual net sales of products worldwide above $750&nbsp;million, payable on a country-by-country basis until the expiration of the
last licensed patent covering such product in such country. Under this license agreement, we have rights to 19 patents and three pending patent applications worldwide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the MRC Agreement will expire upon expiration of all royalty payment
obligations under the MRC Agreement. Either party may terminate the MRC Agreement in the event of an uncured material breach by the other party or upon the occurrence of specified bankruptcy events for the other party. We may terminate the MRC
Agreement upon 60 days&#146; notice to MRC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreement with Millipore </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2009, we signed a non-exclusive research and commercial license agreement with Millipore Corporation, or Millipore, to obtain a
non-exclusive license to patents and patent applications directed to the ubiquitous chromatin opening elements technology for the expression of proteins, particularly antibodies, generated by us, which license may be sublicensed to our contractors
and partners. Under the terms of the agreement, or the Millipore Agreement, we are obligated to pay Millipore $87,500 in annual license fees. Additionally, for each product developed and commercialized under the Millipore Agreement, we are obligated
to pay Millipore up to an additional $75,000 upon the achievement of specified development milestone events and up to an additional $4.4&nbsp;million upon the achievement of specified commercial milestone events.&nbsp;We do not owe Millipore any
royalties on net sales of products commercialized under the Millipore Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless affirmatively terminated by one of the parties,
the Millipore Agreement will continue in effect. Either party may terminate the Millipore Agreement in the event of an uncured material breach by the other party. We may terminate the Millipore Agreement upon 90 days&#146; notice to Millipore. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, we
established a wholly-owned Australian subsidiary called AnaptysBio Pty. Ltd, in order to conduct various preclinical and clinical activities for ANB020 and ANB019. We believe our Australian subsidiary will be eligible for certain financial
incentives made available by the Australian government for biotech research and development expenses. Specifically, Australia provides a refundable tax credit in the form of a cash rebate equal to 45.0% of qualified expenditures on biotech research
and development projects to Australian companies that operate the majority of their research and development activities associated with such projects in Australia. A wholly-owned Australian subsidiary of a non-Australian parent company is eligible
to receive the refundable tax credit, provided that the Australian subsidiary retains the rights to the data and intellectual property generated in Australia, and provided that the total revenues of the parent company and its consolidated
subsidiaries during the period for which the refundable tax credit is claimed are less than $20.0&nbsp;million Australian dollars. During the nine months ended September&nbsp;30, 2016, we received and recognized as a reduction in research and
development expense $3.0 million in refundable tax credits related to fiscal 2015 eligible expenditures. In September 2016, we determined that we would meet the criteria for eligibility for fiscal 2016, therefore we recognized a reduction to
research and development expense of $3.2 million equal to 45% of our eligible expenditures for the nine-month period ended September 30, 2016, as collectability was considered reasonably assured. We recorded $3.3 million as a receivable as of
September&nbsp;30, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, by establishing operations in Australia, we are able to access an established network of
manufacturing and clinical development support contractors located in Australia and benefit from Australia&#146;s streamlined approval processes for the initiation of first-in human studies. We do not have any employees with experience advancing
product candidates through the Australian regulatory review process. However, we have engaged Australian consultants with expertise in the regulatory requirements and clinical development of therapeutic products in Australia, and we&nbsp;plan to
work with established manufacturing and clinical development support contractors located in Australia, who are also familiar with Australian regulatory and product development processes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our intellectual
property is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the United States and internationally for our technology platform, product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, novel biological discoveries, epitopes, new therapeutic approaches and potential indications, and other inventions that are important to our business.&nbsp;In total, our patent
portfolio, including patents to our technology platform licensed from MRC and patents licensed from Kyoto University, consisted of 38&nbsp;issued patents and 43&nbsp;pending patent applications as of November 30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our product candidates, generally we initially pursue patent protection covering compositions of matter, antibody sequence diversity,
epitopes, functional activity and methods of use. Throughout the development of our product candidates, we seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through
additional methods of use and biomarker and companion diagnostic related claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent portfolios for our two internal programs and
platform technology are outlined below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANB020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2016, we owned 15 patent applications in various countries directed to the antibody sequence of ANB020 and its variants,
epitopes, methods of use and related matters. We intend to prosecute the pending applications and pursue patent issuance and protection in key commercial markets where significant product sales may occur. Patents that may issue from these pending
applications would provide protection until January 2037. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANB019 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2016, we owned one international patent application, filed under the PCT, which is directed to the antibody sequence of
ANB019 and its variants, epitopes, methods of use and related matters. We intend to prosecute the pending international application, and pursue patent issuance and protection in key commercial markets where significant product sales may occur.
Patents that may issue from the expected international application would provide protection until April 2036. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Platform Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our platform technology is covered by U.S. and foreign issued patents and pending patent applications, emanating from our in-licensed portfolio
and wholly-owned portfolio, currently under prosecution in various jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our wholly-owned portfolio includes patents and patent
applications directed to platform technology related inventions associated with antibody library design, antibody humanization, mammalian cell display and secretion, and other technical attributes relating to the discovery, maturation and
optimization of antibodies using our technology platform. Patents relating to our platform technology that have been issued to date provide protection through 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual questions.
In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we may not obtain or maintain adequate patent protection for any of
our product candidates or for our technology platform. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide
sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. For a more comprehensive discussion of the risks related to our intellectual property, please see
&#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of
the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisional patent application related to the patent. A U.S. patent also may be accorded a PTA under certain circumstances to compensate for delays in obtaining the patent from the USPTO. In some
instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest date of filing a non-provisional patent application related to the U.S. patent. In addition, in the United States, the term of a U.S. patent that
covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension
of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total
of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug.
In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are
available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on trade secrets relating to our technology platform and product candidates and seek to protect and maintain the confidentiality
of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through
contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not
be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of
employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#146;s relationship
with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the
employee&#146;s use of our confidential information are our exclusive property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must manufacture drug product for clinical trial use in compliance with cGMP. The cGMP regulations include requirements relating to
organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records
and reports, and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and FDA satisfaction before any product is approved and we can manufacture commercial products. Our third-party
manufacturers will also be subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our internal manufacturing capabilities include non-cGMP antibody and reagent production using small scale quantities for
characterization and <I>in vitro</I> and <I>in vivo</I> preclinical assessment of product candidates. We do not have and we do not currently plan to acquire or develop the facilities or capabilities to manufacture cGMP drug substance or filled drug
product for use in human clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party manufacturers to generate cGMP-grade cell lines and will rely on them to
produce cGMP drug product required for our planned clinical trials, and expect to continue to rely on third parties to manufacture clinical trial drug supplies for the foreseeable future. We also contract with additional third parties
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the filling, labeling, packaging, storage and distribution of investigational drug products. We have personnel with significant technical, manufacturing, analytical, quality, including cGMP,
and project management experience to oversee our third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes. While our contract manufacturers have not yet produced cGMP batches of our
product candidates, they have previously manufactured products for other companies in compliance with cGMP and have been previously inspected by regulatory authorities for compliance with cGMP standards. Similarly, our personnel have had experience
with cGMP at previous positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal
or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. These actions could have a
material impact on the availability of our products. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical industries are characterized by continuing technological advancement and significant competition. While we believe that our product candidates, technology, knowledge, experience and scientific resources provide us with competitive
advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Any product candidates that we successfully develop and
commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and
convenience of our products and the ease of use and effectiveness of any companion diagnostics. The level of generic competition and the availability of reimbursement from government and other third-party payors will also significantly affect the
pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market
position before we are able to enter the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the companies against which we may compete have significantly greater financial
resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be
significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical
trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as
our lead product candidates, ANB019 and ANB020, including major pharmaceutical companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For asthma, our competitors include omalizumab
(Xolair; Roche), which has received FDA approval and functions by inhibiting the binding between free IgE and FceRI; antibodies that bind IL-5 and inhibit its interaction with the IL-5 receptor such as mepolizumab (Glaxosmithkline), which the FDA
recently approved for the add-on maintenance treatment in patients aged 12 years or older with severe eosinophilic asthma, and reslizumab (Teva), which the FDA&#146;s Pulmonary-Allergy Drugs Advisory Committee recommended for approval in adult
patients aged 18 years and older for the treatment of inadequately controlled asthma in patients with elevated eosinophils, despite an inhaled corticosteroids treatment regimen; antibodies, such as benralizumab (AstraZeneca) that bind the IL-5
receptor; antibodies that bind to IL-13 such as lebrikizumab (Roche), tralokinumab (AstraZeneca) and anrukinzumab (Pfizer) which are in clinical testing; antibodies that bind the IL-4 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receptor alpha chain such as dupilumab (Regeneron) and AMG 317 (Amgen) each in clinical testing; and an ST2-binding antibody which Roche has in-licensed from Amgen (previously known as AMG 282)
and plans to advance into Phase 2 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For peanut allergy, our competitors include DBV Technologies, which is developing
transdermal products for tolerization of food allergies, while Aimmune Therapeutics is developing oral products for peanut allergy desensitization. For GPP and PPP, our competitors include marketed therapies such as secukinumab (Cosentyx; Novartis)
which binds IL-17A, ustekinumab (Stelara; Janssen) which blocks IL-12 and 23 cytokine function; and acitretin (Soriatane; Glaxosmithkline), as well as therapies in development such as guselkumab (Janssen) which blocks IL-23 cytokine function,
gevokizumab (Xoma 052) which binds IL-1 beta and BI-655130 (Boehringer Ingelheim). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For atopic dermatitis, our competitors include
dupilumab (Regeneron, Sanofi), which has recently been filed for approval by the FDA, crisaborole (Anacor, Pfizer) which has recently been filed for approval by the FDA and VTP-38543 (Vitae) which is currently in a Phase 2 trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the
European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval
monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes
and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FDA approval process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the
FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring
and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment, or cure of a disease or condition of a human being are subject to regulation under the FDC Act, except the section of
the FDC Act which governs the approval of new drug applications, or NDAs. Biological products are approved for marketing under provisions of the Public Health Service Act, or PHSA, via a Biologics License Application, or BLA. However, the
application process and requirements for approval of BLAs are similar to those for NDAs, and biologics are associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a
variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, civil penalties, and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biological product development for a new product or certain changes to an
approved product in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence in the United States, and adequate and
well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required
may vary substantially based upon the type, complexity, and novelty of the product or disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical tests include laboratory
evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preclinical tests must comply with federal regulations and requirements, including GLPs. The results of preclinical testing are submitted to the FDA as part of an IND along with other
information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the
IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial
proposed in the IND may begin. Clinical trials involve the administration of the investigational biologic to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&nbsp;in compliance
with federal regulations; (ii)&nbsp;in compliance with GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&nbsp;under
protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to
the FDA as part of the IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose
other sanctions if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The trial protocol and informed consent information for
patients in clinical trials must also be submitted to an institutional review board, or IRB, for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the
IRB&#146;s requirements, or may impose other conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials to support BLAs for marketing approval are typically conducted
in three sequential phases, but the phases may overlap. In Phase 1, the initial introduction of the biologic into healthy human subjects or patients, the product is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects
associated with increasing doses, and, if possible, early evidence on effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug or biologic for a particular indication, dosage
tolerance, and optimal dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the
additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit risk relationship of the drug or biologic and to
provide adequate information for the labeling of the product. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic. A single Phase 3 trial with other confirmatory
evidence may be sufficient in rare instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention
of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA approval of the BLA is required before
marketing of the product may begin in the United States. The BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture, and controls.
The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application user fee, and the applicant under an approved BLA is also subject to annual product and establishment user
fees. These fees are typically increased annually. The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#146;s threshold determination that it is sufficiently complete to
permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs. Most such applications for standard review biologic products are
reviewed within ten months of the date the FDA files the BLA; most applications for priority review biologics are reviewed within six months of the date the FDA files the BLA. Priority review can be applied to a biologic that the FDA determines has
the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify
information already provided in the submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also refer applications for novel biologic products, or biologic products
that present difficult questions of safety or efficacy, to an advisory committee&#151;typically a panel that includes clinicians and other experts&#151;for review, evaluation, and a recommendation as to whether the application should be approved.
The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the
FDA will inspect the facility or the facilities at which the biologic product is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practice, or cGMP, is satisfactory and the BLA contains data that
provide substantial evidence that the biologic is safe, pure, potent and effective in the indication studied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates the
BLA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information,
in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such
resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. As a condition of BLA approval, the
FDA may require a REMS to help ensure that the benefits of the biologic outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include,
but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the
potential market and profitability of the product. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the product&#146;s safety or efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified
following initial marketing. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA
supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it
does in reviewing BLAs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign clinical studies to support an IND </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA will accept as support for an IND a well-designed, well-conducted, non-IND foreign clinical study if it was conducted in accordance
with GCP and the FDA is able to validate the data from the study through an onsite inspection, if necessary. A sponsor or applicant who wishes to rely on a non-IND foreign clinical study to support an IND must submit the following supporting
information to the FDA to demonstrate that the study conformed to GCP: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the investigator&#146;s qualifications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of the research facilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a detailed summary of the protocol and study results and, if requested, case records or additional background data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of the drug substance and drug product, including the components, formulation, specifications, and, if available, the bioavailability of the drug product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information showing that the study is adequate and well controlled; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name and address of the independent ethics committee that reviewed the study and a statement that the independent ethics committee meets the required definition; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a summary of the independent ethics committee&#146;s decision to approve or modify and approve the study, or to provide a favorable opinion; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of how informed consent was obtained; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of what incentives, if any, were provided to subjects to participate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of how the sponsors monitored the study and ensured that the study was consistent with the protocol; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of how investigators were trained to comply with GCP and to conduct the study in accordance with the study protocol; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a statement on whether written commitments by investigators to comply with GCP and the protocol were obtained. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Orphan drug designation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan
Drug Act, the FDA may grant orphan drug designation to biological products intended to treat a rare disease or condition&#151;generally a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more
than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a product available in the United States for such disease or condition will be recovered from sales of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the
biological product and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to receive
FDA approval for a biological product containing a particular active moiety to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product for that
indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market a biological product containing the same active moiety for the same disease, except in limited circumstances, such as a showing of
clinical superiority to the product with orphan drug exclusivity. A product is clinically superior if it is safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity does not prevent the FDA from approving a
different drug or biological product for the same disease or condition, or the same biological product for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the
BLA user fee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure of clinical trial information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical
trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to
discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly
available information to gain knowledge regarding the progress of development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pediatric information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and
effectiveness of the biological product for the claimed indications in all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or
partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional controls for biologics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To
help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to
immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to
prevent the introduction or spread of communicable diseases in the United States and between states. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a BLA is approved, the product
may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is
subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s
tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of
biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patent term restoration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After approval,
owners of relevant drug or biologic patents may apply for up to a five year patent extension. The allowable patent term extension is calculated as half of the drug&#146;s testing phase&#151;the time between IND application and NDA or BLA
submission&#151;and all of the review phase&#151;the time between NDA or BLA submission and approval up to a maximum of five years. The time can be shortened if FDA determines that the applicant did not pursue approval with due diligence. The total
patent term after the extension may not exceed 14&nbsp;years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For patents that might expire during the application phase, the patent
owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one
year. The director of the United States Patent and Trademark Office must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug or
biologic for which an NDA or BLA has not been submitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biosimilars </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated approval pathway for biological products shown to
be highly similar to or interchangeable with an FDA licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage
form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal trials, and a clinical trial
or trials, unless the Secretary of Health and Human Services waives a required element. A biosimilar product may be deemed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for
products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference
biologic. To date, a handful of biosimilar products and no interchangeable products have been approved under the BPCIA. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by
which such products are manufactured, pose significant hurdles to implementation, which is still being evaluated by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reference
biologic is granted 12 years of exclusivity from the time of first licensure of the reference product, and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biologic
product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of
(i)&nbsp;one year after first commercial marketing of the first interchangeable biosimilar, (ii)&nbsp;18 months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii)&nbsp;18 months after resolution of a
lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv)&nbsp;42 months after the first interchangeable biosimilar&#146;s application has been approved if a patent lawsuit is ongoing
within the 42-month period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-approval requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the
post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the
internet. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse event reporting and submission of periodic reports is required following FDA approval of a BLA. The FDA also may require
post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality
control, biological product manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and
certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue
to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory
standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FDA regulation
of companion diagnostics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If use of an <I>in vitro</I> diagnostic is essential to safe and effective use of a drug or biologic product,
then the FDA generally will require approval or clearance of the diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. The review of an <I>in vitro</I> companion diagnostic in conjunction with
the review of a biologic involves coordination of review by the FDA&#146;s Center for Biologics Evaluation and Research and by the FDA&#146;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and
preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s safety
and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications are subject to an application fee, which exceeds $250,000 for most PMAs. In addition, PMAs for certain devices must generally include the results from extensive preclinical and
adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces
reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will typically inspect the manufacturer&#146;s facilities for compliance with the Quality System
Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PMA approval is not
guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate
and that can substantially delay approval. If the FDA&#146;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#146;s agreement to specific conditions, such as changes in labeling,
or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can
be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on
labeling, promotion, sale and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a device is placed on the market, it remains subject to significant regulatory
requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#146;s
manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling,
packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other U.S. healthcare laws and compliance requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the
FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (such as the Office of Inspector General), the U.S. Department of Justice, or DOJ, and
individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the
false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable
under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors
are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of
the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a
statutory exception or regulatory safe harbor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the intent standard under the Anti-Kickback Statute was amended by the
Patient Protection and Affordable Care Act, or ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the
ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented
or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal false claims and false statement laws, including the federal False Claims Act, prohibit, among other things, any person or entity from
knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal healthcare programs, including Medicare and Medicaid, or knowingly making, using, or causing to be made or used a false record
or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented
to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for
the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, and thus generally non-reimbursable, uses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to
execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party
payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no
longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, many
states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Additionally, to the extent that our product is
sold in a foreign country, we may be subject to similar foreign laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to data privacy and security regulations by both
the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the
privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates, independent contractors or agents of covered
entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties
directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal
civil actions. In addition, many state laws govern the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance
efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain
manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain
payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain
ownership and investment interests held by physicians and their immediate family members. Moreover, the Drug Supply Chain Security Act imposes new obligations on manufacturers of pharmaceutical products related to product tracking and tracing.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale
distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states
also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product
as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public
disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to
pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other
governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as
Medicare and Medicaid, injunctions, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm,
administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Coverage, pricing and reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval.
In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate
reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a
third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to
specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and
reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and
cost-effectiveness of our products, in addition to the costs required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#146;s decision to provide coverage for a product does not imply that an
adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be
available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products
through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only
be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to
currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers
are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and
third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and
third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may
be implemented in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare reform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, President Obama enacted the ACA, which has the potential to substantially change healthcare financing and delivery by both
governmental and private insurers, and significantly impact the pharmaceutical and biotechnology industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the ACA provisions of
importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some
government healthcare programs that began in 2011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January&nbsp;1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and
generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for the manufacturers&#146; outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals beginning in 2014 and by adding new mandatory eligibility categories
for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to report certain financial arrangements with physicians and teaching hospitals; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that the ACA will result in additional downward pressure on coverage and the price that we receive for any approved product, and
could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which
we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. In addition, it is possible that there will be further legislation or regulation that could harm our business, financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in August&nbsp;2011, the President signed into law the Budget Control Act of 2011,
which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least
$1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year, which went
into effect beginning on April&nbsp;1, 2013 and will stay in effect through 2025 unless additional Congressional action is taken. Additionally, in January&nbsp;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other
things, reduced Medicare payments to several providers, including hospitals and imaging centers. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for
our drugs, if approved, and, accordingly, our financial operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Foreign Corrupt Practices Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering
of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining
business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation,
including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the
foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business.
These and other laws govern our use, handling and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose
individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse
effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Europe / rest of world government
regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions
governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior
to the commencement of human clinical trials. In the United Kingdom and other countries in the EU, for example, a clinical trial authorisation must be submitted to each country&#146;s national health authority and an independent ethics committee,
much like the FDA and IRB, respectively. Once the clinical trial authorisation is approved in accordance with a country&#146;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique
contamination risks, their use may be restricted in some countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials
are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing
authorization application. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements. For other countries outside of the EU,
such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted
in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting clinical trials for
therapeutic drug candidates in Australia is subject to regulation by Australian governmental entities. Approval for inclusion in the Australian Register of Therapeutic Goods, or the ARTG, is required before a pharmaceutical drug product may be
marketed in Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Typically, the process of obtaining approval of a new therapeutic drug product for inclusion in the ARTG requires
compilation of clinical trial data. Clinical trials conducted using &#147;unapproved therapeutic goods&#148; in Australia, being those which have not yet been evaluated by the TGA for quality, safety and efficacy must occur pursuant to either the
Clinical Trial Notification, or CTN, or Clinical Trial Exemption, or CTX, process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CTN process broadly involves: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of pre-clinical laboratory and animal testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to a Human Research Ethics Committee, or the HREC, of all material relating to the proposed clinical trial, including the trial protocol. The TGA does not review any data relating to the clinical trial;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the institution or organisation at which the trial will be conducted, referred to as the &#147;Approving Authority&#148; gives the final approval for the conduct of the trial at the site, having due regard to the advice
from the HREC; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CTN trials cannot commence until the trial has been notified to the TGA. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CTX
process: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a sponsor submits an application to conduct a clinical trial to the TGA for evaluation and comment; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a sponsor cannot commence a CTX trial until written advice has been received from the TGA regarding the application and approval for the conduct of the trial has been obtained from an ethics committee and the
institution at which the trial will be conducted. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each case, it is required that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate and well-controlled clinical trials demonstrate the quality, safety and efficacy of the therapeutic product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidence is compiled which demonstrates that the manufacture of the therapeutic drug product complies with the principles of cGMP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing and clinical data is derived to submit to the Australian Committee on Prescription Medicines, which makes recommendations to the TGA as to whether or not to grant approval to include the therapeutic drug
product in the ARTG; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an ultimate decision is made by the TGA whether to include the therapeutic drug product in the ARTG. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pre-clinical studies include laboratory evaluation of the therapeutic drug product as well as animal studies to assess the potential safety
and efficacy of the drug. The results of the pre-clinical studies form part of the materials submitted to the investigators HREC in the case of a CTN trial and part of the application to the TGA in the case of a CTX trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve administering the investigational product to healthy volunteers or patients under the supervision of a qualified
principal investigator. The TGA has developed guidelines for a CTN. Under the CTN process, all material relating to the proposed trial is submitted directly to the HREC of each institution at which the trial is to be conducted. An HREC is an
independent review committee set up under guidelines of the Australian National Health and Medical Research Council. The role of an HREC is to ensure the protection of rights, safety and wellbeing of human subjects involved in a clinical trial by,
among other things, reviewing, approving and providing continuing review of trial protocols and amendments, and of the methods and material to be used in obtaining and documenting informed consent of the trial subjects. The TGA is formally notified
by submission of a CTN application but does not review the safety of the drug or any aspect of the proposed trial. The approving authority of each institution gives the final approval for the conduct of the clinical trial, having due regard to
advice from the HREC. Following approval, responsibility for all aspects of the trial conducted under a CTN application remains with the HREC of each investigator&#146;s institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The standards for clinical research in Australia are set by the TGA and the National Health and Medical Research Council, and compliance with
GCP is mandatory.&nbsp;Guidelines, such as those promulgated by the International Conference on Harmonization&nbsp;of Technical Requirements for Registration of Pharmaceuticals for Human Use, or ICH, are required across all fields, including those
related to pharmaceutical quality, nonclinical and clinical data requirements and study designs. The basic requirements for preclinical data to support a first-in-human study under ICH guidelines are applicable in Australia. Requirements related to
adverse event reporting in Australia are similar to those required in other major jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other regulations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices,
environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2016, we
had 49&nbsp;full-time employees. Of these employees, 41 were primarily engaged in research and development activities and 14 have an M.D. or a Ph.D. None of our employees are represented by a labor union or covered by collective bargaining
agreements, and we believe our relationship with our employees is good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties and Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is located in San Diego, California, and consists of approximately 25,000 square feet of leased office and
laboratory space under a lease which will expire on August&nbsp;31, 2021. We use these facilities for our administrative, research and development and other activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our facilities are adequate to meet our needs for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we
may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of
outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table provides information regarding our executive officers and directors as of January&nbsp;13, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Moyle, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dominic G. Piscitelli, M.B.A., C.P.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tiba Aynechi, Ph.D.*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.(1)(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hollings Renton, M.B.A.(3)(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John P. Schmid, M.B.A.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Schoeneck(1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James N. Topper, M.D., Ph.D.(3)(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi has resigned from our board of directors effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Audit Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Compensation Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Member of the Nominating and Corporate Governance Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Lead Independent Director. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Chairman of the Board of Directors. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hamza Suria</I><I>, M.B.A.,</I> has served as our President and Chief Executive Officer and a member of our board of directors since July
2011. From January 2009 to June 2011 Mr.&nbsp;Suria served as Vice President of Corporate Development. Before joining our company in December 2008, Mr.&nbsp;Suria worked at Maxygen, Inc., a biopharmaceutical company, where he was responsible for
partnering and alliance management of next-generation protein therapeutics in oncology supportive care, hematology and autoimmunity, including partnerships with healthcare and pharmaceutical companies, such as Roche, Sanofi S.A., Bayer Corporation
and Astellas Pharma. Mr.&nbsp;Suria received his M.S. in immunology from the University of Western Ontario, his Executive M.B.A. from the Richard Ivey School of Business of the University of Western Ontario and his B.S. in biochemistry from
Kalamazoo College. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Mr.&nbsp;Suria&#146;s thorough knowledge of our company and technology, and his scientific and
business experience, provide him with the qualifications and skills to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Marco Londei, M.D.</I> has
served as our Chief Medical Officer since October 2016. Prior to that, Dr. Londei served as our Chief Development Officer since October 2014. Before joining our company, Dr.&nbsp;Londei worked as Therapeutic Area Head Immunosciences, at
Bristol-Myers Squibb, a biopharmaceutical company, from November 2012 to September 2014. Before starting at Bristol-Myers Squibb, Dr.&nbsp;Londei served as Global Head Translational Medicine of the Autoimmunity, Transplantation &amp; Inflammation
Department at Novartis AG and Translational Science Officer at the Genomics Institute of the Novartis Research Foundation from October 2005 to October 2012. Dr.&nbsp;Londei was Professor at the Kennedy Institute of Rheumatology, Imperial College
School of Medicine, London, from July 1999 to July 2003 and then Professor and head of the gastroenterology unit at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
University College London, Medical School UK, from July 2003 through September 2007. Dr.&nbsp;Londei received his M.D. from Universit&agrave; di Bologna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B><I>Matthew Moyle, Ph.D. </I><B></B>commenced serving as our Chief Scientific Officer in May 2016. Dr.&nbsp;Moyle has more than 25 years
of industry experience in drug discovery and development of biologics. Before joining us, from October 2010 to August 2015, Dr.&nbsp;Moyle served as Vice President of Biotherapeutics at Boehringer Ingelheim GmbH, a German pharmaceutical company,
where he chaired Boehringer Ingelheim&#146;s International Biologics Council. Prior to that, Dr.&nbsp;Moyle held positions as Senior Vice President of Research and Development and Chief Scientific Officer at Theraclone Sciences, Inc., a private
biotechnology company, from May 2007 to October 2010, and as Vice President of Research and Corporate Officer at Tanox, Inc., a public biotechnology company that was acquired in 2006 by Genentech, Inc., from January 2001 to August 2005, where his
research organizations designed and developed several monoclonal antibody therapeutic candidates, including three that are currently in mid- to late-stage clinical trials and clinical development at leading pharmaceutical companies. Before Tanox,
Dr.&nbsp;Moyle served in various positions at Amgen Inc. from 1995 to 2001, including heading a research department with responsibility for building and running the company&#146;s high-throughput expression-profiling facility. Before that,
Dr.&nbsp;Moyle was a Group Leader at Corvas, International, Inc., from 1991 to 1995, where he co-discovered two novel natural product biologics that subsequently advanced to pivotal clinical trials. Dr.&nbsp;Moyle was a postdoctoral scientist at
Genentech Inc. from 1989 to 1991, where he was part of the company&#146;s first program in small molecule therapeutics. Dr.&nbsp;Moyle earned a Ph.D. and B.Sc. in Biochemistry at the University of Toronto.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dominic G. Piscitelli, M.B.A., C.P.A., </I>commenced serving as our Chief Financial Officer in January 2017. Mr.&nbsp;Piscitelli has more
than 15 years of experience in the pharmaceutical and biopharmaceutical industries, and more than 20 years of experience in finance. Before joining us, from September 2012 to January 2017, Mr.&nbsp;Piscitelli served as the Vice President of Finance
at Medivation, Inc., a biopharmaceutical company. Prior to that, from January 2011 to September 2012, Mr. Piscitelli served as the Senior Director of Global Finance at Astellas Pharma US, Inc., a pharmaceutical company. From September 2001 to
January 2011, Mr.&nbsp;Piscitelli held positions at OSI Pharmaceuticals, Inc., a biotechnology company that was acquired by Astellas Pharma US, Inc. in June 2010, serving as the Vice President of Treasury and Management Finance from 2009 to 2011,
and previously as Senior Director, Oncology Finance &amp; Treasury, Director, Commercial Finance and Associate Director/Assistant Controller, SEC Reporting. Mr. Piscitelli earned both his B.A. in Business Administration and his M.B.A. from Hofstra
University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tiba Aynechi, Ph.D.</I> has served as a member of our board of directors since April 2015.&nbsp;Dr. Aynechi is employed as a Partner at Novo
Ventures (US) Inc., which provides certain consultancy services to Novo A/S, a Danish limited liability company that manages investments and financial assets.&nbsp;Prior to joining Novo Ventures (US) Inc. in March 2010, Dr.&nbsp;Aynechi was employed
from June 2006 to March 2010 by Burrill&nbsp;&amp; Company, a private financial firm specializing in biotechnology and life sciences investment, in various positions, including from January 2009 to March 2010 as a Director in Merchant Banking where
she was responsible for regional and cross-border mergers and acquisitions, licensing, and financing transactions. Dr. Aynechi has served as a director at iRhythm Technologies, Inc., a public digital healthcare company, since May 2014.
Dr.&nbsp;Aynechi has also served as a member of the board of directors of several private biotechnology and medical device companies. Dr.&nbsp;Aynechi received her Ph.D. in biophysics from the University of California, San Francisco, where her
research involved developing computational methods for drug discovery.&nbsp;She received her B.S. in physics from the University of California, Irvine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Dr.&nbsp;Aynechi&#146;s extensive experience in the biotechnology and pharmaceutical industries, makes her qualified to serve
on our own board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Carol G. Gallagher, Pharm.D.</I> has served as a member of our board of directors since October 2011.
Dr.&nbsp;Gallagher has been a partner at New Enterprise Associates, a venture-capital firm, since October 2014.&nbsp;She </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has served as a director at Atara Biotherapeutics, Inc., a public biopharmaceutical company, since February 2013 and she became lead director in October 2014. She has also served as a director at
Atterocor, Inc. since October 2012, as chairperson of the board of directors of eFFECTOR Therapeutics, Inc. from October 2012 to 2014 and as a director of Aragon Pharmaceuticals, Inc. from February 2012 to July 2013. Dr.&nbsp;Gallagher was a venture
partner with Frazier Healthcare, a venture-capital firm, from November 2013 to July 2014. Dr.&nbsp;Gallagher served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from September 2008 to April
2011, when the company was acquired by Gilead Sciences. From 2007 to 2008, Dr.&nbsp;Gallagher was the President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Dr.&nbsp;Gallagher currently serves as a member of the
board of directors of Cleave Biosciences, a private biopharmaceutical company. Dr.&nbsp;Gallagher attended Vanderbilt University and received her B.S. and Pharm.D. degrees from the University of Kentucky. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Dr.&nbsp;Gallagher&#146;s extensive experience in the life sciences industry and as a chief executive officer provide her with
the qualifications and skills to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Nicholas B. Lydon, Ph.D., FRS</I> is a co-founder of our company and
has served on our board of directors since our company was founded in November 2005.&nbsp;Dr. Lydon also co-founded and has served on the board of directors of BluePrint Medicines Inc. since April 2011. Since 2011, Dr.&nbsp;Lydon has served as
Managing Member at Staurus Pharma, LLC, a biotechnology company. Dr.&nbsp;Lydon is also the founder of Granite Biopharma LLC, a consulting company, and has served as sole member of Granite Biopharma since 2003. Dr.&nbsp;Lydon also previously served
as Vice President, Small Molecule Drug Discovery at Amgen Inc. from 2000 to 2002. Prior&nbsp;to joining Amgen, he was the Chief Executive Officer and founder of Kinetix Pharmaceuticals, Inc., a biotechnology&nbsp;company focused on the discovery and
development of selective protein kinase inhibitors, from 1997 to 2000. Kinetix Pharmaceuticals was&nbsp;acquired&nbsp;by Amgen&nbsp;in&nbsp;2000.&nbsp;Prior to joining Kinetix, Dr.&nbsp;Lydon worked at CIBA-GEIGY, AG (Novartis) in Basel, Switzerland
from 1985 to 1997, where he was responsible for the protein kinase inhibitor program, including the discovery and preclinical development of Imatinib (Gleevec).&nbsp;Dr. Lydon began his pharmaceutical career at Schering-Plough Corporation from 1982
to 1985 where his research involved studies on recombinant interferons. Dr.&nbsp;Lydon has been awarded the Lasker~DeBakey Clinical Medical Research Award and the Japan Prize for his work on Imatinib. Other awards include the Warren Alpert
Foundation Prize, the AACR Bruce F. Cain Memorial Award and the Charles F. Kettering&nbsp;Prize from the General Motors Cancer Research Foundation.&nbsp;Dr. Lydon earned his B.S. in Biochemistry and Zoology from the University of Leeds, England, and
received his Ph.D. in Biochemistry from the Medical Sciences Institute, University of Dundee, Scotland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that
Dr.&nbsp;Lydon&#146;s extensive industry experience and significant knowledge of scientific matters provide him with the qualifications and skills to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hollings Renton, M.B.A.</I> has served as a member of our board of directors since June 2015. Mr.&nbsp;Renton previously served as the
Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from 1993 to 2008 and as the chairperson of the board of directors from 2000 to 2008. Before joining Onyx Pharmaceuticals, Mr.&nbsp;Renton served as the President and Chief
Operating Officer of Chiron Corporation, a pharmaceutical company, from 1991 to 1993, following its acquisition of Cetus Corporation. Before joining Onyx Pharmaceuticals, Mr.&nbsp;Renton served as the President of Cetus Corporation from 1990 to
1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987.&nbsp;Mr.&nbsp;Renton currently serves as chairperson of the board of directors of Portola Pharmaceuticals, Inc. He previously served on the boards
of directors of Cepheid, Inc., Kythera Biopharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Affymax Inc., Sangstat Medical Corporation, Special Olympics Northern California and the Biotechnology Industry Organization. Mr.&nbsp;Renton received his
M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Mr.&nbsp;Renton&#146;s
extensive industry experience and board memberships provide him with the qualifications and skills to serve on our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John P. Schmid, M.B.A.</I> has served as a member of our board of directors since June 2015.
Mr.&nbsp;Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 to June 2015. Before joining Auspex Pharmaceuticals, Mr.&nbsp;Schmid co-founded Trius Therapeutics, Inc., a publicly traded biopharmaceutical
company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc., in September 2013. Before he joined Trius Therapeutics, Inc., Mr.&nbsp;Schmid served as the Chief Financial Officer at
GeneFormatics, Inc., a private biotechnology company, from 1998 to 2003, and at Endonetics, Inc., a private medical device company, from 1995 to 1998. Mr.&nbsp;Schmid currently serves as a member of the board of directors of Neos Therapeutics, Inc.,
a pharmaceutical company, and as the chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr.&nbsp;Schmid received his M.B.A. from the University of San Diego and his B.A. from Wesleyan University.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Mr.&nbsp;Schmid&#146;s extensive industry experience and executive positions at multiple biopharmaceutical companies
qualify him to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>James A. Schoeneck</I> has served as a member of our board of directors since November
2015. Mr.&nbsp;Schoeneck has served as the President and Chief Executive Officer of Depomed, Inc. since April 2011 and as a director of Depomed since December 2007. Before joining Depomed, Mr.&nbsp;Schoeneck served as Chief Executive Officer of
BrainCells Inc., a private biopharmaceutical company in San Diego, from September 2005 to April 2011. Mr.&nbsp;Schoeneck has served as a director of FibroGen, Inc., a public biopharmaceutical company since June 2010. Mr.&nbsp;Schoeneck received his
B.S. in Education from Jacksonville State University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Mr.&nbsp;Schoeneck&#146;s extensive industry and leadership
experience provide him with the qualifications and skills to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>James N. Topper, M.D., Ph.D.</I> has
served as a member of our board of directors since November 2007. Dr.&nbsp;Topper has been a partner with Frazier Healthcare since August 2003, serving as General Partner since 2005. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before joining Frazier Healthcare, Dr.&nbsp;Topper served as head of the Cardiovascular Research and Development Division of Millennium
Pharmaceuticals, Inc. and ran Millennium San Francisco (formerly COR Therapeutics, Inc.) from 2002 until 2003. Before the merger of COR and Millennium in 2002, Dr.&nbsp;Topper served as the Vice President of Biology at COR from August 1999 to
February 2002. Dr. Topper has served as a director at ProNai Therapeutics, Inc., a public drug development company, since April 2014. Dr.&nbsp;Topper has served on numerous boards of directors, including Amicus Therapeutics, Inc. and Portola
Pharmaceuticals, Inc. Dr.&nbsp;Topper received his M.D. and Ph.D. in biophysics from Stanford University and his B.S. in biology from the University of Michigan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Dr.&nbsp;Topper&#146;s experience overseeing Frazier Healthcare investments in biotechnology, senior-management experience in
our industry, significant knowledge of medical and scientific matters affecting our business, and understanding of our industry provide him with the qualifications and skills to serve on our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election of Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive
officers are appointed by, and serve at the discretion of, our board of directors. There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors has adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer and other executive and senior officers. The full text of our code of conduct
will be posted on the investor relations section of our website. The reference to our website address in this prospectus does not include or incorporate by reference the information on our website into this prospectus. We intend to disclose future
amendments to certain provisions of our code of conduct, or waivers of these provisions, on our website or in public filings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are organized under the direction of our board of directors, which currently consists of seven members following
Dr.&nbsp;Aynechi&#146;s resignation from our board of directors effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. Our current certificate of incorporation and a voting agreement by
and among us and certain of our investors provides for up to eight directors, of which (i)&nbsp;up to two directors were designated by holders of our Series B, Series B-1 and <FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> Preferred Stock,
voting together as a single class on an as-converted basis, (ii)&nbsp;one director was designed by holders of our common stock, voting as a separate class and (iii)&nbsp;all remaining directors were designated by the holders of our common stock and
convertible preferred stock, voting together as a single class on an as-converted basis. Drs.&nbsp;Aynechi and Topper were the designees of holders of our Series&nbsp;B, Series B-1 and <FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT>
convertible preferred stock, voting together as a single class on an as-converted basis. Mr.&nbsp;Suria was the designee of holders of our common stock. Dr.&nbsp;Gallagher, Dr.&nbsp;Lydon, Mr.&nbsp;Renton and Mr.&nbsp;Schmid were the designees of
holders of our common stock and convertible preferred stock, voting together as a single class on an as-converted basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting
agreement and the provisions of our certificate of incorporation that govern the election and designation of our directors will terminate in connection with the completion of our initial public offering, after which no contractual obligations will
concern the election of our directors. Each of our current directors will continue to serve until the election and qualification of his or her successor, or until his or her earlier death, resignation or removal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Classified Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
completion of this offering, our board of directors will be divided into three staggered classes of directors. At each annual meeting of stockholders, a class of directors will be subject to re-election for a three-year term. As a result, only one
class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class I directors will be Dr.&nbsp;Gallagher and Dr.&nbsp;Topper and their terms will expire at the annual meeting of stockholders to be held in 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class II directors will be Mr.&nbsp;Suria and Dr.&nbsp;Lydon and their terms will expire at the annual meeting of stockholders to be held in 2019; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class III directors will be Mr.&nbsp;Renton, Mr.&nbsp;Schmid and Mr.&nbsp;Schoeneck and their terms will expire at the annual meeting of stockholders to be held in 2020. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each director&#146;s term continues until the election and qualification of his or her successor, or his or her earlier death, resignation or
removal. Our restated certificate of incorporation and restated bylaws that will be in effect upon the closing of this offering authorize only our board of directors to fill vacancies on our board of directors. Any increase or decrease in the number
of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of our board of directors may have the effect of delaying or preventing changes in
control of our company. See &#147;Description of Capital Stock&#151;Anti-Takeover Provisions&#151;Restated Certificate of Incorporation and Restated Bylaw Provisions.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with
this offering, our common stock has been approved for listing on the Nasdaq Global Select Market. Under the rules of the Nasdaq Stock Market, or Nasdaq, independent directors must comprise a majority of a listed company&#146;s board of directors
within a specified period of the closing of this offering. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance committees
be independent. Under the rules of Nasdaq, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as
amended. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board
committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. We
intend to satisfy the audit committee independence requirements of Rule 10A-3 as of the closing of this initial public offering. Additionally, compensation committee members must not have a relationship with us that is material to the
director&#146;s ability to be independent from management in connection with the duties of a compensation committee member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of
directors has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could compromise his ability to exercise independent judgment in carrying out his responsibilities.
As a result of this review, our board of directors determined that all of our directors, except for Mr.&nbsp;Suria, are &#147;independent directors&#148; as defined under the applicable rules and regulations of the Securities and Exchange
Commission, or SEC, and the listing requirements and rules of Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will
have the composition and responsibilities described below as of the closing of our initial public offering. Members serve on these committees until their resignation or until otherwise determined by our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee is
comprised of Dr.&nbsp;Gallagher, Mr.&nbsp;Schoeneck and Mr.&nbsp;Schmid, with Mr.&nbsp;Schmid as the chairman of our audit committee. The composition of our audit committee meets the requirements for independence under the current Nasdaq and SEC
rules and regulations. In addition, our board of directors has determined that Mr.&nbsp;Schmid is an &#147;audit committee financial expert&#148; as defined in Item&nbsp;407(d)(5)(ii) of Regulation&nbsp;S-K promulgated under the Securities Act. This
designation does not impose on him any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our board of directors. Our audit committee is directly responsible for, among other things:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting a firm to serve as the independent registered public accounting firm to audit our financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ensuring the independence of the independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and that firm, our interim and year-end operating results; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">considering the adequacy of our internal controls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing material related party transactions or those that require disclosure; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving or, as permitted, pre-approving all audit and non-audit services to be performed by the independent registered public accounting firm. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee is comprised of Dr.&nbsp;Gallagher, Dr.&nbsp;Lydon and Mr.&nbsp;Schoeneck, with Dr.&nbsp;Gallagher as the
chairperson of our compensation committee. Each member of this committee is a non-employee director, as defined by Rule 16b-3 promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Code and
meets the requirements for independence under the current Nasdaq listing standards and SEC rules and regulations. Our compensation committee is responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors the compensation of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors the terms of any compensatory agreements with our executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering our stock and equity incentive plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or making recommendations to our board of directors with respect to, incentive compensation and equity plans; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing our overall compensation philosophy. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominating and Governance Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and governance committee is comprised of Dr.&nbsp;Gallagher, Mr.&nbsp;Renton and Dr.&nbsp;Topper, with Mr.&nbsp;Renton as the
chairman of our nominating and governance committee. Each member of the Committee meets the requirements for independence under the current Nasdaq listing standards. Our nominating and governance committee is responsible for, among other things:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and recommending candidates for membership on our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending directors to serve on board committees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending our corporate governance guidelines and policies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluating, and overseeing the process of evaluating, the performance of our board of directors and individual directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assisting our board of directors on corporate governance matters. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and
Insider Participation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our executive officers has served as a member of our board of directors, or as a member of our
compensation or similar committee, of any entity that has one or more executive officers who served on our board of directors or compensation committee during the year ended December&nbsp;31, 2016. Prior to establishing the compensation committee,
our full board of directors made decisions relating to the compensation of our officers. For a description of transactions between us and members of our compensation committee and affiliates of such members, please see &#147;Certain Relationships
and Related Party Transactions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation earned or paid in the year ended December&nbsp;31, 2016 for each member of our board of
directors, except for our President and Chief Executive Officer, Mr.&nbsp;Suria, who receives no additional compensation for his service as a director. Other than as described below, none of our non-employee directors are expected to receive any
fees or reimbursement of any expenses (other than customary expenses in connection with the attendance of meetings of our board of directors) or any equity or non-equity awards in the year ended December&nbsp;31, 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fees&nbsp;Earned</B><br><B>or&nbsp;Paid in</B><br><B>Cash(1)($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total(2)($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hollings Renton, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John P. Schmid, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Schoeneck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;52,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;52,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gallagher, Dr. Lydon and Mr. Renton were each paid a $50,000 annual retainer fee in connection with their service on our board of directors. Mr.&nbsp;Schmid was paid an annual retainer fee of $35,000 and $5,000
in connection with his service on our board of directors and audit committee, respectively. Mr. Schoeneck was paid an annual retainer fee of $40,000, $7,500 and $5,000 in connection with his service on our board of directors, audit committee and
compensation committee, respectively. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The following table sets forth the expected aggregate number of shares of our common stock subject to outstanding stock options held by our non-employee directors as of December&nbsp;31, 2016: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:50.85pt; font-size:8pt; font-family:Times New Roman"><B>Director Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of&nbsp;Shares</B><br><B>Underlying Stock</B><br><B>Options Held as</B><br><B>of December&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hollings Renton, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John P. Schmid, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Schoeneck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2015, our board of directors approved a non-employee director compensation policy, which will
take effect following the completion of this offering. Pursuant to this policy, each of our non-employee directors will receive an annual retainer of $40,000. Additionally, a lead independent director will receive an additional annual payment of
$20,000; the chairperson of our board of directors will receive an additional annual payment of $15,000 when a lead independent director is also serving and $30,000 when no lead independent director is serving; the chairpersons of our audit,
compensation and nominating and corporate governance committees will receive an additional annual payment of $15,000, $10,000 and $7,500, respectively; and the members of our audit, compensation and nominating and corporate governance committees
will receive an additional annual payment of $7,500, $5,000 and $3,750, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, each of our
non-employee directors will receive an annual option to purchase 14,258&nbsp;shares of common stock, which vests in a single installment 12 months after the grant date, subject to the applicable director&#146;s continuous service through such date.
Additionally, each new non-employee director will receive upon election to our board of directors, an option to purchase 28,571&nbsp;shares of common stock, which will vest in 36&nbsp;equal monthly installments after the grant date, subject to the
director&#146;s continuous service through such date. The exercise price of such grants will be the fair market value of our common stock as of the grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables and accompanying narrative disclosure set forth information about the compensation provided to our executive officers
during the years ended December&nbsp;31, 2015 and 2016. These executive officers, who include our principal executive officer and the two most highly-compensated executive officers (other than our principal executive officer) serving as executive
officers as of December&nbsp;31, 2016, were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hamza Suria, President, Chief Executive Officer and Director; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Matthew Moyle, Chief Scientific Officer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Marco Londei, Chief Medical Officer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We refer to these individuals in this section as our
&#147;named executive officers.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents summary information regarding the total compensation for services rendered in all capacities that was awarded to
and earned by our named executive officers during the years ended December&nbsp;31, 2015 and 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fiscal</B><br><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bonus(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option</B><br><B>Awards(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>All Other</B><br><B>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria, M.B.A. <I></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><I></I>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2016<BR><I></I>2015</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR><I></I>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">425,000<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">382,083</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">97,431</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1,170,840</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">600<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">540</P></TD>
<TD NOWRAP VALIGN="top">(4)&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">(4)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">425,600<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1,650,894</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Moyle, Ph.D. <I></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">181,250</TD>
<TD NOWRAP VALIGN="top">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">614,546</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">37,726</TD>
<TD NOWRAP VALIGN="top">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">833,522</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D. <I></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR><I></I>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2016<BR><I></I>2015</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR><I></I>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">380,000<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">363,333</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">81,094</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">406,049</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">11,944<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">42,042</P></TD>
<TD NOWRAP VALIGN="top">(6)&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">(7)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="top" ALIGN="right">391,944<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">892,518</P></TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent bonuses awarded at the discretion of our board of directors. Our board of directors has not yet determined the amounts of cash bonuses payable to our named executive
officers earned in 2016. We anticipate that cash bonuses, if any, for 2016 will be determined by our board of directors by March 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant-date fair value of the awards granted under our 2006 Equity Incentive Plan to our named executive officers during the years ended December&nbsp;31, 2015
and 2016, as computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the awards reported in the Stock Option Awards column are set forth in Note 8 to our consolidated financial statements.
Note that the amounts reported in this column reflect the aggregate accounting cost for these awards, and do not necessarily correspond to the actual economic value that may be received by the named executive officers from the awards.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Reflects Dr.&nbsp;Moyle&#146;s salary from the commencement of his employment on May 16, 2016, through December&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Reflects group term life insurance premiums paid by us on behalf of Mr.&nbsp;Suria. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Reflects reimbursements paid to, or on behalf of, Dr. Moyle during the year ended December 31, 2016, consisting of $36,221 for temporary housing and moving expenses and $1,505 for group term life insurance premiums paid
by us on behalf of Dr. Moyle. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Reflects reimbursements paid to, or on behalf of Dr. Londei during the year ended December 31, 2016, consisting of $7,984 for moving expenses and $3,960 for group term life insurance premiums paid by us on behalf of Dr.
Londei. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Reflects reimbursements paid to, or on behalf of, Dr.&nbsp;Londei during the year ended December&nbsp;31, 2015, consisting of $39,462 for temporary housing and moving expenses, including tax gross-up with respect to
temporary housing payments, and $2,580 for group term life insurance premiums paid by us on behalf of Dr.&nbsp;Londei. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial terms and conditions of employment of each of Mr.&nbsp;Suria and Drs. Londei and Moyle were set forth in written employment
agreements. Each of these arrangements was approved by our board of directors. We believed these employment agreements were necessary to induce these individuals to forego other employment opportunities or leave their current employer for the
uncertainty of a demanding position in a new and unfamiliar organization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr.&nbsp;Suria&#146;s Employment Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an employment agreement effective as of January&nbsp;1, 2012 and amended October&nbsp;9, 2012 and September&nbsp;16, 2014, or
collectively the Suria Employment Agreement, Mr.&nbsp;Suria serves as our President and Chief Executive Officer. The Suria Employment Agreement sets forth the principal terms and conditions of his employment, including his initial annual base salary
of $285,000 and an annual target cash bonus opportunity of 25% of his base salary, subject to pro rata adjustment for any partial years worked, which bonus is earned based on our achievement of specified milestones and performance objectives, as
well as Mr.&nbsp;Suria&#146;s performance relative to one or more performance objectives established by Mr.&nbsp;Suria, our compensation committee and our board of directors, the achievement of which is evaluated by us. On August&nbsp;14, 2015, our
board of directors increased Mr.&nbsp;Suria&#146;s annual base salary to $420,000, effective as of August&nbsp;1, 2015. The Suria Employment Agreement provided for the grant of a time-based stock option to purchase up to 214,239 shares of our common
stock under our 2006 Equity Incentive Plan. The Suria Employment Agreement also provided for the grant of a performance-based stock option to purchase up to 97,721 shares of our common stock under our 2006 Equity Incentive Plan, all of which would
vest immediately in the event of a change of control or qualified initial public offering. These options were granted with an exercise price equal to the fair value of our common stock on the date of grant and vest over four years as described in
more detail in &#147;&#151;Outstanding Equity Awards at Fiscal Year-End Table&#148; below. Mr.&nbsp;Suria&#146;s employment is at will and may be terminated at any time, with or without cause. However, pursuant to the terms of the Suria Employment
Agreement, Mr.&nbsp;Suria will be entitled to severance benefits upon a qualifying termination of employment as described in &#147;&#151;Potential Payments upon IPO, Termination or Change in Control&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.&nbsp;Londei&#146;s Employment Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an employment agreement effective as of October&nbsp;20, 2014, or the Londei Employment Agreement, Dr.&nbsp;Londei serves as our
Chief Medical Officer. The Londei Employment Agreement sets forth the principal terms and conditions of his employment, including his initial annual base salary of $350,000 and an annual target cash bonus opportunity of 25% of his base salary, which
bonus is earned based on our achievement of specified milestones and performance objectives, as well as Dr.&nbsp;Londei&#146;s performance relative to one or more performance objectives established by Dr.&nbsp;Londei, our compensation committee and
our board of directors, the achievement of which is evaluated by us. On August&nbsp;14, 2015, our board of directors increased Mr.&nbsp;Londei&#146;s annual base salary to $375,000, effective as of August&nbsp;1, 2015. Likewise, the Londei
Employment Agreement provides for additional discretionary performance-based bonuses. The Londei Employment Agreement provides for the grant of a time-based stock option to purchase 160,965 shares of our common stock under our 2006 Equity Incentive
Plan. This option was granted with an exercise price equal to the fair value of our common stock on the date of grant and vests over four years as described in more detail in &#147;&#151;Outstanding Equity Awards at Fiscal Year-End Table&#148;
below. Dr.&nbsp;Londei&#146;s employment is at will and may be terminated at any time, with or without cause. However, pursuant to the terms of the Londei Employment Agreement, Dr.&nbsp;Londei will be entitled to severance benefits upon a qualifying
termination of employment as described in &#147;&#151;Potential Payments upon IPO, Termination or Change in Control&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr. Moyle&#146;s
Employment Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an employment agreement effective as of March 22, 2016, or the Moyle Employment Agreement, Dr. Moyle
serves as our Chief Scientific Officer. The Moyle Employment Agreement sets forth the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
principal terms and conditions of his employment, including his initial annual base salary of $290,000 and an annual discretionary cash bonus of up to 30% of his base salary, which bonus is
earned based on achievement of certain performance goals established by our Chief Executive Officer, the final determination of which for any given year is made by our Chief Executive Officer and board of directors in their sole and absolute
discretion. The Moyle Employment Agreement provides for reimbursement of actual and reasonable costs that Dr. Moyle may incur to relocate his household from Connecticut to the San Diego area no later than May 2017, up to $135,000 in the aggregate,
and the Moyle Employment Agreement provides further that, in the interim, Dr. Moyle shall be reimbursed for actual and reasonable costs incurred by Dr. Moyle for him to spend at least three weeks per month in the San Diego area, up to a maximum of
an additional $40,000 in the aggregate. The Moyle Employment Agreement provides for the grant, as soon as practicable following the effective date of the Moyle Employment Agreement, of a time-based stock option to purchase up to 169,417 shares of
our common stock under our 2006 Equity Incentive Plan. This option was granted with an exercise price equal to the fair market value of our common stock on the date of grant and vests over four years, with 1/4 of the underlying shares vesting on the
first calendar anniversary of the effective date of the Moyle Employment Agreement and, thereafter, an additional 1/48 of the underlying shares vesting on the same day of each succeeding calendar month. Dr. Moyle&#146;s employment is at-will and may
be terminated at any time, with or without cause. However, pursuant to the terms of the Moyle Employment Agreement, Dr. Moyle will be entitled to severance benefits upon a qualifying termination of employment as described in &#147;&#151;Potential
Payments upon IPO, Termination or Change in Control&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal Year-End Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents, for each of the named executive officers, information regarding outstanding stock options held as of
December&nbsp;31, 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option Awards</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant
Date<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options (#)</B><br><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options (#)</B><br><B>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria, M.B.A.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Dec. 9, 2008</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Dec.&nbsp;8,&nbsp;2018</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Feb.&nbsp;10,&nbsp;2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Feb. 9, 2020</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Feb.&nbsp;24,&nbsp;2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Feb.&nbsp;23,&nbsp;2021</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dec.&nbsp;9,&nbsp;2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Dec. 8, 2021</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Feb.&nbsp;1,&nbsp;2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Jan.&nbsp;31,&nbsp;2022</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Feb.&nbsp;1,&nbsp;2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Jan. 31, 2022</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dec.&nbsp;17,&nbsp;2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Dec.&nbsp;16,&nbsp;2022</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sep.&nbsp;16,&nbsp;2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Sep. 15, 2024</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aug.&nbsp;14,&nbsp;2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Aug.&nbsp;13,&nbsp;2025</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Moyle, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July&nbsp;22,&nbsp;2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;21,&nbsp;2026</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Oct. 28, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Oct. 27, 2024</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aug.&nbsp;14,&nbsp;2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Aug. 13, 2025</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">All stock-option awards have been granted under our 2006 Equity Incentive Plan. Except where otherwise noted, the underlying shares of each option vest over four years, with 1/4 of the underlying shares vesting on the
first calendar anniversary of the grant date and, thereafter, 1/48 of the underlying shares vest on the same day of each succeeding calendar month, subject to the optionee&#146;s employment through each applicable vesting date, such that 100% of the
underlying shares will have vested on the fourth calendar anniversary of the grant date. See &#147;&#151;2006 Equity Incentive Plan&#148; below for a description of the plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">These options are early-exercisable, except for the options granted on August&nbsp;14, 2015. The options vested
as to their underlying shares as follows: (i)&nbsp;the shares underlying the options granted on December&nbsp;9, 2008,&nbsp;February&nbsp;10, 2010, February&nbsp;24, 2011, and December&nbsp;9, 2011 and December 17, 2012, and 73,291
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
shares underlying the options granted on February 1, 2012, have fully vested; (ii) of the 97,721 shares underlying an option granted on February&nbsp;1, 2012, all vest only upon a change in
control (as defined in the 2006 Equity Incentive Plan) or qualified IPO (as defined in our restated certificate of incorporation) that is approved by our board of directors, subject to Mr.&nbsp;Suria&#146;s employment on such date; (iii) of the
51,840 shares underlying the option granted on September&nbsp;16, 2014, 1/4 vested on September&nbsp;16, 2015, and thereafter 1/48 vest on the sixteenth day of each succeeding calendar month, starting October&nbsp;16 2015; and (iv) of the 265,928
shares underlying the option granted on August&nbsp;14, 2015, 1/4 vested on August&nbsp;13, 2016, and 1/48 vest on the thirteenth day of each succeeding calendar month, starting September&nbsp;13, 2016, provided that if Mr.&nbsp;Suria is terminated
without Cause or resigns for Good Reason (as each is defined in his employment agreement) in connection with a Change in Control (as defined in the 2006 Equity Incentive Plan), then all of the shares underlying the option shall vest at that time.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">These options are not early-exercisable. The options vest as to their underlying shares as follows: (i)&nbsp;of the 169,417 shares underlying the option granted on July 22, 2016, 1/4 vest on May 16, 2017, and 1/48 vest
on the 16th&nbsp;day of each succeeding calendar month, starting June 16, 2017, provided that if Mr.&nbsp;Moyle is terminated without Cause or resigns for Good Reason (as each is defined in his employment agreement) in connection with a Change in
Control (as defined in the 2006 Equity Incentive Plan), then all of the shares underlying the options shall vest at that time. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">These options are early-exercisable, except for the options granted on August&nbsp;14, 2015. The options vest as to their underlying shares as follows: (i)&nbsp;of the 160,965 shares underlying the option granted on
October&nbsp;28, 2014, 1/4 of the shares vested on October&nbsp;24, 2015, and thereafter, 1/48 vest on the 24th day of each succeeding calendar month, starting November&nbsp;24, 2015, provided that if Dr.&nbsp;Londei is terminated without Cause or
resigns for Good Reason (as each is defined in his employment agreement) in connection with a Change in Control (as defined in the 2006 Equity Incentive Plan), then all of the shares underlying the option shall vest at that time; and (ii)&nbsp;of
the 92,223 shares underlying the option granted on August&nbsp;14, 2015, 1/4 vested on August&nbsp;13, 2016, and 1/48 vest on the thirteenth day of each succeeding calendar month, starting September&nbsp;13, 2016, provided that if Mr.&nbsp;Londei is
terminated without Cause or resigns for Good Reason (as each is defined in his employment agreement) in connection with a Change in Control (as defined in the 2006 Equity Incentive Plan), then all of the shares underlying the option shall vest at
that time. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments upon IPO, Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IPO </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Suria Employment
Agreement, his option granted on February&nbsp;1, 2012 will vest in full upon a Change in Control (as defined in the 2006 Equity Incentive Plan) or Qualified IPO (as defined in our restated certificate of incorporation) that is approved by our board
of directors, subject to Mr.&nbsp;Suria&#146;s employment on such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Suria Employment Agreement, the Londei Employment Agreement and the Moyle Employment Agreement, in the event that
Mr.&nbsp;Suria, Dr.&nbsp;Londei or Dr. Moyle is terminated without &#147;cause&#148; or resigns for &#147;good reason&#148; (each as defined in the applicable employment agreement), provided that each delivers a signed settlement and general release
in favor of us and satisfies all conditions to make such release effective, (i)&nbsp;each will receive continued severance payments for 12 months, nine months and nine months, respectively and (ii)&nbsp;and if each elects continuation coverage under
the Consolidated Omnibus Budget Reconciliation Act of 1985, or COBRA, we will pay directly to the insurance provider of our group health plans, the monthly premium for such continuation coverage for each officer and his family, for 12 months, nine
months and nine months, respectively, or such earlier date on which coverage with a new employer is obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Suria Employment Agreement and certain of his outstanding stock option agreements, if we experience a change in control and
Mr.&nbsp;Suria is terminated without &#147;cause&#148; or resigns for &#147;good reason&#148; (each as defined in the employment agreement) upon the occurrence of, or within 13 months following, such change in control, and provided that
Mr.&nbsp;Suria delivers a signed settlement and general release in favor of us and satisfies all conditions to make such release effective, (i)&nbsp;Mr.&nbsp;Suria will receive the continued severance payments and COBRA premiums described above for
12 months and (ii)&nbsp;certain of his currently outstanding stock options will vest in full as described in more detail in &#147;&#151;Outstanding Equity Awards at Fiscal Year-End Table&#148; above. In addition, Mr.&nbsp;Suria&#146;s option granted
on February&nbsp;1, 2012, will vest in full upon a change in control, subject to Mr.&nbsp;Suria&#146;s employment on such date. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant
to the Londei Employment Agreement, if we experience a change in control and Dr.&nbsp;Londei is terminated without &#147;cause&#148; or resigns for &#147;good reason&#148; (each as defined in the employment agreement or applicable option agreement)
upon the occurrence of, or within 13 months following, such change in control, and provided that Dr.&nbsp;Londei delivers a signed settlement and general release in favor of us and satisfies all conditions to make such release effective,
(i)&nbsp;Dr.&nbsp;Londei will receive the severance payments and COBRA premiums described above for nine months and (ii)&nbsp;each of his currently outstanding stock options will vest in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Moyle Employment Agreement, if we experience a change in control and Dr. Moyle is terminated without &#147;cause&#148; or
resigns for &#147;good reason&#148; (each as defined in the employment agreement or applicable option agreement) upon the occurrence of, or within 13 months following, such change in control, and provided that Dr. Moyle has permanently relocated his
household to the San Diego area prior to such termination or resignation and delivers a signed settlement and general release in favor of us and satisfies all conditions to make such release effective (i) Dr. Moyle will receive the severance
payments and COBRA premiums described above for nine months and (ii) the stock option granted to him pursuant to his employment agreement will vest in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each employment agreement contains a &#147;better after-tax&#148; provision, which provides that if any of the payments to Mr.&nbsp;Suria,
Dr.&nbsp;Londei, or Dr. Moyle respectively, constitutes a parachute payment under Section&nbsp;280G of the Code, the payments will either be (i)&nbsp;reduced or (ii)&nbsp;provided in full to the executive, whichever results in the executive
receiving the greater amount after taking into consideration the payment of all taxes, including the excise tax under Section&nbsp;4999 of the Code, in each case based upon the highest marginal rate for the applicable tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit and Stock Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2006 Equity
Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2006 Equity Incentive Plan was adopted by our board of directors on April&nbsp;24, 2006 and approved by our
stockholders on May&nbsp;26, 2006, which was later amended by our board of directors on July&nbsp;11, 2014 and approved by our stockholders on April&nbsp;29, 2015. Most recently, on April&nbsp;22, 2016, our board of directors amended and restated
our 2006 Equity Incentive Plan to extend the term of the plan by ten years, such that it now expires on April&nbsp;21, 2026, which was approved by our stockholders on January 13, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2006 Equity Incentive Plan provides for the grant of both incentive stock options, which qualify for favorable tax treatment to their
recipients under Section&nbsp;422 of the Code, and nonstatutory stock options, as well as for the issuance of shares of restricted stock and stock appreciation rights. We may grant incentive stock options only to our employees, including officers
and directors who are also employees. We may grant nonstatutory stock options to our employees, officers, directors and consultants. We have only granted stock options under our 2006 Equity Incentive Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2006 Equity Incentive Plan is administered by our board of directors. Our board of directors
has the authority to construe and interpret our 2006 Equity Incentive Plan, grant awards, determine the terms of such awards and make all other determinations necessary or advisable for the administration of the plan. Subject to the terms of our
2006 equity incentive plan and the consent of any adversely affected participant, our board of directors also has the authority to reduce the exercise or strike price of any outstanding stock option or stock appreciation right, cancel any
outstanding stock option or stock appreciation right in exchange for a new stock option or stock appreciation right, or take any other action that is treated as a repricing under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of each stock option must be at least equal to the fair market value of our common stock on the date of grant. The exercise
price of incentive stock options granted to 10% stockholders must be at least equal to 110% of the fair market value of our common stock on the date of grant. The maximum permitted term of options granted under our 2006 Equity Incentive Plan is ten
years, except that the maximum permitted term of incentive stock options granted to 10% stockholders is five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted under
our 2006 Equity Incentive Plan generally vest over a four-year period based on employment through certain vesting dates. Options granted under our 2006 Equity Incentive Plan may not be transferred in any manner other than by will or by the laws of
descent and distribution or as determined by our board of directors. Unless otherwise permitted by our board of directors, stock options may be exercised during the lifetime of the optionee only by the optionee or the optionee&#146;s guardian or
legal representative. Options granted under our 2006 Equity Incentive Plan generally may be exercised for a period of three months after the termination of the optionee&#146;s service to us for any reason other than due to death or disability, for a
period of 12 months in the case of death, and 18 months in the case of disability, or such longer period as our board of directors may provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined in the 2006 Equity Incentive Plan), the 2006 Equity Incentive Plan provides that awards
may be assumed, continued or substituted by the successor or acquiring entity. If any surviving or acquiring corporation fails to assume, continue or substitute such stock awards, stock awards held by participants whose continuous service has not
terminated will accelerate vesting in full prior to the corporate transaction. All stock awards will terminate at or prior to the corporate transaction. In addition, our board may also provide, in its sole discretion, that the holder of a stock
award that will terminate upon the occurrence of a corporate transaction will receive a payment, if any, equal to the excess of (1)&nbsp;the value of the property the participant would have received upon exercise of the stock award over (2)&nbsp;the
exercise price otherwise payable in connection with the stock award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2016, we had reserved 2,695,896 shares of our
common stock for issuance under our 2006 Equity Incentive Plan. As of September 30, 2016, options to purchase 362,910 of these shares had been exercised, options to purchase 1,856,750 of these shares remained outstanding and 513,407 of these shares
remained available for grant. The options outstanding as of September&nbsp;30, 2016 had a weighted-average exercise price of $4.13 per share. We have ceased issuing awards under our 2006 Equity Incentive Plan as of the effective date of our 2017
Equity Incentive Plan. The remaining shares available for issuance under the 2006 Equity Plan will be rolled over into the 2017 Equity Incentive Plan. Our 2017 Equity Incentive Plan became effective on the date immediately prior to the date of this
prospectus. As a result, we will no longer grant any additional options under the 2006 Equity Incentive Plan. However, any outstanding options granted under the 2006 Equity Incentive Plan will remain outstanding, subject to the terms of our 2006
Equity Incentive Plan and stock option agreements, until such outstanding options are exercised or until they terminate or expire by their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017
Equity Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a 2017 Equity Incentive Plan that became effective on the date immediately prior to the date of
this prospectus and serves as the successor to our 2006 Equity Incentive Plan. We reserved 1,647,163&nbsp;shares of our common stock to be issued under our 2017 Equity Incentive Plan. The number of shares
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reserved for issuance under our 2017 Equity Incentive Plan will increase automatically on January&nbsp;1 of each of 2018 through 2027 by the number of shares equal to 4% of the aggregate number
of outstanding shares of our common stock as of the immediately preceding December&nbsp;31. However, our board of directors may reduce the amount of the increase in any particular year. In addition, the following shares will again be available for
grant and issuance under our 2017 Equity Incentive Plan: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares subject to options or stock appreciation rights granted under our 2017 Equity Incentive Plan that cease to be subject to the option or stock appreciation right for any reason other than exercise of the option or
stock appreciation right; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares subject to awards granted under our 2017 Equity Incentive Plan that are subsequently forfeited or repurchased by us at the original issue price; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares subject to awards granted under our 2017 Equity Incentive Plan that otherwise terminate without shares being issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares surrendered, cancelled or exchanged for cash or a different award (or combination thereof); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of common stock reserved but not issued or subject to outstanding grants under our 2006 Equity Incentive Plan on the date of this prospectus will be available for grant and issuance under our 2017 Equity
Incentive Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of common stock issuable upon the exercise of options or subject to other awards under our 2006 Equity Incentive Plan prior to the date of this prospectus that cease to be subject to such options or other awards
by forfeiture or otherwise after the date of this prospectus will be available for grant and issuance under our 2017 Equity Incentive Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of common stock issued under our 2006 Equity Incentive Plan that are forfeited or repurchased by us at the original issue price after the date of this prospectus will be available for grant and issuance under our
2017 Equity Incentive Plan; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of common stock subject to awards under our 2006 Equity Incentive Plan that are used to pay the exercise price of an option or withheld to satisfy the tax withholding obligations related to any award will be
available for grant and issuance under our 2017 Equity Incentive Plan. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2017 Equity Incentive Plan authorizes the award
of stock options, restricted stock awards, or RSAs, stock appreciation rights, or SARs, restricted stock units, or RSUs, performance awards and stock bonuses. No person is eligible to receive more than 1,000,000&nbsp;shares in any calendar year
under our 2017 Equity Incentive Plan other than a new employee of ours, who will be eligible to receive no more than 2,000,000&nbsp;shares under the plan in the calendar year in which the employee commences employment. No more than
12,000,000&nbsp;shares will be issued pursuant to the exercise of incentive stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2017 Equity Incentive Plan is administered
by our compensation committee, all of the members of which are outside directors as defined under applicable federal tax laws, or by our board of directors acting in place of our compensation committee. The compensation committee has the authority
to construe and interpret our 2017 Equity Incentive Plan, grant awards, determine the terms of such awards and make all other determinations necessary or advisable for the administration of the plan, including, but not limited to, repricing options
or SARs without prior stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2017 Equity Incentive Plan provides for the grant of awards to our employees, directors,
consultants, independent contractors and advisors, provided the consultants, independent contractors, directors and advisors are natural persons who render services to us. The aggregate number of shares granted to non-employee directors shall not
exceed 100,000&nbsp;shares in a calendar year. The exercise price of stock options must be at least equal to the fair market value of our common stock on the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that in general, options will vest over a four-year period. Options may vest based
on time or achievement of performance conditions. Our compensation committee may provide for options to be exercised only as they vest or to be immediately exercisable with any shares issued on exercise being subject to our right of repurchase that
lapses as the shares vest. The maximum term of options granted under our 2017 Equity Incentive Plan is ten years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An RSA is an offer by
us to sell shares of our common stock subject to restrictions, which may vest based on time or achievement of performance conditions. The price (if any) of an RSA will be determined by the compensation committee. Unless otherwise determined by the
compensation committee at the time of award, vesting will cease on the date the participant no longer provides services to us and unvested shares will be forfeited to or repurchased by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SARs provide for a payment, or payments, in cash or shares of our common stock, to the holder based upon the difference between the fair
market value of our common stock on the date of exercise and the stated exercise price up to a maximum amount of cash or number of shares. SARs may vest based on time or achievement of performance conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RSUs represent the right to receive shares of our common stock at a specified date in the future, subject to forfeiture of that right because
of termination of employment or failure to achieve certain performance conditions. If an RSU has not been forfeited, then on the date specified in the RSU agreement, we will deliver to the holder of the RSU whole shares of our common stock (which
may be subject to additional restrictions), cash or a combination of our common stock and cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Performance shares are performance awards
that cover a number of shares of our common stock that may be settled upon achievement of the pre-established performance conditions in cash or by issuance of the underlying shares. These awards are subject to forfeiture prior to settlement because
of termination of service or failure to achieve the performance conditions. No participant will be eligible to receive more than $5,000,000 in performance awards in any calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock bonuses may be granted as additional compensation for service or performance and, therefore, will not be issued in exchange for cash.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure without our receipt of consideration, such as a stock split,
appropriate adjustments will be made to the number of shares reserved under our 2017 Equity Incentive Plan, the maximum number of shares that can be granted in a calendar year and the number of shares and exercise price, if applicable, of all
outstanding awards under our 2017 Equity Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards granted under our 2017 Equity Incentive Plan may not be transferred in
any manner other than by will or by the laws of descent and distribution or as determined by our compensation committee. Unless otherwise permitted by our compensation committee, stock options may be exercised during the lifetime of the optionee
only by the optionee or the optionee&#146;s guardian or legal representative. Options granted under our 2017 Equity Incentive Plan generally may be exercised for a period of three months after the termination of the optionee&#146;s service to us for
any reason other than for cause or due to death or disability, for a period of 12 months in the case of death or disability, or such longer period as our compensation committee may provide. Options generally terminate immediately upon termination of
employment for cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined in our 2017 Equity Incentive Plan), any and all outstanding
awards may be assumed or replaced by the successor corporation. In the alternative, the successor corporation may substitute equivalent awards or provide substantially similar consideration to participants as was provided to stockholders. The
successor corporation may also issue, in place of outstanding shares held by the participant, substantially similar shares or other property subject to repurchase restrictions no less favorable to the participant. If the outstanding awards are not
assumed, converted, replaced or substituted by the successor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation, the awards will expire upon the closing of the corporate transaction in which case our compensation committee will notify the participant that the award will be exercisable for a
period of time determined by the committee. Our compensation committee may accelerate the vesting of the awards in connection with the transaction. Awards need not be treated similarly in a corporate transaction. In the event of a corporate
transaction, the vesting of all awards granted to non-employee directors shall accelerate and such awards shall become exercisable (as applicable) in full prior to the consummation of the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2017 Equity Incentive Plan will terminate ten years from the date our board of directors adopts the plan, unless it is terminated earlier
by our board of directors. Our board of directors may amend or terminate our 2017 Equity Incentive Plan at any time. Our board of directors generally may amend our 2017 Equity Incentive Plan, without stockholder approval unless required by
applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Employee Stock Purchase Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a 2017 Employee Stock Purchase Plan that became effective on the date of this prospectus and enables eligible employees to
purchase shares of our common stock at a discount beginning on a date determined by our board of directors. Purchases will be accomplished through participation in discrete offering periods. We initially reserved 218,000&nbsp;shares of our common
stock for issuance under our 2017 Employee Stock Purchase Plan. The number of shares reserved for issuance under our 2017 Employee Stock Purchase Plan will increase automatically on January&nbsp;1st of each of the first ten calendar years following
the first offering date by the number of shares equal to the greater of 1% of the total outstanding shares of our common stock as of the immediately preceding December&nbsp;31 (rounded to the nearest whole share). However, our board of directors or
compensation committee may reduce the amount of the increase in any particular year. The aggregate number of shares issued over the term of our 2017 Employee Stock Purchase Plan will not exceed 2,180,000&nbsp;shares of our common stock. Our 2017
Employee Stock Purchase Plan is intended to qualify as an employee stock purchase plan under Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
compensation committee administers our 2017 Employee Stock Purchase Plan. While our employees generally are eligible to participate in our 2017 Employee Stock Purchase Plan, our compensation committee may in its discretion elect to exclude employees
who work less than 20 hours per week or less than five months in a calendar year. In addition, employees who are 5% stockholders, or would become 5% stockholders as a result of their participation in our 2017 Employee Stock Purchase Plan, are
ineligible to participate in our 2017 Employee Stock Purchase Plan. We may impose additional restrictions on eligibility within the limits permitted by the Code. Under our 2017 Employee Stock Purchase Plan, eligible employees will be able to acquire
shares of our common stock by accumulating funds through payroll deductions. Our eligible employees will be able to select a rate of payroll deduction between 1% and 15% of their base cash compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When an initial first offering period commences, our employees who meet the eligibility requirements for participation in that offering period
will be eligible to enroll. For subsequent offering periods, new participants will be required to enroll in a timely manner. Once an employee is enrolled, participation will be automatic in subsequent offering periods. Each offering period will be
determined by our compensation committee. An employee&#146;s participation automatically ends upon termination of employment for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first offering period will begin on a future date to be designated by our board of directors or compensation committee. Each subsequent
offering period will be designated by our compensation committee, but will in no event be longer than 27&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No participant will
have the right to purchase our shares in an amount, when aggregated with purchase rights under all our employee stock purchase plans that are also in effect in the same calendar years, that has a fair market value of more than $25,000, determined as
of the first day of the applicable purchase period, for each calendar year in which that right is outstanding. In addition, no participant will be permitted to purchase more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than 1,500&nbsp;shares during any one purchase period or such lesser amount determined by our compensation committee. The purchase price for shares of our common stock purchased under our 2017
Employee Stock Purchase Plan will be 85% of the lesser of the fair market value of our common stock on (i)&nbsp;the first trading day of the applicable offering period or (ii)&nbsp;the last trading day of each purchase period in the applicable
offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience a corporate transaction (as defined in the 2017 Employee Stock Purchase Plan), each outstanding right
to purchase shares under our 2017 Employee Stock Purchase Plan will be assumed or an equivalent option substituted by the successor corporation. In the event that the successor corporation refuses to assume or substitute for the outstanding purchase
rights, any offering period that commenced prior to the closing of the proposed corporate transaction will be shortened and terminated on a new purchase date. The new purchase date will occur on or prior to the closing of the corporate transaction
and our 2017 Employee Stock Purchase Plan will then terminate on the closing of the corporate transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also have the right to
amend or terminate our 2017 Employee Stock Purchase Plan at any time. Our 2016 Employee Stock Purchase Plan will terminate on the tenth anniversary of the last day of the first purchase period, unless it is terminated earlier by our board of
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sponsor a
retirement savings plan established January&nbsp;1, 2007, that is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of
Section&nbsp;401(k) of the Code. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50
years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law. No minimum benefit is provided under the plan. An employee&#146;s
interest in his or her salary deferral contributions is 100% vested when contributed. We have the ability to make discretionary contributions under the plan but have not done so to date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive
officers are eligible to participate in our employee benefit plans on the same basis as our other employees, including our health and welfare plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation that will become effective in connection with the closing of this offering contains provisions that
limit the liability of our directors for monetary damages to the fullest extent permitted by the Delaware General Corporation Law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any
breach of fiduciary duties as directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General Corporation Law; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated
certificate of incorporation and our restated bylaws that will become effective in connection with the closing of this offering require us to indemnify our directors and officers to the maximum extent not prohibited by the Delaware General
Corporation Law and allow us to indemnify other employees and agents as set forth in the Delaware General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered, and intend to continue to enter, into separate indemnification agreements with
our directors, officers and certain of our key employees, in addition to the indemnification provided for in our restated certificate of incorporation and restated bylaws. These agreements, among other things, require us to indemnify our directors,
officers and key employees for certain expenses, including attorneys&#146; fees, judgments, penalties, fines and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to us or any of our
subsidiaries or any other company or enterprise to which these individuals provide services at our request. Subject to certain limitations, our indemnification agreements also require us to advance expenses incurred by our directors, officers and
key employees for the defense of any action for which indemnification is required or permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these indemnification
provisions and agreements are necessary to attract and retain qualified directors, officers and key employees. We also maintain directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our restated certificate of incorporation and restated bylaws may discourage
stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might
benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification
is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, executive officers or persons
controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We describe below transactions and series of similar transactions since January&nbsp;1, 2014 to which we were a party or will be a party, in
which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts involved exceeded or will exceed $120,000; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our directors, executive officers or beneficial holders of more than 5% of any class of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect
material interest. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described below, there have not been, nor are there any currently proposed, transactions
or series of similar transactions to which we have been or will be a party other than compensation arrangements, which are described where required under &#147;Executive Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Financings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series&nbsp;C-1 Preferred Stock
Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, we issued an aggregate of 474,001 shares of our Series C-1 convertible preferred stock at a purchase price of
$4.55 per share, in exchange for the cancellation of secured convertible promissory notes originally issued in July 2013, which as of April 2014 had an aggregate principal and unpaid interest of $2.2 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series C-1 convertible preferred stock issued to our executive officers, members of our board of directors
and persons who hold more than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:71.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares of</B><br><B>Series C-1</B><br><B>Convertible</B><br><B>Preferred</B><br><B>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Purchase</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">890,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">890,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alloy Ventures 2005, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">351,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Ventures. Dr.&nbsp;Topper, a member of our Board of Directors, is a General Partner of Frazier Healthcare and may be deemed to
have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi, a member of our board of directors, is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership of or
pecuniary interest in these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Suria is our President and Chief Executive Officer and is a member of our Board of Directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of our Series C-1 convertible preferred stock will convert automatically into one share of our common stock upon the closing of
this offering. The purchasers of our Series C-1 convertible preferred stock are entitled to specified registration rights, as described below under &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series D Preferred Stock Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
July 2015, we sold an aggregate of 5,490,973 shares of our Series D convertible preferred stock at a purchase price of $7.42 per share, for an aggregate cash purchase price of $40.8 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series D convertible preferred stock purchased by our
executive officers, members of our board of directors and persons who hold more than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:71.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares of</B><br><B>Series D</B><br><B>Convertible</B><br><B>Preferred</B><br><B>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Purchase</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund, L.P</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,503,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HBM Healthcare Investments (Cayman) Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">159,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert E. Hoffman(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P., both affiliates of Frazier Healthcare. Dr.&nbsp;Topper, a member of our Board of Directors, is a General Partner of Frazier
Healthcare and may be deemed to have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi, a member of our board of directors, is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership of or
pecuniary interest in these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lydon is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gallagher is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hoffman is our former Chief Financial Officer. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Suria is our President and Chief Executive Officer and is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Londei is our Chief Medical Officer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of our Series D convertible
preferred stock will convert automatically into one share of our common stock upon the closing of this offering. The purchasers of our Series D convertible preferred stock are entitled to specified registration rights, as described below under
&#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders and their affiliated entities, including stockholders affiliated with certain of our directors, have
agreed to purchase an aggregate of 1,946,666&nbsp;shares of our common stock in this offering at the initial public offering price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amended and
Restated Investors&#146; Rights Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an amended and restated investors&#146; rights agreement with certain
holders of our convertible preferred stock, including entities with which certain of our directors are affiliated. These stockholders are entitled to rights with respect to the registration of their shares following our initial public offering under
the Securities Act. For a description of these registration rights, see &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
entered into indemnification agreements with each of our directors and executive officers. The indemnification agreements, our restated certificate of incorporation and our restated bylaws will require us to indemnify our directors to the fullest
extent not prohibited by Delaware law. Subject to certain limitations, our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restated bylaws also require us to advance expenses incurred by our directors and officers. For more information regarding these agreements, see &#147;Executive Compensation&#151;Limitations on
Liability and Indemnification Matters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to adopt a written related person transactions policy that our executive officers, directors, nominees for election as a director,
beneficial owners of more than 5% of our common stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the
review and approval of our audit committee, or a committee composed solely of independent directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. We expect the policy to provide
that any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our common stock or with any of their immediate family members or affiliates in which
the amount involved exceeds $120,000 will be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, we expect that our audit committee will consider the relevant facts and circumstances
available and deemed relevant to the audit committee, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the
extent of the related person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock at December 31, 2016, and as
adjusted to reflect the sale of common stock in this offering,&nbsp;for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our current directors and executive officers as a group; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, who beneficially owned more than 5% of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of
beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect
to all shares of common stock that they beneficially owned, subject to applicable community property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage
ownership is based on 14,171,984 shares of common stock outstanding as of December 31, 2016 and assumes the automatic conversion of all outstanding shares of our convertible preferred stock into 11,520,698 shares of common stock as of immediately
prior to the closing of this offering. The applicable percentage ownership after this offering includes 5,000,000&nbsp;shares of common stock that will be issued by us in our initial public offering (assuming no exercise of the underwriters&#146;
option to purchase additional shares). In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options held by
that person or entity that are currently exercisable or that will become exercisable within 60 days of December 31, 2016. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.
Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o AnaptysBio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, California 92121. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders and their affiliated entities, including stockholders affiliated with certain of our directors, have
agreed to purchase an aggregate of 1,946,666&nbsp;shares of our common stock in this offering at the initial public offering price. The information set forth in the table below does not reflect the purchases by these stockholders, which purchases
will increase the percentage of shares owned after the offering of such stockholders from that set forth in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Beneficial Ownership</B><br><B>Prior to this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Beneficial&nbsp;Ownership</B><br><B>After this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Stockholders</I></B><I>:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,288,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,288,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,019,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,019,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avalon Ventures VII, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,154,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,154,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alloy Ventures 2005, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund, L.P.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HBM Healthcare Investments (Cayman) Ltd.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">942,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Named Executive Officers</I></B><I>:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">518,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">518,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Moyle Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tiba Aynechi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hollings Renton(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Schmid(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Schoeneck(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James N. Topper, M.D., Ph.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,288,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,288,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (ten persons)(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,620,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,620,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;2,228,377 shares of common stock following conversion of convertible preferred stock held directly by Frazier Healthcare V, L.P., (b)&nbsp;733,740 shares of common stock following conversion of
convertible preferred stock held directly by Frazier Healthcare VII, L.P., (c)&nbsp;209,095 shares of common stock following conversion of convertible preferred stock held directly by Frazier Healthcare VII-A, L.P. and (d)&nbsp;117,235 shares of
common stock issuable upon the exercise of a warrant held directly by Frazier Healthcare V, L.P. The general partner of Frazier Healthcare V, L.P. is FHM V, L.P., a Delaware limited partnership. The general partner of FHM V, L.P. is FHM V, LLC, a
Delaware limited liability company. The general partner of Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. is FHM VII, L.P., a Delaware limited partnership. The general partner of FHM VII, L.P. is FHM VII, LLC, a Delaware limited
liability company. Dr.&nbsp;Topper, a member of our Board of Directors, Alan Frazier, Nader Naini, Nathan Every and Patrick Heron are members of FHM&nbsp;V, LLC and FHM&nbsp;VII, LLC and may be deemed to share voting and investment power with
respect to the shares held by FHM&nbsp;V, LLC and FHM VII, LLC. The address of Frazier Healthcare is 601 Union, Two Union Square, Suite 3200, Seattle WA 98101. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;2,901,831 shares of common stock following conversion of convertible preferred stock held directly by Novo A/S and (b)&nbsp;117,235 shares of common stock issuable upon the exercise of a warrants
held directly by Novo A/S. The board of directors of Novo A/S, which is currently comprised of Sten Scheibye, G&#246;ran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared voting and investment power with respect to these
shares and may exercise such control only with the support of a majority of the board. As such, no individual member of the board is deemed to hold any beneficiary ownership in these shares. Dr.&nbsp;Aynechi, a member of our board of directors, is
employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership of or pecuniary interest in these shares. The address of Novo A/S is Tuborg Havnevej&nbsp;19,
2900&nbsp;Hellerup, Denmark. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;2,036,932 shares of common stock held directly by Avalon Ventures VII, L.P. and (b)&nbsp;117,483 shares of common stock issuable upon the exercise of a warrant held directly by Avalon
Ventures&nbsp;VII, L.P. The general partner of Avalon Ventures&nbsp;II, L.P. is Avalon Ventures&nbsp;VII GP, LLC. The managing members of Avalon Ventures&nbsp;VII GP, LLC are Kevin&nbsp;J. Kinsella and Stephen&nbsp;L. Tomlin. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,282,485 shares of common stock following conversion of convertible preferred stock held directly by Alloy Ventures 2005, L.P. The general partner of Alloy Ventures 2005, L.P. is Alloy Ventures 2005, LLC.
The managing members of Alloy Ventures 2005, LLC are Craig Taylor, Doug Kelly John Shoch, Dan Rubin and Tony Di Bona. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;492,743 shares of common stock following conversion of convertible preferred stock held directly by Biotechnology Value Fund, L.P., (b)&nbsp;282,000 shares of common stock following conversion of
convertible preferred stock held directly by Biotechnology Value Fund II, L.P., (c)&nbsp;91,000 shares of common stock following conversion of convertible preferred stock held directly by Investment 10, L.L.C. and (d)&nbsp;144,857 shares of common
stock following conversion of convertible preferred stock held directly by MSI BVF SPV, L.L.C. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Represents 942,835 shares of common stock following conversion of convertible preferred stock held directly by HBM Healthcare Investments (Cayman) Ltd. The board of directors of HBM Healthcare Investments (Cayman) Ltd.
has sole vesting and investment power with respect to the shares. The board of directors of HBM Healthcare Investments (Cayman) Ltd. is comprised of Jean-Mar Lesieur, Richard Coles, Sophia Harris, Dr.&nbsp;Andrea Wicki, Paul Woodhouse and John
Urquhart, none of whom has individual voting or investment power with respect to the shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;4,998 shares of common stock following conversion of convertible preferred stock held directly by Mr.&nbsp;Suria and (b)&nbsp;513,010 shares of common stock issuable to Mr.&nbsp;Suria upon the
exercise of stock options that are exercisable within 60 days of December 31, 2016, of which 118,241 shares were unvested but were early exercisable, as of 60 days after December 31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;2,020 shares of common stock following conversion of convertible preferred stock held directly by Dr.&nbsp;Londei and (b)&nbsp;195,548 shares of common stock issuable to Dr.&nbsp;Londei upon the
exercise of stock options that are exercisable within 60 days of December 31, 2016, of which 67,069 shares were unvested but were early exercisable, as of 60 days after December 31, 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;64,296&nbsp;shares of common stock following conversion of convertible preferred stock held directly by Dr.&nbsp;Gallagher and (b)&nbsp;97,722&nbsp;shares of common stock issuable to
Dr.&nbsp;Gallagher upon the exercise of stock options that are exercisable within 60 days of December 31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;67,332&nbsp;shares of common stock held directly by Dr.&nbsp;Lydon, (b)&nbsp;203,625&nbsp;shares of common stock following conversion of convertible preferred stock held directly by Dr.&nbsp;Lydon,
(c)&nbsp;16,483 shares of common stock issuable upon the exercise of a warrant held directly by Dr.&nbsp;Lydon and (d)&nbsp;31,012 shares of common stock issuable to Dr.&nbsp;Lydon upon the exercise of stock options that are exercisable within 60
days of December 31, 2016, of which 7,113 shares were unvested but were early exercisable, as of 60 days after December 31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Represents 51,156&nbsp;shares of common stock issuable to Mr.&nbsp;Renton upon the exercise of stock options that are exercisable within 60 days of December 31, 2016, of which 23,020 shares were unvested but were early
exercisable, as of 60 days after December 31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Represents 42,337&nbsp;shares of common stock issuable to Mr.&nbsp;Schmid upon the exercise of stock options that are exercisable within 60 days of December 31, 2016, of which 21,684 shares were unvested but were early
exercisable, as of 60 days after December 31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Represents 42,337&nbsp;shares of common stock issuable to Mr.&nbsp;Schoeneck upon the exercise of stock options that are exercisable within 60 days of December 31, 2016, of which 24,697&nbsp;shares were unvested but
were early exercisable, as of 60 days after December 31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Includes shares beneficially owned by our executive officers and directors. Consists of (a)&nbsp;67,332 shares of common stock, (b)&nbsp;3,446,151&nbsp;shares of common stock following conversion of convertible
preferred stock, (c)&nbsp;133,718&nbsp;shares of common stock issuable upon the exercise of warrants and (d)&nbsp;973,122&nbsp;shares of common stock issuable upon the exercise of stock options that are exercisable within 60 days of December 31,
2016, of which 261,824 shares were unvested but early exercisable, as of 60 days after December&nbsp;31, 2016. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above
table does not include Dominic G. Piscitelli, who commenced his employment with us as our Chief Financial Officer in January 2017. In connection with his employment, Mr. Piscitelli was granted an option to purchase 170,241 shares of our common
stock, none of which are exercisable within 60 days of December&nbsp;31, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our authorized capital stock will consist of 500,000,000 shares of common stock, $0.001 par value per
share, and 10,000,000 shares of undesignated preferred stock, $0.001 par value per share. The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that
may be important to you. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the
applicable provisions of Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of our certificate of incorporation all of the outstanding convertible
preferred stock will automatically convert into common stock in connection with the closing of this offering. Assuming the effectiveness of this conversion as of September&nbsp;30, 2016, there were 14,159,333 shares of our common stock issued, held
by approximately 78 stockholders of record, and no shares of our preferred stock outstanding. Our board of directors is authorized, without stockholder approval, to issue additional shares of our capital stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to
receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. See &#147;Dividend Policy&#148;
above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our
common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation. Accordingly,
pursuant to our restated certificate of incorporation that will be in effect upon the closing of this offering, holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of
incorporation establishes a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing
for the remainder of their respective three-year terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Preemptive or Similar Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Right to Receive Liquidation Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable
ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation
preferences, if any, on any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of our certificate of incorporation, all of our outstanding convertible preferred stock will automatically convert
into common stock, with such conversion to be effective in connection with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
closing of this offering. As a result, each currently outstanding share of convertible preferred stock will be converted into common stock. All series of convertible preferred stock will convert
at a ratio of one share of common stock for each share of convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this offering, our board of directors
will be authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences
and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors can also increase or decrease the number of shares of any
series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion
rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among
other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no
current plan to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2016, we had outstanding the following warrants to purchase shares of our capital stock: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:74.40pt; font-size:8pt; font-family:Times New Roman"><B>Type of Capital Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Number</B><br><B>of Shares</B><br><B>Subject to</B><br><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Exercise</B><br><B>Price</B><br><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Expiration Dates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">November&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">November 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">December 2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to September 30, 2016, we issued warrants to purchase 82,416 shares of our Series&nbsp;C
convertible preferred stock with an exercise price of $4.55 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2016, we had outstanding options to purchase an aggregate 1,856,750 shares of our common stock, with a weighted-average
exercise price of $4.13. Subsequent to September&nbsp;30, 2016, we granted stock options to purchase 221,953&nbsp;shares of common stock, with a weighted-average exercise price of $11.31&nbsp;per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
terms of our Amended and Restated Investor Rights Agreement, immediately following this offering, the holders of 11,932,960 shares of our common stock will be entitled to rights with respect to the registration of these shares under the Securities
Act, as described below. We refer to these shares collectively as registrable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Demand Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning 180&nbsp;days after the closing of this offering, the holders of at least a majority of the then-outstanding registrable securities
may make a written request to us for the registration of any of the registrable securities under the Securities Act. Within 30&nbsp;days of such request, we are obligated provide written notice of such request to all stockholders to file&nbsp;a
registration statement under the Securities Act covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any other holders.
We are only required to file two registration statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that are declared effective upon exercise of these demand registration rights. We may postpone taking action with respect to such filing not more than once during any 12-month period for a total
period of not more than 60&nbsp;days if our board of directors determines in its good faith judgment that it would be seriously detrimental to us and our stockholders for such registration statement to be effected at such time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form S-3 Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any holder
of then-outstanding registrable securities can request that we register all or part of their shares on Form&nbsp;S-3 if we are eligible to file&nbsp;a registration statement on Form&nbsp;S-3 and if the aggregate price to the public of the shares
offered is at least $2,000,000. The stockholders may only require us to effect two registration statements on Form&nbsp;S-3 in a 12-month period. We may postpone taking action with respect to such filing once during any 12-month period for a total
cumulative period of not more than 90&nbsp;days if our board of directors determines in its good faith judgment that the filing would be materially detrimental to us and our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Piggyback Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with this offering, holders of registrable securities were entitled to, and the necessary percentage of holders waived, their rights to notice of this offering and to include their registrable securities in this offering. If we register
any of our securities for public sale in another offering, holders of registrable securities will have the right to include their shares in the registration statement. However, this right does not apply to a registration relating to employee benefit
plans, a registration relating to a corporate reorganization or a registration of only common stock issuable upon conversion of debt securities that are also being registered. We have the right to terminate any registration we have initiated before
the effective date of such registration, whether or not any holder has elected to include registrable securities in such registration. The underwriters of any underwritten offering will have the right to limit the number of shares registered by
these holders if they determine in good faith that marketing factors require limitation, in which case the number of shares to be registered will be apportioned pro rata among these holders, according to the total amount of securities entitled to be
included by each holder, or in a manner mutually agreed upon by the holders. However, in any underwriting not in connection with an initial public offering, the number of shares to be registered by these holders cannot be reduced below 30% of the
total shares covered by the registration statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expenses of Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally will pay all expenses, other than underwriting discounts and commissions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expiration of Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
registration rights described above will expire, with respect to any particular holder of these rights, on the earlier of the fifth anniversary of the closing of this offering, a merger, consolidation, sale or disposition of our company or a sale by
a holder of equity securities representing at least a majority of the voting power of our company, or when that holder can sell all of its registrable securities in a three-month period without restriction under Rule&nbsp;144 of the Securities Act.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
provisions of Delaware law, our restated certificate of incorporation and our restated bylaws, as we expect they will be in effect upon the closing of this offering, could have the effect of delaying, deferring or discouraging another person from
acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our
board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of
these proposals could result in an improvement of their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law regulating corporate takeovers. In general,
Section&nbsp;203 prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the
outstanding voting stock owned by the interested stockholder, (1)&nbsp;shares owned by persons who are directors and also officers and (2)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine
confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written
consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in
a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a
corporation&#146;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section&nbsp;203 may also
discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restated Certificate of
Incorporation and Restated Bylaw Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our restated bylaws, as we expect they will
be in effect upon the closing of this offering, include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Board of Directors Vacancies.</I> Our restated certificate of incorporation and restated bylaws will authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the
number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of
directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Classified Board.</I> Our restated certificate of incorporation and restated bylaws will provide that our board is classified into three classes of directors, each with staggered three-year terms. A third party may
be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. See
&#147;Management&#151;Board Composition.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stockholder Action; Special Meetings of Stockholders.</I> Our restated certificate of incorporation will
provide that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our
restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws will provide that </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
special meetings of our stockholders may be called only by a majority of our board of directors, the chairman of our board of directors, our Chief Executive Officer or our President, thus
prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including
the removal of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations.</I> Our restated bylaws will provide advance notice procedures for stockholders seeking to bring business before our annual meeting of
stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also will specify certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions might
preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might
also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of our company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>No Cumulative Voting.</I> The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#146;s certificate of
incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws will not provide for cumulative voting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Directors Removed Only for Cause.</I> Our restated certificate of incorporation will provide that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least
two-thirds of our outstanding common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Amendment of Charter Provisions.</I> Any amendment of the above expected provisions in our restated certificate of incorporation would require approval by holders of at least two-thirds of our outstanding common
stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Issuance of Undesignated Preferred Stock.</I> Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and
preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt
to obtain control of us by merger, tender offer, proxy contest or other means. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Choice of Forum.</I> Our restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our
behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our restated certificate of incorporation or our restated bylaws; or any action asserting a
claim against us that is governed by the internal affairs doctrine. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, the transfer agent and registrar for our common stock will be American Stock Transfer and Trust Company,
LLC. The transfer agent&#146;s address is 6201 15th Avenue, Brooklyn, New York 11219, and its telephone number is (800)&nbsp;937-5449. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange
Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol &#147;ANAB.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock, and we cannot predict the effect, if any, that market sales of
shares of our common stock or the availability of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Nevertheless, sales of substantial amounts of our common stock, including shares
issued upon exercise of outstanding options and warrants, in the public market following this offering could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through the sale of our equity
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will have a total of 19,159,333 shares of our common stock outstanding, based on the
14,159,333&nbsp;shares of our capital stock outstanding as of September 30, 2016, assuming the automatic conversion of all outstanding shares of our convertible preferred stock into 11,520,698&nbsp;shares of common stock as of immediately prior to
the closing of this offering. Of these outstanding shares, all of the 5,000,000 shares of common stock sold in this offering will be freely tradable, except that any shares purchased in this offering by our affiliates, as that term is defined in
Rule 144 under the Securities Act, could only be sold in compliance with Rule&nbsp;144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining outstanding shares of our common
stock will be deemed &#147;restricted securities&#148; as defined in Rule 144. Restricted securities may be sold in the public market only if they are registered under the Securities Act or if they qualify for an exemption from registration under
Rule 144 or Rule 701 promulgated under the Securities Act, which rules are summarized below. In addition, substantially all of our security holders have entered into market standoff agreements with us or lock-up agreements with the underwriters
under which they have agreed, subject to specific exceptions, not to sell any of our stock for at least 180 days following the date of this prospectus, as described below. As a result of these agreements and the provisions of our amended and
restated investors&#146; rights agreement described above under &#147;Description of Capital Stock&#151;Registration Rights,&#148; subject to the provisions of Rule&nbsp;144 or Rule&nbsp;701, 19,159,333&nbsp;shares will be available for sale in the
public market as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beginning on the date of this prospectus, all of the shares sold in this offering will be immediately available for sale in the public market; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beginning 181 days after the date of this prospectus, 14,159,133 additional shares will become eligible for sale in the public market, of which 11,688,156&nbsp;shares will be held by affiliates and subject to the volume
and other restrictions of Rule&nbsp;144, as described below. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-Up/Market Standoff Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our directors and officers and substantially all of our security holders are subject to lock-up agreements or market standoff provisions
that prohibit them from offering for sale, selling, contracting to sell, granting any option for the sale of, transferring or otherwise disposing of any shares of our common stock, options or warrants to acquire shares of our common stock or any
security or instrument related to our common stock, or entering into any swap, hedge or other arrangement that transfers any of the economic consequences of ownership of our common stock, for a period of 180 days following the date of this
prospectus without the prior written consent of Credit Suisse Securities (USA) LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated. See &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144
as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days
preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates, is entitled to sell those shares without complying with the manner of
sale, volume limitation or notice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year,
including the holding period of any prior owner other than our affiliates, then that person would be entitled to sell those shares without complying with any of the requirements of Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule&nbsp;144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to
sell upon expiration of the lock-up and market standoff agreements described above, within any three-month period, a number of shares that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of shares of our common stock then outstanding, which will equal approximately shares 191,593 immediately after this offering; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to that sale. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale
provisions and notice requirements and to the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 generally allows a stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who is
not deemed to have been an affiliate of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or
notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by
that rule to wait until 90 days after the date of this prospectus before selling those shares pursuant to Rule 701. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the closing of this offering, we intend to file one or more registration statements on Form S-8 under the
Securities Act covering all of the shares of our common stock subject to outstanding options and the shares of our common stock reserved for issuance under our stock plans. However, the shares registered on Form S-8 may be subject to the volume
limitations and the manner of sale, notice and public information requirements of Rule 144 and will not be eligible for resale until expiration of the lock-up and market standoff agreements to which they are subject. Of the 1,856,750 shares of our
common stock that were subject to stock options outstanding as of September 30, 2016, options to purchase 868,017 shares of common stock were vested as of September&nbsp;30, 2016. Shares of our common stock underlying outstanding options will not be
eligible for sale until expiration of the 180 day lock-up and market standoff agreements to which they are subject. See the section titled &#147;Executive Compensation&#151;Employee Benefit and Stock Plans&#148; for a description of our equity
incentive plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted demand, piggyback and Form S-3 registration rights to certain of our stockholders to sell our common stock. Registration of the
sale of these shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. For a
further description of these rights, see &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section summarizes the material U.S. federal income tax considerations relating to the acquisition, ownership and disposition of
our common stock by &#147;non-U.S. holders&#148; (as defined below) pursuant to this offering. This summary does not provide a complete analysis of all potential U.S. federal income tax considerations relating thereto. The information provided below
is based upon provisions of the Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, administrative rulings and judicial decisions currently in effect. These authorities may change at any time,
possibly retroactively, or the Internal Revenue Service, or IRS, might interpret the existing authorities differently. In either case, the tax considerations of owning or disposing of our common stock could differ from those described below. As a
result, we cannot assure you that the tax consequences described in this discussion will not be challenged by the IRS or will be sustained by a court if challenged by the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not address the tax considerations arising under the laws of any non-U.S., state or local jurisdiction, or under U.S.
federal gift and estate tax laws, except to the limited extent provided below. In addition, this discussion does not address tax considerations applicable to an investor&#146;s particular circumstances or to investors that may be subject to special
tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies or other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships or entities or arrangements treated as partnerships or other pass-through entities for U.S. federal tax purposes (or investors in such entities); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">corporations that accumulate earnings to avoid U.S. federal income tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax or the Medicare contribution tax on net investment income; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-exempt organizations or tax-qualified retirement plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations or passive foreign investment companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who acquired our common stock as compensation for services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dealers in securities or currencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">traders in securities that elect to use a mark-to-market method of accounting for their securities holdings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion transaction&#148; or other risk reduction transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, for investment purposes); or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if a partnership or entity classified as a partnership or other pass-through entity for U.S. federal income tax purposes is a
beneficial owner of our common stock, the tax treatment of a partner in the partnership or an owner of the entity will depend upon the status of the partner or other owner and the activities of the partnership or other entity. Accordingly, this
summary does not address tax considerations applicable to partnerships that hold our common stock, and partners in such partnerships should consult their tax advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">INVESTORS CONSIDERING THE PURCHASE OF OUR COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL
INCOME AND ESTATE TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE CONSEQUENCES OF FOREIGN, STATE OR LOCAL LAWS, AND TAX TREATIES. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-U.S. Holder Defined </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this summary, a &#147;non-U.S. holder&#148; is any holder of our common stock, other than a partnership, that is not: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state therein or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust if it (i)&nbsp;is subject to the primary supervision of a U.S. court and one of more U.S. persons have authority to control all substantial decisions of the trust or (ii)&nbsp;has a valid election in effect
under the applicable Treasury regulations to be treated as a U.S. person; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate whose income is subject to U.S. income tax regardless of source. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a
non-U.S. citizen who is an individual, you may, in many cases, be deemed to be a resident alien, as opposed to a nonresident alien, by virtue of being present in the United States for at least 31 days in the calendar year and for an aggregate of at
least 183 days during a three-year period ending in the current calendar year. For these purposes, all the days present in the current year, one-third of the days present in the immediately preceding year, and one-sixth of the days present in the
second preceding year are counted. Resident aliens are subject to U.S. federal income tax as if they were U.S. citizens. Such an individual is urged to consult his or her own tax advisor regarding the U.S. federal income tax consequences of the
ownership or disposition of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to declare or make any distributions on our common stock in the foreseeable future. If we do pay dividends on shares of our
common stock, however, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions
in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not below zero, a non-U.S. holder&#146;s adjusted tax basis in shares of our common stock. Any remaining
excess will be treated as gain realized on the sale or other disposition of our common stock. See &#147;&#151;Sale of Common Stock.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any dividend paid to a non-U.S. holder on our common stock that is not effectively connected with a non-U.S. holder&#146;s conduct of a trade
or business in the United States will generally be subject to U.S. withholding tax at a 30% rate. The withholding tax might apply at a reduced rate, however, under the terms of an applicable income tax treaty between the United States and the
non-U.S. holder&#146;s country of residence. You should consult your tax advisors regarding your entitlement to benefits under a relevant income tax treaty. Generally, in order for us or our paying agent to withhold tax at a lower treaty rate, a
non-U.S. holder must certify its entitlement to treaty benefits. A non-U.S. holder generally can meet this certification requirement by providing a <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or Form&nbsp;W-8BEN-E (or any successor of
such forms) or appropriate substitute form to us or our paying agent. If the non-U.S. holder holds the stock through a financial institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate
documentation to the agent. The holder&#146;s agent will then be required to provide certification to us or our paying agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax
under an income tax treaty, you may obtain a refund or credit of any excess amounts withheld by filing an appropriate claim for a refund with the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends received by a non-U.S. holder that are effectively connected with a U.S. trade or business conducted by the non-U.S. holder, and if
required by an applicable income tax treaty between the United States and the non-U.S. holder&#146;s country of residence, are attributable to a permanent establishment maintained by the non-U.S. holder in the United States, are not subject to U.S.
withholding tax. To obtain this exemption, a non-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. holder must provide us or our paying agent with an IRS Form W-8ECI properly certifying such exemption. Such effectively connected dividends, although not subject to withholding tax, are
taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition to being taxed at graduated tax rates, dividends received by corporate non-U.S. holders that are effectively connected with a U.S. trade
or business of the corporate non-U.S. holder may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable tax treaty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale of Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the
discussions below regarding Backup Withholding and Information Reporting and the Foreign Account Tax Compliance Act, non-U.S. holders will generally not be subject to U.S. federal income tax on any gains realized on the sale, exchange or other
disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain (i)&nbsp;is effectively connected with the conduct by the non-U.S. holder of a U.S. trade or business and (ii)&nbsp;if required by an applicable income tax treaty between the United States and the non-U.S.
holder&#146;s country of residence, is attributable to a permanent establishment maintained by the non-U.S. holder in the United States (in which case the special rules described below apply); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the non-U.S. holder is an individual who is present in the United States for 183 days or more in the taxable year of the sale, exchange or other disposition of our common stock, and certain other requirements are met
(in which case the gain would be subject to a flat 30% tax, or such reduced rate as may be specified by an applicable income tax treaty, which may be offset by U.S. source capital losses, even though the individual is not considered a resident of
the United States); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules of the Foreign Investment in Real Property Tax Act, or FIRPTA, treat the gain as effectively connected with a U.S. trade or business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FIRPTA rules may apply to a sale, exchange or other disposition of our common stock if we are, or were within the shorter of the five-year
period preceding the disposition and the non-U.S. holder&#146;s holding period, a &#147;U.S. real property holding corporation,&#148; or USRPHC. In general, we would be a USRPHC if interests in U.S. real estate comprised at least half of the value
of our business assets. We do not believe that we are a USRPHC and we do not anticipate becoming one in the future. Even if we become a USRPHC, as long as our common stock is regularly traded on an established securities market, such common stock
will be treated as U.S. real property interests only if beneficially owned by a non-U.S. holder that actually or constructively owned more than 5% of our outstanding common stock at some time within the five-year period preceding the disposition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any gain from the sale, exchange or other disposition of our common stock, (i)&nbsp;is effectively connected with a U.S. trade or
business conducted by a non-U.S. holder and (ii)&nbsp;if required by an applicable income tax treaty between the United States and the non-U.S. holder&#146;s country of residence, is attributable to a permanent establishment maintained by such
non-U.S. holder in the United States, then the gain generally will be subject to U.S. federal income tax at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. If the non-U.S. holder is a corporation, under
certain circumstances, that portion of its earnings and profits that is effectively connected with its U.S. trade or business, subject to certain adjustments, generally would be subject also to a &#147;branch profits tax.&#148; The branch profits
tax rate is 30%, although an applicable income tax treaty between the United States and the non-U.S. holder&#146;s country of residence might provide for a lower rate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Estate Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estates of
nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a U.S. corporation, our common stock will be U.S. situs property and therefore will be included in the taxable estate of a
nonresident alien decedent, unless an applicable estate tax treaty between the United States and the decedent&#146;s country of residence provides otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Code and the Treasury regulations require those who make specified payments to report the payments to the IRS. Among the specified payments
are dividends and proceeds paid by brokers to their customers. The required information returns enable the IRS to determine whether the recipient properly included the payments in income. This reporting regime is reinforced by &#147;backup
withholding&#148; rules. These rules require the payors to withhold tax from payments subject to information reporting if the recipient fails to cooperate with the reporting regime by failing to provide his taxpayer identification number to the
payor, furnishing an incorrect identification number, or failing to report interest or dividends on his returns. The backup withholding tax rate is currently 28%. The backup withholding rules do not apply to payments to corporations, whether
domestic or foreign, provided they establish such exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments to non-U.S. holders of dividends on common stock generally will not
be subject to backup withholding, and payments of proceeds made to non-U.S. holders by a broker upon a sale of common stock will not be subject to information reporting or backup withholding, in each case so long as the non-U.S. holder certifies its
nonresident status (and we or our paying agent do not have actual knowledge or reason to know the holder is a U.S. person or that the conditions of any other exemption are not, in fact, satisfied) or otherwise establishes an exemption. The
certification procedures to claim treaty benefits described under &#147;&#151;Dividends&#148; will generally satisfy the certification requirements necessary to avoid the backup withholding tax. We must report annually to the IRS any dividends paid
to each non-U.S. holder and the tax withheld, if any, with respect to these dividends. Copies of these reports may be made available to tax authorities in the country where the non-U.S. holder resides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treasury regulations, the payment of proceeds from the disposition of shares of our common stock by a non-U.S. holder made to or
through a U.S. office of a broker generally will be subject to information reporting and backup withholding unless the beneficial owner certifies, under penalties of perjury, among other things, its status as a non-U.S. holder (and the broker does
not have actual knowledge or reason to know the holder is a U.S. person) or otherwise establishes an exemption. The payment of proceeds from the disposition of shares of our common stock by a non-U.S. holder made to or through a non-U.S. office of a
broker generally will not be subject to backup withholding and information reporting, except as noted below. Information reporting, but not backup withholding, will apply to a payment of proceeds, even if that payment is made outside of the United
States, if you sell our common stock through a non-U.S. office of a broker that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a U.S. person (including a foreign branch or office of such person); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;controlled foreign corporation&#148; for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign partnership if at any time during its tax year (a)&nbsp;one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or
(b)&nbsp;the foreign partnership is engaged in a U.S. trade or business; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unless the broker has documentary evidence that the beneficial
owner is a non-U.S. holder and certain other conditions are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no actual knowledge or reason to know to the contrary). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld from a payment to a holder of common stock under the backup withholding
rules can be credited against any U.S. federal income tax liability of the holder and may entitle the holder to a refund, provided that the required information is furnished to the IRS in a timely manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. federal withholding tax of 30% may apply to dividends and the gross proceeds of a disposition of our common stock paid to a foreign
financial institution (as specifically defined by the applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial
information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). This U.S. federal withholding tax of 30% will
also apply to dividends and the gross proceeds of a disposition of our common stock paid to a non-financial foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or
indirect U.S. owners or provides information regarding direct and indirect U.S. owners of the entity. The 30% federal withholding tax described in this paragraph cannot be reduced under an income tax treaty with the United States or by providing an
IRS Form W-8BEN or similar documentation. The withholding tax described above will not apply if the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from the rules. Under certain circumstances, a
non-U.S. holder might be eligible for refunds or credits of such taxes. Holders should consult with their own tax advisors regarding the possible implications of the withholding described herein. Foreign financial institutions located in
jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
withholding provisions described above generally will apply to proceeds from a sale or other disposition of common stock if such sale or other disposition occurs on or after January&nbsp;1, 2019 and currently apply to payments of dividends on our
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE PRECEDING DISCUSSION OF U.S. FEDERAL TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE. EACH
PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN
APPLICABLE LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters named below have entered into an underwriting agreement, dated January 25, 2017, with respect to the shares being
offered. Subject to certain conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Credit Suisse Securities (USA) LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, are the
representatives of the underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman"><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JMP Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other
than the shares covered by the option described below unless and until that option is exercised. If an underwriter fails or refuses to purchase any of its committed shares, the purchase commitments of the non-defaulting underwriters may be increased
or the offering may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have an option to buy up to an additional 750,000&nbsp;shares from us to cover sales
by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise this option for 30 days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in
approximately the same proportion as set forth in the table above, and the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the shares of our common stock directly to the public at the initial public offering price set forth on the
cover of this prospectus and to certain dealers at such offering price less a concession not in excess of $0.63 per share. After the initial public offering of the shares, the offering price and the selling concession may be changed by the
underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total underwriting discounts and commissions to be paid by us to the
underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,037,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of the offering, including registration, filing and listing fees, printing
fees and legal and accounting expenses, but excluding underwriting discounts and commissions, will be approximately $4,000,000, all of which will be paid by us. We have agreed to reimburse the underwriters for certain of their expenses incurred in
connection with the clearance of this offering with the Financial Industry Regulatory Authority, Inc., in an amount up to $35,000. If after the initial closing of this offering, but before the underwriters have exercised their option to purchase
additional shares, we terminate the underwriting agreement, or if we are unable to perform on our obligations under the underwriting agreement and the underwriters terminate the agreement, we have agreed to reimburse the underwriters for certain
expenses incurred in connection with this offering in an amount up to $50,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our officers and directors and the holders of
substantially all of our capital stock and options have agreed with the underwriters that, for a period of 180 days after the date of this prospectus, subject to certain exceptions, we and they will not (1)&nbsp;offer, sell, pledge, contract to
sell, sell any option or contract to purchase, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of (or enter into any transaction which is designed to, or might
reasonably be expected to, result in the disposition), directly or indirectly, including the filing (or participation in the filing) with the SEC of a registration statement under the Securities Act to register, any shares of our common stock or any
securities convertible into or exercisable or exchangeable for our common stock or warrants or other rights to acquire shares of our common stock of which such officer, director or holder is now, or may in the future become, the beneficial owner
(within the meaning of Rule 13d-3 under the Exchange Act), or (2)&nbsp;enter into any swap or other derivatives transaction that transfers to another, in whole or in part, directly or indirectly, any of the economic benefits or risks of ownership of
such common stock, securities, warrants or other rights to acquire common stock, whether any such transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of common stock or other securities, in cash or otherwise, or
(3)&nbsp;publicly disclose the intention to enter into any transaction described in clause (1)&nbsp;or (2)&nbsp;above, except with the prior written consent of Credit Suisse Securities (USA) LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated;
provided that Credit Suisse Securities (USA) LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, on behalf of the underwriters, have agreed to notify us at least three business days before the effective date of any release or waiver granted
to one of our officers or directors, and we have agreed to announce the impending release or waiver by issuing a press release through a major news service at least two business days before the effective date of the release or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions above do not apply to the following, subject to certain limitations set forth in the lock-up agreements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities as a bona fide gift; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of securities to any trust for the direct or indirect benefit of the lock-up signatory or any member of the immediate family of the lock-up signatory; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities to affiliates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the lock-up signatory; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of shares of our common stock or securities convertible or exchangeable into shares of our common stock acquired in open market purchases after the closing of this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entry into any trading plan established pursuant to Rule 10b5-1 under the Exchange Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exercise of options, warrants or other rights to acquire shares of common stock in accordance with their terms pursuant to an employee benefit plan, option, warrant or other right; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers pursuant to a court order or settlement agreement related to the distribution of assets in connection with the dissolution of a marriage or civil union; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers to us pursuant to agreements under which we have the option to repurchase such shares or a right of first refusal with respect to transfers of such shares upon termination of service of the lock-up signatory;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers by certain stockholders of shares purchased in this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conversion of outstanding shares of preferred stock into shares of common stock; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of shares of our common stock or any security convertible into or exercisable or exchangeable for common stock pursuant to a liquidation, tender offer, merger, consolidation or similar transaction that results
in all of our stockholders having the right to exchange their securities for cash, securities or other property. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See
&#147;Shares Eligible for Future Sale&#148; for a discussion of certain transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the offering, there has been no
public market for our common stock. The initial public offering price was negotiated among us and the representatives. Among the factors considered in determining the initial public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering price of the shares, in addition to prevailing market conditions, were our historical performance, estimates of our business potential and earnings prospects, an assessment of our
management and the consideration of the above factors in relation to market valuation of companies in related businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common
stock has been approved for listing on the Nasdaq Global Select Market under the symbol &#147;ANAB.&#148; In connection with the offering, the underwriters may purchase and sell shares of our common stock in the open market. These transactions may
include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering, and a short
position represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that is not greater than the amount of additional shares for which the underwriters&#146;
option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the
covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above.
&#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked short position by
purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely
affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the closing of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may
have the effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result, the price of
our common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the
Nasdaq Global Select Market, in the over-the- counter market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may engage
in passive market making transactions in the common stock on the Nasdaq Global Select Market in accordance with Rule 103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of common stock and extending
through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid,
that bid must then be lowered when specified purchase limits are exceeded. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions.
The underwriters are not required to engage in passive market making and may end passive market making activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
underwriters do not expect sales to discretionary accounts to exceed five percent of the total number of shares offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed
to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act and to contribute to payments that the underwriters may be required to make for these liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or more
underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of our common stock to underwriters for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non- financial activities and services. Certain of the
underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they received or will receive customary
fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriters and their respective affiliates,
officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for
the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise) and/or persons and entities
with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such
assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offer Restrictions Outside the United States </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or
advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction.
Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a
solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in the European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), no offer of the securities offered
by this prospectus may be made to the public in that Relevant Member State other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall require us or the representatives to publish a prospectus pursuant to Article 3 of the
Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant Member State who initially acquires any of the securities or to whom
any offer is made will be deemed to have represented, acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. In the
case of any of the securities being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the
securities acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any securities
to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the representatives and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of securities in any Relevant Member State will be made
pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of securities. Accordingly, any person making or intending to make an offer in that Relevant Member State of securities which are the
subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such
offer. Neither we nor the underwriters have authorized, nor do they authorize, the making of any offer of securities in circumstances in which an obligation arises for us or the underwriters to publish a prospectus for such offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any securities in any Relevant
Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be
varied in the Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the
extent implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">who have professional experience in matters relating to investments falling within Article 19 (5)&nbsp;of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order; and/or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as relevant persons).
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this
document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. Any person in the United Kingdom that is not a
relevant person should not act or rely on this document or any of its contents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Resale Restrictions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of shares of common stock offered hereby in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British
Columbia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares offered hereby in
Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable
Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Representations of Canadian Purchasers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By purchasing shares of common stock offered hereby in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to
us and the dealer from whom the purchase confirmation is received that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is entitled under applicable provincial securities laws to purchase the shares without the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as
defined under National Instrument 45-106 &#150;<I> Prospectus Exemptions</I>, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is a &#147;permitted client&#148; as defined in National Instrument 31-103 &#150;<I> Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where required by law, the purchaser is purchasing as principal and not as agent, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser has reviewed the text above under Resale Restrictions. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of
Interest </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canadian purchasers are hereby notified that the underwriters are relying on the exemption set out in section 3A.3 or
3A.4, if applicable, of National Instrument 33-105 &#150;<I> Underwriting Conflicts </I>from having to provide certain conflict of interest disclosure in this document. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Statutory Rights of Action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the
offering memorandum (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Enforcement of Legal Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible
for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to
satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation and Eligibility for Investment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canadian purchasers of shares of common stock offered hereby should consult their own legal and tax advisors with respect to the tax
consequences of an investment in the shares in their particular circumstances and about the eligibility of the shares for investment by the purchaser under relevant Canadian legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX
or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art.
652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither
this document nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, us, the securities have been or will be filed
with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of
securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to
acquirers of securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority, or DFSA. This
document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents
in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this document relates may be
illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document, you should consult an
authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to its use in the Dubai International Financial Centre, or DIFC, this document is strictly
private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may
not be offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in the United Arab Emirates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab
Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this
prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central
Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors
in Australia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not constitute a disclosure document under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the Corporations Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure document for the purposes of the Corporations Act and does not purport to include the information
required of a disclosure document under Chapter 6D.2 of the Corporations Act; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, or Exempt Investors, available under section 708 of the Corporations
Act. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus may not be directly or indirectly offered for subscription or purchased or
sold, and no invitations to subscribe for or buy the securities may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any securities may be distributed in Australia, except where
disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the securities, you represent and warrant to us that
you are an Exempt Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As any offer of securities under this document will be made without disclosure in Australia under Chapter
6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies
to that resale. By applying for the securities you undertake to us that you will not, for a period of 12 months from the date of issue of the securities, offer, transfer, assign or otherwise alienate those securities to investors in Australia except
in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus have not been and will not be registered under the Financial Instruments and Exchange Act.
Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity
organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in
compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
prospective investors in Hong Kong </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus have not been offered or sold and will not be offered or
sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other
circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement,
invitation or document relating to the securities has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely
to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Warning </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this document, you should obtain
independent professional advice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in Singapore </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in
Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities
pursuant to an offer made under Section&nbsp;275 of the SFA except: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in Bermuda </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business
Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under
applicable Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in Saudi Arabia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities
Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or CMA pursuant to resolution number 2-11-2004 dated 4&nbsp;October 2004 as amended by resolution number 1-28-2008, as amended, or the CMA Regulations. The CMA does
not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the
securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in the British Virgin Islands </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription
by us or on our behalf. The securities may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (each a BVI Company), but only where the offer will be made to, and received by, the relevant BVI
Company entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been, and will not be, registered with the Financial
Services Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of the securities for the purposes of the Securities and Investment Business Act, 2010, or SIBA or the Public Issuers Code of the
British Virgin Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be offered to persons located in the British Virgin Islands who are &#147;qualified
investors&#148; for the purposes of SIBA. Qualified investors include (i)&nbsp;certain entities which are regulated by the Financial Services Commission in the British Virgin Islands, including banks, insurance companies, licensees under SIBA and
public, professional and private mutual funds; (ii)&nbsp;a company, any securities of which are listed on a recognised exchange; and (iii)&nbsp;persons defined as &#147;professional investors&#148; under SIBA, which is any person (a)&nbsp;whose
ordinary business involves, whether for that person&#146;s own account or the account of others, the acquisition or disposal of property of the same kind as the property, or a substantial part of our property; or (b)&nbsp;who has signed a
declaration that he, whether individually or jointly with his spouse, has net worth in excess of US$1,000,000 and that he consents to being treated as a professional investor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in China </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a public offer of the securities offered by this prospectus, whether by sale or subscription, in the
People&#146;s Republic of China, or the PRC. The securities are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the securities without obtaining all prior
PRC&#146;s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in Korea </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the
decrees and regulations thereunder, or the FSCMA, and the securities have been and will be offered in Korea as a private placement under the FSCMA. None of the securities may be offered, sold or delivered directly or indirectly, or offered or sold
to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the
decrees and regulations thereunder, or the FETL. The securities have not been listed on any of securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the securities shall comply
with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the securities. By the purchase of the securities, the relevant holder thereof will be deemed to represent and
warrant that if it is in Korea or is a resident of Korea, it purchased the securities pursuant to the applicable laws and regulations of Korea. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice
to prospective investors in Malaysia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No prospectus or other offering material or document in connection with the offer and sale of the
Securities has been or will be registered with the Securities Commission of Malaysia, or the Commission for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital
Markets Services Licence; (iii)&nbsp;a person who acquires the securities, as principal, if the offer is on terms that the securities may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for
each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3 million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual;
(v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of
RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets exceeding RM10 million (or its equivalent in a foreign currencies) based on the last audited accounts;
(viii)&nbsp;a partnership with total net assets exceeding RM10 million (or its equivalent in foreign currencies); (ix)&nbsp;a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x)&nbsp;an
Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to
(xi), the distribution of the securities is made by a holder of a Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus
does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under
the Capital Markets and Services Act 2007. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in Taiwan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities
laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or
approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the securities in Taiwan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to prospective investors in South Africa </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to restrictions under the securities laws of South Africa, the securities are not offered, and the Offer shall not be transferred, sold,
renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offer, transfer, sale, renunciation or delivery is to duly registered banks, mutual banks, financial services provider, financial institution, the Public Investment Corporation (in each case registered as such in
South Africa), a person who deals with securities in their ordinary course of business, or a wholly-owned subsidiary of a bank, mutual bank, authorised services provider or financial institution, acting as agent in the capacity of an authorised
portfolio manager for a pension fund (duly registered in South Africa), or as manager for a collective investment scheme (registered in South Africa); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than R1,000,000. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not, nor is it intended to, constitute an &#147;offer to the public&#148; (as that term is defined in the South African
Companies Act, 2008, or the SA Companies Act and does not, nor is it intended to, constitute a prospectus prepared and registered under the SA Companies Act. This document is not an &#147;offer to the public&#148; and must not be acted on or relied
on by persons who do not fall within Section&nbsp;96(1)(a) of the SA Companies Act (such persons being referred to as &#147;relevant persons&#148;). Any investment or investment activity to which this document relates is available only to relevant
persons and will be engaged in only with relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A South African resident person or company or any non-South African company
which is a subsidiary of a South African company is not permitted to acquire the securities unless such person has obtained exchange control approval to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Fenwick&nbsp;&amp; West LLP, San
Francisco, California. Certain legal matters relating to the offering will be passed upon for the underwriters by Cooley LLP, San Diego, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of AnaptysBio, Inc. as of December&nbsp;31, 2014 and 2015, and for each of the years in the two-year period ended
December&nbsp;31, 2015, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, an independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts
in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx320192_23"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits filed therewith. For further information about us and the common stock
offered hereby, reference is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration
statement are not necessarily complete, and in each instance we refer you to the copy of such contract or other document filed as an exhibit to the registration statement. We currently do not file periodic reports with the SEC. Upon the closing of
our initial public offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. A copy of the registration statement and the exhibits filed therewith may be inspected
without charge at the public reference room maintained by the SEC, located at 100&nbsp;F&nbsp;Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from that office. Please call the SEC at
1-800-SEC-0330 for further information about the public reference room. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The
address of the website is www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_24"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AnaptysBio, Inc. Audited Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_2">Consolidated Balance Sheets as of December&nbsp;31, 2014 and
2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_3">Consolidated Statements of Operations for the Years ended December&nbsp;
31, 2014 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_4">Consolidated Statements of Convertible Preferred Stock and Stockholders&#146;
 Deficit for the Years ended December&nbsp;31, 2014 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_5">Consolidated Statements of Cash Flows for the Years ended December&nbsp;
31, 2014 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AnaptysBio, Inc. Unaudited Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_7">Consolidated Balance Sheets as of December&nbsp;31, 2015 and September&nbsp;
30, 2016 (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_8">Unaudited Consolidated Statements of Operations for the Nine Months Ended September&nbsp;30,
 2015 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_9">Unaudited Consolidated Statements of Cash Flows for the Nine Months Ended September&nbsp;30,
 2015 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin320192_10">Notes to Unaudited Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">The Board of Directors and Stockholders </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of AnaptysBio, Inc. and subsidiary as of December&nbsp;31, 2014 and 2015, and the
related consolidated statements of operations, convertible preferred stock and stockholders&#146; deficit, and cash flows for each of the years in the two-year period ended December&nbsp;31, 2015. These consolidated financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable
basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects,
the financial position of AnaptysBio, Inc. and subsidiary as of December&nbsp;31, 2014 and 2015, and the results of their operations and their cash flows for each of the years in the two-year period ended December&nbsp;31, 2015, in conformity with
U.S.&nbsp;generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">February&nbsp;12, 2016, except for the reverse stock split described in Note&nbsp;12, which is dated January&nbsp;13, 2017.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_2"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except par value data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from collaborative partner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK AND</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.001 par value, 3,963 shares authorized, issued and
outstanding at December&nbsp;31, 2014 and 2015; aggregate liquidation preference at December&nbsp;31, 2015 of $24,991</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred stock, $0.001 par value, 1,887 shares authorized, 1,593 shares
issued and outstanding at December&nbsp;31, 2014 and 2015; aggregate liquidation preference at December&nbsp;31, 2015 of $7,246</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C-1 convertible preferred stock, $0.001 par value, 474 shares authorized, issued and
outstanding at December&nbsp;31, 2014 and 2015, respectively; aggregate liquidation preference at December&nbsp;31, 2015 of $6,470</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D convertible preferred stock, $0.001 par value, 5,491 shares authorized, no shares and
5,491 shares issued and outstanding at December&nbsp;31, 2014 and 2015, respectively; aggregate liquidation preference at December&nbsp;31, 2015 of $40,767</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 17,214 shares authorized, 2,481 shares and 2,630 shares issued and
outstanding at December&nbsp;31, 2014 and 2015, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,259</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,664</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,835</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,179</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,322</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(460</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,277</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(207</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,266</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share (unaudited):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding (unaudited):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_4"></A>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series B</B><br><B>Convertible</B><br><B>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series C</B><br><B>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series C-1</B><br><B>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series D</B><br><B>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B>Paid-in</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance, January&nbsp;1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,791</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,527</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of promissory notes payable to related parties into shares of Series C-1 Preferred
Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,259</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,835</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series D Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Reclassification of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shares issued under employee stock plans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,664</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,179</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_5"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OPERATING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from collaborative partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,455</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(514</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,078</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,669</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from notes payable, net of costs to issue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred stock, net of costs to issue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,445</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible promissory notes payable to related parties into shares of Series C-1
Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of warrants to equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts accrued for property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts accrued for deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc. (&#147;we,&#148; &#147;us,&#148; &#147;our,&#148; or the &#147;Company&#148;) was incorporated in the state of Delaware in
November 2005. We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. We develop our product candidates using our proprietary, antibody discovery
technology platform (&#147;SHM&#148;), which is designed to replicate, <I>in vitro,</I> the natural process of antibody generation. We currently generate revenue from our collaborative research and development arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the Company and its wholly-owned Australian subsidiary, which was established in
March 2015. All intercompany accounts and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have devoted our
primary effort to raising capital and research and development activities, and have, aside from the year ended December&nbsp;31, 2014, incurred losses and negative cash flows from operations through the year ended December&nbsp;31, 2015 and have an
accumulated deficit at December&nbsp;31, 2015 of $50.7 million. Through 2015, all of our financial support has been provided primarily from the sale of our common and preferred stock and proceeds from the issuance of convertible debt. Going forward,
as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events
or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended
business objectives. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles
(&#147;GAAP&#148;). The preparation of consolidated financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in our consolidated financial statements and
accompanying notes. Significant estimates in the consolidated financial statements have been made for preferred stock warrant liabilities and stock-based compensation. Actual results could differ materially from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consider all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents. Cash equivalents
consist primarily of money market and mutual funds with original maturities of 90 days or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014 and 2015, we held restricted cash of $85,000 and $60,000, respectively, used to secure a letter of credit provided as
security for our operating leases for our facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment is carried at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are
charged to operations as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, which range from three to seven years. Leasehold improvements are amortized using the
straight line method over the shorter of the lease term or the estimated useful life of the asset. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is
reflected in operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Long Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, consisting of property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that
the carrying value of an asset may not be recoverable based on undiscounted cash flows. If long-lived assets are impaired, an impairment loss is recognized and is measured as the amount by which the carrying value exceeds the estimated fair value of
the assets. No impairment charges were recorded during the years ended December&nbsp;31, 2014 or 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, we incurred an aggregate of $2.2 million in direct costs related to our anticipated
public offering of common stock. These costs were deferred and recorded as a long-term asset at December&nbsp;31, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred
Rent and Operating Lease Incentives </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When an operating lease includes lease incentives, such as a rent abatements or leasehold
improvement allowances, or requires fixed escalations of the minimum lease payments, the aggregate rental expense, including such incentives or increases, is recognized on a straight-line basis over the term of the lease. The cumulative difference
between the actual rental payments and rent charged to expense is recorded as deferred rent in the accompanying balance sheets. For leasehold improvement allowances, the costs are capitalized as leasehold improvement assets and amortized to expense
over the appropriate recognition period for such assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Issuance Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt issuance costs incurred to obtain debt financing are deferred and are amortized over the term of the debt using the effective interest
method. The costs are recorded as a reduction to the carrying value of the debt and the amortization expense is included in interest expense in the statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue
can be recognized: (i)&nbsp;persuasive evidence that an arrangement exists; (ii)&nbsp;delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (iii)&nbsp;the price is
fixed or determinable; and (iv)&nbsp;collectability is reasonably assured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple-Element Revenue Arrangements.</I> We evaluate
deliverables in a multiple-element arrangement to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered
element does not have standalone value without one of the undelivered elements in the arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the
inception of the arrangement based on the relative selling price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize consideration allocated to an individual element when all other revenue recognition
criteria are met for that element. Our multiple-element revenue arrangements may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>License arrangements</B>. The deliverables under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. As the
delivered licenses have not historically had standalone value apart from the undelivered elements, these have been recognized as revenue as a combined unit of accounting. Accordingly, we recognize revenue from nonrefundable upfront fees in the same
manner as the undelivered item(s), which is generally the period over which we provide research and development services. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Research and Development Services.</B> The deliverables under our collaboration and license arrangements include research and development services we perform on behalf of or with our collaborators. As the provision
of research and development services is an integral part of our operations and we may be principally responsible for the performance of these services under the agreements, we recognize revenue on a gross basis for research and development services
as we perform those services. Additionally, we recognize research related funding under collaboration research and development efforts as revenue as we perform or deliver the related services in accordance with contract terms. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Revenue.</I> Our collaboration and license agreements generally include contingent contractual payments related to achievement of
specific research, development and regulatory milestones and sales-based milestones that are dependent upon the performance of the licensor or collaborator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is
achieved. A milestone is defined as an event that can only be achieved based in whole or in part either on our performance, or the performance of our collaborators, or the occurrence of a specific outcome resulting from our past performance for
which there is a substantive uncertainty at the date the arrangement is entered into that the event will be achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs associated with research and development activities are expensed as incurred. Research and development costs
primarily include salaries and personnel-related costs, supplies and materials, contract manufacturing, in-licensing fees, outside services, and an allocation of information technology, fringe benefits, and facility overhead costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront and milestone payments incurred under our in-licensing agreements are expensed as acquired in-process research and development in the
period in which they are incurred, provided that the technology or method has no alternative future use. Royalties incurred on fees received under our sublicensing arrangements are expensed in the period in which we recognize the related
collaborative revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize stock-based compensation expense using a fair-value-based method for costs related to all share-based payments, including stock
options. Stock-based compensation cost for stock options granted to our employees and directors is measured at the grant date based on the fair-value of the award which is estimated using the Black-Scholes option-pricing model, and is recognized as
expense over the requisite service period on a straight-line basis. We estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. We use historical data to estimate
prevesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options
granted to individual service providers who are not employees or directors are accounted for at estimated fair values using the Black-Scholes option pricing model and are subject to periodic remeasurement over the period during which the services
are rendered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No tax benefits for stock-based compensation have been recognized in the statements of changes in
stockholders&#146; equity or cash flows. We have not recognized, and do not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of our full valuation allowance on net deferred tax assets and
net operating loss carryforwards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants for Shares of Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for warrants for shares of preferred stock with conversion features that provide for reductions in the warrant price as derivative
liabilities in the accompanying balance sheets at their fair value on the date of issuance. The derivative liabilities are revalued at each balance sheet date until such instruments are exercised or expire, with changes in the fair value between
reporting periods recorded as other income or expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial instruments consist principally of cash, cash equivalents, restricted cash, receivables from collaborative partners, accounts
payable, notes payable and preferred stock warrant liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and
minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Includes other inputs that are directly or indirectly observable in the marketplace. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own
assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our policy is to place our cash and cash equivalents with high quality financial institutions in order to limit our credit risk exposure, and,
at times, balances may exceed federally insured limits. To date, we have not experienced any credit losses associated with these financial instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
account for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using
enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more
likely than not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize an uncertain tax position in our consolidated financial statements when we conclude that a tax position is more likely than not
to be sustained upon examination based solely on technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit
that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. We have
elected to accrue any interest or penalties related to income taxes as part of our income tax expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Functional Currency of Foreign Operations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Australian subsidiary operates in a United States dollar (&#147;U.S. dollar&#148;) functional currency environment. Assets and liabilities
of our foreign subsidiary that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets and capital accounts, which are
remeasured at historical foreign currency exchange rates in effect at the date of transaction. Expenses are generally remeasured at monthly foreign currency exchange rates which approximate average rates in effect during each period. Net realized
and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), net, in the consolidated statements of operations and totaled ($0.2) million during the year ended December&nbsp;31, 2015.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Per Common Share and Pro Forma Net Income Per Common Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net income (loss) per share of common stock is determined using the two-class method for participating securities to the extent this method is
more dilutive than the if-converted method. All series of our convertible preferred stock are considered to be participating securities. In accordance with the two-class method, earnings allocated to these participating securities, which include
participation rights in undistributed earnings, are subtracted from net income to determine total earnings to be attributed to common stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share is computed by dividing net income (loss) attributed to common stockholders by the weighted-average
number of common shares outstanding during the period. All participating securities are excluded from basic weighted-average common shares outstanding. In computing diluted net income (loss) attributed to common stockholders, undistributed earnings
(if any) are re-allocated to reflect the potential impact of dilutive securities, including stock options and warrants that reduce the preferred stockholders participation in earnings to be attributed to common stockholders. Diluted net income
(loss) per share attributed to common stockholders is computed by dividing net income (loss) attributed to common stockholders by the weighted-average number of common equivalent shares outstanding for the period. Diluted net income (loss) per share
attributed to common stockholders includes any dilutive effect from outstanding stock options and warrants using the treasury stock method. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Computations for basic and diluted net income (loss) per common share are below. The unaudited
pro forma basic and diluted net income (loss) per common share calculation assumes the conversion of all outstanding shares of convertible preferred stock into common stock as if such conversion had occurred on January&nbsp;1, 2015 or the original
issuance date, if later. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Net Income</B><br><B>(Loss)</B><br><B>(Numerator)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B><br><B>(Denominator)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ended December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ended December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma for the Year Ended December&nbsp;31, 2015 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect the assumed conversion of convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,405</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common stock equivalents issuable upon the conversion or exercise of dilutive securities that could
potentially reduce net income per common share in the future that were excluded from the determination of diluted net income (loss) per common share as their effects were antidilutive are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU 2014-09, <I>Revenue from Contracts with Customers</I>, which outlines a single comprehensive model for
entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance. This standard is based on the principle that
an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires
additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract and becomes effective for our annual reporting period beginning January&nbsp;1, 2018, including interim periods
within that reporting period; adoption is permitted as early as January&nbsp;1, 2017. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. We are currently assessing
the impact that this standard will have on our consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, the FASB issued ASU 2016-01, <I>Financial Instruments&#151;Overall (Subtopic
825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</I>, which intends to enhance the reporting model for financial instruments by providing users of financial instruments with more decision-useful information. The
standard also addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments and requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs
incurred to fulfill a contract and becomes effective for our annual reporting period beginning January&nbsp;1, 2018, including interim periods within that reporting period; early adoption is permitted for nonpublic entities. We are currently
assessing the impact that this standard will have on our consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Balance Sheet Accounts and Supplemental Disclosures
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,355</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,583</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and contract manufacturing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Collaborative Research and Development Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>TESARO Collaboration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014, we entered into a Collaboration and Exclusive License Agreement (TESARO Agreement) with TESARO, Inc. and TESARO Development,
Inc. (collectively, &#147;TESARO&#148;), an oncology-focused biopharmaceutical company. Under the terms of the agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating
immunotherapy antibodies for subsequent preclinical, clinical, regulatory and commercial development to be performed by TESARO. Under the terms of the agreement, TESARO paid an upfront license fee of $17.0 million in March 2014 and agreed to provide
funding to us for research and development services related to antibody discovery programs for three specific targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2014,
we and TESARO entered into an Amendment No.&nbsp;1 to the Agreement to add an antibody discovery program against a fourth target for an upfront license fee of $2.0 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each development program, we are eligible to receive milestone payments of up to $18.0
million if certain clinical trial events are achieved by TESARO, up to an additional $90.0 million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional $165.0 million upon
the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration and certain commercial milestone
payments if specified levels of annual worldwide net sales are attained. Unless earlier terminated by either party upon specified circumstances, the agreement will terminate, with respect to each specific developed product, upon the later of the
12th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. We determined that the upfront license fees and research funding under the agreement, as amended, should be accounted for as a single
unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In December 2015, we determined that the research and development
services would be extended through December&nbsp;31, 2016. As a result, the period over which the unrecognized license fees and milestones will be recognized has been extended through December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognized revenue of $1.7&nbsp;million during the year ended December&nbsp;31, 2015, for the achievement of two $1.0 million milestones
upon initiation of <I>in vivo</I> toxicology studies, under the principles of good laboratory practice, using the AnaptysBio-generated anti-PD-1 antagonist antibody (TSR-042) and the AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022),
each being advanced by TESARO. The remaining unrecognized milestone payments of $0.3 million at December&nbsp;31, 2015 will be recognized ratably through December 2016. Revenue from future contingent milestone payments will be recognized if and when
such payments become due, subject to satisfaction of all of the criteria necessary to recognize revenue at that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue recognized
under this agreement aggregated $11.5 million during the year ended December&nbsp;31, 2014, which includes $7.0 million for the amortization of the upfront fee and $4.5 million in funding for research and development services. Revenue recognized
under this agreement aggregated $17.6 million during the year ended December&nbsp;31, 2015, which includes $9.4 million for the amortization of the upfront fee, $6.5 million in funding for research and development services, and $1.7 million for
milestones earned, of which $1.2 million was receivable at December&nbsp;31, 2015. Deferred revenue for this agreement was $2.9 million at December&nbsp;31, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Celgene Antibody Generation Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2011, we entered into an Antibody Generation Agreement with Celgene Corporation (&#147;Celgene&#148;), under which we agreed to
develop human therapeutic agents against multiple targets. We successfully delivered three antibodies against three targets under this agreement. The final deliverable under this agreement was completed in 2014. Under the terms of the agreement,
Celgene agreed to pay an initial fee of $6.0&nbsp;million, followed by a success fee of $0.5 million upon successful delivery of therapeutic antibodies against each of the targets involved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The upfront payment was recognized as revenue ratably over the estimated time to project completion, or nine months, beginning January 2014
when the project commenced. Revenue recognized under this agreement aggregated $0.6 million during the year ended December&nbsp;31, 2014, which includes $0.5 million in success fees and $92,000 in funding for research and development costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Momenta Antibody Generation Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2013, we entered into an Antibody Generation Agreement, with Momenta Pharmaceuticals, Inc. (&#147;Momenta&#148;) under which we
agreed to generate certain antibodies with enhanced affinity specific for a particular target for use in the development of human therapeutic agents by Momenta. Under the terms of the agreement, Momenta agreed to pay an upfront fee of $1.1 million,
followed by a $2.0 million success fee in the event of a successful outcome, which occurred in 2014. This agreement expired in accordance with its terms in 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The upfront payment was recognized as revenue ratably over the estimated time to project
completion, or nine months, beginning January 2014 when the project commenced. Revenue recognized under this agreement aggregated $3.1 million during the year ended December&nbsp;31, 2014, which includes $2.0 million in success fees and $1.1 million
for the amortization of the upfront fee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Collaborative Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2014, we recognized revenue from other collaborative partners aggregating $0.6 million for the
development of antibodies for specified targets. Revenue from these agreements consisted primarily of the amortization of upfront payments and funding for research and development services that were recognized as the related services were provided.
Our obligations under these collaborative agreements were completed by the end of 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Notes Payable and Convertible Promissory Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Notes Payable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;24, 2014, we entered into a Loan and Security Agreement (the &#147;LSA Agreement&#148;) with a bank and a financial institution whereby we may borrow up to $15.0 million in three separate draws of $5.0&nbsp;million each. The Term A
Loans, for an aggregate of $5.0 million, were drawn on December&nbsp;24, 2014. The Term B Loans for an aggregate of $5.0 million were available for draw through December&nbsp;31, 2015, contingent upon our first multi-dose PK/toxicology studies on at
least two development programs and the Term C Loans for an aggregate of $5.0 million are available for draw through December&nbsp;31, 2016, contingent upon receiving FDA approval on IND submission on at least two development programs. The Term A
Loans each bear a fixed rate of interest of 6.97%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, the LSA Agreement was amended (the &#147;LSA Amendment&#148;) to
combine Term B Loans and Term C Loans for a total of $10.0 million available for draw and delay the beginning of our Term A Loans&#146; principal repayments from February&nbsp;1, 2016 until February&nbsp;1, 2017. The Term B Loans and Term C Loans
are available for draw upon the later to occur of (i)&nbsp;receiving regulatory approval pertaining to an IND submission or foreign equivalent with respect to at least two development programs, provided that at least one of which must be an internal
development program and only one of which may be a foreign equivalent and (ii)&nbsp;July&nbsp;1, 2016. The draw period will end upon the earlier of (i)&nbsp;an event of default as defined in the LSA Agreement and (ii)&nbsp;December&nbsp;31, 2016. If
the Term B Loans and Term C Loans are issued, they will bear interest at the greater of 6.95% or the 3-month LIBOR plus 6.72%, with principal payments beginning February&nbsp;1, 2017 and with final maturity in January 2019. At December&nbsp;31,
2015, the Term A Loans are due in 13 monthly interest-only payments through January 2017, followed by 24 equal monthly principal and interest payments, with final maturity in January 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The costs incurred to issue the Term A Loans of $85,000 were deferred and are included in the discount to the carrying value of the Term A
Loans in the accompanying balance sheet. The Term A Loans also include a final payment fee of $0.3 million due at the earlier of prepayment or the maturity date of the Term A Loans. The deferred costs and the final payment fee are being amortized to
interest expense over the expected term of the Term A Loans using the effective interest method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the
Term A Loans, we issued detachable, fully vested warrants to purchase an aggregate of 41,208 shares of Series C Preferred Stock at an exercise price of $4.55 per share to the lenders, which are subject to change under anti-dilution provisions. The
warrants are exercisable at any time through December 2024. The grant-date fair value of the warrants of $0.1 million was recorded as a liability, with a reduction to the carrying value of the Term A Loans, and which is recognized as additional
interest expense over the remaining term of the Loans. The initial fair value of the warrants was determined using the Black-Scholes option pricing model with the following assumptions: a stock price volatility of 70.2%, an expected life equal to
the contractual term of the warrants of ten years and a risk-free interest rate of 1.97%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2015, the carrying amount of the Term A Loans was $4.9 million, which is net
of discounts of $97,000. The Term A Loans were classified as noncurrent in the Consolidated Balance Sheets at December&nbsp;31, 2015 as a result of the LSA Amendment in January 2016. The effective interest rate on the Term A Loans at
December&nbsp;31, 2015 was 9.25%. As of December&nbsp;31, 2015, future principal maturities of the Term A Loans were $2.2 million, $2.6 million and $0.2 million in 2017, 2018 and 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term A Loans are secured by a first priority interest in most of our assets, excluding intellectual property. At December&nbsp;31, 2015,
we were in compliance with the covenants contained in the Loan and Security Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Promissory Notes Payable to
Related Parties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2013, pursuant to a Purchase Agreement, we issued convertible promissory notes to existing investors
aggregating $2.0 million. The notes, which bear interest at 10%&nbsp;per annum, were unsecured and subordinated to all current and future indebtedness and were convertible at any time at the option of the holders into shares of Series C-1 Preferred
Stock at a conversion price of $4.55 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Authoritative accounting guidance requires that a portion of the note proceeds be
allocated to additional paid-in capital for the intrinsic value, if any, of the conversion option (the &#147;beneficial conversion feature&#148;) based upon the difference between the fair value of the underlying preferred stock at the date of
issuance of the notes and the effective conversion price embedded in the notes. The resulting discount on the notes is amortized over the term of the related notes to the stated date of redemption. At August&nbsp;30, 2013, the date of issuance of
the notes, the intrinsic value of the conversion option exceeded the net proceeds of the notes, and therefore the resulting discount attributed to the notes was limited to $2.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the principal and accrued interest on the notes, which aggregated $2.2 million, were converted into 476,190 shares of Series
C-1 Preferred Stock. The unamortized discount of $0.4 million at the date of conversion was recognized as interest expense. Total interest expense resulting from the amortization and write-off of the discount totaled $1.2 million during the year
ended December&nbsp;31, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assets and Liabilities Measured at Fair Value on a Recurring Basis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input
levels based on the fair value hierarchy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;End&nbsp;of&nbsp;Period&nbsp;Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;Market</B><br><B>Prices for</B><br><B>Identical&nbsp;Assets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant</B><br><B>Other</B><br><B>Observable</B><br><B>Inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant</B><br><B>Unobservable</B><br><B>Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>At December&nbsp;31, 2014</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual funds(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury security(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>At December&nbsp;31, 2015</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual funds(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury security(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Included in cash and cash equivalents in the Consolidated Balance Sheets. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Included in cash and cash equivalents, and restricted cash in the Consolidated Balance Sheets. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Marketable Securities.</I> For fair values determined by Level 1 inputs, which utilize quoted
prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. The fair values of investments in money market funds, mutual funds and U.S. treasury securities were determined using Level 1
inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrant Liabilities.</I> Our preferred stock warrants are accounted for as derivative liabilities and measured at fair value
on a recurring basis as they contain features that are either not afforded equity classification or embody risks that are not clearly and closely related to host contracts. We estimate fair values of these derivatives utilizing the Black-Scholes
option-pricing model, which requires Level 3 inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimating fair values of derivative financial instruments, including Level 3
instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors, including changes in the estimated fair value of
our equity securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average assumptions were employed in estimating the value of the liabilities for Series C
preferred stock warrants using the Black Scholes option-pricing model: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.32</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61.3</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.0</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend Yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average measurement date fair value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 10% increase in the fair values of preferred stock at December&nbsp;31, 2014 and 2015 would result in
increases in the estimated fair values of the preferred stock warrant liabilities of $89,000 and $0.2 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes the activity in liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Inputs): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Warrant Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(569</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized net losses included in other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,277</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of warrant liabilities to equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(569</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,549</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, the Company reclassified 41,208 Series&nbsp;C Preferred Stock warrants from Preferred stock
warrant liabilities to Additional paid in capital on the Consolidated Balance Sheets, at fair value on the date of transfer. The reclassification occurred upon the expiration of a feature within the warrant contract that had previously precluded
equity classification. As a result, these warrants are no longer remeasured at fair value on a recurring basis at December&nbsp;31, 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Other Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair values of the Company&#146;s financial instruments estimated as of December&nbsp;31, 2014 and 2015 are presented below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying</B><br><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying</B><br><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes Payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of certain of our financial instruments, including cash and cash equivalents, receivable
from collaborative partner, accounts payable, and accrued expenses approximate fair value due to their short-term nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
methods and assumptions were used to estimate the fair value of the Company&#146;s financial instruments for which it is practicable to estimate that value: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Notes Payable</I> &#151;We use the income approach to value the aforementioned debt instrument. We use a present value calculation to
discount principal and interest payments and the final maturity payment on these liabilities using a discounted cash flow model based on observable inputs. The Company discounts these debt instruments based on what the current market rates would
offer the Company as of the reporting date. Based on the assumptions used to value these liabilities at fair value, these debt instruments are categorized as Level 2 in the fair value hierarchy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Issuance of Series D Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;13, 2015, we issued and sold 5,490,973 shares of Series&nbsp;D Convertible Preferred Stock at $7.42 per share for net proceeds of
$40.7&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Amendments to Certificate of Incorporation and 2006 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;13, 2015, we amended our amended and restated certificate of incorporation to increase the total number of shares authorized for
issuance from 20,215,271 shares to 29,029,772 shares. Of these shares, 17,214,285 shares are designated as common stock and 11,815,487 shares are designated as preferred stock, which are designated as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,646,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,887,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,490,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total designated Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,815,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the amended and restated certificate of incorporation provided for the split of Series&nbsp;B
and Series&nbsp;B-1 Preferred Stock into ten shares for every nine shares outstanding. The consolidated financial statements and accompanying footnotes have been retroactively restated to reflect the Series&nbsp;B and Series B-1 Preferred Stock
splits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series B, B-1, and B-2 Preferred Stock (collectively, the &#147;Series B Preferred Stock&#148;) generally have consistent
rights and preferences discussed below, except that the conversion price of the Series B-2 Preferred Stock shall not be subject to adjustment in the event that we issue additional equity securities at a purchase price less than the Series B-2
conversion price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The convertible preferred stock has been classified as temporary equity in the accompanying
balance sheets as the shares include provisions allowing the holder to cause redemption of the shares upon certain change in control events that are outside of our control. We have elected not to adjust the carrying values of the convertible
preferred stock to the respective liquidation preferences of such shares as we are uncertain whether or when an event would occur that would obligate us to pay the liquidation preference to the holders of such shares, as discussed below. Adjustments
to increase the carrying values to the respective liquidation preferences will be made if and when it becomes probable that an event would occur obligating us to pay such amounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Dividend Rights.</B> The holders of the Series Preferred Stock are entitled to receive noncumulative dividends at a rate of 8% of the
respective Series issue price per annum. The Series D Preferred Stock dividends are payable in preference and in priority to any Series C-1 Preferred Stock. The Series C-1 Preferred Stock dividends are payable in preference and in priority to any
Series C Preferred Stock. The Series C Preferred Stock dividends are payable in preference and in priority to any Series B Preferred Stock. The Series B and Series A Preferred Stock dividends are payable in preference and in priority to any
dividends on common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock dividends are payable when, as and if declared by our board of directors. As of
December&nbsp;31, 2015, the board of directors has not declared any dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Voting Rights.</B> The holders of Series Preferred
Stock are entitled to one vote for each share of common stock into which such Series Preferred Stock could then be converted; and with respect to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers
of the holders of common stock, except that the holders of the Series B Preferred shares, voting as a separate class, are entitled to elect two members of the board of directors, the holders of the Series A Preferred and common stock shares, each
voting as a separate class, are each entitled to elect one member of the board of directors, and the holders of the Preferred and common shares, voting as a single class, are entitled to elect all remaining members of the board of the directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights.</B> Upon liquidation, dissolution or winding up of the Company, the holders of Preferred Stock are entitled to
receive distributions to be paid out of the assets of the Company, before any distributions are made to the holders of common stock. The holders of the Series D are entitled to receive liquidation preference at one (1)&nbsp;times the original issue
price of $7.42 per share plus all declared and unpaid dividends. Liquidation payments to the holders of Series D Preferred Stock have priority and are made in preference to any payments to the holders of Series C-1 Preferred Stock. The holders of
the Series C-1 are entitled to receive liquidation preference at three (3)&nbsp;times the original issue price of $4.55 per share plus all declared and unpaid dividends. Liquidation payments to the holders of Series C-1 Preferred Stock have priority
and are made in preference to any payments to the holders of Series C Preferred Stock. The holders of the Series C Preferred Stock are entitled to receive liquidation preferences at the rate of $4.55 per share plus all declared and unpaid dividends.
Liquidation payments to the holders of Series C Preferred Stock have priority and are made in preference to any payments to the holders of Series B Preferred Stock. The holders of the Series B and Series B-1 Preferred Stock are entitled to receive
liquidation preferences at the rate of $6.30 per share plus all declared and unpaid dividends and the holders of Series A and Series B-2 Preferred Stock are entitled to receive liquidation preferences at the rate of $7.00 per share plus all declared
and unpaid dividends. Liquidation payments to the holders of Series B and Series A Preferred Stock have priority and are made in preference to any payments to the holders of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Conversion Rights.</B> The shares of Series A Preferred Stock are convertible into shares of common stock at a conversion price of $6.30
per share and the shares of Series B, C, C-1 and D Preferred Stock are convertible into an equal number of shares of common stock. The shares of Series Preferred Stock are convertible at any time, at the option of the holder, subject to certain
antidilutive adjustments. Each share of Series Preferred Stock is automatically converted into common stock (i)&nbsp;upon the affirmative election of the holders of at least a majority of the outstanding shares of the Series Preferred Stock, voting
together as a single class on an as if converted basis, or (ii)&nbsp;immediately upon the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, in which the
gross cash proceeds to the Company (before underwriting discounts, commissions and fees) are at least $50.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Common Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have authorized 17,214,285 shares of common stock, of which 2,629,544 shares were issued and outstanding at December&nbsp;31, 2015. Common
shares reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at December&nbsp;31, 2015 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,520,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued and Outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,050,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants for shares of convertible preferred stock and common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares reserved for future award grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,312,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants for Shares of Preferred and Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the activity related to our warrants during the year ended December&nbsp;31, 2015 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B><br><B>Subject<BR>to</B><br><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Warrant</B><br><B>Price per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B><br><B>(in</B><br><B>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Warrants to Purchase Shares of Series C Preferred Stock</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at December&nbsp;31, 2014 and 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Warrants to Purchase Shares of Common Stock</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at December&nbsp;31, 2014 and 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2006 Equity Incentive Plan (the &#147;Plan&#148;) provides for the grant of incentive stock options, nonstatutory stock options, stock
appreciation rights, and rights to purchase restricted stock to our employees, nonemployee directors and consultants. Recipients of incentive stock options shall be eligible to purchase shares of our common stock at an exercise price equal to no
less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Plan is ten years. On April&nbsp;29, 2015, our stockholders approved an amendment to the Plan which provided for an increase
in the number of shares of common stock available for issuance under the plan by 544,285 and on July&nbsp;9, 2015, we amended our 2006 Equity Incentive Plan to increase the number of shares reserved for issuance under the plan by 680,978 shares. As
of December&nbsp;31, 2015, awards for up to 2,379,158 shares of common stock are reserved for issuance under the Plan, of which 2,050,196 are reserved for issuance upon exercise of granted and outstanding options and 328,962 shares are available for
future grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to employees and nonemployees generally vest over a four-year period and have a maximum term of ten years from the date
of grant, subject to earlier cancellation prior to vesting upon cessation of service to the Company. A summary of the activity related to stock option awards during the year ended December&nbsp;31, 2015 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B><br><B>Subject to</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise</B><br><B>Price per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B><br><B>(in</B><br><B>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,244,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,040,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(148,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeitures and cancellations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86,339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,050,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,900.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested or expected to vest at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,885,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,400.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total cash received from the exercise of stock options was $0.2 million during the year ended
December&nbsp;31, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stock option grants under the Plan provide for exercise of the stock option prior to vesting. Shares of
common stock issued upon exercise of unvested options are subject to repurchase by us at the respective original exercise price until vested. Consideration received for the exercise of unvested stock options is recorded as a liability and
reclassified into equity as the related award vests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the
following weighted average assumptions for options granted to employees during the years ended December&nbsp;31, 2014 and 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.8</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.2</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend Yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average grant date fair value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determine the appropriate, risk free interest rate, expected term for employee stock based awards,
contractual term for nonemployee stock based awards, and volatility assumptions. The weighted-average expected option term for employee stock based awards reflects the application of the simplified method, which defines the life as the average of
the contractual term of the options and the weighted average vesting period for all option tranches. The weighted average expected term for nonemployee stock based awards is the remaining contractual life of the award. Estimated volatility
incorporates historical volatility of similar entities whose share prices are publicly available. The risk free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the share based
payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total non-cash stock-based compensation expense for all stock awards that was recognized in the
statements of operations is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2015, there was $4.3 million of unrecognized compensation cost related to unvested stock
option awards, which is expected to be recognized over a remaining weighted average vesting period of 3.6&nbsp;years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Employee Benefit Plan
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a defined-contribution 401(k) plan for our employees. Employees are eligible to participate in the plan beginning on the first
day of the month following date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation and we have the option to make a discretionary match as determined by the board of directors, within
prescribed limits. There were no employer contributions to the plan during the years ended December&nbsp;31, 2014 or 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Commitments and
Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease our facility under a non-cancellable operating lease for which we exercised our option to renew for an additional five-year period.
The lease now expires in August 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rent expense was $0.4 million during the years ended December&nbsp;31, 2014 and 2015, respectively.
At December&nbsp;31, 2015, deferred rent aggregated $0.1 million, of which $21,000 is included in other current liabilities and $0.1 million is included in noncurrent liabilities in the accompanying consolidated balance sheet. At December&nbsp;31,
2015, the future minimum annual obligations under non-cancellable operating lease commitments are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Years Ending December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum payments required</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into collaborative license agreements that provide us with rights to use certain know-how, technology and patent rights
maintained by the licensors in our research and development efforts. Terms of the license agreements may require us to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and royalty
payments on fees received under our sublicensing arrangements and/or future sales, if any, of commercial products resulting from the collaboration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the licensing agreements require guaranteed minimum annual payments. Terms of the
licensing agreements generally range from the remaining life of the patent up to 17 years and, in some cases, may be subject to earlier termination by either party upon specified circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total expense incurred under all collaborative licensing agreements for upfront, milestone and royalty payments were $0.2 million during each
of the years ended December&nbsp;31, 2014 and 2015. Total cash paid under these agreements was $0.2 million during each of the years ended December&nbsp;31, 2014 and 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum annual obligations under all such license agreements were $0.2 million in aggregate. These obligations are payable through ten
years from the first commercial sale, if any, or expiration of the last patent to expire, the dates of which are not determinable at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Letter of Credit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014 and 2015, we were contingently liable for a standby letter of credit issued by a commercial bank for $85,000 and
$60,000, respectively, for security on our lease. A restricted cash account with these amounts was held as cash collateral for the letter of credit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are, from time to time, involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. Currently, we are not a defendant in any lawsuit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components
of our deferred tax assets and liabilities are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Tax Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Tax Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,836</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,090</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets, net of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have recorded a full valuation allowance against our net deferred tax assets due to the uncertainty
surrounding the realization of such assets. Management has determined it more likely than not that the deferred tax assets are not realizable due to our historical loss position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2015, we had federal and state net operating loss carryforwards (&#147;NOL&#148;) of $34.5 million and $41.5 million,
respectively. The federal and state NOLs will begin to expire in 2028 and 2017, respectively, unless previously utilized. At December&nbsp;31, 2015 we had federal and California research tax credit carryforwards of $1.4 million and $1.7 million,
respectively. The federal research tax credit carryforward will begin to expire in 2026 and the California state credits carryforward indefinitely. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above NOL carryforward and the research tax credit carryforwards may be subject to an annual
limitation under Section&nbsp;382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if we experience one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to
offset future taxable income and tax, respectively. In general, an ownership change as defined by Section&nbsp;382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by
more than 50 percentage points over a three-year period. In September 2015, we completed a Section&nbsp;382 analysis through December&nbsp;31, 2014 and determined that there was an ownership change in 2007 that may limit the utilization of
approximately $5.3&nbsp;million and $5.4&nbsp;million in federal and state NOLs, respectively, and $0.2&nbsp;million in both federal and state research tax credits. Our use of federal NOL carryforwards could be limited further by the provisions of
Section&nbsp;382 of the U.S. Internal Revenue Code of 1986, as amended, depending upon the timing and amount of additional equity securities that we have issued or will issue. State NOL carryforwards may be similarly limited. If eliminated, the
related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact
our effective tax rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a reconciliation of the expected statutory federal income tax provision to our actual income tax
provision: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected income tax expense (benefit) at federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,790</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(206</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return to provision adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(314</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in the valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,235</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize a tax benefit from an uncertain tax position when it is more likely than not that the position
will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. At
December&nbsp;31, 2014 and 2015, we had no unrecognized tax benefits that if recognized and realized, would affect the effective tax rate due to the valuation allowance against deferred tax assets. The following table summarizes the activity related
to our unrecognized tax benefits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not anticipate there will be a significant change in unrecognized tax benefits within the next 12
months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our policy is to recognize interest and penalties related to income tax matters in the provision for income taxes. At
December&nbsp;31, 2014 and 2015, there were no interest or penalties on uncertain tax benefits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file income tax returns in the United States, California and Australia. Due to our losses
incurred, we are essentially subject to income tax examination by tax authorities from inception to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Subsequent Event </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated subsequent events from the balance sheet date through February&nbsp;12, 2016, the date at which the consolidated financial
statements were issued, except for the reverse stock split discussed below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Milestone Payment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, we earned a $4.0 million milestone payment from one of our collaborators. We expect to receive this $4.0 million milestone
payment in February 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;13, 2017, we amended and restated our certificate of incorporation to effect a seven-to-one reverse stock split of every
outstanding share of our preferred and common stock. The financial statements and accompanying footnotes have been retroactively restated to reflect the reverse stock split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_7"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except par value data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma</B><br><B>Stockholders&#146;</B><br><B>Equity&nbsp;at</B><br><B>September&nbsp;30,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Receivable from collaborative partner</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Australian tax incentive receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK AND</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Notes payable, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Income taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B convertible preferred stock, $0.001 par value, 3,963 shares authorized, issued and
outstanding at December&nbsp;31, 2015 and September&nbsp;30, 2016; aggregate liquidation preference at September 30, 2016 of $24,991</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C convertible preferred stock, $0.001 par value, 1,887 shares authorized, 1,593 shares
issued and outstanding at December&nbsp;31, 2015 and September&nbsp;30, 2016; aggregate liquidation preference at September 30, 2016 of $7,246</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C-1 convertible preferred stock, $0.001 par value, 474 shares authorized, issued and
outstanding at December&nbsp;31, 2015 and September 30, 2016, respectively; aggregate liquidation preference at September&nbsp;30, 2016 of $6,470</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series D convertible preferred stock, $0.001 par value, 5,491 shares authorized, issued and
outstanding at December&nbsp;31, 2015 and September 30, 2016, respectively; aggregate liquidation preference at September 30, 2016 of $40,767</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock, $0.001 par value, 17,214 shares authorized, 2,630 shares and 2,639 shares issued and
outstanding at December&nbsp;31, 2015 and September 30, 2016, respectively; 14,159 issued and outstanding, pro forma, at September 30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,973</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_8"></A>UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:150pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_9"></A>UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OPERATING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from collaborative partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(458</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australian tax incentive receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for repurchase of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of preferred stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts accrued for property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts accrued for deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin320192_10"></A>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc. (&#147;we,&#148; &#147;us,&#148; &#147;our,&#148; or the &#147;Company&#148;) was incorporated in the state of Delaware in
November 2005. We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates using our proprietary, antibody discovery technology platform,
which is designed to replicate, <I>in vitro,</I> the natural process of antibody generation. We currently generate revenue from our collaborative research and development arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the Company and its wholly-owned Australian subsidiary, which was established in
March 2015. All intercompany accounts and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited consolidated
financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#147;SEC&#148;). Certain information and note disclosures normally included in annual financial statements prepared in
accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;) have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of
interim periods as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Actual results may materially differ from these estimates. Operating
results for the nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31, 2016. The financial statements should be read in conjunction with our audited financial
statements for the year ended December&nbsp;31, 2015, included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have devoted our
primary effort to raising capital and research and development activities, and at September 30, 2016, have an accumulated deficit of $50.3 million. Through September 30, 2016, all of our financial support has been provided primarily from the sale of
our common and preferred stock, proceeds from the issuance of convertible debt and funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or
strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding,
we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. The accompanying unaudited consolidated financial
statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro
Forma Stockholders&#146; Equity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of the offering contemplated by this prospectus, we expect all of our
convertible preferred stock outstanding to convert into shares of common stock at the then applicable conversion rate. The unaudited pro forma stockholders&#146; equity is based on the assumed conversion of shares of convertible preferred stock
outstanding at September 30, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of consolidated financial
statements in conformity with GAAP requires management to make </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
judgments, assumptions and estimates that affect the amounts reported in our consolidated financial statements and accompanying notes. Significant estimates in the consolidated financial
statements have been made for preferred stock warrant liabilities and stock-based compensation. Actual results could differ materially from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consider all highly liquid investments with a maturity at date of purchase of six months or less to be cash equivalents. Cash equivalents
consist primarily of money market and mutual funds with original maturities of 90 days or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We held restricted cash of $60,000 at December&nbsp;31, 2015 and September 30, 2016, respectively, which we used to secure a letter of credit
provided as security for our operating lease for our facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2016, we have incurred an aggregate of $3.0 million in direct costs related to our anticipated public offering of common
stock. These costs were deferred and recorded as a long-term asset at September 30, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue
can be recognized: (i)&nbsp;persuasive evidence that an arrangement exists; (ii)&nbsp;delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (iii)&nbsp;the price is
fixed or determinable; and (iv)&nbsp;collectability is reasonably assured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple-Element Revenue Arrangements.</I> We evaluate
deliverables in a multiple-element arrangement to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered
element does not have standalone value without one of the undelivered elements in the arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the
inception of the arrangement based on the relative selling price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize consideration allocated to an individual element when all
other revenue recognition criteria are met for that element. Our multiple-element revenue arrangements may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>License arrangements</B>. The deliverables under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. As the
delivered licenses have not historically had standalone value apart from the undelivered elements, these have been recognized as revenue as a combined unit of accounting. Accordingly, we recognize revenue from nonrefundable upfront fees in the same
manner as the undelivered item(s), which is generally the period over which we provide research and development services. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Research and Development Services</B>. The deliverables under our collaboration and license arrangements include research and development services we perform on behalf of or with our collaborators. As the provision
of research and development services is an integral part of our operations and we may be principally responsible for the performance of these services under the agreements, we recognize revenue on a gross basis for research and development services
as we perform those services. Additionally, we recognize research related funding under collaboration research and development efforts as revenue as we perform or deliver the related services in accordance with contract terms. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Revenue.</I> Our collaboration and license agreements generally include contingent
contractual payments related to achievement of specific research, development and regulatory milestones and sales-based milestones that are dependent upon the performance of the licensor or collaborator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which the milestone is
achieved. A milestone is defined as an event that can only be achieved based in whole or in part either on our performance, or the performance of our collaborators, or the occurrence of a specific outcome resulting from our past performance for
which there is a substantive uncertainty at the date the arrangement is entered into that the event will be achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Australian
Research and Development Tax Incentive </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are eligible under the Australian Research and Development Tax Incentive Program (the
&#147;Tax Incentive&#148;) to obtain a cash refund from the Australian Taxation Office for eligible research and development expenditures. However, we must have revenue of less than AUD $20.0 million during the reimbursable period and cannot be
controlled by income tax exempt entities. The Tax Incentive is recognized as a reduction to research and development expense when there is reasonable assurance that the Tax Incentive will be received, the relevant expenditure has been incurred, and
the amount can be reliably measured. The Tax Incentive is denominated in Australian dollars and, therefore, the related receivable is remeasured into U.S. dollars as of each reporting date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize stock-based compensation expense using a fair-value-based method for costs related to all share-based payments, including stock
options. Stock-based compensation cost for stock options granted to our employees and directors is measured at the grant date based on the fair-value of the award which is estimated using the Black-Scholes option-pricing model, and is recognized as
expense over the requisite service period on a straight-line basis. We estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. We use historical data to estimate
prevesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options
granted to individual service providers who are not employees or directors are accounted for at estimated fair values using the Black-Scholes option pricing model and are subject to periodic remeasurement over the period during which the services
are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No tax benefits for stock-based compensation have been recognized in the statements of changes in stockholders&#146; equity
or cash flows. We have not recognized, and do not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of our full valuation allowance on net deferred tax assets and net operating loss
carryforwards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants for Shares of Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for warrants for shares of preferred stock with conversion features that provide for reductions in the warrant price as derivative
liabilities in the accompanying balance sheets at their fair value on the date of issuance. The derivative liabilities are revalued at each balance sheet date until such instruments are exercised or expire, with changes in the fair value between
reporting periods recorded as other income or expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial instruments consist principally of cash, cash equivalents, restricted cash, receivables from collaborative partners, accounts
payable, notes payable and preferred stock warrant liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level
1&#151;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level
2&#151;Includes other inputs that are directly or indirectly observable in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs that are
supported by little or no market activities, therefore requiring an entity to develop its own assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Functional Currency of
Foreign Operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Australian subsidiary operates in a United States dollar (&#147;U.S. dollar&#148;) functional currency
environment. Assets and liabilities of our foreign subsidiary that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets
and capital accounts, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Expenses are generally remeasured at monthly foreign currency exchange rates which approximate average rates in effect
during each period. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), net, in the consolidated statements of operations and totaled $(0.3) million and $84,000
during the nine months ended September&nbsp;30, 2015 and 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Per Common Share and Pro Forma Net Income Per
Common Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net income (loss) per share of common stock is determined using the two-class method for participating securities to
the extent this method is more dilutive than the if-converted method. All series of our convertible preferred stock are considered to be participating securities. In accordance with the two-class method, earnings allocated to these participating
securities, which include participation rights in undistributed earnings, are subtracted from net income to determine total earnings to be attributed to common stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share is computed by dividing net income (loss) attributed to common stockholders by the weighted-average
number of common shares outstanding during the period. All participating securities are excluded from basic weighted-average common shares outstanding. In computing diluted net income (loss) attributed to common stockholders, undistributed earnings
(if any) are re-allocated to reflect the potential impact of dilutive securities, including stock options and warrants that reduce the preferred stockholders&#146; participation in earnings to be attributed to common stockholders. Diluted net income
(loss) per share attributed to common stockholders is computed by dividing net income (loss) attributed to common stockholders by the weighted-average number of common equivalent shares outstanding for the period. Diluted net income (loss) per share
attributed to common stockholders includes any dilutive effect from outstanding stock options and warrants using the treasury stock method. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Computations for basic and diluted net income (loss) per common share are below. The unaudited
pro forma basic and diluted net income (loss) per common share calculation assumes the conversion of all outstanding shares of convertible preferred stock into common stock as if such conversion had occurred on January&nbsp;1, 2016 or the original
issuance date, if later. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted-average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted-average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect the assumed conversion of convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic weighted-average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma diluted weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common stock equivalents issuable upon the conversion or exercise of dilutive securities that could
potentially reduce net income per common share in the future that were excluded from the determination of diluted net income (loss) per common share as their effects were antidilutive are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">7,601<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Pronouncements Recently Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2016, the FASB issued ASU 2016-15, <I>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash
Payments</I>, which addresses eight specific cash flows issues for which it provides specific guidance on treatment within the cash flow statement, with the intent of reducing diversity in practice. As permitted by this ASU, we elected to early
adopt the standard beginning with our quarterly reporting period ended September 30, 2016, with retrospective application of the amended guidance.&nbsp;Upon adoption, there was no effect to our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (the &#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2014-09,
<I>Revenue from Contracts with Customers</I>, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers and supersedes most current revenue
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognition guidance, including industry-specific guidance. This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to
customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets
recognized from costs incurred to fulfill a contract and becomes effective for our annual reporting period beginning January&nbsp;1, 2018, including interim periods within that reporting period; adoption is permitted as early as January&nbsp;1,
2017. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. We have not yet selected a transition method, and we are currently assessing the impact that this standard
will have on our consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, the FASB issued ASU 2016-01, <I>Financial Instruments&#151;Overall
(Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</I>, which intends to enhance the reporting model for financial instruments by providing users of financial instruments with more decision-useful
information. The standard also addresses certain aspects of the recognition, measurement, presentation, and disclosure of financial instruments and requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized
from costs incurred to fulfill a contract and becomes effective for our annual reporting period beginning January&nbsp;1, 2018, including interim periods within that reporting period; early adoption is permitted. We are currently assessing the
impact that this standard will have on our consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU 2016-02,<I> Leases
(Topic 842)</I>, which requires that lessees recognize a right-of-use asset and a related lease liability arising from leases on the balance sheet. ASU 2016-02 becomes effective for our annual reporting period beginning January&nbsp;1, 2019,
including interim periods thereafter; early adoption is permitted. We are currently assessing the impact that this standard will have on our consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU 2016-09,<I> Compensation&#151;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment
Accounting</I>, which is intended to simplify the accounting for share-based payments including forfeiture rates, expected option terms, intrinsic value, income taxes as they relate to awards, and cash flow presentation. ASU 2016-09 becomes
effective for our annual reporting period beginning January&nbsp;1, 2017, including interim periods thereafter; early adoption is permitted.&nbsp;We are currently assessing the impact that this standard will have on our consolidated financial
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Balance Sheet Accounts and Supplemental Disclosures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and contract manufacturing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Collaborative Research and Development Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>TESARO Collaboration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014, we entered into a Collaboration and Exclusive License Agreement (TESARO Agreement) with TESARO, Inc. and TESARO Development,
Inc. (collectively, &#147;TESARO&#148;), an oncology-focused biopharmaceutical company. Under the terms of the agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating
immunotherapy antibodies for subsequent preclinical, clinical, regulatory and commercial development to be performed by TESARO. Under the terms of the agreement, TESARO paid an upfront license fee of $17.0 million in March 2014 and agreed to provide
funding to us for research and development services related to antibody discovery programs for three specific targets. In November 2014, we and TESARO entered into an Amendment No.&nbsp;1 to the Agreement to add an antibody discovery program against
an undisclosed fourth target for an upfront license fee of $2.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each development program, we are eligible to receive
milestone payments of up to $18.0 million if certain clinical trial events are achieved by TESARO, up to an additional $90.0 million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an
additional $165.0 million upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration and
certain commercial milestone payments if specified levels of annual worldwide net sales are attained. Unless earlier terminated by either party upon specified circumstances, the agreement will terminate, with respect to each specific developed
product, upon the later of the 12th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. We determined that the upfront license fees and research funding under the agreement, as amended,
should be accounted for as a single unit of accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. In December 2015, we determined that
the research and development services would be extended through December&nbsp;31, 2016. As a result, the period over which the unrecognized license fees and milestones will be recognized has been extended through December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, we achieved two $1.0 million milestones upon initiation of <I>in vivo</I> toxicology studies,
using good laboratory practices (GLPs), for an AnaptysBio-generated anti-PD-1 antagonist antibody (TSR-042) and an AnaptysBio-generated anti-TIM-3 antagonist antibody (TSR-022), each being advanced by TESARO, for which we recognized revenue of
$1.7&nbsp;million. The remaining unrecognized milestone payments of $0.3 million at December&nbsp;31, 2015 will be recognized ratably through December&nbsp;2016, for which $0.2 million was recognized during the nine months ended September 30, 2016.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, TESARO received clearance of their IND from the FDA for an AnaptysBio-generated anti-PD-1 antagonist antibody (TSR-042)
resulting in us earning a $4.0 million milestone payment. We recognized $3.6 million of the $4.0 million milestone payment as revenue during the nine months ended September 30, 2016. The remaining unrecognized milestone payment of $0.4&nbsp;million
at September 30, 2016 will be recognized ratably through December&nbsp;31, 2016. The $4.0 million milestone payment was received in February 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2016, TESARO received clearance of their IND from the FDA for an AnaptysBio-generated
anti-TIM-3 antagonist antibody (TSR-022) resulting in us earning a $4.0 million milestone payment. We recognized $3.6 million of the $4.0 million milestone payment as revenue during the nine months ended September 30, 2016. The remaining
unrecognized milestone payment of $0.4&nbsp;million at September 30, 2016 will be recognized ratably through December&nbsp;31, 2016. The $4.0 million milestone payment was received in June 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2016, we achieved a $1.0 million milestone upon initiation of <I>in vivo</I> toxicology studies, using GLPs, for an
AnaptysBio-generated anti-LAG-3 antagonist antibody (TSR-033), being advanced by TESARO, for which we recognized revenue of approximately $0.9&nbsp;million. The remaining unrecognized milestone payment of $0.1 million at September 30, 2016 will be
recognized ratably through December&nbsp;2016. The $1.0 million milestone payment was received in September 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from future
contingent milestone payments will be recognized if and when such payments become due, subject to satisfaction of all of the criteria necessary to recognize revenue at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue recognized under this agreement aggregated $13.5 million during the nine months ended September&nbsp;30, 2015, which primarily
includes $8.2 million for the amortization of the upfront fee and $5.3 million in funding for research and development services. Revenue recognized under this agreement aggregated $13.4 million during the nine months ended September 30, 2016, which
includes $8.4 million related to five milestones for which we are recognizing revenue pro rata over the collaboration term, $3.0 million in funding for research and development services, and $2.0 million for the amortization of the upfront fee, of
which $0.9 million was receivable at September 30, 2016. Deferred revenue under this agreement totaled $1.5 million at September 30, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Antibody Generation Agreement with Celgene Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2011, we entered into a license and collaboration agreement with Celgene to develop therapeutic antibodies against multiple
targets. We granted Celgene the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting
certain pre-specified parameters pertaining to each target under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement provided for an upfront payment of $6.0
million from Celgene, which we received in 2011 and recognized through 2014, milestone payments of up to $53.0 million per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and
development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, Celgene successfully completed an <I>in vivo</I> toxicology study using good laboratory practices for an
AnaptysBio-generated antibody resulting in us earning a $0.5&nbsp;million milestone payment in June&nbsp;2016, which we recognized in full as revenue in June 2016. The $0.5&nbsp;million milestone payment was received in June&nbsp;2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Notes Payable and Convertible Promissory Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Notes Payable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;24, 2014, we entered into a Loan and Security Agreement (the &#147;LSA Agreement&#148;) with a bank and a financial institution whereby we may borrow up to $15.0 million in three separate draws of $5.0&nbsp;million each. The Term A
Loans, for an aggregate of $5.0 million, were drawn on December&nbsp;24, 2014. The Term B Loans for an aggregate of $5.0 million were available for draw through December&nbsp;31, 2015, contingent upon our first multi-dose PK/toxicology studies on at
least two development programs and the Term C Loans for an aggregate of $5.0 million are available for draw through December&nbsp;31, 2016, contingent upon receiving FDA approval on IND submission on at least two development programs. The Term A
Loans each bear a fixed rate of interest of 6.97%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The costs incurred to issue the Term A Loans of $85,000 were deferred and are included in the
discount to the carrying value of the Term A Loans in the accompanying balance sheet. The Term A Loans also include a final payment fee of $0.3 million due at the earlier of prepayment or the maturity date of the Term A Loans. The deferred costs and
the final payment fee are being amortized to interest expense over the expected term of the Term A Loans using the effective interest method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Term A Loans, we issued detachable, fully vested warrants to purchase an aggregate of 41,208 shares of
Series C Preferred Stock at an exercise price of $4.55 per share to the lenders, which are subject to change under anti-dilution provisions. The warrants are exercisable at any time through December 2024. The grant-date fair value of the warrants of
$0.1 million was recorded as a liability, with a reduction to the carrying value of the Term A Loans, and which is recognized as additional interest expense over the remaining term of the Loans. The initial fair value of the warrants was determined
using the Black-Scholes option pricing model with the following assumptions: a stock price volatility of 70.2%, an expected life equal to the contractual term of the warrants of ten years and a risk-free interest rate of 1.97%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, the LSA Agreement was amended (the &#147;LSA Amendment&#148;) to combine Term B Loans and Term C Loans for a total of $10.0
million available for draw and delay the beginning of our Term A Loans&#146; principal repayments from February&nbsp;1, 2016 until February&nbsp;1, 2017. The Term B Loans and Term C Loans became available for draw on July&nbsp;1, 2016 which was the
later to occur of (i)&nbsp;receiving regulatory approval pertaining to an IND submission or foreign equivalent with respect to at least two development programs, provided that at least one of which must be an internal development program and only
one of which may be a foreign equivalent (which occurred in the first quarter of 2016) and (ii)&nbsp;July&nbsp;1, 2016. The draw period will end upon the earlier of (i)&nbsp;an event of default as defined in the LSA Agreement and
(ii)&nbsp;December&nbsp;31, 2016. If the Term B Loans and Term C Loans are issued, they will bear interest at the greater of 6.95% or the 3-month LIBOR plus 6.72%, with principal payments beginning February&nbsp;1, 2017 and with final maturity in
January 2019. At September 30, 2016, the Term A Loans are due in 4 monthly interest-only payments through January 2017, followed by 24 equal monthly principal and interest payments, with final maturity in January 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At September 30, 2016, the carrying amount of the Term A Loans was $5.0 million, which is net of discounts of $17,000, of which $1.6 million
is classified as current liabilities, and $3.4 million is classified as noncurrent liabilities at September 30, 2016. The effective interest rate on the Term A Loans at September 30, 2016 was 9.29%. As of September 30, 2016, future principal
maturities of the Term A Loans were $2.2 million, $2.6 million and $0.2 million in 2017, 2018 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term A Loans
are secured by a first priority interest in most of our assets, excluding intellectual property. At September 30, 2016, we were in compliance with the covenants contained in the Loan and Security Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Assets and Liabilities Measured at Fair Value on a Recurring Basis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input
levels based on the fair value hierarchy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;End&nbsp;of&nbsp;Period&nbsp;Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Quoted&nbsp;Market<BR>Prices for<BR>Identical&nbsp;Assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Significant<BR>Unobservable<BR>Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>At December&nbsp;31, 2015</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual funds(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury security(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>At September 30, 2016</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual funds(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury security(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Included in cash and cash equivalents, and restricted cash in the accompanying balance sheets. </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Included in cash and cash equivalents in the accompanying balance sheets. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Marketable Securities.</I> For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical
assets, the level of judgment required to estimate fair value is relatively low. The fair values of investments in money market funds, mutual funds and U.S. treasury securities were determined using Level 1 inputs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrant Liabilities.</I> Our preferred stock warrants are accounted for as derivative liabilities and measured at fair value on a recurring
basis as they contain features that are either not afforded equity classification or embody risks that are not clearly and closely related to host contracts. We estimate fair values of these derivatives utilizing the Black-Scholes option-pricing
model, which requires Level 3 inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimating fair values of derivative financial instruments, including Level 3 instruments, require
the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors, including changes in the estimated fair value of our equity
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average assumptions were employed in estimating the value of the liabilities for Series C preferred
stock warrants using the Black-Scholes option-pricing model: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend Yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average measurement date fair value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 10% increase in the fair values of preferred stock at December&nbsp;31, 2015 and September 30,
2016 would each result in increases in the estimated fair values of the preferred stock warrant liabilities of $0.2 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes the activity in liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Inputs): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Warrant Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized net (losses) income included in other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of warrant liabilities to equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Other Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of our financial instruments estimated as of December&nbsp;31, 2015 and September 30, 2016 are presented below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September 30, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes Payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of certain of our financial instruments, including cash and cash equivalents, receivable
from collaborative partner, Australian tax incentive receivable, accounts payable, and accrued expenses approximate fair value due to their short-term nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following methods and assumptions were used to estimate the fair value of our financial instruments for which it is practicable to
estimate that value: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Notes Payable</I>&#151;We use the income approach to value the aforementioned debt instrument. We use a present
value calculation to discount principal and interest payments and the final maturity payment on these liabilities using a discounted cash flow model based on observable inputs. We discount these debt instruments based on what the current market
rates would offer us as of the reporting date. Based on the assumptions used to value these liabilities at fair value, these debt instruments are categorized as Level 2 in the fair value hierarchy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Repurchase of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain stock option grants under our 2006 Equity Incentive Plan (the &#147;Plan&#148;) are subject to an early exercise provision. Shares of
common stock obtained upon early exercise of unvested options are subject to repurchase by us at the applicable original issue price. During the nine months ended September 30, 2016, we repurchased 1,457 shares of Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Equity Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2006 Equity
Incentive Plan (the &#147;Plan&#148;) provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, and rights to purchase restricted stock to our employees, nonemployee directors and consultants.
Recipients of incentive stock options shall be eligible to purchase shares of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Plan is ten years. As of
September 30, 2016, awards for up to 2,370,157 shares of common stock are reserved for issuance under the Plan, of which 1,856,750 are reserved for issuance upon exercise of granted and outstanding options and 513,407 shares are available for future
grants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to employees and nonemployees generally vest over a four-year period and have a maximum term of ten years from the date
of grant, subject to earlier cancellation prior to vesting upon cessation of service to us. A summary of the activity related to stock option awards during the nine months ended September 30, 2016 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>Subject to<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR>(in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,050,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeitures and cancellations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(461,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at September 30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,856,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,440.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested or expected to vest at September 30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,748,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,324.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total cash received from the exercise of stock options was approximately $16,000 during the nine months ended
September 30, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stock option grants under the Plan provide for exercise of the stock option prior to vesting. Shares of common
stock issued upon exercise of unvested options are subject to repurchase by us at the respective original exercise price until vested. Consideration received for the exercise of unvested stock options is recorded as a liability and reclassified into
equity as the related award vests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option
valuation model with the following weighted average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average grant date fair value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determine the appropriate, risk free interest rate, expected term for employee stock based awards,
contractual term for nonemployee stock based awards, and volatility assumptions. The weighted-average expected option term for employee stock based awards reflects the application of the simplified method, which defines the life as the average of
the contractual term of the options and the weighted average vesting period for all option tranches. The weighted average expected term for nonemployee stock based awards is the remaining </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contractual life of the award. Estimated volatility incorporates historical volatility of similar entities whose share prices are publicly available. The risk free interest rate is based upon
U.S. Treasury securities with remaining terms similar to the expected or contractual term of the share based payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations is as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At September 30, 2016, there was $2.8 million of unrecognized compensation cost related to unvested stock
option awards, which is expected to be recognized over a remaining weighted average vesting period of 2.8&nbsp;years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Australia Research and
Development Tax Incentive </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Australian subsidiary, which conducts core research and development activities on our behalf, is
eligible to receive a 45% refundable tax incentive for qualified research and development activities. For the nine months ended September 30, 2016, $6.2 million was recorded as a reduction to research and development expenses in the consolidated
statements of operations, of which $3.0 million related to fiscal 2015. We received the $3.0 million in cash during the nine months ended September 30, 2016. In September 2016, we determined that we would meet the criteria for eligibility for fiscal
2016, therefore we recorded a reduction to research and development expenses of $3.2 million equal to 45% of our eligible expenditures for the nine-month period ended September 30, 2016, as collectability was considered reasonably assured. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated
subsequent events from the balance sheet date through November&nbsp;10, 2016, the date at which the consolidated financial statements were issued, except for the items discussed below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reverse Stock Split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;13,
2017, we amended and restated our certificate of incorporation to effect a seven to one reverse stock split of every outstanding share of our preferred and common stock. The financial statements and accompanying footnotes have been retroactively
restated to reflect the reverse stock split. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Loan Amendment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, the Loan Agreement was further amended to (i)&nbsp;allow for the Term B Loans and Term C Loans to be drawn on
December&nbsp;30, 2016, (ii)&nbsp;delay principal repayments of all Term Loans until February&nbsp;1, 2018 and (iii)&nbsp;amend the interest rate for each Loan. The Term B Loans and the Term C Loans were drawn on December&nbsp;30, 2016. As of
December&nbsp;31, 2016, the Loans are due in 13 monthly interest-only payments through January 2018, followed by 24 equal monthly principal and interest payments, with final maturity in January 2020. Each Loan bears interest equal to 3-month U.S.
LIBOR plus 6.37%, with principal payments beginning February&nbsp;1, 2018 and final maturity in January 2020. In conjunction with the December&nbsp;30, 2016 draw, we issued 82,416 Series C Preferred warrants to the lenders with an exercise price of
$4.55 which expire December&nbsp;30, 2026. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>5,000,000 Shares </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320192g56x38.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:24pt; font-family:ARIAL" ALIGN="center"><B>AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Credit Suisse </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>JMP Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Wedbush PacGrow </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">January 25, 2017 </P>
<P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g320192g05u85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g05u85.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1\04&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&='
M5          *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             "E0   V\          0
M                   !              -O   "E0
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "E0    !29VAT;&]N9P
M V\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   I4     4F=H=&QO;F<   -O     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !X * # 2(  A$! Q$!_]T !  *_\0!/P
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M3?\ 0]1__6UD68;+<G(?17D8XL-EC'XF957ZSK7,9N]%CF,WN;8ZUMMOO_\
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MO$FR&6?28'#&6@^B#,Z@ZRZEM%AJ :+8.FYQD"JS^2W;^D6I58+:VV#0/ <
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M>UC6[O<]ZTE\JI)(?JI<P_/ZG7=;6<W(9L>X@'I[[/8U[PZSU&.<U[+6UO\
M1_S_ $_YM?/B22GZ"/4.JUVAMF=D%D[FD=-?^D:!ZCFU.#G>GZ;/9^F8SWIS
MU#J#6UV,S\CT'L>\/?T][CNW.K]-X:66M=[7NQ_T'T/YRVS_  GSXDDE^@V]
M0ZB]@]/-R7Y-->ZQHP"&V2_;[66.8UMU?J,J_I/^#NM_FTF=5SFV->_/N?43
M]#]F6@GV_0+Q_G_17SXDDI^H.EV66X%-EMKK[' EUCJC03J><=WNJV_15I?*
MJ22'ZBS<VO#J%MC++ YVV*6.L=)!=]"L.=M]JR<SK7VFIAQ'Y6"]I)>Y^%;:
M 0T[F/;M#?T3G;G['_\ %KYS224_0(ZEU5['/KSKG$,+VT_LYPM=JVL[6V.K
M;MJ?=4][?]$KV#UVJNKTLFS)R[YDO&';5[726?HMCMK=K?I+YP224_46%FTY
MU/K4ML:S<6Q;6^ITC^1<UC]JL+Y5224__]D .$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M 2Y-30 J    "  ' 1(  P    $  0   1H !0    $   !B 1L !0    $
M  !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !
M  $   "D    T  <:I(  "<0 !QJD@  )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$V.C$R.C(R(#$T.C R.C0Q   #H $  P    '__P
MH ( !     $   -OH , !     $   *5          8! P #     0 &   !
M&@ %     0   1X!&P %     0   28!*  #     0 "   " 0 $     0
M 2X" @ $     0              2     $   !(     3A"24T#_0
M"           _^$!,$U- "H    (  <!$@ #     0     !&@ %     0
M &(!&P %     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "
M%    )"':0 $     0   *0   #0   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,3(Z,C(@,30Z,#(Z-#$   .@
M 0 #     ?__  "@ @ $     0   V^@ P $     0   I4         !@$#
M  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (
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M 0$! 0$! 0$! 0'_P  1" %5 <4# 1$  A$! Q$!_\0 '@ !  $$ P$!
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MI,CFFX!E'",D10P0RTW:Z\Q835!?O"E<0&2:W2GZCMO JS[:0(M?>!.+O,5
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M:1CHY0B[3?/OL],<6O'S&GX&Q_#SC=&#OU>DJSB'&5>D*!6+%3:Q.2.2#-4
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M9.!H;,H## &O1;F.( @XAQ(%3-,2UT32_E ;!AQ)\E[-]K=L8OM#BZNT7%F
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MQ<;" E;/++*13=T<!W2;*+*@ \FPX.T\=3V9L_&8^K=N%P]2KEXO>!%.F/\
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MW!&D;$L'DG(.E-P3;,6#=1T[<*;;CR(MTE%#;!ORE'0";"Y-@!Q4$AH+B0
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M^$+YS&B##Z)+KDT779R82P "FJ/M&V)2P^,&U\&UHI8IP;C&TXRMK.:UU.O
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M (@.JO?$:?,2?JLE5C U1K<G&RZTK:[&]AW17L;[]E6J;-N\3*<J+I2,KT;
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M\!/OZY)S$8W?OZC+JSU;<K"J"D3,+1,E!JOFW34(45CQ,O),A!4JB?2=J"!
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M8Q2PU%]9YXY6-+H$_P 3HAHXD@"Y5_"X>IB\10PU$35KU64F#J]P$GH-7'@
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MLF>9)(%M>G&?P/6_I]9T".(@<KQ GTGEJ%O\X7*B2,FL=.>3E=.;A'%:)?\
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M8G"U\CPUU.MAZ]-K@"!H6N!:7 W1J%F)HB:(FB)HB:(FB+X5 134  W$2'
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ML!8\KN),OX[B+_;Y^)M3_,6-%*L@_CV%3DY=FTK,A[\=E]Z$?-$U71#MS_\
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MRH]@.8->X ] 3_99HU*H31$T1-$31%C"^X\4NEFQ)822A&!<8WMY<E6IFIG
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M0796]_V#[*/V(_&'%AKMH4<FSF%@FE2PU1K-IU!3<0'/<^KC VL\M8V<,QC
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M"*N&)[O;T62B)IF8M$D7QL6SDQ6:5Z.;I-&+8C\LA(/^:PM!C)-1C20T%Q>
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MRX QHTP7+NA7K2:1;-PEA%2.;H'.L*Y^5H40!7D3+MNXY!/R@(@/.("4PE(
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M'!W<'= *\LD'82P;QS[R$J(NT0%H"YS=?D$Y#*BH/9/D,<G*3< .',)^42$
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M&#Z)D)!H]58E:2:+%=T>-D&#\K1\UWW:&K0J;!VG7%ZCO@ZL.-A4HUF4VEH
M!#G4ZCV.,F9MJZ>1[!T<=ANVFP,.TY*+&;6PCBT',</B\'5K/8\Z.93K4:=5
MD@97-F9#8W-(/_#LG;!%LBDBY.!B$2*"2;<GP@"**)  A4B$*4J1"@4$RAL
M"78 \6WARO:8[[LQ/A,^M@9T^B^J=PW-2<"1NFAK1:X%A)X<9YVT7.:84,,:
M/1('NX"@7XC""HE*4OQ!_=^$@!VYMAW'N&Q0DU"=W8?=Q'6X-_32/-0,.T"M
MWC]\23;Y;DB.<%WG8+Z),J$<2"X(DW?D @E$PAT^4HD((& /BV*(@/\ +S#L
M.Y0#;3>NFHZ/\2Q )[HM<6N0!TZ=1PS2VDW,?NC/#O7DCI)TY#GJN 9-06#9
MCTR[-U^L"NXB8P@8YBE$O8 V$X[CN.X;  !L.])=--M.(#7%TZW//W/FJA1
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MJ,QW>[@1,S>>MM+\_HJ]R-]OI,Y8R\)B)GPX<[SP7<-.*F?-GHH)@+=$403
MQMC <IBF,)MA$/YMP  ';8/YM5FL[.VIE;+6Y8O#A!&O F>HL%0,,!2?3S&'
MNS3 M!! CR_LH4<1L#[POM6EU$R[62LV&'4..X%]X0$FSFXQDF!C !E7#&<M
M#LA2[G\/%.CF$"I]^I[*8WX>OBJ<AIJY*@\6N=F%^6<&-3)X"1YY]HFQQCL'
ML^J&YAAC5H^ J-8YIXZFE!L. N3:&]LJ!CQLY!+-DW$78F@1DFW6()RJMC*
M)PV 2[&,7J)"8>8.DJ<.7FY3%]7P>*I8AU!U;O&D7PVT/;4::3Z;IF6.:;CF
M.(L?F_:NS<5@Z6,9A_NQB&TY< 0^G4P]5M>A5ID$9:E-[.ZZ\28[P!&R#A7:
M-ZI@/%1FR+A9[9<<5"T3[V36!:3DK+::[&SDW*2+@B#<JKA9^]63303;MFK%
MDDSBX]LRC6#-FAX-BWEF+Q;6P6BI4HMU(#*;RUI%[S$G29,7U^R,$QV*V?@:
MM4D5*E&C7JV$E]6FUSQT@G*+& !JLZ>\E/=Z3 $R\J*_6!7<=Q[F.!!+Y=C&
M'OOW* !L'<=8I>2QM.P <73Q,](CCK].*S]T-ZZK)ES<N7APO/@%W#3JPR)'
MXH)[D;^&%(#FV,7F,<3<X@(@(G-N'8=B_".X_%JO?$U!5RB<N7+)T(XDS<]9
MCK<FU\*T4C2S&[\^:!8V&G@.>M^BZI910K5ZVZ1!!ZJ*IC[F_AB8P"8I2]]P
M';8NXAMW$>;THSG(YD-(>[,3<7\+SRNKAHC>4WR1NVY0.8@@7\_/HN4TPJ8\
M8;HD#W<3D*',/\7<I""(]O@W*F78 WV-N/<-BA)J&:9@#=QSO @S<18>O2RI
M^'$5AF/WQDV'=N3;G<GRY:JI9I4BT@L")-WY.02B8VR6Q1(40[?%L4>X#MN/
M<!*';4BHX&H8$O$>$:>,7Y3*'#M+:32X_=$'AWN?A)'D.>JX1DE!8MF0)I@5
MJOUP.(F$3B!SG*42^0;&.;<0'O\ " ;#YTFJ<C*<6:XD$:DS(GU/6.5U5N1O
M:E23+VY"+6$-!,_[H^NJ[03J@2 O^@3<4/#]+G'8"]AYN?EWWYPWVY>Y?A\]
MC:KWSMX:D"[<L7T@=0)G3D+7F5;^%;N=UF/S9LT#7P\.NM^BZ82:@,'+$4R"
M5RMUC*;CN7<Q#&*4OEW%,NP[]MS=A$0$M >13=3$0YV8GB+#UNT&_P"05PT0
M:K*LGN,RAO _-!GA\QMS@R-%WD9!1_(1('3*3PYT4@$HB/./,7<X[_R[\H?#
MWVV'<1\@K%0OJ4I@97,;'@YO/V9X65LT12I8B"3G:]U^ RN@?4WX\EF#71KF
M5AMG')/"2RRASE.T*<Z8%VV$VRQOC 0$1#^%ML'*(;[[]MM<TQF=M0F6Y!(Z
MD$V/2WC^?45:Q8^BUH!%1T$GE+1:#_FF\A#QB(,8UR"BG.\<%14 >7E IS'
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MF H(\0/OR?R58%+ L==2K0-?KD4@;R:$?QK>S2[HG)\(N)<TA#-Y X=U0K[
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M<*&3B,@JY@,_[P#!O.;/NY)M-C>(NLS?=GOBG.S8?.ZCE<<I^'<)T(R[O>0
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M2;@O5!5RDJFJ?=/PXD'8"%: (\A3D*4 1,0.<@!L<><1WT\=H=_BGASP7LJ
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M3O)!!C>"G $7@4X![\@](B-T*P?( 5YTG#@JBX&,7Q2AP$><4C";J],X\HJ
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MJMG8@XG 83$$WJX6B]PD2'NIM+QIP<2WF(YJ-/ Y'&2M/&+*J) 0\OQ39"5
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MW!2I6:P.6H/XN+;-'0-W'(0%T 62/TU0(0#EV-RAOMH0UQ)C4GCU\;>"I'=
M;QYB\CI.HF3UTXE9+Y0^8_=V_P OO[=@#TU!8. CK_2?9Z*9YF=#XZ1PZS'"
M/-?0E#TW#S'_  \Q]>WF']1$-,HY?B?I/"RDN\CKKY6)%I%^$>,J@E^8C^GK
MW_T'_0-3D;R^I]^^2C-X\S?]!UCB0.$@0 NW]X?7L/\ M^6P]M,HY<O>L^^*
M!T<SK:=.7#\-.7!.7Z^7W?3Y!^OR[ .HRB=+<HZ<2?P%])4YO/K/42! \!)L
M>"KMMZ]_KY_T]-@\]OQTRCEYCEKS\N/-,QT$ QJ3UCB!>T_DOGD#;;<=OP_8
M?O8=,@Y?73PYWYIF&DDS[CSZ"QT)"KRAZ?Z]_IY=O/Y /UWTRCEXZGT\?PY$
MI(\[@$ZR;F1R!_H-5"CC"0-7'V",M-]DU,>Y09$EG0E3W1J#TB%CM! 5%!=1
M,[V/I/NI+D .8\F9,/C5(8NPP(!;C,/PKX6H0#)E] C$-T(BU,MG6#PU6CVP
M,C]E8VX.$VE0:YP@Q2QK*F J&_ '$,?XME9_SVY]W8,S4_$#F%AB3)+OE(/Q
MB+6F32VQ=A ><>38.X#OV#;MMA-:W,#''K'O\M.:W<_@-3;4&_/J>IM"QCP3
MLQ9\+&&D3)F2-]G7BP)B(".SFQ3+DIAY1,'QE5*< W';GV[" [55X=5>XC^)
MQUX3;\951/??%SG=Q GO<[\1&O&RE-R^6_?U]._F/?;Y;^7IOW\]6LK>7X^[
M_P!M%&8Q.H&O"=>4]+>L@R % /F/81VV_,?KY=Q]-QTRM]GP_7Q)B_,'$:GR
MN?&;:Z<XOX)R=_4._EOL&X=_73*WZ<+F^AM_73HA-SPN(DVD7(,_30WO'"G*
M'S'\_/4Y&_TNHGEFT)/">L01?@>>JJ) \AW'81[_ +_H';4!K8!C6^IX_HA-
MHGCSUY&UA'*8''A+D#R^?UW#T^\/3[OGY=F4:Q]#)'K^4\ASF=(MYZ018&./
MISL @E^8CY?/T_U^OGL&F0>_+U_"9MP29YZ:3PO,^7F1%[K%M_I\O8[/A^6C
M2MS,Z5?WMCG!77Z*I8Q:A7.NIF:)\H^(7]Y3K !2 2;(BLKSCTA*-0#1F XB
M(OXQQX GV%3$Y.0N3<1:+>9L>)F="LH@4/7?RV_I]WI^_749!R^I4SX:03H+
MQP$::=8GA:O('EY_GO\ /Z=OI^.VHRM\//\ NIS<!)ZWD^$'3^VLJG(7;S']
M[?Z_/[N^IR-Y?4^_[\5$D3<\(,S''\K P>@DIRA_AMV[>NX;^O\ IIE'+\9]
MZ=-;!,T\].8B=9$S!U',#2]E4"^7F/RW[^OF'^@>FHRMGW]3]?Z:2#'!Q/C/
MN]B>'B2$$H"'Y?>&W;Y=_P!?PTRMG3^OH?I Z6!0FQ'AH;@1X&1P)DSKH4Y0
M$>_;L/G]?P[^?U^?S'4Y6\OQ]_U49N(X:\-3K'_^A?G=4Y0V\Q_Q[!M\OD/Z
M?7<64<OQ_";IFM8\NAM;ZCE,<>).)<]5IQ:\,Y*A&#;QDLI49:0@6P$!45;)
M!-QG*URD'<#G).QL<<A?AW.78#%$>8+V%J?#XBC7;8TJS*@YPUX=Q(BPYS'H
ML3:.&;CL#B\$_P"7$X:O0.IG>TW4Y%KY9GA?2>-O\+L\WL> ,7.VSD7B,76R
MU$CXPF$TB%#>O:1[R,8XF.?WF-?]X <3"!P<@H78IBAJK&T6T\5B&-%A6>&\
M!D+B6F 0/E(T5O9-=U?9N!JU/\1^%HFK)_UHIAM4&Q-J@<#))!'18%X6E4G?
M$MQU/$TS@*F0,=-#+&$!Z@Q,1;(D2%'F,( D9D<-M@#8_8 'F **@!92')KH
MZ$N).GDMA>&7_@/2.^[CX 3YV4]>7T[^>_U_8_XZM96QX<?UOZIF,Z'A:3.G
MX6O8_5.4/TV  V_?]0W]/73*WEZDZ)(X#^&-1Z<SX?15V^7T^7;Z_OZ:C(/?
M&/S.OX<TS'E;WIJ#&G+UA4Y0[_=\@'_;?U_IID'+CS.GU]\DS 3,R1I:W]]3
M:Z 4 _?U\@V]/GY?TU.5O+ZE,T3'/C//D!$$7.AUU7*BW%8W*'8O]XVP?"'R
M#[P^?UU+:8)TMSDZ>]%0YX:+<=.FEATYGCKJO:*4I"@4H;%*&P!K(    T"Q
MR222=2OK4J$T1-$31%\F*4Y1*8-P'L(:$2(32X7DK(&1-\R#_*;;?S]!#Y_A
M]0[]M6'-(X3X6GSY]/RNLAC@8N01P\KD6\.<=5P^?[[^OKW[CMY?7L&J?(FX
M&DWX6\_IT50TX>MXXCS@?E:4_KVV\]]_N_#8/O#\$&8CRCWK,^7K'7^E^D<H
M@>(3R]?0/\_G\^W?[]->'$_IQZ7^BGCKYW,^,'6?9X]-\0BK)XDH4#$5:N4U
M"F #%,11$Y# 8! 0$! P@(#V$!VU,>GO^BB?S_)1&X$7+M?APJ23I0ZHMW;\
MR?. <P#*%:SSO<0*43">4EY!8YA^(553B8=QVUD8LEV)<[^9E(Z<329F\Y\;
M@K V6T,P-)@T;4Q  G1HQ%7(.)LVW21*MW@<*HM&\0DH=$R193B*NKHAC"4>
MJ52,@'//V,;X=W0AL(A^6V]EPTY91?IXVCZ::+9/L6S_ "4ST^4'0SPGGY\9
MS=O3S_#;\!_W^>^J+\=/,'T_MRA4V\#X@B(YZ=-9\T]/W^_ZZ<??O\%'.^L^
M^'E;R"=O7_7?]-_GW^OGZK^["/R\NG#2=;'UZ\YD3S\SKJ@[!]?Q\_\ (?WM
MH)/3RT_4>Y2UM/&8)G3H(UO^J=MOK^_I]WE]=+ST]]?'7HFG'I;UGR,>FHL@
M_C^/^_[WT$\@/#RZ?VLCO>D_0F?'29XRJ&'E*(COL ";;;OY=]OGN :F.GA/
MT^J3[MR(Z3 Z<])O:M%MS"_TNK7B*;O&D9;8&+L+!J_*B1Z@TEF:3U!%T5NL
MN@#A--4I52HK*IE. @50P;#I!%CPF]^%N/2.,W4 R)%IU!C2Q MUY6%N"NO?
M\?O^OZZB/+PZ?1)YW_K^G#6Z=^_KZ??O^OII$Q8\(Z=+6\N/6%))\KCA)O/&
M_G'U3M^_3]/WOY[Z7]\?K[C2$$>_8Y><ZSJ_7]_GI]/?HA(\^-Y$?UU.A!TA
M V]?\/D/^G^^AGA^?,?U_LEKS?CKT/$\[<SSNJ?O]_O].^I]^_?Z(-#Y$7X\
M_+WS'UV^H@'?;\M_EL _/S^FHN>%^)Y"_CIZ=4D3K:-.<1STF+'6VF@7S^_/
M?]_I]VI34WZ7'*?(3?4QI=1IXO(%"R8(LT:X$H$5G:"43"D17^$XOU;8O$P*
MH40+XF/>.V9CA\9$W)N4?363@B6XJA8P7Y22>#FY3TT=!X<];Z[:S0_9V+%I
M%(O;$_-3<*C#IP<T$<=!X=G*TBYEN$N_2,BL*CR;P!/J/ER !15=35 <E<J%
M*&X *BSLXE#N!>8 []M8P^86_BF+G0C\AZWC4+9-@Y8C5NMIF.&NI/ESLO2X
M644T>'3#1$BB4AJ! KE W\V[EKXDPCYCN8RPF\_7<>WD=)<X\W$Q'"9\+<R)
MCJCKO=I\SITYG3EPT(%KVTSYZ_+T_3;]^OXZCAQYQH=9CRTCR4&)^G \+_7I
MS.HA.^WT_?\ AJ8Z><?FHX>OKK]=+_D F_S_ 'W'S^O?SU$<O=AITMHIGF?Z
M_-K(YGZ\U7S$1#_??[OG\OO -(, > YQ[X:GQNEOQ\QY3'40.-Q9?/[_ ']V
MI2W#4\]+@<^1XZ^*?L=+^_?'@H\?7RM^G7IJJ_[;_=^PVU']_9_'W,SP\IU_
M4C4:1II.EHV.Y1]8EZ1#/6[Q9S?+(O6(M1L5 R+9ZWKD]93K/Q563.1J+*ON
MT"B@1=7Q*K<#) EU%$T6-M+\1Q&G.^AY\5!.G,P!>8L=2= ;VZWT5W?/\O3;
MR]>W[\]](/EQU_7Q_2%,ZS?P\^AO?A;C,H'Z;_O]C\OOT/&.'2WX=.%_H@N9
MTD\_6(\;3ZZIW]?/UWWW_>W;Y?UTB+1Y1X=+7OS_  0GKP_7F9TM)TGP*IJ5
M$\.$S[T/X*OK^_Z>?^?UTZ7_ #/]_<*;:V'X3X&3RX'CP5?\NW?Z?X]]P\^^
MWWQ$^O+6_P#8 _CP<_#^8>?/C)(U\.-/0/+[O7\?]_\ '4]/K[]_25N!UM!C
MZWB.O41)%J?O]_OU_#3W[]\/-1:T?7A:]OJ#KXE5 =A ?/80'\O33P0^-NAU
MTUN8M^ 41.#)N6*QK8JRV$_NRJ7EQ"Q)%!*)TV9JE4)-83F*  =1S)2+]\L?
ME*)EG:AMN^^LK%DNJM>=74<.28B7;A@)/4Q*UVS&Y,,^GPIXO'-:.3?C*[F@
M#@ '0!I 5H<(D45#)W&#-\QSGE\Y3+43G,([IQ%CNQ4BE 1V*4A7HE+MYI\@
M;B !M8<;,')OXE;-TAM/_D'ZU'_D5.L/+[A^7SV\OK_OVU;OK%C:;ZB3?I[N
MH$1J?0?2_._#GJ%\_O[_ /'4^_#\E'2=.LCQ\#TO/)5\@_IV^X?Z#Y;CJ+VX
M<_KI]#-I$*;0=.GG'X7XF+@SJ@A_C^_+\O/Y]M].=CP]Q/#C8);3777GSMZ:
MD<2N1)(RI@ O_P#<;_I#MW\^_J !Z_3TD-+CT^G'6W'WQF'.#1QGQGD1I:WA
MUULO833*D4"E\@\Q]1'YC^^WIJ^! A8Y))DK[U*A-$31$T1-$31%02@8-C
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M!9=2GU:$KAY--J+$C\8A@@Q,\(S,X=BV*X%'J W%TN*0&Y.J?;F$J6C* -3
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M,SN,_P 6O/4K.&_;?][_ ._K^.BB;3[\]?/DF_[W[?AMO^H!HGO^WL( [_D
M_G^]M$!D3II]?<)OWV#S^O;M\_\ #1)O UZVMS_)-]O/\?I_I]?J'ST28U]_
MTZV0!W_S#_'T_(1T0&?<^1X3YE-_W]?EHI5@7&DJ6N>QK-EDB,0Q_<'5J4;&
M:BY&5*YJ%GJW@2+ X0!F8AK$5Z+@R3H# T,WZ)16!=)JHUC2Q/7F/[CZJ_\
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MMY=@_,!^@_/[M)/,^I21QX?3PO'&( @Q/0N4O?L'Z?U_P[Z2>9]2DCSYF3X
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MLF2=C;*)U.Q]F$]9P-.?536X25C-K'BPQ")B+V5L<4J<Q=SD;K4*R2QRIFW
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M%M+U]K6C$3 X<H@,E2I-<X)"8A5'.YP*<X@.TV0 ,43S F\3P\_#5<KVL/\
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M:(M6&4LB7Z*X]Z33VESM#.GOY.BE6K+><D48%=-]%E(Z(K%$<%9*$<."F56
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M[1KAU=N&)X)[=):'*JLE898V,\I-?=+Y+"=NSJI4HYBG1GCB9R4PI]37<3]
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MD&J2"-$E?=$_+VT&$FE<7WVBG%?MF[&16(O$6X6?9=D+2(!Q=&-G9R,#>K#
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:(R<RA4J%4F#*EL:>1;GM$31$T1-$31%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g320192g28j55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g28j55.jpg
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M 0$! 0$! ?_  !$( 3<"#0,!$0 "$0$#$0'_Q  >  $  @(# 0$!
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MM%FLMF=9Z#G4*9<ZDPDE@DDM!)/E)Q)W2NCM->NVT5VMK50!6J@ 5'@ ![@
M #  &  5N/<U>Q[^11Q>\R6OO0-9]9V7B]+F!8=<6CAZWI7])/<U>Q[^11Q>
M\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZ
MWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0
M--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/
M<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B
M]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^
M11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<
M6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R
M6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI
M7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--
M9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U
M>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+
MF!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11
MQ>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6C
MAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6O
MO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7]
M)/<U>Q[^11Q>\R6OO0--9V7B]+F!-<6CAZWI7])/<U>Q[^11Q>\R6OO0--9V
M7B]+F!-<6CAZWI7])?S+L:_8]<,<L\N%/%VV..-\LKWTEK[HMCC;IO>__0/]
MEK=--9V7B]+F!-<6CAZWI7])03"..?8>-AAQAR-<?>&5F9E6Z(IO(]/0.$&G
M^5HT"F>&;6.3:-1Z0JMW$.E$:ES-UB+[V>Q>0A)"T56$%6+Q?$VED]X!;3H0
M=%YH:3M0[ . /<D.F.Y(.@K(Y]L:2#4M&&F*CW 8EN):XCN@6Z<""-(67*<5
M^Q#!B*(HCH#A @]4670<8X:XU4Y;A[H1DS,<EI(]:BEV,69J1F/&B[5_)' I
MB];L%L&;A=?))+.30L ,9NSSYFX;4ND[PNM)DP,% J6PB14M$?TE3';!N&.V
MVQ ($D3BN5SQ4[$ S277=Z3X!M4&S@$T<+.8UHU!)NZE+5V^C+9=15/'!)Q(
MV3!\\!(J7Q4+M63MP/Q<)-EL\&8L'@6;")[C"]B-W=&(W]Q,Y;#H?:3I/=5>
M]P.[N'3O;J[>?$7L1R>*&>>AN!V&#I6*H-<\XCI/'%RO.F"A2$(H970M9968
MC$E2,533OEG(6":CL19XWPR4M.8L'!V?O? [X2W=[X8MWQH3.VOA+3WW?U>]
M,.W>].#MXX%:2^T-V&D<(C<C<:'X7*1>61*5ST-+6&GH*5A]X7"'38?*)05E
MHR,O(W'0@LL\:@[D)"4%H/)"X1CP_-V;4Q87IFLG@-.;H0YKG A@+;K3#B7
M0 "0,2,<-*D/MI)&<M$AP:1G'AUYV(:&ETDD F #AB<,5N6?$KL1*=^A317
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M*-2[+#%(1F_PN_[\$]T\*C23-HS%@DC-T 6NN&0T;: ;N,2<1HG'#2"$-2V
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M"8N1,;TF/.NYR34?4UQG'NJ7<U=ON+HG.3%XF)@3YEZM^QL_<]>#WXIW'_\
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MRN>6.'L<53-]MX,4P<Y,_1X6GSV[U[?\''S8Z$S57@JG,=OW=[PMKY\-*W2
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M7=1JMB6.,@D%NV$-):[;-D8$8XX83I65RY2\9,!Z);/D7HK 4X0;.FY/+;D
MQ'KMGO?W>;A![>06;*H.O!A*[=9-3)-:P][DGEE9JO?"<]1B<[2C?SC(W?+Y
M#R%1F:NC-5)T=P[V>4<JY3O)OCI&@<IDAK>>IVH:%)R!25.DY]&7J@7.*L,R
MDB9NV3 DZ?>$Q##"[EX)2;*%$\<D\;-,E%4L,QK40'$U:<-F]MVF+HD@@&9
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M$JN-:XEAS[#)W9U462D'W]MW+6W;T@W77Q),N.,=]!C&58VFJ6W26]TYUX-
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M58.X'CR<(+M7P_%)21IOY)'G 0LT>>")&%92Q51N DT>,1(00^>5>FBA?/\
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M.Q__ (FW&[]T<3HL+^[=])WWE7UHJI1$HB41*(E$2B)1$HB415;VWR&.ZKV
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MSR3Z<K9=KVV.-[=KDG+64<AUJEHR;7;0JUJ69J.=2I5IIWVONW:S'M&V8TR
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M4&=;3NO&KR,^.?FW@/J33MSVGQ!0_O"IU1.T[9_']H]09UM.Z\:O(SXY^;>
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M]D%G*5ACYNL-R=C]0,\L'F"K9JD_'#D5UF;5V]<5FIOM%9Q J2X!N+R-!<&
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MI>U0\'0Y:/O%PY*:\PMVV;Y?#&Z*CBV66;C&UT$K8757Z;IVMW%.RB=U%/\
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MXO\ FJ_34[4]H_23(_[?33MKV?\ 1W*W*SH)U8GOC_%_S5?IJ=J>T?I)D?\
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M]<%D+(0^QX=8-C%W>"K7.-N%VJRZI*^)6Q)^/+$3YUEI=PKALL%/8^XV)M+
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MT_=VBYEXUNFGFRRDL>P&2-,>KC=<>@529.,U%T%,\BA291$HBT6>_P"K6?\
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M=9VLBZ*9LP[,ZY=L<4!^361L&;9#.[!1^_*%-%$2B)1%5KE=]ID=_P 3X_\
MQ1&O(?EC^8LE_P!K#]SM2];^1_Y[RG_91_>[,J&5\ZKZ%2B)1$HB41=MA_UY
ME_M;;_WL*RT/S]'^EI_XPL5?\Q6_HJG^ J_M?2:^=%IVPW\L%Z_G).!#&YN=
M#H=)G\+#.\<<FA>6- KUQ'!CK'-\,PR;OS";-JMCD2'XW35RMD^:6Z5T[,#2
M]@>2&%S0\C2&DB\1@<0).@^8JKRX,<6"7!KBT;[H,#2-WRCSA4JD_('D+K8
M?D3O6S^8Z_%'(X,"3>11YS%)L2 RQ_)V*\MDD(OE&&8K&"D@0X>\"O4X@I*1
MLMC9IR\@Z";[-SRVT:-1P:'AKR"2QK@YH+0TW6NAQ-^\2""Z[=<(>87&=6K,
M!<67F M <YI:^'$B2W "Z0!!NW@X$EN[EQ.\^3\D0P>A]*-;(N H5R/>N6TE
M' ,W9R=" .:R[<Z,%2(NT::^4MMADJQ]C]T&\AOKN1-FDKB!]XG!I6=I@U3I
M,]R2 &%VD$MF_P#DB#.+;[26N:ISM<P13D%H,P0)+P-V"=KMQ$8&Z<6DJ6N-
M^[)-NEMLMQ*8E:$/83L8]"F\?S;D\GJ#4*Y698N2)9QC860=O5FRSG%$=9JX
M9-%&N3\>W3=L'+[%7I-I9NZZ\'TPZ]A$G' :0!AIF3,'>R4:CJ@?>;=+7%MV
M#.!(Q)P,Q(C&-($B;*U@693#"/\ 4EO]K<?_ .)UNV0?Y /Z:I_^JTG+W\O/
M]#3_ /V6WUW2Z5*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1%X9_LR'[9>Q\_@/D[^WZ%HN10[_P#5_%>DOL=&[->ZTX!<
M*M=SYU*8E.(-Q7T-$IA%CFN-D,C,<DL?UE&A9L(59J1/NC4B+(M7#-XWS_EH
MN$5$\O?QO187]T[Z1^]7,ZT>D/&LK\P=B^J=%5.M'I#QK*_,'8OJG1$ZT>D/
M&LK\P=B^J=$3K1Z0\:ROS!V+ZIT1.M'I#QK*_,'8OJG1$ZT>D/&LK\P=B^J=
M$3K1Z0\:ROS!V+ZIT1.M'I#QK*_,'8OJG1$ZT>D/&LK\P=B^J=$3K1Z0\:RO
MS!V+ZIT1.M'I#QK*_,'8OJG1$ZT>D/&LK\P=B^J=$3K1Z0\:ROS!V+ZIT1.M
M'I#QK*_,'8OJG1$ZT>D/&LK\P=B^J=$3K1Z0\:ROS!V+ZIT1.M'I#QK*_,'8
MOJG1$ZT>D/&LK\P=B^J=$3K1Z0\:ROS!V+ZIT1.M'I#QK*_,'8OJG1$ZT>D/
M&LK\P=B^J=$49;1VUHG9H<>(<;!-B,6!*Q&RZ.MMA.\E<K-7#;N5\,XTA;&W
M0XOGV]LKWZ<;6[7W^FVIZKM2M/598K-8JEL?8A9K4+4*C*+:Y>11J4KA:ZI3
M $5+TR=$1C*VO4EJHJ:E+;:;93L;+:;19=;&F^LZ@&#.TZM\.;3J2?R=V(&F
M9PA0=X-X_?'#(_--/?0E>?\ :8LOC^T>H4^M+?NW):?$-#^\*G54\&\?OCAD
M?FFGOH2G:8LOC^T>H4^M)VY+3XAH?WA4ZJG@WC]\<,C\TT]]"4[3%E\?VCU"
MGUI.W):?$-#^\*G54\&\?OCAD?FFGOH2G:8LOC^T>H4^M)VY+3XAH?WA4ZJG
M@WC]\<,C\TT]]"4[3%E\?VCU"GUI.W):?$-#^\*G55RH,N/R"Z*UMOR+*Z*J
M:ML;ZGGMK973SMG:U[^!/>Z>CHZ:LSY&K*Q['[/6@W'-=&L*8FZ08G76["J_
MY8;2]CV;!4!?:YLZ_J&+P(F-:[DJ=O;CT3X_&O-QL+U9KT7L<I\:?Z)O37GO
M9'4XJSTKN@GMQZ)\?C7FXV%ZLT['*?&G^B;TT[(ZG%6>E=T$]N/1/C\:\W&P
MO5FG8Y3XT_T3>FG9'4XJSTKN@GMQZ)\?C7FXV%ZLT['*?&G^B;TT[(ZG%6>E
M=T$]N/1/C\:\W&PO5FG8Y3XT_P!$WIIV1U.*L]*[H)[<>B?'XUYN-A>K-.QR
MGQI_HF]-.R.IQ5GI7=!;:&Y':.#LN\\9B77MW517NF6OMB)W_E]K[W:VBN5O
M>[7^GI]_IKN;#8Q8J&8:\U!?<^\6AIVT80"=$;ZZ:W6PVVOGW,%,W&LNAQ<-
MK.,D#3.\LMUH](>-97Y@[%]4ZYBX:=:/2'C65^8.Q?5.B)UH](>-97Y@[%]4
MZ(G6CTAXUE?F#L7U3HB=:/2'C65^8.Q?5.B)UH](>-97Y@[%]4Z(G6CTAXUE
M?F#L7U3HB=:/2'C65^8.Q?5.B)UH](>-97Y@[%]4Z(G6CTAXUE?F#L7U3HB=
M:/2'C65^8.Q?5.B)UH](>-97Y@[%]4Z(G6CTAXUE?F#L7U3HB=:/2'C65^8.
MQ?5.B)UH](>-97Y@[%]4Z(G6CTAXUE?F#L7U3HB=:/2'C65^8.Q?5.B)UH](
M>-97Y@[%]4Z(G6CTAXUE?F#L7U3HB=:/2'C65^8.Q?5.B)UH](>-97Y@[%]4
MZ(G6CTAXUE?F#L7U3HB=:/2'C65^8.Q?5.B)UH](>-97Y@[%]4Z(G6CTAXUE
M?F#L7U3HB=:/2'C65^8.Q?5.B)UH](>-97Y@[%]4Z(G6CTAXUE?F#L7U3HB=
M:/2'C65^8.Q?5.B+R _93<5GG+(]PE<<:M6[AW8A!1'(-&8JZ]T[M"081Q61
MO=,Y@DRUVL2OWID5P"%\F5L_]-8<ZOC_ *+*BST2!>D@3&D@;Z]O]%@2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
/1*(E$2B)1$HB41*(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g320192g29m66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g29m66.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Y.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !D< 5H  QLE1QP"   "   < @4 !5!R:6YT #A"24T$)0      $'&R
M'N^RK%WYEXQ?IGQ&?D$X0DE-!#H      74    0     0      "W!R:6YT
M3W5T<'5T    !P    !#;')396YU;0    !#;')3     %)'0D,     3FT@
M(%1%6%0    1 $$ 9 !O &( 90 @ %( 1P!" "  *  Q #D .0 X "D
M  !);G1E96YU;0    !);G1E     $-L<FT     37!";&)O;VP!    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585    "( 7 !<
M %  2 !8 $8 0@!5 "T 30!7 $4 +0!& %  ,0 P %P 00!: #  ,0 U #$
M+0!8 $4 4@!/ %@ +0 Q #@       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M>/            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 !
M \     !  $X0DE-!"8       X             /X   #A"24T$#0
M!    !XX0DE-!!D       0    >.$))30/S       )           ! #A"
M24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      S4    &              (D   "F@         !
M                      $              IH   (D
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   (D     %)G:'1L;VYG
M   "F@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   ")     !29VAT;&]N9P   IH    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
M$SX    !    H    (0   '@  #W@   $R( &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( (0 H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MV$XEGZ1HFRA_ML;_ %J_W?\ A&?HUH)I!&ZE))))*4HOL96POL<&,:)<XF
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M?M#6CZ/N'TO\STE:HRJ,@?HW>X<L.CA_9_\ (K)Q,/*S;/3Q:S8X?2/#6_\
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M\)ZO^"7SHDMMJ/TM=^RXJ]7UI]%N_P#GMWHP[T_MVSW?Z3^D^_?ZW_#H5W[
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MZNW=Z;?0WS[?Z/L^G_UQ:R^54D%/_]DX0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !?DU-
M "H    (  P!   #     0@T   ! 0 #     0>>   ! @ #    !    )X!
M!@ #     0 %   !$@ #     0 !   !%0 #     0 $   !&@ %     0
M *8!&P %     0   *X!*  #     0 "   !,0 "    '@   +8!,@ "
M%    -2':0 $     0   .@   $@  @ "  (  @ /.'P   G$  \X?   "<0
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP,3HQ," Q-#HT
M,#HR,P  !)    <    $,#(R,: !  ,    !__\  * "  0    !   "FJ #
M  0    !   ")          & 0,  P    $ !@   1H !0    $   %N 1L
M!0    $   %V 2@  P    $  @   @$ !     $   %^ @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 8!-
M30 J    "  , 0   P    $(-    0$  P    $'G@   0(  P    0   ">
M 08  P    $ !0   1(  P    $      14  P    $ !    1H !0    $
M  "F 1L !0    $   "N 2@  P    $  @   3$  @   !X   "V 3(  @
M !0   #4AVD !     $   #H   !(  (  @ "  (   #P     $   /
M 4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#$Z,3 @,30Z
M-# Z,C,   20   '    !# R,C&@ 0 #     ?__  "@ @ $     0   IJ@
M P $     0   B0         !@$#  ,    !  8   $:  4    !   !;@$;
M  4    !   !=@$H  ,    !  (   (!  0    !   !?@("  0    !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( (0
MH ,!$0 "$0$#$0'_Q  ?  $  04  P$!            "@4&!P@) @0+ P'_
MQ  _$  !! ("  4!! @$ @L    % @,$!@$'  @)$1(3%!4*%B%V(C$V.#ET
MM;<8)"6X%U$C,S=!87%S>:&RMO_$ !T! 0 " P$! 0$            !!@4'
M" 0#"0+_Q !,$0 " @$" P,(!0@&!@L    ! @ #! 41!A(A$S%!!Q0B46%Q
ML? R-5)RM @C)$)B=(&S%5.1P='Q%C,V-Z'A1%15<W5VE+6VQ-3_V@ , P$
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MM3E*I4;%F',HFO\ *P\G"M-.53918/U7! 8?:1ANCKZG0L#W;R.;,ARQ\N5
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MF&"%J$72KB%1(:!X(^<%G7 10N74'N(6/A$K,'LENMP.4MA?KS.#5\7 >*O
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M0X-UP-S*;G=D"*>4;,X:XASS@IBN*+$Q=J:G=+.T[-5!16*VJIY 0BD*#R*
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ML^G5,BS;F2D;[=RO[/78?7)'4@>V:TG^N-(%8=S'*VI?HPKR]Z<(5^K]7GZ
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L-V*R)C0I0BLA*<-?=A_5OBSG(M=KH@<E4YJ1EUN,XJ1EY<R:J0B9CXB?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g320192g34o44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g34o44.jpg
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M5YC6EA<8&C@Y5%5S=Y>VM]0A(B,W=':X)"4Q)C)!,U%A<31"@9'_Q  < 0$
M P$! 0$!             0($ P8'!0C_Q !=$0 " 0(# @0,$0H% @4$ @,!
M @ #$002(043!B(Q00<545)487%RDI71U!06%S(T-E56D9.AL;*SM<'P(S-3
M8X&$I-+3U1A"0T3AA?$D-6*CPP@E-[8F98*4XO_:  P# 0 "$0,1 #\ N9ZC
M=1NO%F]>*[G$XKM,Y*3B<GR4*9D\T'Y=9'S21B6><LQ,C8CT?,CV+1O_ -.T
M2\YYKSJOEK;J*;_M=&?HS]$K@IT2N$NP-@<)6P&R, VR1A,(-D["Q.Y]$["V
M7C*_Y?&;+Q&)?/B<16J?E*SY<^1,J*JK3H4]"G@#PCX [ VUMK8 QNT\:-IG
M$XD[3VQ0-4T-L;0PM+\EA=H4*"9*%"E3_)TEOES-=RS&2'WA74WX2I?;2Q/J
M[GR__$1T8_?BWB'@Q_99]#]0[H6^]9?''"#^ZQ]X5U-^$J7VTL3ZNX_Q$=&/
MWXMXAX,?V6/4.Z%OO67QQP@_NL?>%=3?A*E]M+$^KN/\1'1C]^+>(>#']ECU
M#NA;[UE\<<(/[K'WA74WX2I?;2Q/J[C_ !$=&/WXMXAX,?V6/4.Z%OO67QQP
M@_NL?>%=3?A*E]M+$^KN/\1'1C]^+>(>#']ECU#NA;[UE\<<(/[K'WA74WX2
MI?;2Q/J[C_$1T8_?BWB'@Q_98]0[H6^]9?''"#^ZQ]X5U-^$J7VTL3ZNX_Q$
M=&/WXMXAX,?V6/4.Z%OO67QQP@_NL?>%=3?A*E]M+$^KN/\ $1T8_?BWB'@Q
M_98]0[H6^]9?''"#^ZQ]X5U-^$J7VTL3ZNX_Q$=&/WXMXAX,?V6/4.Z%OO67
MQQP@_NL?>%=3?A*E]M+$^KN/\1'1C]^+>(>#']ECU#NA;[UE\<<(/[K'WA74
MWX2I?;2Q/J[C_$1T8_?BWB'@Q_98]0[H6^]9?''"#^ZQ]X5U-^$J7VTL3ZNX
M_P 1'1C]^+>(>#']ECU#NA;[UE\<<(/[K'WA74WX2I?;2Q/J[C_$1T8_?BWB
M'@Q_98]0[H6^]9?''"#^ZQ]X5U-^$J7VTL3ZNX_Q$=&/WXMXAX,?V6/4.Z%O
MO67QQP@_NL?>%=3?A*E]M+$^KN/\1'1C]^+>(>#']ECU#NA;[UE\<<(/[K'W
MA74WX2I?;2Q/J[C_ !$=&/WXMXAX,?V6/4.Z%OO67QQP@_NL?>%=3?A*E]M+
M$^KN/\1'1C]^+>(>#']ECU#NA;[UE\<<(/[K'WA74WX2I?;2Q/J[C_$1T8_?
MBWB'@Q_98]0[H6^]9?''"#^ZQ]X5U-^$J7VTL3ZNX_Q$=&/WXMXAX,?V6/4.
MZ%OO67QQP@_NL?>%=3?A*E]M+$^KN/\ $1T8_?BWB'@Q_98]0[H6^]9?''"#
M^ZQ]X5U-^$J7VTL3ZNX_Q$=&/WXMXAX,?V6/4.Z%OO67QQP@_NL?>%=3?A*E
M]M+$^KN/\1'1C]^+>(>#']ECU#NA;[UE\<<(/[K'WA74WX2I?;2Q/J[C_$1T
M8_?BWB'@Q_98]0[H6^]9?''"#^ZQ]X5U-^$J7VTL3ZNX_P 1'1C]^+>(>#']
MECU#NA;[UE\<<(/[K'WA74WX2I?;2Q/J[C_$1T8_?BWB'@Q_98]0[H6^]9?'
M'"#^ZR)7:2.^#BZ?.JA0N6JY(T;W--MX/'2<?+V$9&@W39%LZ)'I<MF>-%0\
M8#LW6KXL400(*,V23EULTV1;J[:_I[.Z.71NVH,4<+PQ4G"416=:FQ.#*LX)
M(5*0Z1MFJ,195)6YL+W(GYV/Z$/0CV:<-Z)X+,!B:NZ1DVMP@94( +/4/3<%
M::@W9@#E )(L#,-M CX-BKKQFW75Y3$SDMI02D9C>9@?'I!)6X#(2$QQ.6E(
MGB62JU8U'V,V4CCP,:28&'HT(U&2 (]+'QJ#[7?3MANC9T;\3@Z..'#.G3PU
M;&4L&K/L/@X7SUJAIK4W5/8-1S2#JZW4,Y9&"HQ$YU^A-T(J&*JX(\%7>O1P
MM7%N$VMMT)EI(*C4]Y4VRB"KNRKV8JH5U+.N83+8)&O!W2LM?#*35HSJ4-U]
M*50*F,MM&V2,<BRCFW:JB-K -6Y_%HN@J660Z8,0;[98EZ,X--U\"7)%BHV=
MK<JW1RZ-M)<&:?#!\4^-7$M2I8?@[P>J5+87$U,,Y*=(@_&:F7'%N%(S!3<#
MK2Z$/0EJ-BP_!=<.N#;#K4J5]M[;2G?$8>GB$L_3DKH*H0\:Q8'*6%B=S$.O
MW@WQ+J+,2KFIACZ< U9-"F9"]B[)U,(V@T5?KR&+-W-BIK2 &BQ06>JEA.CM
M@FT15<;N,(I[[XR+T?.C<PJ%>$^+847W=4KP:X.D4JA-A3J$;#LCDD#*UFN;
M6O-#=!GH1J:8;@_A5-5-Y2#;>VX#40 MGI@[7NZ6!.9;BP)O::V@D:\%%8M2
MC+TC\BJMK5)8X[B[:8RJXI9"1R,F9KKH*1PCK+IR%<"CRNB'IS0.21:D7HI=
MF6:-EAKYHZ6T5^CET=</BFP=3A)BCB41:AI4^#O!NLV[8 BHNZV(X9-<I925
M# H2&! XTNA#T':V'7%IL'###LQIBK4VYMZDH<$W1MYM92KZ7"L 2MF *D$[
M-,=>?!R1TD'#2!6J@1>0YC>  HQ>9D82.9F67^L0P'8O;$0=$\RK(HIB-X9)
M+^O,C7^!GI66;CS>=.CYT;JBL]/A/BW1-X79.#?!UE3=6WN9AL,A=UF7>7(R
M9AFM<3NW08Z$:,JOP?PRL^3(K;>VXK/O;[O*#M<%MYE;):^?*<M[&??CK)X/
MC::%:VU95SM8@,3L>-P'%SR',T#@]4$W.QHK%L6!Z\'B=6RR+C8B[8HL\(*I
MJY6\VIKMFOJ_]&S=+7]-.)W#MD2MZ7.#FZ9[D9%J=(\C-<$902;@BTGU%NA+
MO6H>EW#[Y%SO1Z>[=WJK8',U/IOG5;$&Y %B#>??!>I_0NT FTFK,!"+$C>K
MYT+VD$%MN4RT)J38^;]-';%@$\(,,/F?G4O2FF7'I#?SJ?G4]/+U\=:W_P!0
M/1IP[[O$<*Z]"I8-DK<'>#=)\IY&ROL16L;&QM8\TM2Z"G0GKKGH<&Z-9+E<
M]+;FW:BYARC,FUR+BXN+W$CMUQ$^#1[1M[J>UM "#$?0LO?1:<$IG)9W&1RH
MYLB_<L+!"/5Y\X;O:XD#829<@9.[4'ZO&X<BNLT:I(8WWWX_HX]'#9QPBU^%
MV9L92%2DM'8?!FHP8V#4' V&"*Z%D#TQFL64 D\F+!="+H18_P!%&AP8L,)4
M-.J:FU]OH+6)%9"=KD&BX5BCFUPI-@!/,*^ZW$6Q!:X<-*\VCD_JF;6H%N;6
M^5]:CRWA$ZAE?NXOF7[VCJP<28@;F;;#%FT463SZN?-U5-'>$T<V7HW]')L-
M6Q'IIQ J4<31PS87TM<'_1-ZU&M6%3==(KBF$HFY/7*0+:RK="3H/KB*5 \'
M</DK8>K77$]/]M>A_P E5I433WG3FQ<M5%@+\A'+-J?<6Z#,)+= 685N,KL!
M1V:_S)[%G=OJ X&02L2/Z'Q*[ E]U]P4#HLM5$AKS>;AXEZ<062VCN#@_?#_
M )F]7GHU-3PCTN%]2N^,W^[H4>#O!]ZR[A\C KT@"N38L-RU6R@Y\C<6:/4;
MZ$X?%+4X+I13"[G>5JNW-M)1(K('4JW3HLH%\IWJT[MZS.-9F2/6[P=S@81-
MMTJR7#!XH.GA<NC=IU48+@QCTWU1,R+_ $L+9HQBA3U<0]72)RJD(?>@/?1G
MBOHJ_D<CT?>C:&5#PHQ0=JC450\&^#F9JR6STE7I'<U%S+FI@9EN+@7$ZCH+
M]"0JS#@]ARJTUK,PV[MPJM)KY:K'IO84VRG*YXIL;'0S]6'6?P>I66FX"+:5
MN2G<:%ZG)'"F%TR!Y+8^%V306U,&XXWL%0P*%[(NFRNI!^S0:93<(;X6\E9/
M.T-T?NC8M-*S<*<2M&HV2G5;@YP<%-WN1E1SL/*S7!&523<'32!T%NA*U1J*
M\'<.U5%S/2&W=NFHBZ',R#:^95L0;D :B:CJ:O\ P>-WW-9M/5? 1,VS6$$K
MB=D9_$[5/2F!F6UCF)\$:APQF/6,2\\7 O*^):'$5TD4V^[MJDFHHKHXT3U8
MGHZ]&S"83#XO$<+ZE+T17Q% 4*O![@Y3K(<.E%RS*^PUXKBNN0CEL>:TSX?H
M/="7%8FOAJ'!FG5W%*C5:M3VYMRI2;?-64*K)M=N,AHMG!M:X[<T_&#G0"<5
MO.[?A?4^\CM81%;9*/S]R](Q6&VGHVLUM5!-:O9),[OCPO&1<D67<*LIRXA!
M0B(8/70)@67T2:*ZJG1KZ-=+$4,+5X=81,15%WHC8W!VK5P]\.<2N_ITN#U1
MN-3  -$555B [*-1F3H3]":K0K8FEP.Q+T*9.2L=J[<IT\1:N,.QHO5VVBZ.
M2;5329E!*!B+27#'K9X/ G,]:Y&HUF0L+;)G&L#8W8>=S/;,=<+-)!C6+H6$
MH;SD$Z;N&QG&&/\ VQP@LB]\PHEOKK^8W1^Z-BTM^W"C%+0XGY9N#?!P4OR@
M!3\H=AY..""FO&!!%[S]$=!?H2M4W*\'<.U;C?DAMW;AJ<0V?\F-KYN(00VG
M%(L;3P]Z4\&6G'Y++5#=+IQ6&&DXY,)-OV"?ZQ^)R%53*20&2F=K)P.!&E5<
M933%E'+5]NIC.FJ&=L>+EO5YZ.&\ITO3+C-[57/2I^EG@]O*B<N>FG2+,ZV_
MS*".W.?J-]"'(]3I#@]W28)4J>F#;>2FYT".W3C*C$Z!6(/:GY7%0G0JDZ*F
MW8J25FH=K."PEQ8+\C"YG-I"X+QE!JF]3>QSR9\U'%]7K59)=@KH22:.DE-%
M='7F]L;YG"='OHU8S&4<!3X8%,16K"@JUM@\&J86I<BU3_[&66Q!!XI(/-&)
MZ#/0GPN$JXU^"X>A2I;XM2VQM]RR6!!3_P"[A6S @J<UB#>]IE#/K!T">HHJ
MZ H2BHM(0<.W9N;;E"#YK-9(+9&@4)>-=I]YUM,2HLBQ?L(RIC!AXT=MG+5H
ML@NDIOS/1_Z-:DCTUUS:F]6XX.\&RIHTV*O6!Z1ZTE92&J>L!!!((,Z#H+="
M8@?_ ,<HZNE.QVYMT$5*BATI$=-[BHRD,J>N(((!!FEZ!A?@Z;\IYO<;*#@H
M&)T&2H_(0,ZMLV,/0V,1:?3.O5)3+44K'7; XX4+04XX&&7SA(>LV;JZ;.-7
M+1XBAKQW1SZ-N"Q9PAX6U:[9J:(]'@[P=9*M2I0I5]W2/2,%ZBK60,@!8$\E
MB"<V$Z#_ $),7AQB!P9ITE"U'=*NW-N*])*=6I1-2H.G!"HS4G*L2 0.6X('
MG]J8ET0ZCQ=E-YWUCNB;0O(M_(9++JE'67-8S (P-="6CF23@[M8(D8)'9W,
M(+-FK1R2-/638D_:"5V0YVNG;9O1SZ-.TZAHT>'&&I5<PITZ6)V3P7HU*U1@
MQ%.BG2-F9N*020J@E5+ L!(Q_0@Z%&SJ8JU>"&(JTK%GJ8?:7"&JE% 5!>J_
M3=55>,+ %G(!(6P)F"DY%X,D?< 2I4*<L,PU+36K*Q>6T'^Z0XIZ-6?=L;9R
MRJZ]D<H7G[4JTDLO"%02S?#*.$! AU( PZ1%0Y!WELEV7HU='!L*^*/#*BA6
MCB,2,*^Q^# Q53#X2H:>(KTZ8V&4:G2=7!O4#,$=D5@+SBW0GZ$(Q"X?TJU&
M#5,/0.(7:?" X9*^*05,/1=SM<,'J*R$<0JI=5=E)M.Z1[P9SB*=JYFWI6S_
M %)T^R#^Z?@BPM>.E3"4C"X/!7D$!2F:@S!P>4';).19(BR!L##1RR+!G!$(
M_8DW ]&KHX"KLVB>&=#/M3/Z'R[(X+NJ&F^1Q6>GL1U1E:X95+E2"K!74J'J
M3]"$T]H51P4K9-G9-_FVEPBILV=<R&DE3:R,RL-59@@8$,I*$,9*4QUBZH7)
M$G$L4ZK6M4NS<V\"XC%SKSR&2U?#-JP=>MVXAM8QM-0(ZR^RV9O<N]-UG3)^
MEE#35#7=3\_%]'_HQ82J*7IZP^*N@?>838W!FK2%R1E+'82<<6N1;0$:ZS=A
M>@MT+<33-3TG5L/9BN[Q6U-OTJAL <P4;8?BF]@;ZD'32;;^\*ZF_"5+[:6)
M]7<R_P"(CHQ^_%O$/!C^RS1ZAW0M]ZR^..$']UC[PKJ;\)4OMI8GU=Q_B(Z,
M?OQ;Q#P8_LL>H=T+?>LOCCA!_=8^\*ZF_"5+[:6)]7<?XB.C'[\6\0\&/[+'
MJ'="WWK+XXX0?W6/O"NIOPE2^VEB?5W'^(CHQ^_%O$/!C^RQZAW0M]ZR^..$
M']UC[PKJ;\)4OMI8GU=Q_B(Z,?OQ;Q#P8_LL>H=T+?>LOCCA!_=8^\*ZF_"5
M+[:6)]7<?XB.C'[\6\0\&/[+'J'="WWK+XXX0?W6/O"NIOPE2^VEB?5W'^(C
MHQ^_%O$/!C^RQZAW0M]ZR^..$']UC[PKJ;\)4OMI8GU=Q_B(Z,?OQ;Q#P8_L
ML>H=T+?>LOCCA!_=8^\*ZF_"5+[:6)]7<?XB.C'[\6\0\&/[+'J'="WWK+XX
MX0?W6/O"NIOPE2^VEB?5W'^(CHQ^_%O$/!C^RQZAW0M]ZR^..$']UC[PKJ;\
M)4OMI8GU=Q_B(Z,?OQ;Q#P8_LL>H=T+?>LOCCA!_=8^\*ZF_"5+[:6)]7<?X
MB.C'[\6\0\&/[+'J'="WWK+XXX0?W6/O"NIOPE2^VEB?5W'^(CHQ^_%O$/!C
M^RQZAW0M]ZR^..$']UC[PKJ;\)4OMI8GU=Q_B(Z,?OQ;Q#P8_LL>H=T+?>LO
MCCA!_=8^\*ZF_"5+[:6)]7<?XB.C'[\6\0\&/[+'J'="WWK+XXX0?W6/O"NI
MOPE2^VEB?5W'^(CHQ^_%O$/!C^RQZAW0M]ZR^..$']UC[PKJ;\)4OMI8GU=Q
M_B(Z,?OQ;Q#P8_LL>H=T+?>LOCCA!_=8^\*ZF_"5+[:6)]7<?XB.C'[\6\0\
M&/[+'J'="WWK+XXX0?W6/O"NIOPE2^VEB?5W'^(CHQ^_%O$/!C^RQZAW0M]Z
MR^..$']UC[PKJ;\)4OMI8GU=Q_B(Z,?OQ;Q#P8_LL>H=T+?>LOCCA!_=8^\*
MZF_"5+[:6)]7<?XB.C'[\6\0\&/[+'J'="WWK+XXX0?W6/O"NIOPE2^VEB?5
MW'^(CHQ^_%O$/!C^RQZAW0M]ZR^..$']UC[PKJ;\)4OMI8GU=Q_B(Z,?OQ;Q
M#P8_LL>H=T+?>LOCCA!_=8^\*ZF_"5+[:6)]7<?XB.C'[\6\0\&/[+'J'="W
MWK+XXX0?W6/O"NIOPE2^VEB?5W'^(CHQ^_%O$/!C^RQZAW0M]ZR^..$']UD;
MNV_4CKU6'7^<SB"UXF"E(5Q#L#"NLGF9'+7!*<QH2]\3,M(GX];SX]^[;_X[
M17S?G?.I>0MHFII]2Z"_1EZ)7"SHD\'M@<(.$K;0V1CEVR<5A#LG86%WOH78
M.T\90_+X+9F'Q*;O$X>C4_)UDS9,CYD9E;YUT6.A7P"X-\ =O;:V+L!<%M/!
MG9?H;$C:6V,1N_1&V=GX6M^1Q6T*]!\^'KU:?'I-ES9ERN%821Z%?BFU+^JF
MG\Q)=SY;_P#41_\ F/ACWVP?_P!8V+/HO0.__%O!;O=L?_L&U9+_ )\5GUB.
M(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB5_P#=
M?IDZ[>2ZA&Y-['4*UA0_LJ LUH37(:R%R(N_KS-*@"O(<T;BG;!V7!2"2,32
MNQ,H#PQ;L_3A[ET_01:;_M[(VJ-ETL:5%3T15;9[X<J%R!L)CJ6)<526#!71
M"@RJ^8G*P"DF?D;3V8=HU,(&*"A2&-6N&+9RN*P=7#*:0"D%D=P_&9+ 74E@
M!*[F/@H^SCZL&F\]M"J9GV!FM!^$#A%W3UZ;F&HV163V8K&I*?I%8,]V@>2C
MB&PR"5%'ATM</QH\@+6U7<  9_9XOXOW6X2[/&(.YP^)I8&CC=AUL'0"4LU.
MAL_$8K%8L.-]E%6K6Q3FF%9E86#NEA/QAP?QQH#>U\/4QE7";8I8JJ6JY7KX
MZAA\/A<AW.8TJ5+#HM0LJLO*B5+F9#8'@ONQ)0V;FT<F%<O28^]NL]N1Z&Z3
MZ50QG*!M0=.!/6Z5L2DR^Y/-M89)V\G2(R. F481.&>PK5/)1J&($-TQE*'"
M+ JBTGI5PK8/:&&>J:-.J:38K:C8ZF5I>B:6]IFGE2LN]HG-ZW.J\:];86,9
MGJI5HEAB\%B4I"M4I"H,-LU<%4#5?0]7=5 X9Z+BE5&7UP0L<N>5[X.FVZSL
MSJT?KB/5?7$<KV.!XI>3MU=LKN).85HC/;3GQFG]:\FW7@*"E*C8Q8BB\#MH
M=(:G-Q70B>&JQ)Z)&@62_"OM[#8C#[12O4Q->I7=JF# PE/"[K$&CAJ*XK?T
M<<ST[I0_+X9J>)2H0C;P,SF=:.QL30Q& >@E"@E%%IXHG%5,3O*&]Q%9L-N:
MN"1*A#5OR.(5\.U,,R[LJJ@Z_@7@X.S%71#K8B,@73ZQ"_6HMVLB:,#F<IF8
MVO+6AO8/()2-VU(7+>DSB\>M"()"]XL6BBD>EK$E",K,1=@#5G6K-OWK;?V?
MB*N/+5]J4%V@NS:N_I4Z35\-5P.?/AD!Q:9\/5S"HM0/3*UM6HL!<\:6Q<=0
MIX$"CLVLV!;'T]U5J511Q%/&9,F(<C"L4KT[%&3)4#4B0M92;3&W?@<+)3IZ
M<5]F2TW-)=OTFZT==:RGLOT.I%(M8=36O*[#FQ=D[]C3I.*0]=H6!"XD\!.W
MQQUH#8H%A(Q)BW7VZCA7ASBJ-?)BZ5(;6VACL11IY,M2AB<-3H458;U%JU05
M=JJN @SL59LQ$J>#=?T-4H[S#5:G2O X*C6JY\R5L/B*E:JP.Z=J=,AD6F4N
MQR@,J@ S9#/P8UE:7W=4LF(:OK7@,UM+M7<$),&[]L&"OFZO8^L)C!U*UEE;
MQJC"SG=@FC*/8<Q,QESJ:M8 V'EA$+5/A!X7;*>$-#T%A*5)Z^&K4L/LW"UD
M3!4*RD8#$4JWHBGB*F+49B:>]2DV$%ZQ97JY'+3L-A5_1>*J55I8BE5Q&T,3
M19\96I$>C:%2D:%2@F$8V&\W1JKB3:B%9:1=0LDOU_ZX=M:;Z8WG3K:65ZSM
MP]B>L.M^C^:E)8(J2.%((!B5?")O;PRFZ^DUBD(83'/C*$D>UAD[ZHU!1AR1
M*I"DB6F#'8_9F+VM@\4:=<X5-RV/(HK3?%5%K/5KM2PK8JM3H+55E0H,1DS9
MZ@5<V6;<'@MHX;9F+PPJ41B6WPP5ZK5%PZ-22G16KB5PU%ZS4F4L*AP^?+D0
MLP4$0JD7@>KRC4/FE;57V.#RR$65T_C/7.3MK2  (=D:8I2:QB:4BDU&U%7(
ME&71(BU^Z+!+ -S5^2GR<:FBKO<C-%],#T?UZ?"G!5*E&OB< ]*MA]J5,?3]
M#.]4,N+I5*6+);$UV-*JIW%:@E(+1WE*UJ5\T_,?@WBDI5:&'QJU*5?9M/!.
M*Z)2RMA:M.KA;##4%WE,C?4JSU2U;)4N6JG0;HL/P>]J7R??32QJJZAP!TXZ
M:]J:*"5_!W1V41:+6W<3N$I5]/&A(I3\8U448B0)Q*3RQA'ALA")D&@D&+D*
M&KDDICH;;PV#04J&)VI7 VKLW&/7K!*=2KA<**V_HD+BJE@S5$W=,NR/E+.R
M7"S56V/B,6YJUJ&SJ1.S<?A$HTB]2G3Q&)-(4:P9L,GK51A4J*BNH8*BN+L=
M6S7P7/8\JV?'!4XKAS(1$XZ'3\, 2G<NC+:8N>KO6@_2$_#&IEO5LJ4B+LC(
MI!M+*[DND-G&GG0X]R= "7BWB8::/"' *P1J-<4WI;9HM4-"E4-$;0Q]/%T'
M2EZ(I;T*B;JO3WM'UQR.P'&SU=@XU@66M1+K6V365-[5IBJ<!@6PM97J;BIN
MRSOO*+[NMJJET5M5^H_X)RQR SKB#A3^O*XA;D(:K+N? WUBS.R%9=2SGM,&
M[2#(S7,S7K"%>OC6Y_2;QDBH>B4%#,@-BGA(EIL/2UPX4^$V'5L>]45Z]4.N
M(V37%"EA]WBQLY]G&I7I#$5MVN3=5%W=2J[/01F(8FTOP?KE<$E)J-&D5:AM
M.B:U6MO,+Z/7'K3H5=Q2+-GWJ-GITE"UG51EY?.SX)ZWR4F[!BSL@BS@;/7/
M=@Q5MU-[CEZ$DC[SMS%YD!RPE-(-J8;,";D9K*4!TG.;7D09OQH,42#QQH3;
M-6S"?3-A5IX)T2H&HC9*8G"'"TC3<;,J4GS4\8<464-NRU-/0@(9V5W*W+1Z
M7\27QBNZ9:IVH^'Q(Q-4.AVBE5+5,(,,%)&\"U']%$,$5E0-8++7H=U!N2A+
M=MFU;2B77&OFU@TAUQJP?#>O)&3/QR9FD$9^)+R0\L>KZ!HN5Y(./ 73%PW;
MK.F39+$;>>E:Q]N?._F;9VIA<;A<+AL-5Q]<T,9C\2U7'"F&R8O<,E- E:L0
M$9'# D G\H+9RB?H;)V;B<'B,17KT\%1%;"X+#K3P;5&&;"BLK5'+T:-RZNA
M! ) XAOD#O$*2>##[+3-+L]L%9=<^O >\8+# S^HJFL^X)#3MAV^$OV 6B8O
MTY')!7(@=5)K,-B9:*C8Y"X_)%"+X^Y5-'M4]%2#W]5.$.SZ72[,V/QSX.O4
M=<5BL/A4Q6'PK8.MAUP25*=9FQ*;VHM1JE5TRA!D2]E'YU386.J^C\HP6#7%
MTJ2MA\/7Q+X>MB4QE'$/BW1Z*KAVW5-J:TZ2/<N<[\K':Y#P8,]?38A-V1:I
MXO+3G?CLGV,)6.!];Z6$TI6Z*3GE;1V.M#.D09/WDO!GI,++/8NX,MXF@W9K
M.6<E=.TTD%LJ\(:*T5HE<34IIL7 8%:#Y30.+PF,I8BHY7>E12>G3914"FH2
M0#3 U'<["JFJU4-ATJ/M?'8TUDS;X87$X6M1IH&W8)J([JQIYMV "0Y.AUMM
MX.'M(M1O5^$:Q;J[$Y7U)D<'08-*NL.8PQ/L,!BM3SBL7<WG4\=T =<0>P$U
M93I)8TR6@=F-&9(M.%'4@05/H[M='3[9WHS:%7>[1JT]II6+'$T*5;T ]3$T
M<0*-"B,:HK42*9IU"*V')5:%D(0WX])<?Z%P%+=X"G4V>]$ 4*U6EZ,2GAZM
M!JM:J<&QI5AO ].]&N S5B7X^DH[6Z;7(Y\&JQZ1T@'JB-')/$W%9RW$ZM">
M2.,0&%RAR?)R(E$)>UK!H?G9< 2?#D 8PO#((+>BLO$]=PFK$>P<?FX7:N$7
M;[;7QCXJHE.H,12W.'HI4KU:8146K3.)*45=0Q=EJUF#6-GNQ&_$;-Q+;$&R
M\*N'IN]/<5-[7K/3I4G+LYI5!AP]5E8J$5J5%2MQQ;*#JX[T'[-X[ /7L;-T
M>XH1_P!X.N7<IT=.2"=,K8SM4U=0JNI- FL380I_$T]G"457/!S:\PWT>95:
MB73(=EVX(BM*[:V><"JU%Q@QJ[(Q^RPBTZ)PW_B<14Q%.L:IK"J?S@1D%(6L
M6#&P5N#[(QWHLFF^%.$.U,%M(N[U1B/_  ]&E1J4136D:>HIYU<U-=%(%RR1
M5FO@X;;B>.@E(X60*/+ +W!2W<$I! \I/P$UU?9=C5NXPUD7E[X"%:Q=[AV.
M5KH?M(&C-P;?V?)  -(FT]+76_2I;>PU7IWC+95H+A<9LM*[TTKKM!L -E,5
MI!W-06;?MD+!!AZ;N0;"8*VQ<0AV3AKYC6;$X7:345J/1; #&=,0&J%%%-KK
MN5+@%FKNB!A<FR[P@W7WM#V3:5?7%4(T@:Z_)'-I%V"K>S[&L&LBEO:@'@\C
M"8 I(X14UH[MZV4+-<E9V,1;"BTF38C@21)D*6)^E^?V'CMG;/.(Q&*]&+CL
MF[P5?#T*&(7#;Q66M6W=;$X:^(RG+18ETIW9RI8+;]O;&#Q^-%"CAQA7P>?/
MC*%>M6H-B<A#4J.>EAZ]J.89JH 5GLJ9@I:\?2O0?LC(+C+ZO'M&A:)LWM?U
MI[H6&N)E$U?3Z'SBCX=!&4DJ&#@E:]$@9+$)+,*^!J1^>$S\/)!XJJ23=0I0
MGEHEC<NVL F$6PQCXS#[-VALF@&ITA1JT<95K%,56??L].K3I5GST52JK5 M
MJF6YF-MD8U\0P)PB82OM#!;3K97JM5I5<-3I"IAZ2&BJ5*=2I17)59Z96F6O
M2S6$R\)U;[8NK*[]RVS*HZ@SR$]NV5;+C*Z?W;;KP<Y<55$(K6K"+S593KH,
M]"#3")##!\@=$Y-.HS)=1(A #(Q:KLPVY/M'9@P^Q*6'Q.U*-799Q ;$#"84
M,!B:M3$-4I 8]LSTJC*BHV05*>9RZ, AZ+@,>:^UZE?#[.K4MHB@5H'%8@K?
M#TJ= 4ZI]!+9:E-6<NN8TWRJ$=;L) ] NM%D]:(/:PNPW<5#I6-<)VQ894%>
MS&:3ZNZ/BA(''Q3>"Q*63\4 D!1)R0$OY(6PC'H^";%3#E$,(00PJX=8=M[0
MP^T*V&;#BJYH85*%7%5Z5*C7QE17=C6JTJ+.BV5A37CNY506;D V;(P-? TL
M0M8TU%;$M6I8:C4JUJ.%IE$44J=2LJ.;E2[ (B!F.5>4F>O/Q9^M'$1Q$<1'
M$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1(?=]?Q4[-_U,
M _F5#^?;?_IT_P#S#P2[SA#_ /K&V9\DZ.G_ .+.$_=V)_\ L.R9^_0?H/U?
MN?J74MEV'!S1>829.:[&"+2PK"!MW&1-C2\$Q\V+"28>+:^:&"V2&V&K-'SV
MZ>SA;RW"JJN_]3=$+AWPEV-PPVQLW 8K"T\)AC@-RE39>S<0Z[W9F"KOFK8C
M"5*SWJ57(SNV4$*ME4 ?S5P,X)[$VGP:V;CL71Q+XBOZ,WC4]H8Z@AW>/Q5%
M+4J.(2FMDIJ#E49B"QNQ),P?=;=*_AK(_P![%K_6?/&>J?PP[-P/B78_F,]1
MZ1.#G8^,\:[3\[CW6W2OX:R/][%K_6?'JG\,.S<#XEV/YC'I$X.=CXSQKM/S
MN/=;=*_AK(_WL6O]9\>J?PP[-P/B78_F,>D3@YV/C/&NT_.X]UMTK^&LC_>Q
M:_UGQZI_##LW ^)=C^8QZ1.#G8^,\:[3\[CW6W2OX:R/][%K_6?'JG\,.S<#
MXEV/YC'I$X.=CXSQKM/SN/=;=*_AK(_WL6O]9\>J?PP[-P/B78_F,>D3@YV/
MC/&NT_.X]UMTK^&LC_>Q:_UGQZI_##LW ^)=C^8QZ1.#G8^,\:[3\[CW6W2O
MX:R/][%K_6?'JG\,.S<#XEV/YC'I$X.=CXSQKM/SN/=;=*_AK(_WL6O]9\>J
M?PP[-P/B78_F,>D3@YV/C/&NT_.X]UMTK^&LC_>Q:_UGQZI_##LW ^)=C^8Q
MZ1.#G8^,\:[3\[GA2CP;/1B'QF12TW7,H2#18$7D1=5"TK9<+IC @]P3?J(H
M:3/RUU=&K579-'3^\IOC&FO]NV./5/X8=FX'Q+L?S&/2)P<['QGC7:?G<C)2
MU&>#!NI,KJA6]HU>1%02O[3W$W1-K8KQP0K&U-C2, GP4D_L!S'#4=D+R.'1
MV-QIQP0$D1VS(\/%+/!VKQZI_##LW ^)=C^8R?2'P<[&QG+;_P UVGR__P"W
M_P!^:2":= ?!R$#0*-L&HQ[(I0!2E,: -.P4Y<FI%&%T,ND)&"%(V%N^+ 5F
MVNSA(NP0<#U$-<K:.,IXSMQZI_##LW ^)=C^8R/2)P<[&QG4_P#-=I^=SX6_
M17P:3LJ;!-5X\Y-QI?T61AV_8V9+%8^Y]:, ?HYL>G8VSL4OZZ*# _F7Z*"G
MK0BP'^3Z6[;HJ/5/X8=FX'Q+L?S&/2)P<[&QGC7:?G<_<;T*\&X9*@ (?0*5
M.2L+B218,-[#S9\5DL=RFHM@^ '-;$5>& N44E5<%1R+ECYM)3?S_DZ;9P]4
M_AAV;@?$NQ_,8](G!SL;&>-=I^=SY-NC7@S=,.]MW<:TU'NXZP?YV[(3#7#)
M]+T_.Q-F[SFQ\8;.Y0E_BQUNMY"QM/\ OC='.O\ ;QZI_##LW ^)=C^8QZ1.
M#G8V,\:[3\[FR/=;=*_AK(_WL6O]9\>J?PP[-P/B78_F,>D3@YV/C/&NT_.X
M]UMTK^&LC_>Q:_UGQZI_##LW ^)=C^8QZ1.#G8^,\:[3\[CW6W2OX:R/][%K
M_6?'JG\,.S<#XEV/YC'I$X.=CXSQKM/SN/=;=*_AK(_WL6O]9\>J?PP[-P/B
M78_F,>D3@YV/C/&NT_.X]UMTK^&LC_>Q:_UGQZI_##LW ^)=C^8QZ1.#G8^,
M\:[3\[CW6W2OX:R/][%K_6?'JG\,.S<#XEV/YC'I$X.=CXSQKM/SN/=;=*_A
MK(_WL6O]9\>J?PP[-P/B78_F,>D3@YV/C/&NT_.X]UMTK^&LC_>Q:_UGQZI_
M##LW ^)=C^8QZ1.#G8^,\:[3\[CW6W2OX:R/][%K_6?'JG\,.S<#XEV/YC'I
M$X.=CXSQKM/SN/=;=*_AK(_WL6O]9\>J?PP[-P/B78_F,>D3@YV/C/&NT_.X
M]UMTK^&LC_>Q:_UGQZI_##LW ^)=C^8QZ1.#G8^,\:[3\[E;_A>N@'5ZGO!J
M]OK,KV&2,#-(?5NY6/%_NF62_P#0'WM$!;>>]#(RMVQ<?X+A73R'+=73^]Y7
MD^5C7.,.TN'W";:V!Q.SL=BL'5PF+I[JO379.RZ+,F96L*E+!I4351JC*>W-
MFS^".Q-G8W#8W"T<4F(P]0/2=MH[0JJ&(*ZTZF)9&%F(LRD=J33I7P973@W3
M=2F25=R-P1+UE R9!Q]U6TT_/O7\6%.G2WFTICHDGYU=53?R$]---?*\G377
M7&,8U4NB5PNHTJ=&GC,"*=*FE- =C;(8A$4*H+-@B390!<DD\I),SU> _!VI
M5J5'P^,+5*CNQ&U-I %F8L; 8H :DZ 6'--F^ZVZ5_#61_O8M?ZSYT]4_AAV
M;@?$NQ_,9S](G!SL?&>-=I^=Q[K;I7\-9'^]BU_K/CU3^&'9N!\2['\QCTB<
M'.Q\9XUVGYW'NMNE?PUD?[V+7^L^/5/X8=FX'Q+L?S&/2)P<['QGC7:?G<>Z
MVZ5_#61_O8M?ZSX]4_AAV;@?$NQ_,8](G!SL?&>-=I^=Q[K;I7\-9'^]BU_K
M/CU3^&'9N!\2['\QCTB<'.Q\9XUVGYW'NMNE?PUD?[V+7^L^/5/X8=FX'Q+L
M?S&/2)P<['QGC7:?G<>ZVZ5_#61_O8M?ZSX]4_AAV;@?$NQ_,8](G!SL?&>-
M=I^=Q[K;I7\-9'^]BU_K/CU3^&'9N!\2['\QCTB<'.Q\9XUVGYW(PU[UY\%?
M9:O8Y($$E##[U"52:*W<K);!NF/-XQF))&=S,D;KD96DF8ANBT9E;%O)ANS@
M:Y(Q.2,DU//B7.F'JG\,.S<#XEV/YC)](G!S3_PV,UY/_NNT^YV7->AZU\%[
M(Z;C]\QVG+R+5U)00TZ.?[R6U01-/)"[!M"*!206560!(BI ,G!'*Q,600;[
MH V#]ZDHX=Z-Q[EZI_##LW ^)=C^8QZ0^#ER/0^+T_\ [7:?4)N/_%]KYI,%
M+P<70)P;*1I"-*+2,&R0)&X^E>-C*&PXYUKC=J_*"M)YE^/9.=-M=T'3M!%!
M;7.-DU-L9QGCU3^&'9N!\2['\QD>D3@YV-C/&NT_.YKS/3KP7?MA ($DZ&.Y
M7:8B5':\%L+ULHCI+1<*)@0LE7$$F$W<"EE!Q:2AQVC/=\F](.UG2(UN\W%E
M<,GJG\,.S<#XEV/YC'I$X.=C8SQKM/SN9TT\'=X/<@O(&S (D]<Q-VFPE+=I
M>]@N5XT^6VSHBRD"2,^W4#.U=]=M4VQ'5LMOMKG773.<9QQZI_##LW ^)=C^
M8QZ1.#G8V,\:[3\[GS[>#Y\'9I&W4RW',M(@Q<+-'TKVOZ>ZQMFZ;O?5KALZ
M.9L# MNX0(YPP616=:*)/<^B[ZZK_P"'QZI_##LW ^)=C^8QZ1.#G8V,\:[3
M\[F5H^"]Z2N44G#>NSSANX236071MNU%45D5=,;I*I*Z33;11)33;7=-33;;
M3?3;&VN<XSC/'JG\,.S<#XEV/YC'I$X.=CXSQKM/SN?K[K;I7\-9'^]BU_K/
MCU3^&'9N!\2['\QCTB<'.Q\9XUVGYW'NMNE?PUD?[V+7^L^/5/X8=FX'Q+L?
MS&/2)P<['QGC7:?G<>ZVZ5_#61_O8M?ZSX]4_AAV;@?$NQ_,8](G!SL?&>-=
MI^=Q[K;I7\-9'^]BU_K/CU3^&'9N!\2['\QCTB<'.Q\9XUVGYW'NMNE?PUD?
M[V+7^L^/5/X8=FX'Q+L?S&/2)P<['QGC7:?G<>ZVZ5_#61_O8M?ZSX]4_AAV
M;@?$NQ_,8](G!SL?&>-=I^=Q[K;I7\-9'^]BU_K/CU3^&'9N!\2['\QCTB<'
M.Q\9XUVGYW'NMNE?PUD?[V+7^L^/5/X8=FX'Q+L?S&/2)P<['QGC7:?G<J1Z
M4=%>MDW\)1X82LI-$I&1A5-S#I>TKL1]TBQFWJ%O-^OY.025/TUK*$7Q#! L
M@DZQDDY=Y;>3E)KE%';;3/YV%X=<(\'CMI;0P^)P:8K:S86ICJAV5LQUJMA*
M)P] K2?"-2HY:7%.Y1-X>-4S-K/T,3P4V+B<%L[!UJ.*;#[/3$KA5&T,>C(,
M36WM7-47$AZN9Q<&HS%!Q5LNDMN]UMTK^&LC_>Q:_P!9\_1]4_AAV;@?$NQ_
M,9^?Z1.#G8^,\:[3\[CW6W2OX:R/][%K_6?'JG\,.S<#XEV/YC'I$X.=CXSQ
MKM/SN/=;=*_AK(_WL6O]9\>J?PP[-P/B78_F,>D3@YV/C/&NT_.X]UMTK^&L
MC_>Q:_UGQZI_##LW ^)=C^8QZ1.#G8^,\:[3\[CW6W2OX:R/][%K_6?'JG\,
M.S<#XEV/YC'I$X.=CXSQKM/SN/=;=*_AK(_WL6O]9\>J?PP[-P/B78_F,>D3
M@YV/C/&NT_.X]UMTK^&LC_>Q:_UGQZI_##LW ^)=C^8QZ1.#G8^,\:[3\[CW
M6W2OX:R/][%K_6?'JG\,.S<#XEV/YC'I$X.=CXSQKM/SN:$['=/O!^]7ZS/6
M[/Z0N@Y!HD'D,EF1.O)1<,Q5B$5B@ A)9#*)"T93I%=F"%B!;Q=P[3U7W\K3
M5)-'???7''JG\,.S<#XEV/YC X"<'";>A\9K_P#VNTQ\^+G[0#IET-G;G#9W
M05V5QMD QD'EVI,K/A6NJ).3NXF,';IO+(6<:%2)-KHHP:[(83>-7X_9LX4<
MN<-='JG\,.S<#XEV/YC'I$X.=CXSQKM/SN;%&>#W\'@<W') 0Z!YR9%/C@1H
M$OF?%'1L.,=98OR8=!G8"RA)@S?XRP<O6F%6K=[_ -*LLFM_<X]4_AAV;@?$
MNQ_,8](G!SL?&>-=I^=SQ(GT0\'I*P$!-YAAB-/;( QX]'8C++HGPB99Q) >
MDA8B'(+6QG2FQQ$=LKN\8#UW^J>S1WLBNX;H;+Y>J?PP[-P/B78_F,>D3@YV
M/C/&NT_.YD2'@\/!ZN9*YAC8,BXF#/7&[N*(7Q8"LE:Z9;:O,;.02<^V*(:Y
M:;:NL;*M=<>C;:K^/S6<;<>J?PP[-P/B78_F,>D3@YV-C/&NT_.YE/NMNE?P
MUD?[V+7^L^/5/X8=FX'Q+L?S&/2)P<['QGC7:?G<>ZVZ5_#61_O8M?ZSX]4_
MAAV;@?$NQ_,8](G!SL?&>-=I^=Q[K;I7\-9'^]BU_K/CU3^&'9N!\2['\QCT
MB<'.Q\9XUVGYW'NMNE?PUD?[V+7^L^/5/X8=FX'Q+L?S&/2)P<['QGC7:?G<
M>ZVZ5_#61_O8M?ZSX]4_AAV;@?$NQ_,8](G!SL?&>-=I^=Q[K;I7\-9'^]BU
M_K/CU3^&'9N!\2['\QCTB<'.Q\9XUVGYW'NMNE?PUD?[V+7^L^/5/X8=FX'Q
M+L?S&/2)P<['QGC7:?G<>ZVZ5_#61_O8M?ZSX]4_AAV;@?$NQ_,8](G!SL?&
M>-=I^=R'O??H3UAI7JC9]EUW"#0>8QMQ7^!!%W85@G&[?!BS(<!(><%G),0%
MNO.C"CU#3TEFKYC=35PCYMPDDKI[3H>\.^$FV>%VRMF[0Q6%J83$+M#>I3V7
MLW#N=SLS&UZ>6MA\+2K):I20G(XS %6NK$'RW#3@GL79G!K:.-PE'$IB*)P>
M[:IM#'5T&\QV&I/>E6Q#TVNCL!F0Y20PLP!$R?!:?B'4/^IL?^;L_P">.Z*W
MM^V_W=F?8VSIZ7H>>T_9'_4/M3&RP+GSR>TCB(XB.(CB(XB.(CB(XB.(F VM
M&2,TJZR8<(V;:%I9 9C&1>[U7=%GH1/1TB+9;.UDTEU$FVKETEE=5-%;=-+&
M^VJ2FV,:91*TT?!IQUCU\IZ!KCF]@64WDG1?%Y&K<GDNLP8>KSK#8T8FARNX
MUK,O7+!A QWCG3F+P84#C\<,$#[E8VUU<$7+K1+9M?AM^T<NG/R7,^(_TFM+
M:Y)/J'@E-IP<YW-HCM@$OYN><,;<@T$I4'43;>B@<%0@._\ ?(M*L)U*'7&V
M$,B+>G+#.>DL4"S1U'9$B_;/(1VM;^6_=^2MOJ-UOF]X5KO4DOJ1-[*Y'3G4
M9.5')8Q*B(C!Z_I'MU6URS[K_<4:.=8:H(C[FF0TW8)'>-EK"['/W"<.=A99
M8&BFV)]9D$7'P7_8;R38<AYSH.X1?0D:?LY=--!9E:W43L%+.V-?S6+CZJ!4
M77%Y4;9<1;QU2!PQZ+AD&A6T:FH<V'8T.3L22V Z,$#Z(%VTNV-U^C6KL5'<
MQ] HP,)R.9%Q;GOS]V_=ZG:Y1\&E&'@J7B-1QB(NJYH%:6CO!P=E>M)<EL)'
MJINK_MPI#R,9E^2"D0]*<L4=DIWN3F2J6)"P4D9'#1BYU-DL[(S:_P#^0/[!
M^!+LXB/(B(I&!1A?#HL,CP4>4=:K*.<.2+(:V;/5\.%M=%G&%G*:JF%E=-5%
M<;>7OKKMMG&$K,AXB.(CB(XB.(CB(XB.(CB(XB52>''_ "3/>3]CF_\ %,;X
MED]>O?+\XD_^O_\ D/2?[(ZW_@T-Q(/*>Z?GFW.)$<1'$1Q$<1'$1Q$<1*5#
M'@\;I(V$L3&G(6&@EXWMV $]MQ&Q!\X=S[JK*.QI+LE5P4>FD/31=R)??::4
MU)0SU1-FQ@?8ZS7;9XX(BAJO$M<6[G)U+WY>7J6UZH Y)\.O@_KZUAR0+RX/
MZ;I#Y@"SG$B=>8]-.>$8']HV.<*>I\;>8Q6+93593R/*3D?DB<:;HY]/P@FY
M)[7W6GSQWP=D^UEMXHVG%G=JBI.8[QF 1YG<, KH3/XEVU>6!NG7TA?1CKXG
M>H\LE$IH(@Y-626C+(A%G\(C,QB6%V\>B,4CB,UAIH=.KRBVO+SVZDSNL.H=
M^@[!ZR67/8)5,F?5D[[*0)5XXWK879T"KFV#-0F*NGYPK!ZIB5=S>RZ^5K>1
MZE?8Z.1/5Q[5!]FCXD31DYT@B_+:XO;Y!;J^7J30#'P;-YFJ?CM9DJRHVO2E
M;=+)-U3E,EB\O5+9[9S"43^@I$ZLZ<XQ!PY >&2;4_,I:IK.7<GF:\UN.2M?
M2-&Z)L_,$9M;_P#J#=RW,.;Y!R#DY!MVX_!^6AO8$FE5.B8G'ZV8]MXQ>X&G
MX0YK6)-S,>QTJ ]<S)40'L&I+*J<1-@4Y9*&6+ [#LLRT>T(OVLD 2782MAU
M?QS" WPVM<WZM^;7D_%I9IUGJM*D:%JVJ4&+X4C"(LU$)"",E8RYP&3\\X=Z
M!=3XJ+PD.\9A]7.!HU +$H^$&CFK46&&-A;)IIQ*S>G$1Q$<1'$1Q$<1'$1Q
M$I&\'Y^5E\.G_OGH)_QF,\CG/<'SF7;UM/N-](R[GDRD<1'$1Q$<1'$1Q$<1
M(W=R:KE%Z]0^U%)0?(W$TN'KE=U6Q#)EWN/#XD]@5I)HH R5?IMW2C(;@J6:
M>G.]&KG=LV\ZMJ@MMIA/9)&A![<BKVSZ<SR_)W)G[0="S4*E%<=08.6#2A[Y
M38LVIWNF!O*RQI,6L,>-78DA6K(@T8HK^<2,%%O5#E%NW6W=820;"W/<GY+3
M$HCX/YS!+B!67#8!4D3<B_"$3_L'DU&AXP*>0HB7=2K%J3,8:NAH)LY3W>6=
M,O7#^%IN4P>VKXG(ME%"2JNJR"?H@? 0?NFD*_\ !G6,%IP )DT7J9_<,1Z\
M>"IK.'3'=P@0+1.5=.) !-V^I&Y2X 8+ F*RXC1S&WHK9LI(W#5EZ>BR\PCE
M*!H .U%^7EU+'X1I,.Z%!##3NV?/S2MW#TXI+_"#MXF3%#G ^2T_';4[29LT
MF_[ "3%$Q,H.>6$A'8HQIQXXOFTG*4<=E6@,:O'S1 A')_Y^>#R?!^T@6T-^
MWU+=N_+_ $$<2L<1'$1Q$<1'$1Q$<1*^O"F?B*W9_J:L_G)7W/HG0H]ONP^]
MVK]C;0GBNB'[3]K=W ?:>#E(W6SP5_5GL92D*N6Q75XIS*9Z']C.D0ORT(9'
M=<@92<C##U=&H](60<9C(P*RRZPS:I8=O<N7R_EN72RF_P"YT2<!AZ_#7;56
MHK%V.S[V<@<796!4:=P"?F\!<;7I<%=E4T*95]'6O30G7:.+)U(N=29O+W(7
M2/\ />RWS275]5\\-TKPG6OX9GK>F.)ZM/XJG_+'N0ND?Y[V6^:2ZOJOCI7A
M.M?PS'3'$]6G\53_ )8]R%TC_/>RWS275]5\=*\)UK^&8Z8XGJT_BJ?\L>Y"
MZ1_GO9;YI+J^J^.E>$ZU_#,=,<3U:?Q5/^6/<A=(_P ][+?-)=7U7QTKPG6O
MX9CICB>K3^*I_P L>Y"Z1_GO9;YI+J^J^.E>$ZU_#,=,<3U:?Q5/^6/<A=(_
MSWLM\TEU?5?'2O"=:_AF.F.)ZM/XJG_+'N0ND?Y[V6^:2ZOJOCI7A.M?PS'3
M'$]6G\53_ECW(72/\][+?-)=7U7QTKPG6OX9CICB>K3^*I_RQ[D+I'^>]EOF
MDNKZKXZ5X3K7\,QTQQ/5I_%4_P"6/<A=(_SWLM\TEU?5?'2O"=:_AF.F.)ZM
M/XJG_+'N0ND?Y[V6^:2ZOJOCI7A.M?PS'3'$]6G\53_ECW(72/\ />RWS275
M]5\=*\)UK^&8Z8XGJT_BJ?\ +'N0ND?Y[V6^:2ZOJOCI7A.M?PS'3'$]6G\5
M3_ECW(72/\][+?-)=7U7QTKPG6OX9CICB>K3^*I_RQ[D+I'^>]EOFDNKZKXZ
M5X3K7\,QTQQ/5I_%4_Y8]R%TC_/>RWS275]5\=*\)UK^&8Z8XGJT_BJ?\L>Y
M"Z1_GO9;YI+J^J^.E>$ZU_#,=,<3U:?Q5/\ ECW(72/\][+?-)=7U7QTKPG6
MOX9CICB>K3^*I_RQ[D+I'^>]EOFDNKZKXZ5X3K7\,QTQQ/5I_%4_Y8]R%TC_
M #WLM\TEU?5?'2O"=:_AF.F.)ZM/XJG_ "Q[D+I'^>]EOFDNKZKXZ5X3K7\,
MQTQQ/5I_%4_Y8]R%TC_/>RWS275]5\=*\)UK^&8Z8XGJT_BJ?\L>Y"Z1_GO9
M;YI+J^J^.E>$ZU_#,=,<3U:?Q5/^6/<A=(_SWLM\TEU?5?'2O"=:_AF.F.)Z
MM/XJG_+'N0ND?Y[V6^:2ZOJOCI7A.M?PS'3'$]6G\53_ )8]R%TC_/>RWS27
M5]5\=*\)UK^&8Z8XGJT_BJ?\L@MX3+P3/4ZCNAW9FV8.[OG>60:O<F0>DF["
M6K*@.SS!P.U\1./&Y&[%%6_FG*O_ $SYLJCY?D*>3Y>FN<9\7L_#4</5J(K9
ME4$7<D:L!R?MFC"8[$5,321BF5FL;4T!M8\X (DJZJ\"STN/U=6YX@]['8?F
MX##R[W#3LY<K-KAV2CPYXYPV:-Y3H@U;^>6W\RW0TT103\E)/77377&.R;,P
MA125>Y52>.>4@&<7VAB0[@&G8,P'Y*GS$_\ IF?>Y"Z1_GO9;YI+J^J^6Z5X
M3K7\,RO3'$]6G\53_ECW(72/\][+?-)=7U7QTKPG6OX9CICB>K3^*I_RQ[D+
MI'^>]EOFDNKZKXZ5X3K7\,QTQQ/5I_%4_P"6/<A=(_SWLM\TEU?5?'2O"=:_
MAF.F.)ZM/XJG_+'N0ND?Y[V6^:2ZOJOCI7A.M?PS'3'$]6G\53_ECW(72/\
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MI7A.M?PS'3'$]6G\53_ECW(72/\ />RWS275]5\=*\)UK^&8Z8XGJT_BJ?\
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M4X*&$-W3P84>#UN3TLS!U=Z;A2A9,INI-[$.K#0Z@VN+G6QG1*F52I177-F
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M$X8>L AEN4@2,\RJNY#1V2F!#-BT5RT=K- $A>9RGLNU&N=LZMLFJ@;[3\R
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M:QLMQRB7;$%E]:N=A4#/8W&\J,[!0&RV(-M5N+M;F(VI8/4P38)V['SFV+0
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M@Q8]JUT1;MF:2:>,<ZTJ8I(M-22%O8FU]23S #GY@!VIRJ.:CEVL"UKVO;0
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M!-V(+'0WN)<X@EE;)3TJ&J1Q[-4:UV/'ORC0*54=2>L7Z81H^1C[\U:MI/\
M1O%Z9A\^8[:5JV:VT$Z_6(<L^J$9=Z%7398(N DDD-(/W5=JPE>0!7WJ\MNX
M4:L7C63AP;7=^2F&]:-X*3ET#672Q)U7+<:&0*Y%[(GKJC+Z_B&HH1RO'UN%
M&C9K$::7!F5S1.$<1'$1Q$<1'$1Q$<1(7>$*_%%M3_4UW_-"%\]MT.O;ALGO
M=H_9>-GE>&WM8VG^Y?:&$G;P>OXGU/?JIS_,N9<CHB>W';/=P'V9@HX$^UC9
MG[[]H8N3/YXJ>JCB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(X
MB.(CB(XB.(CB(XB5F>&3_)A=R?V4;?Q+'^8]H>PZ_>CZ:S7@?9=#O_N,G%1_
M^2M0?LNK_P#A,3S33_-T^\7Z(F>I^<J=^WTC-H\O*1Q$<1'$1Q$<1'$1Q$<1
M'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$IXZ-?E/O#/?[QZ/_P#'@QS#A_9>
M/[[#_5&;L1[$P'>XCZT2X?FZ88XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB
M(XB.(CB(XB.(D+O"%?BBVI_J:[_FA"^>VZ'7MPV3WNT?LO&SRO#;VL;3_<OM
M#"3MX/7\3ZGOU4Y_F7,N1T1/;CMGNX#[,P4<"?:QLS]]^T,7)G\\5/51Q$<1
M'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1*S/#
M)_DPNY/[*-OXEC_,>T/8=?O1]-9KP/LNAW_W&3BH_P#R5J#]EU?_ ,)B>::?
MYNGWB_1$SU/SE3OV^D9M'EY2.(CB(XB.(CB(XB.(CB(XB.(G&VVNFNVVVV-=
M=<9VVVVSC&NNN,>/.VV<^+&,8QCQYSG^S&/[<\1&,XSC&<9QG&<8SC.,^/&<
M9_MQG&<?V9QG'_C/$3GB(XB===M=\8VTVUVUSX_%MKG&V,^+/BSXLX\>,^+.
M,XS_ /G'BXB=N(CB(XB.(CB(XB.(E/'1K\I]X9[_ 'CT?_X\&.8</[+Q_?8?
MZHS=B/8F [W$?6B7#\W3#'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q
M$<1'$1Q$A=X0K\46U/\ 4UW_ #0A?/;=#KVX;)[W:/V7C9Y7AM[6-I_N7VAA
M)V\'K^)]3WZJ<_S+F7(Z(GMQVSW<!]F8*.!/M8V9^^_:&+DS^>*GJHXB.(CB
M(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(E9GAD_
MR87<G]E&W\2Q_F/:'L.OWH^FLUX'V70[_P"XR<5'_P"2M0?LNK_^$Q/--/\
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M!\UDX<&Q+N>+35O6#.*3ETOQ=""3?+EN+ \@M KD7LB7)=E/&XAJ*$>P+:W
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M26/;&,!JIFQNG"DXG6!H5N48[1DK6]JSZM&.LA?K*QL5[9V!$]FY=HNY.X#
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M;"---5W_ *DM@OJLDKIJ+R17PJBFWU7L2MX>'_KQNDO;T11[N7$6^HO\D%K
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M8U,KV-PP6F& RV):[W(%@+W)!'*G<4:A+*4;BY,R@@@JQJ%20Q( RI;4DZ:
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M'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1*>.C7Y3[PSW^\>C_\
MQX,<PX?V7C^^P_U1F[$>Q,!WN(^M$N'YNF&.(CB(XB.(CB(XB.(CB)QC&,>/
MQ8QCQYSG/BQXO'G/]N<Y\7_SG/\ ;G/_ ,\1.>(CB(XB.(CB(XB.(CB(XB.(
MCB)"[PA7XHMJ?ZFN_P":$+Y[;H=>W#9/>[1^R\;/*\-O:QM/]R^T,).W@]?Q
M/J>_53G^9<RY'1$]N.V>[@/LS!1P)]K&S/WW[0Q<F?SQ4]5'$1Q$<1'$1Q$<
M1'$1Q$<1'$1Q$<1(H]D^MQ/L@9KD04L$O":TB+&S"4@8Q4=#"4FDDLF,.4K
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M]*J)M&F@X#5SL)G5BF:6+1>;90)>@I:1IE4EN6?-&>SQK_WAOF81&*Z:#_\
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M1&$EIJ[,.7L-M<9' B#TE8U:V4V>H;"L011S-O%*[NC4 I +Q3=N*I:_%<
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ME/P%\D?@_72+XB]TOFWM/^MXWE3](_A-Y8S#K*?@+Y(_!^ND7Q%[I?-O:?\
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M=-NJBY(A476Y)DW62=M%$EG+9)-1-TWWTVSJLGG9$_5[*HP-."(P1D8%A)9
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M?^^>@G_&8SR.<]P?.9=O6T^XWTC+N>3*1Q$<1'$1Q$<1'$1Q$T7:_7&JKF-
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M1Q$<1'$1Q$<1*^O"F?B*W9_J:L_G)7W/HG0H]ONP^]VK]C;0GBNB'[3]K=W
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M9TGH>>T_9'_4/M3&RP+GSR>TCB)I*ZNP]5=>V (K:Q.4A1<C)-@PLD!K*S[
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M'15ALJ0V:4^C1A4,1V9DL:LFVJEN#\/FFV2"FS%37U?L^;\=K[XT_;W/OO\
M=!J4=B&ULB@$?INKR]*K[#L&;.)WN>!SX;HLWWW*;,*C0HPV'+;,'6$T&>JU
MLBL$4=]G"FP[;3#?=\WX[7WR=.W?N?\ /W1(I1V(9VJ$ Q>FZO.TTYV%8D%E
M&+W/1R>"-%\J8,[#*G;49(A!S8;KA++'5>U0GK;*F^%=A7F\94?-^.U]\C3]
MO<^^_P!T2>4=B&-I1\%$*;J^14\[V#XDUCG+W/1:<@]'#E70[L)JII1DH$R'
M84TU1<#M7%I1_!E951LML'U1PY5?-^.U]\:?@?\ ,2Z4=B!]G1D)"*<J^45$
M]V!XEMB2&]CT/F\>U=$ET9#L$JYG1LO%2?(<3JW(#-75G1GUZ]65&+[ TD-2
M2[YOQVOOC3\#_F)K*.Q RRHH%@%-U?+JG?[1_$SL&2WN?A$TC6CLVX;2;8#6
M3&C)J+EFP./Z-BXG1W9<4Q(2:ZH-QO'T&^IMPU_!_P"(T_ _YB=RCL0*L2*!
MZXINKYI5S_4)F:3N57N>@,PC.[HX[:R'4!7 ^C)X-ENH>/)LC S9Y8D3R=*.
M5P2^H-NTT..WX_&D:?@?\REKJ'(;P#>&'\,TSJNK*]GT8*65T&1L0[,KB,UL
M7AHK'7-1+1_%HZ,J"QVT\>;#US#S8:0D,%2U=#6#'!+=,JL^%1S_ +!?Y?AG
M1K9$UULW-_ZCVY=+8TH[$!IG%AM5TW5\]@3[5AF82V8WN?K:21O=4JH@2U!0
MH91ECLI5JR#83)-=W<SBV2#_ 'V$J:,$4\%5)_'XTG/\?C6+,E'8@)*8PQJ2
MFZOL.'/M6^9?))K>YZL#L=WW(X1<Z@XH+HRS&DIU0%^-^CL[E47RX>?]MVU;
MI9]8X?C\:1IS_-?[Q%HRCL0#D499T_3=7V/%WNNN9<>G-[GJK,1[?+Y-+?4)
M'!-&6DVE&NH[*KS&SJ11C.SK31AY.J:F7R;\?C2/Q^-8M>4=B !B--J7INK[
M,!/=5<RPK/;W/5*1C^^KINFCJ%#"*-M="3849[N7*FSHS&O-+H(M,:JZ.-G3
M=^/QI)TY[_!_R(MR4=B(^1C:-)4W5]H"WNKO,K?V!>YZGW@#=-=IJRU##@]&
M6XG)=7+=1ZLXV=$8WEHJU;H::N]7FZ[1^/QI(TY_FO\ >(N*4=B(ZO'=*+IR
MK[5;/-2692M8M['J95 [([L,"M0[<+1MQ:R3!!-4EN]V<KQSU9LR::):DL$%
M-Q[7F^>WW&-.?YK_ 'B<W+*.PT<S'<4/3E86QJ\P6]J<V/>IZEL@<M\C?4N
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MMZ0.ES&&"&J2K/9:IQ&22BFZ*NH[">%5'S_CM?=&G[.Y]U_OG!:3]A&]2#9
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M)'H&U6?INS188=J71B[PSPXPY*32, V^F"[M%JY1E-K]WNBP!U^'3]L]]OW
MZ[LT "<ZMNL:QD$H-&@H")32U*OU/%5!5C22KVKMA@!,3HMZW,RN,OAC71H2
M7=#RV^(P?;B)<U(@62+'J?(>[)-<2(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB
M.(CB(XB.(CB)5)X<?\DSWD_8YO\ Q3&^)9/7KWR_.)/_ *__ .0])_LCK?\
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MHX\WMOKC*+'J0)NZF#\\(U8"MVL#5G!]GVI>N1,^BA&>"MAF-,DM2,09EEI
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M M)LDST13'10BZ=/XVQUTPV!/7*[H6DU7644V1-=..N-+O;.:6X_@$;(RX8
M# 0FQ ('>BH[L#EDKFS*01T8X8*(A9;M(IK(7SF2C\H%%]WV^=E\*;*J*HN?
MQV_^TWAQ$<1/C(#AY9DY&E6+,F.>);(/&!!J@]9.T=O%Y2+EJYT4072V\6/*
M353VTSXL>/'$3R6D0B; ,YCC&+QUE'GOGO3 +0(-;!G?I.NNKCTD6BVT8K^D
M:Z::K>=0W\[KKKC?RL:X\2(91")C0[N.CHO'1\??^D8? V04:U#O?2T]477I
M8Q!LFR<^DHZ:).//(;^>3TU34\K77&,(AA$(F*$/(^,B\=&@2/I." 1@%&LQ
M#_TQ#1L[],&MVR;)UZ4V3T;N?/H[^?0TT25\I/7&N$0.B$3#B7P$3%XZ+!D_
M2?608<$&LA)#TQMHS=^G#FS9)F[]*:)IM7/GT5//MD]$%?*2UUUPB!D1B848
M]"AHQ'1(8EY_)$2,"C6 Q_ETWU:.<O6#5LDU=>D-=-&R_GTE//-]-45/*3UQ
MKA$"HA$P8]Z("1>.AQ)+SN2(P4%&CQ[_ ,^AALOZ:R:-D6SKSS;75NKY])3S
MB&,);^-/&->(G(F(Q, Q># 48CP4:1SOD@/$A1HUB^RJCZ.IEXT9MD6[K*C?
M_ W\^GOY:/\ A;>/3^[Q$X#Q")QYH\'@(O'0; CX\D&0<*-&-'WE)91V],;,
MFR"+KRD<Y2SY_3?QI9RGG^YG..(@-$8G'&SQG'HQ'0+,AXLOVH8*-%MGV<)[
M)8R\08MD$G/B2WW3QY[7?_#VVT_]NV<91 2(1.-(NVT<B\=C[<AY'IZ 0(-%
M(OO(TW3T]+28-D-'/D:*J::>>UW\G13?7'BQOMC*(!1")Q?1VE&8O'8ZF_\
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M:99#W395HU]&:**-6_F$4_,M]]T$_)2VVURB"$0B9<2R %8O'28(9Z-ZM"D
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M!%C\&G=%^;X.6\C?UYNJQR3VC$B$_DLB>C/")7;UR+C/NBIVI&RU8%.KUGW
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M' [7R2D=-'W0HJV\TY4_Z9ZW51\YY"GD^7IKG&?%[/PU'#U:B*V95!%W)&K
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M(@6]V'BF3PF]P@Q:KN$Z/42F 7-KZ 6))-KV"@$G34V!L->271'<D*+V%R=
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M5B%]<0#9>7EZG(3KS GF,V)R\K'$1Q$<1'$1Q$<1'$2%WA"OQ1;4_P!37?\
M-"%\]MT.O;ALGO=H_9>-GE>&WM8VG^Y?:&$G;P>OXGU/?JIS_,N9<CHB>W';
M/=P'V9@HX$^UC9G[[]H8N3/YXJ>JD;[U[+QVARL?#%(%9,]?&X-:%G/$J[90
MY[O&Z]IU2#)3Z4F$99-8>Z?I"]K#C>6H.)-Y/*R^%7>!0!WNUVTVXU:PI$ J
M[75WX@4V6GES$W92;9AHMR>I.M.D:@)#*MF1!FS:M4S90,JMRY#<FP'.9E O
ML;0!EP28C[KJM4F#A>UC2 *K/(RT/1N!I"!IYS+Y,!=DT#$;C[$*8$DR)0XR
M8-!K(DQ</U6Z;I'.]A5I$D"HEPN<C,+A+7S$$W L023:UQ>5-.H+71[%LH.4
MV+7(R@VL3<$6%^28@'[D]5I!+C,)"=@JA*&0,%VL@DLQL*)N@J4.;%I8$+EM
M#R);<0MI&GT)D.)4DD[V5C+=JB[-ZLFSMLHI48B@S%150D+G/&%LMR";WYLI
MOU!J;7%[&A6 #&FX!;*.*;WLI M:^H89=->:\RO/97KGK#,6-M?M+:U[M('$
M3UG6;2@^(=M*6C51ZZC>)-DYZER>;,D5GK@1A[ZP19I*.E&^J">RF)-:B%SF
MK3RWRYLZVS<N6][7MK;EMK(W57-EW=3-;-ER-FR]=:U[=ODGV&NPM!1LF8"R
M*[ZA F8\';2$^),V3#1A,( >[1W1D;+L'IE%T-$/-Y?$]&A%XDBS<[2B/:H+
M;Y-#<.9-:D"0:M,%1<@NHL#:Q.N@.9;$\MQU9 I5" 13<@FP(1B"==!IJ>*V
MG:/4,PV/=L:-D%K/Z@3L2#L90L.@A:!:/)S$=,VT-G\9=RP6^K)EJ8R0ES-
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M"P"3 $+' VYH+;\H<I3N-F7Y+1W+X4G.%6D58U,J-=505*=)<X 1AG5J;$
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M-D+8LO+.$B6B@"#,&C_:-"9.%;-4-U)<N0Q/*'J*^[913];8;LG._%&B@'*
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M2,>H4B4,^6DDKKK.JMLBDYZM"AK[*>CJ+3:PFJ&<O90(41HV'J9F=;7>O2+
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MV/3MPG]T_P""V?YI'O%.X/Q82^P-:?1_'J<\#O<@^,-I^>QZ=N$_NG_!;/\
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GW=HX6K@\9CM]AJV3>4_0V#IYMW42JG'I8=*@M416XK"]K&ZD@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g320192g46g27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g46g27.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[3K^4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300]     !OD @   "!N:5<
M7 !< %  2 !8 $8 0@!5 "T 30!7 $4 +0!& %  ,0 P %P 00!: #  ,0 U
M #$ +0!8 $4 4@!/ %@       $$  ;< -@:4_\  @$  0#J"F\(9  !  \
M6 (!  $ 6 (#  $ 3 !E '0 = !E '( (  H #@ +@ U "  >  @ #$ ,0 B
M "D
M 0         !     @    $                              %!225;B
M,
M                                                   8       0
M)Q G$"<  ! G          #  )0#
M P        !$%Q  7$L# &A#!             $  0
M    S#ZV\ 4   #_  $ _P    ,
M
M
M
M
M
M
M
M
M
M
M                                      $                   #
M    4TU42@     0 +  6 !E '( ;P!X "  4 !H &$ <P!E '( (  U #4
M-0 P $0 3@ @ %  4P   $QE861I;F=%9&=E  !086=E4VEZ90!,971T97(
M4&%G95)E9VEO;@  1'5P;&5X $YO;F4 4F5S;VQU=&EO;@ V,#!X-C P9'!I
M
M              !$%P  ,4Y26 $    ,%P
M                             &D=;X<%  $ RP80     0 '(,(3Z ,
M    35-#1@    "N!@       "P          P$!  $    Y,   4@    $
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M  0 $ !R '( ,0 Y #( ,0 P #0 #  $       -  8  0!O".H*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                     0 !
M                        .$))300Z      %U    $     $       MP
M<FEN=$]U='!U=     <     0VQR4V5N=6T     0VQR4P    !21T)#
M $YM("!415A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @ "@ ,0 Y #D .  I
M        26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L 0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    B
M %P 7 !0 $@ 6 !& $( 50 M $T 5P!% "T 1@!0 #$ , !< $$ 6@ P #$
M-0 Q "T 6 !% %( 3P!8 "T ,0 X       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'CP           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4W1R1@    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'1 20P\F=5$P     !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG   "
M^P    QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P   D8    +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P
M  $  0/      0 !.$))300F       .  $     /S(>(3^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             &!0  !UP
M 0                         !              =<   &!0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   &!0    !29VAT
M;&]N9P  !UP    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P  !@4     4F=H=&QO;F<   =<     W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      $N34T
M*@    @ !P$2  ,    !  $   $:  4    !    8@$;  4    !    :@$H
M  ,    !  (   $Q  (    >    <@$R  (    4    D(=I  0    !
MI    -  /.'P   G$  \X?   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD ,C Q-SHP,3HQ," Q-#HR-CHQ-0   Z !  ,    !__\  * "  0
M   !   '7* #  0    !   &!0         & 0,  P    $ !@   1H !0
M  $   $> 1L !0    $   $F 2@  P    $  @   @$ !     $   $N @(
M!     $              $@    !    2     $X0DE- _T       @
M     /_A 3!-30 J    "  ' 1(  P    $      1H !0    $   !B 1L
M!0    $   !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0   "0
MAVD !     $   "D    T    \     !   #P     %!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$W.C Q.C$P(#$T.C(V.C$U   #H $  P
M  '__P  H ( !     $   =<H , !     $   8%          8! P #
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!<P'% P$1  (1 0,1 ?_$ !\  0 !! ,! 0$            ( 04&!P($
M"0,*"__$ %80   & 0($ P4%!00'!04$"P$" P0%!@< $0@2(3%!46$3%'&!
M\ D5D:&Q%B+!T>$C,E+Q%QE"5V*8UQ@D,W*B"B5SDK(G0T=3*#0U-E1C>).7
MPL/_Q  < 0$  @,! 0$              0(#! 4&!PC_Q !*$0 ! P(#!08$
M! 0$! 4"!P$!  (#!!$2(3$%$T%1809Q@9&A\"*QP=$4,N'Q!R-"4A5B<I(6
M)#-30X*BPM(UDP@7-%1S@[+B_]H # ,!  (1 Q$ /P#]_&B)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O*!_;>+PEPE;'/T[*##
M'>7<C4*XTEK5%[=/2V-:K3\KP5-+ 6NF1%90LE"3REB.?J%VMU7=N96*@;)5
M,KN;":*(Y6(8BQ#&6:/M '-;I4 E1%F"[.LX0K[]QD;&&:9*U(1$A&XHA+;D
MF:DYFIUZ#LUT1L,W<7=PJC[(L=/1\,QD))Q"M?V6?66SD7?L/%AQ2)76=H-&
M2AKM:HY;,1;3!(XFN9?V#JV.>(W%N+8*Z5BQUI&W)95D)G%MGL-NG8"EU>WO
M:Y=4G;"2@6+JN.L:N7Z_M[Y(I X?R%QAS]JI+S),%!Q]2?9%9U&<B8C&ESBC
M+T>1P/9[TWR.O.6Q2$FX)8N0(^H5AW#RE.BB0$S+V.I2J3F55AU8,BG]HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB+4!>(#"!X16QDRO0S0J"L>@J^"RQG(1>6<E9QC<4_>/;^\2#
MLY&[- $A6<+&!-(AC#MK0_Q39V[,WXZEW8P NWS-9#A8+7Q8GNR:+7)R NMO
M\!6XQ'^%GQG%8;MV> 7<;VM9HS)O8!720S+BB*Y/O'(E0:@I%FFTQ4G&'*:*
M+)H0OO@&*L8OLS2SE&.3#?VBKPQD$R&434*2[MH4++8JNG%V;P?S6_DQB/%D
M=,9#.>*XU!M5M'5._+3S&SL'_3=^;"7X<QK@&+HW/0A8Q%<3& 9JJJ76/R[0
MU*T@WF7;B24L+!N#="O2Y8"=.NV753=D"*FE$8Q[NA_9.UVR?7WIN*N%FV-E
MR0&I97TIA#9'%^]8+-BDW4A+20X8)"&.RR<0#J+Y7[-KV2[EU).)"6-#=VXW
M,C-Y& 0"/C9\3<\P">!7<;<16!W;::>(9@QT9O7%IMO/'/;(9$T0K6YY6L3H
M2":SM-5L2+GT31;M50A4DW)D0YQ(X0.I8;6V8X2$5]):(RMEO/&,!AE,,N(%
MP($<H+'$BP=87S%ZG9]<TL::2HO((RS^4\XQ*S>1X; @XX_B%N%^17>1SQA-
MQ.M*PAEO'"UA?QYY5E#)W.OGD74<FHNDH\0:ED!540(JV<)F.4H\IT%BCU3.
M 6&T]G&5L(KZ,S.;C;&*F+&YF8Q!N.Y%P1<<CR*J:&M##*:2I$;78'/,,F$.
ML#A)PVO8@VY%7I[E7&,<$(+[(5+:ELJQ4*\=:S0Y"32QRE.1.,.+SD>&,4Q!
M+[ 3@/.3KN8N^0UM&W=XJJG&^-HKS1_S#K\!Q?%?A:]^&JH*:I=CPP3$Q_\
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MWF,-&^9\1EBDFBL0;''%#(]IOFUF6HO8;.KBUSQ25!:W'B.Z?ENWLB?<6O\
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M<#0?'?@>WNS*OM--MSM!L_;'9FJ:Z796SFT>YVML^:+:%+*R-YBIHHMS!&#
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M(;[SAC!)W;,KBX:VXN+'/D02" =+@ZH9'D6+W'.^9)' C+H1<<CF+%<DN'C
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M(0@"!2@ 1NX#8F&/D+QLTO<VRTN;V'$D\U(FE'_B/UN?C=G;+///EGP '!<
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M_7\?CJ; ?;A[^>IN<T3D#S'\O'Y:6]W*)RAU[^'RWVZ_+Z#MNL+6T'0^B(!
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M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(N"BA$BB=0Q2$#N8P[!_4?(
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M2G%D/KK[M8^=LC<>)O'[["T\2$7#(^R62K.+:PU=+;@;V,O*6"YR+EB<H?O
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MYJO('K\_#^'T/R)C.EAZ^'516XR,G95Q!@^7N>':R%BM*$Q#L'2YHIU/EK4
M]46"2LYH1D8JTA[F=-JQ 3\[&+&2+.RB+B+BWS=3G;7J:VCV;55.SJ3\=61,
M8Z&EPO?O"98V/.[B<V67=Q.?*8XG-D?@LTC,KTG9'9^Q]L=HMF[-[0;4&QMD
MU+Y6U=?O(83%@IY9(HQ/4M?34YGG9' )YV/BB,EW-=E?)N%J^Y'RC@JB7C+-
M9_92\33:4-)1H1SR&!VT9S<BPA9TL/('5>QA;!#-F,Q[JL<2#[[[PT*FR7;)
M$R[/FJ:BAI)ZRG_"54T+7STV?\F0WNVSB7LN '[MY,D6+=R$O:XG5[1TFSMF
M[<VI0;'K_P#%=F4M6^&BVA\!_$P@ XB^,-BD+'ET6^B:V*?=F:)K8WM D%R
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M$BRT^X^_$+RV8_M%5FKE!&+*^^Y; 0T*Q%@'/P-C;;DVM/M.%^S:F@_PZI$
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M>1-:B2T]/TFFSMJ@S5BSS54KTO8ZT8YU#5Z>DHAF\F((RB@ =0T1(+.6!CG
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MF!<QCANA$':QDU6_;?=9U$A^\:[,1<TP<*?O241)Q\H@99F\;+*896!C@ "
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M26_LC-IV(8G.;]Y#VB1B&-@DADB-GM(Y'5IZAVBNU[7:&_SUY>[<5NSE+OT
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M71[[_EZZ'IK7E+_A+UZ]N_7L >'0>GRZ;]@'$Z>_*_"^J$\N[Y^?6V:B!]H
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M0TMEX'DG7ML.V_E\-O0=N@#X;!OU[Z6=RZ:<K<]>XY<E%V\^NO?WV\,^'1!
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MI@FDH<$SGWO&\QO:\:M.G,<1XC)01<$<UF.-<>5C$V/J5C&E,"QE4H59A:G
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MV0GE<_\ F<,^Z]SS[LN!3_5W85_WC<6/_-]Q%?\ 4/3?.Y,_V-^R ZW_ /\
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M<O9U\TZ]/S'RTL> /3(YCWX*+#D/WU7(G4Q \1, =O'< ^O#UVT#3<9'4(0
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MK_[ ^/VXT\X>Z8^XU*-_I0JY=BI,F>?L,Q\?7<D1+-)(03*\NV,EZK;G*BP
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MNH[_ '^WAW+T=33313(DD0B221"IIIIE*1--,A0*0A"% "D(0H 4I2@!2E
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M0<R4E14:[?:\TFF[1URA(0SX1.UFJY+IEZ(35:FFTA S+</_ -7E(YVD B!
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M! J?O4W=)!=T!G!=RR>7+Y\??)%Z :A$T1-$7$YRIE,<YBD(0HG.<X@4I"E
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MVMD<_(!CA=IU7C%>E3W$2:;P=')LJ&RHKAC>WD/%.82KO9A9R8\2U:,56S-
MLB00:K&,DU0]JFV>*)@;9TJOW-M-VE2]D/PW::8R;4EVHV79<=1.RIKHJ=K
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M6;F3^F_\6=J:GM#3;,K-G1PP54U/!4;'EI&2-DIIL#9I'S2,,A&[<Z3'BW#
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M#RQ GR%SZ*UJVB(3WY555Q#P21/^0J^R ?QUD%/*=0&]Y'TNM=VT:5NCG/\
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M-P582BB: R/B^Y5];G$3F=1+H?9[@;?,R%TF0( &I)X$FQ U/RTN<UKS5+(
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MI=7ZC&<%MU?%MS>T&11*;D[^[FYBNM]O]GW45N?_ (.;?5H[XVVYCRX^BQ5
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M-_\ NYQ_\P]4A'R.(E__ )F^P:TI*=S<V_$/_4/#CX>2ZD-<Q_PR_P MW//
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MY '9//N5<PLQEI$2&6UGCQ!@! N+\;@W-\C;E?NRZVTYW-?*Y["2'6.8M8V
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#O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g320192g50j92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g50j92.jpg
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ML[8B(R0G,S1!47%49'B!H?!#1V.3)3)$@Y&D)C=%A-3_Q  ; 0$  P$! 0$
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MY-;#R910 B5&+/![9RW9!R"CQ9\Y:LV2B239VY1=.V:*XFSYMV\R6VE<7>2
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M.[#;WDH#(R)VPDD]RY^D=2[['SZ"C6(5QS$8;09Q&TBC(#1(S=1<C !\_C@
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MWX[BI^3.\_V $?7"MWV&>%G=6H?&%;T,Q/91X.=!K?[%3])'WX[BI^3.\_V
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MTV?M0TU^_P!KUE:%V[I_ZZ\J9I:9VIJ_P=7^D2%*U3-% * 4 H!0"@% * 4
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MY7E>T&ZOYD[:81YG)HYQ>$E9+'41QA5A\9$?'<6M9\CVJF1%P->V!*%[SQ<
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M-6G"\TUAJWNY+"KR6)YK"LH.UXYT..\$<X[&]8@&<[$HW@$*XD15\X9Q"[/
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M?M0TU^_VO65H7;NG_KKRIFEIG:FK_!U?Z1(4K5,T4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4!'Y[):]&LK[?-5_1);6;K7M1^$A]YI:J[;7@Y_<>_L;#T9
MP7VV[8^D ZC5/:K\+/\ E$:U[;?@X?>=]ZTS-% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0$?J.?A(L^_1X,_XUA59L??2?S5>5$T
MI>]</G3\F1(%K2,T4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$>OHMO
M2K]-G[4--?O]KUE:%V[I_P"NO*F:6F=J:O\ !U?Z1(4K5,T4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4!'Y[):]&LK[?-5_1);6;K7M1^$A]YI:J[;7@Y_<
M>_L;#T9P7VV[8^D ZC5/:K\+/^41K7MM^#A]YWWK3,T4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 1^HY^$BS[]'@S_C6%5FQ]])_
M-5Y432E[UP^=/R9$@6M(S10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M1Z^BV]*OTV?M0TU^_P!KUE:%V[I_ZZ\J9I:9VIJ_P=7^D2%*U3-% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% 1^>R6O1K*^WS5?T26UFZU[4?A(?>:6JNVU
MX.?W'O[&P]&<%]MNV/I .HU3VJ_"S_E$:U[;?@X?>=]ZTS-% * 4 H!0"@%
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MOHMO2K]-G[4--?O]KUE:%V[I_P"NO*F:6F=J:O\ !U?Z1(4K5,T4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4!'Y[):]&LK[?-5_1);6;K7M1^$A]YI:J[;7
M@Y_<>_L;#T9P7VV[8^D ZC5/:K\+/^41K7MM^#A]YWWK3,T4 H!0"@% * 4
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MT>#/^-856;'WTG\U7E1-*7O7#YT_)D2!:TC-% * 4 H!0"@% * 4 H!0"@%
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M+CE4A/"XNUE1=&2R?*GB3YTDURG&VO!QDF[TY0<L6=W659/-/_5&S^5O?O\
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M/[CW]C8>C."^VW;'T@'4:I[5?A9_RB-:]MOP</O.^]:9FB@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"/U'/PD6??H\&?\:PJLV/O
MI/YJO*B:4O>N'SI^3(D"UI&:* 4 H!0"@% +WM;Y;]KY+>?_ #O?M6M_SO>U
MK?YW\U ?EKVO;MVO:]K_ .-O/:@/V@% +WM;Y;]K_#S_ .=_DM_SH!0"@% *
M 4 H!V[7[?:O\GFO^:_:M?M7_P O->U_]+VO0"@% * CU]%MZ5?IL_:AIK]_
MM>LK0NW=/_77E3-+3.U-7^#J_P!(D*5JF:* 4 H!0"@% * 4 H!0"@% * 4
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M)Y0C96>*2986R-8&-9[3YD;5TOKU05L(9HW39S4<C;PTC)V..RI5(]]MMBD
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M'O[&P]&<%]MNV/I .HU3VJ_"S_E$:U[;?@X?>=]ZTS-% * 4 H!0"@% * 4
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MZ^BV]*OTV?M0TU^_VO65H7;NG_KKRIFEIG:FK_!U?Z1(4K5,T4 H!0"@% *
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M/:K\+/\ E$:U[;?@X?>=]ZTS-% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M5FQ]])_-5Y432E[UP^=/R9$@6M(S10"@% * 4 H!0"@% * 4 H!0"@% * 4
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M/O.^]:9FB@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0$>OHMO2K]-G[4--?O\ :]96A=NZ?^NO*F:6F=J:O\'5_I$A2M4S10"@% *
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M#W4;97O>-FDU%V:=FU)V:3;3WK)F:JL*Q0"@% * 4 H!0"@% * 4 H!0"@%
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MZZ)WYNWV_P"=^7M_Y_TS_"FPJ]UU_P!FAYDG;4^YJ/75R_B?S%]12WUT3O\
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M:M>W;_OG^/RW_P!*;"KW77_9H>9&VI]S4NNKYP?%%+?71.__ '?]/]\_-?\
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MF9>[&P]&<%]MNV/I .KM4]JOPL_Y1*M:]MOP</O.^]:9FB@% * 4 H!0"@%
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M\>.6%/$HVE:3L[]Z+S(ITXS4FYJ.%8FG&3RNE=6[\DK'W<\K= #7<S8&]DA
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MI .HU3VJ_"S_ )1&M>VWX.'WG?>M,S10"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4!'ZCGX2+/OT>#/^-856;'WTG\U7E1-*7O7#YT
M_)D2!:TC-% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!'KZ+;TJ_39^U
M#37[_:]96A=NZ?\ KKRIFEIG:FK_  =7^D2%*U3-% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% 1^>R6O1K*^WS5?T26UFZU[4?A(?>:6JNVUX.?W'O[&P]&
M<%]MNV/I .HU3VJ_"S_E$:U[;?@X?>=]ZTS-% * 4 H!0"@% * 4 H!0"@%
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MQ[^QL/1G!?;;MCZ0#J-4]JOPL_Y1&M>VWX.'WG?>M,S10"@% * 4 H!0"@%
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M6BXM-W=E9-7=WDN^4Z)[\TC/K1_.!;8U].D93("43 NH5*PTL9/Y,'C+F9E
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M$YY-.V3+%6IJK*;E"<-I"JDU5QMQQ>XMA6);OSCP9IJ^:-L^1<;V,GMV %X
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M(!X1^^7U=(PJ+EQ(6+Y%)F3,1-UC=!Z78K\.A5:=KII3<+3:2F](G-.RDE?
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M&+PY*"DK7OB>)WC=)>IU*5G3C*:INGLXWBKI[2G4<I+%QL;BT[6PK"E?"7C
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MWTG\U7E1-*7O7#YT_)D2!:TC-% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4!'KZ+;TJ_39^U#37[_:]96A=NZ?\ KKRIFEIG:FK_  =7^D2%*U3-% *
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M?.> [B:B]\*S)'4.PH](&1<1NB0"@44.(9XZC$SVZ[9_ 8WL)9HDS%RLM+'
MZ:8/A;1.=%<&P\<JEW#%&6C.2J8MG---5&DMU-2R:C)K)WM*_NCB=G'2<+IX
M<<6K;--R5L;C;C..]Q4>+;W*S9].C,#3X(6V#>8QZ6L4S.I]'NEB!F([&A:C
M.2L26T\C4>VRGL0"$QV-RE;-RX[X[=SQ#P<)/$6L/37AL)2#!U96T-23EBC)
M7ITWG&4>->=U/%&..MTE2.4\LE97C2G%X<+B[3J;I1ED\%G#"W@HY?FZ<KRC
MQN-*[P];:]YXQ0"@% * 4 H!0$?GLEKT:ROM\U7]$EM9NM>U'X2'WFEJKMM>
M#G]Q[^QL/1G!?;;MCZ0#J-4]JOPL_P"41K7MM^#A]YWWK3,T4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 1^HY^$BS[]'@S_C6%5F
MQ]])_-5Y432E[UP^=/R9$@6M(S10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% 1Z^BV]*OTV?M0TU^_VO65H7;NG_ *Z\J9I:9VIJ_P '5_I$A2M4S10"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$?GLEKT:ROM\U7]$EM9NM>U'X2'W
MFEJKMM>#G]Q[^QL/1G!?;;MCZ0#J-4]JOPL_Y1&M>VWX.'WG?>M,S10"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!'ZCGX2+/OT>#/
M^-856;'WTG\U7E1-*7O7#YT_)D2!:TC-% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4!'KZ+;TJ_39^U#37[_ &O65H7;NG_KKRIFEIG:FK_!U?Z1(4K5
M,T4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!'Y[):]&LK[?-5_1);6;K7M1
M^$A]YI:J[;7@Y_<>_L;#T9P7VV[8^D ZC5/:K\+/^41K7MM^#A]YWWK3,T4
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M2K]-G[4--?O]KUE:%V[I_P"NO*F:6F=J:O\ !U?Z1(4K5,T4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4!'Y[):]&LK[?-5_1);6;K7M1^$A]YI:J[;7@Y_<
M>_L;#T9P7VV[8^D ZC5/:K\+/^41K7MM^#A]YWWK3,T4 H!0"@% * 4 H!0"
M@% * 4!@#E7%)[.>-N[X?J_PK.?236LJ$1IHP,8QTB5>O!:Z2@(9(LW++"/%
M) TNY"##V;YA@%?OVY/)^RQ:W=(U5XRE1J1A[IP:5LGNW)\C:R3RM?>BRDXQ
MJTY3]RI1;RNDK[VK.Z6]JSNE;E-(I'I\3/#.HGO';2VSN+8*+8;:7D!"&ZUB
MND#BIY33N0:(LU6-A3EVNBR+)"PF!A,:D/+YCFP<4<-Q?X1;N/,Z:DX;&G4H
M)8VW&"IN^"T5:W(\KVL^1M'H51P515)PK2>#"I2=564[O.]LU=VO?.^3L6NR
M?=(25EIXHJ;DD>FJ>M&Q37<0>:\>/M8RMXYX>#UU THD+55#7<*/M>6SLV]?
M+215K-4DP0N/#4'6MR^5\N5V6VW>2E@O&+B\#_,+)M<6+VUV[\;+"N*R?^G2
M2LG'&U*6*TU^>WI.\Y+8VMAXN;;6-']DP6^U]G<:]B:]'\E2L$CD9V1'-Z$]
MG"!XW=WW-2:><7"9(-"<'HMKA@@O)(R2,R%G\%Y$R^O([MP?IX@U=YZQ6OU:
MKBI3@JKBHR51U%^<PMT6U&ZYU=JUW%5,&> B]/#6C)T\3<'3P-[.ZC65Y9_]
MLDEG93<-HGQT65%ISR\F3*3R& F>0IT/B?W*#VP\)!XCX(R 1OG1KV) ,.-W
M?!*+4I+!'%07R&2;8A[&".4@81'"4)*SS[G6BW"E7EB<'6:Q34V[6M'2HQ6Q
MNLY*BJNZ^=L7&PHZ<:,<*DJ2=J;AG+?*A*3VN=TG5=+?9).5GAN7T[#\O"-D
M7\8OMIF.S&[; :XFTC 1FVY0T ,\E.)F46^ZE>0 73UF:R@++=!,0+E@M0F]
M@X80]V((>2U@YQ3ZM7>:QKW<:<FEM%!UJ%L6)7NXJ;2DKX4G)8DSF]%7O@;X
MCE%-[-S5*O>UFKK$Z:;3LI-X6HLR) =?[H#\G]1GIZ7WL<A,.3YC:U!&7)%T
M4&O19W8.@Y9IM79%A+---^)?18+LQ@.EY]NG9;*)Q<85+9G'+'X;[A"HJU-R
M=5QCMX)[TTY4I0QV6:PJ?&>_"E>[LXE*#HS4=FI2=";5DK-1JJI@ONLW#)?]
MTFE:]L33WCWO<;RQVYR&@,'"OR2N_)4\UF]2AX@9*\S)'HU]=:P@LTE6QUWJ
MY&2:";[4&'8)(]:XL!+1K/E@&PGA==A#7;!Q7.E4V]2K&*;VCP/"E)2[$C",
MI3S<J6.\7"UE*TFVHV.XU*;HPIRDTMG'&L3:LM*E*48PM95,#4E.[XMX6XUS
MW1%3E4VBD+<3>8\ES<")3MO\8[2)ZT. ]VQ,@EJ(SBFQ:.9"S?&I#!RVU\ [
M\P^@PM:)AC^35D**9Z><GV8M';X8XI5G%RXZC!JI'\V\DY*[BYV;<;Q3LD\%
MT0]C>2C&FI**P.4TZ<EC6^UDI8$UQGB:S_26;M[94MYD0L1RHG9^>[-BSN*@
M-YN(S'V, 2=!%HI]W09'CY((1-RN*NGVTY'Z_P &N1<2SLY=%92>E[?8 N[(
M1'W8^)2TB*K3<IQPQJM)Q;6'$MDXR?YO$HVNE=MN6+)(F"HR=&*C!IRIIMSS
MOA>T4HI*IAQ+)[DL.!W;O<C*+<CR&PH9/6B_(E]%8ULW>(32&$]\.9G,PLCT
MGJ9Q#%MZ@&#%F83A3K?H;;H]H8E@]ID-@JD:1?.60Y\'55FU9RC);;#&=14\
M::=G2AAVJ2OAVJJ*\K<7#R6;ANFHN/YK$X0=3#:UU4GBV;W8]FX9)YN]L[GK
MA CEI,',1 X2GD]'(":+<>FVS)!.6D:CVR!DURB>^U^2;:.N5(_E89KYR_1T
MD.2*QMC>'LCKP@OIPLV1P</VLQ5>3BKUE%NEC<[*:DXU75MEE%/9JZ6%/W#(
MFZ*Q-1HN253 HW<<.*GLKY^Z2VCLWB:MC3R3ZYX8]QACAW66?<XXX]UG?MYY
M=S:UNZROVK=O*_:[>5^U;MWO>_:KWGC/ZH!0"@(_4<_"19]^CP9_QK"JS8^^
MD_FJ\J)I2]ZX?.GY,B0+6D9HH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@(]?1;>E7Z;/VH::_?[7K*T+MW3_P!=>5,TM,[4U?X.K_2)"E:IFB@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@(_/9+7HUE?;YJOZ)+:S=:]J/PD/O-+57
M;:\'/[CW]C8>C."^VW;'T@'4:I[5?A9_RB-:]MOP</O.^]:9FB@% * 4 H!0
M"@% * 4 H!0"@% * 4 H#6[??(6$\9A^O,S4=*$6<[V TCCE"+H#4DH9''BJ
MY&;;:E"2[AGBV@L(LX0)3,HUQ</$EC+*^#9RY?6ME35JQHJ%T^-+#Q;<5;Y3
MES1COD^^N<MITY5<5FEAC?._&:7%A')\:5FHKEL520<H=$169'8'(M@-0Y^,
M#)*7DB[T))TXL 8PV)CIU+<C4[^!+P88ZC41,A#YT>]D2) 6P/ ,WK5',X)P
M>2ZU*,G&4K-)MW4K+#%2E>5L.46FU>ZNK[U>%2J.*DHW3LEFL3Q2<8VC?$[R
M32LL[.VYE >\Q^.(T)8Z1V$LP2^'#$;5"/83L%K-FIT!&A\U,BW^O%XIA/!S
MH?""H^<KX/HVWM:$.DYCCEE&NZ*8QV112NY\K5L,\5U'$UAPXEQ7BW>YXV[,
ME4:C=E&^2E?%'#9MQ34[X6G).*L_=)QWY%9&\E]7/I01BMSS5V0RFPV'Q9.*
MI&9TZD:+_6^IMD*29TSB80GE&HR/'[CAZ1*2&%,(L-:&XR4)R%CA*!K2TJM"
M[5_]2C&UY.5X0G>R3LDJD;MY)--M7(=*:BI6LL.)XK1MQIQMQFKMN$K)9MII
M+)EQ:0WE".0,0(S: HRM ,+FDX@;K"7Q _#2-S<!E!2)F5&S$^R9JNQRS\4L
MLS>-N^][P4N/*)C) Q+A1LTJL:L7*.))2E%J47%WC)Q>32RNON=FFE%2G*FU
M&5KN,9<62DK22:S3>>?WJZ:;RR[:-7[=5F^;-WC1QCW"[5VBFX;K8=NU^X50
M6QS24Q[=K7[G/&]NW:U^UYJL.#T4 H!0"@% * C]1S\)%GWZ/!G_ !K"JS8^
M^D_FJ\J)I2]ZX?.GY,B0+6D9HH!0"@-+.:;*=&!G'R.0-N=(N9+R'&"CX4+M
MG8FD&YR/):@W(74'R'9>K69&81X$D9%A2F=V0]ZB]*CA3)=#M+X*I^;25)JB
MHW>*LDTIRIW6SJNSG"\HJZ6=M]B^AA6U<K94KIN$*EGM*:NH3:BW9M;UDV:N
M0/QH-&;,Q:R'8B.P4P3?@AJO9#8M&Y)*%)H[V%(Y7 )A(PT[(FV)!'.'HG&!
MG,Z\CBQ>2JA;DYKE94NHFPHCMJ4TG/';L6$[IR4L<IPDU)M-84TW*UY-+%O+
M9;*I'*.&_9,XV<5APQ4XJ44G[JUK)V5[1W%E#>=VZ34)VA+V)Z,,(M&+:0EX
M\Q*8Q$8G/E0VQ1^[',QU5&XVZV,5@&&XH\]UO$TF.M9Y-ADJ'KFI'!9*3;SG
M..Y)PM)J.$Y8HX8[.5Y*,)6GM,4$G-QQIPBE"4E+.46\5K==CPQ05I7EM%9-
MN-XX,,F\"E@:D[SC%K=)+#<V5T=R.W=LKDG*85(4H+&X8),3P:IK4[BE'=N"
MXF$:!5M>[%;QQR5=2ERTFOA2I$JL6#LHPW'R$4($D4C\3,6DUU*M4G6E!X5%
M.7%>4U%)8986\5I;VVK9I)WB[U5*=.-*,EB<FHO$LX7;>*#=DDXVRL[W3;R:
MM>FL)L!PYT<EH,AM@E)[OM*<<C+"$EYZJ:&QR:,9OR@:["%PZ(W>?!$8>"HK
M\4N<Q9 QC0DJU>Q O+57KTHQ(.NH2CV36BIMO9TGA<FTI*5;$HQ>2LL&)16Y
MQ;WW(G%]CTI8$OSE58E&S<<-)Q<GO=WM,-W;>HY*QA&2BIAJ":\QIUK0QL9]
M*(DXT6QU>PV+LK>>T-="W.RK"6<P<I:[.;*^ BC1)R26?*-F'@*PCO%D!+T,
MCCVL:Y)TY5YP<W*.SPXIU9Q6-K%Q'.SWW[W(T=K#.-",E%*6T<W"%.,WAW+$
MHWY+=\L'?G)[=/'D-R'2&%<BNPH]L GA$3;^$Y+139!*"\.>/\\P#K,Y+LL>
M+C[F8S*0E10R ZD8OI3,%69:T9%MC@B7R=QQ4K5*.USO)2LI./%FXT*4K.\D
MDY2;2A"\I9V5U*1U3I0JNGEQ7%76+C04JU6-^+!WPI+C5.+&\<3:<8F7I::G
MK71'2!&@SV6B9$CN!^ZA[D4\,M3(]JKIW0:F-HRZ:YHOD&Z;U4ICAD+R33\)
MR?WM:RN3BU63<MEI36)/%>-KI_HJ3XML]]]W+<XBH[31E)*V!8D[6]W4WW^C
M>8_VSOKDDVA'(-\_Q"FHR[USTC(R&Q0/"IC&3P-]QQ?DANJ2*TUCLU;GR;N9
ML$GZ#_(&G%WC[!0"[B;T02&$'Y[B56M:K>SCATM12C*+6Q=H/$I7;ERVPW_T
MVMGU"G2<J:3::GHN)N46FJJ3G:+C;BNV_$MZDFFK?R0W9M2"RF9O)3-#&PW$
M!Y@;PPRB0F&''\JU_JT5PMY);6A&+:&1F7 %9XRDA"-Q]C#@\F4Q#R![CGB$
M7:2AV&.1^=I.,IWFYN->HL*B[P@M'JSCQ8M8[N*PW5F]W&S4JG"2CA2CBH4^
M,Y+#*;KTH2XSB\+6)N5LXK?Q;ITW7/)/>6QYCI(@9V@*B\!'\R)#ILF?:QV+
M.@6W8D<XN1?:,+&$Y!')4<@]R#S8<B/:X D8::?"R,A;!$6N3Z3"'#8IS&K4
MFZ;=11BM(=-M*-IIT%.*<DW%\9N*PY7_ /\ )"5*G&,[0;DZ"J)7E>#55P;2
ME&,FL*4WB2LK[D\OCISE)O'(9Q\CRZX(*;?Q[A<)9:/+Q68&IOM>&;?C,'6W
M?MT3-))*R$D;B=+)')<]>J/$SV0=35)QK/B[]].H\L+4JU2U*.2=J"V;C)RG
M&HHNI-2;O:G=OEM@>)MR1$Z5/\Z\VKUWM%**4)0E)4X.*2CQVH[K74U@2PM/
M9GB/N#?.P"0%'<;F/$6TXXZ:NW2PQ!0(G";Q"12<[+ QZ'.%7TCD'PSA@.&1
M]_?)S8>0:EKFG%D<!)44( W:/4JS:VEK2HPJ91<<,I2DG'-N^23S=_H>5=:%
M.-\%^+5J4W>2EB4;6DK)6WM<J:MRIWWQKU'G% * 4 H"/7T6WI5^FS]J&FOW
M^UZRM"[=T_\ 77E3-+3.U-7^#J_TB0I6J9HH!0"@% * 4 H#S/%4$6;M9TM=
MNU2;+JN7%E,TKH()I99K+65PO;-.Z2=LL[*87MGAW/=8WM>UJA[G?)6W\P.'
M,/V'"I"B.E(K>&P&'$N;<I@K>8"R_(#:I68:ZU:/XV[=;1B2[3V&5G3S96G0
M.ZM^1F(&,8@^EH3O-DXB.F#,1(IYL&'M<V,HNS56>PE66).K-RA!4IJ+G)RQ
MTU4JQ3PXDMR:4I21[W&2R=..VC1;BU3@E.>UIW4(J."<J=)M747RN-\,9/+N
MJM@&1DWX$--@;GF@R;S'3^Q Q"%SF<E&;DL$(MU$--RV=0$H\8N#FQ)6B@P1
MN9G#1])W1\62&LLQY563)/NX2:EHV.I+'*G-.,Y/.]MFY1>^<LLY)RO?OWXG
M%..DX81<8SBU*,=S_P!:C*V48YNT<DFKY6+LZ/QULW.9;%&'9RQV="@6G=$"
M3&QX[O#9.]H3.]]-2.TTMGRL :V#&@+:%R,Z'3AI.=ZUAKHQ&8;X7$AZ:S8A
M=^EGUHF/%-.6.*A33FJDZL95;U%-IS2PMI1<H1O&.7+<C2<-HM1P2<ZCPNG"
MG*-.T,$6HMN45FHSEQI6?)OZC5[CR"@% * 4 H!0"@(_/9+7HUE?;YJOZ)+:
MS=:]J/PD/O-+57;:\'/[CW]C8>C."^VW;'T@'4:I[5?A9_RB-:]MOP</O.^]
M:9FB@% * 4 H!0"@% * 4 H!0"@% * 4 H#5[=G$G5W(B3+G-L+2PX)^*B6:
MC'Q41+9)$!+$'L-^U=;%=.%8F5#NSN<Q: X>,(B3ZI(!BUBC*]A:BCIWEG14
MH0JRO-R:P."BI2BEB:<GQ6F[VBFG=<59%L*TZ<;0PIXXS;<5)WA[BV).V&\F
MFK.[WY(TF"]'[M1[LW9=M@3W*20/9PB3Q:439W*V9&691\IIR#P$;*X)#'&L
MD64$W23F&O8G*)[*7DND\0.!@24>RBI%@\',8KYUHM3'-3EBA.+BY-WDU@C%
M2C' E"I>*<GBE%I6MNPWO28X8X8X90LTE&T;J<I892QWE32G)1CABT\\2:O+
M;<)Q#&(R]YL>7;'D\QV&;*2TG(SZ@F. 6!"TEU0$T\S', (EA@U%#0,9 MR#
M7&Z[Y\]D+\L]?/U6"[$6.O5#C.<IN4VY-NR2S@J:5ENLHWYVV[NUDJ76>'!&
M*C')15VVK3<[W;NVV^\K)65[MV6VX$Q,</ #16PY,.Q"["UQL' VB$C'W9L'
MVMM.:%TNQ0B$RQ'IG(2H>C.A1B$G<AE[I'!DSF (BQ<L%@]Q//8L4HI3DK2A
M*Z2Q<2%*GQ96O&ZI)2L\U*2:W6Z[(D[WBLXRC:[PM2J5*CQ1O:5G4=K[FHM.
M][[.Z=U9;4 &2QEK)B4D#F-E[-V(&2*,1K5S'4]I3H]L8S&\'(U!O\*L1TGE
M!VXI^^2^$<1*S%@]6>+LLW[J^G#9IK$VG*4E=++')R:R2OQF[-\EER7=4YXV
MG:S4(0=KYX(J">>Z\4K\E[M6O99:KLX% * 4 H!0"@(_4<_"19]^CP9_QK"J
MS8^^D_FJ\J)I2]ZX?.GY,B0+6D9HH!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@(]?1;>E7Z;/VH::_?[7K*T+MW3_P!=>5,TM,[4U?X.K_2)"E:IFB@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@(_/9+7HUE?;YJOZ)+:S=:]J/PD/O
M-+57;:\'/[CW]C8>C."^VW;'T@'4:I[5?A9_RB-:]MOP</O.^]:9FB@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"/U'/PD6??H\&?
M\:PJLV/OI/YJO*B:4O>N'SI^3(D"UI&:* 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H"/7T6WI5^FS]J&FOW^UZRM"[=T_P#77E3-+3.U-7^#J_TB0I6J
M9HH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"/SV2UZ-97V^:K^B2VLW6O:C
M\)#[S2U5VVO!S^XYW]"?TL_!+AUP@&:9Y![>)PO8;;:&P9(L$:ZTV=*DL0YY
M87F+=6*Q2(F1.63C%LM?)OB]NX1[CM+))WRQ[?CU?INCZ/0V=634MI*5E&3R
M:C;-*W(>K6&AZ37TASI4\4<$5?'3CFKWRE)/]QUP\H/Z*+YQ1SJ0WE]G=>[U
M4T/I)?5S_ \/J;IO0_Q*7G!Y0?T47SBCG4AO+[.Z>JFA])+ZN?X#U-TWH?XE
M+S@\H/Z*+YQ1SJ0WE]G=/530^DE]7/\  >INF]#_ !*7G!Y0?T47SBCG4AO+
M[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^DE]7/\!ZFZ;T
M/\2EYP>4']%%\XHYU(;R^SNGJIH?22^KG^ ]3=-Z'^)2\X/*#^BB^<4<ZD-Y
M?9W3U4T/I)?5S_ >INF]#_$I><'E!_11?.*.=2&\OL[IZJ:'TDOJY_@/4W3>
MA_B4O.#R@_HHOG%'.I#>7V=T]5-#Z27U<_P'J;IO0_Q*7G!Y0?T47SBCG4AO
M+[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^DE]7/\  >IN
MF]#_ !*7G!Y0?T47SBCG4AO+[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1S
MJ0WE]G=/530^DE]7/\!ZFZ;T/\2EYP>4']%%\XHYU(;R^SNGJIH?22^KG^ ]
M3=-Z'^)2\X/*#^BB^<4<ZD-Y?9W3U4T/I)?5S_ >INF]#_$I><'E!_11?.*.
M=2&\OL[IZJ:'TDOJY_@/4W3>A_B4O.#R@_HHOG%'.I#>7V=T]5-#Z27U<_P'
MJ;IO0_Q*7G!Y0?T47SBCG4AO+[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1
MSJ0WE]G=/530^DE]7/\  >INF]#_ !*7G!Y0?T47SBCG4AO+[.Z>JFA])+ZN
M?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^DE]7/\!ZFZ;T/\2EYP>4']%%
M\XHYU(;R^SNGJIH?22^KG^ ]3=-Z'^)2\X/*#^BB^<4<ZD-Y?9W3U4T/I)?5
MS_ >INF]#_$I><'E!_11?.*.=2&\OL[IZJ:'TDOJY_@/4W3>A_B4O.#R@_HH
MOG%'.I#>7V=T]5-#Z27U<_P'J;IO0_Q*7G!Y0?T47SBCG4AO+[.Z>JFA])+Z
MN?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^DE]7/\  >INF]#_ !*7G!Y0
M?T47SBCG4AO+[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^
MDE]7/\!ZFZ;T/\2EYP>4']%%\XHYU(;R^SNGJIH?22^KG^ ]3=-Z'^)2\X<A
M O2Q<%6?352WF$XVZ3PX_%>'+;4C&9VUKLS)TK/$Y-&"68>\6QB5Y4FE9H->
M*?":@;$9>Z=D[.^[43QR\2TW1UI\J^)[-T,">&5\6*+M:U^3>>YZ'I+T"-'9
M_G57QN..'N;25\6+#RK*]SKWY0?T47SBCG4AO+[.Z]OJIH?22^KG^!X?4W3>
MA_B4O.#R@_HHOG%'.I#>7V=T]5-#Z27U<_P'J;IO0_Q*7G!Y0?T47SBCG4AO
M+[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^DE]7/\  >IN
MF]#_ !*7G!Y0?T47SBCG4AO+[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1S
MJ0WE]G=/530^DE]7/\!ZFZ;T/\2EYP>4']%%\XHYU(;R^SNGJIH?22^KG^ ]
M3=-Z'^)2\X/*#^BB^<4<ZD-Y?9W3U4T/I)?5S_ >INF]#_$I><'E!_11?.*.
M=2&\OL[IZJ:'TDOJY_@/4W3>A_B4O.#R@_HHOG%'.I#>7V=T]5-#Z27U<_P'
MJ;IO0_Q*7G!Y0?T47SBCG4AO+[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1
MSJ0WE]G=/530^DE]7/\  >INF]#_ !*7G!Y0?T47SBCG4AO+[.Z>JFA])+ZN
M?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^DE]7/\!ZFZ;T/\2EYP>4']%%
M\XHYU(;R^SNGJIH?22^KG^ ]3=-Z'^)2\X/*#^BB^<4<ZD-Y?9W3U4T/I)?5
MS_ >INF]#_$I><'E!_11?.*.=2&\OL[IZJ:'TDOJY_@/4W3>A_B4O.#R@_HH
MOG%'.I#>7V=T]5-#Z27U<_P'J;IO0_Q*7G!Y0?T47SBCG4AO+[.Z>JFA])+Z
MN?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^DE]7/\  >INF]#_ !*7G!Y0
M?T47SBCG4AO+[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^
MDE]7/\!ZFZ;T/\2EYPX\\#NE=X,:1Y]])_O+9.VR8+6?)*=:V-Z?/HZVV676
MDPV.K3_(LNX#AXF^,@,F^)T9?%$^P&K+]_RLA@I=%:V'@T;3-'IZ3I=6<VH5
M9)P>&3;5Y/<EEO6\]VDZ'I-31]#A"G>=*$U46."PN6"V;DD_<O<V=AO*#^BB
M^<4<ZD-Y?9W7O]5-#Z27U<_P/#ZFZ;T/\2EYP>4']%%\XHYU(;R^SNGJIH?2
M2^KG^ ]3=-Z'^)2\X/*#^BB^<4<ZD-Y?9W3U4T/I)?5S_ >INF]#_$I><'E!
M_11?.*.=2&\OL[IZJ:'TDOJY_@/4W3>A_B4O.#R@_HHOG%'.I#>7V=T]5-#Z
M27U<_P !ZFZ;T/\ $I><'E!_11?.*.=2&\OL[IZJ:'TDOJY_@/4W3>A_B4O.
M#R@_HHOG%'.I#>7V=T]5-#Z27U<_P'J;IO0_Q*7G!Y0?T47SBCG4AO+[.Z>J
MFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]G=/530^DE]7/\!ZFZ;T/\2EY
MP>4']%%\XHYU(;R^SNGJIH?22^KG^ ]3=-Z'^)2\X/*#^BB^<4<ZD-Y?9W3U
M4T/I)?5S_ >INF]#_$I><'E!_11?.*.=2&\OL[IZJ:'TDOJY_@/4W3>A_B4O
M.#R@_HHOG%'.I#>7V=T]5-#Z27U<_P !ZFZ;T/\ $I><'E!_11?.*.=2&\OL
M[IZJ:'TDOJY_@/4W3>A_B4O.#R@_HHOG%'.I#>7V=T]5-#Z27U<_P'J;IO0_
MQ*7G!Y0?T47SBCG4AO+[.Z>JFA])+ZN?X#U-TWH?XE+S@\H/Z*+YQ1SJ0WE]
MG=/530^DE]7/\!ZFZ;T/\2EYP>4']%%\XHYU(;R^SNGJIH?22^KG^ ]3=-Z'
M^)2\X/*#^BB^<4<ZD-Y?9W3U4T/I)?5S_ >INF]#_$I><'E!_11?.*.=2&\O
ML[IZJ:'TDOJY_@/4W3>A_B4O.'(3IN>EBX*\R>$RFG./6W2<UV%EMN RFP5W
MK79L52N$!MY"F3=_"LLB043W2&3]K:S;PWPE;OE[HI*6PS[GQ:?INCU]'=.G
M)N6.+LXR62O?-JQ[M7Z'I-#2%.K3PQP25\=.6;M;*,F_W'7#L8K3>H9OT70,
M[--5:WEYO/>FWFN1B40:,'RN39NY!6;MLB!46[=W00MEE9%&ZUTTK996PQQ[
M=ZQ#1JMXY9ODY>\B0OXMG'7U!:5ZK(-[BH5W?.^MCQ;..OJ"TKU60;W%07?.
M^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;
MW%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"
MTKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ
M;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07
M?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU6
M0;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..O
MJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^M
MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%
M07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TK
MU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;..OJ"TKU60;W%07?.^MCQ;.
M.OJ"TKU60;W%07?.^MD=F,Z<U%GV37L*$YZKUQG#$>C>9&48CE!XQE&$C%YQ
M!TKEDP%Q=Q6!*Z2JJ=WV+2SJZ:BF'?>YSRM<67>RO=WVG_J2)O%LXZ^H+2O5
M9!O<5"N[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9Q
MU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YW
MUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>
MXJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06
ME>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+
M9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[
MYWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR
M#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWUL>+9QU]06E>JR#>XJ"[YWULCD=%#I
M[49_I;^G/CYW5FN30&+;4TJA&0A:$1DB(CJ#EQMNSE$$->#%F0A)Q9NAW],>
MBWP5[PCWRV7>\.Y%DF\%-W=^/Y2)&_BV<=?4%I7JL@WN*A7=\[ZV/%LXZ^H+
M2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%
MLXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=
M\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59
M!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^
MH+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV
M/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5
M!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV/%LXZ^H+2O59!O<5!=\[ZV1V.R@=.:B@
M_1AK'(5JO7$/->,)J5G\+Q:#QF/E/!'#2877:_" D6T=^#KW33NLAW[O2ET\
M+YXY=SCVA92;QQS?+R]YF6.Q8_13 ?;WN3Z4 H15_22^CR42.:%8H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * C;1?\*2V/\ HS&/
M\>0.A9_M?^3_ -2230K% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!&D
MZ(OTPW3V>UG1WTC<-"R7Z.G_ ,_*)+="L4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4!&U[*J]%>O_Q&:@^AS.A92_21^GR65'L6/T4P'V][D^E *"K^DE]'
MDHD<T*Q0"@% * 4 H!0"@% * 4 H!0"@,8M]V:9=DR05KMS6+DR&1+.# EO/
M8JL3%-P"2ZYU<DP3+9.F*(5!JY6+*NDDL!R3==1YDC@DI?$39\S/>WVQJQW>
M*8M-EP!UE.T[JP?%O,HZM>9)8K6;Y*12R9'*\B3Q<7LA?,1X9C9:]DKW[N_<
MT(*Y*)C$80.3,324QR("%GS08B4E!L8 '*DG^=TV(]-\6=-&V;YZICE@T:8J
MW<.,\;XHIYY6O:@/:[/ V!%F'?&A+,L08DB8\6[(LVY%\-#79V+D&;%9;!RY
M8BKD&%B3M%+-!C=\SLZ42NY1[L#R1B712;!TY##)/'I< 66<MT3D8-#3P=5P
MR6S;O$$R0IR[9*+-'":B#E+%:^:"V&:2N.&>-\; >F/2$#+0 2518R+D<9DH
M@:?CL@"/FQ0,=!F&:) 28$$F:BS,@,)L'#=ZP?-%E6SMJLDN@IFDICE<"L4!
M;N4OB>(!_*LI1'<8N*R+XE))D;&V #<H^^=BSV+\Q=S\',\@A,>_'%[.'"=Q
MKYD[:/>\N&RR> % <;:U4T'1PN[V9KYJ)F"JR$2*.)G'$1TI7;JX(+HQQZH2
MQ;&U4%U4T5DQBKK--53!/.V.>>-K@7TZ=-F+9R]>N4&;-F@LZ=NW2R;=LU;-
MT\E5W+E=7+!)!!!+#-5997/%--/'+//+''&][ 45A+8L5*6!C)&#(F,H\+EN
M(MB59.GZD6..'S0-(TVJ"^:RH,HZ&D&[ JGADR=+,W":*^>2>5J N&@% * 4
M!&VB_P"%);'_ $9C'^/('0L_VO\ R?\ J22:%8H!0"@/&/(,"[!B5%/F9,63
M9MB TD/<HO6!!@]1P<LWS%XVS4;NV;MNHFNV<H**(KHJ8*I9YX9XY7 I.$OB
M2D>'2["41W.*%\ RHF3X&QN4>*)R)TS8Q]0<:LYN->X'7I$>S#9MG*N)-T^9
MMV5UU72&&8%Q4 H"UQ$WA<@,FXX!E\7-R&-*=YD8$0?%$C(!;OF27>C8MF[6
M?"E.^XY)]P^00R[YCEAVNZM>U!8NB@*<-,"3.#M4.4'%4F!%^'?*#7K9]@R+
M"G&;,F+=YM55<6Y$<[34:OV2U\'+-QAF@X235QRQL!4: _,LL<<;Y97MCCC:
M^6665[6QQQM;MWO>]_-:UK>>][^:UO/>@/ )+"CXH8=!$QYH(:'LRP<P)>-B
M(HL*(MDW@\F,(,U%FC\>_:+(NF;QJLJV=-E4UT%,TL\<K@>ERY;,FSAX\<(-
M&C1!5RZ=.54T&S9L@GDJNX<+JY8)(H(I89**JJ98IIIXY9YY6QM>]@++B.TM
M9; </&D#V-!)L['(IN2#6(R^/R1PQ;JYW227>(AB#U1LBJI:Z::JV.&&>=KX
M8Y7RMVJ"S6]6+J%F!)QLJ\"E!Q=H@1+AUW0MZV(-D2T?*O 1X6JNT5623(A#
M@X@&+LL\K.1I5@\'/$D7;5=' #X@I !E Q(U&C8B1!UUWS5 L"),RPQ9R+?N
M11-ND_8+.&JBXXHR>#7R6"MU&C]HY9N,4W""J> %7H!0"@% 1I.B+],-T]GM
M9T=](W#0LE^CI_\ /RB2W0K% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 1M
M>RJO17K_ /$9J#Z',Z%E+])'Z?)94>Q8_13 ?;WN3Z4 H*OZ27T>2B1S0K%
M* 4 H!0"@% * 4 H!0"@% * YD;:XOB)1-N:A.1Z@E1.&;0UEQM%1@EI]GK5
MKLE]((G)-EE)48AV$R>L@"Y:)$"L7E!D;+4'@F7LFJ@9:/S>SE6,$1/-S+D=
M[?)ESFF6P.+'+3<<?$RR9Z[:)NH7JF7MW4+80S3L4DFZXQ'.73/9 .)KM1IL
MZ#TIO?;6H@5I$K*-?R 0- ;-/X$UWD0<>$ (\.KJV_E[]U>*W/F3RMS&ZG)C
M6NZ'^RH#/IMK8-RKUL&B7*&$#]6ZW@0.,%(Z_P!N!=>M-9EI6SVQN4O'Y6]9
M@XO/]:'IZ'5B2(YOM!9VM#Q,8=2)Z.$)Y6O;=^Z_,O\ .<UFUOQ7Y;:PW3Q_
MV)MW6VO-^B==<9)1IN6&X]L=X3E:T)B^B=>@6&M&<"F\#!Q4B<V1L\5/3KM\
M_P!@*#9<_F>:,OD &/Q"*,$P;3W-K._>OG].5\LN?+,S=JG6FU\^'?. @PU/
M*-*\B.1@_<.P[0+X/C B/Q?91WC_ !S5>N8SK6\3.ET2C"+Q_7L!#&9@\;1]
M_.-@-I1-L(\ :'FH,6%\US+E^F]S'S?/DE-=M:!E_'J+[#CW')77 S$0:"3<
MBZUY+M-2+A#L4K ".$:>[@%0R&EQ/(1]K*.L!0[1AK8RC@$UE3O:86!&%XPJ
M&23Y[9?+B7>ONOORSY]]OD.-O(_,?J?">X\E-F (5)N$NXI&@GOJ29SOXSUX
MKM^)<FE 11ELN+ND!0@FZUD<(0@24'081@Z-D->@DL7)5FH%UF^7/*RMR6RZ
MS-&Q-,<L9KP\WUKI=W%7I"7K\H&,=UT;A*I>=$74EY-[0D&KC-I^GML5#;PU
M75C^'*HPMW"4"]V>'>'DP'.E<V#$1E=?1GU7RMS_ /X6J:XIO-)[<@$L?Z/(
M\LHU,(QS(([8CD#@6H(["V>R=V$N(C>-!H[K#96P T7B4+-1?2DB:NE7\KD*
MBQ_,X?EYY=]+7KM43?OVW6W]_E2[]OD,N1#1NXH5PH%Z=W8*A^] H#C="X+G
MI4% U9=-%-A"!()L@T=;'G>ST8AL./10LVPP&+$=?10FNT"L3SLP]?MU&I 0
MWG=9;W_EBWN.HZ5-ML\%@)>)2&%2;5O1X;6B&X8R?Q%_"D:)N)OQ+BL"9'[@
MBAH4I>2E=4[8*P9XD4=XJA0,HS3Q:K/'S?$.1_*OO.H="!0"@% 1MHO^%);'
M_1F,?X\@="S_ &O_ "?^I))H5B@% * XK<<=!\NM?0?C)@47VS''NG]?='/K
MNVO&VR$$=>C(Z%U>$A7+-D<A R0Y165N!EK*XN7IQL<<#"H$>:UNJT?*D7I4
M=2:;=N5MWMGFW;?WK%KZ[X\<FHRL%DI2'[BRVM+>*?1;1V4'L]GJD(.SF6E]
M\^$<G8L5B2VPU8@PDXR#O&!U%Z+A^;!^S>SYS$SF9Z2S- T%UWM\LK<ZRY.?
M_,D4*5Z=Y?;49;I^,/7G()I"<=J<*MI@M;A-W3' T@=U3S8<2[=Z>N9IER.>
MD"N2>A&(B1"T8LRTK %C0^*N->P)GL",M#*(E-+FW27>]RDO]//?[^=[?\<X
M7RM9\H-BR;;LLV2WAWP_O%(;&GHET5U<=UN5G@U?CS<7(G?(>2@1$MA^MF8X
M<9PB6@8/(RTC5GGQB'Y)VXY)Y .7:W^999];S6>7>-3RO%+ES#)EN#;.K1*F
M4^EC+I+A6H,VC#6H8WJ^7[=VZTG^J9@O(\WXA[-@NT(S%U$ (V<2"XF!3E:%
MN"K-B,>/G\5$W3M_QOOS5K/J,&<CI_OK2H/7<,GFX-] 8C,!7)G82KEY.36E
M-BZPC,23XEB0Y2,923F!,=K<@BL8($]VE8KJTONJ4R.7%=C.!8O6[J.P[7+E
M,2L_EROE?GY+67(KVY+\IO8V@G)]OMZ$.' G<1R#DM[;]:&(VSG9J 1,=J:>
M[3(+1W:#N:0G;<8,YR2(:]Q2<B8-L& 3KX<;$6*$/?Z_G;(H8N.?\_S_ /><
MQMH#1')+6^E-2@VL4Y$HN] <$)#'1^GR?(LS'A6PN6T:')QUD*SE>&P))G>-
M&$FQ-AK=8J_OK*+"2XV0)15@\CL5N"$Y7Y,Y;]]EER?SROE;G1^:@TGR-=;3
MT3/=PQS?QV-ZTY.[20A7?=F3@43C6I]@:!U2J /3<$<Y);*E,G@C7<H_8; @
MPV%/-C29L)>6%.XN'B3].'" NL]V:YN_R9*SM;-)<I_>E8#SB$7XZ#IR,WDT
MV%'0O")G>0M=D DM"QS54;U#K5CR]B6W8,/G*8N6;9+S=IN5D)/+0:5EK$Y#
MJ,C!)..!1V6N@X/#=VW9VWWWNV_O6^COV-E^#VM>1<$;"6N^#>T),E*^(/%$
MML"VU)]EL*S3E*HGMIMR*&"$W9<LC'V^#'+6S(H$C2;. N/ F1$,@Y-OI24)
MA*V=MV*5M_N>3?\ 3W^?D+#9\:-E,&9B.18)*=7")YS^F<NGIC4\E9:WDY/C
M>3B4H52[F51(B-D8N/F) F 97;@GX^6#%%\"(7(*3:MRS(<F+I7$N<3(_JX7
M%8EM%E\#<J=B3-S,1&P7:X8AJ61])%-#C^.2Z)#]RP6'XA<N(+P2:9F)]#MR
ME"(4Y]S<3BT1GH5X8L.^+G;F77A5]Z?^J_*OI1T/XC0B4Z[T/'(G,Q"H*0LI
M9MP@Z&+KM'*B3.1;AGLD#+W68N'3;+%\$+#G^&."V6::;G%-?%)?!5+ <&RE
M * 4 H"-)T1?IANGL]K.COI&X:%DOT=/_GY1);H5B@% * 4 H!0"@,",.2^H
M23*#$6YY]X'L25[9AD764!&,?"CNDK3N^PT7*=F>2S- 5CK>69-7*Z>*96S)
M"PZ[C)ZULJ!6=<[U@.UM5/=RPJTO(0U@_P!FBW#5UKZ<#)Q8IJ*9RS7\W#XZ
MT?@&^PKR!A*X5(!+2,WC5I*1=MD6K00H\=(-LQ-FG;Y/W[C".?//1"8)X2\$
MVNK(A,OF<)D&L&NG]@/=KQLOKN)1[8$V<FH&S".##8& @LPALI5/(X.!1)E,
MX@.".B<ADP4,]"S_ ,[_ /G\^9F2@?*+4$JF#F"Q$I(98?2T^AO1A\ PJ6N@
MTDU\\;Q]X/=0^2JAV\>EQE\TE4;<)1Z.DR1=LF<%?"+5EF_:X*B+?Y^/-])4
M]-<@H7O AL0/& T_ &M5G0L:FX:?P4_"2(DU((R,F(QAWDTV1P<N58P;"&UD
M&ZBBS0>:#N72:2)-EFN):M_^I_R,YT(% * 4 H!0"@(VO957HKU_^(S4'T.9
MT+*7Z2/T^2RH]BQ^BF ^WO<GTH!05?TDOH\E$CFA6* 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@(VT7_"DMC_ *,QC_'D#H6?[7_D
M_P#4DDT*Q0"@% * 4 H!0"@/FHDDK=.ZJ2:ETE+*I74PQSNFKC:]L5$^ZM?N
M%,;996MGCVLK6RO:U_/>@/I0"@% * 4 H!0"@% * 4 H"-)T1?IANGL]K.CO
MI&X:%DOT=/\ Y^426Z%8H!0"@% * 4 H#FWK7H_PVJYCJ;9\96BGQE0#:W*#
M9$D.J('TL)HVWLON%W'@2V-WSI(;C'E]B <2[MNRRR=)@G>3-/')REC0EN_[
MN1;TK?B9GT%JC>VH]';0A;\WJ=79IS8W)G:.O#(]I+B4(&R/?>W-E[O$LI@,
M=YACC\/$Y;L7($_P#OV3LY'@^+Q!P*(O\D6@EM-KFLEU)+G?,:W1+AOR)A@Z
M#3$+-=-WWM'FW((%-)A(&4UD8K:6/)-MK(K.-GRO-NG''J,^#SC5$0>@(L(8
ML(.UU^+;ZPCWW& 6@-< %U]'5NOEO?/]^?+F/5'&38FH]P:->@C4&?Z5T?Q;
M8\8!2)#.0VV66#C&.OW#.3.\4F=XTD^L;UZQ:+,<'.22@@BZ>6<8/FZ;141O
MN^6_T&=..VHB.GH$_'2@TSE.QIQ-IIM/:<M8M5VC0_/)Z<<EGJ8Y%THJ\3CD
M1#? >O(2@]4S>,8)#HP.<9759Y7H09WH!0"@% * 4 H"-KV55Z*]?_B,U!]#
MF="RE^DC]/DLJ/8L?HI@/M[W)]* 4%7])+Z/)1(YH5B@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"-M%_PI+8_P"C,8_QY Z%G^U_
MY/\ U))-"L4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$:3HB_3#=/9[
M6='?2-PT+)?HZ?\ S\HDMT*Q0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$;
M7LJKT5Z__$9J#Z',Z%E+])'Z?)94>Q8_13 ?;WN3Z4 H*OZ27T>2B1S0K% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$;:+_A26Q_
MT9C'^/('0L_VO_)_ZDDFA6* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M"-)T1?IANGL]K.COI&X:%DOT=/\ Y^426Z%8H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H"-KV55Z*]?_B,U!]#F="RE^DC]/DLJ/8L?HI@/M[W)]* 4%7])
M+Z/)1(YH5B@.=FU]/Q0UT@?'4H[QG'@TFT?R7F\H8CME;.%18E,=7S'AV'UR
M4?1D3+646Q< Q4@E#9JSL+39DL"IA4DU(*N'*F0GD?RK_P!O\_\ Q',32!R'
M2K@O$"IOECQWA&QFQ+0\@VAC.N6^U7K"=DV06:OW>HN51=2;,C^@B$W?(F%[
MY1W+)LI,(T@,*QJ;C!ZL+,#II7R3L[\G[UONNKDSY2[I)RBV[*RFA>1VN]0\
MCXGI+AEK319[:H-&?"#D1%L=P#!KSD<+W:ML'9$:V?N'/3'% C!]O:LE+: S
M<X:/2S Z?;1@NY762"W?6;=LL\MUK9+$\O\ X6>=.<J8A*^1.PM>OIR.D,O3
MZ72-Z(*1S8>S-CDMK;EUU,)D2TYK0WJ*5W1UI""T,B<2DLIT,K$6,M<RMK!"
MX-Z3A8UT[ S(+++Y8WRW*W/OMGGNY-_)O9QF.:;=\JH SX=;8DVU]-NN-&SW
MW(QUGM^?;EC8O9+>;Z/3T4]FQ.:R:3Y1/?1L0\WG]T(550--# 5@07V&+[L!
M#;MQ#O;-9WRY,L[_ "YV^3Z3K)0Y% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H"-M%_P *2V/^C,8_QY Z%G^U_P"3_P!2230K% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4!&DZ(OTPW3V>UG1WTC<-"R7Z.G_P _*)+="L4
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MKD67[TK[RQ(OO@S H9H3&%\I@O)B=<IC6O :,KVQ(-8-=8ZS7*Z;W-N-Y/F
M33T,A\@0"[*1U>5B,0A920Y#LRH\;8&48N14PRD(6WY6M_\ %W]U[EF!ND*W
MU.VD/-034>H&X8N.XH,#7W2[ F*N3B3\K-E; U&(,Q D'AF;0OKN+'8B,G D
MPY:MB&QH0:2;M6T0=JH%;B;+GY^3F5WRF/R'/K<P><$-A+-]98C(KH?!W/\
M4!2=GF><HE.M>8^W^.<X=:)$Y"LG!&13-S'62D>7.XK*-G*D$@Y%D0=2;X?"
MB$K_ .;OE=GS??D;>Z+YBR[:VYX_"2D9@3:([#PY2911G&Y(3);*@-^+NXP6
MHB5]K!W+)(<A:;.3-WZN([X-R@!_!C"75Y@L3O(606RY>2][<O-_F>_(PX7V
M-NG24WY=29CM6>[FMJ[9O&36VM-8[1,P@# K..1;_4P-XY.&X1JAM*T< 1>?
M.G@MXEF3R9L4+-W TME:W= K/*UM^:O?)/OV+6WAS_G_ !K <H'QEI%)=L'3
M$OE)Q_#7"DL<AI'%M3\+.)N[=E-]>N68IFVUW$_NJW-B-1,SP_(GPDD>9OVX
MB8N#B@(".L*O'?QMV6[C-+Y7ENROSJQOIQFE4CE*O(FTB-$#-HWR>VA%0%G[
MC->PF."F46S&A6/=?V ]EF[<Y-V^/\A.ZZE[?_->AR_N7\D;/4(% * 4!&DZ
M(OTPW3V>UG1WTC<-"R7Z.G_S\HDMT*Q0"@% * 4 H!0&OX[DWJ4FR@9!L4+7
M:;'ENW83%\[@"F:C@[H_[O;[ 2<-D$%G2"+&VM95<<I9%3(O=LTP8)JJ/F^&
M0%;UMO:#;8U0]W)#&TT=Q-@1V@(7&OX%+A4\L6T_-Y=KR:AK:Y?B$)QB?:RN
M$'AC*-J@4Y&]<HMVJ8K%\XP:4#5M_P#E\S!V?/32V(9ZZQ [?<2\/+YO"I'J
M9GJZ1/=K1HGK>'QG84W?&(HTP6QQ @8+-X-)KFV!!^Q+(3>(AP*A63R$8"<"
M;?\ [R?Y?\=V9DP#REU++I@M!H:YE4M.7TRWWP'6"PF3V RV /6\==C5H5)R
M8T='9<8?MI;&U<! $F^<,LC+)N6N.=*]XL(M8JFF.044W>1V0% QK845.:GD
M 2+S8-L&)KQA\,.2"+"IJ-'X=MT]:N7646/@#;ELDYNY9CSH9RY021)LLUA+
M5K=_=_(SM0@4 H!0"@% * C:]E5>BO7_ .(S4'T.9T+*7Z2/T^2RH]BQ^BF
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MO_Q&:@^AS.A92_21^GR65'L6/T4P'V][D^E *"K^DE]'DHD<T*Q0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!&VB_X4EL?]&8Q_CR
M!T+/]K_R?^I))H5B@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * C2=$7Z
M8;I[/:SH[Z1N&A9+]'3_ .?E$ENA6* 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * C:]E5>BO7_XC-0?0YG0LI?I(_3Y+*CV+'Z*8#[>]R?2@%!5_22^CR42.
M:%8H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * C;1?
M\*2V/^C,8_QY Z%G^U_Y/_4DDT*Q0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% 1I.B+],-T]GM9T=](W#0LE^CI_\_*)+="L4 H!0"@% * 4 H!0"@%
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MLX8/8MB5:@6>H%PRCU@]05,HHR%O*D!:C?/#-,<DP3=98JI$L,,L5 3M^_\
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MT7_"DMC_ *,QC_'D#H6?[7_D_P#4DDT*Q0"@% * 4 H!0"@% * 4 H!0"@%
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-[A3E&:;M;/EYTT?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g320192g56g27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g56g27.jpg
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MM+;4UB-55I77,C@S=R0E)SE'46%B979X_\0 '0$! 0$  @,! 0
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M>H0_W>WJO%\K[R+!<B[B]4** 4 H"#&_DU7UU)?YD*U7CS+N1%ASOO9>J%%
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M%% * 4! E?FM)/4!C[N<T(\'R/N+]"B@% * _+_%?Z+_ +J A17S8CGJ$/\
M=[>J\7ROO(L%R+N+U0HH!0"@(,;^35?74E_F0K5>/,NY$6'.^]EZH44 H!0$
M$+^ER3U]^"AJ$6+Y?4B]0HH!0"@(++S@._J83\3H97UHN;N+U#0H!0"@(&7G
M2EZ@<?>+6@+] * 4 H" 1^7([]);^"QH"_0"@% * 4 H!0'JWWWKO5F[4-A\
MD>0;I^2@O%@[,,8EJ8#R/FT9UF9?Z;.E7GN[VU#XPWB8S#::;](RSA<=D92;
M1UJ(<1PFNFB2-K-1 TF\%KXEZYW7<6N9[$M=0]Y H<(B9"9RS8+H5D3OG+9P
MX&.Y.3P(%WY-!$@X#BPP]1(2W>I!AO<CD5,!0]C@Z4=N\5W:XR9M0"@% * U
MWMB81S7L /3N8$K!XI#LA,FDA;)J]?8C0@4X-($WUV8UL\(.K-6;=9:[=DT<
MNE>QV$$%5,L<+\5-34=7H:6GIHM"BH:..EI(Y11:,$$+BBBT85%$Y)-RA3;U
M)L\RSK.KML6A4;*LZA^<U^TJY5JC4JNJ2BHG3UJLTT%#042I*:.CH8/E*2.&
M'3I:2"CAG.**%39TX\JOP%^?]M]G&WO[ KT>RJP-\%U:N>[GU3:$SM<$:3MG
M)[\6'E5^ OS_ +;[.-O?V!3958&^"ZM7/=QM"9VN"-)VSD]^+#RJ_ 7Y_P!M
M]G&WO[ ILJL#?!=6KGNXVA,[7!&D[9R>_%AY5?@+\_[;[.-O?V!3958&^"ZM
M7/=QM"9VN"-)VSD]^+$B0=*;P,? #;)KOMLJY>""35NE^3O;>'>+N&2R2*?;
M4@6">';4SQQ[6>6.&/7UY96QM>]FRJP-\%U:N>[D>8/.VTUL1I+UOSD]^+E?
MRJ_ 7Y_VWV<;>_L"FRJP-\%U:N>[EVA,[7!&D[9R>_%AY5?@+\_[;[.-O?V!
M3958&^"ZM7/=QM"9VN"-)VSD]^+#RJ_ 7Y_VWV<;>_L"FRJP-\%U:N>[C:$S
MM<$:3MG)[\6'E5^ OS_MOLXV]_8%-E5@;X+JU<]W&T)G:X(TG;.3WXL?E^E7
MX"]5_P#V_MOBO_\ #G;W]@4V56!O@NK5SW<;0F=K@C2=LY/?BQ) =*=P,9 0
MC-UOMLDY:"!K9PG^3O;>?=KH,T4E<.VG LT\NPIAECVL,LL,NKKQRO:]KWKR
MKL";_L@L7_-JY[N19@\[:26Q&DN6_.3WXN5_*K\!?G_;?9QM[^P*FRJP-\%U
M:N>[EVA,[7!&D[9R>_%AY5?@+\_[;[.-O?V!3958&^"ZM7/=QM"9VN"-)VSD
M]^+#RJ_ 7Y_VWV<;>_L"FRJP-\%U:N>[C:$SM<$:3MG)[\6'E5^ OS_MOLXV
M]_8%-E5@;X+JU<]W&T)G:X(TG;.3WXL2 G2G<#&C)1%QOMLFID4..+8_D[VW
MEUHO#9!VVSZ\(%EC_B-UTE.SU]K#M=G/''.V6-J\J[ WP6"_FU<W%_FY%F#S
MMK_%&DQ?^&<GM;GON=[==;$AVV83'=C:^,XR&&2QC<E'S6+$F-Q(,K+K-KKV
M8F&0\FV_QVZV'=O&3=7\SM=CL98Y7]U5JQ0UN@HZS5X_E*&EATJ./1BATH9M
M3T8X88E>G=%"F?,[9L>TLG[3KEC6O5G4[2L^E^0K=6=+0TSH:71ACT?E:O24
MU!'^;'"YT=)'#?*<YHS6N8]8* 4!!"_I<D]??@H:A%B^7U(O4** 4 H""R\X
M#OZF$_$Z&5]:+F[B]0T* 4 H"!EYTI>H''WBUH"_0"@% * @$?ER._26_@L:
M OT H!0"@% * 4!TUG_1Z<)=I[[!\H-A\9]5RW?4>=!" _8Y<!98JL4C.""<
M:,F6."Z8.2&XXFT9)Q\W(A94J%3'C4QCQK@.8XMQ9N4IN6Y/XYSN50@H#%I'
M-XC$,D<91(A(&Z[(B21\:/$FEE!XCP6Q5]C=6^-O!!OAS+PYQ>_=-?"VW?Y8
M=^EVDF\%,C:6)0,R$%'&*9,^68!1ZKEHSP>%'*3%O=T^5P0:(75<9)XX*+*Y
MXX8XYWQO:_7?+LVQRO9*>!6TL3S&)%@2P65'/&SY)NZ<L5E6BV#A%-XS5R0>
M-;JI99)^$-'&&;9TE;*^;=RFJW6M@LDIAB!U2Y\?]F/)7_REE7\'7K+:_DBT
M_P#4*W_[$9W?-I_?$R&_WMR?_P#M:J?#37PH_JR* 4 H!0"@% * 4 H!0"@%
M * 4 H#[..&Y!\(Z-+6A4817$DQNDI0^&$6UV]G#4BU6DB[!1#PI%PA=:[O!
M'!/')'/++/*V*=K*WPO;[=DU_(MF_P!#_P#LC/Y>YZ?[Z&6G^U/_ .2K&20O
M;NS5YOJ(26'%CD8(P+1[*W@SMTU?&I#/(M-2DRV"2=HME+G&L*>0MH'- 7#E
MLS89'G)8E98AF&1Q]ZTI-K=BYI-27/.[HW9?+IN<.Y)7:]=_'A?JXCOI6#8H
M""%_2Y)Z^_!0U"+%\OJ1>H44 H!0$%EYP'?U,)^)T,KZT7-W%ZAH4 H!0$#+
MSI2]0./O%K0%^@% * 4! (_+D=^DM_!8T!?H!0"@% * 4 H!0"@% :6VWIAA
MMG)E=\<>!\6<8F46ZFC1%S=1I-+QZ[YSVEE<+8.&GN=:^"?FYI?XZ_?8*?X?
M8J<O1Z"-3]/I*DJUEG,QKX:>DY19N8SQ3*H-K+-62;)JZ>/1.4?:)OKVCYT,
M]4'/F<B15=O578AKD^3=M\LFV).6KXNGTWW:IDENM_&$MR5S->1SC2'BN+%
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M=K91UJKT-4K%K5GYS2U>KQ1Q4-%%\E1T6C1Q4C<;AE1I_G-N;9MZO,.NB@%
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M&_DU7UU)?YD*U7CS+N1%ASOO9>J%% * 4!!"_I<D]??@H:A%B^7U(O4** 4
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M 0X1J1,R*024Z4&!(Z!!L'Y4T6(,V YHX<+X87#$XX;N./R^53&#K@IG#9=
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MI(X1(YSOCP>B4<V:(>B7C7%@1G,$$[*C'B=W?#-M($",--C"N68E1SFSS<^
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MEL@%;L2%B8^V,(MC<KU/N:+Q@U(2L>AJ4_#1=^%W'?K6&.KTINYGM7H9% *
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8XE]QVTH04 H!0"@% * 4 H!0"@% ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g320192g56x38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g56x38.jpg
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MN9VV0PH7D;:S;5'D[5!8_< 34)?Y4ND?];9'_MS)?_R>7WXI:]_B2_[5:_\
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M&8_NG9&2/#^[578;?3MO6T[;?LTCDU <<'O1+&2?J+B9B/F5S\ZUZXU'=T3
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M=C!"U#6-KBCZZ'GF/QG.,1(=;EU34Q)%MDH!OXU7:8GVM@^&_P!_I_WK4_\
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MY&5,ZR2#T[4.9I ?EE$*_>0/)JJUR[]BTF^N =KB!HXSZB6;$,9'KE7<-QZ
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M Q 7.U0%SC) YR<DZI=7#W=Q/<R*BR7$CS2"-2J;Y"6<JI+8W,2V,X!)Q@8
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MC%022%)(!)P.3GH\FRK M!X=3L-7S*W&F6#ZBL@4\=TYX9,MEC;D14E2V/\
M SQ2R/*0[U]Q41>S7*YLBTL]1ZBO9RLJ2W1C$TLD[=L,J&*$? A&0&0 !0-H
M^F#'N[S3NG;*$-$\5J)##%' O<*NXEF/QN#@D.22Q]XCT\6CZ#K";,WQE&U&
M59(./UTZYMHJ$&GK2SN$+$KHA'-\A%G,@R)-E,<)SD%*&,B^*'"KMRZBE&E=
M/6FD&827,L<$+8//:@*O*XSAA&9%6*,,!E"5YVM6F=.Q'5>H;O5Q"8[:*2>9
M,CCNS[DB0^09!&SROM)"N >-RYR"6597W,"75VT*+8UTX+H\R#,".1&DA?\
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'4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g320192g58l58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g58l58.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1A<4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@     !=0   !     !       +<')I;G1/=71P=70    '
M     $-L<E-E;G5M     $-L<E,     4D="0P    !.;2 @5$585    !$
M00!D &\ 8@!E "  4@!' $( (  H #$ .0 Y #@ *0       $EN=&5E;G5M
M     $EN=&4     0VQR;0    !-<$)L8F]O; $    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4    (@!< %P 4 !( %@ 1@!"
M %4 +0!- %< 10 M $8 4  Q #  7 !! %H ,  Q #4 ,0 M %@ 10!2 $\
M6  M #$ .       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!W<
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 \     !  $#P     $  3A"
M24T$)@      #@             _@   .$))300-       $    'CA"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #-0    8             !(,   .$          $
M         0             #A   !(,                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P  !(,     4F=H=&QO;F<   .$    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   2#     %)G:'1L;VYG   #A     -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M*623I)*62A.DDI9).DDI9).DDI9).DDI9*$Z22G_V3A"24T$(0      50
M  $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D
M &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M      %^34T *@    @ # $   ,    ! X0   $!  ,    !!+    $"  ,
M   #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !  ,   $:
M  4    !    I $;  4    !    K $H  ,    !  (   $Q  (    >
MM $R  (    4    TH=I  0    !    Z    2  "  (  @ .3AP   G$  Y
M.'   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP,3HQ
M," Q-#HS-CHP.      $D   !P    0P,C(QH $  P    '__P  H ( !
M  $   .$H , !     $   2#          8! P #     0 &   !&@ %
M 0   6X!&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $
M     0              2     $   !(     3A"24T#_0      "
M    _^$!@$U- "H    (  P!   #     0.$   ! 0 #     02P   ! @ #
M     P   )X!!@ #     0 "   !$@ #     0     !%0 #     0 #   !
M&@ %     0   *0!&P %     0   *P!*  #     0 "   !,0 "    '@
M +0!,@ "    %    -*':0 $     0   .@   $@  @ "  (   #P     $
M  /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#$Z
M,3 @,30Z,S8Z,#@     !)    <    $,#(R,: !  ,    !__\  * "  0
M   !   #A* #  0    !   $@P         & 0,  P    $ !@   1H !0
M  $   %N 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @(
M!     $              \     !   #P     '_X4%-:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U
M33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB
M861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC
M,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*
M(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @
M(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HP,$%%,S,X-#8S1#=%
M-C$Q.#4V,T1!,T5#,35"0S1#-CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HX,3@Q.3E#0S=#1#=%-C$Q
M.#4V,T1!,T5#,35"0S1#-CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @
M/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#Y&1D4T.3E#,D,V0C T04$U-S,P
M-3)".#8X0C5#-D(S1#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z1D9!1#,S.#0V,T0W138Q,3@U-C-$03-%0S$U0D,T0S8\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,3<M,#$M,3!4,30Z,S4Z-3$M,#<Z,# \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@:6UA9V4O
M:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC
M;VYV97)T960@9G)O;2!I;6%G92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA
M9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C P044S,S@T-C-$-T4V,3$X-38S
M1$$S14,Q-4)#-$,V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#$W+3 Q+3$P5#$T.C,U.C4Q+3 W.C P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z,#%!13,S.#0V,T0W138Q,3@U-C-$03-%0S$U0D,T0S8\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,3<M,#$M,3!4,30Z,S8Z,#@M,#<Z,# \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC
M;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C@Q.#$Y.4-#-T-$-T4V,3$X-38S
M1$$S14,Q-4)#-$,V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#$W+3 Q+3$P5#$T.C,V.C X+3 W.C P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C Q044S,S@T-C-$-T4V,3$X-38S1$$S14,Q-4)#-$,V/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.C P044S,S@T-C-$-T4V,3$X-38S1$$S14,Q-4)#-$,V/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/D9&130Y.4,R0S9",#1!034W,S U,D(X-CA"-4,V0C-$/"]S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z
M9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L
M;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q-RTP,2TQ
M,%0Q-#HQ.3HR-BTP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z36]D:69Y1&%T93XR,#$W+3 Q+3$P5#$T.C,V.C X+3 W.C P/"]X;7 Z
M36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C Q-RTP
M,2TQ,%0Q-#HS-CHP."TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E
M;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_P  1" $H .8# 1$  A$! Q$!_\0 '@ !  $$ P$!
M          $&!P@) @,%! K_Q !?$   !0(#!08$ P((!P@0!P ! @,$!081
M  <A$C%!46$($W&AT? 4%8&1L<'A%B()%Q@R0E+4\2,D5EB5E],9)S,U-D=5
M<B8H-$1&4U1B8W62EJ*FM+9F=G=XAK7"_\0 '0$! 0 " P$! 0
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M$ID9"=ZLA@I4C+'OO)MAN5/;*R+S3RVHG,1O5;6G2UA3L;.*0$L5V:2@W3M
MIGL.]409BW77C7@+LCN6XBW==S\0@(HJDQK<9#+@XI_"O"%*</%.RI."@#10
MT"DR5(U$Y&H;,5JU<S':&RW84ZZJ:'DE:L8,5)=%Z6 3*99LK$435E=J$4"1
M/'DNZBZ.DFS;8.8!>K-2J]T@95=+YF-5]5YIT31JIV\Q,)J.FTE3\9*,HLOS
M5_!*52Z!E .)Q@Q%9Y&-9=V8C:-4<(%4D5C=W'I.CE4 AC>G1U<05=-IAS!B
M_*,!..*<EVLG&NXMZQEVS*/DE&B[9XDFH50&$K'KJ$U5:*KJ1S]-I*LW[%J8
MU88,9@QF#&8,9@QF#&8,9@QF#&8,9@QF#&8,9@QF#&8,:V&=&;=(Y#Y65OF]
M7:KM*E:#A59F5+'H%<R#K_#(M&,='H**H)*R$I(NF<:Q(NNW;BZ=(]^X01VU
M2?1"PSV,B',*Y +Q\L(3>,DC,J4:R2E(*C($R!D":,-*MK'_ (/+^$?RV[2.
M8^8&49:/GJ$JVHZDKC,ZE"R<DQEX^<BG;U!V_B!<M4&:K.>C&1OCQ;"W<,W3
M)N_53?$4:E17[JUO#L19;A,07R(AV5)0\*4*07:E8&1*KR"?EO3!F4_+6F(4
M#JVX?&NMDS!C,&,P8S!C,&-I=[4W\&:GVDLXZ]SBJ5NU:J-'#1Q'@6I73-Q6
MT/%1C7X>'?E:(O/@&[5!N>,1<"K#2!2"F@D\(S0;N&_JEE^(_#<-9EC0#U$;
M\5LBYBGD&Z=H1#O%OER>O-LF3]9*PLETEY--%35_+.@OG'C2'CK<?P;RSE6>
M7_Q,$YM%3Q\\>)#A!6[ARY6##H^0IN/U)0'A)2E*27C;0L@'=*NLF,MPHFG6
MU(TJPI=A"PM,,Q.9I!-($#0ORUJJJ)EG#=LHP4(BZ<&.Z=I[+ET<SA54PZ';
M\"]LVV;0@GS[XAXYB"2_(D7H>I2^0M211*E(>)*TCY4JF$T ;:;#M--L65!6
MDEV77Q3HJ4Z)O7'CM:W+U(5BI(>.UW%$ E,B0"9-<"I*5IZKXX\34L4VEX\Z
M<@F+=R"@ 4LI#R=/OQ242.FLBHYA9F4CCJHJ$5*W?+E(<IC 8.G;M6IR<RRI
MZH(!E2[]Y4ZD*U?D>N6R]4SDHXETBN/BC1\Q)SCR5E7C(S@J2J0@]2?,!02+
M%O6*8&(8QO1HRAX>AT)I*+7E7KBH9L]03,C-2"DE(R$C\KBH)!5PY.4FV+6$
M@XB-*J)/B796(/Y-P_EW<A(O#&K+!C,&,P8S!C,&,P8S!C,&,P8S!C,&,P8S
M!C,&,P8U"9I9B4[E#EIF#FM5QW"=+9:455%>5&=HD59V$)24(]GI0&B)CIE6
M=&9L%BMDC*)E46$A#*$ 1,'*X<KB'SEP[EM'[UVZ1.@O/%!"9G(3(F<@QOSO
M9U5-_"G_ ,(/DKDF_0R*RZH#LGY_9L94U*]B\LJZDGN?#'(Z2ERNT)/,9U/2
M3>BY"DI:%>,JL.,- ED&3R/@G<E#M&Z3E$VX0J;#L:*B/^:?/K0@W#]"2_=
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MRLDWHQ"IIIQ-,//&]%:Z% 4'.TK6==RSDS1A2LL6'CZ.IF$JFHWT!#Q405V
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M:=A&=NXC&NT6UCJ$[]0! -X*+BH<!\#8^<AX=98RG3ICE4_ORTGOZMZP)E*
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MNQO#7I:#7,!P8$;*@(B15D<[0Y#;@,4$#D)?CJ0?OOS!># ]XG"LY@"<_:$
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MB82): 4\S6;=V[=.W0DE.55'$XXG%O;*BFD4I$TR$(4 *4A"%*!0  V0 @
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MRWR;]O>'[O\ PYX?,C_^DV252$Z""A[U!,FAI*9HU8_Q]43QIS.R_P#^W'M
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MAWAS[["^-#T[U9W8\P]_AAWA[ZLOC0[^^_LS8'F&'G2N6.F;-H-#T\^Y^\[
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MOXXLQP&\ \<N^,@QG=GW"%^>H<PW:_C;4.6@R8[X]*?M2;&=V<?Z-N.@AO\
MOH'3QUOBSGRU^YF98TWU,F,[L_ /N(6'?PX!TYC]0$BF[6IK4Y"?G^QH[M0?
MZ/\ \06_'WRQ*?MZD?8?9C?7CDV7]PZ>K8S5^BG$,]^]/?/#9']0YC_Y-1>/
M]!\B#7O]FB_NP^GVYXES^[OFTFK]/4,ON]!]/3#9[^GNR:OT]0R_NP^FF&SP
M^;'O5DU?IZAIO[]_CNP" ?ZAIE])S9-7Z>H9[XX;/?WS9-7Z>H9[]Z>/ESPV
M?]PZ2YSDR:OT]0W YP(0YQ X@0HF$"D.<X@4!$0*0A3'.8;:%(4QC#8"@(B
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MK39L&7@NJD"%J=%04#F"#.;%VI:3Y #R+BEA0$TF(6$F8K--Z7D06R$*!2%
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MP_ ?3$XU^^M6-:_.]0A<F,W1,8I0'+&O"@)AV0$QJ6E2D+<;!<QS 4H7N)A
M N(VQR.ZK1+)23__ &$SCP[%1PQ[Y\&MUV,5$S=D#LK@4Y3"3LYY)$.!1 PE
M.&6E,")36OLF ! 1*-AL(#;7%?"3YX/_ -Q>F:CIOP;%'Y$_[4_0-DKM%Y^0
M^F.+IWN#9,VB\_QQ>/*4OI+U8S:+S\A]_EAN'[^7'#]I.^^YMRQ/;N7?5C1[
M\.GX8OTW>>O?T:]\=_U:<.Z=D=AHS#Z]]^LZ&<??L/SP[[]\&9=]G[-/OEU_
M'ZVTQ]%-V&_VKW5N"GKY:9U^O1^GO\=VGX8&7>'KA+&NK-W==3++AK)H]^^'
MWP/EY3Y&>C3O=Z]X-/KI[Z:;\)C/N<]W*DMX%!:=]YG3"N6+W[_7[AA3IUZX
M]#N9/R(P[P^GFS?O^X_>^F_"GUGAOEKKWBTR_>?HU%9BU,_HZC9NHXR.))NX
MU-H()J@Z,S9-W,@T8O9V3(P1<2"L-3;)RXJ*:1CVZT@M$Q;Q)@D=V=$@L>)\
MOMG^[*=]^GFV.T5GQ55;U<PRQH5>D9RH&S(:BF<P87YFG23B$@:GIYE,BPIZ
M:;&57;ST+4\.[@E8JKYB.E.ZJUE$56*U.)2CZRD)^4I"=0?H1I28.;6FG?=-
M-Q:OJAH?.V8K_):HF.<$73].4C'OOXW**B:3(2-S$DG4>@B#B+&2D962A8XC
M\JPM&KF3>KQB!TU2/7SPIS'^UP_@T0D8Z>PFUB'MSX6)VBD["ZJ:II%%$C_+
M R%6\^\0V!XSM'QEX-M>Q/&:;%\,6-_$%>)_#/\ #'$4KQ&F(=)1"2BUJ#QP
M'*P4TEL9[=U>>32U@QS'@JR99I]INC.RI6T[GGDM)2N4],Q51,5:>JVL(=O*
MM$7ZM/+)IR:9V+=I-2;Y4"13Z4(@D]BV:JOQHD-V?PJW"H2RW]KN'<!'(3&/
M5.E;1RX>%"BD/!-%27:4CYDH)*5* NS'EI\4V=;KCQC^+5A?@SX@M'\1? $7
M&^"K(A+5AE65;5NP+J,<.XE=EO$IBTJAG;FT(R)41!1$8ETB)@W"U_$%)S=I
M*6DYZE::FYR!<TK,S,#$RDM3#UR@\>4[)R$>W=OH-TZ;E*BX<13I51@NNB4J
M:RB!E$RE*;9QT3Y"';UZ[0\2^0[>+0AZD%(>H2LA+Q(54!8DH U QP;] 6+&
M1=HV/95H6A9KZQH^.LV!C(VR(AZ[?O[+BXF&=/HFSG[]U)T^>P3U:X9;UV E
MXMV5) "@![_Y>OT'\\<>OT&#=GO]/I7WW,T]\/,?UZ83['#R]-Q9^WOGT9S\
M/?,?MY!IAZY$8>7EE+%FF''#.7#?]V:>/V >/Y]=V_AARRU[QKGR93G@-*Y]
M[V>^'Y;M_APX84UY]^TM&G?>O5G/V'OEA3TIQQK3KNHUXXU,YZZX][ZM&T%]
MX7Y:=>&N@?IB33A.NDQEIGZ>=$C+#2LC^WG+%N7N_+CH(>-[6#ZC; R[_<LP
MEUSP.A%.^#6SSDROI_.O*K,'*:J0$(+,&DYFEWKA,H&<1QI-HHBSEV=S$V)&
M&??#2T<J!R&1?,VZI3D,0#!DE5PA8(!2H&N8F*'*N'/<"(G3=*G#S''5J5[,
MV1\-V;\A<K<DX-9)VWH"E(Z)D)-),R19NH5"F?5//"FIM'3^=U"ZDI,J!S&%
MNFZ(V*.PB4 JUA:U+Q"B3($RE@ . D/)H!=$I5[/6?E@U]??+=[^O4<8=X-:
M=_7VIEO9H'](+ZA:_CJ'CRU#77":00)B>AEC+2O[-94G+4]=WMPU: / ;>>[
M3%IEWV-YK.E6Q[[[^C3]O8] "^_J.F_"E<ZZ##[<I<@V4SKEK[\L-*UG ^_N
M/VW!ZXDAV!I03GO/>"9H9]3W]ISR9[\^N[S^V$A3[RX_7,[M&3-?FX8[^7#3
MR9OW  >[?3^_7%(&$AGGQ^M>.E:IF4YGG[SZ?1FX=/, 'WY#T# <!SD/J...
M;)_W'O=27#[2+=U@Y!]L4 U^50_\D]][C*2WCKZ,L'(/L&)(_H7S#);QU]&6
M#D'VQ2#^A7^23WWO9+>.OHRP<@^V$CDE6L[R:\#UX,_\L<<>M/)E@Y!]L)$_
MT*\U)S[[+/\ R^N_=W-E@Y!]@PK^A?-.G7'[,E_<.OHRP<@^V%1_0OR4G[=X
ML_\ (=?1E@Y!]L)']"O\D]]R9+^X=?1K*_Q"4/\ Q\!VBOB*D_;T*%_B]^$^
M<F_9CY)\;\=WWR?N.\^.[P1)_P!V_+K_ .-?+OF/^.X^[^(17\/_ (;<3\-\
M1\23=3MMI=E^>]A*7]-[^F]=^5M"_P#3CP]_ZC?^J.VM3_B3_AS_ (7V7Q[S
M^$_P[XGXF_\  [*]\1>^7_K_  O_ 'OA?BO^8:F'[.J<R\W:+K7+'/6/;9;9
M73=;45FWEO$1S*62J"L&"7PB\-*2@*@I&RE/NEVP/&:Q#*,.[(JU %7BHXKI
M]#NX**<O8(OHE^79AHHO+I<)2J9DC,*$Z@R,Y*HEL+<\.^,+0\;^$;>LGQHJ
MR/"MC.;3=^(_"@LYT_1XB>13E2(1:HPJ"W'P[PH5)25;+9!3B2WSTMDC8.0?
M;'P2/Z5\+R>^(X4;T"6\=?1E@Y!]L)&7Y%:XIR[^LF?^0Z^C+!R#[82/Z%?Y
M)/T9+>.OHRP<@^V$E?H5_DEG_D.OHRP<@^V$C+\BY?[DZZ=ZLE_<.OHRP<@^
MV$C^E4I$RF-W<MVYGG]?1L%.V-G#4^7C-"/AC':QXMH!9V=-_P#)S/U)^ID:
M>V596P_#L8]-;XI9,!3(Y-MHN3E3[LY/ /Q:\16V[MF!\+6?%Q5EP<19CVT8
MJ(A L1,6I*8V4,EX[*7FQ2(0I4[=*27BGW\P+2E*#NOAF A%0CZT'SI$0^0_
M#EVAY=V;H'9"_)4Q?)>3"E#Y0FA$R6UNK=H63C*A39I4M(/5CK/NZD(*1DU5
MS*LJ>:3@.&2OR5-M+ME%'"B;IU 24J:':MOB9--)>0B63_Q1Q8CVY\<ZM9Y"
MQ"=FO:/#L7H4N*7#_.]3%;:'>I"04)B$.=NM=URI27;]XZVU42D$.E0X>(,Q
M($J29.PNB2[NK2;Q!V95=2D%8!4E*MMG9TS'J"JZ2G!FU!G1I]DP>L)-%;XP
M\@B]:.W ,ROQ*!G^R+0IFCQ0HK+HN""J(V)C] ?A-XLMFU[(MR'M8Q-H+L (
M5#1#T'XQ^AXZBE_!Q"S>+R(=JA@E*UWGI#P(6I5Q).E>);-A8:*@UPH0X$:5
M!XA-'2%)4[&V0!^5VK:5"9)^6:0)EL <V^T!5+ZKVT=+B+\LBS&33;+33R*B
M8IJI(EC@*W9H1<@T*SC"'^9SD@[5;K,X%C)2YAD56*C=3PNU+;M_QBJ*M.U+
M5B@[^(4[<P#D$PD. [+U#ES#_$.4A:DA,.X(0]?1,2IT[?/07NT&X0\)!V6$
M0\/#.PJ[-;]1 >KJ!>6\N*,A5:Q>2EV["BE)NR:DLE.T/F*M6ZX1+52"@6K:
M673(1=Y(,GJ\0^@V(?%JJ*MFCZ-E5W4Z@U5&%9?OPRY6$BX>-9!./YH:T;5\
M&"'C[)MJ+$2'T,7T&\>$040Z>NWSQ3F)@25H4I#MW#[3^:MZ@/TO$[ EP\7@
M]AX>U-HYBH5!04J"'@ +U"D*0@*=OA=(!*EW?E"57""526!M!SGS%GX#+ZFY
M*#24B7]6$:?$.P()EXE)>-(^6:HG,6R3U0RG<IKB'>))H.3I%(L!%4O=?Q*\
M8VO9'A&Q8VRT/8"*\0)<%[$RF\L]V]@Q%+<.U*2 [BE7MF[>$7TH=OE.PEX$
MK1IU@V5#1-I1CN((?NH$KNH)DA^4OB[2I0!^9V F\4@R45)!)$PK415O:-<1
MKZJ'ZL2]J%C$EA/EE5(3ZCYG-R<O/2,,=BN\39NC,#$-$R)F;_O7K-W(1[J&
M768R)XU*1_/+NR(^T7D*^BK6B?CHI<0N(1%%\N,=(<PSI_MKSY^%OE*+YT%H
M)0]2Z>(B$AXZ#U3K>%1#ERE:7<.C9(2["=E=#E96M2+DDH*4T0J2A>25 H-U
M12%;".R=G'4U82BU/R82*T4H>:108S*BZLU3ZL,ILI_,2N4B+L ?(@54(U0[
MAN1%[&.V;DR;DQE_6?PG\3VZFWD>%XZ-?6M9\1 +BW#]ZM41\&MV[2\G#Q2E
M/%K@U5ABA:@E$1((0Z4'B%ZWXEL^#^!5'N7*(5\A\EVM"$A&V"E%,EH$@EZ/
M^H"!.X:E0ND9]6#D'V#'Z3N#4]^3:"RP<@^V%P:EC+!R#[87!J>?MHQE@Y>P
MPN#4SW_M6C&FP!N#"X-3WY,;NV"\O/$*B)UUI+"M#//3SU8S8+R\Q]<)G?R!
MR%#2F=>A8S8+^OO3 $STXRE*L@"*\,3.=*5,V"\O,?7"9F1,D\ .IW;F,V"\
MO,<+QWUK.@\LZX8]&,V"\O,<"HY3WSEE*=.Y5G/(S8+R\Q]<0J.1)EG30Y2G
MWYL9L%Y>8^N%XYD\A7A3+/ABQN)]@A#'-<"D*)C" &,.R4+C8I;F'0-Q0$1W
M %\4*-<3IAI7*NZG%C:\OX/:NJ(K5IVLC4A5E/503^65GA40'@)AE+)A U/)
ML5J<EQ48KKD!A.(QSY6+<B8$WR31=1N90B9A#F?!0V5""7:<LQCD,)\.$VP2
M17>HGR;8?L%Y>8XX+QD:GD!ZY3Y<\V;!<6\9#,G< *><S]SAH3-@N%XG">9(
MH>6!\I;Y',T;!>OOW?\ 3 */TTS\Z:<L#5C-@.OOZ8MZ68Q YXDC=A+$9L9L
M!UQ+_P!9=UX:RK.D@QJ%KK+:E,Q8XD?4C$RPH;?PCYN8B3YIWEN\*BJ=-5(Z
M2FR45&[A%=N<Q2',D)R$,76/%'A*Q/%D.[<6M#K+QQ>,+&0SS8QD(5RO;%]=
M6"E4A?=O$/'2I)447D@CL;.M2+LQXI<,M-U<MHZ>"^Z> 87DS!F)F2DE*AA.
M4PUCT.R;223A,QZCFA:)"($;HM8U!<A+ &P5SW"I"?NE HB5J4!   "A8+>7
MH_ >Q ^O/;;M9ZX*IETE$*AZH3F$E\7:TDU$R'$ZT K+8#XRC+ORPD.%C!16
M]4D<$7@9;K^Z;9#4K1]/T7$I0M.L",628[9["*B[E82E*9PZ7/<ZRQ@*4NT8
M=DA"E22*FD0B9?7;!L&RO#5GHLVR(=,-#I45O"25OGSU4@I^_>J^=\]4 )J4
M9) 2A"4("4C68R-B8]\7\4\+Q9%T"4D(0,$.TBB4B> Q,RHE1)-DJ_[/.7$D
MI+5:=TO20HLWCZ8=-4FR\:1DW(H\?+G:K)"JBD4I%'"J3=P1O<#&*VVQ$1\]
M\0_@[X<MN+>1D(^C+&B'[PO7KJ#V3R">/UGYGR85XD;-XLX[!Z[=FLG8)FW=
M07BF/A'0=/4NXI"$W4J>7DO@D8)+Q,[R0/U)*O[BWGY8Y"Y7K1=-UG&RKFLH
M.6BHJ?IE0Z*;"$=Q$BS0D(AZ$<"";A1%9FLW72;NCD2!,Q4UV>@D#BL/\%_#
M=DQB(VT'\9;3YP\#Q+F+V+J$VB3>"GKAV%+?D*%ZZ\?J<KP6[6)MG%^+(^)=
M%TY0[A4+3(K05J?2(E)*U$! EH@*&2@V0E1TM!U9$+P<\Q3?1Z^R;NS")%$5
M4P$$G#98FRHW72VA[M1,0&PF(;:3.<AO3+:L6S/$-G/K,M6$3%0CV[_+,TJ=
MK3.X]<O$%*W+YW4)>(((!*2"A:DGH(6+B()^F(AGA=O4SK(*"@9%25I4"%)5
M*H(T.(!;'!?LF4F*Q@8U%+M&(B&RT49Q[@Q" 83[ +$(V3$ ,8PE$6V@B)AV
MA$1'QQ_^!%BK?%XXMVU'3HJFET\=0T0]3@);<)<SE*2271,I S,RVT)\8Q83
M)Y".%*E525O$))_V?/G65[75KT4%E92>72+@()LNJ_>% CV6?J)KR#A,NR((
M[::2**#<#$*;N4$4P.)$Q7%8R9#%]'\)^"+!\'.G@LMT]>13]*41$?%K2]BW
MKL$*#H*2[=NW3F]->S<NW:5*"5/"\4E*FZ*TK8C;54GXA24NT$J0Y=)NNTJ(
ME>J5*4J5+RE&0F$R!(:XFP'7&XW]QXTZX=R ;JV; =< O]M],],<2QIV"\O,
M<"HC$Y92^A&FAD30'0T; =<+QKY2PGRGGC[$$&G8+R\\ ;U/.LO17=9UD#=N
MP/3&5T;SQ/?8;.X=>Z>^631L&PNC/'"?<^]U&7.Y#U9L&]_AA='VKR]N'-ES
MCR'+%FP/3[^]^%T<_;AI7,SQ9<W]/?DS8-A=$I??#AS++A[ ]3@T[!NGOC@4
MBN->7+O<UN;^G7%HV#<O/"X-^$FEP]R]2T[ ],2X-3WW@)8-;F_I[M058YD4
M=0@)EJ.73;.EB[:$>W25>2"R=Q+W@-FY#F21$P&*5=P**!C%,0J@G#9QJWB/
MQEX;\*!'\9M!#A^]3?<P;I#R(BWB)E-\.'04I""00'KTNW94@A*RI)2WWP-D
M1UHE7PKDJ0E12IZHI0Z2=+ZE"\J52E%Y0%2)5;$SLZF[,^1 9BQ67B<C3"6:
MF:U79L5"M*Q946@5#6#A ZK!FI'_ !)6$'&(-D&<4S5!-LP1!00,D54]M7A/
MQE\$6@_0X>QL; DW7;M]'0:W;B<Y J>N%1 = _U+>AV@8K4D"8[![X4M5R@O
M$NW3Z52EP\2I<LY)7<G+1!43*@FV=3=5)T@DY;+).&ZZ9%D%T%"*HK)*% Z:
MJ2J9C$434((&(<IA*<H@8HB A?TYVIT^=H?.7B7KIZA+QT]=K2\=O$+3>0M"
MTS2M*DD*2I)((((-6Z NU)*DJ"DJ22E2%)NJ209$*23,$&8(,B)'S[M@W3')
M='27<^DI,N;^GOZ,V!Z871/REIGNDRYO\Y>\V; ],+LQ(ZS\_3=U9<W]\^Z[
MIM@>GOZ8EW"N'+ZXS)S:7#N9L#TQ;NIGEY#*AX,N'<S8'IB7!],M!Y]XSR7#
MN:-@WA[Z7Q+@U8$'AWN9L&Q;DL^FZ6N_O-</#OBU!YJ$$,L,Q]VE!U>/_P O
M2.,D)^=%<%)Z&FF4AY-%(("L) $]#N:C.S*01[-_9_$+#_O*96?_ &/!8R>)
M_F+_ -ZI[ZR_?7R#1*"4@B1H&OAL#TQA=GG]?(XY?4DME<.YHV#8EP>G>.%,
M9;ILN'OOO>T[ ],6Z*[]W>_=NE1EP[F;!NGOW;],+O"F&..N++A[[\FC8-[_
M !Q"@5W_ %UQX]XRXKOZLV#87=_3CSG//4LN*9L&]^_=O"]N#O3NIWSU9<5W
MWW+A.=@>F)<T)'?DU"#G3JW9KX<QMI^/+C?&;8;8RHD3IF?3'#5FOL/U^OAR
MP:[8_I&F)QE7++'AA/%FO$0Z:?K@TVQK)(.>)R\M-_6C1KX^ :^8Z;@\?/!@
M?'$I&^N5..O35IUZ?;]?7Z8,V]!0;ZGTP'7)FM]X?;?Y^],&;8RG=&^7*IRW
M?24IM>EO#]?RP9MS^FG$^G>C1KNN'VUX]<&;91_IY:;M[:4NWQ3.>[:=DYK*
M5-&1K=DYS"J*E"/I1FV@Y%^?(_-"'R^BIM-X^9-7D<WS'DZ':O8QXJ5-N*2$
MNN"#1I\P1_(OCZQXFS?&UK1OBAQ%_P %MJ)@U05I!R]>.EP/\3LQ;]Q"OTNU
MAU$P=FN8MR78D\ 1\J5)?(VGI=B1KJ)LN'<V<^<F+@W3P/X;:)"TOOAWX0MZ
M[*@2[>OUNES/RS-2"DRP&CZ1[5,M7E'5)F##B63COXL&-3SM,RD&QH]$],9U
MY@RE<2%*=UFS$2T%2=09;R5-%2C)W+JNJJJ*$!"DJDD&,JU=3">L0Z;(BW;R
MR[$=Q$8_BUQX@+/1"Q49:42\B;)@W<$X6X=67$&*C74>[B#.&BX1PY>SB8=V
MMVI+INP?+?0P^+CWCF&<N$N51$2\>NG,*Z0ZB7JGKS:KB'8<N5.5._\ J.UJ
M6/Y:R%34WZ%>SI5E.FHB'IH]94](3^V^<H0:$RQ<23-BNX.L@V^'*X%50Q"F
M.X423 XM@7[E0"&2,0OZX_#SP9XP\,>![,=>);(M2!6E40]2[C(5^[,##Q#]
M;QQ#/RM/\EY(J>%T\*5.B\V)2E2"D>4VIXG\/6M;40BR;5LZ-6H)3*&BG*U/
MWCM "WCI*53>HP25H!!";X)35LDM>?D([_KT'WOVEN,OE?I XG24_;,C+5KT
MZ:?K@TVQT&ZI].&,N#->G72X?B X,VV%.?<M,\\F:\;=-/U]AXZ&;8_IX<9&
M4AGESW@LU]_WZ^7Y@:[:<_EX5ZF0W_6M&:^P\]_ZX-"^.29Z&M3NIWT:=?8?
MK@S;&5$]3NED,R >;1R]!]A]<&;<C^GC67*G>5&H/-2XY89CAI_R#K#_ .WI
M#WTZXR3123HH?5BGTTD2J1+'45Y>VK47V9+_ ,F[L_Z_\R>5=N'_ (#06GY;
ML5Y_U%_[U?\ W%HA[=2D$3^43.$J:?MYM?#72WUT_NXZ==^[&#9;;=]^Y8G=
MF#1FOX?;C[UP:[8:=?89#@,V7'P$?K[X>[7--MC))EKENR]]S/II^5O73!FV
M$OR\1/IA(YGR:<&NV%/E->_K3FT7]_C?D/+\L&FV'Z989ZZ4YTX3S!?C;Z>^
M>#-MNGO$_/ECG3)GTOX?K;WX7P:[89BF(K['.<]&YB4=+#J._IK;K?CPW .+
M+?IU$_0'2;8[(4Q.HTRP'#B9<6;(!K>_.P#X[_I]K#NMA*LN\>G/'HV0QF3+
M&0$J#AU(SG@:MCGOX;OIQX[OQPE6E=^[5FSQF2#Y9R\J\",=*-GF/Y\;;OON
MUYVPD-_8[ZR-)ELAGZXT^Q(E.1T9LAS^X?37EKI]^&$O/'#=IKJS9IUET.,O
M*N)QIG6;9W:]0T][@W\>%APE]0.Z\M=S-D-344$IX&<J@\2)DSI(YA( <0_#
M?O\ R\NEP$^]\N^#"Z D+Q.&,@,_I]^#83=NO/%YD=E(I+M%WS)*0^8JRLA%
MJLV\DA"Q:+8SU%B[?OHUFR<.U7S0AGKF09I(,R.A.Y;@;OD_0_P\L>!CX^-C
M[1=IB(>R7#I\F'6$E"W[Y:@[6\2LA"T.TNGANK(07ETJFE)!\^_$*U(VSX&"
M@+.>J<1%K1#QRJ)25!:(=TA)>(=J=S6[6]4]=@*=@KN!80+R@1HY6[5,*Q.O
M*HPDVT.BZE?ECZ7>(1"4PXIMDI*5&_BJ@4*YI26BV2B:<,REHBI91"5JA_$1
M>RV:2K>4Q[;'/++M&#?0-H6=#QL ^2IT\A(]PY?0D0[=I*G@*'R'D(^=( "$
M%*GB5/B[1\H4%MXE"PMH0D2ZBH6.>P\6Z4AXF(A7CU,0Y6\7==&;HIB7;U4R
M\6%(0L.4O%F924-EOGUVAXO]@J2J"0IYI$1\8A2D5-H0<93M-KS%5U=5;"DH
M^5D5)%U3\:V;E-+PZSPKY\V2C!4EA;(J+"FU4U;PO^'OA/P-$VI:MEV'9<(_
MBXI#N&B(6 @H:)AH&)+A"88/@ARI*1$/7@?*4]O/'3MT5E:DR/?^(/&%O>+G
M-FV;%1T2M$-"/%1+I;Y\MS$QD/MGBXE3M&T"U&'=(4Z0EW==O5O;@2E5X88T
MYVL8^4=(23"DIZ.B%'D4[BYT':CIW#P1HN5EY.KJT:4TQFU\OHF*&+;IQTE-
MN$F,V$K'249(?*0>2+3<!:;J(24JAE*</0$F_)XDN5NWBGBXE"$O0X=!*9 O
MOD>AXDI.SO*3K9LE[#J2I,4D1#LJ(N'9JVZ'B$NW<*M:D%^^)5>*77\QT7:D
MJ2'EU*OTH=G^M)*O\JZ:GYE0RTN!7<7).A  %XXBWBS,KT]K *SMND@LY$H%
M*+DZPD*0NR7'YP\9V3#V-XACX.%%R&)=1#AW_I(B':7I="9G==+4M#N9*MF$
M3F9EOT7X-M)];7AZ!C8I15$D/(=^\('\U4.\4Z2]/][Q*$+7( %X52^4@->7
M8WWTM;EZ_0.=^&N-7EAOXZRX]&VC9XS)ICAGF=^$CF9;VG9\?J&[@%]>/U&V
MN$JRGV-/+AHS9C4S-9YB<I3R$_,RJ-P26'?RX:CJ&X.-KW\<)=\_3KQ870_4
M:4'G+ 9T/23-G7?PW[[AN#7CKX[^>F$N\..>6>$O-FS%:ZD85KEH9RPX&HDS
M9W7OKT"_O\.(X2[]->Y,V0IB)Y<Y'''Z9TQC9Y=>701UONU'[<+#:W?WKRE*
M<^\2&FS&ITE,:#3B:[JTG*=FU]]PX6ZCKO\ J/TUW8DM_G7TK6E&NS%:F8RD
M"98;S(#6F&XM0>:A;98YCA?7]@JP'_Y?D=W]P?GC)(F1C^9(PU\VBG8$\B$D
M[I2RUSZUI2B^S(7_ +6[L_:CKDGE7]QH6!T +W^P?3%>#YUG^]7_ -Q#1+L%
M*3,_E2*2E,I%!69Q_=KX 7?J.G37AOU"U^'/7&$N\O+7Z>56RV0)I.F@EYG3
M=/&6K0)?KJ(?:PWW_P!V$N0$SZ=RFPNP-]2,M\\,)S).FX-($UY7N-[7'EKQ
M#?\ 3=NO@0)8Z9:]Z9<)MG/,_651.8&>$\:XZB-D1W?ANM:X?GZCI@1+IPK.
M7TSERJTV<\U3K[^==.M&;)M!"P^'F :^07_#"7???5A=;Z;B-YTJ174R:-D=
MP" #?B ^PO\ ?ZCA+W[[SR$V;.9D2:4ENUP'6I98>8#?A8;Z[@#\^NFF$JRP
M:;,:\L3/RE3=P9L&XZ^%P'ZV'C8=WI@!/,#BUV<M>%#*IU!WMV@0XCNUWWN&
M\>MMV^X;AW>-D0*X:'T]M[924321,YX:[YR^V-*R8)#!<-X?@/W$>(#R$;>(
M "<)4E+#N=)U8;V>M<Y:\YC=7-@@;7IRW7MPUXCIRMK8=1!)0Y=/;I3.3)JW
M2!]OIQG7BS8-KIIXZ!P$!UT'H ;QY:8?-SEI7"7E3'#JR2O(8UH-9;R3@:RR
MJT[!N/#K>WG_ $@XV$!Y!;"1/8'EEAIDT-_C+.<Y3YT,\,]364;)_#C>X?8+
M6X?01 ;:[P!TPRE]MW,4:_.)])2&4\=]998XF;!(/TMQ#4>H7Y[]X;\ %999
M3'6OEPHTFK-..!I*1WFO3ABV.6?N5U(Y_0LOE:Z?1_[6T['0M7ILW[95PU;Q
M]0NZ@C(D94G<'34BYMW2LXW'X<RKIJZADW9VYDTD47>T>$_$2_#EH*B'CDQ,
M#$NQ#1L."+RG84%H6ZO$)+URJJ0KY5(4M$TWPM.K^*_#O_$=GI<)>B'CH9Y\
M1!OR#=2\*2E;I[=%\.GPF%%,U(*7;RZL(+M>!D1V%J_-4ZSA:DZ)A%7A6[.0
MJ\%(555RP9&:E;IF%BD><>)-R,V@L6KIN@DF+1H3:; BF9/V)[^(_A1TY5$N
M"_?Q2D "'1!J=OU* %Q#Q^\2EP$@I2"0^>70F:$K*0&\@<_ASXL>OT0S_8N8
M5*S.(7%NWC@ DWUNW+M:WQ40I1 +EW>)(4I$R6OAGMV-D):DJ72HB-:5&K34
M?&M9:#DRMB*SSF(E_P!H6-0-BN1!F:6;3>T^^&55(  BQ!DH*S,B*^L^&OQ$
M=+C(]UXBNNH>.C!%0SY*2]<P:DATA$,\2 IYL4)<N2[>I02EZ%+>@!96C9/$
MGX=OT0< ]\/S>1$#"&$B7)4AV]C$J+Q;R)=J)2@OEJ?/4O'2E"\[*4.R2@)7
MBJQ[*-?U_),XF8RJ)W2$@V? _K2":H148\9D.@A*D6E6J@G=,D5E2-U8U)R^
M(DJH1L42G, [[:'C'PK"0Q?O;1@HRY);N'A5.XM^MX ;@0[22$+R"WJG:4X%
M:6T.S_!_BR*B X=V?&P05-#R(B0N$<H=DB_>>*NEXDF1*70>*7*80IMM>6\+
M3.7D7$92QDF1S.0%.MIU\W%)5-PY:RLE((+31_W!1*B]F6\BD@AWZBZ":!4C
M 8A"*'_.EN6J_MRU8RU'R0@Q+WY'85>2Y<NT)=N705@2ATE 4H !2YJD"J3?
MHBPK*=V'9<)9;DE:89V0MX:*?/GBU/'SPI_IOO%KNI)-U-U )"9M<_9$0W7_
M 'O*UK?F :Z<]V.I^8]@88GCJ<=6[::CERECD,J2I+49!FP/._#CKTZ7U]CH
MDKE7(>?OP9-9R.F,\?/I2<]U6R(6Y;P#6^H\->6[7??QPDKEC4'RW\&LU2 E
MO&G'7'#=7&8:1(.F_?Q$?I8 MY6M?EA(X_<<_?C-I-<ZCAE6F\R\AAR9L#OU
M^O2X -[>.GWW6PD:=*CI5DWFFA-.(.)RJ,=TLQQV!'Q\?OO#33Q\M5U6GT&[
MS[U9-7UXBAWUP$\*=)V!UTZ:#X!R#?81X7W>#YO>FHSTPEEHSYYRETSTH3(T
M P.9:@\U"C_%AF/;_(.L+ZC_ )/2.M]W34-V\<5((6B?ZD_5H2N2J&4C,_68
MF<LY^345V9"#_)M[/VG_ #)Y57$?_P C077P  MZXKR9>+E^I6FI--^9EFQ-
MZZ#=I=$N$A*<]17@U\=@W 1_7?ZCP'CKC&2OMB.'WDU!7H93UXG7'/[C%FR-
M]XZ\;^(<=_(.6O+5)4MPWZR.'+SWLFO'ZYY#/*OVEE.P/7<(6"_YCKY<,)'=
MS$M)\=#BR:\+ITE/+,;LM6;(];AOM>]@WAO#3S\1PNG3'>,V3>3PPF,< ,)R
MGYMQV1X7 0#=?\[\K=+VY"&'S2E+#=7SZRXLFJ?W!W#[]!A@P2B-]^X>8AOT
M#[WL([_()(Z8[N^36:SC44!X:G'RY5Q(2B !^Z/+C;76VMN=^%N(\[\T]]3E
M/3[8,^;20PKGG*A,LCA7$, !XW >M[6#Z@/AK;?B&>?V&/#O!A*QA7S(/[?=
MOIV1N(Z;K:^&M]!O]_3%F*4P,\=^4L,LM92:;48R,Y2RZZ]XAFR.FNX>8Z^7
MASW?>WA,S&/>Z=>'$TE-J*?FU[Z:X<9QLB'$+>(VX;]-W/S'3"_3#SSSSR(]
M928'@G0'AEO&-9Z<,6G9$!T'3Q&X_KIPX!XWEX'$5\L:Y&=*S.<_)J'HR"I9
MUX<M)\!QBPCQ#=8>(^?Z87A+#?I(\,Y;V%[N(F ,,1YZ[FG9'ITL(WMR'I</
MQL.%[4?2IUE+&7'*AQ9M1H1I+Z3G49R^C-G6^G6_GNL%OQX[\+U)8</>9G]*
M:29M$SG=/KRD.E=6L7G#EEEK*1E49E5+14;4%24Y0TCW3M=Y)Q[AY&4PWG)^
M,AW3F,=MCJ,D'\A**H%4*H+4\F].C85U-K(*H!PWSP'E0 4GP:7TDF0-</M,
MZ3+:RH?-"AZO?4A1T9D/%4GF0];9,MZ_IQ<N969KNCYO,O+SM+Y@.30L)3M2
MTC(5C2,A&Y%04A1-5MW<4#^GZP=/)V+B9^GYBEXZSWSQTK4"<R!+'A]UX;Z3
MTW8<Z:_6^N:->=CG)6J<I\OJ[RYK=Q6.;M6/LOZ6%A2&8U.P#VKH>?R\I>1,
MXFJXG*?@H6F7DMF1!E@:K?3Z])3CD?V8A*FF*RD::I^H4R1/"0F<*XYR-<*2
M#6^/TDYUTH<CI7DT9)QM YB9JU50E1Y31$;%(26?Z5+/4VV8U/*JL<C,]#Y/
MK_#R4O54G'5W\T:NX>;EY6#0IYI3#UVTBS,I<LPDYC5Z0!GF*"68GY;L_J)>
M$IR^AE/S^O)L[J+RARYR[D)*6HVEF,)*3#-G'24@FN_=.W;"/6=.6;,Z\@[>
M*%;-W#UVNFBF8B8+.%5!*(FQC?/+ =\N&^K-HG])GF>^Y[J-<;9][[CUTW7W
M^[+V%,/*0TY<"-[-H,@?.1PX\Y9\F;/A]1Y:<2^'3 *QU/&66A&_CKBUVB:?
M*<M#EK7ENPTG9'IUUW\K_NZ\;\^.$QOY4'#YJ92TDS:C0[\*Z3USGKFS9$>
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..!C,&,P8S!C,&,P8W_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g320192g64c21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g64c21.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1@$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      %U    $     $       MP<FEN=$]U
M='!U=     <     0VQR4V5N=6T     0VQR4P    !21T)#     $YM("!4
M15A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @ "@ ,0 Y #D .  I
M26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L 0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    B %P 7 !0
M $@ 6 !& $( 50 M $T 5P!% "T 1@!0 #$ , !< $$ 6@ P #$ -0 Q "T
M6 !% %( 3P!8 "T ,0 X       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'CP
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE- _(       H
M /_______P  .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     SX   9/          $                          0
M   &3P   SX                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   SX     4F=H=&QO;F<   9/    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   ,^     %)G
M:'1L;VYG   &3P    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M" 11;G2^G/Q<[-MN-EKGO8:+[2UQ]/TZV%C=@;[FOKVV/<WU+F>AZOJ;%ID
M\B8X7.MZ]F%K7#,Z8_<X#Z=C>7AGT/<]KMF__P!1UK;P'Y+\2M^4ZI]SP7.=
M02:R"2:_3+O<[]'L24!0T3P/!4NK]'P^KXC\;*8-Q:X571[ZW.&WU*G?]4W_
M  O\W9^C5Y9S\#J;LGU1U BKU?4%(K  9&WT=P=[V^W\_P#?L_X+TE=)8Y@S
M,'!LSV"O(RJJQ9D-?N:U_IUN#_LT>J[']WO9_/?Z+_">LKV-O^SU>I8+G[&[
MK0-H>8UL:SW;&O\ W5S3>JYUCJGU9>7M>Z0TX0<T;AZ>RRRMX]E3G>_])^CL
M_G'K9IPNK-R:[+NH^K2QTNI%+6;AL=7M=8UW^E=ZW_0256MVZ&UO@$@ .$Z2
M2G+S>E/>,AV,]S#?2]I&XN._W%K6>MZE;:;?5L]:O_BO36ACUMKI8QK2P #0
MZF3]+>[\Y_[[T1));&$8DD=7_]3U50M_FW\_1/T>>/S5\L))%1?J7'^@?H\_
MF<<!%7RJD@-D#9^JDE\JI(I?JI)?*J22GZJ6=D_SMO\ 0_\ KOTOS/YW_7_1
MKYF224_1E_\ ,V_\F?1?S_U[Z7_?_P#T(6U1_,5_1^BW^;^AQ_@_Y'[B^64D
ME/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3_ /_9.$))300A      !5
M     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!!
M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-
M!"(      7Y-30 J    "  , 0   P    $#E@   0$  P    $%6    0(
M P    ,   "> 08  P    $  @   1(  P    $  0   14  P    $  P
M 1H !0    $   "D 1L !0    $   "L 2@  P    $  @   3$  @   !X
M  "T 3(  @   !0   #2AVD !     $   #H   !(  (  @ "  \X?   "<0
M #SA\   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C Q
M.C$P(#$U.C(P.C W      20   '    !# R,C&@ 0 #     ?__  "@ @ $
M     0  !D^@ P $     0   SX         !@$#  ,    !  8   $:  4
M   !   !;@$;  4    !   !=@$H  ,    !  (   (!  0    !   !?@("
M  0    !              !(     0   $@    !.$))30/]       (
M      #_X0& 34T *@    @ # $   ,    ! Y8   $!  ,    !!5@   $"
M  ,    #    G@$&  ,    !  (   $2  ,    !      $5  ,    !  ,
M  $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (    >
M    M $R  (    4    TH=I  0    !    Z    2  "  (  @   /
M 0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP
M,3HQ," Q-3HR,#HP-P     $D   !P    0P,C(QH $  P    '__P  H (
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M @,! 0$            &!P4( P0) @$*_\0 3!   00" 0($ P0&!0<)"0
M! $" P4&!P ($1(3%"$5,4$)%B)1%R,R87&!&"1"8J$S5UB1EYC7)4-2<H*2
ML=CQ)DAC<X.RP='P_\0 ' $!  (# 0$!              0% @,& 0<(_\0
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MDD,8CC;IKV0;X2RXN[7P). M++-Y.,8W%QQ(\UQ88K+VW:@54&%3%=R^ME4
MKW?O&U%DAUSCBREJP!,?,S_[/+JZWIOW.J.KV7D>+Y/2YSTX ;N/&!/TNVPP
M+,2LGQJJ;C>,4FJ<ZS#):[7YXV07E= )NB$/8M5>8,2.98'EF755CD3JS XS
M%VTCV<4\,EMEWQJEDR/"ZMUAF?O32WUM;PO=JT4;EL<6M)(KE2JH%CDFD=*Y
MW)Y2YC2\EAFCN<2N1;BV.Y6UP9H4[,,=C<W$R6KB65 N1"W<<EL59W9I$AU\
MU[NG8P_6#4=<=GKG9@/3UOC<M_TMQ[7/R36DVH9M!6)V,:TZ:,DJL;$V0?LF
MO,MNH[$+F_"R*]UU0TJXYU%WLCK>42*C]?:W>.M#@).FTN[-LKB\?%FS8K#>
M#(#**LUYF87F:T6S98\1<1Q-#%=RR=[$1>X&,H6KM<A=C/1]1M:7@Q63R$N&
M]M:6S-B<6[0V>'F2(7;7:L^6@DE662TBC[.6E)<J(MP;:/45U79)TAA7&;;W
M'D_I(_9\[TZA)2L8P+&\+*U9>Z;V#TWUWI<9N 7R&E5698/N:YK<SEOIRY0K
M.O\ C>+3XV#+\''E66)P<&>:.WQA_P!4=58S% 3W4UP+V+(6F8?<T; *KV]S
MCXWMA$%#(W;G$S#N-&O<KFYL$LEQDQ_K;I;)94M#:PVYLI+"[Q" 0R+MFCGM
M\A(EP92Q#IW(3"I,8DEAGYI'5=CLT?4QKW1$55L3K5J8MXDX]KIX6?CUW3_T
M$Y1'<3PWTT&!6%Y?*1/D9]JT:6.3"*6QJJ!*M_P^ZK-*VJC!3#[GNLF9+7IQ
MSC1+><K4OE.J(3&IB#721Q:$*1E@1<R))+W/?C?:UTQSD)^^+7&!;OJ*/[Q,
M5H5N@F,Z9E$A$I%L\DG^U9P#NWB9(N'NR)*L?Z_.HC(\(=M#)LXP366;8CB_
M1:?CW3$1B%<RTZCY>H7']?6F77-,W)C6[%"BR2^RW)<&U6#B$T*XED6$V$F:
MQY@UAU:/HEZ6Q,-S[%#;75[;3S=1++F5N&,>(&*ENTMXY#"GLC&&*WAN;YK@
M'OQ7*"V-OM7;?#U/EIK;VR:YMK.Y@AZ>:+#&! ^7.5AM7FDC[S&[432SS6UD
MMN5,$ULYN1. R".2[CW]N[;VA,CQ3?V OWQ;P?:!#87T_OQ?$O%HG.]=8]E.
M(8+0Y3#"8F4V C)ZJJI]AOSI9);2X.DM\.EQJL1@"[1C\5CK#)Q3XNZ&,C;I
M4W.4[\Y&3MKN2&XN98"4$"-IWDM/9M!(U$=P)G)8:CD,ID;_ !DL.4M3DY/[
M4BWQ9@@_U;<VD4]O;13@-WW4%(TN_:22\C%X#$FEKTUZ*>HW).K+'<ZWE"'+
M1Z?N;3$\:U)CQ]6@5W&7CF%4\^WK2Y)EAB->77[;NLIU=)6DHUE>5JHLF*&"
M6U):O'=18B'!36V-+B6_C2>:^E1^4166YD%@D8!*\7L8X+T.OXEO57;! :[#
MI[+2YR*YR04QV$DD$-C$R<9 8K>,W[R$@-R2^DGLBA_ ;)F !=A7D=]F3@F"
M$Z)T#=:W@^SLQ'J,N.FLJ/ -A8U>5M_U35NS[G4]D(%<Y=BA]0BGVS)B2I]D
M5GK9Y9:E+N%RR1NE<G=]8W5T,GE([P]63XB/+H;JUFC>+"O91WT;-'!.KZ1"
M HM).('<[9\'5</TA:VIQN,DLUZ5M\M)B&%K=PRI+F4O)+%U62>!HQR<%F-V
MG(GAW!Y&S6R&/]=.[MU-USDU;E--TXZBV7MW7?3CD&=Y-BU$6=K+:&*:!V-M
MO?40168I+C:7-CN*'%>F/&2\KBLL7K,GP;,W 5.0W=]0JZIEZ9QN.]KA>&3+
MW]G87>7AM8)Y M[93Y2TL,66%OJ;MICS/FIA 4G>&YMP[PQQ2U:Q=29'(^R3
M)-'B;"\OK3$RW,T,3-97D.+N[[)A&N-PF1[\0X:)IP\*36]QP2626*JBH>KS
M9$.S0-UW&78H2RO$TGI7(-LPU8=5@.=:6A^U/RKI[M]Q#BE%E4N/5><:O\R]
MDOPSW8]7G'2WF/&LHOA:LG2X&S-H^.C@G7D<CD8K$NSW5KD3T3#E4QY95629
M[:]_9")D$S*@BF7N]RH$>>NQ>+D))X"%7'8Z6^"*EK<X\=:38I\@%9C'$ES9
M[D[BL8D9S)"W;X$<VZ^IC*]G;+R')*[=6/$ZSP7(/M$M<8C05\&*V. ;(#U_
MTSZDR&FQNWEF\P?+CI;O(<Q#BE%(F/D!980UDC87ER2,=AH+*SBA?'3+>7,/
M2=Y<2N9TNK-KK,WT,DR :,"]N*W8\@%#E2_GB![D<Q/>7<TJ9"(VEM)U9:01
M(('M;M;7#V$L<,A.Q.QDEN%VI+<>830Y5;& ]7^W&6>(D?I*P6G,I^I#IEZ:
M:OI%'Q7'(;_)]8;.Q#4,EWM4<R0IN?0VU;29UDVWL?L*9PNNP-=X$51V=/8F
MP6^0"P+K V!CG'L=RZR8?,9A\\9Y3%#>V=Q?B.Q*A?9>V\EK#82I(&NWN[I9
M4D16CB:=;9Z^#P'VRVC:/+X?#QX(01=V:SO+>P[EZ&)]J#K'<SW\3IQM$M+5
MHG1V$DHMWHGW[U$9]EW39^E[9-/GE/U)]&V?]09-*#K^AP^+ LKU]L#0V, @
MX\?3RO/LZR^HMQ%2Y%'D$M@_X_20GT+J.J-=0BP>H\5B;2#,>P6DEM)A^H;7
M$K(]U)<&Z@NK7*3L\JN B/%)CU$7:"?LI"LO==>Z9W3N4RMU/A_;[N.YCS'3
M]UE6B6UB@%K/:W6+A58FC/-TDBR#&42ESW8PT9C1NV/5WG#5V].*4XI3BE.*
M4XI3BE:E9;T^[?O\PN\HH^J3),1$LKQMU6T@>E= 77P)PP\X-7"/?9!K^PR"
MPFJ:XHBN"LK.P*LF!SS0>I\N:1KKV#*X^*WBAEPD-PR1]MY&R.4C[O(AG)BB
MNDB02. S(B*A8 ZV!5'/B[^6>2:+-2P*TG<2,8[&2=H@%4 EEMFE8HK%%=V+
MA21R\FL6%T\]0U;%)!7]:^=@02E&G2PA:,Z<!8I#;(N8^Q,DC@ULQCRCSB2#
M32'(LQ1<\Q,[Y)I7O=L;+8ER"W3ELQ"JH+9/+DA44*B@F[/NJH"J/15  T *
MUKBLL@(7J*X4%F8A<9B0"SL6=B!:CWF8EF/JS$D[)-=).F?>K19@F]8^7-#)
MMOCY B:"Z:$%GO?B<=U\:F@36?E2VWQF**V^(O8XSXG%&?YWJF-E3+[XQ>PW
M]GH.0C[0;[TS&Q%P,?;!]LV(^V3'P'N\"5UQ.JQ^Y\GHK]_S<2_=*_=>(T9.
M8D[A'LFB_,!^9][F V]^:X:[I?W=3G&VE3U@Y15V=D0<78V-=T^],P)QY5G(
M+-9$FEC:QB(*(L)@0I3IIY))"Y Q7SND</$K/7S6-D54DP$+HBJJ(^5S+*BH
M&"*JM>$*J!F"@ !0S :V:)ALE&S.F>F1W+,[IBL0K,SE2Y9A: L7*J6))+%5
M)WH5^T?3#N_&&'18UUA93CT=H?-:V<='T_=,U2RQM"?"A%D<P#6([2SR$:WS
MC"$D(E\+?,D=V3B7-8V<J9L!#,44(AERN9D*(OHB\[P\5'P4: ^ I'ALE"&$
M.>FB#L7<1XK$(&=O5V"V@Y,=#;'9/Q-=?^BKN1,F^^J=7&0_?)1/0+EO]'?I
MB^\R@^6D/H_CWZ+_ (KZ3RD2+T_J_)\M$9X/#[<]^^\=V?9_N&+V?ER['WMF
M>SRWOEVO;.'+?G?'>_-8_<N1[WM'W[)W^/'O_=.'[W'6N/<]DY\=>-<M:\5W
MV=-.]XP8*MG63F#*T4Z&S%KF:#Z:6@C60]DER/80")K-!X3H+AK;6$N.-I$5
MDB',D:4B2\Q^^,66+GIZ#FRE&?[TS')D*=LJ6]LV5,?N%2=%/=(UXK+[GR84
M)]_S<%8.J?=>(XAP_<#A?9-!A)[X8#8?WM\O-<*=,.\$;&Q.L+*D9"+< Q,3
MI^Z9D;$%D1$9>0!QM_1EV8+>%0PDW [42*S(BCF-9/(QKD]^^L;Y/]GX?+1L
M?]:YGRT(*Q,?],\M$I*QGU0$A= T^YLEX'W]-X$BC_56(\+*0TJC_1/ E8!I
M!Z.0"VR*VTPVDM,;Q6@H+K(I\MM*>L%KS<D*J:6AGN)1HTC]9)38X%6T58KV
M(UK0ZH 0*%K6LA@8U.W*&XD2:>66.$0)([.L(DDE$8)WQ$DS/*__ !.S,?B3
M5Y;QO#!%%)*9WC15:8I'$9"!KEVXE2)/^%%"@> *DW--;J<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2JOVY@F3;$Q:#'\5V(=K,YEW6VI%Z#A^#YN\L:
MM\^>&LDIM@4604;&I:?#;>&PB!99!FU(CA"86NF1\VPNH;2<RSVBWB]MT$37
M%S;<2^@7[EK)%*?<YQE"W!ED;D#XJ'?6TUW"(H+MK-NXCF58+:YY*FR$,=U'
M+'^/@X8*'5D7B1YWK'9])&V+J&Q&N.JVXMA[BT&N[:"SZ<.ET^&TN0HF#AV]
MC$5JV5AMH)!&R$8\ELI<$3&1Q2L8U&I<IGK",H8\'&AC0Q1E,OFE*1L=M&A6
M]!5&))*+I23LC=4SX._D#B3-NXD<22!\1AF#R*-*[@V9#.H\!FVP'@&LD;TQ
M;QLAK<*QZP\JL \@&B#OA#>G_IG*&NPX85&A$MX)]92160T0ZJ/% 8R:*.%5
MB8U(U\/,5S6,0QLG3\*M$Q:)ERN84QL3LM&1> HQ/DE=$GSZUFV'R3AU?/S,
MLH"R*V*Q#"10- .#:$. / #; 'CTK%Q](VUH0AJV'JKMHJX,RML! (^F_I<8
M$*?3"-KZ<X85NK$@@,J@&,"K28HVS B,:,*^*%J,3,YZQ+%S@T+LKHS',9HL
MRR-SD4M[;LK(Y+."=,QY,"?-8#!7P4(,VX561E48C#!5:-0L; >QZ#(H"H0-
MJH 70K.C]-V_ Y@B!.LW,Q9ZRL=2ULX^ANFN":OIW.$>ZI"DBUHUXE8YX +W
M 0.C%5P0CEB[CPJS4<OBF#!NGK<AW[C@Y3,$/(.0$C WFF<!V]X[;WF\^3O8
M,3E%*E>H)U*)VT(Q>)!6/W?<4BU]U/=7W1I?=7QX%=6IZ8-WT!%P71=8.4TI
M60FK97Y-3T_=,U<1>6+D<UQ]Q,'K&&2S-<U[FJ4:Z>=4<Y%D[*O?*3-8V41K
M+@(9%B7A$LF5S+B)/'NQAKPA%\#W5T/ \5XF&R41D://31M*W.4IBL0AD;_%
M(5M 7;R?+;/UKD7IEWHM-!CB]8V6KCPL04 M$N@>FA:8:&NEAGKX8*O]&7H8
M8@)QAY@HXX&L%E@AD@1CXF*WS[YQG<,W]GX.ZQ8M+]ZYCN$N"')?VSD2X8AB
M3[P)!WLT^Y\GVQ%]_P W:4*%C^Z\1VP$(* )[)Q 4@%0![I (UH5Q+TO[M48
M<)>L#*%#$J#\?%$7I]Z95&&H;5!4M*0>#]&/E0U%D@(*'UL;&A&(&*A$,GIX
M?![]]8WD6^X(>32+*S?>N9Y-*G+A*3[9LR)S;BY]Y>3:(V=^?<V2XA?OZ7BL
M;1!?NK$<1$_'G&![)H1OQ7D@]UN*[!T*Q!/1_L\T&&K,ZI;$NM'5CH*XGIKZ
M69P85C951QK")+JMX\:QQT5(QBLC:K64]4UO9M>(D.P9^R5BZX15<[!<9C-A
MCLN3MA>[.S+(3L^3(_\ C;>!P-ZRA&S3,@UI#A\,5&@@&E-GH:$48'CP(T']
MQ=9@WI@W?97%5D5CUA92?D%$V=E'>&]/W3,5<4S"F+&2RJLY]8R&US2&.<R=
MHD\*3,<K9$<BJG-:YK&I&\*=/PK%+HR1+E<RL<G'R.:"\"OHC8Y Z^%9MALD
M\B2MGI6EBV(Y&Q6(,D>P0>#FT+)L$@\2-@FL2?TD[I,FO;$3K*S:BR/(AIH#
M\QQ_0G3'69@DTE=-516,.0QZM<>ED$#/(."7,^=PT2^4U%A5T:YKG<<HB1NG
MK>6&%@4MY<IF7M]!PY0Q&]X\&8 LH V?/KYK!\'D6,K#J"XCEE4JUQ%B\0EQ
MLH4#"46?+FJG2L=Z'CT\5T]6]'FYM.8!C.M,$ZUMG 8MBH4HE?&;J30-M9%3
MEF$V=K;7%M8:_(/M[R]N#C[J\MCIY3+.W/-/)D?,0]5RO>H,=D+J:\NNG;-Y
MYVY.5O\ *(BA5"1QQQI=!(XHHU2**-0%2-%0>!6-E@,CC[6&SMNHKQ88%*KS
ML,9([%F9WDDD:V+2222,TDCL2SNS,3LFONGZ-=C8]9#7-!U.E4=N&LK@[6GZ
M9>E6LLA730R#S.&."U3 5 LH\TT$JQ2M62&62)W=CW-5)U#9RH8Y<*)8VURC
MDS.;=&T01M6OBIT0"-CP0#ZBO8\!>1.)(LR8Y%WQ>/#X5'78(.F6S!&P2#H^
M02/0UG3>EW=EE36&.6/5_D]ACUM,81:T1O3YTRE4UF18'269\]A5SZQD!,F.
MLI9; R4F"1Y)TDA<SGSO=(NI<UC4D25,!"LL854D7*YE9$"KP4(XO RA4 10
M" %]T>/%;&PV2:-HFSTK1.69XVQ6(,;EFYL60VG%BS^^Q()+>\?/FODCI:W2
M6%+7%=7N2DUY%*S&IP".GOIDF"FQV+Q>702BR:P=!)2Q^-_@JGL<"SQ.\,">
M)>X9O'*P=<!"K"0S!AELR&$Q]901>;$A^,F^1^=#ALB5*'/2E#&(2IQ6(*F$
M>D14VFC&-^$UQ^E=3^B7MM0A:Q>J^Z6M!)0P*O\ Z.72]Z(,MM8E*TH43]%O
MD#DMIFI4I/%&R5*Q$ 1WI42+F7W[8<B_W%'S8<6?[WS7)EY]SB6]MV1W/?T3
MKG[WXO-8_<=_Q"??C\%;DJ_=&'XJW#M\@OL>@W;]S8&^'N_A\5W&]+>ZFW0.
M2-ZO<F;D596+2UM\WI[Z9$NJ^G7OWJ0;1-8>N$K%[KW @GC%7NOZKWYC]]XT
MQM"<!"8G?N/%][9GMM)_ZC)[9Q9_]X@M]:R^Y<B)%F&=E$J)VTE^ZL/W%C_]
M-7]DY*G^Z"%^E6!K'1>S\%RNBO,CZBKW8%#0U-G2"X@9J'2&(A-KK&&%&A"W
M&$X/27]6 .<'663J^ML!0C":L%IL,T,+6)%O<G97,$L4.)CM999$D:X6_P E
M<-S0GWFCN;F2)V*LZ<W5F4.W$@G=2K/&WMM/')-EI+J**-XU@:PQT"\7 ]U9
M+>WCE10RH_!&"L47D"!6SW*6KFG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4K#TF18_DHY9>.7M/?B@6=C2'$TEF%:CA7-.2\*VJ"Y@9YXQ[.
MK,CD$L0)G,*")C? 3%%*US$V2PS0%5FBDA9XTE194:,M%(H:.10X!:.12&1Q
MM64@J2* @^AW\/'S'J/TK,<UTIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4K66Q&SW&<HL<%QO)9B \UM5M*ZQNRC[:QQQ
M;U<HN;*" PPR:8$,:&AM(Z^ >*0>08>MKJH6GLI;C*8KU#:7%NEW/ %:UC[<
MB1*D4<_9]GBC8JB@.[&:,NS:(8R22-*@BMCJ(8$@'PQ\;.R-@D_7X>/\CMJV
M"QZKGHZ&FIB;:QOB*JK!KI[NWD9-:6TH8T8\EC8RQLC9*:8Z-9R9$:GCE>YR
M]U556FFD$LTLJQI"LDCN(HP1'&'8L(T!)(1-\5&_  %; - #>] #9]3]3^=:
MP0,S&AV%GN):QF%5UE:2F&Q&"0*/4),'27Y!ZVI!*#TUAY^<2U@5C+BF<Q24
M=/BU/7XS:18KD7I+T^S2V=I<7P;W(PJ%7.Y.+2PA.TJ\I4U:!V07%H1-)<2/
M.AN(.6OW@2%^?Z :!]?@=DZ.F\  *='6Q>$U&24F.C5^6Y/-E]ZAEP63=3@U
MU>_T]C<'6%=4MBJ@JT.>''ZTH2A@L$KPR+2"MCL3!H2RIXVTUU)!+,7MX!;1
M<8U6(.[^4C1'DW([L#,ZM*4YL(RY16*J"=@! \G9^?@?'Z:]/2I9R/7M.*4X
MI3BE.*4XI3BE.*4XI3BE.*5JWU1=4E!TO4^%7&18T5;@YGD1M!\<.R7$\ P7
M&'5](;>.DS#8N>6M)AV,$W30EI\2&O;6O'O\@(@KW6%? TDX=3TJ.WG71HC#
M:3=>4["+S'!<1T3M>'4F791:X#F=G3$W$NM,8VF^]J"<;HKKUF*CXYDK4(OF
MI\/80 [PSOBM:&2T5YOU^E9^QZP-1P9_0:YIH\ZRF[M=\ ].MH?0ZXSN?&\;
MV%8:JS3;T<1F3S8]!06U2!B^&J[(+;&K&Y Q9]_1D9(15 DR$Q*]J.8OUX].
MEZ3KRHLLM-Q^_P!AX/B^=A-*P_8$V&U-;EV 9GLVE&N]FR8>'@=,=889KG.[
MJO OKJGM#A<7L$CKFDN'&F4JX--=06K]]BWY6M[')2ONQ)1,NPLKU]L'7%L&
MS**,;)<<*2FV+C&+6Q -WCYH=O7'#!S"3AE0N\Y)%=&U2KJXI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*51
M6:V&S\*R2RS$2PAR7 )1@FRXP0*"%!B\8PR,L#YK "IGR)(B9V/.EOW$9$$
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MRO9%%$QTDDDCFLCCC8U7/>][E1K&,:BN<YRHUK4555$3D  D@ ;)\ #R23Z
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M^;=^N;,<&@UK48%,5CV;O@\8Y^$FU5U2AP5.05MK%*=(8I7"-T.ZB!PS-L.
MNM@B/V%B>!XQEF3K=TI]_<%8%M[9V]HLGL1K;&K#$[:VR[9NX,\NL_H[G%[+
M7V75EQ-B5EA*X?*70E*5B(.AW7V':6VWJW6A<T1VR])VVEXK#.XX;:CKJLK+
M=UYW4ESTF(CX8L;:G*=[YC/%!0DT;XZT2@"KIZTBL0^52MH=4Z\J]3:TP36=
M,698U^"XI28S%;V;HY+>]FJ0(!3,AO)XV,:9?9":PBZO3W-\VPMSS39G/F(D
M>Y2I_P 4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O*3=EWU+4
MO4QM / AMTYO39)KK-AL,925&UL0P[4*!=.=S849U<<W'[SI^W"E_N*K"@#6
M7(L*Z@\:SC+!JX6NR?5] YB*\.]'7K\*A.=#_:5V3RQ::V'H\NCK>AJSP\S%
M0,BGUN39UN8=0EMNFBV N0!$V,(62C5NL\<W5/3L8768?;TI=+.!<>D+8IY_
MZ?7^6JW#Z-%ZEYA>H2PZGF6062WN^!\EP3&R)*\NAP+763:%T7?0:TPZYJH8
MJ_)Z36V;6.;X/:9<(Z6#+,VH<MR*)1X[)H0JO:W.XI3BE.*4XI3BE5-<#YO6
MT[HS[4>XAB4:2:R<*"R24P4F @*0@*&.E&IJ4@R.**V=(3DCA@'2N>^(=)SA
MZJ9;V.$B259@.):0J@+.K*R%D A6"%G $I+7/&/>R%Y.M-,F0B@U),LX7@6F
M*1@M(C*R,T:BW2W@:0*)B6NN$>_*KRD6Q:/T/P:J;6N>ZO97B1!K+XDF0>*!
MD43)VO1)&$,:Q&3LD:V1DS7LD:U[7(EA#P[,7;),8C0)O>^(4 !M^>0 TP/D
M'8(W5G;]OL0]HDQB- G+?+BJ@ -OR& &F! (8$$ @UE.;:W5%*H5N,OR'XA9
M PU)]^5<4T<TS!U @LQ0R;4:>2;RTE>1DCKNU8_S)/!%9QC-\$8\<;8H:.U[
MIFFBCB:5I(^XZQ\0X5I 2Q4'<QDD!V?#Z\  5NXO/P$<;NZH%?@I8L5)"D!=
M^D?!?0?AW\=U]RYIBD*]GWU>O_RIO/3_ %PI(G^/([9C%J=&^MS_ ,+\Q^].
M0_C6X8^](W[-*/\ B7C_  ;1KE@R_%R51(KZL[K[(DI4<"JOY(DZQJJ_NYDF
M5QLATM];;^32JA/Y<RNZ\:PO$&S;3:^:H7'_ -NZD$<D<K&R1/9)&Y.[7QN:
M]CD_-KFJK53]Z+R>K*P#*P93Y#*00?R(\&HI!4D,""/!!&B/S!\BH5EDI]A.
M%B]9Y+GV<!)-F]\D3D&K891H$]6,LL<S@2WD2ND;&QZ6309J15$992VM9#NB
M\C);1Z_:*S2DD'C&I5??78)1RQ) WW!&T/N"1I8JZ],DK1V<6MS*SRDD>Y$K
M(OOIL,8W+DD#?=$;6_N"9IX<Z%CM* V%8JX20B'LY3R!AY;":?NKWE3EK$DL
MA,LBNEDE[M[O<JM1K>S4WI;PQA=1J6&CS95,C-Z\F?6RQ/DGYGQJI$=K!$%X
MQ(771[K*K2LWJ79];+D^2?'GTT-"LWS=4BG%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*@F79E%2#7H-6Z&;)ZS&#,G'#.#M%KE $>YDT\I@PZ#D2P(R2;X1 ;'9$L8S
MPM@AF:4R.EY:MD%QK2-[4T N> CD"F$R=K8G*>S\^>MQ=SNA2)"G#35$RCW5
MIB;[(VT<3M;0RNG>8]OG%&96+QQ'ONJH&;B@7NLHB$B,W)>X#F%4S&A<@R*R
MJ*"-OJ [28ZQ&$K1;:M((!M1H33)8HY8(3@C&C2JY'3CQMF\*(Y4288V+E$#
M/Z%=#9*G14D#Z$;^ -18<M:KCH[_ "%Q:V"CN17+SW$<5O%=6[R0W4:32LBL
MB30S"-B07C4/H;($LCDCEC9+$]DD4C&R1R1N1\<D;T1S'L>U5:]CVJCFN:JH
MY%14547FNK16# ,I#*P#*RD$,"-@@CP01Y!'@BOOBO:B%UL' L;R/&,.R+-\
M1H<NS5YL>&XM=9)35>1Y;)6QLEL68S2'&P6=Z\"*2.0UM6,4HK)&/G1C7M55
M*SKKFH9<0X\^UKF7Y-:5<CTCC1FV\]0$4("9:PURRH9+7"&V  A)K(7#0$FB
M02RME(A:]2N8ZPKZR&,BR.#KQY3*^OBG.)A$AEL+8X>KJP8Y9WQL>9969@E=
M7C-<LQAQ0X@[)")XHW*4K[&OM@AK*J.#LJXV)LX9X!,)@1<#_P!B88H=\D,\
M3O[,D3W,=]%7BE=SBE.*4XI5-Y#LHA(HK+&?+^&4.6V%)F#;BBLVD3BU=858
MDMI)WFU<,"%Q"RQU5R^*U$/LOA]7"$]++UHF](@?#^K(&3BR^"6"^\-,?!.V
M7W2%VQ/C1Y/(=0.JI/CBGL]EE9K++"[LKCFT5M;2W$JV;M/:I&94C9;6\874
M,UP8+5(6]I[T-@SY?BXU@-52WU8EB62,)$'&5'-.A)C/,"BG;"LGI'&M[(%Z
MI86EO<R,=99'L:[6(W(+<&T 3O6AH>I&_77QUO7QJ\?*XV.XCM7OK87$LD<2
MPB56<23+RA1PI;M&8?['N\.\2%CY,0#(^8584XI3BE.*4XI3BE.*4XI59[1S
M\S7E/4V0%$/D)5I?152 $W$E(UHD-3<7UF3 5'472D6$=91F1U-;(.*/:6TP
M(!-K4P$2'P;H(A*S*6X!5Y;XAO)944:++XY,.1!)"[(5B-%6:QO/<<RRYRRA
MII;%]CA=C%67;3::VK!G3S*5&V6J,L0QA+L%I0%@!(?4S&"1GUY@KYDEA5%Q
M>)XUC9@-2+R73*QUX\,%)*G1!TP!TP.O-/K4RYKI3BE.*4XI3BE.*5Q30PDP
MRCD11SP3Q20SPRL;)%-#*Q6212,<BM?'(QSF/8Y%:YJJBHJ+SQE# JP#*P*L
M"-@@C1!!]01X(KQE5U96 96!5E8 AE(T00?!!!T0?!%0 <\+!'6%?;VCY 'P
MQVM2\EJJ>7--+/#:B0HCU0XADT8=D=.QL;I#KH@HEL4<S5;5O<P8M)?:IM1:
M$D)8?M)&8LLD:#?[1P5620@#WYF=^*G8TXZTF-R]C&QEYJ)XB^P0"2L_)R2&
MXL(Y9' !:6X8\=NHJMKO9E[;2/AIT^#@]U:DC?"\^5OR17SKW; KOGX!FMDC
M]VK.]/?G)7O4E[=,4M/]$AWKDNFG8?,OK2$^O&, J3KN,/-=G;8>V@"M/_I$
MOG8.Q"IUZ!?5M>GOG1]>*^*@[H)B9'3ES3$3/7N^4F5\TKOWJYZN<O\ VG)_
MX]Z4QR2L7E=I'/XGD8NQ/U).S^I)JRY(@X(JJNM!44*OS\ : \>/&_&ZYF!M
M^2-5>WY-1/\ Q1?Y<V"W'_@?#Z^/_/TK R[\C7Z>?Y>E'!M^K53V_M-14[?Z
MD_/\^&M_W_4?P]/\Q02'Y?'\OY[^.O4?I\N8(JSJ9/.JCB0G]T<OIY7)&]4^
MDL"]XI6]_P"R]CT_=V]N>PR75FW.VFDA;U/;;W3]&395P/DP(\^E>2)!..,L
M:./3WU&Q^3>J^/3BRGTU\*L/#-@L"643)61^JL#)BR;X>'RXR)YG(R%IH[?&
MZ.,05@X \L;WI&*,.R2-J,?,O28SJ,*>UD5"O(Y)NXUTK,? [R#RO%0J!EV
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M+"7"WL]C<*?<>3V>;2<;JV$LD<5Q&$>1=/VVY!78QR*\3'E&P&%O.M] D\9
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MI;6EW=XRYC?$-=W3WCS6TDY-S=7;2VYD-Q+WQ#'<)P: !H>W,C(I21&18YL
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MP/1\JO\ JQG?OS=C&D6^(C5#N-_QR,NP>).]1OK1 (T#OT\5%R37/:(CB@9
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MAT,=396S3\VR/'[2;)MT5&Q[B7X?#K?*M3W &,4^$TPM*<.EYB=^=36O]8)
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M)C8VNEGD=-/*K6(B+)-,]\LKU3Q22/<]ZJYRJJL51$!"*J LS$*H4%G8N[$
M <G=F9CZLQ+'9)-4SHG3(>B\5R'#ZN])NJ:TV+GN<TPY ,(+,:K\WR$K(4Q8
M-D,Y'J0Z@DPEL)LCHY2G322/@@14C;)NKDW4B2,H5Q##$Y!WW&BC$?</@:+!
M1L>@UZUQG0G1D/0N*R.'M;Z6\LKKJ3J'/644D*0+C+?/9.?)_=4 1W[D%G-<
M2A)F*O+S9F1-\1=7(U=K3BE.*5C;.J%M84B(:J/9W6&=G9)87+]6K]6K[>.-
MW=KNR=T1R-<D:ZM8KN/A)X(WP<:Y(3ZZWZ@CP0?!]?! (W0SR0-M#X/XE/X6
M'U^1'P(\C\B0:Z-H;2N<Y4B<3#W[H0,U7HJ?3S8$[R1K_P!+LCF(OR>OSYS=
MQC[JW)(3NQCT:,%O'U4>^I^/G:CTY-5O'=P3  D(W^%SK]S> ?T()^0K%(4]
MJ^%43NB^Z=U8Y/S[M=\E^G\?GR)W"/78UZ[&_/Y_+8K>8P1X/[_(-?:&*Y\<
M;6JLDKU9$Q'(KY'HUTBMC:GXGN1C'O\ "WNJ-8Y?9$54R#\M*OECO0"DD^O@
M#R3XWOQZ>?ANL6"+KFZKLZ7EH;(!;QL^2%!/CX GT!K-B45N;V5T30HE[*LA
M'=']O[L7^45R?-/$UC5^7CY.AQ]W.1R4Q)\6D]T_I&/>/TY!0?'GY1Y+JWCV
M.7=;Y)Z;^K>G[BQ^E36LHPZW]8U%G)5.SB9417_O2-O[,3?^KW<J>SGN3EY;
M6,-MH@<Y/C(WKY&B%'H@]?3WB#HL15;-<R3>#[J?!%]/U/JQ_/QOR *R9 \!
M4$HQ,4<X\\;XIH96H^.6-Z*U['M7V5KD545%Y+90P*L 5(T0?((/P-: 2""#
MHCR"/4&JV9:Y30WA.,PB+ER3!NNJL@FQ&K"PJ]24$D%L2987M+2$E\:13112
M$>2Y[WI)WC'@GB&WD@28N;?BPA<<7EYL$!#KYV"R@\N3:+?+R3@2W(^ =^1K
M0T-^E6?R#65.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE5F1NC4(FR!-.%;/P$
M?;!XR%A:WFRRCCS8J!U<5<L6#&GFI;2R24P!]S% P59Y:@$VTCC< (01&I4X
ML[REI75;+BVKJM]W:#T=.RP-'#=:W14)! M37H1)&IEB1 &5-"$/YA$L0T\C
M(U;$]6J5^T]S59!6C7%*=!8UA?G>F-&<KH)O3SRC3>!RHBKY9$,L3O9.SV.3
MBE?@-U561MS7 '#E'8Z</6W8L3O%+6'EU8%V,*4WLG@EFJK2O/8B*O<<N%W?
MNY412LIQ2L'CV2X_EM=);XS<5][5Q6^0T,A]83&6*RZQ/(+/%<FK'31*YB&T
M>24MM264'?QBV5>6+(B20O1%*SG%*<4IQ2G%*\]@OM$=8W62]2.*XW4CWUGT
M\;*U5@,\8.94$\F7";"VN-HR_OH@0T-M,9FU]MBNSG&+FBO 6%GBXU29 &1'
M3YQ1DL4_K^OZ^%2/"NLJ<W,"0]I8-BNL=8VN4=46.83L]-JQ74"LZ4=E9)K_
M #NPVE27F%80-K<:Y#Q>UR['S:K(]@T(]4"8%DU]C]H^F&NE*SV4]:^L\6R<
MJB94Y'G %B-JI=<VFJA$V'-LT_:V%[BV#4#8X'3HT*.MAQ33&06C<D)N/@$P
MY0Y11U:#%(8Y2H99_:'Z<=D>MZ[#J?,\SQ',[:$+(]DB8[<UV'87 =TC9GUE
M5@4Q158\BTS S4]+AEQ]UWP54,5=L.MF^.27=588TY3^O\ZLVUZQ-0 %LKJD
M#8&9Y.1=!44&*8/@=QDF5EQ/U1A^[K"W&JPV),328]KW/\;LK*6*1YDUS:BX
MG1 7&6V-92GJ\\;WKSZ;UY\>=?/_ ,_6H69]HCTNBYKLO7T686-KE6L)KRLL
MZBBIY;RROLHQO-\6UE=87CE-5S%7TN5#[(S?%,&KP+NJHQLDR"VE9BQMX!1Y
M(=3*]J[NGC=K-_8';YPS#[S!?A6SMN:WEQS)DDCOAR-4[)R;71)=H*\05H)5
MD1C<A[PAGV((R$)'77=X @UN8I5Z<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4KB?!!+[R0Q2+^;XV/_ /N1>8LB-Y9%8_[R@_S%9!F7T9A^1(_E4<RCP U4
M)T BR2UUO2%0L&2..=$?;!B&(.YT@\;))JXHT5_F310O@(EBG>D$DG(]R%CB
M5U3S'- RA-*WF5$?CY4 F-G4[(4JQ#'B34.]9EB67BTC13V[J 1ST9D23@69
M0"T3NAVRJ59E8\2:D(I,)@PY@[_,'+@A)@D[*WQPSQMEB?X7(CD\3'-7LY$5
M._941>2%8.JNIVKJ&4_,,-@_J#4A'61%=3M7574Z(VK $'1T1L'T/FN?F594
MXI7#Z<?U'J_(A]5Y/I_4^4SU'I_'YOD>=X?,\GS/UGE>+P>/\?A\7OSWD=<=
MGCOEQV=;UK>O3>O&_75*YN>4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K1;(
MNEJ_=M"\R$G:N)5.F,NZC-;=2=[C)N"3Q[.=M7#*' ,0QG&Z7;#\Z%J \1OK
M[ ,)D(#+P"SR@NI(OM9@728]D56S'5/G]?\ I6J'3_\ 9U9U@FJM16>RLHTU
M2YK@3ND3/;;%&ZP,.P6JS7I]Q7-@<]S[+B"MI6L>2;WS&#8UC69)NNIM*F"Q
M77."69%8<&-(/$KS]=?U]?Y_K]*G3/L[M=7N>X99;$V+AFQ[3$6ZZQAV/Y#0
M1G&F5V&R]2^89=B:!F98:Z +8=%U"XF1E5(\*8:WQ_7=/+D0=[4&U,=(KW^O
MZ_2N[!]GIF46"8-@=ULS7NRZZBS'1.4Y9-L_6%KD5AD4>E.GC4VG?A]/</SI
MUQBR9GF.L&[$RHP QYUT!9RX/;%'5!N1D9 I4>$^SHR0JUZC"F]0U'F4VQ-B
MP9$E-DN".M*PIG](2EZDW:XW\!C^:T<^SJ&/&DK-0U0=U.(?4:MN3XJWR,5R
M2?"'J\U]?Z_K]?KZUOATNZ3+Z>=+T6JC;FAOB:G*-IY+(=B^-FXACD*;)VOF
M^S(JBCQRQR/+3JNKQZ++V4 4)61VLTD%8PAQ#?.\F)7M;!<4IQ2G%*<4JD5Z
M;M%N!Q:N76>->CPJE(Q[&8O((1U;4%YGAFQ3!%F0A)SE,SO7N&Y8638REEE7
MM$/83SR3SF.)4KZP;ISTGK?-\AV1AFOZFISG*#,O.L\ED)M;:P@EV!E#LVSJ
M&A6ZL+&'%*_,LP<W)LHJL6BIJR]O(!+*S$)*#$EA4K2RVZN>E$[*MT;-RS6Q
M=69TY[1P_#\QS_(\DU %:U&1"[$ROI@J,GM\.3;#]B8'C%5!M;/;2GR;9>$X
M;4Y)JR_LLPQF>Y$L*AI"O/7]/K_7\:K*MW+]F()LK7=A589A\E0#G62Z"Q#<
MU18T=SHFGL=4].>&5$=S:Y!69F?A\0)VK-L573Q39U<UA%Y8%S1ZFLSHJN6A
M%+5[5]].6E>B_J#Z?<;R_ -%F8_KS(LSRRW JLQ^\U'G:9!@)EUH*R/OBG9,
M9E,"6V)X4F&&T=Q=.=9:YBK,*RRH;6BR8Z&IZULT?TR:&M"-AD6&M:,QNU!3
MA<Y!GELWT]LMH77V5L>)1^O^#8]>7%M44UW<Y#C8%1>V]]2TM[96)5O45QHR
ME3C6NKL"T_C#<-UOC@V,8Y\5N;Z2O'*L#GEWV261%SD=[8'VI9]C8W60W1AM
MW?6QY9-A<W1Q]O9$%6)Q9,RE3_BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*5#\YLQ:['3("7)YMTV2B!B]_,G,L1B&HR%C5:^:>,>,DF$6)S239!T##\9
MDX\;XE[*L=NZL?,VX(Q\6>16\*!HLP4,ZH"&<KP3WV4&#D94BM9%8Z:X!MXQ
M\6DE1O"@:+,$#NJ AY"O;CW(R@]/'#+^O(#QZTH9(!$%D< <#+ZP*O&':Q8*
MTLQ(X(YO31/B#A(?""61*WRXJTH48BYEPMVGC9+>6 JG$F-T/-(U4#C$[Z4'
MB"$#$(S$:6-U5ICA:O<Q.EM-;E4X$QR1GN1Q(H'&)Y-*&X B-6*QR,1I8I$1
M[@SSDZK&G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M*NM'IHV#U4X
M]A6O,<V-5ZQP^ELL@SB\OG4LV3Y!+L&EHY*[34M902SUM2X7",LNR=NAWI5O
M'8X[LC6VLK&IJK!6F%U:E:\;:Z+^I7<M/NPC(]PMJ[S>. ;.U]>8C6[@W3/J
M.@QO8?15B.HV4..X*YHF-5T%3U-5>0[*;DM?C-?E\^*6;R'VKK&UM,717FOU
M]?W:]/3Y_K]?A6/VOT==2.;)37]2=C*6]9G3,IJ\19U4]0V!R8@ ;T@8IH>8
M&HWGA>!.V3<34>S*NUS5\I=)4_?>N>VSOW@7]J:*.KW^OZ\5G;SI5ZTCLAV'
M+7]1THQE_K7+J"GVLFT-I!%V%Q<Z'QW7F/8\[IZ!JDU3K.+']MUMGN5NX\%R
M S8[")UH0JN*._ORN*5!JCIGZG\$LZ"NHK>\PLK=O5!:%[*#PG>&XMU46'=-
M=EH_38&:%Y!MG9-1A.7S[6^\G3^#AFL,P(KC;S%JO95C68X2-7E6TE.I7L1Q
M2G%*<4IQ2G%*<4IQ2M4[/HPT7?9M<[!R8+/,MR:V<*P4K+MJ['R>#&:\?:^#
M[NDH\0$N\F-@QW'B]F:VP>^EHP&LK1A,<KL:JQZ_%8EI'*5G,@Z2.GK+KC);
MG+];4V7NS&]R7),GJ,J<5D.,W5KEN.:TQ6[F/QBVG+HIX9:G4. (**X!1J\Z
MD^)@Q#V!AI$ZE7#@^"XUKJCGQS$@9*ZH)R?.,PE&D++-<M]L7-L@V%EA23FS
M3S-CL,JRBZ/A%;(@P$1+ 0HH AQX(U*E_%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
&4IQ2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g320192g66f36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g66f36.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[33*4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300]     !OD @   "!N:5<
M7 !< %  2 !8 $8 0@!5 "T 30!7 $4 +0!& %  ,0 P %P 00!: #  ,0 U
M #$ +0!8 $4 4@!/ %@       $$  ;< -@:4_\  @$  0#J"F\(9  !  \
M6 (!  $ 6 (#  $ 3 !E '0 = !E '( (  H #@ +@ U "  >  @ #$ ,0 B
M "D
M 0         !     @    $                              %!225;B
M,
M                                                   8       0
M)Q G$"<  ! G          #  )0#
M P        !$%Q  7$L# &A#!             $  0
M    S#ZV\ 4   #_  $ _P    ,
M
M
M
M
M
M
M
M
M
M
M                                      $                   #
M    4TU42@     0 +  6 !E '( ;P!X "  4 !H &$ <P!E '( (  U #4
M-0 P $0 3@ @ %  4P   $QE861I;F=%9&=E  !086=E4VEZ90!,971T97(
M4&%G95)E9VEO;@  1'5P;&5X $YO;F4 4F5S;VQU=&EO;@ V,#!X-C P9'!I
M
M              !$%P  ,4Y26 $    ,%P
M                             &D=;X<%  $ RP80     0 '(,(3Z ,
M    35-#1@    "N!@       "P          P$!  $    Y,   4@    $
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M  0 $ !R '( ,0 Y #( ,0 P #0 #  $       -  8  0!O".H*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                     0 !
M                        .$))300Z      %U    $     $       MP
M<FEN=$]U='!U=     <     0VQR4V5N=6T     0VQR4P    !21T)#
M $YM("!415A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @ "@ ,0 Y #D .  I
M        26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L 0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    B
M %P 7 !0 $@ 6 !& $( 50 M $T 5P!% "T 1@!0 #$ , !< $$ 6@ P #$
M-0 Q "T 6 !% %( 3P!8 "T ,0 X       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O
M;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M        4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U
M8D!OX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M                0FQD(%5N=$8C4FQT                4G-L=%5N=$8C
M4'AL0'CP           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4W1R1@    !,969T56YT1B-2;'0],             !4;W @
M56YT1B-2;'1 ;+"7 2X"70    !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG   "
M^P    QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P   D8    +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P
M  $  0/      0 !.$))300F       .  $F8XXY0$P$,C^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             #$0  !=\
M 0                         !              7?   #$0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #$0    !29VAT
M;&]N9P  !=\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M       !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H # ,!  (1 Q$ /P#U5))))2DDDDE*7'_6)GU4.>;;+<%N347.
MRJB:/4>\;';+][VV>IM]OO:NP0S12XEQK:7'DD"4W)#CB8V8WUBF)HWN^49U
MOU?'4QF5.I%!V,^QM-(J$M]-UCGM=^]^D_F5HX]OU5HQ*K[/LF0^^H$TDX^Z
MMVW?#O<_WZ[/H,7HWH4CBMOW!,*L8DQ6R>_M"62''CA#BE'VP/4#K*APW)(G
M1)K=\IQ<SZO9/1LBIU=6/D/,,N>:?5:/T;IK'Z-W[S?IKN/J*SI#.CL9@6T7
M9('ZY97Z?JF76FC[5Z+GN^CO]+U'+?--')8W[@I,KK9.QH;/, !2<7SW9XY\
M?]W3AX$'IX"F222;<TD@$2.1\=/X)J%TDVYH$DB)B?.=L?YR=)2DDDP((D&0
M>"$E+I)))*4DDDDI_]#U5)<'U/%+FY#.GT=5:;3^BM:,IIJ@M_FVVN_2>I[_
M *:#ATYC<=S\K#ZF^\>QM)=DPX;1^G-C7>U_J?F)O%Z#+@GZ9<'#P^N7]>,?
M\VNX=:L;6^A)+SC'Q^HVMP/M6+U7&].PG/:UV19ZE<_S=FP_N_Z!>BLC8V)
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MKMU-E=_Z#Z+O56=@X#,;&?\ :.F8;\B89NOQ75^FYK?2<_U,G?ZSG?G)O$>
MRX38EP\/64?WUW"+WZ/I%;RYNYS361RUQ!/_ $"YJR.J6?6%^7]GZ<VBBBQH
M R[RYQ#I=N;736-F[9[V.LL7*X_U7ZBX=/\ MW06?J=ILN%#Z/TC2?YNSU;_
M -8;M_,N7H;0 T #: !#=-/+12:#QUD/\67#&7^'\RTCQ<>CZL89N;E=2L?U
M3*8 &V9,%C8.[]%CM#:*_=_(6I;CUVT.H.YC'C:36YU;@/Y%E198S^PY%23;
M4XUOU2Z'?/KU76SH=^3D.TX[WJ+_ *G?5^RD8]E%CZ "!4[(O+ "=Y&PW_O^
M];1( DF .256HO#KG-)'>//5$1TTVB>(>$NZC+7?=J8OU8Z/B7LR,9EM=M4!
MI&1?&T0?3<UUVQ]7M_FW^Q:JR\G,^L%67:S'Z;5D8P<WT;3D"MQ;M9OWUNJL
M_P +ZC5&S-^L0>\5],J<QKB&..2/<V7-99'H^SV[+-B'[%.LDJV#=FW4E^=C
MMQ;=Q K99ZHVZ0[?LJ]W\A64E*22224I))))2DDDDE*22224_P#_TO4K:JKJ
MW56L;96\%KV/ <T@\M<UWTE4'0NB @CI^*"#(/HUS/\ F>2;]O\ 0C_WHXO_
M &_7_P"32_;_ $+_ ,L<7_M^O_R:-'L5-])4#U_H0!)ZEB #4GUZ]/\ IJMU
M'KN31DG#P,*W.R7,#V%I:RD [@'6Y#S^_L^@RQ^S])^D2H]D$UN["';>RFI]
MKMQ;6)<&-=8[3]VJIK[7_P!ABQG](ZSU%SQU+/-.&\F,3%:*W&LG<RJ_+W/M
M]K?T=OH>CZBUCCNJQC5AEM=C6!E3K ZQH@;6;V[ZWO;_ -=22YC_ *X?5]C6
M%]]C6W/%59./D .>>*F?H/?9_(4&]?\ J_C66V.?<PUGWAV-D 5SVUQ_T>[^
M4JN7]5.IY0:#U"FD5N#ZA5C. 8\#2ZK=E.].[_A&IK_JIUB_#.([J[6ES=MF
M0VAWJOUWM=:]V6[U',_FV;O\&FQ,^&-@ F59 #MC_>BDB%^7R^;I4?6CHN1F
M5X-5MCLJX![*C1>'%A.WU?=2W;3_ ,,[]$M.RVNMI+CQV[K!Z?\ 5SJ6'U"K
M.?G59#ZZQ0[?CNWFJ6EP9;]I<YC_ &_\7_P2V[\?U08,.[>"<*TO3]Y$NM(<
M_J^#TYK'Y3GM9;]![*K+6SI])^/7:UF[=[-_TT/]N87^CR__ &"R_P#WF39W
M3<FZBO'Q;::JFDN?ZU3KB7<M<S;?CM9^>LO_ )M=?]>N[]NO_1.#O3].S8Z-
MOML;]L]S7;4!\Q'Z-7$]Y?NI%4._5T'_ %FZ37:VFPY#+; 2RMV+DAS@.2UC
ML?<Y&Z5USIG6*WW=.M==56=KK#78QL_NM?<RMCW-CW[/H+(N^J_6KLZO-=UH
MA]0>&UBE^SW_ -;++_;^;[EH]"Z/?TK&?B67U75.<7L].GT2'.)-F_\ 2W,?
M^9L]K$AJ-16@ZWZKEQ?]PHUTU=(75FSTPX%T2LV_ZS=&QK;:K[;&/HGU0:+X
M:&_2>7>CM]+_ (7^;5P8;/6%A)(;JT?RO%974>B]6S;+G?:L6EENYAC'>7.J
M,M;5<XY.VSV'W^Q*=BN <6HNSPZ(CUXM.S/_ )Y_5KT_6^V'THGU/2MVP?Y?
MI;4[OKE]7&UBUV46U.<&"PTW!I<?HUA_I;=[OW%FX_U.SZ:;*'9>+D4V;=M=
MN*2U@:=^RI@R=K6.0Z_J7U-N.,:SJ5.14RX7M;;C$@.'T6AGVC;M9]']](;D
M$:<0J0.GM]_[T5QX:%'I^+UM5C;:VVM#@UX#@'M<QT']ZNP,L8[^0]JFH4BT
M5,%Q:ZT-'J.8"UI='NV-<Y[FM_MJ:2U__]/JNJ="ZQU!F37]BPZZ\PC[0UV1
M8[=M+2SW-Q6.9]#\Q9_3^G]0HOMZ76[IUG5:FRYC;G[JZ=E3&MLI^R;?\)4_
M>_\ 2/7=I)GM8^ PX?3*7N$7+Y_WEW&;OL*>)Q_JO]8*QTXY-&#D/Z9:;JBV
MVRL%Q.[V[<;^K_.>HNS-;7;7/:-[=0? ^3E-)27^<I?7)+CG_P Z2TZ_R[*2
M2204I))))2DDDDE*22224I))9/7[\ZBNJS#S*L5TD/9<UIW#3W-+WL_FT)2$
M02= -T@6:#K*CZ[K;_2)B'%LCR/_ %2Y!WUKZP.HG%;U'%=186-QK35#G.=L
MW^LWU-E36N>C/^L^=7GT85G5J ;6.=8X8X.US)EK'"S8YOM1]R$:)(]4#ECO
M_-B/'Q;?NH,)';H:+VP  @<!5,FPX]@+3H=8\%F?53J/4^I=/NR>H9-#[=Q8
MUE &VL-W#U'>XN=ZG\K]Q9/4NN]<PJK?2ZGB79#7 4M=6T,>W=L=98^NP^F[
M^0B9"$Q"6\Y< &NLBKA,@:.VMO95.+JVN/+@"?FIK@'?6SK;\)N;B]0Q+*=Y
M99ZE>P@,!?8YE>_U'(^%]9>K9N1TYE'4\8TYNXWO=4&.K#0YS/2:^SW^IL_P
MB;&49;'6S'AHB0D(RGK'^Y!<82CO_+]%_]3U5)?*J22GZJ27RJDDI^JDE\JI
M)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI4NH?L;=7^T_LVZ#Z7VG9,:;_3];
M^QOVKYB21&_7Z*?H[-_YL_8LCTOLN_TG[?LWV?UIVNV_9_5_1>O_ *'U?T?J
M(?2O^;7[/9ZGH[I=O^V^AZ\[G?SWI_H_^*V?X'TU\ZI)W^,I^G</]C1=]A^S
M1 ^T>AZ?T?=L];T_S?YS;O51G_-*!L_9\=MOHQ^"^;4D!UW4^X6;/M#MOKQ.
MD?L;Z._\S=^9L_F?4_2;/^$6Y@_\WOL=/VS[+]HVCU?M/V7UMW_#_9OU?U?^
M*7SFDC_C)?_9.$))300A      !5     0$    / $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(  P
M  $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$
M @   !X   !R 3(  @   !0   "0AVD !     $   "D    T  \X?   "<0
M #SA\   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C Q
M.C$P(#$T.C4W.C(T   #H $  P    '__P  H ( !     $   7?H , !
M  $   ,1          8! P #     0 &   !&@ %     0   1X!&P %
M 0   28!*  #     0 "   " 0 $     0   2X" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$!,$U- "H
M   (  <!$@ #     0     !&@ %     0   &(!&P %     0   &H!*  #
M     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0   *0
M  #0   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3<Z,#$Z,3 @,30Z-3<Z,C0   .@ 0 #     ?__  "@ @ $
M 0  !=^@ P $     0   Q$         !@$#  ,    !  8   $:  4    !
M   !'@$;  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0
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M<8&6E\'6UQHD4EF1F/ E)F.2DZ&QM<+_Q  = 0$  04! 0$
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M+$XY')2!LD=:1S"627'QO < 2U[7-/LX$=ES#5OW'V8&/L/<QTK&N;QC&P7
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M3$MK^"G%XQ56@HSO*#5<45P\*=D0YSDB-LD553! )(& JI^T^LE8EDE21P.
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ML4GUW2M<YT9+?50,DXENV\HB-'?<$!09DL<H)BD9( =$L>UX!_ EI.BO4-D
M5:81,(F$3")A%ALIL;7L&_<1<U>Z;$2;42 ZCI2T0D>_;"JD19,'#1V^2<(B
MHBHFL0%$RB=)0BA>I#%$?5L,S@'-BE<T^SFQO(/T[$#1[HNO_:YJG^L[7O\
MKI6_[RS[Z>Q_03?ZI_\ =1/VN:I_K.U[_KI6_P"\L>GL?T$W^J?_ '43]KFJ
M?ZSM>_ZZ5O\ O+'I[']!-_JG_P!U$_:YJG^L[7O^NE;_ +RQZ>Q_03?ZI_\
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M^3S#;FR3VR$KQ4F47-*UB+-JYO&2<JVBT5W<:RD7;)J]?E2:.7S%NH=VCO\
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M(F$3")A$PBHQY(\_=(7:QPAZO7>0#U.'8/HZ0%[Q2W\V.D[!^8>PJ<KK))<
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M86[C"*:F$3")A$PB81,(F$3")A$PBPZZ.;:QBS2%328O'+0#J.HYVV576=(
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MZ5+CQ:3K>OZEB,I?$8P3 :-46[?SZ.2D_40_5$W\,RD.*=, ?.#=_P#XR?\
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M61?=X]1;_O'Z5_Y':+_SASHCU>'_ ,CS?]J2?^E4+3[O'J+?]X_2O_([1?\
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M9FS>+H3?J:M&W+9*W5-7T%G(VG4VP30.+8'RO?#]A&\OB8(]  L 9V:=$@+
M0"1L,3923((V!Y)Y$O#0'$N^I)^JFA88.0D1-[9-,W40$.Y4A/\ \YCZ=J*$
M /)';Z-)5A:JS2D\ T_Q<!^Z HWWVJS,2=F5TV*8\FHLBR2;'!RJNJF")13*
MFEW'$YC+I%3* "8YC="@(Y,<3>K6.98_0A#'2N>.#6 \SLN=H:TTDG>@!W40
MRE&S7+.;!N=Q;&&'FYQ;K;0&[.SR  UW)TMKZHU42HF-8YCJ>R/6QD"($4$4
M(IFL)#G;#V&\;AVJ)""Y5'N32[01;]0!19?!Y_/'(ZIUNU*)_,N(^:>0; ?W
M&V1M!/!O9QV7/^C6YO 8$8[^66.]V2/AQ!^6O&[1+.W9\CM#FX[:W7%G[SGP
M)YR\[>*U/<26D[7:GCG8E,N$(XLE9?:)VC=8M@FYK#U^W<MY8FLI^H/U1:S<
M:8KF)DG:R(.U6PJ$.1XD33WB?T7U=U1TM2AZ8Q%7*6#F*]ET-J7 %GI8JN0B
MDE\K-SLA#FS21,!#1/\ ,>'V9D*V1TW:IT[\DMZ9\$)JR,:]AL-)D,L)#=UO
MM-%K7GO\FQW[\53#L?GQ#H3SUCK"TR["FG8($081G'FQ1L>9RL@(/_\ J+S5
M#<X"JJ)O,)TO&KU'Y, ]<YN;X/?I P9F@:O2E"'%QVJ;YQ%9\.8V-C$[767!
MC;C9=\-D^6.9/W-NTIT[-=+.KR!UZ4SF.0-V[+DEW$A@V6\??0[]OQTH S'(
MB;A7-==T6!3@EQGDD; [J7&2L0,@K &C)10K1^[)JJ-=*P"EA3@%)UI%.B3"
ML:BNI$"612;*I_J)UK@/#_J+$QT9<;B<RUEV*R*N4AEO5V/9%/'Y[(<D):XG
M8R9[(I.')OF.'[-SP=*8F7,U+#Y'V+%<&%T8?%8#'$E\9X[@>'<2&DD?=[#M
MO2GUQ_YEZCC=9S<9ME^ZD;3]K[^6%<6?BW*N9AQ4%II[]CA>_0-7S\4B8T.9
MJ -59=\Y0+T3?KG7!0P\'^*/@]UG+U;/9\/>BNGH<&VCCC6-&+HFI&S(1UFF
MVZ)F0?7MM<VR"1(8V-) ='VTMJ8;-XP4&,RN1M.LF27S!)/DY"8R\\ XQ%S"
M./TV3^/=0DY$\CA2HU-/QMID%5[\DX:-KB^K/%Z(@GD@Q*:T Z,=Y/:P*U,U
M<)I5!RZ:,3-DS28+'09$;H 5&?>!U'QXH]6&;Q-FR];!#HZ[ ]\_4V*N1R]3
M'.X\UGLCQ6;N66%^'BG>Y[8XJ@E=.TAKG0,&)ZB'2\U(MQ8KRSG(1O ]-.PM
MJ>ED#@3-!&P\;! &R^3CP[D!Q6>:%YP[<@-3L(#8%HLC&P^XG@?1Q=$][<[9
MX_=&;%.2"UBI$G*NT4)Y ()A$#"#@O?WAD(\9>@?&7J#Q=^-]*XF/)=*$].!
MUZQ?Z1?*6U8:K<B"<U<&7(B<V4-''V'\FVWBLC@K_3U7!>FM3F"Z!;U%&+[6
MASW/,7:NWTXY;!)_/;^^U,+TWN:>B]([TLMMV^++7]:>:KG8!C-UKBU/1;]>
M;=VJE/VT:HXUEITL^9JNPBY)RHBY'Z295FB9P'NR,<[CZ[I8&[B*\73HCEO#
M(PR2M]38;JJ*UMLAW>F;#VE= --/F=_E'$/6JZ#,BV9QMEQC,9#=OC</,YLU
MH,<3]WE]-?3\%ZU(>683T3%SD6J=>,F8YE+1RZK9TS4682+9)XT549O46SUJ
M=1NLF<[9VW0=(&$4G"*2I3D+HQS2USFN]VDM.B#W!T>X)![_ %!(/T*RR['/
MB)A$PB810Z5]0[@6@JJ@MS.XNIJHJ'253-O36O<11,PD.0W_ +R?F4P" _VA
MF1^$93_)UW_9IO[B+\_Y1/@/_EH\7/\ ;KK7_B/'PC*_Y.N_[--_<1/Y1/@/
M_EH\7/\ ;KK7_B/'PC*_Y.N_[--_<1/Y1/@/_EH\7/\ ;KK7_B/'PC*_Y.N_
M[--_<1/Y1/@/_EH\7/\ ;KK7_B/'PC*_Y.N_[--_<1/Y1/@/_EH\7/\ ;KK7
M_B/'PC*_Y.N_[--_<1=U6^=_":XV&#J=4Y;\;[):+-+1\!7:]";GU[)S,[.2
M[M)A%0\1&M+ J[D).2?+H,V#%JDJY=NEDF[=)150A!I?B\E&QTCZ%QC&-+WO
M=7E#6M:-N<XEN@UH!))[  D]D46.?.V]MUV"=RFE6H2,G6;?2*]8TF=%F-F6
M1E19:RL8;8%DI=&A)F%=6"TU1K*&L*,>=:13=1%=DDD(*8D%&3%67XNC8JX>
M.Q"PF6S*R:7C&Z:05WD,:8XPYO-S6:D#=_O/&CV4"R=^"UEY*\K]0UHWPQDR
MB&,V&-+R)'N#@QKY-Q<NW<,)<!M5?T;A%RYY0OW%BY%[JL!:_L"';HVO0<1
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MH/Z#^0_YP'#F.9]X$;]C]#_6OK7M>-M._P#O_P#?YK]\H52_A11-(@G4.4A
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M#NY((:'>V$$%ZX&2RL#8QS$3CITY&_D:">X'WG^YX]@-;+9?
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MU$"_?"W+7.H_#S%9WJ2I0;G;+<R;8&-K5 #4RV0K5?Y,R,-9NM7KDZ'S_?\
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0GBI%]'.K+-D4R,(F$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g320192g68g50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g68g50.jpg
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M ?_$ !\  0$  04! 0$!           %! ,&!P@)"@(!"__$ $00   & @$
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MUD\ F/=SD".YX/(O@4        (%:]6K^.VGXGEQ7?N62(KM[S9?$*
M! :]YIKP:N^UV,":W@LV7P*        $:Q]WIWP:4]A7%5ZQ69'<\'D4V_U=
M#^BE_840IK        (%;^H._'[1\1R@KOW+)$5V]YLOB%       @-N],QX
M!6_>-K FMX+-E\"@      0)CUC5/'W/PM9!5<\.]$=ZQ[F7Q"@      0+7
MW6LG@$Q[N<@1W/!Y%\"@       ! K7JU?QVT_$\N*[]RR1%=O>;+XA0
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M;4?^@FO_ !R3"&3S@
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M!6_J#OQ^T?$<H*[]RR1%=O>;+XA0      (#;O3,> 5OWC:P)K>"S9? H
M   $"8]8U3Q]S\+6057/#O1'>L>YE\0H      $"U]UK)X!,>[G($=SP>1?
MH        0*UZM7\=M/Q/+BN_<LD17;WFR^(4      " U[S37@U=]KL8$UO
M!9LO@4        (UC[O3O@TI["N*KUBLR.YX/(IM_JZ']%+^PHA36
M 0*W]0=^/VCXCE!7?N62(KM[S9?$*      ! ;=Z9CP"M^\;6!-;P6;+X%
M     @3'K&J>/N?A:R"JYX=Z([UCW,OB%       @6ONM9/ )CW<Y CN>#R+
MX%        "!6O5J_CMI^)Y<5W[EDB*[>\V7Q"@      0&O>::\&KOM=C F
MMX+-E\"@       !&L?=Z=\&E/85Q5>L5F1W/!Y%-O\ 5T/Z*7]A1"FL
M    @5OZ@[\?M'Q'*"N_<LD17;WFR^(4      " V[TS'@%;]XVL":W@LV7P
M*      ! F/6-4\?<_"UD%5SP[T1WK'N9?$*      ! M?=:R> 3'NYR!'<\
M'D7P*        $"M>K5_';3\3RXKOW+)$5V]YLOB%       @->\TUX-7?:[
M&!-;P6;+X%        "=,-E7L3*,T.SE9W'/6R.#9[)?*KME4D^T;Z>R7MGQ
MUYZL]6/I%5C3ZR.U-=1FHER1)(AO^8B9"YZO_92XQG_^X$*:@       "5#L
MUF35=)?!<'4E9MX7LF[6/(OYA\];YSGJQU&R@X3R<O\ XFZR]>>KK%?<O<H$
M7>_>XE40H      $I%FL2<D7YL%^3N8J&9I9P;^?RS%W.K+X,7J^@N"2#?LF
MZ_YLY/CJQV?I$UQZEW_>50*      !*D6:SEW!+)8+V(^56>..T;JSA$\',L
M"Y)CJ_F-\H?(8R7Z/Y,F-U_R]6;MZUWIDV=3[FBJ(4      "5.LUI"#F6#?
M!<N'T5(LT,'-V296<M%D4L&-U9[)>V<O:-U9ZL=>>H".U-=15 H        2
MH9FLQ9JH+]GMGE)QWCL&[6/(OYJ0?M_IZL?S90<IY.7_ ,3]HO7GJZQ7W+W*
M!%WO-E40H      $I!FLG-23XV"^0=1T0V2S@W6?RK)Q,*+X,7J^@N"O4.SG
MK_FSDV/H[($UQZEW_>50*        $V7F(N!CUI28?-XZ/;F;IJ.G)^P3RSQ
MRBR9MT\8ZSK.GKUPW9,FJ)5'#QXX0:MDE7"R:9@NM9^HF6C)V-93$,^:R<7(
MMR.F+]FJ5=LY04QUE424)G.,X_Q*8N>HQ#E,0Y2G*8N%UC%]J*        #9
M]5O],O"DTE4;%&V ]=?YBYOS:J98L=(8,L7+1=3L83\MC*"O7A,Q\8P7M=?9
M,7)JTU>B)IW,W@(4     _)C%(4QSF*4A2Y,8QLX*4I2XZS&,;/5C!<8QG.<
MYSU8Q].0!L0NTM='CXZ63NM<6BY>1DXF-D4)-LNR>/864S"S!$72)SHF0BY?
M&(Z0>Y/ADS>*(H.'"9UT<*7BO8["16V_Z^F;]$*      !L][L&CQY[8D\M4
M&BK1(]E*W)+,@W.K66$D1\I'N)E),YSL?EJ<:^.V26*598C<QB)Y*9/)[!V=
M=Q(JVVZ\JURR0=NA&%CK4FVF(.4346CY-GDQFSM))=5N=1$QRD,8F%D52=KL
MXP;),Y+UESC.8U"QE3C:BV      -HSE^I=9G*[6K!9H>(GK8ZPQKD6_>)H.
MI=X;!_)-FI#YQC*SDR2B3-,YB&>+IG;M<++D,GBP=\"15T3+KMNK%M2=K5F<
MCIM)BLDBZ4CW!%RI&<-TW;53K+_SMGK15)TQ>)]MH^;'*X:++)9[8--7H)IW
M,W&(4     VU;;C5Z'!NK)<)R/KT$R[.',E)+81;IY-@V<%^C!CG-@A%%3%3
M(<Q$$EESX*BBJ<E2;L2BPVE>2V>S*!(V5G3HZVPK^S2$.A86,0R=E=N'4&Z:
ME>MI5$R&%$#LG#0Y'*"^%>PJBJDHGDQ54\F0<(PL)%1A'K-\B%     -%PX0
M:(+NG2R3=LV14<.'"YRI(H((DRHJLJH?.")IIIE,<YS9P4I2Y,;.,8SD <?L
M=NZSDF[)TSNL"JE(2C^%;=;OR*V)6+F(VOR3)RW7*FX8K,9V:A89U\N2;E1D
MYJ'8G-AS*QZ;BN2U>KN_Z]SV,D5M.1A"@       !Q7N*@OMC5%G"1KY%B_B
M[IKZYM<NCJD9/3T:[05L/%O#H)+*IHR2,0JS(N5%;Y*Y5;NS(+%0RD>IP=NQ
MKTIKW$:C=>FFC^Z5H#S5^M*[2I%^C)2$:K/OWSIN94[7#RR668LSIHT47316
M59QZ\P>/9K*H-U%FS9)4[9N8^4$S<6V$H)(Y3$*     ::WE?(J^0*F9?R9_
M(E5.=-(RO9SY,JJB9%#D3R?JP<Y$SG*7K,4ALXQC('"FD=:R^MHJ6:/W"[)G
M*J1KIK3R7RU[(A:J];M5&\K\W+/=F$=8R1,N?Y,X+".6YFT8X;K+-5C?+U4T
MM2G'[X*3'98K/KJ(E##9&,#F\9*     ?PW:[.>SC&3=6>S@V<E+DW5]&,FP
M4V2XSGZ,YP4V<8^G!<_X #SXE^(][L%-8U]]8*S'/S$Y!03\["2F'K)M [OV
M?%7Y"9CU5X"/64G*\TC<QZT:HV;M9!PHFH27;)(_S>3CI.,(_DW_ ,V2Y.UV
M/ZNMPY+>S7MUN.R^/N@>@^,=6,8Z\YZL8QUYSUYSU?1UYSGZ<Y_]YS_B/&;/
MZ      .K=GT];IBX[OG#Q=5G('9L'IZ&BXE6_W2E2A<:]EI]Y*N'L]5:TK)
MP+@Z<X1U"K0SR0,J\CR-9#"3-VL8FHJ$F^*CJ6O?];3,'&5<TX:WJ.<M?5N1
MJ%/A:W*SDE8G<2DZ;XE9=^O+2:C(S]TO&,WTPZ20=S+B*C56D4I,O$$'DOEE
MYQ=H(N'*B98[6W=];-6&HJN-Y"%     ."-L4R^W:PTAE$1%#=TB)F8Z?GWM
M@L=@CK(WEV#I5./?PT1%5.18R1ZVU<NYJ'0>V2'([LGFXSE1FSCULR.DTD[X
MM04$H;[>XRTVUL7UL=QMGCCHN;TTG,YG)F/DUG=.U51F:<69V9L9CJZO2,.G
M-K%=-VV6KZ>7EG"J\>EATFS0:-"^<'1SG*BE2D[E9&4_2XPW"2FHQZO<=G1D
MT     <:[:B;M/4F4@Z&RJSV7F2FBGGSLG96O,6\%((+M9I5E(0]8M;LLLJQ
M549,<YC2(H&=G>G7/EJ5F[JA&V[J4?=%9D<86?7N9QGKC4-DK5W:6]XWBJ<1
M"O1L#*0-+V%>+%3[(T856!A(UL>DVF)80U96JKB)PUA9N#6R^DHAL3SFV2<2
MKTC:MIK;LBDH6VVID2MC=@VXV04<-O[3LL,F@    ";,GF$XF24K[6->SA&+
MDT0TF'KF-BG,B5$^6:$C(,V$J[9,E5^P1RY;1K]=%+)E$VBYRX3,&!T0FN']
MEDWLZ]:6E!BTN6+.WD8=_.S5@5IS6X;&T[L295@K(^C$I.RO/.M MCPBDRA&
MKG=66+9Y>$91)G!_)QU9U>^QK;9JN]%ICBOJM]-Z=\+;M?I/0$>,V
M
M                     $&8M57KSABUG[) P;J4.9.-;3$Q'QKB14*=),Q&
M*+UPBH[.51=%,Q6Y5,X.LD7..TH3&0/RI;:JE.&K*MFKZ=D(W;NSUY29CB3A
M6KM=-JT<FB3.</RMW+E9%NW6RWPFLNJFBF8RARER!N  84C)1T.P=RDN_91<
M8P04=/Y&1=(,6#)JB7)U7+MXY42;MD$BXR91990B9"XSDQL8^D :,1-PU@9)
MR4#+QDW'+8)E)_$/VLDR5PHDFN3*;IFJL@?!T54EB9*IG!DE$U,=9#ESD"F
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MIJ)?)Y58RD2];24<\2*<R9E&KYFJLV<)X4(=/)T53EP<AB9SVBYQ@"B
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M"*J\VK']I@6R-:D\S,JQQ5$WCB%1\_(-,Q"Z#HX-0;6QM1P<#M0!
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4ZRWGJ4!D               __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g320192g76f81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g76f81.jpg
M_]C_X  02D9)1@ ! 0$ E0"5  #_X4GA:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]T:69F+S$N,"\B/@H@(" @(" @(" \=&EF9CI);6%G95=I9'1H/C4Y
M-SPO=&EF9CI);6%G95=I9'1H/@H@(" @(" @(" \=&EF9CI);6%G94QE;F=T
M:#XS-#4\+W1I9F8Z26UA9V5,96YG=&@^"B @(" @(" @(#QT:69F.E!H;W1O
M;65T<FEC26YT97)P<F5T871I;VX^,CPO=&EF9CI0:&]T;VUE=')I8TEN=&5R
M<')E=&%T:6]N/@H@(" @(" @(" \=&EF9CI386UP;&5S4&5R4&EX96P^,SPO
M=&EF9CI386UP;&5S4&5R4&EX96P^"B @(" @(" @(#QT:69F.EA297-O;'5T
M:6]N/C<R,# P,"\Q,# P,#PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @
M/'1I9F8Z65)E<V]L=71I;VX^-S(P,# P+S$P,# P/"]T:69F.EE297-O;'5T
M:6]N/@H@(" @(" @(" \=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E
M<V]L=71I;VY5;FET/@H@(" @(" @(" \=&EF9CI#;VUP<F5S<VEO;CXV/"]T
M:69F.D-O;7!R97-S:6]N/@H@(" @(" @(" \=&EF9CI*4$5'26YT97)C:&%N
M9V5&;W)M870^,S@R/"]T:69F.DI014=);G1E<F-H86YG949O<FUA=#X*(" @
M(" @(" @/'1I9F8Z2E!%1TEN=&5R8VAA;F=E1F]R;6%T3&5N9W1H/C(W,C0\
M+W1I9F8Z2E!%1TEN=&5R8VAA;F=E1F]R;6%T3&5N9W1H/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#$W+3 Q+3 T5# U.C,S.C0U*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3<M,#$M,#14,#4Z,S,Z-#4K,#4Z
M,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#$W+3 Q+3 T5# U.C,S.C0U*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,34R/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G06U!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ-T98
M67$X)B-X03MP.'AA4BMA5W!.<E$P5F(W4U!R.3="0D$P.3=%-%,R:FIU0S$S
M04DU<$1$5UIO955A.&%O=C)39593<5EW*U=V3G5R43AD4VLQ4%1$)B-X03MD
M-C-C6&MN<#9I,%IT<D--9U%X03(P>F-H36M9+V1Q94ML,EDW<711<C!81EA9
M<6=D86%Y6%0R3C8W>#(O<5$Q84UK3GE->4)"='91)B-X03MV44@R>7I(9#=C
M,DTV<F1(6E=Y9&ER<U9D:7)S5F1I<D8O>D9G,2LV,$0V;&]D=&546'1Z27%F
M5TQ'-6IT2'1L3F%Z;#-L9TQC3V]1)B-X03M%.&HY;T9A9W%S4#!842]Z64YX
M66Y72F)O<&,V:%I486DX9#)G14UD<W,P.3!W5DI6+V,S17-S8T-X4FHK-U1K
M>6=N8W%Q4C(O=T-C)B-X03MT;C5/,4-A0T9P9DUT.69V2D9B;35G;2MR,C,Q
M675O:4YW-U%J+U-!27IV5&=E65)4.$E#;TQ55B]W0V-G1U15;U5I1GIB5$DP
M9'%O)B-X03M/;DQ)049N6%ES471:1VEI3$9U:7EM9S5*:%97,4AY<"M935=T
M959D3S!.3'5Z.'8V3EHV9F)857-D-FM-56AJ;58W9W5I>6QM2WA1)B-X03M"
M2W1#+U!M=S(K,$960S,Q2#@W2G)Y3T),<4]4545I86)6.4Y63$QJ84Y)>4EK
M2T]/45IV5&UA94QN2CA8<&=.,4E+<7-P+S5Y1%,X)B-X03M*64I,6FQ744M"
M<"]Q2T=K:4EE=%5$4TI$331!,E%V168R6%A&5V(O04IC84YQ1VME5$Y0=$Y3
M:#E$5D<Y5S4Q0TES:FM81GI-.#AO)B-X03M,4F9!9FEK4#)D=D1B07)*8U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-644]T>E=-
M3VY.2F921V$R16M))B-X03M-86=%.&UM4EEZ=58K>35">7I%0UIB8S)->4%.
M,&1L8DHR2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU)B-X03MX5C)+;T-F55IO2D-J>$0R3F1I4'5Y2FLR>'AG.590.4U.+W9O
M9F8O04=93TIL-%1V,'<S*RMH.2]W1%IJ>$PT5'8P=S,K*V@Y+SA!)B-X03M:
M:GA,-%1V,'<S*RMH.2\Y;5!%=FA/+U1$9C<V2#,O,EDX4RM%-SE-3B]V;V9F
M.$$R63A3*T5V6%9(9%=623$Y86XW=%=A:7-F0W1.)B-X03MS4$5G-'$Y>550
M-79U16-O.6]&9%12;$Q%145F4FM016-G85%(<3$O:DM8+T%*6E8O=T-$4#E-
M9D58.&U/.3,K37!F*U=69BM$4#A!)B-X03M42'A&+TIJ=E=3*V)F5E1H3%I*
M26Q194Q.5595,4)O4C))<FA'56AF>5DW,'HP:GI(1&931T=60D1-9C=S5G%'
M*U(R,W=X;F)6;# U)B-X03MI3$<T5&I*=4TW1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%P,T9V2%!(=V8O04=,9'=C0D1+
M37%3)B-X03M/94-31U%O-#-(43EI4$A+>4A*:6)9:#5J+TUZ>7@U8C%.-TA7
M6&MT5FIJ4V%3-U!P=$=%:U=5<3-"6$TU*TM(:#A-6BM*;$AF1%-M)B-X03M3
M:% K8EAK>4<T;6E-.'I*8GE*1DY/<U1E;7!E8U=X3%9O=T-Y<T%35CEX55DP
M:FE#<&5F;6HU6'1J0S,K:WI15%1V84Q/:T1+=C%I)B-X03M+5TM/5T5*2C9C
M:D]G;4QK26@R4G=+<W9(1VLX455F*U9W95)"04IN=34P5G!(:&I"=$QL=5IJ
M<'5'5TYL05E/<"M):6QD-D=T1VMC)B-X03M14E=M+VUJ-48Q3V948F5W,4DS
M1GAQ-D=7=VA3,W5#-WAR33%U>G-V<#%24DEJ06PV0V=**WE+-#!M=WER06Q4
M=G)&3#E+:6DS:6EI)B-X03MS9&A)0BMY,W8T2$5I,E5*.$@Y5FI6,',X56-Q
M<6XW.4%W5D=(-UE'=TE*6'8W:DLS379B6FA%6&U(.#%O3DA5,U!L4S-V9%AQ
M42\Q)B-X03M7.6EH9S1S<4UJ8UI79'%R>EI'6&XQ46M.4FAH;TU/2UAC;457
M=CA!;F@Y4FIH:SAR96Q:16A:8FXV.6)T44<V.4ES1D9'*T<S+V95)B-X03MP
M=CA!6G%#3C)G;35D>DM14W!$2V%%8F=J<41G6G-V,$18>&1!5S%Y85A)*W<O
M6G@O=T$Q6F1'5G5U>C1/2&-C:SAY8FEU>%8R2W5X)B-X03M6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W!8<60Q1S5%4T%-5D\W*T(X
M0FM*1G9X>$DS63EF95=V3'5O5&UE)B-X03LO=T)+<S=U9'502U=E,VEL8SA!
M46Q79%-F:#5';FA5-4<R,FYK2V%L8U=R=W<V>BM6.7)Q1#-3,C@X,7A:-E1+
M:4M7:VU2:DEP9W5V)B-X03MJ:EAI=UAN5VI(;V9H>51#+TIL;FQZ5DQR5TY'
M,#%,+T%-;WEA6D%D5FMH;7-T4VAL=EA%8SEP3$I*9$(U159K-7IY=$=:2$)Q
M<$E.)B-X03M/97=316AU:VMS2DQN-C$U03 W5T)A1S97,DYR<$5T=7IE;3EW
M,&-A0F\W=&%3;4AM6D$Q2WE+07 U8W-+4&=Z-WDQ;S)J5#)6<F9Z)B-X03MA
M2%HR9#EA4WIX5WA7>E<S94I)<FE616%.6%AM9V1F:D9/=DMO,D]!<V='4C1%
M<C!4;'E9:TI'9S533V5I9V1Z:6=L2717=F\W>38Y)B-X03M33D]+2T%G8R]A
M96XW5&4K46MB8W9&07A$>"]5=DLO:WE,,30Y3CAZ6#-L*U8U*T53;S53,U=F
M,4AT3U5+4TEO*T)81G5(:6-C07%#)B-X03MV.'AS<U1'4&5N,FAE6#E%;#%H
M8C9Z.#%A:'%L,6)Y4&-01#EE5V%(:$QY2&]T1V<T*VMR35-&-B]:<5-!=$%7
M8U%,-7,P=TYI4#!J)B-X03M3-VTO=5%)>55J46=Y5&9Y+TPS.$UL1TYT5UA+
M241D;FER>%5,5711059053 X8W9D4U<X5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER)B-X03MS5F1I<G-69&ER<U9D:7)S5E,O54PO:E='22]&,&1V1#)'4FM7
M,TA$<55R>41E-T9867$W1EA9<3=&5CAC6F-N8TMQ:7)U9&=O2%5K)B-X03LT
M;TI38E9D544O.$%O.7533%)$6'=,="]-9C1$27E,:S1S5F)N;6QU4F(P=6XX
M="M88F@S9693-U-6-4-79'!)26U,37IR25-35C-*)B-X03MD1F(U9TA',E!#
M3S55<TY$,%14<%=L,"]4-V%Z;&11:GE147AX37E+4U%P2T%%9T4Y36)326=*
M,7!E;#-';UA(<'@O1$=U.&MH-DM0)B-X03LV-%EX=')Y-5)!5U=C,F1N0EHR
M-G=1<E)&*SAN=51L-$9/<FY->4YL5W=S6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ)B-X03LW1EA9<3=&6%EQ=#E+4#A!:T@S1$9.;#-P4F9Y
M3#EW>%=Y-S!O=C5&*S19<EID-E58.&DO8TU6<W4Y2TPK4F9U1TLR6&5L1B])
M=C-$)B-X03M&8DQV4VDO:U@W:&ET;'AI:DML4V<T;G%+0VAX5WES*W$R=BLK
M52\T168P=U5%.%(W,V968E@O9DMF.$%!:BMM3D)E23DW=G%T<B]V)B-X03ML
M4#A!9U(O5$=G=D5E.4)A>G!L<&-71%)'4T]Z0FMH8C$K2VEN0U97-#E6*S-4
M:C$W-5IJ,E!+,DTU16IM;4-2;VEK4G%%0C-O0E%6)B-X03LK:DE*2DI3>34Q
M4SET-51(2D=L97@S;U(T:F9-865A55121$%L4B]4='HO=G10>"]R:U!Z0E)X
M3R]4='HO=G10>"]R:BM92SA463$R)B-X03ME;W)';$\Y2S$O6&@O34AU6&E3
M=E@O3E=T-EDV>E$R.$TQ:$MA4E1%4%97+VME:F).*W9-9E4V>DIJ,T%":553
M:U%K+R]+>3E7+S5:)B-X03MB9CA!-&8X035Q>D4O;%=F8T=0:48S+TMY.5<O
M-5IB9B]H+RMA<V8U5FXS0F9%3'8K5FPV="]Y>3(O.$%W+SA!>E9J+T%#<E!U
M0RM))B-X03M89CA!2WDY5R]W0U=7,R\T9B]M<D@K5EHY=UAX0S<O;%IE<F8X
M<W1V+W=!4"]W03%9+WER4'5#*TE89CAR3#%B+VQL="]W1&@O=T1M)B-X03MR
M2"M66CEW6'A#-R]!2E=8<3,O3$QB+SA0+WI6:B]+<RLT3#1H9"]Y<W96=BM7
M5S,O=T-(+W=#87-F-59N,T)F14QV*U9L-G0O=T%S)B-X03MT=CA!.% X03@Q
M62]Y<E!U0RM)6&8X<DPQ8B]L;'0O*T@O-7%X+VQ79F-&.%%U+S576'$S+TQ,
M8B]W1$0O=T1.5U X04MS*S1,-&AD)B-X03LO=T%R3#%B+T%*6F)F+V@O*V%S
M9C56;C-"9D5,269++VY+2%9M3G1D2W-&-W555F$X6$@K5%AU4$1--U-A-%ID
M:G1*;D=D<VQZ64TS)B-X03M9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%G
M3F1I<TID3EI,*U9O8F(Q24-:1C8X,6U1>&IO,U9W;S9:6FE*171U92]W0GI'
M649B)B-X03MO+TLR4VID5W-6>D558V(O04Q,9'=C:$]!:TM+0T=/,T9V3&)Y
M;4]154DV2'-2-&I-0U5413!70D1W-U=V4%AL-U9D6%16-2].,G)E)B-X03M7
M8DLR;&I35%(R=' K57AE<&A)3G,X<2ML2CE89&@X4$EG-VUH55IC26M#<718
M<%!K+U4W4#9V1F]-9#=0<4YZ<#%J851Y-FAD37!L)B-X03MN4S96:6MJ2UA-
M>7-F5$I):U5(<#%Y<5$V<7E91TUX=D1-9VQT-5)X;&EB;W<O9U(R3U)"1E5D
M=U996#5G,$8Y3FU%:U)-;&A+9C-%)B-X03MP-F<O>5 T35!X>E9A;E1E1V)(
M,&QR;$=K;WI&67%6>F0R=')#6G)Q6DE)45%$2DMW4E%3841D:4)V:$%*-4MH
M269-3V=4>G!"0G%D)B-X03MP3%!)-WAX>$I01WIS.&1/84MO87!:86EO-UI)
M-'!$8V=P5C=(53E/=C1V5G-B<4<W:7!8,4E*1FM7:$I&87%33W%N-W-%;T=0
M355H)B-X03M5=4QQ,71W:'5*:VA%:G)&1UI'0VAP2$Y&459)<7I(;TU!0E!*
M5G1R9C).,C!Y,G1X1F-.8G59<'A%-G59-48R6D@T:SA72&-(17A))B-X03LU
M:%926EEN<'AD5W)7;$-$6&EA2#=J,7=5<FML:61M5DA6;50W86=G:V12=CDR
M3DMH,C%F4U9V2'-7=EE"97AR-FML<5I517%P4W9))B-X03MP6&M"-S!Y6$)+
M<G):2TE35THS9$5D5V5):%I&0D)+:V=-07<W8D5(23!H9FER84\X8G$V359D
M4T-R03!)239%2$-$5S16-EHU43@S)B-X03MP<6%,6EAR0F(Y4CA,9$)+0C-(
M*U8T:D]G,%=T.%0P>2MR-S(K13=:4FUX6G5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMO1%A8,#E.)B-X03M.6G11:F%3,3E3049&<41Z37E#33=&96MN13EC
M<WA!.%<S4&8W;4TV<F1(-5=Y8U-!2VYP:7%287)F2F-/231W0VE(-V9C;C(Y
M<W=S)B-X03LR5&DR1$%L-4QD87(K855'=#,R;398<4]H86A-8FMU66)Y648W
M0S-K1F)E3V%+05<P=C=W=6=6:4=0>G%-:E5A-F]::#58;#AX>E)8)B-X03MS
M*W14,DTV>5A,+V\X-F,W4$=T=79W2W)&,54X=U904#1M,W)39S)%2E8P5D]W
M0U-!0E5N64%91E-N>E)R149P85,V5D9X;75P<4,V)B-X03MR4FMI03,T:B],
M.2LS>GI',65C4FE91&-N;C5F=%EY3F)-37I5=&%#,5A3;W12:&IJ95=30C1:
M0DQ$3D-1<G$T57)58V=W*WDU2%0X)B-X03MC;$-F0VQ,3DTX:V%.<#@Y=%!'
M,# P='$X<VE03S1K6FUL0VER<U8U3G<T,5AF<E4W;F9,2EHU4W1B4W4T+TMN
M44IM:5IB<3=H84I))B-X03LT=S!:="M2.4M55$MZ33!,16YM0C=5,C9:64Y8
M261".78V,71(84HU03!F4G1+9E,W3V4U*W)36&DS-VU2;S)C>7%624A,9TM,
M5TYE)B-X03ML1'0Q>4=455-M8DYC<5<P0G)N-5=A6'%C;'I/="]D=UA%-WIY
M9SAK84Y(=6Q+4T5)1E5N-$-1;S552%AQ5W)02'$U4G)99C),8E5V)B-X03LU
M4RM82G)I931N;G5:6G)G<U@U96=657-R<CA#;4EH94EK*TAW;U!P4G$U1&PK
M;CEA,C!N-51A1TQ5,G-L+V93=RMG.7-G6G)C1D5K)B-X03M"-4975T)7-69&
M,4HY=G,W62]N2EAD1#=F,7)A839J-4DP,B]I:6EN=4QJ:D1"1D%L4%-9,6=7
M4EDU9FIJ9CA!940Q:3%F14$P>75/)B-X03MC>%<P6#5D.'1796=X6&-6<DY.
M36PS8U-85&E9>&YI.'!Q=U1G:V9W,3AA-4A,;$TV=F]Q8C57:#)+<VHX;V57
M3&I63&QB<#)A1WEG)B-X03M917E+4T=::'9X43EV8S5N-DA32$EE23=21$]%
M8F5P6C!B93=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%G3F1U-V4P,#%P<FE"
M8FU))B-X03M344M95W!1;#5K4E<S0DAW<W=B-DUS>%)*;%%.8R]U67I.0D@U
M5WE36%9.4SE1;4-%+W4K:G-/+W-08DU43FQV64U#57-Z1U%X+UAF)B-X03M)
M4&Q06')M934Q87A.,4QC46DR;$IM;E5E:W!*0W%Q3W%R,4\V9T4U351)-4MM
M=6HV4%EA4G P1VUA9$59<E-#;VAJ3'9+,WA-5TY8)B-X03MK3'5X3$UE<'E*
M2DI66G(R=6I2,$YT8FM.<6-I+T4R>$5#;B]!23-0-%I4<612-%%O9E@Y,S=5
M13!W66MS4WI'<$\U2C9K-7!M<')&)B-X03M867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&52\X<2M6<'1:=5!5:W)(65)':W-G-G-E=D)F9GA08DTS4C9--51:
M*VM--'AT-FQB5S!&)B-X03MT06M%0T-/1TUC55)E9T=D2$=):4M(2G9636MR
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<40Q93AU3$]X864S:3EE55-224DV
M13=3)B-X03M3<6I(8F8T5EEN2C0T9VUI>&MA0TUY1$IB-FMF.'<K.%E/24IO
M=3E34"M99F5-94E,4F0V:V8X04U0=D=0149O=3E34"M99F5-94E,)B-X03M2
M9#9K9CAW*SA9.%%7:3<Q22\U:#DT>#1G=$8S<5(O>D0W>&IX0F%,56QX0DA4
M,4I%5&PY;FMW1F9V=T=C4GI+4D%N:T9N,39Y+S5A)B-X03M)+SA!9S$O<FMF
M1F@S:C5S=D-N,T8S,39Y+S5A22\X06<Q+W)J-'-/.&9.9D-N,T8S,39Y+W=#
M5VE0.$$T3F8V-"M,1'9(>EAW<#EX)B-X03MD.65S=BM7:5 O9S$O<FHT<T\X
M9DYF0VXS1C,Q-GDO-6%)+RM$6"MU4&EW-W@X,3A+9F-89EAR3"]L;VHO=T-$
M6"MU4&EW-W@X,3A+)B-X03MF8UAF6'),+T%*84DO=T1G,2]R:C1S3SAF3F9#
M;C-&,S$V>2\U84DO*T18*W50:7<W>#@Q.$MF8U933V%+545X=7)G8D5Q468Q
M6DM-)B-X03MG95)94VE2>D,W2DED:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9197)V<4-73$YP-C@W<C%)9T9O1#A";%539&9#4&QK.%E&)B-X03LW
M.&U-<G):1UI":VAB;3(V=6<O,6QY;6-/;V)O5#9&0UI3,T]X5C)+=7A6,DMU
M>%9B3D1$8U%M0V-643=Q,V1$-&I"2TEK3T5P:DEX)B-X03M.:&ID-5IZ5VMX
M:6Q(=7)$;W<X4FUP>31J03!8831S;VU,0TAY='-D:7)S5F1I<G-69&ER<U92
M5VXV:%!9>FE333%5-T]H-DU-=7<U)B-X03MJ:DYH<'I94FM&1FU6;F516&-!
M;6A.5E!59'=F035V8U=55$9H,&5815E':7(U63%U>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6)B-X03M"-G9$9GI73%(R16YP6$IK:4EE=%!G5U97:T9D
M*W%":&LX6D%/+TIJ24=T:UIK1U1S5E%6-45I:T]$5&PQ6"M/55I)9V)T*T]2
M3WE5)B-X03LV-7!I-G)O;6]A5WI"1G8W86$Q6C)8;4%*;WEH2E-O-54U9$LW
M-55'=W-"6#AO3D$P;E5B9EA*2C)A,S R83%V2&AH=&YK;%DR3G%9)B-X03M5
M-"MK>G54-FQ*4&A1,$$T2T%#87HT,E!#>&%04E!,;G S3V]E6&90,&5J5%A%
M;W9.45=+,VYI;%!R5'I856%',49X038Q:5%$:7E&)B-X03MI:6QV<W5C;%HW
M:U8U<W<P,SAR+T%$1&(R1C5A-FPU<6LQ=C9X3F%Y=V9P2T-39$QC5S!J>4XV
M4VTU-4(U4%5P-FY+;V]+9$9P2&E4)B-X03MW=E)C9WID:7$R5S)I=31J0DU0
M:#-+=C-1*U!Y.&-%<UEM3T4O=T)I67I-1%DO=%ET2V=34FM$0G=P241R,$Y/
M-'I44T9';F)X3FDR)B-X03M&*UI.8S@X,C)R6$YV;W1L1%!A4G@R9V=K;71P
M,S581GI0-F)G>4I):6Q)-#%,3W=(=V)6<C!Y,D5)16)L<FY+64]W44UV;68X
M>4ED)B-X03M',#(X3VQW>3-C,%8U3F4R-C)T,$-V;W%V,61E2W9).&)/>%!W
M:T]7,BMZ=E-1:$-Y3%DX8S9'>6YB9FUB-6]N,4=X=% X1F%G<U9Z)B-X03MC
M=W=83C!W=4530TM223)E62MP8DIY0T8S5VTS,F5O<4U4:&I8,40X9D92;6QF
M,&Q-9CA!13-M='14,4,S:7-38F%Z=G)E1T=2<D<W)B-X03M4,7)E5UAH3#9B
M37EO5VE73GE:9C=S,5AS9#0X16%'+U1V5'AY<S=)3%4O3W9N6%-T5'5)5S!2
M=%AS,6YM:FAL=$Q7.6AB:DA!2DEW)B-X03MA3&1++W%3=44Y44962$4W1W4P
M:&EI4GIR-4E/4U%02S)6*U=.579D53!3,W9R,C%E>G5:5$QZ='!9-4E854I+
M>4QY:FPK3596460O)B-X03MO,GEM8U%$46)916M753!Y3$Y&-F)F,T9N8T(T
M9FE$541X.6U(:#@O1$QS1V%52E=';E!H:D].1FTV35=25TML4U%#5E!55C='
M;61!)B-X03M$661!4E)B=V]D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-644]T
M5VAU=%!A151I,DIK:&(Q4V%!8TIK9FHQ2#)U4$@V8W-X>6\S5G-:)B-X03MI
M=VIS<EI,2EI6:E=P-CEH-#5'57%:4FIA6$\W3WA::G9M351B:V=5,6=3<VQI
M4U=*-&YR=VM5<3%#5DY#2T=H56=J-DU666AD9FQ$)B-X03LK6#DP45HY4&UA
M:5)X:B]48C1F1$-N<'@Y2FAU<69$>38P>5A%5U!#1UI:1FLW1E<Q5FU92V]Q
M5&A!=$).2E)Q*W%+43%P8D=S9E-A)B-X03M59G1%9&@O:R]R>D(Q3V\O:&IY
M-G5B<'10+T9,;C!39DU&>FY9<3=&6%EQ-T9867$W1E=W0U118FLY0FER2V1$
M,%%7=T9X8T-T=V0Q)B-X03M5+W-$*W5B:E-A5&@Y579Q*S4P*W$Q6$8V63AV
M=E1N33EW6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<6=.9&=S-3E.84\X
M;4U%)B-X03M";&=*:T@X>7I)>41V.7!W0FQM26M3,C@O=5EZ04DS4BM6<VM0
M2F%.23-*<%!K2V8R-59,2&96=&IK<F]S*V]F-68T9C(T4$,X,"M,)B-X03LU
M3RMO9C5F-&8R-"M&-7(T=FLW-F@O;"]H+V)J-%AM=FDK5'9Q2"M8*T@Y=5!H
M96$K3#5/*V]F-68T9C(T*T8U<C1V:S<V:"]L+V@O)B-X03MB:C18;79I*U-Y
M-C R5U<S34U5+V\X+S=X*TY34C1$8U5'4GE91$M.03!Y>#5X1U9K5VQN*T5F
M*UAV.$$U2B\X,UIH+WEB+U,K>CER)B-X03ML+WEJ+U(K,SEJ=CA)+SA!3#,O
M>50O-75X+VLS*VPY;C=6+VQ(*VHY=C=(9C12+S5E+SA!:VXO>F1J+TIV.4PW
M4#)R+T%#:B]!169T)B-X03LO63<O04%J+T%-=F8O2E O04IU>"]K,RML.6XW
M5B]L2"MJ.78W2&8T4B\U92]W1&MN+WID:B]*=CE,-U R<B]+4#E(-V8R3R]W
M:B]Y)B-X03LY+SA!2E X035U>"]K,RML.6XW5B]L2"MJ.78W2&8T4B]W0UAV
M+VMN+W=!,UDO>6(O4RMZ.7$O>6HO4BLS.6IV.$DO.'9F.$%Y5"\U)B-X03MU
M>"]K,RML.6XW5B]L2"MJ.78W15IP=FPK0WIM.5HS.6519C-D5C1H9F5L5'9L
M*T120T)S;7DP6CE96FEG2T-A-6UU1S=&6%EQ-T98)B-X03M9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ9TYD1VYN5%=';T9H82MR0E5P5W90,6LY4' O=T%78V-S
M>%AX8F,Y+W59>G%T,&9L8DHR2W5X)B-X03M6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5D%A-U!:)B-X03MW86$P;#5#6C1"3$%$1U U;6U255!B-TQK2$Q-
M44IL=#4O8WAM44)U:CAR6D]X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X)B-X03M6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+;TA7<G,R=6YT34E"8VM347(V4D9196-Y2GDV2#=03&PY)B-X03M'
M5UDT,F%U;4UZ45(R5G-N67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98)B-X03M9<3=&6%EQ-T98
M67$W1E9'.48T8F-I>EI&;C5*47E!;&5036,K;F9H5VYV:V\Q939$9E)7>4M8
M67$W1EA9<3=&6%EQ-T9867$W1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<2\O,E$]/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X
M;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O(CX*(" @
M(" @(" @/&5X:68Z0V]L;W)3<&%C93XV-34S-3PO97AI9CI#;VQO<E-P86-E
M/@H@(" @(" @(" \97AI9CI0:7AE;%A$:6UE;G-I;VX^-3DW/"]E>&EF.E!I
M>&5L6$1I;65N<VEO;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM96YS:6]N
M/C,T-3PO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O
M<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @
M(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ
M;&%N9STB>"UD969A=6QT(CYG-S9F.#$\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B
M"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX
M;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I
M<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L
M94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*
M(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T
M1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM
M.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI
M=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX
M;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E1I;65S+5)O;6%N/"]S=$9N
M=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI
M;'D^5&EM97,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%C93Y2;VUA;CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O
M;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN
M9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^5$E27U]?
M7U\N4$9".R!425)?7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^5&EM97,M0F]L9$ET86QI8SPO<W1&;G0Z9F]N=$YA
M;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/E1I;65S
M/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A8V4^0F]L9"!)=&%L:6,\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT
M5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^
M,# Q+C P,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/E1)0DE?7U]?
M+E!&0CL@5$E"25]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @
M(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E
M3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-
M86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0
M;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.
M86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP
M1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P
M<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X
M;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^
M"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z.#DT,31$-C P
M1$0R138Q,3DW0S,Y-C-$-#8T04$T-S<\+WAM<$U-.D1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z.#DT,31$-C P1$0R
M138Q,3DW0S,Y-C-$-#8T04$T-S<\+WAM<$U-.DEN<W1A;F-E240^"B @(" @
M(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HS140R,C)"
M-S R1#)%-C$Q0D(T-C@U-T%"1C%$.#DU-SPO>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/G5U:60Z9# W,#,U9#$M-68T92TT-3@U+3EC
M-C(M9#@W-C8S8F1D8C@X/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @
M(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C@W-#$T1#8P,$1$,D4V,3$Y
M-T,S.38S1#0V-$%!-#<W/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,T5$,C(R0C<P
M,D0R138Q,4)"-#8X-3=!0D8Q1#@Y-3<\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U
M;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E
M<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,T5$,C(R0C<P,D0R138Q,4)"-#8X
M-3=!0D8Q1#@Y-3<\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,3<M,#$M,#14,#0Z,#<Z,C<K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C@Y-#$T1#8P,$1$,D4V,3$Y-T,S.38S1#0V-$%!-#<W/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#$W+3 Q+3 T5# U.C,S.C0U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$
M1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %-
M CT# 1$  A$! Q$!_\0 '@ !  (# 0$! 0$           <(!08)! ," 0K_
MQ !,$   !@(  @8##08$ P<%     @,$!08!!P@1$A,4%187&"%6"1DB(R0Q
M5%64E9;3UB4RD]'2U#1!<=5189$F-4)#1(&A,S929'+_Q  < 0$  04! 0
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M*1[!BFX=2>FX6";,RJ)TB?+>32YK"V:50JX+::W#2X^K30?\[P%<7=O%UO\
M@/=4>$O@;U>\U>^UULK4^RN('?AY"BV%SL>B:SI3=U 5 \3:2;#S6U6^P=DM
M'->65<Z_:N89JFCAH]>N%#JX*T 82[N( ^\_^WQ4&\:>W?=<M=;?K;71EQX+
M:S2]W[SKNE^'C3EUH>R=A[KFV":.5;MLFV3,!::[4F5;KE1KUWW7.D:<_#%
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MX:N5&)2YEU ZNCTCWBS3.%V[68D\34[98^)8&E6K%5DG6%T5(UG)*2A3E5P
MPCMM<ZWX\/Y6/\>U57X@_='=TT_W3/>7"O6-U:,U9P_\/W!GZ0FSKQM"BIRL
MS7MK2>$L5#6D<\QL&K(SS:PQD_2[2G#(M"6B3:N)Z)AWB;@T4X1*H;U<6MR[
M"!?CI<GA_!73X-..NR;!X'^';B.XV*4SX9]M[L>.*VUU4E"W TY;K2XLM@BZ
M@WUMK1=O/[/EWU]K$.A>(:G,V-CL+2ONEY+*[^%9GF#E1PLX@&X':/\ G8I3
M1]T;X)G$?&RJ'$!5E(V9X?;3Q40[TL7;>SRV@Z0F=2W[!C#YKN,/VU;RBZ;R
M\$UZVU,GK&2CUH,KZ-?MVQ4L>[MM_'N6]7;C0X8M>5JO6VT;:AT82T:E?;\B
M%(6)L]MDO(V+BV4S*[DE8&I0<Y/5_5L3'R4>M+WZP1D95HM5ZV:2$HW>+$0R
M0 G3MX?Q[OO]2\MVXW^%'75EIE1N.[*G%3VQ==OMLT-NF29E6=PUO'Q9YA:W
MUV8AHN0AI:(7:8;I1BK.055F9.2A(2(2?3,]"L'Y+'NX<?5]_<OC'\<G"G,:
M2U?Q$0NX8><U-NR9:5O3TW!PMMFI_:-G>R<G#MZK0=>Q=?=[&M=K[PA9E%:L
M0M3>3S5.(E'3J.1:1[Q=$EC<BVHX^I5=]RMXH]R<8E3XI-S7RSQMBU"QXM-L
M:FX77+&G-*DZF-,ZL>H0C6\2V$B$>/I&V3CF2;JD?%;F8>'NJ*P8KJNTLE5P
M L.W""[[SK;\++JD"M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$6M7*7G*_4K+.5FIO[Y8XB"E)&!I,7*0<)(VR89LUEXZO
M,YFS2$57HE>7=D28DD9J19QK+*W:7:Q44S<R+C5P@5WW0+8'$A=-E\67!+2>
M'JPW.AV>OV'B*5XFZ)O>P1](;X<-Z#P]Z-UY3H&)5U)56D]-);'M-A?35@7N
M<Y69):T/7\G*U/%6*]V&VCC]UOQ-[_T55N%[W)W=<17/<ON'[;52:TW17N;U
MJV9Q$;#D"6.H39N)+BBD=@STYJAW18Z"L$M(1M(IZSV1N3^:V,TJ\R[C9V&I
M2-<153F74"52_5Y[7:<.#;=_\O7:ZN;PH</W$0Y]U-XX.-3?VE;!0*K?M7:@
MT/PMOI&Y:DLR\1JBG%7EMC-;&RI>Q;/+0;ZY7Z*@[;%,$&#MHF@]=HR+YN[;
MX3,5"1A#0>TD\>W0?R"M=JG2^R[;Q<[AXIM[PC>$3IS%WH'A%I&9>*GRU73Y
ME8B<V9N)X>)=OF,==^("YL(Q [(QDIFNZSUY2(62(SE)6RL 5#:P ^\_?V#^
M'?ZSZE>@%:@(@(@(@(@(H@\[:7Y]8X<NA,^86=2^='3["EX?\'>+_!/1[R[7
MU_>_?7K[#V'JNQ_']JZ?Q0W',=;S!TDO#S=SOS);,.\;YN>_7RL&')R?KYE\
M?5P6ZRU?.]+SUS%:;?>;>=;X&Y&Z[SNELS'BS<WZF"V#7%?12^-.MH@(@(@(
M@(@(@(@(@(@(@(@(@(@(J7\<UZXO:9I_#;@KT)G>.V[1+(PKA5?:6M-4LM>U
M8Y<&G+8UFMDDE8Y];LM3&94EH:H6R#8SBA)VUQ$I$1.:S92JVU]38?=?_GXK
ME;<N!/B$XCN NGZ@NW"U3^&E6F<:6C-U3/#=7MTU[>%QVKK:F["B)_=]NV'O
MJ3-6(#8&Z-N)S]SM!E[4XCB/9.N03>P68KV=<N8TK\0#CK>[2+VPV)!M8"^G
MW6^Y6$TEPR\1>J]N^Z&>Z)636#NV\4O$Z1A2.'S0L?:]=9=:TT]JBLYKNJ8.
MYVN4N,9KUC-WV<BX6W[0:5VV6>*@2-V)8.0L,H:51,5"00UO8+W.NI/J]7 *
M!N''@2XNM/>XSQ/"[78ZR:\XJY&_DON]TFVQ:?$VC;#2S;Y87O=5=IVU:3<)
M6+KTQ?=19?:XKEHD)NMN^T(((2[FL-GJD^R(2W'?ZO :<-+-N-.&E_ZJT_!-
MP2R6B.-KC(XD:?JQ/AHT7OBD:0K$!H5O(4LV9S8E 8S6;;MQY6=:V.UT.FM7
M#6385V%81LXXEYQ^:W6*<CXE1^T/*E0NNUHXD7U^_LOQTU]6OJ7.OC9X+_=&
M=A[3]V LNL]*L]AS'%;I;AVT#PQ[/<[7U?#QU;X;V)6#'B%T]6:W9K;#6" M
MEG>S<_99(EH3KE%FE6DI+L[0M,EAJ_8"N:X#!KP))'K[#P[@/6%,&V.!?BUG
M>(=SN?7NI("N0'!Y[EG/:"X":(GLNIO&"O%5;(E\Q82"CIR\B4F*.O:\QJM9
M1EK1&5F!?6>#B+%#R#1M&MY-J0.%K'M?=Q_R_=KWG_2Q4(ZB]S^XYM!3WN7Y
M:GP_5>TTWA%X,MV0<747VVZ C7-0\<.TTGZDSN#9;-S+H>-F5AQ,RZK%/6K.
MYK5J7DW\8WGD&93723(7 XN]SA_%O=VVUL?X?P75_P!R1X>ML\*/ %J+4F[:
M5BM[AB<76W;#B4+57+?8IV]7RU3-YM4E/6"$?+5%Q-2-EG9-G&]VV26C$ZXV
MKN7DPU>9?QT65KC<DCAV>H#@/P7&US[GQQK[*K7NP=AV)P?14AQ!>Z-;08U[
M2EEV/LG04K0M):1K361@-;6>R6" V#<KI"7:A5R5P[PRH5*L+A>QU:HG9/L-
MDCNHLK\0^CL39HZP[SQ(MPUX?ZJ=]F>YW<9$%O7W.&2G%ME<5NK^&;@AMG#O
M;;!K_<U(U3=83B!M\(6GV_:DS9-HR[&WL:#?*&JWI$C=-6*3F^*S#1JTQ"ME
M9XC5.5*F($.[,3L7"^@N;??KVZ>M;]Q3\+R-ZXC?<M:AP:2&JZR;0U>XJ.';
M<L?JV48O8#47#U;M.Q6L]E+I,FKE^[:R^O[6DQB-?QEG*N\+M:<@O%#=PAXE
M61*@=H[%<WPG7O!N./>+Z]RU+<ON>/%M,;&]U)K.N:C"%B>.;7?"_P ,.@-Q
M/+34T-=<.W"C5*(^IFXZC(4Y:Q([':/8^-=V#$75ZA4I6&N5AF*U,.9Z**I9
MG$*50X -_P I+B-=77T/^E]>'X+"[>]S<XJ8O:F_[QI6D)2\;PP>Y3T;@$]S
M?3F;_38]_;;E,U9:-O>SUR.9ULWJ-MIC,^:_&O[SF C)B0PP>M3*L6*$DT*@
M<+ 'M?B=IV:6'K^M^*U*L<!_'IHW8_!U*:MT/6[+6.%WW+#96E=%M'.VM?-8
M317''<I&03L.UKS&RLLS=V*P;"HI&T?(N=>,IRL^,Y1W775JAJ>DK?E"KB!#
MKG4ON>.K>[[AQX_P77WW*SAZO'"KP!\-FA=E5!K1K]1**3%VKR%DC+:Y1N]E
MD7UNOKV3GX-5U!OW\K>I^R273B)*79$9.F2>)5ZN1=0%:X@N)'"^GW+H."M0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$51_)"Y>G;CB/ZZ$\OL<*'DKU';G'B/QAYMYN_7=V]
MA[)W+W-\#MO>7:.V_$=BZOX\=?S[1= ^C6&?G'I9SWBP-W;<^:-QMF9F/.SM
M<&5AP=;'?JKF>:*KIAS]>'<NCG-6'&[/WKG+>[Y>##E96F/,Q8],%M5;@<@N
MF0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$47ZZTCIK4#^
M\RNJ=4ZZUM*;.M+V[['DJ+3*]59"^W&2<.73^T7%["1[)S9)YTY>/%UI275=
MO#JNW)^NZ2ZN3DN3Q-[:#[NY2@"("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("*&//.
MH>D)CAJ[%8/'N=/>=W>/8V'A7PEXS\#=C[P[T[T[_P"^/CNQ]R]A[O\ CN\^
MO^2C=<PUG1WI-CI^;^>>8\O')O>^;EOV/+RLK=\GJX\_,S.KE8>LM5SQ2\]\
MP8)]\YKYVS,+-VW;>MTP8\S,SLW7#E8,&N9BZJF<:5;5 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 15/\ (JW>G%CB7[QKG@3'"QY']T]LD_%OBSS7S>N\.P=T=S^'NZ/D_:^_
MN\N\?B>Z>S?*QUO/U'T%Z,9=3O\ TJY\SL$6Y[IS3N&7F9V=O&=UL&[Y67KG
M8NHN;YGJNE_/^.#<^CO-.7BDWG>><=[QX,K*R<K3%G8\>F7AZRM@.272("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("*,IG8V8%^K'R$ Z(JGZR'P[2RDX1SG."+H'R
MCCIIGY9_X&*;!DSX*H4Q<1)*K*=A?&Z_8018CO![O^'5;FFV1O4398JJ,M.A
M!8[$QW:QXOHX?@19S26D$XKS?9?4CK[6E^2+-^9]F[\0L_1^7SB/V'?%/-]E
M]2.OM:7Y(;\S[-WXA.C\OG$?L.^*>;[+ZD=?:TOR0WYGV;OQ"='Y?.(_8=\4
M\WV7U(Z^UI?DAOS/LW?B$Z/R^<1^P[XIYOLOJ1U]K2_)#?F?9N_$)T?E\XC]
MAWQ3S?9?4CK[6E^2&_,^S=^(3H_+YQ'[#OBGF^R^I'7VM+\D-^9]F[\0G1^7
MSB/V'?%/-]E]2.OM:7Y(;\S[-WXA.C\OG$?L.^*>;[+ZD=?:TOR0WYGV;OQ"
M='Y?.(_8=\4\WV7U(Z^UI?DAOS/LW?B$Z/R^<1^P[XIYOLOJ1U]K2_)#?F?9
MN_$)T?E\XC]AWQ3S?9?4CK[6E^2&_,^S=^(3H_+YQ'[#OBGF^R^I'7VM+\D-
M^9]F[\0G1^7SB/V'?%/-]E]2.OM:7Y(;\S[-WXA.C\OG$?L.^*>;[+ZD=?:T
MOR0WYGV;OQ"='Y?.(_8=\5E8;:$3)ODF3EJM&87^ DY76340Z[.<8(FJ8I2=
M5@_S%4SS)@W+!\E+GI8OCK(WN#2"R_ DBU^P>J_>L-1L2HAB=(Q[9BW4L8UP
M=A[2V]\1'DC4B]KD6..VEM)WK!%I(.:B_FX1UG")Y9B_1239/,FS@C5ZBHV4
M,AA8N,9;+Y.9)8W32YD5*4IZ554:4!QA<]ATQM<+-/<X$:7[#P/#BLVP]AQ[
M;=)"S:$5-4LZPIY8G.,L=M7Q.#P'83X[;!S19VK22(6],*$]B97[V:?V@A<\
MQ_8/]IOP72^#RI])P>[R?W$],*$]B97[V:?V@<\Q_8/]IOP3P>5/I.#W>3^X
MGIA0GL3*_>S3^T#GF/[!_M-^">#RI])P>[R?W$],*$]B97[V:?V@<\Q_8/\
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M)^H[^A[1Z[KT3DURDBVU"(9BV+:,3?I8QHV=HT,\([OM(^,9/:P@J!AKUU2
MB B B B B B B BNYH+?O^"HUY>^OXMK7K"Z4_T(C%2JQ\__ ,IL7RAO_P 6
MSDW/JE1O-G[0OA@G=KPCD/\ )CS_ ":X\>!["O,^5?)2V;M39<6FLE721C^+
MIX&C^)EB TU>P>,T7<&\7F: B B B B B B B B B B B B B B B B B B
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MX)I(-)]CBR%GVJV3SF#G<H0SJ*BL1[E&PR,,Z>P3>7NRW@7+7#4  M==V*_
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ML]9VL5I 0<ZM$$<8C2R5%V0E2I9Y9EVIG->UN]V9DKE!H]=9%\)8X/C>0T.
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MO1T<5'$(X]7'620CK2.[SW-'!K>#1WN+G'7AB4M 1 1 1 1 1 1 1 1 1 1
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M.I*_8*B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B\$G)LH=DO(/UBHMD"\S9SZS'-G]Q)(O/&
M5%5,_!(3'KSGY^6,9SBU[VL:7.-@/^6'K/8LL,,E1(V*)N)[CIW =KG'L:!J
M3_715=M-H>V=_EPMTDF:.3%9,\&YD03SG]XW+E@[A3&,954Y>OE@A>1"EQC3
MS3.F=<Z-'BM[AWGUGM/\.Q=M0T4=%%@;UI'6,LEM7.[AW,;KA;]Y.I)6L#"I
MJ B B B B B B B B B B B B B BD>CT@\\IB2DBF1AD#YSRSG)#/SDS\)-
M,WJR1N3..2ZV,XSG/-)+/3ZPZ,NFI\SKOTC'9Y7P;WGMX#M(T^T]I"E:882#
M4N''B(0>#B.!>1JQITX.<"VP=!^_-Y$F<+T&CN"HUUMCLDQ*,\X3)+92^!F-
MCS)\L%AT>CT%E4^6)$Q>K3_9Y<F?1*^O#P:> _1CJO>/K6TP-_R#M/UNSJ\>
MHY*<F#38=J[3875C_I*:"34T^+7/FO<FI=>[6NUA!Q.^F-HJD#3KT! 1 1 1
M 1 1 1 1 168T1HQ>].4;19D%6]/:+<T&YNFDK8G")^1D$38Z)R1:1RY(\=$
MS@RQ\&9M3=9APLUVE!09Y$LHM"#H.!D([/4T?6/$\!VD<5RIY4-V6QU#0O:_
M:,C;/>+.;1L<-'N&H,[@08HSHT$2R##@9+T;000:H(MFR*3=LW230;H()E21
M012)A-)%)(F"D333(4I"$(7!2%Q@I<8QC&!T8      %@!H !P '8 O'G.<]
MSGO<Y[WN+GO<2YSG.-W.<XW+G.))))))-SJOJ*JU 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 11M:Z9,VAV4ZDTW;,$.?9&.&RIBIYSCD994V%BX5<']>,GZ.,)DY)DQC'3,
M>+/3OF<+R -'!N&_\3J+D_R[%N*#:-/11D"F<^5W[R7&T7UT:T83A:.Z^IU/
M8!J?E \^NVWV-7\\8-Q/V@]D_%3^D$?FS_S&_*GE \^NVWV-7\\-Q/V@]D_%
M.D$?FS_S&_*GE \^NVWV-7\\-Q/V@]D_%.D$?FS_ ,QORIY0//KMM]C5_/#<
M3]H/9/Q3I!'YL_\ ,;\J>4#SZ[;?8U?SPW$_:#V3\4Z01^;/_,;\J>4#SZ[;
M?8U?SPW$_:#V3\4Z01^;/_,;\J>4#SZ[;?8U?SPW$_:#V3\4Z01^;/\ S&_*
MGE \^NVWV-7\\-Q/V@]D_%.D$?FS_P QORIY0//KMM]C5_/#<3]H/9/Q3I!'
MYL_\QORIY0//KMM]C5_/#<3]H/9/Q3I!'YL_\QORIY0//KMM]C5_/#<3]H/9
M/Q3I!'YL_P#,;\J>4#SZ[;?8U?SPW$_:#V3\4Z01^;/_ #&_*GE \^NVWV-7
M\\-Q/V@]D_%.D$?FS_S&_*GE \^NVWV-7\\-Q/V@]D_%.D$?FS_S&_*GE \^
MNVWV-7\\-Q/V@]D_%.D$?FS_ ,QORKUL-1X3=HJ2$J1RS(?!EFZ#<Z*BQ<>O
M"?6Y5-U939Y8.8I<GZ'/!,E-G!RW-H0' N?=O: +$^J]RL<NW[QN$,!9(19K
MWO#@W_-APC$1V FU[$W&ASFR:=9;97"5>K6!E4X]PGEO**E9++N7##!2D)'-
M3(+MRM&JA>D5WDO24<)=%O@Q$#+D7RU,,DL65%(V%IT<<))+?)%B,([SQ/#0
M7O'V-M&BH*TUU=225\K#C@;FM8QDQ))FD#F/,DC38QWLUCKOL7AA95_T/9CV
MXC?N5U_?C5\S/^W;^6?F7;^$.G]&3>\L_M)Z'LQ[<1OW*Z_OPYF?]NW\L_,G
MA#I_1DWO+/[2>A[,>W$;]RNO[\.9G_;M_+/S)X0Z?T9-[RS^TGH>S'MQ&_<K
MK^_#F9_V[?RS\R>$.G]&3>\L_M)Z'LQ[<1OW*Z_OPYF?]NW\L_,GA#I_1DWO
M+/[2>A[,>W$;]RNO[\.9G_;M_+/S)X0Z?T9-[RS^TGH>S'MQ&_<KK^_#F9_V
M[?RS\R>$.G]&3>\L_M)Z'LQ[<1OW*Z_OPYF?]NW\L_,GA#I_1DWO+/[2K]Y<
MN?2FQPO]Z(=YYT+Y[>+NS*=@[!Y@> O#O=76]H[7VC]H]O[9U/4_)^S=/XP=
M#T&GZ*]*><(LKG_F'<\A^9F<W\X;SFYF'!A^BR\%[];%;1:7PNTG2+H]S)49
MG,W/&\[Y%@P;[N>1EY&+%?Z3'BM;JX>U6;KO"*FTF&+JQVE&5AVZN%7<:RCU
MV2S[!/61L9V9VIE!!0_1PX,F3KLH],B)T5#E63T,>QPU[3)*'L!N6M:6EWJO
MB-AWVUMPMQ6QK/V@.DIY64="Z"H>W#'-+,V5L5]"\1B-N-[1? ''"'6<X/:"
MQUS&K5LQ;-V3-NBU:-$4V[9LW3*D@W01)A-)%%(F"D333(7!2$+C!2EQC&,<
MAN@ T!K0     +  <  O.'O?*]\DCW222.+WO>2YSW.-W.<XW)<2222;DKT"
MJM0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$5=?( GI98XH_%9NLQP^>0_@CN3'0Z'F)F_^*?$?>W2
MZ72SW5W+W%RY?+>]>?R0=)T@/1'HKNFG2+G_ '[/UOS=S?NN[9/_ .7/S_\
M)E?76BYE_P#,O2+>?_HG,^YY/_\ NWW>=XS?_P >3D?Y\WZJL4.;6]3/_+U9
M!%7JZ;$V%3),S-W'UY9FMDYXZ0*PDL(NT<9QZL_M;.$W*6,E*X0SG.2&S@Q<
MG2.FH?B=K;=VWLJH,4M/0OB?<P3B&I#96#L/^*ZLC= ]E]+@B[2TF.^21AL0
MVW8;'7^?XC^EBM.\][A] KOV.1_W8:KIEM3["@_*J/\ =*W/?W-_ _%//>X?
M0*[]CD?]V#IEM3["@_*J/]TF>_N;^!^*>>]P^@5W['(_[L'3+:GV%!^54?[I
M,]_<W\#\4\][A] KOV.1_P!V#IEM3["@_*J/]TF>_N;^!^*>>]P^@5W['(_[
ML'3+:GV%!^54?[I,]_<W\#\4\][A] KOV.1_W8.F6U/L*#\JH_W29[^YOX'X
MIY[W#Z!7?L<C_NP=,MJ?84'Y51_NDSW]S?P/Q66A-[RV9)N2P1\9B*4-U;A6
M-0=INF_2SC!7!<+O7)%B)_.HC@A5#DYY3/TRX(>32<LJDU#!6P4XIB;/=3LE
M;(R_!X#YI X-^LP .(X&X -1.;]8"WJO?_4K(<0-QW76*.E>]$L*;<&\<W4?
M3D#,Q$Q*2;Z*Z.%,2=<5B+!$E<*L28.9Y$J-EG3E'I*LU>T-^Q.<W+7:O*S9
MVR&[8Y'0;*VHR"-TU91U5-55%1-36Q;Q0.I:VF$CH0"9:9S'R2,NZ%QD9DR6
MU3ZED8DIA&^VKFN:2XCO:0YO#M;:Y' W%CR]]\OWY[-:I_#]J_6P^>_#]RS]
M'\F_<MI?JZTW.]5Y,/L.^=/?+]]^S>J?P_:OUL'A^Y9^C^3?N6TOU=.=ZKR8
M?8=\Z>^7[[]F]4_A^U?K8/#]RS]'\F_<MI?JZ<[U7DP^P[YT]\OWW[-ZI_#]
MJ_6P>'[EGZ/Y-^Y;2_5TYWJO)A]AWSI[Y?OOV;U3^'[5^M@\/W+/T?R;]RVE
M^KISO5>3#[#OG3WR_??LWJG\/VK];!X?N6?H_DW[EM+]73G>J\F'V'?.GOE^
M^_9O5/X?M7ZV#P_<L_1_)OW+:7ZNG.]5Y,/L.^=/?+]]^S>J?P_:OUL'A^Y9
M^C^3?N6TOU=.=ZKR8?8=\Z>^7[[]F]4_A^U?K8/#]RS]'\F_<MI?JZ<[U7DP
M^P[YT]\OWW[-ZI_#]J_6P>'[EGZ/Y-^Y;2_5TYWJO)A]AWSI[Y?OOV;U3^'[
M5^M@\/W+/T?R;]RVE^KISO5>3#[#OG3WR_??LWJG\/VK];!X?N6?H_DW[EM+
M]73G>J\F'V'?.GOE^^_9O5/X?M7ZV#P_<L_1_)OW+:7ZNG.]5Y,/L.^=/?+]
M]^S>J?P_:OUL'A^Y9^C^3?N6TOU=.=ZKR8?8=\Z>^7[[]F]4_A^U?K8/#]RS
M]'\F_<MI?JZ<[U7DP^P[YT]\OWW[-ZI_#]J_6P>'[EGZ/Y-^Y;2_5TYWJO)A
M]AWSI[Y?OOV;U3^'[5^M@\/W+/T?R;]RVE^KISO5>3#[#OG3WR_??LWJG\/V
MK];!X?N6?H_DW[EM+]73G>J\F'V'?.GOE^^_9O5/X?M7ZV#P_<L_1_)OW+:7
MZNG.]5Y,/L.^=/?+]]^S>J?P_:OUL'A^Y9^C^3?N6TOU=.=ZKR8?8=\Z>^7[
M[]F]4_A^U?K8/#]RS]'\F_<MI?JZ<[U7DP^P[YT]\OWW[-ZI_#]J_6P>'[EG
MZ/Y-^Y;2_5TYWJO)A]AWSI[Y?OOV;U3^'[5^M@\/W+/T?R;]RVE^KISO5>3#
M[#OG3WR_??LWJG\/VK];!X?N6?H_DW[EM+]73G>J\F'V'?.GOE^^_9O5/X?M
M7ZV#P_<L_1_)OW+:7ZNG.]5Y,/L.^=/?+]]^S>J?P_:OUL'A^Y9^C^3?N6TO
MU=.=ZKR8?8=\Z>^7[[]F]4_A^U?K8/#]RS]'\F_<MI?JZ<[U7DP^P[YT]\OW
MW[-ZI_#]J_6P>'[EGZ/Y-^Y;2_5TYWJO)A]AWSK;Z'[ICL+%JB2[(JE-6IJR
M^$9D]2C)ME/,T%?@8?LC25DE&;G+,V<+*L5&Z9GB13(I.FRABJXV>Q_V_;;Y
MQIAMW9NRG;*<_!5'9E/60UD3':9T1J*^IBDRCUW0N8TRM!8V2-Q#EDBVO+C;
MG,C,?!V .#@.\7<0;=W;PN.*[#UJRP-P@8NSUB4:34#--$WT9)L5.M;NFZO/
MD8N>6#IJ)GP9)PW5*FX;.$U6[A))=)1,OU#05]'M2CI]H;/J(JNBJXFS4]1"
M[$R1CNT<"US2"U['!KXWM<Q[6O:YHWS'MD:U['!S7"[7#@1_SB.(.AU6<$Q7
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("*M?G
MZZ]+_'"]X8;]BSPY>>_C+O53M7:?,G-!\-=R=@ZKJ.JQWGWIWGUG6?)>P]'X
M\=-T?9T.Z4[T['TDYAW+*&#!S9SAO.?F7Q7^BRLJUNMCOU5H>>G=)^CV[MP<
MQ\\;UF'%BW_<\C)P6PV^DS,R]^K@[590<RM\@(L+8*_&6:,7BI5#"S=;',A\
M<L+-ERXSU;ELIG&<IK)9SG)3<LE,7)DU"G2.<AHE;14]?3OIJEF.-_ \'QO'
MBR1NUPO;?0\"+M<"TD&US0X6/#_3UC_G\E2>Y4Z3ILH9B]+UK57IJ1\@0N<(
MO4,9Y<\?/U;A/F4KAOG.3)&SC.,G2.DJIY+M79=1LJH,,HQ1NN8)@+,E8/\
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M[9&M>QP<UPNUPX$?\XCB#H=5G!,5R B B B B B B B B B B B B B B B
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M"X=H)^;?M4_9?'(R;E=R4A;)!(UU5M39M,T%N$]:3:%!&P>)Q?5T[1U#BGC
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M!U?5T[1] <4T0$.8R'6[0H.-13B[3UI&-[.][1W>4T<.(TO;E0/G):5 1 1
M1:W/7"JU=:/;6&P1,0[E>T]ULGSU%%])88E34?'8,LF[6\28)+)*OU6Z*B;)
M%0BSHZ21L'S*IZ*KJVR.IJ::9D.#.DCC<Z.+,)$8EDM@C,A:YL8>X&1P+6!Q
MT5[8WO!+6DAML1MH+\+G@+]@OKV+5UMSZA;%8G<;0U^W2DX=:PQRR]O@4F[^
M ;OBQB\ZS<*/RH.(9&2.FP4E$E#L2/%4F^5\*JID-+;L/;3S(&;(VDYT4[:6
M5K:&I+HZE\9F;3/:(RYL[H@9!"X"0L:YP;A:2+]WGU^BDT=A(PFX=:^$CCBM
MK:U[7T639[/UQ(3JU797VGNK(WEEH!: 1L<0>83G6\<E,+PN8W#OM?>R,0NA
M+*1V$LNR1BR4@9'#10BQL3]E;4CIVU<FSJYE*Z%M2VI=2SB T[I3 V<2EF#)
M=.UT+9<6 S-=$'8P6JTPRAH>8WX"W$'83;"21BOV"X(N=+@CB%_9+9NN86>5
MJTQ?*A$V1 D.HO!2=BB6$JB2PN5V4 =1B[=I."%G'K5TRA\F3QB3>-G#5EU[
MA!5,J+96U)Z=M7!LZNFI7&<-J8J6>2!QI6-DJ0)6,<PFGC>R2?7Z%CVODPM<
M"0AE<S&V-SF=;K $CJ@%W#R007=P()TU6Q0D]"V6.)+UZ6CYN+4<R+).1BW:
M#YDH[B)%W$2;=-RV.HB=5A*,7C!T4I\Y1=M5T#\CIFQB+/3STLAAJ89:>8,B
MD,4S'1R!DT3)X7%CP'!LD,D<K"1UF/:X:$*US7--G M-@;$6-G .!MZP01ZB
MLL,*M7X443134664(DDD0RBJJABD333(7)CJ*'-G!2$(7&3&,;."E+C.<YQC
M J 7$-:"22  !<DG0  :DDZ #BBUJN7:H6]C(R55LT'8F$0^7C)5W#23211C
MI%LV;OEF3XS557LKHK%XS?E16Z"BC!ZS>IE.U=MU5)5305M%)%%64E12R3QM
MFA9/#)$Z6)[W1MDC#V@O89(Y(\3;@21R1FSV.:+W1R,(:]CFEPN X$7!-KB_
MK!'W@A>&J[+UW>3D2IEZJ-K64C^]DD:]8HF765B<N.QXE$D6#M=12-R[^28?
MD*9IESC+?K>NQDF,E9LK:>SP37;.KJ,"7()JJ6> ";#CR296- E#.OEDX\%G
M8<)NJOAEC_>1O9KANYI O:]K\+VUMQLMV$!8UCF4O&23B6:,'S9VY@9 D3,H
M(*E45C)-6,CII-B\*7.<H.3Q,O%R!4C\C9:OVRO+HJE&62&6)L+Y(WL941&:
M!S@0)8A-+3F2,GQF":":(D:8XWMXM*J6D!I((#AB;?M%RVX]5VD?>"LCS^?_
M )>K/_+_ #]?_MG&?_<8E1.?_P ^H$6.B9:,G8]M+0SYK)QKPIS-7S-4J[9<
MJ2IT%,I*DSDI\$6243-RSZCD,7/KQD9)H9:>1T,\;XI66#XY&EKVD@.%VG47
M!!'J(*JYI:2UPL1Q!61&-449I;HU$O*I02.SJ&K-+N6;)"*3M<(>06=R,SFN
MQ[=-H5[E8ZKZP%-!LR%)G+F7QF.1Z;O&41M3L+;3834.V1M)M.UCY'3&BJ1$
M(XH-ZD>7F/"&QTQ%0\DV9!]*ZS.LLV[3AN+*?AL3?";6#<1_!O6/JUX+>\RT
M9B6+!9?-L3)HX\L6,ZTO;,QB;DC,[["'/I]F*Z43;Y5Y='"IRDY\\C7Y,N2:
MC+?D"40F7"<O-+"\1XN&,L!=AXV%UBPG#BMU;X;]E[7M^&J^)I^#+/)5<TO'
M8LB\2XGD8++Q#O92$:/&L>YEBL.GVG,>B^?-&9W?5]1ARX31Z?6&Z(J*:H-.
MZK$,NZMF93.J,MV0*B1CY60F6V#-='&]XCOBP-+K6%U7"[#CPG!B#<5NKB()
M OPO8$V]2RXPJU 1 1 1 1 17"X4N*V=T!.EAY@SN:U?-.RGFX0ALJN85RKD
MJ9[!7R*&P5-VF7!>WL.DFA+()X(?*3M)LY2]0_9Q^T>LY%5@IJDRU?)ZKE!K
M*,'$^E>ZS36T0<0&RM &=#=K*EC0UQ;(V.1D^BK74KL+KNA<>LWM:?+9Z^\<
M'#UV(_T!5NR05P@HNSUB4:34#--$WT9)L5,*MG397&>1BYY8,FHF;!DET%2I
MKMETU6[A))=)1,OVI05]'M2CI]H;/J(JNBJXFS4]1"[$R1CNT<"US2"U['!K
MXWM<Q[6O:YHZ=CVR-:]C@YKA=KAP(_YQ'$'0ZK."8KD!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!% GD+$>D]CB>[_DN_L:*\B_"_9FO
M='=/CWQ[W[VSGVSO'MGR#LW+LW9OC.?6C?\ /\W1?HON\6[\_<_;UB?G9W-^
MX9&#Q,O!])B\;%IP6EYFCZ0](,]^=S/S/N^%N7E[YOF=COBQXNIAMAPZWNI[
M&@6Z0$0$0$0$4)[HL%?;0F8-XW2D)EW@JS%+!N2D7RSG&)%10OPTN>,&321Q
M_BN9BGQU.#Y')<JZVBCH]SE8V>JEL^%M[.I[7&\%PU;VM:W_ +FH(+ Y89G-
MMA.KN(]7K_\ ;M5+;&C"XC%I6<B$IEO72JV%NAW06:?(.HINLX(YAV.$'#E2
M7(0JA&.&*?;5%E,(M\Y.I@N?-V%U\+7%I?U"<6$$.-K.-P,/??3O455LI&[M
M%[8KD)?5ZU6(VLWIG8IEA9;A):@79S<##4F"G[-8<.XRX3V9.-BHQ7-9MN4C
M.7E:E*K*Q]H:QD6QCG[R9)354#W1B1[GQ8&ED8J06N=*YC&6=$S"YSNNR]@\
M/:8RYQ(%Q:YIMVC2PO<:Z#4#MU'WBRW!+8_"\^65K2=PTBX<S9G;1[7\RM*R
MN\4C9&R)OV<M$G5ZTJT=-46V-GS22;D58S52G6CE-*1A7J3?'DUPZ^74]2UG
MVDTN&6+7>MLK""TZMD:1HX$L+M#9WJ-CZCI^(/\ $=Z][2_:DV!L*LUAA%PE
MTD\5&Q7FN7%%C7)R%C$JC;("LR\:QE#.G$M&V!C-2T:L9!%@B@F5N8^7Q7;?
M"&*&*HAAD>7/B&8R)\=WM<[,C>]KB+!KF%K7"Y).O"QNEB 3PU (U!U!(_T*
MG(15:@(@(@(K0T=;RPH4W;M@SB4#5FC7,LHWDL]%**:%Q\-PI@Q3+8=2)SI)
M-XMN0Z[A<Z*1$57SG"!?1-D.Z.[&J]I[;K&T>SHHS4N9/XM-&.+W:%^;.2UK
M*:,%[WEK0QTTF 2&G*C=)*[ P"YOV>O^/8.)^]?Y[]T6JFW79MNL] JY:?5)
M:44<1<*4WK*7D4J[\[8ICMXX\HXPK(&BF1LLHS+CL34QTD2G-\2<JMH[+VMR
M@VGM#8NSALO9M34.?348/BBP#YBP$QP.J'ATYIXB8:<R9,9<U@<[E:A\<DTC
MXF9;'.NUO];<!B.N$:"]AH%%PYY84!$!%6V0@Y^J\1D]LR1B)B<IEKT]4Z+%
MR\"P6G9"BSU6MESG)AHM ,4GDP>/O#:TP;@DI%1<DW3?4XK>P]C;DAE%NICJ
M*>LY+TVR8IH8*ZCVY6[1F@J)&T\6T::LHJ"G@>VID=' )-GOHZEIAFEB>8Z_
M%2XW&H#98<U]*V(%K9&3OD<'$-$C7L8UIQ&PO&6N%B0;/ZM]0(%@M3[/O=OJ
M+79:-FJ;>P</FZ:5?)FNP],;$(XONTX&795TZC6&EJ]'R<S4&+R2?/F; ZJ#
M_"Q73U"8>))J=%4;9V3LZBK7[)=2UCZ;E+L&OV=!535[R6[-V14PR50#YH:F
M2&&MDCBCC?( 8\."-T#'$2'30QL>8L$F&I@?$USI/^W"YN/5P<6M>0 "1<6(
M&$%;EK+02*UUVD2P(VN#I5<XAJ9L36]<RDS;0]@0HVDM2TJMSJ\J[CG5B=M8
MFQU*62(R1FH\SU6$9/)%%[#R1<2D':W*-S:'8YIG4=17U/)BNV7M2JN]T],Z
MOY0;:KZJG9#'*RE8Z>DK829'02X&U$D<1CGA.39-4_1PX2QTCZ:2*5VI<S'/
M*][;7#;N:\'$0;7(%G#3)7+3#G:6]]O,K/XJB]87'2&E*?(N(MM'-V-P=52^
M;DL-CK)Y=_&2#UBBC'6ZND=.HA2+>N$)AXC%2J4C&N%8[%0;=;L?D]L62CW.
M7:]#R@V_6Q-F?*Z2A96[-V#2TM6((Y8XY'.EH:HL9.)HVN@C=-"8IF-EHR<0
MTT!9@,T=1.\ DW8'LA:U^%KA>Y8[0W L"6X3K&=?K^WJ0@H>'@-J+1LTKO&3
ML<+%2[QN5J]GN+"$FZ3*0["15<,8M8^J)^]6*58U="*GK!"HKQ*DBPN"U?=M
M-K4U6Q=H. FJ=CME@;R>AI)YH&.+V4W(RHIZ^&>6)K7RM&V:;9U+#+6.FIJ6
MH<V<124#:EC\KG02'K.AN,@-<X"Y:VD<UX)%B?IFL:"\D--G6,8=?98TG$T1
MG%K1Z$\YG&Y-AP986WJOHYFR5)<]K$U];T)YC.34--H,JZ:FMK-7;NE*+340
M:NR=;LJ<^PF$YF+,>29DF;*ZG93NYLJ-XH0R5\@W#8QVG1.II*:">G=)4[\^
MDJJ!T+8)]ZAJZ0TTD#J>QVZ7=?#A.6[$P7-LN',9A(!:2[&6.9;"X.:\82,,
MVZ9+:&U2L<U:V>SUUI%!E)*U*^EBWLK'232OH-)Z#KB99V=7=,WCUGTL8=39
MH1]*N73BOIM8EU@ZN@VYNCJRFIZ.39 ;$Z2)M;L[.CBEB?4N?3U%474].UKX
MXY+793BHCA8UM27S,L,$^#&QK#"+7&.*X!!==KG=5MG 'L;< #%<K):J@YR(
MG=LV5^ZFGU>O-EA[=!GLD RA[<@L2GPT'+1CF.C(>(>*1$4E!Q<;7TYB.S8<
MF;2*:ZTBRS%R#W%MBHIYZ?8U+&R".JV?2ST50*6IDGHG--;/40RLEFGGC$\S
MJB:6I,$NZ6?$6-BDSHH[9G-<V%@PAT;7,<&.+F6S'.:X%SB+N+G%V$X;6.FH
M%*-5:RWS1JG6Y U9FY:X1O#ILRG:A.\)#11M.;(E7*4K)5NS,RD0;S41L%_7
MZ4\KUQ?'F&U?<0+V(D\-6,IB0>=]MG:W)S:%;5Q"KIX:&7E1LFNVV(S43#;N
MRH&&&*JHY#B=3S[,BJMH,J:%@@?5-J8YH<<D)BCV$TM/(]PQL;&:J*28:G/C
M (:]I-\)B#GA\8#2X$.:2=%N]P?[&0BF$/%6#>48I<X_9<NC&23=VO<Z!G-?
MHT1$6MDSKE@L5PD8&D6Q5T];5RR2$K!6*1LEA1<2<;7HZD-7FNH8]ENEEGGI
MN3\HV?+LF%TL+FMH-I_XG:$\]'))54U-115&T*(,C=5TD<-12Q4E*YL,M3+M
M!S,;!%<N+*=V%T0NVV!_6E+F'&&L#I& "[0'M#6Z%Q>1ND]G<CQILE_1U;F_
M8DV;'V37$3+KVEHSN6OUN'ZBL5JPWLB3U"RTO$EL4UP>Q$V_;2;"&MS5%[8Z
M^Z@)%)T6#3<Q,DV5%M 4,4AV1+2[5G@922/H=ICE-M"1M6ZE,;Z2O,.RQ11S
M4\3XI)Z%YCI:EM3$YBQMR!E"3+!RBR4MRR62;S(<998LDM%E@@$$LN&.#@0?
MA5J9L5&^1L;(H[3C*^MM[?EELJ[.VV)"+DXN1F&MBU<3$BWFS?L?+;LS-%BB
M=K'%(5U R:/9</V(K65VS';/EEC=LB6I&P^3=+2-?1TKIH9HH'4NU_HW4X_Q
M >'R.D<'RDEE3$[&8Y%5[XL!(R"<BG:V[&W:X,+9C;#XU\1UNZ^%PUPE:E6(
MS=LU9]32=MKFVV\! 7K7-HEV,M/++2L<61T=N2H6QO+/8B<:(SW8-CNZ46=[
MNC8:MKF4/9HFKQ-;DELK3:N;8%/1[;BHZG8SZFIV?M2C@D@I@(9<GE#L&NHW
MP1ST[W4V;LIFT-VS):BK: *2>LGJHFX;W.IVMF#'0W='*QI#18_3P/9H6DCZ
M,2%N(N=;JN<YX"S+"/XCG55D6:JMW;6%77+4NKY)Q(NR=U;68[/V XD3;%3R
MZZ$C7Y"HN-7JI9L*4C%GK\1:8UF5*9>X:2>"27DNRLB>!0NI1M5YVO$V)ASM
MBR;*V:R(;,(9]%515C=KM=NIBE%3-1S2%T$>9#:XTH>",LMS"918:Q&&.V5I
MHX/$NC2#B+2>J+C?M41VU6.SHYW9%;ZK79#'%,C-$L$I+2$(W23WQ6GW#[V9
MF_=.&K Y]6.;7B/<QZ*3@T;A&,LBW;6<,S0UVV)=C2;)E92C9PJHNASJ<TT,
M44[B>3E7'REQR1QL?+;;#*(RME<YN=BEI!EOG>[%,8C$0S*Q#=;80T.ON[A4
M:@"XSL-P;ZZMT+BO59:I.XWE?)N,KDH2 -PRQE4@)2.CU4V1;=#V^W3S.*BC
MMBE.C(L&[^(?1ZK8A$DG&4DVCC#UJHDC92UE.>3VSJ>6JA-3TLEK*F&60&0T
M4]%14[YI@ZX=#(Z.:.5KB26!QD;EO#G48]N[L!<W%O1>X$B^!S&M+C?C<@@]
MO;:VJT-./W#6H:L*MF^X[$N\T? KW)KXFDG4FGLA_<=?DL2C5:=7>I-7\;!X
MN,DXBH K-5:)0?1%5<Q<@^A%D=BZ78E7/5M<_8=*UG*"H;0/W2%D1V7'0[2-
M*U[:9L;GQ2U&X1-FJ<QK9G1SUC9HHZAKLI,#R_\ <,M4.RSA &4&2X;AMK@N
MRP"ZXO8N! <#LVHHG9:NRZA-WN%LR1X2F<1U6<2\VCUG092N^ZW):S9J/2R,
MN9R9WKJOMEFRR\G(NNH8%Q*2"[]PFL\B[:GV2-DUU/LZ>E(J*[DK5M@IS:\D
M')NLBVO((S% &!FU*IS7-;%$S%(<F)L32UED[HLI[8W-ZTE*\-;WBG>V4VLV
MUI7'0 #706X7%'#J"@(@(@(@(@(@(NUO!)I'>%9UH]E)/8,QKR'MCMG,5VHF
MA(F:<(-.H6PM-.FL\W<$AE)LBC0Z;-J1)=9LU0=/\=-5!-+ZQ_9+R2Y74&P)
M:F?;=5L2EVE)%54.S#24U6]D>!X=5R1UC'BE=5AT9;%&&O?'&R2;5S WH=G4
M]0R$N,IB;(0YL>$.L+>,0[Q2[30:V )[ATS'OZVZ B B B B B B B B B B
M B B B B B B B B B B B B B B BJ[Y\SOIHXX8^XXGPUGAE\\_$?6/._.
M^_-#-#[EZKK>P=U=A^7=9U/:^U_!ZWJ?@CJN8(.A72C/FWGI1S%NUF9&1S5O
M^=>V9G9G4MBP8/JXM5SO/,W2OH_DQ;OS!SOGW?G9W.&YY5KX,O!U[X<6+MMH
MK1#E5T2 B B BCK85_9TQAT$NK<SCQ,W8&6<\RIE]9>VN\%S@Q6R9L9P0G,I
MW*A<I)Y*4JRJ6BVWMJ+9,-FX9*R5IR(CP X9LMM1&TWL-#(X86V <YN.23 .
M]QX#^I_YK^*I>_?O)1XXD'[A1T\=JF6775STCJ'-_P#!2EQR*0A<8(F0I2$*
M4A2EQY3--+42R3SO=)+*XN>]QN7$_P"@ L !8-     "B$DDD\2L',1^9>)E
M(HK^1BC2<<]C\2D.X(TEHW+ULJVP_BW2B+A-M(L\J=H9.#H+$1<II*&14*7)
M#8VG"YKK!V$@X7"[38WLX:7!X$7U"H/Q^]4*V#P[:7Z>RX*'VE!M]N[&>WQY
M(P%KLNLX5K8[IMK4E>T\Z-.U.+I!VZ+R5K#6'>-732GOW<K8)-*7L$9<62[:
M#4VL5946A<Z!V[PB(!\;)G%L<$[J@!LCI+V#RX$&0!K 6L,9ZRR!YZIMU6VU
MUT#7%W&_W]HMV6XK8Z]PCUR415Q:ME7+QTP)7,S*M4LE)[UC'D79MHWN+E9&
M8B]85%9U9I>P;=N,Z_LY:M6'LNHI&.SM595G)ST[8_:#QXD,>4['AQLEPN#F
M0Q.:UIGD 8UD$; S&\-L1<-(:VA>>X6U[^YH(XG30:=GW:*2M,</5"US-I7>
MIWJV7-;L%Y@BN960I#V+55M=FKTK;5C9J51KZ9Y0EEIA,+8*OA-F\7F6BS7I
M=0DQPU-7+,S*DBCB&*)UFB4.^C8]L8^DD?U<$IMIJ,)O;C0NN+6 O8Z7[ 0.
M)[C_ !XW5F1"5J B BG^CTR'JT.ZV/L-RTB(F'9J2R?>IRH-(]FW)UV9:2RI
MZBF*7&#-&V<9/TLD4R0RQD4R]KLC95+LVEDV]MR2*EIJ6)U2W>2&1P1,&+>9
M\7 @:Q1D%U\+K%Y8!F8UK&F60AK&C%KP \HG_0?ZZ+D1Q:<5DOOVP9@X$[N*
MU= O#FA(L^3(.)]VETDL6.<2QGUK')D^(N/4Z18MJH;GC+UPZ/GYD_:5^T>J
MY:5II*,R4W)ZCE)HZ8W8^LD;=HKJQM]7N!.[PF[:>-QTS7R..AKJUU2["R[8
M6GJCM>?+=_Z1V#UDJFX\M6O0$0$0$0$0$0$0$0$0$0$0$0$6NSM/J5H7C'-E
MJ]=L3F%64<PSB=A(R77B7"W5X57C%9!LX48+*X11PHJU,D<_5)](V>@7E*IZ
MVMI&RMI*NJI6U#0R=M/42PMF8V]FRB-[1(T8G6:_$!<V&I5S7O8"&/<T.\8-
M<6@_?8B_\5L0BJU 1 1 1 1 1 1 1 1 1 1 1 1 1=8."?@T[?F)W)MN*^08
MRC(T6G2"/^.SCHJM+-/-5<?X'&>BM"QBQ?EN>A(NR=CPU3>?2/[)OV5Y^[<J
M>4U-]!U)]C[+G9^_X.BVA61N'[G@^DIWCZ;2>49.6V;=[/H+X:B=NFABC/;W
M/<.[R0>/$Z6OV 'T^MZ@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(H,\AZ]Z2F.)OOF:\5XTEY&^'_ )#X>\/^.?'G>_\ A>\N^.\?
MD?\ C>Q=B_\ 2]?\:-]S_4=&>B^3#NG/G/N\?2;QO&X;AD^/EY.7U_$QX_K8
M=%I^9H.?^D&;+O/-/-&1U,C)WO?,WQ<S-Q]7QL&#ZM]5.8T*W" B BT.^7IC
M2XWK#=!S+.BF+&Q_2]9S8]67+CHYZ1&B)OW\^HRQ^2*6<&R<Z>FVSMB'9,&(
MVDJ9 1!!?QCP+WVU;$WM.A<>JW6Y;C>\,'>X\!_4^K_54KE)1_-/W,G).#NG
MCM3*BRI_^A2$+CX*:29<8(DD3&")D*4A<8QC&!Y/4U,U7-)45#S)+([$YQ_
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M M_?S-SBQE/HZ^N-0<N,D0M/W9A!T<?5VM'\3JJ-CR):U 1 1 1 1 1 1 1
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MT#K9K@*F9N,01P:6OKS.3%$;0@ZG4&0CO_R ZM':;.(N !S^'BRU: B B B
MB B B B B B B B B B B B B B B B B B B B B B B BZ:<%G!L:[JQNV
M]JQAB4Q!1-Y4JL^2R7-M63STD9>504QC/AE(^"G:-3X_;ZA<'5QW,7HROO\
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M.1=1-/#GKDR%3Q?RGY-4W*K9CMDUE?M.AHI'M=4,V7-3T[ZIC=6P3OFI:DF
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M$+Q6>":FFEIZB)\,\+W12Q2M+)(Y&$M<Q[7 %KFD$$$+TC*L2 B B B B B
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M.0#JR-[QW$?6;Q:>\$$]O25<59$)(S8BPDC)&*-W<>\&QPNM9P[B"!C!%4I
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M7&6+<W<^TV-#MZ,Y=IZ]A(&<CF$3<[6UJR[^WP-TM.Q[G.:UX(+6N:W" ?\
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M08*247PQEKA/(341B)I+ZKYW_:K6;"J-IPPT48?MBGO'M.KA<!#A:W#'2S
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MB6JE=+*Z[CP'U6-[&M'8T?B3<FY)*[>FIXJ6)L40LT:D_6>X\7./:3_(6 L
M O$,"SH"("("+X.3F2057(U5>JMTE5D6J&6Y7#A4B1\E0;'=KM6I%U^>44SN
M'+9#!E/CETDLG.4BY/Z6X7-MQ.F/<[]8[#IED8,=*QMSB=\P,-LIA&19$L:[
MLT55#O?"5Z9)VYN6Z.X*4A^Q=Z+Q!T%GRJ4:IA0BT^2>,R5DC' F3"8G%A)\
M=I=;$WJW:"#>U^"AQQ/#*5K@1E@B0!]AXA OA=UNM8CC:U]%KS/3?%['0FE(
M[- N+J6HMFUC99*VXW'7):PDC(CC9+>]F5&0+8=C9CT2V#AP,=EB6@224U?D
M7KV@V^S0,)!,X.WUS*<F0XF@.:\ 99 N:; QPPLOI-K9U@P@/:TN.)MN7-:/
MJN):YAQ9@O85&)P-W6UB[KEP):X@ !U\N$>AV_6ND(VI7J$/7[&CL#=U@6C%
M)"(DS)1EYW=L.]5]3+R#D)./,HO 62,5<(INSG:N3+-E<8.CG.8L[FOD+FFX
MP1"]B-6Q,:>(!XM*DP-<R,-<+'%(;:'1TCG#@2.!':K+#"LJ B B B B BRD
M3$N9=UANACHD+R,NOG&<D03SGETC?-S,;EG":?/&3YQGUX*4QBRJ2DEK)1'&
M+ :R//BQM[SWD\&M&KCW $B)65<5'$9)#=QN(V ]9[NX=P'UG<&BW:0#A]M;
M5C=71/AJM917MCQ#I%SGH*EB4EB\N\W^.62J/%<?"8LSXZ.>15UB8:D21<Z[
MEIRQI>25'S5LHQR;9GCOK9XHF/;_ -74C@ZH>+&GA<+6M)(,EK(YMAR-Y(5/
M*RLYUVH'Q['ADL;78:U[#_TM.>+8&'2HF;K>\<;LYSWQ<^W3IR^<N'CQ=9T[
M=+*.'+E=0RJZZZILG5554/G)SJ*'-DQC&SG.<YSG.1\U2RRSRR3SR/EFF>Z2
M661Q?))(\ESWO<XDN<YQ)<2223<KZ/BBB@BCAAC9%#$QL<44;0QD<; &L8QK
M0 UK6@  "P LO.,:R("("("("("("("("("("("("("("("("("*T6B](GLR
MC:WVUJ8E=1.56*C%BY*:=53-S*X7)GEG$2F;'J+G_O ^,E_PF#]?ZY^SWD =
MK.BVWMJ$C9;'!])22 @[1>TZ22-.NY-/ ?\ S+A;]R'9GDW+_EZ-E-EV+L:8
M':;VEE75QFXV>QPUCC<--]<#Q'_3 XOWQ;EWT*4I"E(0I2$(7!2$+C!2E*7'
M(I2EQRP4I<8QC&,8QC&,<L>H?18 : UH#6M #6@   "P  T  T &@"^>22XE
MSB7.<27.))))-R23J23J2=25^A540$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$49>3]"\X_/ONE?S/\ +;RD[\[SDNS>!?$WB_NK
MN;M7='7=_?*^\NQ=X]#Y+VGLWQ0VG/&T.9N8,YO-?.?.^1E18M_W7<\W.P9V
M'=^IE8\N_6PXM5K^:Z+G7GG+=SAN'-N=F28=SWC>LO*Q96+.ZV9AQVZN+#HI
M-&K6P0$0$6/DY-M%-3N7)O5CX*2>.76+*<N94R8_XY^<QL^HA>9C>K C555%
M21.ED/#1K1XSW=C6_P!3P N3P4BEI9:N411#4ZN<?%8WM<X_Z#B38#4J%Y.3
M<RKH[IR;UY^"DEC/P$4^><E3)C_ACYS&^<YN9C>O(XBJJI:N4RRG4Z-:/%8W
ML:T?ZGB3<G4KMZ6EBI(A%$/6YQ\9[NUSOZ#@!H%CQ'4E 1 1 1 1 1 1 1 1
M 1 1 1 1 19*+BW,LZ*V;EY?,954V,]6BGS]9SYQ_P!"%QZSF]6.7KSB32TL
MM7*(HAZWO/BL;Y3OZ#BXZ#M(C5=7%1Q&60^IC >M([L:/ZG@T:GL!\VTMFQ.
MI8,L-"]2[MC]')VB!^BIAH4^,DS+R9<?.7&<9PS:FY=H4)@N,8;)*F$?E?RM
MH^1M *&@P3;9J6%T,3K.$ <,)K:L#LN+00FV:X6 $3'E9N2/)2LY8UYKJ['#
ML>GD#9I&W;GEO6%%2$]MB#/*/W377),KVA<\7[][*/74C(N5GCYZNHY=.G!\
MJ++KJFR8ZAS9^?.<Y]6,<L%QR*7&"XQC'S)4U,]9/-554LD]1/(Z6::5Q=))
M(\W<YSCQ)/\  #0   +Z5IZ>"D@AI::)D%/!&V*&&-H:R.-@LUK0.  _B3J2
M225Y!A69 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 167T=I-2WK(6JT-SI59
MNITV+)3!B'L"Z1^7K^8Q8I(Y<E75QRR[.7+=+/0PLH3U;]G_ ""=MN2/;&UX
MW,V1$^\%.X%KMI2,/\"*-CA:1X_?.!B8;"1S?+.7W+MNQ62;(V3(U^UI&6J)
MVD.;LV-[=.\&L>T@QL-\EI$KQ<QM=?Y---%--%%,B221"II))E*1--,A<%(F
MF0N,%(0A<8*4I<8*4N,8QC&,#Z0:UK&M8QK6,8T-8QH#6M:T6:UK18-:T
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M>GIY:J5L43;N=Q)\5K>USCV-'XG@ 20%#$M*N9=T9POGHDQS*@AC/,B"?/\
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&$!$!%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g320192g77x14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g77x14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19,4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             ,0   )2          $                          0
M           "4@   ,0                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   ,0     4F=H=&QO;F<   )2    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #$
M     %)G:'1L;VYG   "4@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     CA"24T$#      +U0    $   "@    -0   >
M &-@   +N0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ -0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MXL[C\E.VQ[+&-LK<'L> 6N:9!!X<UP3"RLD .$DEH$CD?2;_ %EG5_5_#8+
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %^34T *@    @ # $   ,    ! E(   $!  ,
M   ! ,0   $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5
M  ,    !  ,   $:  4    !    I $;  4    !    K $H  ,    !  (
M  $Q  (    >    M $R  (    4    TH=I  0    !    Z    2  "  (
M  @ #T)    G$  /0D   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q-SHP,3HP-" P,SHT.3HU-0     $D   !P    0P,C(QH $  P
M  '__P  H ( !     $   )2H , !     $   #$          8! P #
M 0 &   !&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $
M     0   7X" @ $     0              2     $   !(     3A"24T#
M_0      "           _^$!@$U- "H    (  P!   #     0)2   ! 0 #
M     0#$   ! @ #     P   )X!!@ #     0 "   !$@ #     0     !
M%0 #     0 #   !&@ %     0   *0!&P %     0   *P!*  #     0 "
M   !,0 "    '@   +0!,@ "    %    -*':0 $     0   .@   $@  @
M"  (   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3<Z,#$Z,#0@,#,Z-#DZ-34     !)    <    $,#(R,: !  ,
M   !__\  * "  0    !   "4J #  0    !    Q          & 0,  P
M  $ !@   1H !0    $   %N 1L !0    $   %V 2@  P    $  @   @$
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "\ CH# 1$  A$! Q$!_\0
M'@   @(" P$!              $""0<(!08* P3_Q !A$  ! 08$! ,%!00%
M!@8+$0 !$0(#! 4&(0 ',4$(46%Q$H&1"1,4(J$5L<'A\!87,M$8(T)2\1DH
M6&)RDB0G*34W2#,X5E=E@H:BTM;B)C8Y149'55EG:(B7F*:RPM7_Q  = 0$!
M 0$  P$! 0           0(#! 4&!P@)_\0 21$  0(#!08% P,"! 0%  L
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M_"NC?A3S7%HPSD 6;#KP>;Y3!\,8F8B'#3#MM^Z9;>--,.W9>,AMMMAE6W;
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MWI%+@S<-(@Y]ZM'1*.]I9P6UYPX57Q;23.J3N\A**J:-HZ?5M/);.J>9<5=
MB5>*GH.43J @9S,IM%_;LL<RR E\!$Q$SB(QTY@F'SY1C)!'[G=@0G2@ S)+
MIJQ) (P$W2X#%S,,)F5>A)Y:-'=>&/C?X=.+V#J>)R5JN>3)JCO@GD^@*OH:
MLLN9M!P<R8+<OF3$IKJ22"8Q,JBF62'$R<.'D&V060^+6 ?=?]H!:>$@164G
M8UF#-X8MB0X.8$I&AGE*<;9,-!\PR\=M,/';8#3#;MIEIAME+-,M@D-,D:-
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M0WB :EBV/&8LW2'#IJWG5.0,SO!Z3$H]097O8ZCEZ:_@N.3UY89NQX=-*QJ
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M?"UD[*I[PL3;,3."BLSH^=5'6<6RYS>H:<2!IN!K&K&F(=B!CY7/GT7$.X&
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MM,L&2P*2/W[R9N6< J,@'R#ZX10!N))D00D)<$3F202[,)MC2I)QS3^6F=]
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M"'H%"W W'U)'\ARQ7,Q)P*_-<,O4/"%\UU-D/ZV0Z:IJN#RGSY5PH=!0NPA
MI^XDJA1%NE^B[[!<'&KS:IS]VE.$"FWJ3< F_;6VX&!/;4 GQ^QZ0B2BY";=
M=4&U_P":8IJ-)Z\&R+<VI"(Z@("-/UY G4A;:J,8=C-N<CA6N+,9EIDR+HD
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M;A3KZ'\NNA%\1F<T<_/ _E^B(E2H3NAML5N@)^NO1# 3)Q-0,'=I2=G_ )A
M+W*'=%Z )HBZ<KHNV%/*'IAG6KRX',80AWWO=;KK_JV.GF$\\.!UED=&+O\
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M[7VNF]DV2^( SD=!3I@:'\0@0 _ZVOX+I9=TQ:^K^WO"(D!D^&ZV/^\2@\_
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M.VO4Z=<7+ON4(ERL4*!-$UU'+2V^,S#\S_[6YY#'&$!.A"HMTUTLHOK;_%,
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MSRS/<H$M^ 3[1J7G%QT<*F0%;/,N\W<VX&CZR=04!,7DD?TQ7$X>,P<T8+R
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M51.*5G5#S2?R6 FL=1]1F$,]IR(C'0>/)3-?@'\3!,QT&TT742S#/WKMEME
MT0<?!WRP1=;W>+O9WBQOB+"U79IO5W*OHWA*24_5L=X))0I@4N*-C./<V:BI
M"5J2I!6 =Q54DA]WB*'416Q[8S."DLJ>"VLH&I9'%SF.S*CX*A*7$-!N(ES
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MJOT(_P#NK]4?_P"2\,__ .2/T.H+C:8+0?3KAJB[LM,O&);F- H2#XV&F/\
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M+.K,"!RY=LS6H3EV^B&)S0%-O(B'AYO5+]UXF'D,XBFG.0YDX35U$. 2A0!
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M(=PL2\@W#N)C&'#UJ$AGS]J$<1$2P[:+B'?13+F*:AW;U[X7;<0(:(:<L$O
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MA1>Z7'ZVZHNIQ!.3UG($<9D:B<L(0B2#R6P5-/\ >_5L6;-[ENF[PSQQA$=
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M61,WJ(0B$WZ(;G;J@\(*V2V!%>M="*4G2<B!"!#J-5 L"4W)N50*5YWLN D
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M=#S([?GRPFS/.E9_-<L =(L L"B:\[(3J;^6!#SQ'>N<Y3:$!"K>R<D'JF@
M&G3$ 8CC4DX:=<Y//) S<?,""I"$'3GV.M];'7&GUQQ[T+-K" ,+8'H%Y* 2
M$TN>2KKJ<.5';+OKR! A$2#_ 'QYM8F[HG_]/YA'Y9C$O(*71L:Y<LQ+Z$@X
MJ)<PS3]W"LOWKF'>/6(=J)>@NH9EZVR&#$/07;D->\;^5DXN=!F7^TZ<Q@\(
M\R65V8= 5[[1>F)LYF=+PU-S_B=?5":,D>>V2E9S2"X@CEJ]@9C&.7,BDC>9
MDWIR ED/$0+V6P\7^R+,P=O7XFC+;LP;-9DGB$DS +#^U1"7#Y"LX;OE3Y5
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MO/G?3N;)U70[V&DJF0YY<?S"$@O9#MI860IR"!5ZCIB9.<@VH,R[]\90@9(
M"Z#MJBG[]KV[XONV#D=.SZPA!-P$NAV)ZJ!I=%P+M*L(8))75%%O6VYT Q)4
MD_0D'!ZUQKQ-48#XGW<MB\@,TY7-,PX7*IQ.:3F<H=U]%QXESJGHN/=>XAHH
M19>N2PV\>M,P[++IZR];]]X79\1QZG;Y2-C[1WKTFY!5V6D7E1W?I*-"[@N3
MY4@3),C-Q^@?I7:7FP_43PC>KKX;MO%UI=-M72]J\/6%@;RO:=E=U_4M;$V0
M1: I" ;116DH3N.MA%,?L5*V_8=_5.3$RS#D56PU?,5#7],P,#.&GT7))G3,
MZ%.3^$BI?$/FRX:G<']F5#"/'09^,8B8EX0\;</7F/S7]-K\JQM[QLY=X1:V
M=YL[2]6*/KO]%=C:)1:A5FI]U5J%)6DH*@H J)=X_N#_ (YM@_\ /T[+\=77
MPUM#8]KX?5L[P[M6\6]R%G97^Z;3N!VELZVLKQ9(2FT%PMA>=F6R5D_17962
M1N)6A)]#!"&P7Y@I)L+FX74Z"VJDC0X_8)TDTW,M7EQ?+ SF_P#F_ UJ A(Y
MC^SO;FJ<K<[IBC02,W[G$);E&AO$W[17A^X3\R*?RXS4<9@F(CZ>E]7U55=,
M45,ZBH[+&D9O/7M-2JILPIS J9'*8N=N7D)[]B'BBY ]\]9#&* Y+-)L0\Z2
MZL^1:';8G@,3I&,*<]J1E-7^<G!A0.75,5%.Z"XR*?XGJDIG,F=NS3+$FE/#
M3"3=Y,9L*>C'3R,F,FK"(D4P?T[,O?PS$5)GLOF[+HN8MVQC!/F2EGFEB*^8
M6A 9G?\ PR&8U&)$;*2 HXI+$.)&4GH7<T_RGECW)#VFV;_$S5C=69"<&595
MSPENLPIEEZQQ /:]IB31L[9DTP,NFE;T]1$P9=1\=2$&]:8>^\:B68N(A@\>
M. VVRTY8VS#S2469(<8/YLC.::R+R,L*=+AV( ,P35BQ(H6(P.IBS6'SNR8C
M)=4$X@\W,L(N3TD&/VJFT-7]*/I=3 >OS#NQ4$:ZFK4-)?>1#/P[O[2>PWC?
MCW(5X$QDN#37B6IS$WH\*?/?&31VANM*,=4JW73RKJ8=T.S*_MHUDW/Y6S2H
MDS3)>?:QJ!J*$I$K+H!Z)@8SX1IW\X>AD@M&+LTP'D""!D\I /Q$V#0>3]\.
M,=6I+.W)>OYH9'0F;N5]:SOW#R)$HI&OZ4J.:_#N?G?/Q+I/-HV+]PY'S/'W
MNO=NV;M-,@+BOH:_?/#ACZV*]_:$>T$SPX(9=4E?R+@[J7-G(K+B34_/LRLW
M'>8-,4S+I;#3Z9PDI^SY')(P/YQ,HZ C(^!<13YJ']Q[V+=L.V7G@>$7F!@,
MB26 ):1>0U;.*@?47N4(H30L',RS-S>F(C'N<_M9YI*ZFE5(<,O#C4/$'.Y;
MPO4WQ>YJNGU5RVB&,O\ *:K'3J)IZ6>"8PL0]FE<3:!;>1L-)'3+MEU#?#O'
MKPLOS[HS,5"3D!F,V).DVQS#UE$IWJ%BI1 )3(D;HD3)G4 Y) +U8M95PX9]
MT=Q,Y!Y6\0E#B(A*0S3HV6UA+(>9M,,Q<L=Q;EH3"71[T!AT7TGF#B-ET2_8
M\+IZW!MOG89=MLC!08M6;=#7/I[3@002DU22#DX+2./=*1H?PR>U-I'BCXT\
MR^%6B\L9W"TE1E%U)5]+YSQDU<-2?,*&I&K8"C)S$2*3"%=Q+$K,ZB8AS!1[
MQ^67X@7K;++;#;#6"@Z:*<*8C AG&3:^CRBE) WB0Q+-BE@#.>+@T-12-T\Z
M.+OAFX=I@\E&>.==!98344N:S=2VJYNS 1T52_VXZIL3>"A?=MO8YRU.G[J
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M\EGLIF/%_D=%0,SE$RE[U_!1\%%P[;+^&B81\^=/G+3+UAHNSXATL'"[1_\
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M&'6G>>KZUB-_'?;0*0A(!:"DGF"@(VULH5"6>J8R*ZB7,&8F9R+/[0;OI]H
M OB9"$LIJNI*E#9-[%$T&F- 859F)].?*C/!NW/W_&D"E.R @@W-_J5LU_$%
MY8')G?IS[K%@5+BR:JFHLA "74\T'0D&2$ADXGQG,M\3$(%\5FM2NAUZI?0@
MWWY#%GG7IP]V]780AEK?6Z$ VT5-AZ;WUQ &S/\  F_+-O:(SQ AG_5\VCBL
M<R-)?8^YBP!;@:C955$]/S3;"3]X3],_F$>;^72:MX'VP<?-OW74"XE\[S<]
MRU6SI_2KJ!^"E]'&(BGHF;%:,S^,S5B)6]A7CZ0/J7,2XEK >.W1A%?XZ%(8
M$3DY:9%!-J %ZS(G28@)2&*@Z@).215A,-QF7,ISBS#VG-*YMS[AH>3;*"LL
MQZ?G])YE9-S:-IG+.$B7\YKR5Q><N7<IFDIF+^6L/9VZD$LDD=-YW-W,L#+,
M3"P33R8/&9?#/PU@%B&#L09G7++BU")8]+)*%6J!:'R$L4DLDO0*,F!+ EY
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M *"\O2%7^F%P)DJIO_3'R0Z=$('EMCM8/OJ?!/\ _7@[OBWVPO 3F+7'_P#
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M$G&JZ3E.HD>ZC"D(D  0R .3-PK(30!-+( %TQ:X_!QSG_$0R#M2D5]1S/\
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M&XS$R W7":@?N*%AW\R=VJD[H(0$[TDEU*W'(42[;R?(I)%04A0+$D29[_R
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MR2UPJ(=ML:QISQ>F,Z=1ZH7.VNJFZ=;J!UT1+8%\.Y_-,6DPA"0F]K_ZI_\
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M[->@IW@[PAFUTTL57;1.]OIU.&8IP[K7J,81] +!HWOR0H3HN_\ +M:QARY
M,^6(D,9:RF0,7B@S*'@LH"5>V.SRKIY/)Y,V*>H(YPPLBCPX?2Z,GF=<-/:4
MG\JF?C\34=(X*!F,S>0<(_9;9>1#]P8@%F'87]>VGXMOBOTRV+LX62$*M[VO
M9QO"-Y-I9W?8UI=;S=EV1%+8K^FA2TD$!*MUBJ/GK"X)&V[S:E94E*?ZA*5
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M7&QLCC:.A(66@M1C;UCJHH*U*#.I*0$S)2R9.3@Y8YM@3!W&Z227!+)"1Y5
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MTA"!Y:HMQNB*+77R/K@:-RX]/PYEC" A;6"JME-CJJZ?KM!2<_7V?'L4"$+
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M8L1TCF#]J"C&1!S2(:<,OF6O<13$/$N_G<,I E(.\R06.C/6<GK7@,(3( F
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MZ;%/L14T],;CFW'J>^<=0K[C3XE\KZ.G^8-=<!]3RJD:6@A,Z@F3G/6@9@W
M2UA\Z=/XIW!.)&'T2TZ]\&BY='WCP AD[XR",RYD Q E5NS#V^_\]L1%B<@F
M[J?R*23UPZ;<.IU)Y=-W4.\:#3;EU,H-Q&NW338 #3;ME\R[:+(#)+)( TPP
M(..5)RD_?6+'+ZI?GLH34= 1YWPXS#>H=SH_3T=$2T=AT U5%7KZ*-<7 ,<N
M8[I"'H5 ":[!1^5E7\0,0MQ>1U+.'8?@"<(2J$0#INESY+>^P*IOBT;Y&&C
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M3*F6HDX91"DA3?N*6$@R1NE4FJ%%C-3D;S!HVP9PDN" IU3)(43NI4$EG2:
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MQY!S-F503]M&(F,$OBRY<^,LP[YYX6#4B8Y%R1ZEBPH00*S9WC*B0"1]RTJ
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M)W-IO-X>O6YQGD*M9IF8T5"0Y,E$JIU[33AF?.IPZ?1$>Q'OVX%]!_ %B(H
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MK&J8UVY1V(N:/Y=#,NFVG;#T2F'EKHDNW;LXS:,UFP8;IS:1 Q_TAW?U$=0
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M6\WEM:RF,@IEX8J$FK<CDE,/IXZ>L,OV8AW"?$CWKP+JT59DD(5O%*G+)*0
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M)@6'^LA/H39?Q7UP!<G0R9]>1I" %? H%U^FG7%(>$1-R.J!-D1G3U7OB4!
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KC6$/4L]0IZV]+H%MBC/B/4]](1)H*%Y73;3]?@F)@^K?^IO:$?'&H1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g320192g84l93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320192g84l93.jpg
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M 0$! 0$!_\  $0@!80)4 P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
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M(6-PY<"M9)&R$AZA&1#UVXKUG>/F#!-51C.^<?1U_O\ X?;7%G4_PS6ZK?\
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M=>4L<K <1&G;M+M$Y")CA9U>L3CAW.RIE9A_'H+%8-SE4,U;JJOE^?2U;+G
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M>$D@_F=T0\[)AUCX,0 #1.Q@    XF-\   '(  +;R   .X  /4&>T?RH_\
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MS??IY(5/V7KOYDC?NV.3%^2C_47[*>R'$/EUY^\S??K80        #D !W
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M0BX/:<J>=V-L'4=7.TUK9$6]JV/JU3<J5YJT&[DF[!HH\@5-$7\KMT^681I
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M]N(LMU=*R6*-L-U:Z93NJG8B($8DD&Y.8XSJU-'D0P\SO-L@_P#5] ^CTG]
MWR1BM[[R1CD7&O:"X31%%,6$W,,!*1-DD0O9'A8DZ7(I%2E#LGKI$0!L'4T;
MF!<%CH8O;+MBL"R<#X(ZH44P7EW#@+"H&DVEJ5V# =R61<"( QQG7J:.2>;
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M92$>LBF9!K(R(GVT\*W#V-M-&5BE[.R<1DY,4,4KW%G:W]V&YAA8CG<A8I"
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MF"8= %Z>[*9.<YWZY\<^G-*\*<%"(@V*E#120,UC.&@)Q[0@-7!^SZUVP%1
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M +"3[]//O&^S[[\L;_98]T:S^;;G]M%]VGN>77SE;_L)/OT\^\;[/OORQO\
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M0$! 0$!Y" AW@("'> @/J' .-QL1N"/"A&=CN#L0?&KQ:,WF$L#2F7-V 2@
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MC5I &656&DQ2ALABP.D%MG'=;O8+\KQ3A;V[^76.I-#"1EC)5X74ZA+$5P0
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M$'!5U8%'1@'C=61U#*0,9F)653%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7] 1
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MN8I4FC66-@Z. 58="#_ CH0=P=CO7RRRI*YT[*X\I#6>X]I:TD-7UV7C-9[
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MDW=.VC=!<LJP:*O"MDE#/&C<S95^W:E>,Q7QY8)8"1*F@B26(@E21)"P612
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MGCJ'CFC>/7<V"2D'SZ965;F4DG3QRN[,JHLH8UC,S'4S,S8 R6)("@!0"3D
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MYZ #=FPB;9-5.LUFD[5)J24DIZ^9&K4@CX.R;\Q$J"!1_F]:B@AUK'YG./>
M!XKQ?BUWQF\>[NF]*PPJ3R[>+/=CC!];MC4[99O #V/A7"K7@]HMK:K_ %I9
M6 YD\N,&20CU*H[J+A5\2==S5ULZ8I6J+T2CN;FQV,XIM5<;"BX)[5XR]K5Z
M(5N4=6I)TW?2->8V<[0TVT@W[UHU>/8E!\FP=.FS=PNW.JBF<LHFF$1@$LH@
M9Q(T(D?E-(H(5S'G074$@,1J ) .YJ,Q1&43&*,S*AC64HO-5&(+(),:@C$
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M)U>(8LU)5^N^D9%\LZ?&764?2#]X<XN7KI56.:YN+@1B>>:81*$B$LCR"-
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MI",(@Z[DD*&8=+-8:PAM:PP-6H$>3+PB9IF9,F!57:I0Y@@@ \S(1Z!A$$$
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M":?/EUJ'Y 9=<P =8X!W%3(DFGXKQKC5WQN[:YN#I1<K;VZL3';Q_%7IJ=L
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M4,49(P2B*I(]!*@9%12W%Q. )II90IRHDD9P"?$!B<&O-(PD/+BD,K%L)$4
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M*4Q2F*4Q2F*5!G#_ *'KW#S3YVFUJ9FIQC/7ZX[!<NISP'PI&2NDEXS?,D/
M&K1'P%HK\FT[1,[CL_Y990WI9ONT/'[GM'>P7MU#!!);\/LN'*D',T&*RBY4
M;MS'<\QQN^"%SYJ@5I^"<&@X':S6EO++,DU[=7K--HU"2[DYCH-"J-"G9<C.
M.I)J<\T-;BF*4Q2F*4Q2F*5CI52329+*Q*+9P]3#K(W="<I%REY]21#D.3LU
M3!WIF/S()@Z#= &[0DD0B+@3%E0[%DP2OTD$'(](&_B,XP;)#($)C"LPW"MD
M _0".A]&=O XSD0TIM::24.DK$,$U4SF343/X44Y#D$2F(<IE $IBF 0,40
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MF,"BQ?2.0H]V=#VE[02]I+ZWOI;:.U:WX;8\.$<;M(K)8Q<I926"D-(-V7&
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M@'T5-'#KC=P6[C(I54UD\P.0?.'300?SBI*@-Z49RSH[6U6"LUJX6Z,I!G$
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M[UH\M@/Z+5+M$/#)SM&M]\?0\9&QI-P26HO&B%Q\BES3";J3BUTV*,36G?\
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MKHUNR+*N:DX5Y(+CUJKU]94W,RR)0ZCJ1JAS"=VT( F2,)G30HJ=L@ZYOC?
MUOE:YM@%O%&Z[!;@ >:W@) -D<['97VPR;_A'%VM&%O<$M;,>ZW4P$^(\3&3
MYR^'G+X@V"WUH:J[^J:)DUF;.T,F@N:C;&X%63 BY>W38OE$.H7T$_$Q3F @
MJ':G.#YES-VR#KGN <>N^S]VP*N]J[Z;RS;NG*G270-CEW$>XWP' Y<FVEDW
MO&>#V_&K88*)<(NJVN1N,'<(Y7SH7\>I4G6@SD-PVN%/L5"L<G5+5&KQ4W$K
MB@Z:K!S*8!])%RV5#FFZ9NDA*NT=(F.BX0.11,PE-GN=E>6W$+:*[M)5E@F7
M4C#J#\)''5'0Y5T;#*P((KR.ZMI[.>2VN(S'+$V&4_4RGHRL,%6&Q!!%:SF5
M6/3%*8I57XKB)<2VRMA:X3A*(QD-?[7JVM%&TMM,(^SV1M9*A0;VI8ZY55*6
M=1\$;7;T!U(H90@NG\!+M4I$C<J;T=2G$R]W<VHCMU:VO(;4A[O3+*)H+:XY
ML4)@[VB*XR4U[M$X#8PU;5^&A+:WN3).RW%I+= I:ZHHS'+/ (Y9>?W=4D&
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MF*4Q2JT\+&_7G$70;-='U:;556O[2V#KLD>UDU95-RA29CQ6E*&<+,V)DE9
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M3R2<>7Q11D9YV_+Y08' U:B.[6*.* )$GDY/+%B >=U\BDE<;<K;F<T@]=.
M1FO./##,LY:%L\#LXD3:JIYJ%JL^5I@2$0B[UK0;]K5Z2PPQK2W5G8NV5?95
MF1<,6DI!O(=Z,8_82IW##J6I[$R*Z31W>B:'R/E,8 R VMO<VK<V/FCF)-%=
MR@JKQE&T,KY7>[V4C97CDM=<4WE?-7GZ7(NI[>Y7EN(B(VAEMHB&*N'76K*
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M:BI4UVP^B$@<X@':(D* B#D@<SK#R BB8&4.8JA>:N[X5=2EO)F4N@!*M^3
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M>D9HKQP/FSD&JR7IL6?B':#@%CP[B4L%OQ*TBB95F6"X:=I;?F%O>6:*&8$
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MOBJ#G.=4YU%#F444,8ZBAS"<YSG$3&.<QA$QC&,(F,8PB(B(B(B(YWX
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MT))]Q"!R%5=40'H00((AUJ'Y#R#F %*!CG$J93&"6&&2XD$<8R3U/@H\68^
M'U]!DD"HY94A0NYV\!XL?  >G^'4[56*Q6)]8WQG;L>A(G41HU*(BDU1$>?2
M7U=:A^0"LJ( 90P!W%(4A"=5:VR6L>A-R=W<]6;T_0!X#P'I)).AFF>=]3=.
MBJ.BCT#Z?2?'\V ,!F34-?DYP3(=0P&$I"F.8"$.J<0* F$")IE.HH80#T2)
ME,<X\BE*)A !4K@Y'<)=[L/!K%6^TQFR";2UNTW[4-9ZNC-?2,%/0T=N;BAC
M+A.SLQ&OH^5L=PD7-:K-=EH(00CZG'1B[IW(5V3EFS:2C-9R&-OJ(?6O-6-
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MRR*O=DLFU:@S%M0F&&U'*R%@JI&R ]: 'F "'/D( (<P$H]_?WE, " _S@(
M(>H0 <W5:.O[BE,4K9:E4INZS;6!@6HN7CD>I10W,K9DV*)06>O5@*8$&J &
M#K/R,<YS$11(JNJDD?%N[N"Q@>XN'THNP W9V/FHB[:F;&PZ 99B%!(R+6UF
MNYEAA74[=3\%%\7<^"CQ/4G  )(!Z04VFU+352>+KO&C5)JT-(V>SR)DVP+
MU3,=5==4YA!JP:E$X-6@',5(IA$16=+++*^;7M[><:O$54=R[B.UM8P7TZR
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M;#HJ^"C[3U)\?S  :[F34-,4IBE,4IBE,4IBE,4IBE,4IBE,4H <^X.\1[@
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M.1ZE%#<RMF38HE!9Z]6 I@0:H 8.L_(QSG,1%$BJZJ21\6[NX+&![BX?2B[
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M56765.)U5553B8ZBBAS&.<YA$QC"(B(B.>AJJHJHBA44!550 JJ!@  ;  ;
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M*8I3%*N5PN<+C_;S]"W6Y!S':VCG(_.HW=VYVW4Y*1L:H'2HE%I*%%*5E4A
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,,4IBE,4IBE,4K__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
